Entity1,Entity2,Start_Position_1,End_Position_1,Start_Position_2,End_Position_2,Marked Sentence,Interaction,Type
abacavir,lamivudine,30,37,82,91,Pharmacokinetic properties of <e1>abacavir</e1> were not altered by the addition of either <e2>lamivudine</e2> or zidovudine or the combination of lamivudine and zidovudine. ,False,negative
abacavir,zidovudine,30,37,96,105,Pharmacokinetic properties of <e1>abacavir</e1> were not altered by the addition of either lamivudine or <e2>zidovudine</e2> or the combination of lamivudine and zidovudine. ,False,negative
abacavir,lamivudine,30,37,129,138,Pharmacokinetic properties of <e1>abacavir</e1> were not altered by the addition of either lamivudine or zidovudine or the combination of <e2>lamivudine</e2> and zidovudine. ,False,negative
abacavir,zidovudine,30,37,144,153,Pharmacokinetic properties of <e1>abacavir</e1> were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and <e2>zidovudine</e2>. ,False,negative
lamivudine,zidovudine,82,91,96,105,Pharmacokinetic properties of abacavir were not altered by the addition of either <e1>lamivudine</e1> or <e2>zidovudine</e2> or the combination of lamivudine and zidovudine. ,False,negative
lamivudine,lamivudine,82,91,129,138,Pharmacokinetic properties of abacavir were not altered by the addition of either <e1>lamivudine</e1> or zidovudine or the combination of <e2>lamivudine</e2> and zidovudine. ,False,negative
lamivudine,zidovudine,82,91,144,153,Pharmacokinetic properties of abacavir were not altered by the addition of either <e1>lamivudine</e1> or zidovudine or the combination of lamivudine and <e2>zidovudine</e2>. ,False,negative
zidovudine,lamivudine,96,105,129,138,Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or <e1>zidovudine</e1> or the combination of <e2>lamivudine</e2> and zidovudine. ,False,negative
zidovudine,zidovudine,96,105,144,153,Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or <e1>zidovudine</e1> or the combination of lamivudine and <e2>zidovudine</e2>. ,False,negative
lamivudine,zidovudine,129,138,144,153,Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of <e1>lamivudine</e1> and <e2>zidovudine</e2>. ,False,negative
lamivudine,zidovudine,37,46,51,60,No clinically significant changes to <e1>lamivudine</e1> or <e2>zidovudine</e2> pharmacokinetics were observed following concomitant administration of abacavir. ,False,negative
lamivudine,abacavir,37,46,133,140,No clinically significant changes to <e1>lamivudine</e1> or zidovudine pharmacokinetics were observed following concomitant administration of <e2>abacavir</e2>. ,False,negative
zidovudine,abacavir,51,60,133,140,No clinically significant changes to lamivudine or <e1>zidovudine</e1> pharmacokinetics were observed following concomitant administration of <e2>abacavir</e2>. ,False,negative
Abacavir,ethanol,0,7,60,66,<e1>Abacavir</e1> has no effect on the pharmacokinetic properties of <e2>ethanol</e2>. ,False,negative
Ethanol,abacavir,0,6,37,44,<e1>Ethanol</e1> decreases the elimination of <e2>abacavir</e2> causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. ,True,mechanism
Ethanol,methadone,0,6,104,112,<e1>Ethanol</e1> decreases the elimination of abacavir causing an increase in overall exposure . The addition of <e2>methadone</e2> has no clinically significant effect on the pharmacokinetic properties of abacavir. ,False,negative
Ethanol,abacavir,0,6,188,195,<e1>Ethanol</e1> decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of <e2>abacavir</e2>. ,False,negative
abacavir,methadone,37,44,104,112,Ethanol decreases the elimination of <e1>abacavir</e1> causing an increase in overall exposure . The addition of <e2>methadone</e2> has no clinically significant effect on the pharmacokinetic properties of abacavir. ,False,negative
abacavir,abacavir,37,44,188,195,Ethanol decreases the elimination of <e1>abacavir</e1> causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of <e2>abacavir</e2>. ,False,negative
methadone,abacavir,104,112,188,195,Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of <e1>methadone</e1> has no clinically significant effect on the pharmacokinetic properties of <e2>abacavir</e2>. ,False,negative
methadone,ZIAGEN,49,57,118,123,"In a study of 11 HIV-infected patients receiving <e1>methadone</e1>-maintenance therapy (40 mg and 90 mg daily) with 600 mg of <e2>ZIAGEN</e2> twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI 6% to 42%). ",True,mechanism
methadone,methadone,49,57,182,190,"In a study of 11 HIV-infected patients receiving <e1>methadone</e1>-maintenance therapy (40 mg and 90 mg daily) with 600 mg of ZIAGEN twice daily (twice the currently recommended dose), oral <e2>methadone</e2> clearance increased 22% (90% CI 6% to 42%). ",False,negative
ZIAGEN,methadone,118,123,182,190,"In a study of 11 HIV-infected patients receiving methadone-maintenance therapy (40 mg and 90 mg daily) with 600 mg of <e1>ZIAGEN</e1> twice daily (twice the currently recommended dose), oral <e2>methadone</e2> clearance increased 22% (90% CI 6% to 42%). ",False,negative
Cholestyramine,cholestyramine,0,13,28,41,<e1>Cholestyramine</e1>: Concomitant <e2>cholestyramine</e2> administration decreased the mean AUC of total ezetimibe approximately 55%. ,False,negative
Cholestyramine,ezetimibe,0,13,90,98,<e1>Cholestyramine</e1>: Concomitant cholestyramine administration decreased the mean AUC of total <e2>ezetimibe</e2> approximately 55%. ,False,negative
cholestyramine,ezetimibe,28,41,90,98,Cholestyramine: Concomitant <e1>cholestyramine</e1> administration decreased the mean AUC of total <e2>ezetimibe</e2> approximately 55%. ,True,mechanism
ezetimibe,cholestyramine,46,54,59,72,The incremental LDL-C reduction due to adding <e1>ezetimibe</e1> to <e2>cholestyramine</e2> may be reduced by this interaction. ,True,effect
Fibrates,ezetimibe,0,7,42,50,<e1>Fibrates</e1>: The safety and effectiveness of <e2>ezetimibe</e2> administered with fibrates have not been established. ,False,negative
Fibrates,fibrates,0,7,70,77,<e1>Fibrates</e1>: The safety and effectiveness of ezetimibe administered with <e2>fibrates</e2> have not been established. ,False,negative
ezetimibe,fibrates,42,50,70,77,Fibrates: The safety and effectiveness of <e1>ezetimibe</e1> administered with <e2>fibrates</e2> have not been established. ,False,negative
ZETIA,fibrates,21,25,32,39,Co-administration of <e1>ZETIA</e1> with <e2>fibrates</e2> is not recommended until use in patients is studied. ,True,advise
Fenofibrate,fenofibrate,0,10,53,63,"<e1>Fenofibrate</e1>: In a pharmacokinetic study, concomitant <e2>fenofibrate</e2> administration increased total ezetimibe concentrations approximately 1.5-fold. ",False,negative
Fenofibrate,ezetimibe,0,10,96,104,"<e1>Fenofibrate</e1>: In a pharmacokinetic study, concomitant fenofibrate administration increased total <e2>ezetimibe</e2> concentrations approximately 1.5-fold. ",False,negative
fenofibrate,ezetimibe,53,63,96,104,"Fenofibrate: In a pharmacokinetic study, concomitant <e1>fenofibrate</e1> administration increased total <e2>ezetimibe</e2> concentrations approximately 1.5-fold. ",True,mechanism
Gemfibrozil,gemfibrozil,0,10,53,63,"<e1>Gemfibrozil</e1>: In a pharmacokinetic study, concomitant <e2>gemfibrozil</e2> administration increased total ezetimibe concentrations approximately 1.7-fold. ",False,negative
Gemfibrozil,ezetimibe,0,10,96,104,"<e1>Gemfibrozil</e1>: In a pharmacokinetic study, concomitant gemfibrozil administration increased total <e2>ezetimibe</e2> concentrations approximately 1.7-fold. ",False,negative
gemfibrozil,ezetimibe,53,63,96,104,"Gemfibrozil: In a pharmacokinetic study, concomitant <e1>gemfibrozil</e1> administration increased total <e2>ezetimibe</e2> concentrations approximately 1.7-fold. ",False,negative
HMG-CoA reductase inhibitors,ezetimibe,0,27,100,108,"<e1>HMG-CoA reductase inhibitors</e1>: No clinically significant pharmacokinetic interactions were seen when <e2>ezetimibe</e2> was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",False,negative
HMG-CoA reductase inhibitors,atorvastatin,0,27,135,146,"<e1>HMG-CoA reductase inhibitors</e1>: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with <e2>atorvastatin</e2>, simvastatin, pravastatin, lovastatin, or fluvastatin. ",False,negative
HMG-CoA reductase inhibitors,simvastatin,0,27,149,159,"<e1>HMG-CoA reductase inhibitors</e1>: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, <e2>simvastatin</e2>, pravastatin, lovastatin, or fluvastatin. ",False,negative
HMG-CoA reductase inhibitors,pravastatin,0,27,162,172,"<e1>HMG-CoA reductase inhibitors</e1>: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, <e2>pravastatin</e2>, lovastatin, or fluvastatin. ",False,negative
HMG-CoA reductase inhibitors,lovastatin,0,27,175,184,"<e1>HMG-CoA reductase inhibitors</e1>: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, <e2>lovastatin</e2>, or fluvastatin. ",False,negative
HMG-CoA reductase inhibitors,fluvastatin,0,27,190,200,"<e1>HMG-CoA reductase inhibitors</e1>: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or <e2>fluvastatin</e2>. ",False,negative
ezetimibe,atorvastatin,100,108,135,146,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when <e1>ezetimibe</e1> was co-administered with <e2>atorvastatin</e2>, simvastatin, pravastatin, lovastatin, or fluvastatin. ",False,negative
ezetimibe,simvastatin,100,108,149,159,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when <e1>ezetimibe</e1> was co-administered with atorvastatin, <e2>simvastatin</e2>, pravastatin, lovastatin, or fluvastatin. ",False,negative
ezetimibe,pravastatin,100,108,162,172,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when <e1>ezetimibe</e1> was co-administered with atorvastatin, simvastatin, <e2>pravastatin</e2>, lovastatin, or fluvastatin. ",False,negative
ezetimibe,lovastatin,100,108,175,184,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when <e1>ezetimibe</e1> was co-administered with atorvastatin, simvastatin, pravastatin, <e2>lovastatin</e2>, or fluvastatin. ",False,negative
ezetimibe,fluvastatin,100,108,190,200,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when <e1>ezetimibe</e1> was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or <e2>fluvastatin</e2>. ",False,negative
atorvastatin,simvastatin,135,146,149,159,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with <e1>atorvastatin</e1>, <e2>simvastatin</e2>, pravastatin, lovastatin, or fluvastatin. ",False,negative
atorvastatin,pravastatin,135,146,162,172,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with <e1>atorvastatin</e1>, simvastatin, <e2>pravastatin</e2>, lovastatin, or fluvastatin. ",False,negative
atorvastatin,lovastatin,135,146,175,184,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with <e1>atorvastatin</e1>, simvastatin, pravastatin, <e2>lovastatin</e2>, or fluvastatin. ",False,negative
atorvastatin,fluvastatin,135,146,190,200,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with <e1>atorvastatin</e1>, simvastatin, pravastatin, lovastatin, or <e2>fluvastatin</e2>. ",False,negative
simvastatin,pravastatin,149,159,162,172,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, <e1>simvastatin</e1>, <e2>pravastatin</e2>, lovastatin, or fluvastatin. ",False,negative
simvastatin,lovastatin,149,159,175,184,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, <e1>simvastatin</e1>, pravastatin, <e2>lovastatin</e2>, or fluvastatin. ",False,negative
simvastatin,fluvastatin,149,159,190,200,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, <e1>simvastatin</e1>, pravastatin, lovastatin, or <e2>fluvastatin</e2>. ",False,negative
pravastatin,lovastatin,162,172,175,184,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, <e1>pravastatin</e1>, <e2>lovastatin</e2>, or fluvastatin. ",False,negative
pravastatin,fluvastatin,162,172,190,200,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, <e1>pravastatin</e1>, lovastatin, or <e2>fluvastatin</e2>. ",False,negative
lovastatin,fluvastatin,175,184,190,200,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, <e1>lovastatin</e1>, or <e2>fluvastatin</e2>. ",False,negative
Cyclosporine,ezetimibe,0,11,24,32,"<e1>Cyclosporine</e1>: The total <e2>ezetimibe</e2> level increased 12-fold in one renal transplant patient receiving multiple medications, including cyclosporine. ",False,negative
Cyclosporine,cyclosporine,0,11,132,143,"<e1>Cyclosporine</e1>: The total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications, including <e2>cyclosporine</e2>. ",False,negative
ezetimibe,cyclosporine,24,32,132,143,"Cyclosporine: The total <e1>ezetimibe</e1> level increased 12-fold in one renal transplant patient receiving multiple medications, including <e2>cyclosporine</e2>. ",True,mechanism
ezetimibe,cyclosporine,23,31,37,48,Patients who take both <e1>ezetimibe</e1> and <e2>cyclosporine</e2> should be carefully monitored. ,True,advise
ezetimibe,ezetimibe,99,107,271,279,"Carcinogenesis, Mutagenesis, Impairment of Fertility A 104-week dietary carcinogenicity study with <e1>ezetimibe</e1> was conducted in rats at doses up to 1500 mg/kg/day (males) and 500 mg/kg/day (females) (~20 times the human exposure at 10 mg daily based on AUC0-24hr for total <e2>ezetimibe</e2>). ",False,negative
ezetimibe,ezetimibe,46,54,187,195,A 104-week dietary carcinogenicity study with <e1>ezetimibe</e1> was also conducted in mice at doses up to 500 mg/kg/day (>150 times the human exposure at 10 mg daily based on AUC0-24hr for total <e2>ezetimibe</e2>). ,False,negative
ezetimibe,ezetimibe,38,46,240,248,"In oral (gavage) fertility studies of <e1>ezetimibe</e1> conducted in rats, there was no evidence of reproductive toxicity at doses up to 1000 mg/kg/day in male or female rats (~7 times the human exposure at 10 mg daily based on AUC0-24hr for total <e2>ezetimibe</e2>). ",False,negative
ezetimibe,ezetimibe,24,32,186,194,"In rabbits treated with <e1>ezetimibe</e1>, an increased incidence of extra thoracic ribs was observed at 1000 mg/kg/day (150 times the human exposure at 10 mg daily based on AUC0-24hr for total <e2>ezetimibe</e2>). ",False,negative
ezetimibe,HMG-CoA reductase inhibitors,25,33,61,88,Multiple dose studies of <e1>ezetimibe</e1> given in combination with <e2>HMG-CoA reductase inhibitors</e2> (statins) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures. ,False,negative
ezetimibe,statins,25,33,91,97,Multiple dose studies of <e1>ezetimibe</e1> given in combination with HMG-CoA reductase inhibitors (<e2>statins</e2>) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures. ,False,negative
ezetimibe,ezetimibe,25,33,158,166,Multiple dose studies of <e1>ezetimibe</e1> given in combination with HMG-CoA reductase inhibitors (statins) in rats and rabbits during organogenesis result in higher <e2>ezetimibe</e2> and statin exposures. ,False,negative
HMG-CoA reductase inhibitors,statins,61,88,91,97,Multiple dose studies of ezetimibe given in combination with <e1>HMG-CoA reductase inhibitors</e1> (<e2>statins</e2>) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures. ,False,negative
HMG-CoA reductase inhibitors,ezetimibe,61,88,158,166,Multiple dose studies of ezetimibe given in combination with <e1>HMG-CoA reductase inhibitors</e1> (statins) in rats and rabbits during organogenesis result in higher <e2>ezetimibe</e2> and statin exposures. ,False,negative
statins,ezetimibe,91,97,158,166,Multiple dose studies of ezetimibe given in combination with HMG-CoA reductase inhibitors (<e1>statins</e1>) in rats and rabbits during organogenesis result in higher <e2>ezetimibe</e2> and statin exposures. ,False,negative
ZETIA,HMG-CoA reductase inhibitor,5,9,35,61,"When <e1>ZETIA</e1> is administered with an <e2>HMG-CoA reductase inhibitor</e2> in a woman of childbearing potential, refer to the pregnancy category and package labeling for the HMG-CoA reductase inhibitor. ",False,negative
ZETIA,HMG-CoA reductase inhibitor,5,9,162,188,"When <e1>ZETIA</e1> is administered with an HMG-CoA reductase inhibitor in a woman of childbearing potential, refer to the pregnancy category and package labeling for the <e2>HMG-CoA reductase inhibitor</e2>. ",False,negative
HMG-CoA reductase inhibitor,HMG-CoA reductase inhibitor,35,61,162,188,"When ZETIA is administered with an <e1>HMG-CoA reductase inhibitor</e1> in a woman of childbearing potential, refer to the pregnancy category and package labeling for the <e2>HMG-CoA reductase inhibitor</e2>. ",False,negative
hypoglycemics,Coumarin-type anticoagulants,51,63,66,93,"These are described in greater detail below:  Oral <e1>hypoglycemics</e1>, <e2>Coumarin-type anticoagulants</e2>, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
hypoglycemics,Phenytoin,51,63,96,104,"These are described in greater detail below:  Oral <e1>hypoglycemics</e1>, Coumarin-type anticoagulants, <e2>Phenytoin</e2>, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
hypoglycemics,Cyclosporine,51,63,107,118,"These are described in greater detail below:  Oral <e1>hypoglycemics</e1>, Coumarin-type anticoagulants, Phenytoin, <e2>Cyclosporine</e2>, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
hypoglycemics,Rifampin,51,63,121,128,"These are described in greater detail below:  Oral <e1>hypoglycemics</e1>, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, <e2>Rifampin</e2>, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
hypoglycemics,Theophylline,51,63,131,142,"These are described in greater detail below:  Oral <e1>hypoglycemics</e1>, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, <e2>Theophylline</e2>, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
hypoglycemics,Terfenadine,51,63,145,155,"These are described in greater detail below:  Oral <e1>hypoglycemics</e1>, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, <e2>Terfenadine</e2>, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
hypoglycemics,Cisapride,51,63,158,166,"These are described in greater detail below:  Oral <e1>hypoglycemics</e1>, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, <e2>Cisapride</e2>, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
hypoglycemics,Astemizole,51,63,169,178,"These are described in greater detail below:  Oral <e1>hypoglycemics</e1>, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, <e2>Astemizole</e2>, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
hypoglycemics,Rifabutin,51,63,181,189,"These are described in greater detail below:  Oral <e1>hypoglycemics</e1>, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, <e2>Rifabutin</e2>, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
hypoglycemics,Tacrolimus,51,63,192,201,"These are described in greater detail below:  Oral <e1>hypoglycemics</e1>, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, <e2>Tacrolimus</e2>, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
hypoglycemics,Short-acting benzodiazepines,51,63,204,231,"These are described in greater detail below:  Oral <e1>hypoglycemics</e1>, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, <e2>Short-acting benzodiazepines</e2>,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
hypoglycemics,hypoglycemics,51,63,240,252,"These are described in greater detail below:  Oral <e1>hypoglycemics</e1>, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral <e2>hypoglycemics</e2>: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
hypoglycemics,DIFLUCAN,51,63,325,332,"These are described in greater detail below:  Oral <e1>hypoglycemics</e1>, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of <e2>DIFLUCAN</e2> with oral hypoglycemic agents; ",False,negative
hypoglycemics,hypoglycemic agents,51,63,344,362,"These are described in greater detail below:  Oral <e1>hypoglycemics</e1>, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral <e2>hypoglycemic agents</e2>; ",False,negative
Coumarin-type anticoagulants,Phenytoin,66,93,96,104,"These are described in greater detail below:  Oral hypoglycemics, <e1>Coumarin-type anticoagulants</e1>, <e2>Phenytoin</e2>, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Coumarin-type anticoagulants,Cyclosporine,66,93,107,118,"These are described in greater detail below:  Oral hypoglycemics, <e1>Coumarin-type anticoagulants</e1>, Phenytoin, <e2>Cyclosporine</e2>, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Coumarin-type anticoagulants,Rifampin,66,93,121,128,"These are described in greater detail below:  Oral hypoglycemics, <e1>Coumarin-type anticoagulants</e1>, Phenytoin, Cyclosporine, <e2>Rifampin</e2>, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Coumarin-type anticoagulants,Theophylline,66,93,131,142,"These are described in greater detail below:  Oral hypoglycemics, <e1>Coumarin-type anticoagulants</e1>, Phenytoin, Cyclosporine, Rifampin, <e2>Theophylline</e2>, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Coumarin-type anticoagulants,Terfenadine,66,93,145,155,"These are described in greater detail below:  Oral hypoglycemics, <e1>Coumarin-type anticoagulants</e1>, Phenytoin, Cyclosporine, Rifampin, Theophylline, <e2>Terfenadine</e2>, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Coumarin-type anticoagulants,Cisapride,66,93,158,166,"These are described in greater detail below:  Oral hypoglycemics, <e1>Coumarin-type anticoagulants</e1>, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, <e2>Cisapride</e2>, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Coumarin-type anticoagulants,Astemizole,66,93,169,178,"These are described in greater detail below:  Oral hypoglycemics, <e1>Coumarin-type anticoagulants</e1>, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, <e2>Astemizole</e2>, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Coumarin-type anticoagulants,Rifabutin,66,93,181,189,"These are described in greater detail below:  Oral hypoglycemics, <e1>Coumarin-type anticoagulants</e1>, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, <e2>Rifabutin</e2>, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Coumarin-type anticoagulants,Tacrolimus,66,93,192,201,"These are described in greater detail below:  Oral hypoglycemics, <e1>Coumarin-type anticoagulants</e1>, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, <e2>Tacrolimus</e2>, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Coumarin-type anticoagulants,Short-acting benzodiazepines,66,93,204,231,"These are described in greater detail below:  Oral hypoglycemics, <e1>Coumarin-type anticoagulants</e1>, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, <e2>Short-acting benzodiazepines</e2>,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Coumarin-type anticoagulants,hypoglycemics,66,93,240,252,"These are described in greater detail below:  Oral hypoglycemics, <e1>Coumarin-type anticoagulants</e1>, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral <e2>hypoglycemics</e2>: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Coumarin-type anticoagulants,DIFLUCAN,66,93,325,332,"These are described in greater detail below:  Oral hypoglycemics, <e1>Coumarin-type anticoagulants</e1>, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of <e2>DIFLUCAN</e2> with oral hypoglycemic agents; ",False,negative
Coumarin-type anticoagulants,hypoglycemic agents,66,93,344,362,"These are described in greater detail below:  Oral hypoglycemics, <e1>Coumarin-type anticoagulants</e1>, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral <e2>hypoglycemic agents</e2>; ",False,negative
Phenytoin,Cyclosporine,96,104,107,118,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, <e1>Phenytoin</e1>, <e2>Cyclosporine</e2>, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Phenytoin,Rifampin,96,104,121,128,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, <e1>Phenytoin</e1>, Cyclosporine, <e2>Rifampin</e2>, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Phenytoin,Theophylline,96,104,131,142,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, <e1>Phenytoin</e1>, Cyclosporine, Rifampin, <e2>Theophylline</e2>, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Phenytoin,Terfenadine,96,104,145,155,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, <e1>Phenytoin</e1>, Cyclosporine, Rifampin, Theophylline, <e2>Terfenadine</e2>, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Phenytoin,Cisapride,96,104,158,166,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, <e1>Phenytoin</e1>, Cyclosporine, Rifampin, Theophylline, Terfenadine, <e2>Cisapride</e2>, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Phenytoin,Astemizole,96,104,169,178,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, <e1>Phenytoin</e1>, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, <e2>Astemizole</e2>, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Phenytoin,Rifabutin,96,104,181,189,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, <e1>Phenytoin</e1>, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, <e2>Rifabutin</e2>, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Phenytoin,Tacrolimus,96,104,192,201,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, <e1>Phenytoin</e1>, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, <e2>Tacrolimus</e2>, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Phenytoin,Short-acting benzodiazepines,96,104,204,231,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, <e1>Phenytoin</e1>, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, <e2>Short-acting benzodiazepines</e2>,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Phenytoin,hypoglycemics,96,104,240,252,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, <e1>Phenytoin</e1>, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral <e2>hypoglycemics</e2>: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Phenytoin,DIFLUCAN,96,104,325,332,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, <e1>Phenytoin</e1>, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of <e2>DIFLUCAN</e2> with oral hypoglycemic agents; ",False,negative
Phenytoin,hypoglycemic agents,96,104,344,362,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, <e1>Phenytoin</e1>, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral <e2>hypoglycemic agents</e2>; ",False,negative
Cyclosporine,Rifampin,107,118,121,128,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, <e1>Cyclosporine</e1>, <e2>Rifampin</e2>, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Cyclosporine,Theophylline,107,118,131,142,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, <e1>Cyclosporine</e1>, Rifampin, <e2>Theophylline</e2>, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Cyclosporine,Terfenadine,107,118,145,155,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, <e1>Cyclosporine</e1>, Rifampin, Theophylline, <e2>Terfenadine</e2>, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Cyclosporine,Cisapride,107,118,158,166,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, <e1>Cyclosporine</e1>, Rifampin, Theophylline, Terfenadine, <e2>Cisapride</e2>, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Cyclosporine,Astemizole,107,118,169,178,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, <e1>Cyclosporine</e1>, Rifampin, Theophylline, Terfenadine, Cisapride, <e2>Astemizole</e2>, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Cyclosporine,Rifabutin,107,118,181,189,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, <e1>Cyclosporine</e1>, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, <e2>Rifabutin</e2>, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Cyclosporine,Tacrolimus,107,118,192,201,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, <e1>Cyclosporine</e1>, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, <e2>Tacrolimus</e2>, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Cyclosporine,Short-acting benzodiazepines,107,118,204,231,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, <e1>Cyclosporine</e1>, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, <e2>Short-acting benzodiazepines</e2>,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Cyclosporine,hypoglycemics,107,118,240,252,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, <e1>Cyclosporine</e1>, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral <e2>hypoglycemics</e2>: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Cyclosporine,DIFLUCAN,107,118,325,332,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, <e1>Cyclosporine</e1>, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of <e2>DIFLUCAN</e2> with oral hypoglycemic agents; ",False,negative
Cyclosporine,hypoglycemic agents,107,118,344,362,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, <e1>Cyclosporine</e1>, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral <e2>hypoglycemic agents</e2>; ",False,negative
Rifampin,Theophylline,121,128,131,142,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, <e1>Rifampin</e1>, <e2>Theophylline</e2>, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Rifampin,Terfenadine,121,128,145,155,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, <e1>Rifampin</e1>, Theophylline, <e2>Terfenadine</e2>, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Rifampin,Cisapride,121,128,158,166,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, <e1>Rifampin</e1>, Theophylline, Terfenadine, <e2>Cisapride</e2>, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Rifampin,Astemizole,121,128,169,178,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, <e1>Rifampin</e1>, Theophylline, Terfenadine, Cisapride, <e2>Astemizole</e2>, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Rifampin,Rifabutin,121,128,181,189,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, <e1>Rifampin</e1>, Theophylline, Terfenadine, Cisapride, Astemizole, <e2>Rifabutin</e2>, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Rifampin,Tacrolimus,121,128,192,201,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, <e1>Rifampin</e1>, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, <e2>Tacrolimus</e2>, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Rifampin,Short-acting benzodiazepines,121,128,204,231,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, <e1>Rifampin</e1>, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, <e2>Short-acting benzodiazepines</e2>,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Rifampin,hypoglycemics,121,128,240,252,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, <e1>Rifampin</e1>, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral <e2>hypoglycemics</e2>: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Rifampin,DIFLUCAN,121,128,325,332,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, <e1>Rifampin</e1>, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of <e2>DIFLUCAN</e2> with oral hypoglycemic agents; ",False,negative
Rifampin,hypoglycemic agents,121,128,344,362,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, <e1>Rifampin</e1>, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral <e2>hypoglycemic agents</e2>; ",False,negative
Theophylline,Terfenadine,131,142,145,155,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, <e1>Theophylline</e1>, <e2>Terfenadine</e2>, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Theophylline,Cisapride,131,142,158,166,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, <e1>Theophylline</e1>, Terfenadine, <e2>Cisapride</e2>, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Theophylline,Astemizole,131,142,169,178,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, <e1>Theophylline</e1>, Terfenadine, Cisapride, <e2>Astemizole</e2>, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Theophylline,Rifabutin,131,142,181,189,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, <e1>Theophylline</e1>, Terfenadine, Cisapride, Astemizole, <e2>Rifabutin</e2>, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Theophylline,Tacrolimus,131,142,192,201,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, <e1>Theophylline</e1>, Terfenadine, Cisapride, Astemizole, Rifabutin, <e2>Tacrolimus</e2>, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Theophylline,Short-acting benzodiazepines,131,142,204,231,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, <e1>Theophylline</e1>, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, <e2>Short-acting benzodiazepines</e2>,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Theophylline,hypoglycemics,131,142,240,252,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, <e1>Theophylline</e1>, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral <e2>hypoglycemics</e2>: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Theophylline,DIFLUCAN,131,142,325,332,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, <e1>Theophylline</e1>, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of <e2>DIFLUCAN</e2> with oral hypoglycemic agents; ",False,negative
Theophylline,hypoglycemic agents,131,142,344,362,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, <e1>Theophylline</e1>, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral <e2>hypoglycemic agents</e2>; ",False,negative
Terfenadine,Cisapride,145,155,158,166,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, <e1>Terfenadine</e1>, <e2>Cisapride</e2>, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Terfenadine,Astemizole,145,155,169,178,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, <e1>Terfenadine</e1>, Cisapride, <e2>Astemizole</e2>, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Terfenadine,Rifabutin,145,155,181,189,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, <e1>Terfenadine</e1>, Cisapride, Astemizole, <e2>Rifabutin</e2>, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Terfenadine,Tacrolimus,145,155,192,201,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, <e1>Terfenadine</e1>, Cisapride, Astemizole, Rifabutin, <e2>Tacrolimus</e2>, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Terfenadine,Short-acting benzodiazepines,145,155,204,231,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, <e1>Terfenadine</e1>, Cisapride, Astemizole, Rifabutin, Tacrolimus, <e2>Short-acting benzodiazepines</e2>,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Terfenadine,hypoglycemics,145,155,240,252,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, <e1>Terfenadine</e1>, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral <e2>hypoglycemics</e2>: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Terfenadine,DIFLUCAN,145,155,325,332,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, <e1>Terfenadine</e1>, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of <e2>DIFLUCAN</e2> with oral hypoglycemic agents; ",False,negative
Terfenadine,hypoglycemic agents,145,155,344,362,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, <e1>Terfenadine</e1>, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral <e2>hypoglycemic agents</e2>; ",False,negative
Cisapride,Astemizole,158,166,169,178,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, <e1>Cisapride</e1>, <e2>Astemizole</e2>, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Cisapride,Rifabutin,158,166,181,189,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, <e1>Cisapride</e1>, Astemizole, <e2>Rifabutin</e2>, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Cisapride,Tacrolimus,158,166,192,201,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, <e1>Cisapride</e1>, Astemizole, Rifabutin, <e2>Tacrolimus</e2>, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Cisapride,Short-acting benzodiazepines,158,166,204,231,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, <e1>Cisapride</e1>, Astemizole, Rifabutin, Tacrolimus, <e2>Short-acting benzodiazepines</e2>,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Cisapride,hypoglycemics,158,166,240,252,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, <e1>Cisapride</e1>, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral <e2>hypoglycemics</e2>: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Cisapride,DIFLUCAN,158,166,325,332,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, <e1>Cisapride</e1>, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of <e2>DIFLUCAN</e2> with oral hypoglycemic agents; ",False,negative
Cisapride,hypoglycemic agents,158,166,344,362,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, <e1>Cisapride</e1>, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral <e2>hypoglycemic agents</e2>; ",False,negative
Astemizole,Rifabutin,169,178,181,189,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, <e1>Astemizole</e1>, <e2>Rifabutin</e2>, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Astemizole,Tacrolimus,169,178,192,201,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, <e1>Astemizole</e1>, Rifabutin, <e2>Tacrolimus</e2>, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Astemizole,Short-acting benzodiazepines,169,178,204,231,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, <e1>Astemizole</e1>, Rifabutin, Tacrolimus, <e2>Short-acting benzodiazepines</e2>,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Astemizole,hypoglycemics,169,178,240,252,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, <e1>Astemizole</e1>, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral <e2>hypoglycemics</e2>: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Astemizole,DIFLUCAN,169,178,325,332,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, <e1>Astemizole</e1>, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of <e2>DIFLUCAN</e2> with oral hypoglycemic agents; ",False,negative
Astemizole,hypoglycemic agents,169,178,344,362,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, <e1>Astemizole</e1>, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral <e2>hypoglycemic agents</e2>; ",False,negative
Rifabutin,Tacrolimus,181,189,192,201,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, <e1>Rifabutin</e1>, <e2>Tacrolimus</e2>, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Rifabutin,Short-acting benzodiazepines,181,189,204,231,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, <e1>Rifabutin</e1>, Tacrolimus, <e2>Short-acting benzodiazepines</e2>,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Rifabutin,hypoglycemics,181,189,240,252,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, <e1>Rifabutin</e1>, Tacrolimus, Short-acting benzodiazepines,  Oral <e2>hypoglycemics</e2>: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Rifabutin,DIFLUCAN,181,189,325,332,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, <e1>Rifabutin</e1>, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of <e2>DIFLUCAN</e2> with oral hypoglycemic agents; ",False,negative
Rifabutin,hypoglycemic agents,181,189,344,362,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, <e1>Rifabutin</e1>, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral <e2>hypoglycemic agents</e2>; ",False,negative
Tacrolimus,Short-acting benzodiazepines,192,201,204,231,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, <e1>Tacrolimus</e1>, <e2>Short-acting benzodiazepines</e2>,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Tacrolimus,hypoglycemics,192,201,240,252,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, <e1>Tacrolimus</e1>, Short-acting benzodiazepines,  Oral <e2>hypoglycemics</e2>: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Tacrolimus,DIFLUCAN,192,201,325,332,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, <e1>Tacrolimus</e1>, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of <e2>DIFLUCAN</e2> with oral hypoglycemic agents; ",False,negative
Tacrolimus,hypoglycemic agents,192,201,344,362,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, <e1>Tacrolimus</e1>, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral <e2>hypoglycemic agents</e2>; ",False,negative
Short-acting benzodiazepines,hypoglycemics,204,231,240,252,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, <e1>Short-acting benzodiazepines</e1>,  Oral <e2>hypoglycemics</e2>: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",False,negative
Short-acting benzodiazepines,DIFLUCAN,204,231,325,332,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, <e1>Short-acting benzodiazepines</e1>,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of <e2>DIFLUCAN</e2> with oral hypoglycemic agents; ",False,negative
Short-acting benzodiazepines,hypoglycemic agents,204,231,344,362,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, <e1>Short-acting benzodiazepines</e1>,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral <e2>hypoglycemic agents</e2>; ",False,negative
hypoglycemics,DIFLUCAN,240,252,325,332,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral <e1>hypoglycemics</e1>: Clinically significant hypoglycemia may be precipitated by the use of <e2>DIFLUCAN</e2> with oral hypoglycemic agents; ",False,negative
hypoglycemics,hypoglycemic agents,240,252,344,362,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral <e1>hypoglycemics</e1>: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral <e2>hypoglycemic agents</e2>; ",False,negative
DIFLUCAN,hypoglycemic agents,325,332,344,362,"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of <e1>DIFLUCAN</e1> with oral <e2>hypoglycemic agents</e2>; ",True,effect
DIFLUCAN,glyburide,78,85,91,99,one fatality has been reported from hypoglycemia in association with combined <e1>DIFLUCAN</e1> and <e2>glyburide</e2> use. ,True,effect
DIFLUCAN,tolbutamide,0,7,35,45,"<e1>DIFLUCAN</e1> reduces the metabolism of <e2>tolbutamide</e2>, glyburide, and glipizide and increases the plasma concentration of these agents. ",True,mechanism
DIFLUCAN,glyburide,0,7,48,56,"<e1>DIFLUCAN</e1> reduces the metabolism of tolbutamide, <e2>glyburide</e2>, and glipizide and increases the plasma concentration of these agents. ",True,mechanism
DIFLUCAN,glipizide,0,7,63,71,"<e1>DIFLUCAN</e1> reduces the metabolism of tolbutamide, glyburide, and <e2>glipizide</e2> and increases the plasma concentration of these agents. ",True,mechanism
tolbutamide,glyburide,35,45,48,56,"DIFLUCAN reduces the metabolism of <e1>tolbutamide</e1>, <e2>glyburide</e2>, and glipizide and increases the plasma concentration of these agents. ",False,negative
tolbutamide,glipizide,35,45,63,71,"DIFLUCAN reduces the metabolism of <e1>tolbutamide</e1>, glyburide, and <e2>glipizide</e2> and increases the plasma concentration of these agents. ",False,negative
glyburide,glipizide,48,56,63,71,"DIFLUCAN reduces the metabolism of tolbutamide, <e1>glyburide</e1>, and <e2>glipizide</e2> and increases the plasma concentration of these agents. ",False,negative
DIFLUCAN,sulfonylurea oral hypoglycemic agents,5,12,56,92,"When <e1>DIFLUCAN</e1> is used concomitantly with these or other <e2>sulfonylurea oral hypoglycemic agents</e2>, blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary. ",True,advise
DIFLUCAN,sulfonylurea,5,12,174,185,"When <e1>DIFLUCAN</e1> is used concomitantly with these or other sulfonylurea oral hypoglycemic agents, blood glucose concentrations should be carefully monitored and the dose of the <e2>sulfonylurea</e2> should be adjusted as necessary. ",False,negative
sulfonylurea oral hypoglycemic agents,sulfonylurea,56,92,174,185,"When DIFLUCAN is used concomitantly with these or other <e1>sulfonylurea oral hypoglycemic agents</e1>, blood glucose concentrations should be carefully monitored and the dose of the <e2>sulfonylurea</e2> should be adjusted as necessary. ",False,negative
Coumarin-type anticoagulants,DIFLUCAN,0,27,98,105,<e1>Coumarin-type anticoagulants</e1>: Prothrombin time may be increased in patients receiving concomitant <e2>DIFLUCAN</e2> and coumarin-type anticoagulants. ,False,negative
Coumarin-type anticoagulants,coumarin-type anticoagulants,0,27,111,138,<e1>Coumarin-type anticoagulants</e1>: Prothrombin time may be increased in patients receiving concomitant DIFLUCAN and <e2>coumarin-type anticoagulants</e2>. ,False,negative
DIFLUCAN,coumarin-type anticoagulants,98,105,111,138,Coumarin-type anticoagulants: Prothrombin time may be increased in patients receiving concomitant <e1>DIFLUCAN</e1> and <e2>coumarin-type anticoagulants</e2>. ,True,effect
azole antifungals,fluconazole,44,60,242,252,"In post-marketing experience, as with other <e1>azole antifungals</e1>, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving <e2>fluconazole</e2> concurrently with warfarin. ",False,negative
azole antifungals,warfarin,44,60,272,279,"In post-marketing experience, as with other <e1>azole antifungals</e1>, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with <e2>warfarin</e2>. ",False,negative
fluconazole,warfarin,242,252,272,279,"In post-marketing experience, as with other azole antifungals, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving <e1>fluconazole</e1> concurrently with <e2>warfarin</e2>. ",True,effect
DIFLUCAN,coumarin-type anticoagulants,61,68,74,101,Careful monitoring of prothrombin time in patients receiving <e1>DIFLUCAN</e1> and <e2>coumarin-type anticoagulants</e2> is recommended. ,True,advise
Phenytoin,DIFLUCAN,0,8,11,18,<e1>Phenytoin</e1>: <e2>DIFLUCAN</e2> increases the plasma concentrations of phenytoin. ,False,negative
Phenytoin,phenytoin,0,8,59,67,<e1>Phenytoin</e1>: DIFLUCAN increases the plasma concentrations of <e2>phenytoin</e2>. ,False,negative
DIFLUCAN,phenytoin,11,18,59,67,Phenytoin: <e1>DIFLUCAN</e1> increases the plasma concentrations of <e2>phenytoin</e2>. ,True,mechanism
phenytoin,DIFLUCAN,22,30,69,76,Careful monitoring of <e1>phenytoin</e1> concentrations in patients receiving <e2>DIFLUCAN</e2> and phenytoin is recommended. ,False,negative
phenytoin,phenytoin,22,30,82,90,Careful monitoring of <e1>phenytoin</e1> concentrations in patients receiving DIFLUCAN and <e2>phenytoin</e2> is recommended. ,False,negative
DIFLUCAN,phenytoin,69,76,82,90,Careful monitoring of phenytoin concentrations in patients receiving <e1>DIFLUCAN</e1> and <e2>phenytoin</e2> is recommended. ,True,advise
Cyclosporine,DIFLUCAN,0,11,14,21,<e1>Cyclosporine</e1>: <e2>DIFLUCAN</e2> may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment. ,False,negative
Cyclosporine,cyclosporine,0,11,50,61,<e1>Cyclosporine</e1>: DIFLUCAN may significantly increase <e2>cyclosporine</e2> levels in renal transplant patients with or without renal impairment. ,False,negative
DIFLUCAN,cyclosporine,14,21,50,61,Cyclosporine: <e1>DIFLUCAN</e1> may significantly increase <e2>cyclosporine</e2> levels in renal transplant patients with or without renal impairment. ,True,mechanism
cyclosporine,DIFLUCAN,22,33,108,115,Careful monitoring of <e1>cyclosporine</e1> concentrations and serum creatinine is recommended in patients receiving <e2>DIFLUCAN</e2> and cyclosporine. ,False,negative
cyclosporine,cyclosporine,22,33,121,132,Careful monitoring of <e1>cyclosporine</e1> concentrations and serum creatinine is recommended in patients receiving DIFLUCAN and <e2>cyclosporine</e2>. ,False,negative
DIFLUCAN,cyclosporine,108,115,121,132,Careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving <e1>DIFLUCAN</e1> and <e2>cyclosporine</e2>. ,True,advise
Rifampin,Rifampin,0,7,10,17,<e1>Rifampin</e1>: <e2>Rifampin</e2> enhances the metabolism of concurrently administered DIFLUCAN. ,False,negative
Rifampin,DIFLUCAN,0,7,72,79,<e1>Rifampin</e1>: Rifampin enhances the metabolism of concurrently administered <e2>DIFLUCAN</e2>. ,False,negative
Rifampin,DIFLUCAN,10,17,72,79,Rifampin: <e1>Rifampin</e1> enhances the metabolism of concurrently administered <e2>DIFLUCAN</e2>. ,True,mechanism
DIFLUCAN,rifampin,93,100,131,138,"Depending on clinical circumstances, consideration should be given to increasing the dose of <e1>DIFLUCAN</e1> when it is administered with <e2>rifampin</e2>. ",True,advise
Theophylline,DIFLUCAN,0,11,14,21,<e1>Theophylline</e1>: <e2>DIFLUCAN</e2> increases the serum concentrations of theophylline. ,False,negative
Theophylline,theophylline,0,11,61,72,<e1>Theophylline</e1>: DIFLUCAN increases the serum concentrations of <e2>theophylline</e2>. ,False,negative
DIFLUCAN,theophylline,14,21,61,72,Theophylline: <e1>DIFLUCAN</e1> increases the serum concentrations of <e2>theophylline</e2>. ,True,mechanism
theophylline,DIFLUCAN,28,39,78,85,Careful monitoring of serum <e1>theophylline</e1> concentrations in patients receiving <e2>DIFLUCAN</e2> and theophylline is recommended. ,False,negative
theophylline,theophylline,28,39,91,102,Careful monitoring of serum <e1>theophylline</e1> concentrations in patients receiving DIFLUCAN and <e2>theophylline</e2> is recommended. ,False,negative
DIFLUCAN,theophylline,78,85,91,102,Careful monitoring of serum theophylline concentrations in patients receiving <e1>DIFLUCAN</e1> and <e2>theophylline</e2> is recommended. ,True,advise
Terfenadine,azole antifungals,0,10,139,155,"<e1>Terfenadine</e1>: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving <e2>azole antifungals</e2> in conjunction with terfenadine, interaction studies have been performed. ",False,negative
Terfenadine,terfenadine,0,10,177,187,"<e1>Terfenadine</e1>: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving azole antifungals in conjunction with <e2>terfenadine</e2>, interaction studies have been performed. ",False,negative
azole antifungals,terfenadine,139,155,177,187,"Terfenadine: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving <e1>azole antifungals</e1> in conjunction with <e2>terfenadine</e2>, interaction studies have been performed. ",True,effect
fluconazole,DIFLUCAN,51,61,81,88,Another study at a 400-mg and 800-mg daily dose of <e1>fluconazole</e1> demonstrated that <e2>DIFLUCAN</e2> taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly. ,False,negative
fluconazole,terfenadine,51,61,175,185,Another study at a 400-mg and 800-mg daily dose of <e1>fluconazole</e1> demonstrated that DIFLUCAN taken in doses of 400 mg per day or greater significantly increases plasma levels of <e2>terfenadine</e2> when taken concomitantly. ,False,negative
DIFLUCAN,terfenadine,81,88,175,185,Another study at a 400-mg and 800-mg daily dose of fluconazole demonstrated that <e1>DIFLUCAN</e1> taken in doses of 400 mg per day or greater significantly increases plasma levels of <e2>terfenadine</e2> when taken concomitantly. ,True,mechanism
fluconazole,terfenadine,20,30,67,77,The combined use of <e1>fluconazole</e1> at doses of 400 mg or greater with <e2>terfenadine</e2> is contraindicated. ,True,advise
fluconazole,terfenadine,24,34,72,82,The coadministration of <e1>fluconazole</e1> at doses lower than 400 mg/day with <e2>terfenadine</e2> should be carefully monitored. ,True,advise
Cisapride,fluconazole,0,8,103,113,"<e1>Cisapride</e1>: There have been reports of cardiac events, including torsade de pointes in patients to whom <e2>fluconazole</e2> and cisapride were coadministered. ",False,negative
Cisapride,cisapride,0,8,119,127,"<e1>Cisapride</e1>: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and <e2>cisapride</e2> were coadministered. ",False,negative
fluconazole,cisapride,103,113,119,127,"Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom <e1>fluconazole</e1> and <e2>cisapride</e2> were coadministered. ",True,effect
fluconazole,cisapride,42,52,76,84,A controlled study found that concomitant <e1>fluconazole</e1> 200 mg once daily and <e2>cisapride</e2> 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.,True,mechanism
fluconazole,cisapride,42,52,143,151,A controlled study found that concomitant <e1>fluconazole</e1> 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in <e2>cisapride</e2> plasma levels and prolongation of QTc interval.,False,negative
cisapride,cisapride,76,84,143,151,A controlled study found that concomitant fluconazole 200 mg once daily and <e1>cisapride</e1> 20 mg four times a day yielded a significant increase in <e2>cisapride</e2> plasma levels and prolongation of QTc interval.,False,negative
fluconazole,cisapride,20,30,37,45,The combined use of <e1>fluconazole</e1> with <e2>cisapride</e2> is contraindicated. ,True,advise
Astemizole,fluconazole,0,9,23,33,<e1>Astemizole</e1>: The use of <e2>fluconazole</e2> in patients concurrently taking astemizole or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs. ,False,negative
Astemizole,astemizole,0,9,67,76,<e1>Astemizole</e1>: The use of fluconazole in patients concurrently taking <e2>astemizole</e2> or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs. ,False,negative
fluconazole,astemizole,23,33,67,76,Astemizole: The use of <e1>fluconazole</e1> in patients concurrently taking <e2>astemizole</e2> or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs. ,True,mechanism
Rifabutin,fluconazole,0,8,66,76,<e1>Rifabutin</e1>: There have been reports of uveitis in patients to whom <e2>fluconazole</e2> and rifabutin were coadministered. ,False,negative
Rifabutin,rifabutin,0,8,82,90,<e1>Rifabutin</e1>: There have been reports of uveitis in patients to whom fluconazole and <e2>rifabutin</e2> were coadministered. ,False,negative
fluconazole,rifabutin,66,76,82,90,Rifabutin: There have been reports of uveitis in patients to whom <e1>fluconazole</e1> and <e2>rifabutin</e2> were coadministered. ,True,effect
rifabutin,fluconazole,19,27,33,43,Patients receiving <e1>rifabutin</e1> and <e2>fluconazole</e2> concomitantly should be carefully monitored. ,True,advise
Tacrolimus,fluconazole,0,9,74,84,<e1>Tacrolimus</e1>: There have been reports of nephrotoxicity in patients to whom <e2>fluconazole</e2> and tacrolimus were coadministered. ,False,negative
Tacrolimus,tacrolimus,0,9,90,99,<e1>Tacrolimus</e1>: There have been reports of nephrotoxicity in patients to whom fluconazole and <e2>tacrolimus</e2> were coadministered. ,False,negative
fluconazole,tacrolimus,74,84,90,99,Tacrolimus: There have been reports of nephrotoxicity in patients to whom <e1>fluconazole</e1> and <e2>tacrolimus</e2> were coadministered. ,True,effect
tacrolimus,fluconazole,19,28,34,44,Patients receiving <e1>tacrolimus</e1> and <e2>fluconazole</e2> concomitantly should be carefully monitored. ,True,advise
Short-acting Benzodiazepines,midazolam,0,27,63,71,"<e1>Short-acting Benzodiazepines</e1>: Following oral administration of <e2>midazolam</e2>, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. ",False,negative
Short-acting Benzodiazepines,fluconazole,0,27,74,84,"<e1>Short-acting Benzodiazepines</e1>: Following oral administration of midazolam, <e2>fluconazole</e2> resulted in substantial increases in midazolam concentrations and psychomotor effects. ",False,negative
Short-acting Benzodiazepines,midazolam,0,27,123,131,"<e1>Short-acting Benzodiazepines</e1>: Following oral administration of midazolam, fluconazole resulted in substantial increases in <e2>midazolam</e2> concentrations and psychomotor effects. ",False,negative
midazolam,fluconazole,63,71,74,84,"Short-acting Benzodiazepines: Following oral administration of <e1>midazolam</e1>, <e2>fluconazole</e2> resulted in substantial increases in midazolam concentrations and psychomotor effects. ",True,mechanism
midazolam,midazolam,63,71,123,131,"Short-acting Benzodiazepines: Following oral administration of <e1>midazolam</e1>, fluconazole resulted in substantial increases in <e2>midazolam</e2> concentrations and psychomotor effects. ",False,negative
fluconazole,midazolam,74,84,123,131,"Short-acting Benzodiazepines: Following oral administration of midazolam, <e1>fluconazole</e1> resulted in substantial increases in <e2>midazolam</e2> concentrations and psychomotor effects. ",False,negative
midazolam,fluconazole,15,23,88,98,This effect on <e1>midazolam</e1> appears to be more pronounced following oral administration of <e2>fluconazole</e2> than with fluconazole administered intravenously. ,True,effect
midazolam,fluconazole,15,23,110,120,This effect on <e1>midazolam</e1> appears to be more pronounced following oral administration of fluconazole than with <e2>fluconazole</e2> administered intravenously. ,False,negative
fluconazole,fluconazole,88,98,110,120,This effect on midazolam appears to be more pronounced following oral administration of <e1>fluconazole</e1> than with <e2>fluconazole</e2> administered intravenously. ,False,negative
short-acting benzodiazepines,fluconazole,3,30,122,132,"If <e1>short-acting benzodiazepines</e1>, which are metabolized by the cytochrome P450 system, are concomitantly administered with <e2>fluconazole</e2>, consideration should be given to decreasing the benzodiazepine dosage, and the patients should be appropriately monitored. ",True,advise
short-acting benzodiazepines,benzodiazepine,3,30,183,196,"If <e1>short-acting benzodiazepines</e1>, which are metabolized by the cytochrome P450 system, are concomitantly administered with fluconazole, consideration should be given to decreasing the <e2>benzodiazepine</e2> dosage, and the patients should be appropriately monitored. ",False,negative
fluconazole,benzodiazepine,122,132,183,196,"If short-acting benzodiazepines, which are metabolized by the cytochrome P450 system, are concomitantly administered with <e1>fluconazole</e1>, consideration should be given to decreasing the <e2>benzodiazepine</e2> dosage, and the patients should be appropriately monitored. ",False,negative
Fluconazole,ethinyl estradiol,0,10,40,56,<e1>Fluconazole</e1> tablets coadministered with <e2>ethinyl estradiol</e2>- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; ,True,mechanism
Fluconazole,levonorgestrel,0,10,63,76,<e1>Fluconazole</e1> tablets coadministered with ethinyl estradiol- and <e2>levonorgestrel</e2>-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; ,True,mechanism
Fluconazole,contraceptives,0,10,94,107,<e1>Fluconazole</e1> tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral <e2>contraceptives</e2> produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; ,False,negative
Fluconazole,ethinyl estradiol,0,10,146,162,<e1>Fluconazole</e1> tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in <e2>ethinyl estradiol</e2> and levonorgestrel levels; ,False,negative
Fluconazole,levonorgestrel,0,10,168,181,<e1>Fluconazole</e1> tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and <e2>levonorgestrel</e2> levels; ,False,negative
ethinyl estradiol,levonorgestrel,40,56,63,76,Fluconazole tablets coadministered with <e1>ethinyl estradiol</e1>- and <e2>levonorgestrel</e2>-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; ,False,negative
ethinyl estradiol,contraceptives,40,56,94,107,Fluconazole tablets coadministered with <e1>ethinyl estradiol</e1>- and levonorgestrel-containing oral <e2>contraceptives</e2> produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; ,False,negative
ethinyl estradiol,ethinyl estradiol,40,56,146,162,Fluconazole tablets coadministered with <e1>ethinyl estradiol</e1>- and levonorgestrel-containing oral contraceptives produced an overall mean increase in <e2>ethinyl estradiol</e2> and levonorgestrel levels; ,False,negative
ethinyl estradiol,levonorgestrel,40,56,168,181,Fluconazole tablets coadministered with <e1>ethinyl estradiol</e1>- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and <e2>levonorgestrel</e2> levels; ,False,negative
levonorgestrel,contraceptives,63,76,94,107,Fluconazole tablets coadministered with ethinyl estradiol- and <e1>levonorgestrel</e1>-containing oral <e2>contraceptives</e2> produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; ,False,negative
levonorgestrel,ethinyl estradiol,63,76,146,162,Fluconazole tablets coadministered with ethinyl estradiol- and <e1>levonorgestrel</e1>-containing oral contraceptives produced an overall mean increase in <e2>ethinyl estradiol</e2> and levonorgestrel levels; ,False,negative
levonorgestrel,levonorgestrel,63,76,168,181,Fluconazole tablets coadministered with ethinyl estradiol- and <e1>levonorgestrel</e1>-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and <e2>levonorgestrel</e2> levels; ,False,negative
contraceptives,ethinyl estradiol,94,107,146,162,Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral <e1>contraceptives</e1> produced an overall mean increase in <e2>ethinyl estradiol</e2> and levonorgestrel levels; ,False,negative
contraceptives,levonorgestrel,94,107,168,181,Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral <e1>contraceptives</e1> produced an overall mean increase in ethinyl estradiol and <e2>levonorgestrel</e2> levels; ,False,negative
ethinyl estradiol,levonorgestrel,146,162,168,181,Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in <e1>ethinyl estradiol</e1> and <e2>levonorgestrel</e2> levels; ,False,negative
ethinyl estradiol,levonorgestrel,68,84,90,103,"however, in some patients there were decreases up to 47% and 33% of <e1>ethinyl estradiol</e1> and <e2>levonorgestrel</e2> levels. ",False,negative
ethinyl estradiol,levonorgestrel,76,92,98,111,The data presently available indicate that the decreases in some individual <e1>ethinyl estradiol</e1> and <e2>levonorgestrel</e2> AUC values with fluconazole treatment are likely the result of random variation. ,False,negative
ethinyl estradiol,fluconazole,76,92,129,139,The data presently available indicate that the decreases in some individual <e1>ethinyl estradiol</e1> and levonorgestrel AUC values with <e2>fluconazole</e2> treatment are likely the result of random variation. ,False,negative
levonorgestrel,fluconazole,98,111,129,139,The data presently available indicate that the decreases in some individual ethinyl estradiol and <e1>levonorgestrel</e1> AUC values with <e2>fluconazole</e2> treatment are likely the result of random variation. ,False,negative
fluconazole,ethinyl estradiol,29,39,71,87,"While there is evidence that <e1>fluconazole</e1> can inhibit the metabolism of <e2>ethinyl estradiol</e2> and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ",True,mechanism
fluconazole,levonorgestrel,29,39,93,106,"While there is evidence that <e1>fluconazole</e1> can inhibit the metabolism of ethinyl estradiol and <e2>levonorgestrel</e2>, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ",True,mechanism
fluconazole,fluconazole,29,39,135,145,"While there is evidence that <e1>fluconazole</e1> can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that <e2>fluconazole</e2> is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ",False,negative
fluconazole,ethinyl estradiol,29,39,167,183,"While there is evidence that <e1>fluconazole</e1> can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of <e2>ethinyl estradiol</e2> or levonorgestrel metabolism. ",False,negative
fluconazole,levonorgestrel,29,39,188,201,"While there is evidence that <e1>fluconazole</e1> can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or <e2>levonorgestrel</e2> metabolism. ",False,negative
ethinyl estradiol,levonorgestrel,71,87,93,106,"While there is evidence that fluconazole can inhibit the metabolism of <e1>ethinyl estradiol</e1> and <e2>levonorgestrel</e2>, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ",False,negative
ethinyl estradiol,fluconazole,71,87,135,145,"While there is evidence that fluconazole can inhibit the metabolism of <e1>ethinyl estradiol</e1> and levonorgestrel, there is no evidence that <e2>fluconazole</e2> is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ",False,negative
ethinyl estradiol,ethinyl estradiol,71,87,167,183,"While there is evidence that fluconazole can inhibit the metabolism of <e1>ethinyl estradiol</e1> and levonorgestrel, there is no evidence that fluconazole is a net inducer of <e2>ethinyl estradiol</e2> or levonorgestrel metabolism. ",False,negative
ethinyl estradiol,levonorgestrel,71,87,188,201,"While there is evidence that fluconazole can inhibit the metabolism of <e1>ethinyl estradiol</e1> and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or <e2>levonorgestrel</e2> metabolism. ",False,negative
levonorgestrel,fluconazole,93,106,135,145,"While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and <e1>levonorgestrel</e1>, there is no evidence that <e2>fluconazole</e2> is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ",False,negative
levonorgestrel,ethinyl estradiol,93,106,167,183,"While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and <e1>levonorgestrel</e1>, there is no evidence that fluconazole is a net inducer of <e2>ethinyl estradiol</e2> or levonorgestrel metabolism. ",False,negative
levonorgestrel,levonorgestrel,93,106,188,201,"While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and <e1>levonorgestrel</e1>, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or <e2>levonorgestrel</e2> metabolism. ",False,negative
fluconazole,ethinyl estradiol,135,145,167,183,"While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that <e1>fluconazole</e1> is a net inducer of <e2>ethinyl estradiol</e2> or levonorgestrel metabolism. ",False,negative
fluconazole,levonorgestrel,135,145,188,201,"While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that <e1>fluconazole</e1> is a net inducer of ethinyl estradiol or <e2>levonorgestrel</e2> metabolism. ",False,negative
ethinyl estradiol,levonorgestrel,167,183,188,201,"While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of <e1>ethinyl estradiol</e1> or <e2>levonorgestrel</e2> metabolism. ",False,negative
mazindol,monoamine oxidase inhibitor,16,23,45,71,"You cannot take <e1>mazindol</e1> if you have taken a <e2>monoamine oxidase inhibitor</e2> (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",True,advise
mazindol,MAOI,16,23,74,77,"You cannot take <e1>mazindol</e1> if you have taken a monoamine oxidase inhibitor (<e2>MAOI</e2>) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",True,advise
mazindol,isocarboxazid,16,23,88,100,"You cannot take <e1>mazindol</e1> if you have taken a monoamine oxidase inhibitor (MAOI) such as <e2>isocarboxazid</e2> (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",True,advise
mazindol,Marplan,16,23,103,109,"You cannot take <e1>mazindol</e1> if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (<e2>Marplan</e2>), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",True,advise
mazindol,tranylcypromine,16,23,113,127,"You cannot take <e1>mazindol</e1> if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), <e2>tranylcypromine</e2> (Parnate), or phenelzine (Nardil) in the last 14 days. ",True,advise
mazindol,Parnate,16,23,130,136,"You cannot take <e1>mazindol</e1> if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (<e2>Parnate</e2>), or phenelzine (Nardil) in the last 14 days. ",True,advise
mazindol,phenelzine,16,23,143,152,"You cannot take <e1>mazindol</e1> if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or <e2>phenelzine</e2> (Nardil) in the last 14 days. ",True,advise
mazindol,Nardil,16,23,155,160,"You cannot take <e1>mazindol</e1> if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (<e2>Nardil</e2>) in the last 14 days. ",True,advise
monoamine oxidase inhibitor,MAOI,45,71,74,77,"You cannot take mazindol if you have taken a <e1>monoamine oxidase inhibitor</e1> (<e2>MAOI</e2>) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",False,negative
monoamine oxidase inhibitor,isocarboxazid,45,71,88,100,"You cannot take mazindol if you have taken a <e1>monoamine oxidase inhibitor</e1> (MAOI) such as <e2>isocarboxazid</e2> (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",False,negative
monoamine oxidase inhibitor,Marplan,45,71,103,109,"You cannot take mazindol if you have taken a <e1>monoamine oxidase inhibitor</e1> (MAOI) such as isocarboxazid (<e2>Marplan</e2>), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",False,negative
monoamine oxidase inhibitor,tranylcypromine,45,71,113,127,"You cannot take mazindol if you have taken a <e1>monoamine oxidase inhibitor</e1> (MAOI) such as isocarboxazid (Marplan), <e2>tranylcypromine</e2> (Parnate), or phenelzine (Nardil) in the last 14 days. ",False,negative
monoamine oxidase inhibitor,Parnate,45,71,130,136,"You cannot take mazindol if you have taken a <e1>monoamine oxidase inhibitor</e1> (MAOI) such as isocarboxazid (Marplan), tranylcypromine (<e2>Parnate</e2>), or phenelzine (Nardil) in the last 14 days. ",False,negative
monoamine oxidase inhibitor,phenelzine,45,71,143,152,"You cannot take mazindol if you have taken a <e1>monoamine oxidase inhibitor</e1> (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or <e2>phenelzine</e2> (Nardil) in the last 14 days. ",False,negative
monoamine oxidase inhibitor,Nardil,45,71,155,160,"You cannot take mazindol if you have taken a <e1>monoamine oxidase inhibitor</e1> (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (<e2>Nardil</e2>) in the last 14 days. ",False,negative
MAOI,isocarboxazid,74,77,88,100,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (<e1>MAOI</e1>) such as <e2>isocarboxazid</e2> (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",False,negative
MAOI,Marplan,74,77,103,109,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (<e1>MAOI</e1>) such as isocarboxazid (<e2>Marplan</e2>), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",False,negative
MAOI,tranylcypromine,74,77,113,127,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (<e1>MAOI</e1>) such as isocarboxazid (Marplan), <e2>tranylcypromine</e2> (Parnate), or phenelzine (Nardil) in the last 14 days. ",False,negative
MAOI,Parnate,74,77,130,136,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (<e1>MAOI</e1>) such as isocarboxazid (Marplan), tranylcypromine (<e2>Parnate</e2>), or phenelzine (Nardil) in the last 14 days. ",False,negative
MAOI,phenelzine,74,77,143,152,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (<e1>MAOI</e1>) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or <e2>phenelzine</e2> (Nardil) in the last 14 days. ",False,negative
MAOI,Nardil,74,77,155,160,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (<e1>MAOI</e1>) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (<e2>Nardil</e2>) in the last 14 days. ",False,negative
isocarboxazid,Marplan,88,100,103,109,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as <e1>isocarboxazid</e1> (<e2>Marplan</e2>), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",False,negative
isocarboxazid,tranylcypromine,88,100,113,127,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as <e1>isocarboxazid</e1> (Marplan), <e2>tranylcypromine</e2> (Parnate), or phenelzine (Nardil) in the last 14 days. ",False,negative
isocarboxazid,Parnate,88,100,130,136,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as <e1>isocarboxazid</e1> (Marplan), tranylcypromine (<e2>Parnate</e2>), or phenelzine (Nardil) in the last 14 days. ",False,negative
isocarboxazid,phenelzine,88,100,143,152,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as <e1>isocarboxazid</e1> (Marplan), tranylcypromine (Parnate), or <e2>phenelzine</e2> (Nardil) in the last 14 days. ",False,negative
isocarboxazid,Nardil,88,100,155,160,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as <e1>isocarboxazid</e1> (Marplan), tranylcypromine (Parnate), or phenelzine (<e2>Nardil</e2>) in the last 14 days. ",False,negative
Marplan,tranylcypromine,103,109,113,127,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (<e1>Marplan</e1>), <e2>tranylcypromine</e2> (Parnate), or phenelzine (Nardil) in the last 14 days. ",False,negative
Marplan,Parnate,103,109,130,136,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (<e1>Marplan</e1>), tranylcypromine (<e2>Parnate</e2>), or phenelzine (Nardil) in the last 14 days. ",False,negative
Marplan,phenelzine,103,109,143,152,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (<e1>Marplan</e1>), tranylcypromine (Parnate), or <e2>phenelzine</e2> (Nardil) in the last 14 days. ",False,negative
Marplan,Nardil,103,109,155,160,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (<e1>Marplan</e1>), tranylcypromine (Parnate), or phenelzine (<e2>Nardil</e2>) in the last 14 days. ",False,negative
tranylcypromine,Parnate,113,127,130,136,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), <e1>tranylcypromine</e1> (<e2>Parnate</e2>), or phenelzine (Nardil) in the last 14 days. ",False,negative
tranylcypromine,phenelzine,113,127,143,152,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), <e1>tranylcypromine</e1> (Parnate), or <e2>phenelzine</e2> (Nardil) in the last 14 days. ",False,negative
tranylcypromine,Nardil,113,127,155,160,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), <e1>tranylcypromine</e1> (Parnate), or phenelzine (<e2>Nardil</e2>) in the last 14 days. ",False,negative
Parnate,phenelzine,130,136,143,152,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (<e1>Parnate</e1>), or <e2>phenelzine</e2> (Nardil) in the last 14 days. ",False,negative
Parnate,Nardil,130,136,155,160,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (<e1>Parnate</e1>), or phenelzine (<e2>Nardil</e2>) in the last 14 days. ",False,negative
phenelzine,Nardil,143,152,155,160,"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or <e1>phenelzine</e1> (<e2>Nardil</e2>) in the last 14 days. ",False,negative
insulin,mazindol,11,17,92,99,Changes in <e1>insulin</e1> and other diabetes drug therapies may be necessary during treatment with <e2>mazindol</e2>.,True,advise
Mazindol,guanethidine,0,7,35,46,<e1>Mazindol</e1> may reduce the effects of <e2>guanethidine</e2> (Ismelin). ,True,effect
Mazindol,Ismelin,0,7,49,55,<e1>Mazindol</e1> may reduce the effects of guanethidine (<e2>Ismelin</e2>). ,True,effect
guanethidine,Ismelin,35,46,49,55,Mazindol may reduce the effects of <e1>guanethidine</e1> (<e2>Ismelin</e2>). ,False,negative
tricyclic antidepressant,amitriptyline,68,91,101,113,"Before taking this medication, tell your doctor if you are taking a <e1>tricyclic antidepressant</e1> such as <e2>amitriptyline</e2> (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
tricyclic antidepressant,Elavil,68,91,116,121,"Before taking this medication, tell your doctor if you are taking a <e1>tricyclic antidepressant</e1> such as amitriptyline (<e2>Elavil</e2>), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
tricyclic antidepressant,amoxapine,68,91,125,133,"Before taking this medication, tell your doctor if you are taking a <e1>tricyclic antidepressant</e1> such as amitriptyline (Elavil), <e2>amoxapine</e2> (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
tricyclic antidepressant,Asendin,68,91,136,142,"Before taking this medication, tell your doctor if you are taking a <e1>tricyclic antidepressant</e1> such as amitriptyline (Elavil), amoxapine (<e2>Asendin</e2>), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
tricyclic antidepressant,doxepin,68,91,146,152,"Before taking this medication, tell your doctor if you are taking a <e1>tricyclic antidepressant</e1> such as amitriptyline (Elavil), amoxapine (Asendin), <e2>doxepin</e2> (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
tricyclic antidepressant,Sinequan,68,91,155,162,"Before taking this medication, tell your doctor if you are taking a <e1>tricyclic antidepressant</e1> such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (<e2>Sinequan</e2>), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
tricyclic antidepressant,nortriptyline,68,91,166,178,"Before taking this medication, tell your doctor if you are taking a <e1>tricyclic antidepressant</e1> such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), <e2>nortriptyline</e2> (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
tricyclic antidepressant,Pamelor,68,91,181,187,"Before taking this medication, tell your doctor if you are taking a <e1>tricyclic antidepressant</e1> such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (<e2>Pamelor</e2>), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
tricyclic antidepressant,imipramine,68,91,191,200,"Before taking this medication, tell your doctor if you are taking a <e1>tricyclic antidepressant</e1> such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), <e2>imipramine</e2> (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
tricyclic antidepressant,Tofranil,68,91,203,210,"Before taking this medication, tell your doctor if you are taking a <e1>tricyclic antidepressant</e1> such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (<e2>Tofranil</e2>), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
tricyclic antidepressant,clomipramine,68,91,214,225,"Before taking this medication, tell your doctor if you are taking a <e1>tricyclic antidepressant</e1> such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), <e2>clomipramine</e2> (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
tricyclic antidepressant,Anafranil,68,91,228,236,"Before taking this medication, tell your doctor if you are taking a <e1>tricyclic antidepressant</e1> such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (<e2>Anafranil</e2>), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
tricyclic antidepressant,protriptyline,68,91,240,252,"Before taking this medication, tell your doctor if you are taking a <e1>tricyclic antidepressant</e1> such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), <e2>protriptyline</e2> (Vivactil), or desipramine (Norpramin). ",False,negative
tricyclic antidepressant,Vivactil,68,91,255,262,"Before taking this medication, tell your doctor if you are taking a <e1>tricyclic antidepressant</e1> such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (<e2>Vivactil</e2>), or desipramine (Norpramin). ",False,negative
tricyclic antidepressant,desipramine,68,91,269,279,"Before taking this medication, tell your doctor if you are taking a <e1>tricyclic antidepressant</e1> such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or <e2>desipramine</e2> (Norpramin). ",False,negative
tricyclic antidepressant,Norpramin,68,91,282,290,"Before taking this medication, tell your doctor if you are taking a <e1>tricyclic antidepressant</e1> such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (<e2>Norpramin</e2>). ",False,negative
amitriptyline,Elavil,101,113,116,121,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as <e1>amitriptyline</e1> (<e2>Elavil</e2>), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
amitriptyline,amoxapine,101,113,125,133,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as <e1>amitriptyline</e1> (Elavil), <e2>amoxapine</e2> (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
amitriptyline,Asendin,101,113,136,142,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as <e1>amitriptyline</e1> (Elavil), amoxapine (<e2>Asendin</e2>), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
amitriptyline,doxepin,101,113,146,152,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as <e1>amitriptyline</e1> (Elavil), amoxapine (Asendin), <e2>doxepin</e2> (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
amitriptyline,Sinequan,101,113,155,162,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as <e1>amitriptyline</e1> (Elavil), amoxapine (Asendin), doxepin (<e2>Sinequan</e2>), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
amitriptyline,nortriptyline,101,113,166,178,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as <e1>amitriptyline</e1> (Elavil), amoxapine (Asendin), doxepin (Sinequan), <e2>nortriptyline</e2> (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
amitriptyline,Pamelor,101,113,181,187,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as <e1>amitriptyline</e1> (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (<e2>Pamelor</e2>), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
amitriptyline,imipramine,101,113,191,200,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as <e1>amitriptyline</e1> (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), <e2>imipramine</e2> (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
amitriptyline,Tofranil,101,113,203,210,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as <e1>amitriptyline</e1> (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (<e2>Tofranil</e2>), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
amitriptyline,clomipramine,101,113,214,225,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as <e1>amitriptyline</e1> (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), <e2>clomipramine</e2> (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
amitriptyline,Anafranil,101,113,228,236,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as <e1>amitriptyline</e1> (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (<e2>Anafranil</e2>), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
amitriptyline,protriptyline,101,113,240,252,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as <e1>amitriptyline</e1> (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), <e2>protriptyline</e2> (Vivactil), or desipramine (Norpramin). ",False,negative
amitriptyline,Vivactil,101,113,255,262,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as <e1>amitriptyline</e1> (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (<e2>Vivactil</e2>), or desipramine (Norpramin). ",False,negative
amitriptyline,desipramine,101,113,269,279,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as <e1>amitriptyline</e1> (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or <e2>desipramine</e2> (Norpramin). ",False,negative
amitriptyline,Norpramin,101,113,282,290,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as <e1>amitriptyline</e1> (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (<e2>Norpramin</e2>). ",False,negative
Elavil,amoxapine,116,121,125,133,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (<e1>Elavil</e1>), <e2>amoxapine</e2> (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
Elavil,Asendin,116,121,136,142,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (<e1>Elavil</e1>), amoxapine (<e2>Asendin</e2>), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
Elavil,doxepin,116,121,146,152,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (<e1>Elavil</e1>), amoxapine (Asendin), <e2>doxepin</e2> (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
Elavil,Sinequan,116,121,155,162,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (<e1>Elavil</e1>), amoxapine (Asendin), doxepin (<e2>Sinequan</e2>), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
Elavil,nortriptyline,116,121,166,178,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (<e1>Elavil</e1>), amoxapine (Asendin), doxepin (Sinequan), <e2>nortriptyline</e2> (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
Elavil,Pamelor,116,121,181,187,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (<e1>Elavil</e1>), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (<e2>Pamelor</e2>), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
Elavil,imipramine,116,121,191,200,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (<e1>Elavil</e1>), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), <e2>imipramine</e2> (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
Elavil,Tofranil,116,121,203,210,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (<e1>Elavil</e1>), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (<e2>Tofranil</e2>), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
Elavil,clomipramine,116,121,214,225,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (<e1>Elavil</e1>), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), <e2>clomipramine</e2> (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
Elavil,Anafranil,116,121,228,236,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (<e1>Elavil</e1>), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (<e2>Anafranil</e2>), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
Elavil,protriptyline,116,121,240,252,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (<e1>Elavil</e1>), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), <e2>protriptyline</e2> (Vivactil), or desipramine (Norpramin). ",False,negative
Elavil,Vivactil,116,121,255,262,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (<e1>Elavil</e1>), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (<e2>Vivactil</e2>), or desipramine (Norpramin). ",False,negative
Elavil,desipramine,116,121,269,279,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (<e1>Elavil</e1>), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or <e2>desipramine</e2> (Norpramin). ",False,negative
Elavil,Norpramin,116,121,282,290,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (<e1>Elavil</e1>), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (<e2>Norpramin</e2>). ",False,negative
amoxapine,Asendin,125,133,136,142,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), <e1>amoxapine</e1> (<e2>Asendin</e2>), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
amoxapine,doxepin,125,133,146,152,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), <e1>amoxapine</e1> (Asendin), <e2>doxepin</e2> (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
amoxapine,Sinequan,125,133,155,162,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), <e1>amoxapine</e1> (Asendin), doxepin (<e2>Sinequan</e2>), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
amoxapine,nortriptyline,125,133,166,178,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), <e1>amoxapine</e1> (Asendin), doxepin (Sinequan), <e2>nortriptyline</e2> (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
amoxapine,Pamelor,125,133,181,187,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), <e1>amoxapine</e1> (Asendin), doxepin (Sinequan), nortriptyline (<e2>Pamelor</e2>), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
amoxapine,imipramine,125,133,191,200,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), <e1>amoxapine</e1> (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), <e2>imipramine</e2> (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
amoxapine,Tofranil,125,133,203,210,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), <e1>amoxapine</e1> (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (<e2>Tofranil</e2>), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
amoxapine,clomipramine,125,133,214,225,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), <e1>amoxapine</e1> (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), <e2>clomipramine</e2> (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
amoxapine,Anafranil,125,133,228,236,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), <e1>amoxapine</e1> (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (<e2>Anafranil</e2>), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
amoxapine,protriptyline,125,133,240,252,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), <e1>amoxapine</e1> (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), <e2>protriptyline</e2> (Vivactil), or desipramine (Norpramin). ",False,negative
amoxapine,Vivactil,125,133,255,262,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), <e1>amoxapine</e1> (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (<e2>Vivactil</e2>), or desipramine (Norpramin). ",False,negative
amoxapine,desipramine,125,133,269,279,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), <e1>amoxapine</e1> (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or <e2>desipramine</e2> (Norpramin). ",False,negative
amoxapine,Norpramin,125,133,282,290,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), <e1>amoxapine</e1> (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (<e2>Norpramin</e2>). ",False,negative
Asendin,doxepin,136,142,146,152,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (<e1>Asendin</e1>), <e2>doxepin</e2> (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
Asendin,Sinequan,136,142,155,162,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (<e1>Asendin</e1>), doxepin (<e2>Sinequan</e2>), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
Asendin,nortriptyline,136,142,166,178,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (<e1>Asendin</e1>), doxepin (Sinequan), <e2>nortriptyline</e2> (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
Asendin,Pamelor,136,142,181,187,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (<e1>Asendin</e1>), doxepin (Sinequan), nortriptyline (<e2>Pamelor</e2>), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
Asendin,imipramine,136,142,191,200,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (<e1>Asendin</e1>), doxepin (Sinequan), nortriptyline (Pamelor), <e2>imipramine</e2> (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
Asendin,Tofranil,136,142,203,210,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (<e1>Asendin</e1>), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (<e2>Tofranil</e2>), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
Asendin,clomipramine,136,142,214,225,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (<e1>Asendin</e1>), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), <e2>clomipramine</e2> (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
Asendin,Anafranil,136,142,228,236,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (<e1>Asendin</e1>), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (<e2>Anafranil</e2>), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
Asendin,protriptyline,136,142,240,252,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (<e1>Asendin</e1>), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), <e2>protriptyline</e2> (Vivactil), or desipramine (Norpramin). ",False,negative
Asendin,Vivactil,136,142,255,262,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (<e1>Asendin</e1>), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (<e2>Vivactil</e2>), or desipramine (Norpramin). ",False,negative
Asendin,desipramine,136,142,269,279,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (<e1>Asendin</e1>), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or <e2>desipramine</e2> (Norpramin). ",False,negative
Asendin,Norpramin,136,142,282,290,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (<e1>Asendin</e1>), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (<e2>Norpramin</e2>). ",False,negative
doxepin,Sinequan,146,152,155,162,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), <e1>doxepin</e1> (<e2>Sinequan</e2>), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
doxepin,nortriptyline,146,152,166,178,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), <e1>doxepin</e1> (Sinequan), <e2>nortriptyline</e2> (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
doxepin,Pamelor,146,152,181,187,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), <e1>doxepin</e1> (Sinequan), nortriptyline (<e2>Pamelor</e2>), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
doxepin,imipramine,146,152,191,200,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), <e1>doxepin</e1> (Sinequan), nortriptyline (Pamelor), <e2>imipramine</e2> (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
doxepin,Tofranil,146,152,203,210,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), <e1>doxepin</e1> (Sinequan), nortriptyline (Pamelor), imipramine (<e2>Tofranil</e2>), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
doxepin,clomipramine,146,152,214,225,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), <e1>doxepin</e1> (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), <e2>clomipramine</e2> (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
doxepin,Anafranil,146,152,228,236,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), <e1>doxepin</e1> (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (<e2>Anafranil</e2>), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
doxepin,protriptyline,146,152,240,252,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), <e1>doxepin</e1> (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), <e2>protriptyline</e2> (Vivactil), or desipramine (Norpramin). ",False,negative
doxepin,Vivactil,146,152,255,262,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), <e1>doxepin</e1> (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (<e2>Vivactil</e2>), or desipramine (Norpramin). ",False,negative
doxepin,desipramine,146,152,269,279,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), <e1>doxepin</e1> (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or <e2>desipramine</e2> (Norpramin). ",False,negative
doxepin,Norpramin,146,152,282,290,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), <e1>doxepin</e1> (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (<e2>Norpramin</e2>). ",False,negative
Sinequan,nortriptyline,155,162,166,178,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (<e1>Sinequan</e1>), <e2>nortriptyline</e2> (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
Sinequan,Pamelor,155,162,181,187,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (<e1>Sinequan</e1>), nortriptyline (<e2>Pamelor</e2>), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
Sinequan,imipramine,155,162,191,200,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (<e1>Sinequan</e1>), nortriptyline (Pamelor), <e2>imipramine</e2> (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
Sinequan,Tofranil,155,162,203,210,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (<e1>Sinequan</e1>), nortriptyline (Pamelor), imipramine (<e2>Tofranil</e2>), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
Sinequan,clomipramine,155,162,214,225,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (<e1>Sinequan</e1>), nortriptyline (Pamelor), imipramine (Tofranil), <e2>clomipramine</e2> (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
Sinequan,Anafranil,155,162,228,236,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (<e1>Sinequan</e1>), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (<e2>Anafranil</e2>), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
Sinequan,protriptyline,155,162,240,252,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (<e1>Sinequan</e1>), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), <e2>protriptyline</e2> (Vivactil), or desipramine (Norpramin). ",False,negative
Sinequan,Vivactil,155,162,255,262,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (<e1>Sinequan</e1>), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (<e2>Vivactil</e2>), or desipramine (Norpramin). ",False,negative
Sinequan,desipramine,155,162,269,279,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (<e1>Sinequan</e1>), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or <e2>desipramine</e2> (Norpramin). ",False,negative
Sinequan,Norpramin,155,162,282,290,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (<e1>Sinequan</e1>), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (<e2>Norpramin</e2>). ",False,negative
nortriptyline,Pamelor,166,178,181,187,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), <e1>nortriptyline</e1> (<e2>Pamelor</e2>), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
nortriptyline,imipramine,166,178,191,200,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), <e1>nortriptyline</e1> (Pamelor), <e2>imipramine</e2> (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
nortriptyline,Tofranil,166,178,203,210,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), <e1>nortriptyline</e1> (Pamelor), imipramine (<e2>Tofranil</e2>), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
nortriptyline,clomipramine,166,178,214,225,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), <e1>nortriptyline</e1> (Pamelor), imipramine (Tofranil), <e2>clomipramine</e2> (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
nortriptyline,Anafranil,166,178,228,236,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), <e1>nortriptyline</e1> (Pamelor), imipramine (Tofranil), clomipramine (<e2>Anafranil</e2>), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
nortriptyline,protriptyline,166,178,240,252,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), <e1>nortriptyline</e1> (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), <e2>protriptyline</e2> (Vivactil), or desipramine (Norpramin). ",False,negative
nortriptyline,Vivactil,166,178,255,262,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), <e1>nortriptyline</e1> (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (<e2>Vivactil</e2>), or desipramine (Norpramin). ",False,negative
nortriptyline,desipramine,166,178,269,279,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), <e1>nortriptyline</e1> (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or <e2>desipramine</e2> (Norpramin). ",False,negative
nortriptyline,Norpramin,166,178,282,290,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), <e1>nortriptyline</e1> (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (<e2>Norpramin</e2>). ",False,negative
Pamelor,imipramine,181,187,191,200,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (<e1>Pamelor</e1>), <e2>imipramine</e2> (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
Pamelor,Tofranil,181,187,203,210,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (<e1>Pamelor</e1>), imipramine (<e2>Tofranil</e2>), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
Pamelor,clomipramine,181,187,214,225,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (<e1>Pamelor</e1>), imipramine (Tofranil), <e2>clomipramine</e2> (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
Pamelor,Anafranil,181,187,228,236,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (<e1>Pamelor</e1>), imipramine (Tofranil), clomipramine (<e2>Anafranil</e2>), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
Pamelor,protriptyline,181,187,240,252,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (<e1>Pamelor</e1>), imipramine (Tofranil), clomipramine (Anafranil), <e2>protriptyline</e2> (Vivactil), or desipramine (Norpramin). ",False,negative
Pamelor,Vivactil,181,187,255,262,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (<e1>Pamelor</e1>), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (<e2>Vivactil</e2>), or desipramine (Norpramin). ",False,negative
Pamelor,desipramine,181,187,269,279,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (<e1>Pamelor</e1>), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or <e2>desipramine</e2> (Norpramin). ",False,negative
Pamelor,Norpramin,181,187,282,290,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (<e1>Pamelor</e1>), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (<e2>Norpramin</e2>). ",False,negative
imipramine,Tofranil,191,200,203,210,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), <e1>imipramine</e1> (<e2>Tofranil</e2>), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
imipramine,clomipramine,191,200,214,225,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), <e1>imipramine</e1> (Tofranil), <e2>clomipramine</e2> (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
imipramine,Anafranil,191,200,228,236,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), <e1>imipramine</e1> (Tofranil), clomipramine (<e2>Anafranil</e2>), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
imipramine,protriptyline,191,200,240,252,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), <e1>imipramine</e1> (Tofranil), clomipramine (Anafranil), <e2>protriptyline</e2> (Vivactil), or desipramine (Norpramin). ",False,negative
imipramine,Vivactil,191,200,255,262,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), <e1>imipramine</e1> (Tofranil), clomipramine (Anafranil), protriptyline (<e2>Vivactil</e2>), or desipramine (Norpramin). ",False,negative
imipramine,desipramine,191,200,269,279,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), <e1>imipramine</e1> (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or <e2>desipramine</e2> (Norpramin). ",False,negative
imipramine,Norpramin,191,200,282,290,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), <e1>imipramine</e1> (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (<e2>Norpramin</e2>). ",False,negative
Tofranil,clomipramine,203,210,214,225,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (<e1>Tofranil</e1>), <e2>clomipramine</e2> (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
Tofranil,Anafranil,203,210,228,236,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (<e1>Tofranil</e1>), clomipramine (<e2>Anafranil</e2>), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
Tofranil,protriptyline,203,210,240,252,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (<e1>Tofranil</e1>), clomipramine (Anafranil), <e2>protriptyline</e2> (Vivactil), or desipramine (Norpramin). ",False,negative
Tofranil,Vivactil,203,210,255,262,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (<e1>Tofranil</e1>), clomipramine (Anafranil), protriptyline (<e2>Vivactil</e2>), or desipramine (Norpramin). ",False,negative
Tofranil,desipramine,203,210,269,279,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (<e1>Tofranil</e1>), clomipramine (Anafranil), protriptyline (Vivactil), or <e2>desipramine</e2> (Norpramin). ",False,negative
Tofranil,Norpramin,203,210,282,290,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (<e1>Tofranil</e1>), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (<e2>Norpramin</e2>). ",False,negative
clomipramine,Anafranil,214,225,228,236,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), <e1>clomipramine</e1> (<e2>Anafranil</e2>), protriptyline (Vivactil), or desipramine (Norpramin). ",False,negative
clomipramine,protriptyline,214,225,240,252,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), <e1>clomipramine</e1> (Anafranil), <e2>protriptyline</e2> (Vivactil), or desipramine (Norpramin). ",False,negative
clomipramine,Vivactil,214,225,255,262,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), <e1>clomipramine</e1> (Anafranil), protriptyline (<e2>Vivactil</e2>), or desipramine (Norpramin). ",False,negative
clomipramine,desipramine,214,225,269,279,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), <e1>clomipramine</e1> (Anafranil), protriptyline (Vivactil), or <e2>desipramine</e2> (Norpramin). ",False,negative
clomipramine,Norpramin,214,225,282,290,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), <e1>clomipramine</e1> (Anafranil), protriptyline (Vivactil), or desipramine (<e2>Norpramin</e2>). ",False,negative
Anafranil,protriptyline,228,236,240,252,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (<e1>Anafranil</e1>), <e2>protriptyline</e2> (Vivactil), or desipramine (Norpramin). ",False,negative
Anafranil,Vivactil,228,236,255,262,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (<e1>Anafranil</e1>), protriptyline (<e2>Vivactil</e2>), or desipramine (Norpramin). ",False,negative
Anafranil,desipramine,228,236,269,279,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (<e1>Anafranil</e1>), protriptyline (Vivactil), or <e2>desipramine</e2> (Norpramin). ",False,negative
Anafranil,Norpramin,228,236,282,290,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (<e1>Anafranil</e1>), protriptyline (Vivactil), or desipramine (<e2>Norpramin</e2>). ",False,negative
protriptyline,Vivactil,240,252,255,262,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), <e1>protriptyline</e1> (<e2>Vivactil</e2>), or desipramine (Norpramin). ",False,negative
protriptyline,desipramine,240,252,269,279,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), <e1>protriptyline</e1> (Vivactil), or <e2>desipramine</e2> (Norpramin). ",False,negative
protriptyline,Norpramin,240,252,282,290,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), <e1>protriptyline</e1> (Vivactil), or desipramine (<e2>Norpramin</e2>). ",False,negative
Vivactil,desipramine,255,262,269,279,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (<e1>Vivactil</e1>), or <e2>desipramine</e2> (Norpramin). ",False,negative
Vivactil,Norpramin,255,262,282,290,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (<e1>Vivactil</e1>), or desipramine (<e2>Norpramin</e2>). ",False,negative
desipramine,Norpramin,269,279,282,290,"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or <e1>desipramine</e1> (<e2>Norpramin</e2>). ",False,negative
cimetidine,mebendazole,35,44,55,65,Preliminary evidence suggests that <e1>cimetidine</e1> inhibits <e2>mebendazole</e2> metabolism and may result in an increase in plasma concentrations of mebendazole.,True,mechanism
cimetidine,mebendazole,35,44,136,146,Preliminary evidence suggests that <e1>cimetidine</e1> inhibits mebendazole metabolism and may result in an increase in plasma concentrations of <e2>mebendazole</e2>.,False,negative
mebendazole,mebendazole,55,65,136,146,Preliminary evidence suggests that cimetidine inhibits <e1>mebendazole</e1> metabolism and may result in an increase in plasma concentrations of <e2>mebendazole</e2>.,False,negative
antibiotics,sulfonamides,19,29,35,46,Patients receiving <e1>antibiotics</e1> and <e2>sulfonamides</e2> generally should not be treated with ganglion blockers.  ,False,negative
antibiotics,ganglion blockers,19,29,85,101,Patients receiving <e1>antibiotics</e1> and sulfonamides generally should not be treated with <e2>ganglion blockers</e2>.  ,True,advise
sulfonamides,ganglion blockers,35,46,85,101,Patients receiving antibiotics and <e1>sulfonamides</e1> generally should not be treated with <e2>ganglion blockers</e2>.  ,True,advise
Mecamylamine,antihypertensive drugs,14,25,67,88,"The action of <e1>Mecamylamine</e1> may be potentiated by anesthesia, other <e2>antihypertensive drugs</e2> and alcohol.",True,effect
Mecamylamine,alcohol,14,25,94,100,"The action of <e1>Mecamylamine</e1> may be potentiated by anesthesia, other antihypertensive drugs and <e2>alcohol</e2>.",True,effect
antihypertensive drugs,alcohol,67,88,94,100,"The action of Mecamylamine may be potentiated by anesthesia, other <e1>antihypertensive drugs</e1> and <e2>alcohol</e2>.",False,negative
Aminoglutethimide,depo-subQ provera 104,0,16,50,70,<e1>Aminoglutethimide</e1> administered concomitantly with <e2>depo-subQ provera 104</e2> may significantly decrease the serum concentrations of MPA. ,True,mechanism
Aminoglutethimide,MPA,0,16,127,129,<e1>Aminoglutethimide</e1> administered concomitantly with depo-subQ provera 104 may significantly decrease the serum concentrations of <e2>MPA</e2>. ,False,negative
depo-subQ provera 104,MPA,50,70,127,129,Aminoglutethimide administered concomitantly with <e1>depo-subQ provera 104</e1> may significantly decrease the serum concentrations of <e2>MPA</e2>. ,False,negative
zidovudine,rifabutin,104,113,118,126,Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of <e1>zidovudine</e1> or <e2>rifabutin</e2> to warrant dosage adjustment when megestrol acetate is administered with these drugs. ,False,negative
zidovudine,megestrol acetate,104,113,162,178,Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of <e1>zidovudine</e1> or rifabutin to warrant dosage adjustment when <e2>megestrol acetate</e2> is administered with these drugs. ,False,negative
rifabutin,megestrol acetate,118,126,162,178,Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or <e1>rifabutin</e1> to warrant dosage adjustment when <e2>megestrol acetate</e2> is administered with these drugs. ,False,negative
megestrol acetate,indinavir,62,78,84,92,A pharmacokinetic study demonstrated that coadministration of <e1>megestrol acetate</e1> and <e2>indinavir</e2> results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of indinavir. ,True,mechanism
megestrol acetate,indinavir,62,78,198,206,A pharmacokinetic study demonstrated that coadministration of <e1>megestrol acetate</e1> and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of <e2>indinavir</e2>. ,False,negative
indinavir,indinavir,84,92,198,206,A pharmacokinetic study demonstrated that coadministration of megestrol acetate and <e1>indinavir</e1> results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of <e2>indinavir</e2>. ,False,negative
indinavir,megestrol acetate,35,43,92,108,Administration of a higher dose of <e1>indinavir</e1> should be considered when coadministering with <e2>megestrol acetate</e2>. ,True,advise
indinavir,zidovudine,15,23,26,35,"The effects of <e1>indinavir</e1>, <e2>zidovudine</e2> or rifabutin on the pharmacokinetics of megestrol acetate were not studied.",False,negative
indinavir,rifabutin,15,23,40,48,"The effects of <e1>indinavir</e1>, zidovudine or <e2>rifabutin</e2> on the pharmacokinetics of megestrol acetate were not studied.",False,negative
indinavir,megestrol acetate,15,23,77,93,"The effects of <e1>indinavir</e1>, zidovudine or rifabutin on the pharmacokinetics of <e2>megestrol acetate</e2> were not studied.",False,negative
zidovudine,rifabutin,26,35,40,48,"The effects of indinavir, <e1>zidovudine</e1> or <e2>rifabutin</e2> on the pharmacokinetics of megestrol acetate were not studied.",False,negative
zidovudine,megestrol acetate,26,35,77,93,"The effects of indinavir, <e1>zidovudine</e1> or rifabutin on the pharmacokinetics of <e2>megestrol acetate</e2> were not studied.",False,negative
rifabutin,megestrol acetate,40,48,77,93,"The effects of indinavir, zidovudine or <e1>rifabutin</e1> on the pharmacokinetics of <e2>megestrol acetate</e2> were not studied.",False,negative
Melatonin,aspirin,0,8,49,55,"<e1>Melatonin</e1> may interact with the following drugs: <e2>aspirin</e2> and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",True,int
Melatonin,NSAIDs,0,8,67,72,"<e1>Melatonin</e1> may interact with the following drugs: aspirin and other <e2>NSAIDs</e2> (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",True,int
Melatonin,melatonin,0,8,85,93,"<e1>Melatonin</e1> may interact with the following drugs: aspirin and other NSAIDs (may lower <e2>melatonin</e2> levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
Melatonin,fluvoxamine,0,8,104,114,"<e1>Melatonin</e1> may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), <e2>fluvoxamine</e2> (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",True,int
Melatonin,melatonin,0,8,141,149,"<e1>Melatonin</e1> may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral <e2>melatonin</e2> is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
Melatonin,beta blockers,0,8,188,200,"<e1>Melatonin</e1> may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), <e2>beta blockers</e2> (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",True,int
Melatonin,melatonin,0,8,216,224,"<e1>Melatonin</e1> may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease <e2>melatonin</e2> levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
Melatonin,fluoxetine,0,8,235,244,"<e1>Melatonin</e1> may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), <e2>fluoxetine</e2> (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",True,int
Melatonin,progestin,0,8,299,307,"<e1>Melatonin</e1> may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), <e2>progestin</e2> (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",True,int
Melatonin,melatonin,0,8,330,338,"<e1>Melatonin</e1> may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of <e2>melatonin</e2> with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
Melatonin,progestin,0,8,345,353,"<e1>Melatonin</e1> may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e2>progestin</e2> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
Melatonin,benzodiazepenes,0,8,395,409,"<e1>Melatonin</e1> may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), <e2>benzodiazepenes</e2> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",True,int
Melatonin,corticosteroids,0,8,521,535,"<e1>Melatonin</e1> may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e2>corticosteroids</e2> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",True,int
Melatonin,melatonin,0,8,558,566,"<e1>Melatonin</e1> may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of <e2>melatonin</e2> and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
Melatonin,corticosteroids,0,8,572,586,"<e1>Melatonin</e1> may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e2>corticosteroids</e2> may interfere with the efficacy of the corticosteroids).",False,negative
Melatonin,corticosteroids,0,8,627,641,"<e1>Melatonin</e1> may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2>corticosteroids</e2>).",False,negative
aspirin,NSAIDs,49,55,67,72,"Melatonin may interact with the following drugs: <e1>aspirin</e1> and other <e2>NSAIDs</e2> (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
aspirin,melatonin,49,55,85,93,"Melatonin may interact with the following drugs: <e1>aspirin</e1> and other NSAIDs (may lower <e2>melatonin</e2> levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
aspirin,fluvoxamine,49,55,104,114,"Melatonin may interact with the following drugs: <e1>aspirin</e1> and other NSAIDs (may lower melatonin levels), <e2>fluvoxamine</e2> (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
aspirin,melatonin,49,55,141,149,"Melatonin may interact with the following drugs: <e1>aspirin</e1> and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral <e2>melatonin</e2> is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
aspirin,beta blockers,49,55,188,200,"Melatonin may interact with the following drugs: <e1>aspirin</e1> and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), <e2>beta blockers</e2> (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
aspirin,melatonin,49,55,216,224,"Melatonin may interact with the following drugs: <e1>aspirin</e1> and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease <e2>melatonin</e2> levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
aspirin,fluoxetine,49,55,235,244,"Melatonin may interact with the following drugs: <e1>aspirin</e1> and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), <e2>fluoxetine</e2> (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
aspirin,progestin,49,55,299,307,"Melatonin may interact with the following drugs: <e1>aspirin</e1> and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), <e2>progestin</e2> (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
aspirin,melatonin,49,55,330,338,"Melatonin may interact with the following drugs: <e1>aspirin</e1> and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of <e2>melatonin</e2> with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
aspirin,progestin,49,55,345,353,"Melatonin may interact with the following drugs: <e1>aspirin</e1> and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e2>progestin</e2> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
aspirin,benzodiazepenes,49,55,395,409,"Melatonin may interact with the following drugs: <e1>aspirin</e1> and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), <e2>benzodiazepenes</e2> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
aspirin,corticosteroids,49,55,521,535,"Melatonin may interact with the following drugs: <e1>aspirin</e1> and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e2>corticosteroids</e2> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
aspirin,melatonin,49,55,558,566,"Melatonin may interact with the following drugs: <e1>aspirin</e1> and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of <e2>melatonin</e2> and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
aspirin,corticosteroids,49,55,572,586,"Melatonin may interact with the following drugs: <e1>aspirin</e1> and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e2>corticosteroids</e2> may interfere with the efficacy of the corticosteroids).",False,negative
aspirin,corticosteroids,49,55,627,641,"Melatonin may interact with the following drugs: <e1>aspirin</e1> and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2>corticosteroids</e2>).",False,negative
NSAIDs,melatonin,67,72,85,93,"Melatonin may interact with the following drugs: aspirin and other <e1>NSAIDs</e1> (may lower <e2>melatonin</e2> levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
NSAIDs,fluvoxamine,67,72,104,114,"Melatonin may interact with the following drugs: aspirin and other <e1>NSAIDs</e1> (may lower melatonin levels), <e2>fluvoxamine</e2> (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
NSAIDs,melatonin,67,72,141,149,"Melatonin may interact with the following drugs: aspirin and other <e1>NSAIDs</e1> (may lower melatonin levels), fluvoxamine (bioavailability of oral <e2>melatonin</e2> is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
NSAIDs,beta blockers,67,72,188,200,"Melatonin may interact with the following drugs: aspirin and other <e1>NSAIDs</e1> (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), <e2>beta blockers</e2> (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
NSAIDs,melatonin,67,72,216,224,"Melatonin may interact with the following drugs: aspirin and other <e1>NSAIDs</e1> (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease <e2>melatonin</e2> levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
NSAIDs,fluoxetine,67,72,235,244,"Melatonin may interact with the following drugs: aspirin and other <e1>NSAIDs</e1> (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), <e2>fluoxetine</e2> (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
NSAIDs,progestin,67,72,299,307,"Melatonin may interact with the following drugs: aspirin and other <e1>NSAIDs</e1> (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), <e2>progestin</e2> (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
NSAIDs,melatonin,67,72,330,338,"Melatonin may interact with the following drugs: aspirin and other <e1>NSAIDs</e1> (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of <e2>melatonin</e2> with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
NSAIDs,progestin,67,72,345,353,"Melatonin may interact with the following drugs: aspirin and other <e1>NSAIDs</e1> (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e2>progestin</e2> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
NSAIDs,benzodiazepenes,67,72,395,409,"Melatonin may interact with the following drugs: aspirin and other <e1>NSAIDs</e1> (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), <e2>benzodiazepenes</e2> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
NSAIDs,corticosteroids,67,72,521,535,"Melatonin may interact with the following drugs: aspirin and other <e1>NSAIDs</e1> (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e2>corticosteroids</e2> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
NSAIDs,melatonin,67,72,558,566,"Melatonin may interact with the following drugs: aspirin and other <e1>NSAIDs</e1> (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of <e2>melatonin</e2> and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
NSAIDs,corticosteroids,67,72,572,586,"Melatonin may interact with the following drugs: aspirin and other <e1>NSAIDs</e1> (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e2>corticosteroids</e2> may interfere with the efficacy of the corticosteroids).",False,negative
NSAIDs,corticosteroids,67,72,627,641,"Melatonin may interact with the following drugs: aspirin and other <e1>NSAIDs</e1> (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2>corticosteroids</e2>).",False,negative
melatonin,fluvoxamine,85,93,104,114,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower <e1>melatonin</e1> levels), <e2>fluvoxamine</e2> (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
melatonin,melatonin,85,93,141,149,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower <e1>melatonin</e1> levels), fluvoxamine (bioavailability of oral <e2>melatonin</e2> is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
melatonin,beta blockers,85,93,188,200,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower <e1>melatonin</e1> levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), <e2>beta blockers</e2> (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
melatonin,melatonin,85,93,216,224,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower <e1>melatonin</e1> levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease <e2>melatonin</e2> levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
melatonin,fluoxetine,85,93,235,244,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower <e1>melatonin</e1> levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), <e2>fluoxetine</e2> (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
melatonin,progestin,85,93,299,307,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower <e1>melatonin</e1> levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), <e2>progestin</e2> (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
melatonin,melatonin,85,93,330,338,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower <e1>melatonin</e1> levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of <e2>melatonin</e2> with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
melatonin,progestin,85,93,345,353,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower <e1>melatonin</e1> levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e2>progestin</e2> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
melatonin,benzodiazepenes,85,93,395,409,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower <e1>melatonin</e1> levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), <e2>benzodiazepenes</e2> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
melatonin,corticosteroids,85,93,521,535,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower <e1>melatonin</e1> levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e2>corticosteroids</e2> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
melatonin,melatonin,85,93,558,566,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower <e1>melatonin</e1> levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of <e2>melatonin</e2> and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
melatonin,corticosteroids,85,93,572,586,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower <e1>melatonin</e1> levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e2>corticosteroids</e2> may interfere with the efficacy of the corticosteroids).",False,negative
melatonin,corticosteroids,85,93,627,641,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower <e1>melatonin</e1> levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2>corticosteroids</e2>).",False,negative
fluvoxamine,melatonin,104,114,141,149,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), <e1>fluvoxamine</e1> (bioavailability of oral <e2>melatonin</e2> is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
fluvoxamine,beta blockers,104,114,188,200,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), <e1>fluvoxamine</e1> (bioavailability of oral melatonin is increased with coadministration), <e2>beta blockers</e2> (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
fluvoxamine,melatonin,104,114,216,224,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), <e1>fluvoxamine</e1> (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease <e2>melatonin</e2> levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
fluvoxamine,fluoxetine,104,114,235,244,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), <e1>fluvoxamine</e1> (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), <e2>fluoxetine</e2> (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
fluvoxamine,progestin,104,114,299,307,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), <e1>fluvoxamine</e1> (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), <e2>progestin</e2> (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
fluvoxamine,melatonin,104,114,330,338,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), <e1>fluvoxamine</e1> (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of <e2>melatonin</e2> with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
fluvoxamine,progestin,104,114,345,353,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), <e1>fluvoxamine</e1> (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e2>progestin</e2> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
fluvoxamine,benzodiazepenes,104,114,395,409,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), <e1>fluvoxamine</e1> (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), <e2>benzodiazepenes</e2> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
fluvoxamine,corticosteroids,104,114,521,535,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), <e1>fluvoxamine</e1> (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e2>corticosteroids</e2> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
fluvoxamine,melatonin,104,114,558,566,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), <e1>fluvoxamine</e1> (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of <e2>melatonin</e2> and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
fluvoxamine,corticosteroids,104,114,572,586,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), <e1>fluvoxamine</e1> (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e2>corticosteroids</e2> may interfere with the efficacy of the corticosteroids).",False,negative
fluvoxamine,corticosteroids,104,114,627,641,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), <e1>fluvoxamine</e1> (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2>corticosteroids</e2>).",False,negative
melatonin,beta blockers,141,149,188,200,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral <e1>melatonin</e1> is increased with coadministration), <e2>beta blockers</e2> (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
melatonin,melatonin,141,149,216,224,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral <e1>melatonin</e1> is increased with coadministration), beta blockers (may decrease <e2>melatonin</e2> levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
melatonin,fluoxetine,141,149,235,244,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral <e1>melatonin</e1> is increased with coadministration), beta blockers (may decrease melatonin levels), <e2>fluoxetine</e2> (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
melatonin,progestin,141,149,299,307,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral <e1>melatonin</e1> is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), <e2>progestin</e2> (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
melatonin,melatonin,141,149,330,338,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral <e1>melatonin</e1> is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of <e2>melatonin</e2> with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
melatonin,progestin,141,149,345,353,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral <e1>melatonin</e1> is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e2>progestin</e2> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
melatonin,benzodiazepenes,141,149,395,409,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral <e1>melatonin</e1> is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), <e2>benzodiazepenes</e2> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
melatonin,corticosteroids,141,149,521,535,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral <e1>melatonin</e1> is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e2>corticosteroids</e2> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
melatonin,melatonin,141,149,558,566,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral <e1>melatonin</e1> is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of <e2>melatonin</e2> and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
melatonin,corticosteroids,141,149,572,586,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral <e1>melatonin</e1> is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e2>corticosteroids</e2> may interfere with the efficacy of the corticosteroids).",False,negative
melatonin,corticosteroids,141,149,627,641,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral <e1>melatonin</e1> is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2>corticosteroids</e2>).",False,negative
beta blockers,melatonin,188,200,216,224,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), <e1>beta blockers</e1> (may decrease <e2>melatonin</e2> levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
beta blockers,fluoxetine,188,200,235,244,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), <e1>beta blockers</e1> (may decrease melatonin levels), <e2>fluoxetine</e2> (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
beta blockers,progestin,188,200,299,307,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), <e1>beta blockers</e1> (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), <e2>progestin</e2> (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
beta blockers,melatonin,188,200,330,338,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), <e1>beta blockers</e1> (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of <e2>melatonin</e2> with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
beta blockers,progestin,188,200,345,353,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), <e1>beta blockers</e1> (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e2>progestin</e2> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
beta blockers,benzodiazepenes,188,200,395,409,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), <e1>beta blockers</e1> (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), <e2>benzodiazepenes</e2> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
beta blockers,corticosteroids,188,200,521,535,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), <e1>beta blockers</e1> (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e2>corticosteroids</e2> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
beta blockers,melatonin,188,200,558,566,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), <e1>beta blockers</e1> (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of <e2>melatonin</e2> and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
beta blockers,corticosteroids,188,200,572,586,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), <e1>beta blockers</e1> (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e2>corticosteroids</e2> may interfere with the efficacy of the corticosteroids).",False,negative
beta blockers,corticosteroids,188,200,627,641,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), <e1>beta blockers</e1> (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2>corticosteroids</e2>).",False,negative
melatonin,fluoxetine,216,224,235,244,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease <e1>melatonin</e1> levels), <e2>fluoxetine</e2> (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
melatonin,progestin,216,224,299,307,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease <e1>melatonin</e1> levels), fluoxetine (reports of psychotic episodes when coadministered), <e2>progestin</e2> (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
melatonin,melatonin,216,224,330,338,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease <e1>melatonin</e1> levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of <e2>melatonin</e2> with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
melatonin,progestin,216,224,345,353,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease <e1>melatonin</e1> levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e2>progestin</e2> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
melatonin,benzodiazepenes,216,224,395,409,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease <e1>melatonin</e1> levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), <e2>benzodiazepenes</e2> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
melatonin,corticosteroids,216,224,521,535,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease <e1>melatonin</e1> levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e2>corticosteroids</e2> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
melatonin,melatonin,216,224,558,566,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease <e1>melatonin</e1> levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of <e2>melatonin</e2> and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
melatonin,corticosteroids,216,224,572,586,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease <e1>melatonin</e1> levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e2>corticosteroids</e2> may interfere with the efficacy of the corticosteroids).",False,negative
melatonin,corticosteroids,216,224,627,641,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease <e1>melatonin</e1> levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2>corticosteroids</e2>).",False,negative
fluoxetine,progestin,235,244,299,307,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), <e1>fluoxetine</e1> (reports of psychotic episodes when coadministered), <e2>progestin</e2> (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
fluoxetine,melatonin,235,244,330,338,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), <e1>fluoxetine</e1> (reports of psychotic episodes when coadministered), progestin (coadministration of <e2>melatonin</e2> with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
fluoxetine,progestin,235,244,345,353,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), <e1>fluoxetine</e1> (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e2>progestin</e2> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
fluoxetine,benzodiazepenes,235,244,395,409,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), <e1>fluoxetine</e1> (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), <e2>benzodiazepenes</e2> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
fluoxetine,corticosteroids,235,244,521,535,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), <e1>fluoxetine</e1> (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e2>corticosteroids</e2> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
fluoxetine,melatonin,235,244,558,566,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), <e1>fluoxetine</e1> (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of <e2>melatonin</e2> and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
fluoxetine,corticosteroids,235,244,572,586,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), <e1>fluoxetine</e1> (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e2>corticosteroids</e2> may interfere with the efficacy of the corticosteroids).",False,negative
fluoxetine,corticosteroids,235,244,627,641,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), <e1>fluoxetine</e1> (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2>corticosteroids</e2>).",False,negative
progestin,melatonin,299,307,330,338,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), <e1>progestin</e1> (coadministration of <e2>melatonin</e2> with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
progestin,progestin,299,307,345,353,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), <e1>progestin</e1> (coadministration of melatonin with <e2>progestin</e2> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
progestin,benzodiazepenes,299,307,395,409,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), <e1>progestin</e1> (coadministration of melatonin with progestin can inhibit ovarian function in women), <e2>benzodiazepenes</e2> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
progestin,corticosteroids,299,307,521,535,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), <e1>progestin</e1> (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e2>corticosteroids</e2> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
progestin,melatonin,299,307,558,566,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), <e1>progestin</e1> (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of <e2>melatonin</e2> and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
progestin,corticosteroids,299,307,572,586,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), <e1>progestin</e1> (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e2>corticosteroids</e2> may interfere with the efficacy of the corticosteroids).",False,negative
progestin,corticosteroids,299,307,627,641,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), <e1>progestin</e1> (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2>corticosteroids</e2>).",False,negative
melatonin,progestin,330,338,345,353,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of <e1>melatonin</e1> with <e2>progestin</e2> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",True,effect
melatonin,benzodiazepenes,330,338,395,409,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of <e1>melatonin</e1> with progestin can inhibit ovarian function in women), <e2>benzodiazepenes</e2> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
melatonin,corticosteroids,330,338,521,535,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of <e1>melatonin</e1> with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e2>corticosteroids</e2> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
melatonin,melatonin,330,338,558,566,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of <e1>melatonin</e1> with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of <e2>melatonin</e2> and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
melatonin,corticosteroids,330,338,572,586,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of <e1>melatonin</e1> with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e2>corticosteroids</e2> may interfere with the efficacy of the corticosteroids).",False,negative
melatonin,corticosteroids,330,338,627,641,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of <e1>melatonin</e1> with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2>corticosteroids</e2>).",False,negative
progestin,benzodiazepenes,345,353,395,409,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e1>progestin</e1> can inhibit ovarian function in women), <e2>benzodiazepenes</e2> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
progestin,corticosteroids,345,353,521,535,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e1>progestin</e1> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e2>corticosteroids</e2> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
progestin,melatonin,345,353,558,566,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e1>progestin</e1> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of <e2>melatonin</e2> and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
progestin,corticosteroids,345,353,572,586,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e1>progestin</e1> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e2>corticosteroids</e2> may interfere with the efficacy of the corticosteroids).",False,negative
progestin,corticosteroids,345,353,627,641,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e1>progestin</e1> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2>corticosteroids</e2>).",False,negative
benzodiazepenes,corticosteroids,395,409,521,535,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), <e1>benzodiazepenes</e1> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e2>corticosteroids</e2> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
benzodiazepenes,melatonin,395,409,558,566,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), <e1>benzodiazepenes</e1> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of <e2>melatonin</e2> and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
benzodiazepenes,corticosteroids,395,409,572,586,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), <e1>benzodiazepenes</e1> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e2>corticosteroids</e2> may interfere with the efficacy of the corticosteroids).",False,negative
benzodiazepenes,corticosteroids,395,409,627,641,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), <e1>benzodiazepenes</e1> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2>corticosteroids</e2>).",False,negative
corticosteroids,melatonin,521,535,558,566,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e1>corticosteroids</e1> (coadministration of <e2>melatonin</e2> and corticosteroids may interfere with the efficacy of the corticosteroids).",False,negative
corticosteroids,corticosteroids,521,535,572,586,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e1>corticosteroids</e1> (coadministration of melatonin and <e2>corticosteroids</e2> may interfere with the efficacy of the corticosteroids).",False,negative
corticosteroids,corticosteroids,521,535,627,641,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e1>corticosteroids</e1> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2>corticosteroids</e2>).",False,negative
melatonin,corticosteroids,558,566,572,586,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of <e1>melatonin</e1> and <e2>corticosteroids</e2> may interfere with the efficacy of the corticosteroids).",True,effect
melatonin,corticosteroids,558,566,627,641,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of <e1>melatonin</e1> and corticosteroids may interfere with the efficacy of the <e2>corticosteroids</e2>).",False,negative
corticosteroids,corticosteroids,572,586,627,641,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e1>corticosteroids</e1> may interfere with the efficacy of the <e2>corticosteroids</e2>).",False,negative
ACE inhibitors,NSAIDs,0,13,36,41,<e1>ACE inhibitors</e1> Reports suggest that <e2>NSAIDs</e2> may diminish the antihypertensive effect of angiotensin-converting enzyme (ACE) inhibitors. ,False,negative
ACE inhibitors,angiotensin-converting enzyme (ACE) inhibitors,0,13,87,132,<e1>ACE inhibitors</e1> Reports suggest that NSAIDs may diminish the antihypertensive effect of <e2>angiotensin-converting enzyme (ACE) inhibitors</e2>. ,False,negative
NSAIDs,angiotensin-converting enzyme (ACE) inhibitors,36,41,87,132,ACE inhibitors Reports suggest that <e1>NSAIDs</e1> may diminish the antihypertensive effect of <e2>angiotensin-converting enzyme (ACE) inhibitors</e2>. ,True,effect
NSAIDs,ACE inhibitors,66,71,92,105,This interaction should be given consideration in patients taking <e1>NSAIDs</e1> concomitantly with <e2>ACE inhibitors</e2>. ,True,advise
Aspirin,aspirin,0,6,39,45,<e1>Aspirin</e1>: Concomitant administration of <e2>aspirin</e2> (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of meloxicam. ,False,negative
Aspirin,meloxicam,0,6,134,142,<e1>Aspirin</e1>: Concomitant administration of aspirin (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of <e2>meloxicam</e2>. ,False,negative
aspirin,meloxicam,39,45,134,142,Aspirin: Concomitant administration of <e1>aspirin</e1> (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of <e2>meloxicam</e2>. ,True,mechanism
NSAIDs,meloxicam,23,28,61,69,"however, as with other <e1>NSAIDs</e1>, concomitant administration of <e2>meloxicam</e2> and aspirin is not generally recommended because of the potential for increased adverse effects. ",False,negative
NSAIDs,aspirin,23,28,75,81,"however, as with other <e1>NSAIDs</e1>, concomitant administration of meloxicam and <e2>aspirin</e2> is not generally recommended because of the potential for increased adverse effects. ",True,advise
meloxicam,aspirin,61,69,75,81,"however, as with other NSAIDs, concomitant administration of <e1>meloxicam</e1> and <e2>aspirin</e2> is not generally recommended because of the potential for increased adverse effects. ",True,advise
aspirin,MOBIC,39,45,52,56,"Concomitant administration of low-dose <e1>aspirin</e1> with <e2>MOBIC</e2> may result in an increased rate of GI ulceration or other complications, compared to use of MOBIC alone. ",True,effect
aspirin,MOBIC,39,45,150,154,"Concomitant administration of low-dose <e1>aspirin</e1> with MOBIC may result in an increased rate of GI ulceration or other complications, compared to use of <e2>MOBIC</e2> alone. ",False,negative
MOBIC,MOBIC,52,56,150,154,"Concomitant administration of low-dose aspirin with <e1>MOBIC</e1> may result in an increased rate of GI ulceration or other complications, compared to use of <e2>MOBIC</e2> alone. ",False,negative
MOBIC,aspirin,0,4,30,36,<e1>MOBIC</e1> is not a substitute for <e2>aspirin</e2> for cardiovascular prophylaxis. ,False,negative
Cholestyramine,cholestyramine,0,13,48,61,<e1>Cholestyramine</e1>: Pretreatment for four days with <e2>cholestyramine</e2> significantly increased the clearance of meloxicam by 50%. ,False,negative
Cholestyramine,meloxicam,0,13,104,112,<e1>Cholestyramine</e1>: Pretreatment for four days with cholestyramine significantly increased the clearance of <e2>meloxicam</e2> by 50%. ,False,negative
cholestyramine,meloxicam,48,61,104,112,Cholestyramine: Pretreatment for four days with <e1>cholestyramine</e1> significantly increased the clearance of <e2>meloxicam</e2> by 50%. ,True,mechanism
Cimetidine,cimetidine,0,9,49,58,<e1>Cimetidine</e1>: Concomitant administration of 200 mg <e2>cimetidine</e2> QID did not alter the single-dose pharmacokinetics of 30 mg meloxicam. ,False,negative
Cimetidine,meloxicam,0,9,120,128,<e1>Cimetidine</e1>: Concomitant administration of 200 mg cimetidine QID did not alter the single-dose pharmacokinetics of 30 mg <e2>meloxicam</e2>. ,False,negative
cimetidine,meloxicam,49,58,120,128,Cimetidine: Concomitant administration of 200 mg <e1>cimetidine</e1> QID did not alter the single-dose pharmacokinetics of 30 mg <e2>meloxicam</e2>. ,False,negative
Digoxin,Meloxicam,0,6,9,17,<e1>Digoxin</e1>: <e2>Meloxicam</e2> 15 mg once daily for 7 days did not alter the plasma concentration profile of digoxin after b-acetyldigoxin administration for 7 days at clinical doses. ,False,negative
Digoxin,digoxin,0,6,97,103,<e1>Digoxin</e1>: Meloxicam 15 mg once daily for 7 days did not alter the plasma concentration profile of <e2>digoxin</e2> after b-acetyldigoxin administration for 7 days at clinical doses. ,False,negative
Meloxicam,digoxin,9,17,97,103,Digoxin: <e1>Meloxicam</e1> 15 mg once daily for 7 days did not alter the plasma concentration profile of <e2>digoxin</e2> after b-acetyldigoxin administration for 7 days at clinical doses. ,False,negative
digoxin,meloxicam,67,73,79,87,In vitro testing found no protein binding drug interaction between <e1>digoxin</e1> and <e2>meloxicam</e2>. ,False,negative
Furosemide,NSAIDs,0,9,86,91,"<e1>Furosemide</e1>: Clinical studies, as well as post-marketing observations, have shown that <e2>NSAIDs</e2> can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients. ",False,negative
Furosemide,furosemide,0,9,130,139,"<e1>Furosemide</e1>: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of <e2>furosemide</e2> and thiazide diuretics in some patients. ",False,negative
Furosemide,thiazide diuretics,0,9,145,162,"<e1>Furosemide</e1>: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and <e2>thiazide diuretics</e2> in some patients. ",False,negative
NSAIDs,furosemide,86,91,130,139,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that <e1>NSAIDs</e1> can reduce the natriuretic effect of <e2>furosemide</e2> and thiazide diuretics in some patients. ",True,effect
NSAIDs,thiazide diuretics,86,91,145,162,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that <e1>NSAIDs</e1> can reduce the natriuretic effect of furosemide and <e2>thiazide diuretics</e2> in some patients. ",True,effect
furosemide,thiazide diuretics,130,139,145,162,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of <e1>furosemide</e1> and <e2>thiazide diuretics</e2> in some patients. ",False,negative
furosemide,meloxicam,13,22,35,43,Studies with <e1>furosemide</e1> agents and <e2>meloxicam</e2> have not demonstrated a reduction in natriuretic effect. ,False,negative
Furosemide,meloxicam,0,9,113,121,<e1>Furosemide</e1>: single and multiple dose pharmacodynamics and pharmacokinetics are not affected by multiple doses of <e2>meloxicam</e2>. ,False,negative
furosemide,MOBIC,46,55,61,65,"Nevertheless, during concomitant therapy with <e1>furosemide</e1> and <e2>MOBIC</e2>, patients should be observed closely for signs of declining renal function, as well as to assure diuretic efficacy. ",True,advise
Lithium,NSAIDs,0,6,29,34,"<e1>Lithium</e1>: In clinical trials, <e2>NSAIDs</e2> have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. ",False,negative
Lithium,lithium,0,6,73,79,"<e1>Lithium</e1>: In clinical trials, NSAIDs have produced an elevation of plasma <e2>lithium</e2> levels and a reduction in renal lithium clearance. ",False,negative
Lithium,lithium,0,6,113,119,"<e1>Lithium</e1>: In clinical trials, NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal <e2>lithium</e2> clearance. ",False,negative
NSAIDs,lithium,29,34,73,79,"Lithium: In clinical trials, <e1>NSAIDs</e1> have produced an elevation of plasma <e2>lithium</e2> levels and a reduction in renal lithium clearance. ",True,mechanism
NSAIDs,lithium,29,34,113,119,"Lithium: In clinical trials, <e1>NSAIDs</e1> have produced an elevation of plasma lithium levels and a reduction in renal <e2>lithium</e2> clearance. ",False,negative
lithium,lithium,73,79,113,119,"Lithium: In clinical trials, NSAIDs have produced an elevation of plasma <e1>lithium</e1> levels and a reduction in renal <e2>lithium</e2> clearance. ",False,negative
lithium,lithium,56,62,130,136,"In a study conducted in healthy subjects, mean pre-dose <e1>lithium</e1> concentration and AUC were increased by 21% in subjects receiving <e2>lithium</e2> doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone. ",False,negative
lithium,meloxicam,56,62,181,189,"In a study conducted in healthy subjects, mean pre-dose <e1>lithium</e1> concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with <e2>meloxicam</e2> 15 mg QD as compared to subjects receiving lithium alone. ",False,negative
lithium,lithium,56,62,234,240,"In a study conducted in healthy subjects, mean pre-dose <e1>lithium</e1> concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving <e2>lithium</e2> alone. ",False,negative
lithium,meloxicam,130,136,181,189,"In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving <e1>lithium</e1> doses ranging from 804 to 1072 mg BID with <e2>meloxicam</e2> 15 mg QD as compared to subjects receiving lithium alone. ",True,mechanism
lithium,lithium,130,136,234,240,"In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving <e1>lithium</e1> doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving <e2>lithium</e2> alone. ",False,negative
meloxicam,lithium,181,189,234,240,"In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with <e1>meloxicam</e1> 15 mg QD as compared to subjects receiving <e2>lithium</e2> alone. ",False,negative
lithium,MOBIC,12,18,63,67,Patients on <e1>lithium</e1> treatment should be closely monitored when <e2>MOBIC</e2> is introduced or withdrawn. ,True,advise
Methotrexate,meloxicam,0,11,106,114,<e1>Methotrexate</e1>: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of <e2>meloxicam</e2> on the pharmacokinetics of methotrexate taken once weekly. ,False,negative
Methotrexate,methotrexate,0,11,143,154,<e1>Methotrexate</e1>: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of meloxicam on the pharmacokinetics of <e2>methotrexate</e2> taken once weekly. ,False,negative
meloxicam,methotrexate,106,114,143,154,Methotrexate: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of <e1>meloxicam</e1> on the pharmacokinetics of <e2>methotrexate</e2> taken once weekly. ,False,negative
Meloxicam,methotrexate,0,8,87,98,<e1>Meloxicam</e1> did not have a significant effect on the pharmacokinetics of single doses of <e2>methotrexate</e2>. ,False,negative
methotrexate,meloxicam,10,21,40,48,"In vitro, <e1>methotrexate</e1> did not displace <e2>meloxicam</e2> from its human serum binding sites. ",False,negative
Warfarin,MOBIC,0,7,118,122,"<e1>Warfarin</e1>: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing <e2>MOBIC</e2> therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding. ",False,negative
Warfarin,warfarin,0,7,154,161,"<e1>Warfarin</e1>: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing MOBIC therapy in patients receiving <e2>warfarin</e2> or similar agents, since these patients are at an increased risk of bleeding. ",False,negative
MOBIC,warfarin,118,122,154,161,"Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing <e1>MOBIC</e1> therapy in patients receiving <e2>warfarin</e2> or similar agents, since these patients are at an increased risk of bleeding. ",True,advise
meloxicam,warfarin,14,22,55,62,The effect of <e1>meloxicam</e1> on the anticoagulant effect of <e2>warfarin</e2> was studied in a group of healthy subjects receiving daily doses of warfarin that produced an INR (International Normalized Ratio) between 1.2 and 1.8. ,False,negative
meloxicam,warfarin,14,22,132,139,The effect of <e1>meloxicam</e1> on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of <e2>warfarin</e2> that produced an INR (International Normalized Ratio) between 1.2 and 1.8. ,False,negative
warfarin,warfarin,55,62,132,139,The effect of meloxicam on the anticoagulant effect of <e1>warfarin</e1> was studied in a group of healthy subjects receiving daily doses of <e2>warfarin</e2> that produced an INR (International Normalized Ratio) between 1.2 and 1.8. ,False,negative
meloxicam,warfarin,19,27,43,50,"In these subjects, <e1>meloxicam</e1> did not alter <e2>warfarin</e2> pharmacokinetics and the average anticoagulant effect of warfarin as determined by prothrombin time. ",False,negative
meloxicam,warfarin,19,27,109,116,"In these subjects, <e1>meloxicam</e1> did not alter warfarin pharmacokinetics and the average anticoagulant effect of <e2>warfarin</e2> as determined by prothrombin time. ",False,negative
warfarin,warfarin,43,50,109,116,"In these subjects, meloxicam did not alter <e1>warfarin</e1> pharmacokinetics and the average anticoagulant effect of <e2>warfarin</e2> as determined by prothrombin time. ",False,negative
MOBIC,warfarin,42,46,53,60,Caution should be used when administering <e1>MOBIC</e1> with <e2>warfarin</e2> since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.,True,advise
MOBIC,warfarin,42,46,80,87,Caution should be used when administering <e1>MOBIC</e1> with warfarin since patients on <e2>warfarin</e2> may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.,False,negative
warfarin,warfarin,53,60,80,87,Caution should be used when administering MOBIC with <e1>warfarin</e1> since patients on <e2>warfarin</e2> may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.,False,negative
ALKERAN,live organism vaccines,71,77,98,119,DRUG INTERACTIONS  There are no known drug/drug interactions with oral <e1>ALKERAN</e1>  Vaccinations with <e2>live organism vaccines</e2> are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  ,False,negative
ALKERAN,Nalidixic acid,71,77,175,188,DRUG INTERACTIONS  There are no known drug/drug interactions with oral <e1>ALKERAN</e1>  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  <e2>Nalidixic acid</e2> together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  ,False,negative
ALKERAN,melphalan,71,77,226,234,DRUG INTERACTIONS  There are no known drug/drug interactions with oral <e1>ALKERAN</e1>  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous <e2>melphalan</e2> has caused deaths in children due to haemorrhagic enterocolitis.  ,False,negative
live organism vaccines,Nalidixic acid,98,119,175,188,DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with <e1>live organism vaccines</e1> are not recommended in immunocompromised individuals  <e2>Nalidixic acid</e2> together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  ,False,negative
live organism vaccines,melphalan,98,119,226,234,DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with <e1>live organism vaccines</e1> are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous <e2>melphalan</e2> has caused deaths in children due to haemorrhagic enterocolitis.  ,False,negative
Nalidixic acid,melphalan,175,188,226,234,DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  <e1>Nalidixic acid</e1> together with high-dose intravenous <e2>melphalan</e2> has caused deaths in children due to haemorrhagic enterocolitis.  ,True,effect
melphalan,cyclosporin,126,134,166,176,Impaired renal function has been described in bone marrow transplant patients who were conditioned with high-dose intravenous <e1>melphalan</e1> and who subsequently received <e2>cyclosporin</e2> to prevent graft-versus-host disease,True,effect
anticholinergic drugs,amantadine,69,89,92,101,"The following agents may increase certain actions or side effects of <e1>anticholinergic drugs</e1>: <e2>amantadine</e2>, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",True,effect
anticholinergic drugs,antiarrhythmic agents of class I,69,89,104,135,"The following agents may increase certain actions or side effects of <e1>anticholinergic drugs</e1>: amantadine, <e2>antiarrhythmic agents of class I</e2> (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",True,effect
anticholinergic drugs,quinidine,69,89,144,152,"The following agents may increase certain actions or side effects of <e1>anticholinergic drugs</e1>: amantadine, antiarrhythmic agents of class I (e.g., <e2>quinidine</e2>), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",True,effect
anticholinergic drugs,antihistamines,69,89,156,169,"The following agents may increase certain actions or side effects of <e1>anticholinergic drugs</e1>: amantadine, antiarrhythmic agents of class I (e.g., quinidine), <e2>antihistamines</e2>, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",True,effect
anticholinergic drugs,antipsychotic agents,69,89,172,191,"The following agents may increase certain actions or side effects of <e1>anticholinergic drugs</e1>: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, <e2>antipsychotic agents</e2> (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",True,effect
anticholinergic drugs,phenothiazines,69,89,200,213,"The following agents may increase certain actions or side effects of <e1>anticholinergic drugs</e1>: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., <e2>phenothiazines</e2>), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",True,effect
anticholinergic drugs,benzodiazepines,69,89,217,231,"The following agents may increase certain actions or side effects of <e1>anticholinergic drugs</e1>: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), <e2>benzodiazepines</e2>, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",True,effect
anticholinergic drugs,MAO inhibitors,69,89,234,247,"The following agents may increase certain actions or side effects of <e1>anticholinergic drugs</e1>: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, <e2>MAO inhibitors</e2>, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",True,effect
anticholinergic drugs,narcotic analgesics,69,89,250,268,"The following agents may increase certain actions or side effects of <e1>anticholinergic drugs</e1>: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, <e2>narcotic analgesics</e2> (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",True,effect
anticholinergic drugs,meperidine,69,89,277,286,"The following agents may increase certain actions or side effects of <e1>anticholinergic drugs</e1>: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., <e2>meperidine</e2>), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",True,effect
anticholinergic drugs,nitrates,69,89,290,297,"The following agents may increase certain actions or side effects of <e1>anticholinergic drugs</e1>: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), <e2>nitrates</e2> and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",True,effect
anticholinergic drugs,nitrites,69,89,303,310,"The following agents may increase certain actions or side effects of <e1>anticholinergic drugs</e1>: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and <e2>nitrites</e2>, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",True,effect
anticholinergic drugs,sympathomimetic agents,69,89,313,334,"The following agents may increase certain actions or side effects of <e1>anticholinergic drugs</e1>: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, <e2>sympathomimetic agents</e2>, tricyclic antidepressants, and other drugs having anticholinergic activity. ",True,effect
anticholinergic drugs,tricyclic antidepressants,69,89,337,361,"The following agents may increase certain actions or side effects of <e1>anticholinergic drugs</e1>: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, <e2>tricyclic antidepressants</e2>, and other drugs having anticholinergic activity. ",True,effect
amantadine,antiarrhythmic agents of class I,92,101,104,135,"The following agents may increase certain actions or side effects of anticholinergic drugs: <e1>amantadine</e1>, <e2>antiarrhythmic agents of class I</e2> (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
amantadine,quinidine,92,101,144,152,"The following agents may increase certain actions or side effects of anticholinergic drugs: <e1>amantadine</e1>, antiarrhythmic agents of class I (e.g., <e2>quinidine</e2>), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
amantadine,antihistamines,92,101,156,169,"The following agents may increase certain actions or side effects of anticholinergic drugs: <e1>amantadine</e1>, antiarrhythmic agents of class I (e.g., quinidine), <e2>antihistamines</e2>, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
amantadine,antipsychotic agents,92,101,172,191,"The following agents may increase certain actions or side effects of anticholinergic drugs: <e1>amantadine</e1>, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, <e2>antipsychotic agents</e2> (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
amantadine,phenothiazines,92,101,200,213,"The following agents may increase certain actions or side effects of anticholinergic drugs: <e1>amantadine</e1>, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., <e2>phenothiazines</e2>), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
amantadine,benzodiazepines,92,101,217,231,"The following agents may increase certain actions or side effects of anticholinergic drugs: <e1>amantadine</e1>, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), <e2>benzodiazepines</e2>, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
amantadine,MAO inhibitors,92,101,234,247,"The following agents may increase certain actions or side effects of anticholinergic drugs: <e1>amantadine</e1>, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, <e2>MAO inhibitors</e2>, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
amantadine,narcotic analgesics,92,101,250,268,"The following agents may increase certain actions or side effects of anticholinergic drugs: <e1>amantadine</e1>, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, <e2>narcotic analgesics</e2> (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
amantadine,meperidine,92,101,277,286,"The following agents may increase certain actions or side effects of anticholinergic drugs: <e1>amantadine</e1>, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., <e2>meperidine</e2>), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
amantadine,nitrates,92,101,290,297,"The following agents may increase certain actions or side effects of anticholinergic drugs: <e1>amantadine</e1>, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), <e2>nitrates</e2> and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
amantadine,nitrites,92,101,303,310,"The following agents may increase certain actions or side effects of anticholinergic drugs: <e1>amantadine</e1>, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and <e2>nitrites</e2>, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
amantadine,sympathomimetic agents,92,101,313,334,"The following agents may increase certain actions or side effects of anticholinergic drugs: <e1>amantadine</e1>, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, <e2>sympathomimetic agents</e2>, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
amantadine,tricyclic antidepressants,92,101,337,361,"The following agents may increase certain actions or side effects of anticholinergic drugs: <e1>amantadine</e1>, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, <e2>tricyclic antidepressants</e2>, and other drugs having anticholinergic activity. ",False,negative
antiarrhythmic agents of class I,quinidine,104,135,144,152,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, <e1>antiarrhythmic agents of class I</e1> (e.g., <e2>quinidine</e2>), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
antiarrhythmic agents of class I,antihistamines,104,135,156,169,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, <e1>antiarrhythmic agents of class I</e1> (e.g., quinidine), <e2>antihistamines</e2>, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
antiarrhythmic agents of class I,antipsychotic agents,104,135,172,191,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, <e1>antiarrhythmic agents of class I</e1> (e.g., quinidine), antihistamines, <e2>antipsychotic agents</e2> (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
antiarrhythmic agents of class I,phenothiazines,104,135,200,213,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, <e1>antiarrhythmic agents of class I</e1> (e.g., quinidine), antihistamines, antipsychotic agents (e.g., <e2>phenothiazines</e2>), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
antiarrhythmic agents of class I,benzodiazepines,104,135,217,231,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, <e1>antiarrhythmic agents of class I</e1> (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), <e2>benzodiazepines</e2>, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
antiarrhythmic agents of class I,MAO inhibitors,104,135,234,247,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, <e1>antiarrhythmic agents of class I</e1> (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, <e2>MAO inhibitors</e2>, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
antiarrhythmic agents of class I,narcotic analgesics,104,135,250,268,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, <e1>antiarrhythmic agents of class I</e1> (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, <e2>narcotic analgesics</e2> (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
antiarrhythmic agents of class I,meperidine,104,135,277,286,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, <e1>antiarrhythmic agents of class I</e1> (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., <e2>meperidine</e2>), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
antiarrhythmic agents of class I,nitrates,104,135,290,297,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, <e1>antiarrhythmic agents of class I</e1> (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), <e2>nitrates</e2> and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
antiarrhythmic agents of class I,nitrites,104,135,303,310,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, <e1>antiarrhythmic agents of class I</e1> (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and <e2>nitrites</e2>, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
antiarrhythmic agents of class I,sympathomimetic agents,104,135,313,334,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, <e1>antiarrhythmic agents of class I</e1> (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, <e2>sympathomimetic agents</e2>, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
antiarrhythmic agents of class I,tricyclic antidepressants,104,135,337,361,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, <e1>antiarrhythmic agents of class I</e1> (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, <e2>tricyclic antidepressants</e2>, and other drugs having anticholinergic activity. ",False,negative
quinidine,antihistamines,144,152,156,169,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., <e1>quinidine</e1>), <e2>antihistamines</e2>, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
quinidine,antipsychotic agents,144,152,172,191,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., <e1>quinidine</e1>), antihistamines, <e2>antipsychotic agents</e2> (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
quinidine,phenothiazines,144,152,200,213,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., <e1>quinidine</e1>), antihistamines, antipsychotic agents (e.g., <e2>phenothiazines</e2>), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
quinidine,benzodiazepines,144,152,217,231,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., <e1>quinidine</e1>), antihistamines, antipsychotic agents (e.g., phenothiazines), <e2>benzodiazepines</e2>, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
quinidine,MAO inhibitors,144,152,234,247,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., <e1>quinidine</e1>), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, <e2>MAO inhibitors</e2>, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
quinidine,narcotic analgesics,144,152,250,268,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., <e1>quinidine</e1>), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, <e2>narcotic analgesics</e2> (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
quinidine,meperidine,144,152,277,286,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., <e1>quinidine</e1>), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., <e2>meperidine</e2>), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
quinidine,nitrates,144,152,290,297,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., <e1>quinidine</e1>), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), <e2>nitrates</e2> and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
quinidine,nitrites,144,152,303,310,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., <e1>quinidine</e1>), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and <e2>nitrites</e2>, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
quinidine,sympathomimetic agents,144,152,313,334,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., <e1>quinidine</e1>), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, <e2>sympathomimetic agents</e2>, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
quinidine,tricyclic antidepressants,144,152,337,361,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., <e1>quinidine</e1>), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, <e2>tricyclic antidepressants</e2>, and other drugs having anticholinergic activity. ",False,negative
antihistamines,antipsychotic agents,156,169,172,191,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), <e1>antihistamines</e1>, <e2>antipsychotic agents</e2> (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
antihistamines,phenothiazines,156,169,200,213,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), <e1>antihistamines</e1>, antipsychotic agents (e.g., <e2>phenothiazines</e2>), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
antihistamines,benzodiazepines,156,169,217,231,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), <e1>antihistamines</e1>, antipsychotic agents (e.g., phenothiazines), <e2>benzodiazepines</e2>, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
antihistamines,MAO inhibitors,156,169,234,247,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), <e1>antihistamines</e1>, antipsychotic agents (e.g., phenothiazines), benzodiazepines, <e2>MAO inhibitors</e2>, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
antihistamines,narcotic analgesics,156,169,250,268,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), <e1>antihistamines</e1>, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, <e2>narcotic analgesics</e2> (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
antihistamines,meperidine,156,169,277,286,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), <e1>antihistamines</e1>, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., <e2>meperidine</e2>), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
antihistamines,nitrates,156,169,290,297,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), <e1>antihistamines</e1>, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), <e2>nitrates</e2> and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
antihistamines,nitrites,156,169,303,310,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), <e1>antihistamines</e1>, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and <e2>nitrites</e2>, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
antihistamines,sympathomimetic agents,156,169,313,334,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), <e1>antihistamines</e1>, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, <e2>sympathomimetic agents</e2>, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
antihistamines,tricyclic antidepressants,156,169,337,361,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), <e1>antihistamines</e1>, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, <e2>tricyclic antidepressants</e2>, and other drugs having anticholinergic activity. ",False,negative
antipsychotic agents,phenothiazines,172,191,200,213,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, <e1>antipsychotic agents</e1> (e.g., <e2>phenothiazines</e2>), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
antipsychotic agents,benzodiazepines,172,191,217,231,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, <e1>antipsychotic agents</e1> (e.g., phenothiazines), <e2>benzodiazepines</e2>, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
antipsychotic agents,MAO inhibitors,172,191,234,247,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, <e1>antipsychotic agents</e1> (e.g., phenothiazines), benzodiazepines, <e2>MAO inhibitors</e2>, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
antipsychotic agents,narcotic analgesics,172,191,250,268,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, <e1>antipsychotic agents</e1> (e.g., phenothiazines), benzodiazepines, MAO inhibitors, <e2>narcotic analgesics</e2> (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
antipsychotic agents,meperidine,172,191,277,286,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, <e1>antipsychotic agents</e1> (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., <e2>meperidine</e2>), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
antipsychotic agents,nitrates,172,191,290,297,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, <e1>antipsychotic agents</e1> (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), <e2>nitrates</e2> and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
antipsychotic agents,nitrites,172,191,303,310,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, <e1>antipsychotic agents</e1> (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and <e2>nitrites</e2>, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
antipsychotic agents,sympathomimetic agents,172,191,313,334,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, <e1>antipsychotic agents</e1> (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, <e2>sympathomimetic agents</e2>, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
antipsychotic agents,tricyclic antidepressants,172,191,337,361,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, <e1>antipsychotic agents</e1> (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, <e2>tricyclic antidepressants</e2>, and other drugs having anticholinergic activity. ",False,negative
phenothiazines,benzodiazepines,200,213,217,231,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., <e1>phenothiazines</e1>), <e2>benzodiazepines</e2>, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
phenothiazines,MAO inhibitors,200,213,234,247,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., <e1>phenothiazines</e1>), benzodiazepines, <e2>MAO inhibitors</e2>, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
phenothiazines,narcotic analgesics,200,213,250,268,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., <e1>phenothiazines</e1>), benzodiazepines, MAO inhibitors, <e2>narcotic analgesics</e2> (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
phenothiazines,meperidine,200,213,277,286,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., <e1>phenothiazines</e1>), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., <e2>meperidine</e2>), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
phenothiazines,nitrates,200,213,290,297,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., <e1>phenothiazines</e1>), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), <e2>nitrates</e2> and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
phenothiazines,nitrites,200,213,303,310,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., <e1>phenothiazines</e1>), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and <e2>nitrites</e2>, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
phenothiazines,sympathomimetic agents,200,213,313,334,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., <e1>phenothiazines</e1>), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, <e2>sympathomimetic agents</e2>, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
phenothiazines,tricyclic antidepressants,200,213,337,361,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., <e1>phenothiazines</e1>), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, <e2>tricyclic antidepressants</e2>, and other drugs having anticholinergic activity. ",False,negative
benzodiazepines,MAO inhibitors,217,231,234,247,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), <e1>benzodiazepines</e1>, <e2>MAO inhibitors</e2>, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
benzodiazepines,narcotic analgesics,217,231,250,268,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), <e1>benzodiazepines</e1>, MAO inhibitors, <e2>narcotic analgesics</e2> (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
benzodiazepines,meperidine,217,231,277,286,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), <e1>benzodiazepines</e1>, MAO inhibitors, narcotic analgesics (e.g., <e2>meperidine</e2>), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
benzodiazepines,nitrates,217,231,290,297,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), <e1>benzodiazepines</e1>, MAO inhibitors, narcotic analgesics (e.g., meperidine), <e2>nitrates</e2> and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
benzodiazepines,nitrites,217,231,303,310,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), <e1>benzodiazepines</e1>, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and <e2>nitrites</e2>, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
benzodiazepines,sympathomimetic agents,217,231,313,334,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), <e1>benzodiazepines</e1>, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, <e2>sympathomimetic agents</e2>, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
benzodiazepines,tricyclic antidepressants,217,231,337,361,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), <e1>benzodiazepines</e1>, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, <e2>tricyclic antidepressants</e2>, and other drugs having anticholinergic activity. ",False,negative
MAO inhibitors,narcotic analgesics,234,247,250,268,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, <e1>MAO inhibitors</e1>, <e2>narcotic analgesics</e2> (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
MAO inhibitors,meperidine,234,247,277,286,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, <e1>MAO inhibitors</e1>, narcotic analgesics (e.g., <e2>meperidine</e2>), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
MAO inhibitors,nitrates,234,247,290,297,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, <e1>MAO inhibitors</e1>, narcotic analgesics (e.g., meperidine), <e2>nitrates</e2> and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
MAO inhibitors,nitrites,234,247,303,310,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, <e1>MAO inhibitors</e1>, narcotic analgesics (e.g., meperidine), nitrates and <e2>nitrites</e2>, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
MAO inhibitors,sympathomimetic agents,234,247,313,334,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, <e1>MAO inhibitors</e1>, narcotic analgesics (e.g., meperidine), nitrates and nitrites, <e2>sympathomimetic agents</e2>, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
MAO inhibitors,tricyclic antidepressants,234,247,337,361,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, <e1>MAO inhibitors</e1>, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, <e2>tricyclic antidepressants</e2>, and other drugs having anticholinergic activity. ",False,negative
narcotic analgesics,meperidine,250,268,277,286,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, <e1>narcotic analgesics</e1> (e.g., <e2>meperidine</e2>), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
narcotic analgesics,nitrates,250,268,290,297,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, <e1>narcotic analgesics</e1> (e.g., meperidine), <e2>nitrates</e2> and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
narcotic analgesics,nitrites,250,268,303,310,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, <e1>narcotic analgesics</e1> (e.g., meperidine), nitrates and <e2>nitrites</e2>, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
narcotic analgesics,sympathomimetic agents,250,268,313,334,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, <e1>narcotic analgesics</e1> (e.g., meperidine), nitrates and nitrites, <e2>sympathomimetic agents</e2>, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
narcotic analgesics,tricyclic antidepressants,250,268,337,361,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, <e1>narcotic analgesics</e1> (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, <e2>tricyclic antidepressants</e2>, and other drugs having anticholinergic activity. ",False,negative
meperidine,nitrates,277,286,290,297,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., <e1>meperidine</e1>), <e2>nitrates</e2> and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
meperidine,nitrites,277,286,303,310,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., <e1>meperidine</e1>), nitrates and <e2>nitrites</e2>, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
meperidine,sympathomimetic agents,277,286,313,334,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., <e1>meperidine</e1>), nitrates and nitrites, <e2>sympathomimetic agents</e2>, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
meperidine,tricyclic antidepressants,277,286,337,361,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., <e1>meperidine</e1>), nitrates and nitrites, sympathomimetic agents, <e2>tricyclic antidepressants</e2>, and other drugs having anticholinergic activity. ",False,negative
nitrates,nitrites,290,297,303,310,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), <e1>nitrates</e1> and <e2>nitrites</e2>, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
nitrates,sympathomimetic agents,290,297,313,334,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), <e1>nitrates</e1> and nitrites, <e2>sympathomimetic agents</e2>, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
nitrates,tricyclic antidepressants,290,297,337,361,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), <e1>nitrates</e1> and nitrites, sympathomimetic agents, <e2>tricyclic antidepressants</e2>, and other drugs having anticholinergic activity. ",False,negative
nitrites,sympathomimetic agents,303,310,313,334,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and <e1>nitrites</e1>, <e2>sympathomimetic agents</e2>, tricyclic antidepressants, and other drugs having anticholinergic activity. ",False,negative
nitrites,tricyclic antidepressants,303,310,337,361,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and <e1>nitrites</e1>, sympathomimetic agents, <e2>tricyclic antidepressants</e2>, and other drugs having anticholinergic activity. ",False,negative
sympathomimetic agents,tricyclic antidepressants,313,334,337,361,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, <e1>sympathomimetic agents</e1>, <e2>tricyclic antidepressants</e2>, and other drugs having anticholinergic activity. ",False,negative
Anticholinergics,antiglaucoma agents,0,15,43,61,<e1>Anticholinergics</e1> antagonize the effects of <e2>antiglaucoma agents</e2>. ,True,effect
Anticholinergic drugs,corticosteroids,0,20,133,147,<e1>Anticholinergic drugs</e1> in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as <e2>corticosteroids</e2>. ,True,effect
Anticholinergic agents,digoxin,0,21,122,128,"<e1>Anticholinergic agents</e1> may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of <e2>digoxin</e2>; ",True,mechanism
Anticholinergic drugs,metoclopramide,0,20,104,117,"<e1>Anticholinergic drugs</e1> may antagonize the effects of drugs that alter gastrointestinal motility, such as <e2>metoclopramide</e2>. ",True,effect
antacids,anticholinergic agents,8,15,54,75,"Because <e1>antacids</e1> may interfere with the absorption of <e2>anticholinergic agents</e2>, simultaneous use of these drugs should be avoided. ",True,mechanism
Central Nervous System Depressants,MEPERIDINE,23,56,59,68,"Interaction with Other <e1>Central Nervous System Depressants</e1>: <e2>MEPERIDINE</e2> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",False,negative
Central Nervous System Depressants,NARCOTIC ANALGESICS,23,56,175,193,"Interaction with Other <e1>Central Nervous System Depressants</e1>: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER <e2>NARCOTIC ANALGESICS</e2>, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",False,negative
Central Nervous System Depressants,ANESTHETICS,23,56,204,214,"Interaction with Other <e1>Central Nervous System Depressants</e1>: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL <e2>ANESTHETICS</e2>, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",False,negative
Central Nervous System Depressants,PHENOTHIAZINES,23,56,217,230,"Interaction with Other <e1>Central Nervous System Depressants</e1>: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, <e2>PHENOTHIAZINES</e2>, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",False,negative
Central Nervous System Depressants,TRANQUILIZERS,23,56,239,251,"Interaction with Other <e1>Central Nervous System Depressants</e1>: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER <e2>TRANQUILIZERS</e2>, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",False,negative
Central Nervous System Depressants,SEDATIVE-HYPNOTICS,23,56,254,271,"Interaction with Other <e1>Central Nervous System Depressants</e1>: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, <e2>SEDATIVE-HYPNOTICS</e2> (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",False,negative
Central Nervous System Depressants,BARBITURATES,23,56,284,295,"Interaction with Other <e1>Central Nervous System Depressants</e1>: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING <e2>BARBITURATES</e2>), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",False,negative
Central Nervous System Depressants,TRICYCLIC ANTIDEPRESSANTS,23,56,299,323,"Interaction with Other <e1>Central Nervous System Depressants</e1>: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), <e2>TRICYCLIC ANTIDEPRESSANTS</e2> AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",False,negative
Central Nervous System Depressants,CNS DEPRESSANTS,23,56,335,349,"Interaction with Other <e1>Central Nervous System Depressants</e1>: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER <e2>CNS DEPRESSANTS</e2> (INCLUDING ALCOHOL). ",False,negative
Central Nervous System Depressants,ALCOHOL,23,56,362,368,"Interaction with Other <e1>Central Nervous System Depressants</e1>: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING <e2>ALCOHOL</e2>). ",False,negative
MEPERIDINE,NARCOTIC ANALGESICS,59,68,175,193,"Interaction with Other Central Nervous System Depressants: <e1>MEPERIDINE</e1> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER <e2>NARCOTIC ANALGESICS</e2>, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",True,advise
MEPERIDINE,ANESTHETICS,59,68,204,214,"Interaction with Other Central Nervous System Depressants: <e1>MEPERIDINE</e1> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL <e2>ANESTHETICS</e2>, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",True,advise
MEPERIDINE,PHENOTHIAZINES,59,68,217,230,"Interaction with Other Central Nervous System Depressants: <e1>MEPERIDINE</e1> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, <e2>PHENOTHIAZINES</e2>, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",True,advise
MEPERIDINE,TRANQUILIZERS,59,68,239,251,"Interaction with Other Central Nervous System Depressants: <e1>MEPERIDINE</e1> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER <e2>TRANQUILIZERS</e2>, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",True,advise
MEPERIDINE,SEDATIVE-HYPNOTICS,59,68,254,271,"Interaction with Other Central Nervous System Depressants: <e1>MEPERIDINE</e1> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, <e2>SEDATIVE-HYPNOTICS</e2> (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",True,advise
MEPERIDINE,BARBITURATES,59,68,284,295,"Interaction with Other Central Nervous System Depressants: <e1>MEPERIDINE</e1> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING <e2>BARBITURATES</e2>), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",True,advise
MEPERIDINE,TRICYCLIC ANTIDEPRESSANTS,59,68,299,323,"Interaction with Other Central Nervous System Depressants: <e1>MEPERIDINE</e1> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), <e2>TRICYCLIC ANTIDEPRESSANTS</e2> AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",True,advise
MEPERIDINE,CNS DEPRESSANTS,59,68,335,349,"Interaction with Other Central Nervous System Depressants: <e1>MEPERIDINE</e1> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER <e2>CNS DEPRESSANTS</e2> (INCLUDING ALCOHOL). ",True,advise
MEPERIDINE,ALCOHOL,59,68,362,368,"Interaction with Other Central Nervous System Depressants: <e1>MEPERIDINE</e1> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING <e2>ALCOHOL</e2>). ",True,advise
NARCOTIC ANALGESICS,ANESTHETICS,175,193,204,214,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER <e1>NARCOTIC ANALGESICS</e1>, GENERAL <e2>ANESTHETICS</e2>, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",False,negative
NARCOTIC ANALGESICS,PHENOTHIAZINES,175,193,217,230,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER <e1>NARCOTIC ANALGESICS</e1>, GENERAL ANESTHETICS, <e2>PHENOTHIAZINES</e2>, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",False,negative
NARCOTIC ANALGESICS,TRANQUILIZERS,175,193,239,251,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER <e1>NARCOTIC ANALGESICS</e1>, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER <e2>TRANQUILIZERS</e2>, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",False,negative
NARCOTIC ANALGESICS,SEDATIVE-HYPNOTICS,175,193,254,271,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER <e1>NARCOTIC ANALGESICS</e1>, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, <e2>SEDATIVE-HYPNOTICS</e2> (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",False,negative
NARCOTIC ANALGESICS,BARBITURATES,175,193,284,295,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER <e1>NARCOTIC ANALGESICS</e1>, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING <e2>BARBITURATES</e2>), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",False,negative
NARCOTIC ANALGESICS,TRICYCLIC ANTIDEPRESSANTS,175,193,299,323,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER <e1>NARCOTIC ANALGESICS</e1>, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), <e2>TRICYCLIC ANTIDEPRESSANTS</e2> AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",False,negative
NARCOTIC ANALGESICS,CNS DEPRESSANTS,175,193,335,349,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER <e1>NARCOTIC ANALGESICS</e1>, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER <e2>CNS DEPRESSANTS</e2> (INCLUDING ALCOHOL). ",False,negative
NARCOTIC ANALGESICS,ALCOHOL,175,193,362,368,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER <e1>NARCOTIC ANALGESICS</e1>, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING <e2>ALCOHOL</e2>). ",False,negative
ANESTHETICS,PHENOTHIAZINES,204,214,217,230,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL <e1>ANESTHETICS</e1>, <e2>PHENOTHIAZINES</e2>, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",False,negative
ANESTHETICS,TRANQUILIZERS,204,214,239,251,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL <e1>ANESTHETICS</e1>, PHENOTHIAZINES, OTHER <e2>TRANQUILIZERS</e2>, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",False,negative
ANESTHETICS,SEDATIVE-HYPNOTICS,204,214,254,271,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL <e1>ANESTHETICS</e1>, PHENOTHIAZINES, OTHER TRANQUILIZERS, <e2>SEDATIVE-HYPNOTICS</e2> (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",False,negative
ANESTHETICS,BARBITURATES,204,214,284,295,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL <e1>ANESTHETICS</e1>, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING <e2>BARBITURATES</e2>), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",False,negative
ANESTHETICS,TRICYCLIC ANTIDEPRESSANTS,204,214,299,323,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL <e1>ANESTHETICS</e1>, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), <e2>TRICYCLIC ANTIDEPRESSANTS</e2> AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",False,negative
ANESTHETICS,CNS DEPRESSANTS,204,214,335,349,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL <e1>ANESTHETICS</e1>, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER <e2>CNS DEPRESSANTS</e2> (INCLUDING ALCOHOL). ",False,negative
ANESTHETICS,ALCOHOL,204,214,362,368,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL <e1>ANESTHETICS</e1>, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING <e2>ALCOHOL</e2>). ",False,negative
PHENOTHIAZINES,TRANQUILIZERS,217,230,239,251,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, <e1>PHENOTHIAZINES</e1>, OTHER <e2>TRANQUILIZERS</e2>, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",False,negative
PHENOTHIAZINES,SEDATIVE-HYPNOTICS,217,230,254,271,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, <e1>PHENOTHIAZINES</e1>, OTHER TRANQUILIZERS, <e2>SEDATIVE-HYPNOTICS</e2> (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",False,negative
PHENOTHIAZINES,BARBITURATES,217,230,284,295,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, <e1>PHENOTHIAZINES</e1>, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING <e2>BARBITURATES</e2>), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",False,negative
PHENOTHIAZINES,TRICYCLIC ANTIDEPRESSANTS,217,230,299,323,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, <e1>PHENOTHIAZINES</e1>, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), <e2>TRICYCLIC ANTIDEPRESSANTS</e2> AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",False,negative
PHENOTHIAZINES,CNS DEPRESSANTS,217,230,335,349,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, <e1>PHENOTHIAZINES</e1>, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER <e2>CNS DEPRESSANTS</e2> (INCLUDING ALCOHOL). ",False,negative
PHENOTHIAZINES,ALCOHOL,217,230,362,368,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, <e1>PHENOTHIAZINES</e1>, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING <e2>ALCOHOL</e2>). ",False,negative
TRANQUILIZERS,SEDATIVE-HYPNOTICS,239,251,254,271,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER <e1>TRANQUILIZERS</e1>, <e2>SEDATIVE-HYPNOTICS</e2> (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",False,negative
TRANQUILIZERS,BARBITURATES,239,251,284,295,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER <e1>TRANQUILIZERS</e1>, SEDATIVE-HYPNOTICS (INCLUDING <e2>BARBITURATES</e2>), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",False,negative
TRANQUILIZERS,TRICYCLIC ANTIDEPRESSANTS,239,251,299,323,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER <e1>TRANQUILIZERS</e1>, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), <e2>TRICYCLIC ANTIDEPRESSANTS</e2> AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",False,negative
TRANQUILIZERS,CNS DEPRESSANTS,239,251,335,349,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER <e1>TRANQUILIZERS</e1>, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER <e2>CNS DEPRESSANTS</e2> (INCLUDING ALCOHOL). ",False,negative
TRANQUILIZERS,ALCOHOL,239,251,362,368,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER <e1>TRANQUILIZERS</e1>, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING <e2>ALCOHOL</e2>). ",False,negative
SEDATIVE-HYPNOTICS,BARBITURATES,254,271,284,295,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, <e1>SEDATIVE-HYPNOTICS</e1> (INCLUDING <e2>BARBITURATES</e2>), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",False,negative
SEDATIVE-HYPNOTICS,TRICYCLIC ANTIDEPRESSANTS,254,271,299,323,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, <e1>SEDATIVE-HYPNOTICS</e1> (INCLUDING BARBITURATES), <e2>TRICYCLIC ANTIDEPRESSANTS</e2> AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",False,negative
SEDATIVE-HYPNOTICS,CNS DEPRESSANTS,254,271,335,349,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, <e1>SEDATIVE-HYPNOTICS</e1> (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER <e2>CNS DEPRESSANTS</e2> (INCLUDING ALCOHOL). ",False,negative
SEDATIVE-HYPNOTICS,ALCOHOL,254,271,362,368,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, <e1>SEDATIVE-HYPNOTICS</e1> (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING <e2>ALCOHOL</e2>). ",False,negative
BARBITURATES,TRICYCLIC ANTIDEPRESSANTS,284,295,299,323,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING <e1>BARBITURATES</e1>), <e2>TRICYCLIC ANTIDEPRESSANTS</e2> AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",False,negative
BARBITURATES,CNS DEPRESSANTS,284,295,335,349,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING <e1>BARBITURATES</e1>), TRICYCLIC ANTIDEPRESSANTS AND OTHER <e2>CNS DEPRESSANTS</e2> (INCLUDING ALCOHOL). ",False,negative
BARBITURATES,ALCOHOL,284,295,362,368,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING <e1>BARBITURATES</e1>), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING <e2>ALCOHOL</e2>). ",False,negative
TRICYCLIC ANTIDEPRESSANTS,CNS DEPRESSANTS,299,323,335,349,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), <e1>TRICYCLIC ANTIDEPRESSANTS</e1> AND OTHER <e2>CNS DEPRESSANTS</e2> (INCLUDING ALCOHOL). ",False,negative
TRICYCLIC ANTIDEPRESSANTS,ALCOHOL,299,323,362,368,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), <e1>TRICYCLIC ANTIDEPRESSANTS</e1> AND OTHER CNS DEPRESSANTS (INCLUDING <e2>ALCOHOL</e2>). ",False,negative
CNS DEPRESSANTS,ALCOHOL,335,349,362,368,"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER <e1>CNS DEPRESSANTS</e1> (INCLUDING <e2>ALCOHOL</e2>). ",False,negative
anticonvulsants,Mephenytoin,5,19,39,49,Some <e1>anticonvulsants</e1> may interact with <e2>Mephenytoin</e2>. ,True,int
anticonvulsants,divalproex sodium,6,20,30,46,"Those <e1>anticonvulsants</e1> include <e2>divalproex sodium</e2>, valproic acid, and phenobarbital. ",False,negative
anticonvulsants,valproic acid,6,20,49,61,"Those <e1>anticonvulsants</e1> include divalproex sodium, <e2>valproic acid</e2>, and phenobarbital. ",False,negative
anticonvulsants,phenobarbital,6,20,68,80,"Those <e1>anticonvulsants</e1> include divalproex sodium, valproic acid, and <e2>phenobarbital</e2>. ",False,negative
divalproex sodium,valproic acid,30,46,49,61,"Those anticonvulsants include <e1>divalproex sodium</e1>, <e2>valproic acid</e2>, and phenobarbital. ",False,negative
divalproex sodium,phenobarbital,30,46,68,80,"Those anticonvulsants include <e1>divalproex sodium</e1>, valproic acid, and <e2>phenobarbital</e2>. ",False,negative
valproic acid,phenobarbital,49,61,68,80,"Those anticonvulsants include divalproex sodium, <e1>valproic acid</e1>, and <e2>phenobarbital</e2>. ",False,negative
Mephenytoin,steroid medications,0,10,75,93,"<e1>Mephenytoin</e1> may also affect the effects of other drugs, which include some <e2>steroid medications</e2>, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.",True,effect
Mephenytoin,warfarin,0,10,96,103,"<e1>Mephenytoin</e1> may also affect the effects of other drugs, which include some steroid medications, <e2>warfarin</e2>, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.",True,effect
Mephenytoin,anti-infective medicines,0,10,152,175,"<e1>Mephenytoin</e1> may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, <e2>anti-infective medicines</e2>, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.",True,effect
Mephenytoin,furosemide,0,10,178,187,"<e1>Mephenytoin</e1> may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, <e2>furosemide</e2> and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.",True,effect
Mephenytoin,theophylline,0,10,193,204,"<e1>Mephenytoin</e1> may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and <e2>theophylline</e2> Please note that Mephenytoin may interact with other drugs that are not listed here.",True,effect
Mephenytoin,Mephenytoin,0,10,223,233,"<e1>Mephenytoin</e1> may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that <e2>Mephenytoin</e2> may interact with other drugs that are not listed here.",False,negative
steroid medications,warfarin,75,93,96,103,"Mephenytoin may also affect the effects of other drugs, which include some <e1>steroid medications</e1>, <e2>warfarin</e2>, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.",False,negative
steroid medications,anti-infective medicines,75,93,152,175,"Mephenytoin may also affect the effects of other drugs, which include some <e1>steroid medications</e1>, warfarin, certain heart medicines, birth control pills, <e2>anti-infective medicines</e2>, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.",False,negative
steroid medications,furosemide,75,93,178,187,"Mephenytoin may also affect the effects of other drugs, which include some <e1>steroid medications</e1>, warfarin, certain heart medicines, birth control pills, anti-infective medicines, <e2>furosemide</e2> and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.",False,negative
steroid medications,theophylline,75,93,193,204,"Mephenytoin may also affect the effects of other drugs, which include some <e1>steroid medications</e1>, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and <e2>theophylline</e2> Please note that Mephenytoin may interact with other drugs that are not listed here.",False,negative
steroid medications,Mephenytoin,75,93,223,233,"Mephenytoin may also affect the effects of other drugs, which include some <e1>steroid medications</e1>, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that <e2>Mephenytoin</e2> may interact with other drugs that are not listed here.",False,negative
warfarin,anti-infective medicines,96,103,152,175,"Mephenytoin may also affect the effects of other drugs, which include some steroid medications, <e1>warfarin</e1>, certain heart medicines, birth control pills, <e2>anti-infective medicines</e2>, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.",False,negative
warfarin,furosemide,96,103,178,187,"Mephenytoin may also affect the effects of other drugs, which include some steroid medications, <e1>warfarin</e1>, certain heart medicines, birth control pills, anti-infective medicines, <e2>furosemide</e2> and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.",False,negative
warfarin,theophylline,96,103,193,204,"Mephenytoin may also affect the effects of other drugs, which include some steroid medications, <e1>warfarin</e1>, certain heart medicines, birth control pills, anti-infective medicines, furosemide and <e2>theophylline</e2> Please note that Mephenytoin may interact with other drugs that are not listed here.",False,negative
warfarin,Mephenytoin,96,103,223,233,"Mephenytoin may also affect the effects of other drugs, which include some steroid medications, <e1>warfarin</e1>, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that <e2>Mephenytoin</e2> may interact with other drugs that are not listed here.",False,negative
anti-infective medicines,furosemide,152,175,178,187,"Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, <e1>anti-infective medicines</e1>, <e2>furosemide</e2> and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.",False,negative
anti-infective medicines,theophylline,152,175,193,204,"Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, <e1>anti-infective medicines</e1>, furosemide and <e2>theophylline</e2> Please note that Mephenytoin may interact with other drugs that are not listed here.",False,negative
anti-infective medicines,Mephenytoin,152,175,223,233,"Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, <e1>anti-infective medicines</e1>, furosemide and theophylline Please note that <e2>Mephenytoin</e2> may interact with other drugs that are not listed here.",False,negative
furosemide,theophylline,178,187,193,204,"Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, <e1>furosemide</e1> and <e2>theophylline</e2> Please note that Mephenytoin may interact with other drugs that are not listed here.",False,negative
furosemide,Mephenytoin,178,187,223,233,"Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, <e1>furosemide</e1> and theophylline Please note that <e2>Mephenytoin</e2> may interact with other drugs that are not listed here.",False,negative
theophylline,Mephenytoin,193,204,223,233,"Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and <e1>theophylline</e1> Please note that <e2>Mephenytoin</e2> may interact with other drugs that are not listed here.",False,negative
Mequitazine,CNS depressant,0,10,30,43,"<e1>Mequitazine</e1> can interact with <e2>CNS depressant</e2>, antichlolinergic, TCA, MAOIs, and alcohol.",True,int
Mequitazine,antichlolinergic,0,10,46,61,"<e1>Mequitazine</e1> can interact with CNS depressant, <e2>antichlolinergic</e2>, TCA, MAOIs, and alcohol.",True,int
Mequitazine,TCA,0,10,64,66,"<e1>Mequitazine</e1> can interact with CNS depressant, antichlolinergic, <e2>TCA</e2>, MAOIs, and alcohol.",True,int
Mequitazine,MAOIs,0,10,69,73,"<e1>Mequitazine</e1> can interact with CNS depressant, antichlolinergic, TCA, <e2>MAOIs</e2>, and alcohol.",True,int
Mequitazine,alcohol,0,10,80,86,"<e1>Mequitazine</e1> can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and <e2>alcohol</e2>.",True,int
CNS depressant,antichlolinergic,30,43,46,61,"Mequitazine can interact with <e1>CNS depressant</e1>, <e2>antichlolinergic</e2>, TCA, MAOIs, and alcohol.",False,negative
CNS depressant,TCA,30,43,64,66,"Mequitazine can interact with <e1>CNS depressant</e1>, antichlolinergic, <e2>TCA</e2>, MAOIs, and alcohol.",False,negative
CNS depressant,MAOIs,30,43,69,73,"Mequitazine can interact with <e1>CNS depressant</e1>, antichlolinergic, TCA, <e2>MAOIs</e2>, and alcohol.",False,negative
CNS depressant,alcohol,30,43,80,86,"Mequitazine can interact with <e1>CNS depressant</e1>, antichlolinergic, TCA, MAOIs, and <e2>alcohol</e2>.",False,negative
antichlolinergic,TCA,46,61,64,66,"Mequitazine can interact with CNS depressant, <e1>antichlolinergic</e1>, <e2>TCA</e2>, MAOIs, and alcohol.",False,negative
antichlolinergic,MAOIs,46,61,69,73,"Mequitazine can interact with CNS depressant, <e1>antichlolinergic</e1>, TCA, <e2>MAOIs</e2>, and alcohol.",False,negative
antichlolinergic,alcohol,46,61,80,86,"Mequitazine can interact with CNS depressant, <e1>antichlolinergic</e1>, TCA, MAOIs, and <e2>alcohol</e2>.",False,negative
TCA,MAOIs,64,66,69,73,"Mequitazine can interact with CNS depressant, antichlolinergic, <e1>TCA</e1>, <e2>MAOIs</e2>, and alcohol.",False,negative
TCA,alcohol,64,66,80,86,"Mequitazine can interact with CNS depressant, antichlolinergic, <e1>TCA</e1>, MAOIs, and <e2>alcohol</e2>.",False,negative
MAOIs,alcohol,69,73,80,86,"Mequitazine can interact with CNS depressant, antichlolinergic, TCA, <e1>MAOIs</e1>, and <e2>alcohol</e2>.",False,negative
Probenecid,meropenem,0,9,25,33,<e1>Probenecid</e1> competes with <e2>meropenem</e2> for active tubular secretion and thus inhibits the renal excretion of meropenem. ,True,mechanism
Probenecid,meropenem,0,9,105,113,<e1>Probenecid</e1> competes with meropenem for active tubular secretion and thus inhibits the renal excretion of <e2>meropenem</e2>. ,False,negative
meropenem,meropenem,25,33,105,113,Probenecid competes with <e1>meropenem</e1> for active tubular secretion and thus inhibits the renal excretion of <e2>meropenem</e2>. ,False,negative
probenecid,meropenem,35,44,51,59,"Therefore, the coadministration of <e1>probenecid</e1> with <e2>meropenem</e2> is not recommended. ",True,advise
meropenem,valproic acid,23,31,60,72,There is evidence that <e1>meropenem</e1> may reduce serum levels of <e2>valproic acid</e2> to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total valproate).,True,mechanism
meropenem,valproate,23,31,159,167,There is evidence that <e1>meropenem</e1> may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total <e2>valproate</e2>).,False,negative
valproic acid,valproate,60,72,159,167,There is evidence that meropenem may reduce serum levels of <e1>valproic acid</e1> to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total <e2>valproate</e2>).,False,negative
ARAMINE,digitalis,0,6,86,94,"<e1>ARAMINE</e1> should be used with caution in digitalized patients, since the combination of <e2>digitalis</e2> and sympathomimetic amines may cause ectopic arrhythmias. ",False,negative
ARAMINE,sympathomimetic amines,0,6,100,121,"<e1>ARAMINE</e1> should be used with caution in digitalized patients, since the combination of digitalis and <e2>sympathomimetic amines</e2> may cause ectopic arrhythmias. ",False,negative
digitalis,sympathomimetic amines,86,94,100,121,"ARAMINE should be used with caution in digitalized patients, since the combination of <e1>digitalis</e1> and <e2>sympathomimetic amines</e2> may cause ectopic arrhythmias. ",True,effect
Monoamine oxidase inhibitors,tricyclic antidepressants,0,27,32,56,<e1>Monoamine oxidase inhibitors</e1> or <e2>tricyclic antidepressants</e2> may potentiate the action of sympathomimetic amines. ,False,negative
Monoamine oxidase inhibitors,sympathomimetic amines,0,27,87,108,<e1>Monoamine oxidase inhibitors</e1> or tricyclic antidepressants may potentiate the action of <e2>sympathomimetic amines</e2>. ,True,effect
tricyclic antidepressants,sympathomimetic amines,32,56,87,108,Monoamine oxidase inhibitors or <e1>tricyclic antidepressants</e1> may potentiate the action of <e2>sympathomimetic amines</e2>. ,True,effect
SKELAXIN,alcohol,0,7,36,42,"<e1>SKELAXIN</e1> may enhance the effects of <e2>alcohol</e2>, barbiturates and other CNS depressants.",True,effect
SKELAXIN,barbiturates,0,7,45,56,"<e1>SKELAXIN</e1> may enhance the effects of alcohol, <e2>barbiturates</e2> and other CNS depressants.",True,effect
SKELAXIN,CNS depressants,0,7,68,82,"<e1>SKELAXIN</e1> may enhance the effects of alcohol, barbiturates and other <e2>CNS depressants</e2>.",True,effect
alcohol,barbiturates,36,42,45,56,"SKELAXIN may enhance the effects of <e1>alcohol</e1>, <e2>barbiturates</e2> and other CNS depressants.",False,negative
alcohol,CNS depressants,36,42,68,82,"SKELAXIN may enhance the effects of <e1>alcohol</e1>, barbiturates and other <e2>CNS depressants</e2>.",False,negative
barbiturates,CNS depressants,45,56,68,82,"SKELAXIN may enhance the effects of alcohol, <e1>barbiturates</e1> and other <e2>CNS depressants</e2>.",False,negative
aspirin,methazolamide,52,58,64,76,"Caution is advised for patients receiving high-dose <e1>aspirin</e1> and <e2>methazolamide</e2> concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.",True,advise
aspirin,aspirin,52,58,195,201,"Caution is advised for patients receiving high-dose <e1>aspirin</e1> and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose <e2>aspirin</e2> and carbonic anhydrase inhibitors.",False,negative
aspirin,carbonic anhydrase inhibitors,52,58,207,235,"Caution is advised for patients receiving high-dose <e1>aspirin</e1> and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and <e2>carbonic anhydrase inhibitors</e2>.",False,negative
methazolamide,aspirin,64,76,195,201,"Caution is advised for patients receiving high-dose aspirin and <e1>methazolamide</e1> concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose <e2>aspirin</e2> and carbonic anhydrase inhibitors.",False,negative
methazolamide,carbonic anhydrase inhibitors,64,76,207,235,"Caution is advised for patients receiving high-dose aspirin and <e1>methazolamide</e1> concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and <e2>carbonic anhydrase inhibitors</e2>.",False,negative
aspirin,carbonic anhydrase inhibitors,195,201,207,235,"Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose <e1>aspirin</e1> and <e2>carbonic anhydrase inhibitors</e2>.",True,effect
Anticoagulants,anticoagulants,0,13,44,57,<e1>Anticoagulants</e1> (oral): The activity of oral <e2>anticoagulants</e2> may be potentiated by anti-vitamin-K activity attributed to methimazole.    ,False,negative
Anticoagulants,methimazole,0,13,119,129,<e1>Anticoagulants</e1> (oral): The activity of oral anticoagulants may be potentiated by anti-vitamin-K activity attributed to <e2>methimazole</e2>.    ,False,negative
anticoagulants,methimazole,44,57,119,129,Anticoagulants (oral): The activity of oral <e1>anticoagulants</e1> may be potentiated by anti-vitamin-K activity attributed to <e2>methimazole</e2>.    ,True,effect
Digitalis glycosides,digitalis glycoside,0,19,101,119,<e1>Digitalis glycosides</e1>: Serum digitalis levels may be increased when hyperthyroid patients on a stable <e2>digitalis glycoside</e2> regimen become euthyroid; ,False,negative
Theophylline,Theophylline,0,11,14,25,<e1>Theophylline</e1>: <e2>Theophylline</e2> clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid; ,False,negative
Theophylline,theophylline,0,11,89,100,<e1>Theophylline</e1>: Theophylline clearance may decrease when hyperthyroid patients on a stable <e2>theophylline</e2> regimen become euthyroid; ,False,negative
Theophylline,theophylline,14,25,89,100,Theophylline: <e1>Theophylline</e1> clearance may decrease when hyperthyroid patients on a stable <e2>theophylline</e2> regimen become euthyroid; ,False,negative
opioids,levomepromazine,38,44,95,109,"Dosages of concomitantly administered <e1>opioids</e1> should be reduced by approximately half, because <e2>levomepromazine</e2> amplifies the therapeutic actions and side-effects of opioids. ",True,effect
opioids,opioids,38,44,165,171,"Dosages of concomitantly administered <e1>opioids</e1> should be reduced by approximately half, because levomepromazine amplifies the therapeutic actions and side-effects of <e2>opioids</e2>. ",False,negative
levomepromazine,opioids,95,109,165,171,"Dosages of concomitantly administered opioids should be reduced by approximately half, because <e1>levomepromazine</e1> amplifies the therapeutic actions and side-effects of <e2>opioids</e2>. ",True,effect
tramadol,Ultram,17,24,27,32,Combination with <e1>tramadol</e1> (<e2>Ultram</e2>) is associated with increased risk of seizures. ,False,negative
levomepromazine,benzodiazepines,63,77,93,107,Additive sedative effects and confusional states may emerge if <e1>levomepromazine</e1> is given with <e2>benzodiazepines</e2> or barbiturates. ,True,effect
levomepromazine,barbiturates,63,77,112,123,Additive sedative effects and confusional states may emerge if <e1>levomepromazine</e1> is given with benzodiazepines or <e2>barbiturates</e2>. ,True,effect
benzodiazepines,barbiturates,93,107,112,123,Additive sedative effects and confusional states may emerge if levomepromazine is given with <e1>benzodiazepines</e1> or <e2>barbiturates</e2>. ,False,negative
levomepromazine,anticholinergic drugs,38,52,65,85,"Exert particular caution in combining <e1>levomepromazine</e1> with other <e2>anticholinergic drugs</e2> (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",True,advise
levomepromazine,tricyclic antidepressants,38,52,88,112,"Exert particular caution in combining <e1>levomepromazine</e1> with other anticholinergic drugs (<e2>tricyclic antidepressants</e2> and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",True,advise
levomepromazine,antiparkinsonian-agents,38,52,118,140,"Exert particular caution in combining <e1>levomepromazine</e1> with other anticholinergic drugs (tricyclic antidepressants and <e2>antiparkinsonian-agents</e2>): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",True,advise
anticholinergic drugs,tricyclic antidepressants,65,85,88,112,"Exert particular caution in combining levomepromazine with other <e1>anticholinergic drugs</e1> (<e2>tricyclic antidepressants</e2> and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",False,negative
anticholinergic drugs,antiparkinsonian-agents,65,85,118,140,"Exert particular caution in combining levomepromazine with other <e1>anticholinergic drugs</e1> (tricyclic antidepressants and <e2>antiparkinsonian-agents</e2>): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",False,negative
tricyclic antidepressants,antiparkinsonian-agents,88,112,118,140,"Exert particular caution in combining levomepromazine with other anticholinergic drugs (<e1>tricyclic antidepressants</e1> and <e2>antiparkinsonian-agents</e2>): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",False,negative
Caffeine,ephedrine,0,7,35,43,<e1>Caffeine</e1> and/or stimulantes of the <e2>ephedrine</e2>/amphetamine type may counteract the specific actions of levomepromazine. ,False,negative
Caffeine,amphetamine,0,7,45,55,<e1>Caffeine</e1> and/or stimulantes of the ephedrine/<e2>amphetamine</e2> type may counteract the specific actions of levomepromazine. ,False,negative
Caffeine,levomepromazine,0,7,101,115,<e1>Caffeine</e1> and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of <e2>levomepromazine</e2>. ,True,effect
ephedrine,amphetamine,35,43,45,55,Caffeine and/or stimulantes of the <e1>ephedrine</e1>/<e2>amphetamine</e2> type may counteract the specific actions of levomepromazine. ,False,negative
ephedrine,levomepromazine,35,43,101,115,Caffeine and/or stimulantes of the <e1>ephedrine</e1>/amphetamine type may counteract the specific actions of <e2>levomepromazine</e2>. ,True,effect
amphetamine,levomepromazine,45,55,101,115,Caffeine and/or stimulantes of the ephedrine/<e1>amphetamine</e1> type may counteract the specific actions of <e2>levomepromazine</e2>. ,True,effect
Celontin,methsuximide,6,13,16,27,"Since <e1>Celontin</e1> (<e2>methsuximide</e2>) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",False,negative
Celontin,antiepileptic drugs,6,13,74,92,"Since <e1>Celontin</e1> (methsuximide) may interact with concurrently administered <e2>antiepileptic drugs</e2>, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",True,advise
Celontin,methsuximide,6,13,167,178,"Since <e1>Celontin</e1> (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg <e2>methsuximide</e2> may increase the plasma concentrations of phenytoin and phenobarbital).",False,negative
Celontin,phenytoin,6,13,222,230,"Since <e1>Celontin</e1> (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of <e2>phenytoin</e2> and phenobarbital).",False,negative
Celontin,phenobarbital,6,13,236,248,"Since <e1>Celontin</e1> (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and <e2>phenobarbital</e2>).",False,negative
methsuximide,antiepileptic drugs,16,27,74,92,"Since Celontin (<e1>methsuximide</e1>) may interact with concurrently administered <e2>antiepileptic drugs</e2>, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",True,advise
methsuximide,methsuximide,16,27,167,178,"Since Celontin (<e1>methsuximide</e1>) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg <e2>methsuximide</e2> may increase the plasma concentrations of phenytoin and phenobarbital).",False,negative
methsuximide,phenytoin,16,27,222,230,"Since Celontin (<e1>methsuximide</e1>) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of <e2>phenytoin</e2> and phenobarbital).",False,negative
methsuximide,phenobarbital,16,27,236,248,"Since Celontin (<e1>methsuximide</e1>) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and <e2>phenobarbital</e2>).",False,negative
antiepileptic drugs,methsuximide,74,92,167,178,"Since Celontin (methsuximide) may interact with concurrently administered <e1>antiepileptic drugs</e1>, periodic serum level determinations of these drugs may be necessary (eg <e2>methsuximide</e2> may increase the plasma concentrations of phenytoin and phenobarbital).",False,negative
antiepileptic drugs,phenytoin,74,92,222,230,"Since Celontin (methsuximide) may interact with concurrently administered <e1>antiepileptic drugs</e1>, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of <e2>phenytoin</e2> and phenobarbital).",False,negative
antiepileptic drugs,phenobarbital,74,92,236,248,"Since Celontin (methsuximide) may interact with concurrently administered <e1>antiepileptic drugs</e1>, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and <e2>phenobarbital</e2>).",False,negative
methsuximide,phenytoin,167,178,222,230,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg <e1>methsuximide</e1> may increase the plasma concentrations of <e2>phenytoin</e2> and phenobarbital).",True,mechanism
methsuximide,phenobarbital,167,178,236,248,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg <e1>methsuximide</e1> may increase the plasma concentrations of phenytoin and <e2>phenobarbital</e2>).",True,mechanism
phenytoin,phenobarbital,222,230,236,248,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of <e1>phenytoin</e1> and <e2>phenobarbital</e2>).",False,negative
steroids,ACTH,50,57,62,65,Hypokalemia may develop during concomitant use of <e1>steroids</e1> or <e2>ACTH</e2>. ,False,negative
Thiazides,norepinephrine,0,8,50,63,<e1>Thiazides</e1> may decrease arterial responsiveness to <e2>norepinephrine</e2>. ,True,effect
Thiazide drugs,tubocurarine,0,13,50,61,<e1>Thiazide drugs</e1> may increase the responsiveness of <e2>tubocurarine</e2>. ,True,effect
Lithium,thiazides,0,6,38,46,"<e1>Lithium</e1> renal clearance is reduced by <e2>thiazides</e2>, increasing the risk of lithium toxicity. ",True,mechanism
Lithium,lithium,0,6,72,78,"<e1>Lithium</e1> renal clearance is reduced by thiazides, increasing the risk of <e2>lithium</e2> toxicity. ",False,negative
thiazides,lithium,38,46,72,78,"Lithium renal clearance is reduced by <e1>thiazides</e1>, increasing the risk of <e2>lithium</e2> toxicity. ",False,negative
Thiazides,antihypertensive drugs,0,8,55,76,<e1>Thiazides</e1> may add to or potentiate the action of other <e2>antihypertensive drugs</e2>. ,True,effect
ganglionic adrenergic blocking drugs,peripheral adrenergic blocking drugs,25,34,39,74,Potentiation occurs with <e1>ganglionic adrenergic blocking drugs</e1> or <e2>peripheral adrenergic blocking drugs</e2>.,False,negative
methyldopa,antihypertensive drugs,5,14,35,56,"When <e1>methyldopa</e1> is used with other <e2>antihypertensive drugs</e2>, potentiation of antihypertensive effect may occur. ",True,effect
anesthetics,methyldopa,38,48,58,67,Patients may require reduced doses of <e1>anesthetics</e1> when on <e2>methyldopa</e2>. ,True,advise
methyldopa,lithium,5,14,20,26,When <e1>methyldopa</e1> and <e2>lithium</e2> are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity. ,True,advise
methyldopa,lithium,5,14,110,116,When <e1>methyldopa</e1> and lithium are given concomitantly the patient should be carefully monitored for symptoms of <e2>lithium</e2> toxicity. ,False,negative
lithium,lithium,20,26,110,116,When methyldopa and <e1>lithium</e1> are given concomitantly the patient should be carefully monitored for symptoms of <e2>lithium</e2> toxicity. ,False,negative
methyldopa,ferrous sulfate,65,74,101,115,Several studies demonstrate a decrease in the bioavailability of <e1>methyldopa</e1> when it is ingested with <e2>ferrous sulfate</e2> or ferrous gluconate. ,True,mechanism
methyldopa,ferrous gluconate,65,74,120,136,Several studies demonstrate a decrease in the bioavailability of <e1>methyldopa</e1> when it is ingested with ferrous sulfate or <e2>ferrous gluconate</e2>. ,True,mechanism
ferrous sulfate,ferrous gluconate,101,115,120,136,Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with <e1>ferrous sulfate</e1> or <e2>ferrous gluconate</e2>. ,False,negative
methyldopa,ferrous sulfate,20,29,36,50,Coadministration of <e1>methyldopa</e1> with <e2>ferrous sulfate</e2> or ferrous gluconate is not recommended. ,True,advise
methyldopa,ferrous gluconate,20,29,55,71,Coadministration of <e1>methyldopa</e1> with ferrous sulfate or <e2>ferrous gluconate</e2> is not recommended. ,True,advise
ferrous sulfate,ferrous gluconate,36,50,55,71,Coadministration of methyldopa with <e1>ferrous sulfate</e1> or <e2>ferrous gluconate</e2> is not recommended. ,False,negative
Methyldopa,VMA,0,9,50,52,"<e1>Methyldopa</e1> does not interfere with measurement of <e2>VMA</e2> (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin. ",False,negative
Methyldopa,vanillylmandelic acid,0,9,55,75,"<e1>Methyldopa</e1> does not interfere with measurement of VMA (<e2>vanillylmandelic acid</e2>), a test for pheochromocytoma, by those methods which convert VMA to vanillin. ",False,negative
Methyldopa,VMA,0,9,139,141,"<e1>Methyldopa</e1> does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert <e2>VMA</e2> to vanillin. ",False,negative
Methyldopa,vanillin,0,9,146,153,"<e1>Methyldopa</e1> does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to <e2>vanillin</e2>. ",False,negative
VMA,vanillylmandelic acid,50,52,55,75,"Methyldopa does not interfere with measurement of <e1>VMA</e1> (<e2>vanillylmandelic acid</e2>), a test for pheochromocytoma, by those methods which convert VMA to vanillin. ",False,negative
VMA,VMA,50,52,139,141,"Methyldopa does not interfere with measurement of <e1>VMA</e1> (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert <e2>VMA</e2> to vanillin. ",False,negative
VMA,vanillin,50,52,146,153,"Methyldopa does not interfere with measurement of <e1>VMA</e1> (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to <e2>vanillin</e2>. ",False,negative
vanillylmandelic acid,VMA,55,75,139,141,"Methyldopa does not interfere with measurement of VMA (<e1>vanillylmandelic acid</e1>), a test for pheochromocytoma, by those methods which convert <e2>VMA</e2> to vanillin. ",False,negative
vanillylmandelic acid,vanillin,55,75,146,153,"Methyldopa does not interfere with measurement of VMA (<e1>vanillylmandelic acid</e1>), a test for pheochromocytoma, by those methods which convert VMA to <e2>vanillin</e2>. ",False,negative
VMA,vanillin,139,141,146,153,"Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert <e1>VMA</e1> to <e2>vanillin</e2>. ",False,negative
Macrolide Antibiotics,Protease Inhibitors,25,45,51,69,"CYP 3A4 Inhibitors (e.g. <e1>Macrolide Antibiotics</e1> and <e2>Protease Inhibitors</e2>) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",False,negative
Macrolide Antibiotics,ergot alkaloid drugs,25,45,178,197,"CYP 3A4 Inhibitors (e.g. <e1>Macrolide Antibiotics</e1> and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain <e2>ergot alkaloid drugs</e2> (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",False,negative
Macrolide Antibiotics,dihydroergotamine,25,45,205,221,"CYP 3A4 Inhibitors (e.g. <e1>Macrolide Antibiotics</e1> and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. <e2>dihydroergotamine</e2> and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",False,negative
Macrolide Antibiotics,ergotamine,25,45,227,236,"CYP 3A4 Inhibitors (e.g. <e1>Macrolide Antibiotics</e1> and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and <e2>ergotamine</e2>) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",False,negative
Protease Inhibitors,ergot alkaloid drugs,51,69,178,197,"CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and <e1>Protease Inhibitors</e1>) There have been rare reports of serious adverse events in connection with the coadministration of certain <e2>ergot alkaloid drugs</e2> (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",False,negative
Protease Inhibitors,dihydroergotamine,51,69,205,221,"CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and <e1>Protease Inhibitors</e1>) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. <e2>dihydroergotamine</e2> and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",False,negative
Protease Inhibitors,ergotamine,51,69,227,236,"CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and <e1>Protease Inhibitors</e1>) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and <e2>ergotamine</e2>) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",False,negative
ergot alkaloid drugs,dihydroergotamine,178,197,205,221,"CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain <e1>ergot alkaloid drugs</e1> (e.g. <e2>dihydroergotamine</e2> and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",False,negative
ergot alkaloid drugs,ergotamine,178,197,227,236,"CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain <e1>ergot alkaloid drugs</e1> (e.g. dihydroergotamine and <e2>ergotamine</e2>) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",False,negative
dihydroergotamine,ergotamine,205,221,227,236,"CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. <e1>dihydroergotamine</e1> and <e2>ergotamine</e2>) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",False,negative
macrolide antibiotics,erythromycin,63,83,92,103,"Examples of some of the more potent CYP 3A4 inhibitors include <e1>macrolide antibiotics</e1> (e.g., <e2>erythromycin</e2>, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
macrolide antibiotics,troleandomycin,63,83,106,119,"Examples of some of the more potent CYP 3A4 inhibitors include <e1>macrolide antibiotics</e1> (e.g., erythromycin, <e2>troleandomycin</e2>, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
macrolide antibiotics,clarithromycin,63,83,122,135,"Examples of some of the more potent CYP 3A4 inhibitors include <e1>macrolide antibiotics</e1> (e.g., erythromycin, troleandomycin, <e2>clarithromycin</e2>), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
macrolide antibiotics,HIV protease inhibitors,63,83,139,150,"Examples of some of the more potent CYP 3A4 inhibitors include <e1>macrolide antibiotics</e1> (e.g., erythromycin, troleandomycin, clarithromycin), <e2>HIV protease inhibitors</e2> or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
macrolide antibiotics,reverse transcriptase inhibitors,63,83,155,186,"Examples of some of the more potent CYP 3A4 inhibitors include <e1>macrolide antibiotics</e1> (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or <e2>reverse transcriptase inhibitors</e2> (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
macrolide antibiotics,ritonavir,63,83,195,203,"Examples of some of the more potent CYP 3A4 inhibitors include <e1>macrolide antibiotics</e1> (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., <e2>ritonavir</e2>, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
macrolide antibiotics,indinavir,63,83,206,214,"Examples of some of the more potent CYP 3A4 inhibitors include <e1>macrolide antibiotics</e1> (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, <e2>indinavir</e2>, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
macrolide antibiotics,nelfinavir,63,83,217,226,"Examples of some of the more potent CYP 3A4 inhibitors include <e1>macrolide antibiotics</e1> (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, <e2>nelfinavir</e2>, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
macrolide antibiotics,delavirdine,63,83,229,239,"Examples of some of the more potent CYP 3A4 inhibitors include <e1>macrolide antibiotics</e1> (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, <e2>delavirdine</e2>) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
macrolide antibiotics,azole antifungals,63,83,245,261,"Examples of some of the more potent CYP 3A4 inhibitors include <e1>macrolide antibiotics</e1> (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or <e2>azole antifungals</e2> (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
macrolide antibiotics,ketoconazole,63,83,270,281,"Examples of some of the more potent CYP 3A4 inhibitors include <e1>macrolide antibiotics</e1> (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., <e2>ketoconazole</e2>, itraconazole, voriconazole). ",False,negative
macrolide antibiotics,itraconazole,63,83,284,295,"Examples of some of the more potent CYP 3A4 inhibitors include <e1>macrolide antibiotics</e1> (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, <e2>itraconazole</e2>, voriconazole). ",False,negative
macrolide antibiotics,voriconazole,63,83,298,309,"Examples of some of the more potent CYP 3A4 inhibitors include <e1>macrolide antibiotics</e1> (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, <e2>voriconazole</e2>). ",False,negative
erythromycin,troleandomycin,92,103,106,119,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., <e1>erythromycin</e1>, <e2>troleandomycin</e2>, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
erythromycin,clarithromycin,92,103,122,135,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., <e1>erythromycin</e1>, troleandomycin, <e2>clarithromycin</e2>), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
erythromycin,HIV protease inhibitors,92,103,139,150,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., <e1>erythromycin</e1>, troleandomycin, clarithromycin), <e2>HIV protease inhibitors</e2> or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
erythromycin,reverse transcriptase inhibitors,92,103,155,186,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., <e1>erythromycin</e1>, troleandomycin, clarithromycin), HIV protease or <e2>reverse transcriptase inhibitors</e2> (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
erythromycin,ritonavir,92,103,195,203,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., <e1>erythromycin</e1>, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., <e2>ritonavir</e2>, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
erythromycin,indinavir,92,103,206,214,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., <e1>erythromycin</e1>, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, <e2>indinavir</e2>, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
erythromycin,nelfinavir,92,103,217,226,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., <e1>erythromycin</e1>, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, <e2>nelfinavir</e2>, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
erythromycin,delavirdine,92,103,229,239,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., <e1>erythromycin</e1>, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, <e2>delavirdine</e2>) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
erythromycin,azole antifungals,92,103,245,261,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., <e1>erythromycin</e1>, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or <e2>azole antifungals</e2> (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
erythromycin,ketoconazole,92,103,270,281,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., <e1>erythromycin</e1>, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., <e2>ketoconazole</e2>, itraconazole, voriconazole). ",False,negative
erythromycin,itraconazole,92,103,284,295,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., <e1>erythromycin</e1>, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, <e2>itraconazole</e2>, voriconazole). ",False,negative
erythromycin,voriconazole,92,103,298,309,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., <e1>erythromycin</e1>, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, <e2>voriconazole</e2>). ",False,negative
troleandomycin,clarithromycin,106,119,122,135,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, <e1>troleandomycin</e1>, <e2>clarithromycin</e2>), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
troleandomycin,HIV protease inhibitors,106,119,139,150,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, <e1>troleandomycin</e1>, clarithromycin), <e2>HIV protease inhibitors</e2> or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
troleandomycin,reverse transcriptase inhibitors,106,119,155,186,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, <e1>troleandomycin</e1>, clarithromycin), HIV protease or <e2>reverse transcriptase inhibitors</e2> (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
troleandomycin,ritonavir,106,119,195,203,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, <e1>troleandomycin</e1>, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., <e2>ritonavir</e2>, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
troleandomycin,indinavir,106,119,206,214,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, <e1>troleandomycin</e1>, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, <e2>indinavir</e2>, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
troleandomycin,nelfinavir,106,119,217,226,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, <e1>troleandomycin</e1>, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, <e2>nelfinavir</e2>, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
troleandomycin,delavirdine,106,119,229,239,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, <e1>troleandomycin</e1>, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, <e2>delavirdine</e2>) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
troleandomycin,azole antifungals,106,119,245,261,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, <e1>troleandomycin</e1>, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or <e2>azole antifungals</e2> (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
troleandomycin,ketoconazole,106,119,270,281,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, <e1>troleandomycin</e1>, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., <e2>ketoconazole</e2>, itraconazole, voriconazole). ",False,negative
troleandomycin,itraconazole,106,119,284,295,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, <e1>troleandomycin</e1>, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, <e2>itraconazole</e2>, voriconazole). ",False,negative
troleandomycin,voriconazole,106,119,298,309,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, <e1>troleandomycin</e1>, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, <e2>voriconazole</e2>). ",False,negative
clarithromycin,HIV protease inhibitors,122,135,139,150,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, <e1>clarithromycin</e1>), <e2>HIV protease inhibitors</e2> or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
clarithromycin,reverse transcriptase inhibitors,122,135,155,186,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, <e1>clarithromycin</e1>), HIV protease or <e2>reverse transcriptase inhibitors</e2> (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
clarithromycin,ritonavir,122,135,195,203,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, <e1>clarithromycin</e1>), HIV protease or reverse transcriptase inhibitors (e.g., <e2>ritonavir</e2>, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
clarithromycin,indinavir,122,135,206,214,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, <e1>clarithromycin</e1>), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, <e2>indinavir</e2>, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
clarithromycin,nelfinavir,122,135,217,226,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, <e1>clarithromycin</e1>), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, <e2>nelfinavir</e2>, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
clarithromycin,delavirdine,122,135,229,239,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, <e1>clarithromycin</e1>), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, <e2>delavirdine</e2>) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
clarithromycin,azole antifungals,122,135,245,261,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, <e1>clarithromycin</e1>), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or <e2>azole antifungals</e2> (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
clarithromycin,ketoconazole,122,135,270,281,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, <e1>clarithromycin</e1>), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., <e2>ketoconazole</e2>, itraconazole, voriconazole). ",False,negative
clarithromycin,itraconazole,122,135,284,295,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, <e1>clarithromycin</e1>), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, <e2>itraconazole</e2>, voriconazole). ",False,negative
clarithromycin,voriconazole,122,135,298,309,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, <e1>clarithromycin</e1>), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, <e2>voriconazole</e2>). ",False,negative
HIV protease inhibitors,reverse transcriptase inhibitors,139,150,155,186,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), <e1>HIV protease inhibitors</e1> or <e2>reverse transcriptase inhibitors</e2> (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
HIV protease inhibitors,ritonavir,139,150,195,203,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), <e1>HIV protease inhibitors</e1> or reverse transcriptase inhibitors (e.g., <e2>ritonavir</e2>, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
HIV protease inhibitors,indinavir,139,150,206,214,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), <e1>HIV protease inhibitors</e1> or reverse transcriptase inhibitors (e.g., ritonavir, <e2>indinavir</e2>, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
HIV protease inhibitors,nelfinavir,139,150,217,226,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), <e1>HIV protease inhibitors</e1> or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, <e2>nelfinavir</e2>, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
HIV protease inhibitors,delavirdine,139,150,229,239,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), <e1>HIV protease inhibitors</e1> or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, <e2>delavirdine</e2>) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
HIV protease inhibitors,azole antifungals,139,150,245,261,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), <e1>HIV protease inhibitors</e1> or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or <e2>azole antifungals</e2> (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
HIV protease inhibitors,ketoconazole,139,150,270,281,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), <e1>HIV protease inhibitors</e1> or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., <e2>ketoconazole</e2>, itraconazole, voriconazole). ",False,negative
HIV protease inhibitors,itraconazole,139,150,284,295,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), <e1>HIV protease inhibitors</e1> or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, <e2>itraconazole</e2>, voriconazole). ",False,negative
HIV protease inhibitors,voriconazole,139,150,298,309,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), <e1>HIV protease inhibitors</e1> or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, <e2>voriconazole</e2>). ",False,negative
reverse transcriptase inhibitors,ritonavir,155,186,195,203,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or <e1>reverse transcriptase inhibitors</e1> (e.g., <e2>ritonavir</e2>, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
reverse transcriptase inhibitors,indinavir,155,186,206,214,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or <e1>reverse transcriptase inhibitors</e1> (e.g., ritonavir, <e2>indinavir</e2>, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
reverse transcriptase inhibitors,nelfinavir,155,186,217,226,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or <e1>reverse transcriptase inhibitors</e1> (e.g., ritonavir, indinavir, <e2>nelfinavir</e2>, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
reverse transcriptase inhibitors,delavirdine,155,186,229,239,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or <e1>reverse transcriptase inhibitors</e1> (e.g., ritonavir, indinavir, nelfinavir, <e2>delavirdine</e2>) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
reverse transcriptase inhibitors,azole antifungals,155,186,245,261,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or <e1>reverse transcriptase inhibitors</e1> (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or <e2>azole antifungals</e2> (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
reverse transcriptase inhibitors,ketoconazole,155,186,270,281,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or <e1>reverse transcriptase inhibitors</e1> (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., <e2>ketoconazole</e2>, itraconazole, voriconazole). ",False,negative
reverse transcriptase inhibitors,itraconazole,155,186,284,295,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or <e1>reverse transcriptase inhibitors</e1> (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, <e2>itraconazole</e2>, voriconazole). ",False,negative
reverse transcriptase inhibitors,voriconazole,155,186,298,309,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or <e1>reverse transcriptase inhibitors</e1> (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, <e2>voriconazole</e2>). ",False,negative
ritonavir,indinavir,195,203,206,214,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., <e1>ritonavir</e1>, <e2>indinavir</e2>, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
ritonavir,nelfinavir,195,203,217,226,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., <e1>ritonavir</e1>, indinavir, <e2>nelfinavir</e2>, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
ritonavir,delavirdine,195,203,229,239,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., <e1>ritonavir</e1>, indinavir, nelfinavir, <e2>delavirdine</e2>) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
ritonavir,azole antifungals,195,203,245,261,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., <e1>ritonavir</e1>, indinavir, nelfinavir, delavirdine) or <e2>azole antifungals</e2> (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
ritonavir,ketoconazole,195,203,270,281,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., <e1>ritonavir</e1>, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., <e2>ketoconazole</e2>, itraconazole, voriconazole). ",False,negative
ritonavir,itraconazole,195,203,284,295,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., <e1>ritonavir</e1>, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, <e2>itraconazole</e2>, voriconazole). ",False,negative
ritonavir,voriconazole,195,203,298,309,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., <e1>ritonavir</e1>, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, <e2>voriconazole</e2>). ",False,negative
indinavir,nelfinavir,206,214,217,226,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, <e1>indinavir</e1>, <e2>nelfinavir</e2>, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
indinavir,delavirdine,206,214,229,239,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, <e1>indinavir</e1>, nelfinavir, <e2>delavirdine</e2>) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
indinavir,azole antifungals,206,214,245,261,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, <e1>indinavir</e1>, nelfinavir, delavirdine) or <e2>azole antifungals</e2> (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
indinavir,ketoconazole,206,214,270,281,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, <e1>indinavir</e1>, nelfinavir, delavirdine) or azole antifungals (e.g., <e2>ketoconazole</e2>, itraconazole, voriconazole). ",False,negative
indinavir,itraconazole,206,214,284,295,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, <e1>indinavir</e1>, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, <e2>itraconazole</e2>, voriconazole). ",False,negative
indinavir,voriconazole,206,214,298,309,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, <e1>indinavir</e1>, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, <e2>voriconazole</e2>). ",False,negative
nelfinavir,delavirdine,217,226,229,239,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, <e1>nelfinavir</e1>, <e2>delavirdine</e2>) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
nelfinavir,azole antifungals,217,226,245,261,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, <e1>nelfinavir</e1>, delavirdine) or <e2>azole antifungals</e2> (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
nelfinavir,ketoconazole,217,226,270,281,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, <e1>nelfinavir</e1>, delavirdine) or azole antifungals (e.g., <e2>ketoconazole</e2>, itraconazole, voriconazole). ",False,negative
nelfinavir,itraconazole,217,226,284,295,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, <e1>nelfinavir</e1>, delavirdine) or azole antifungals (e.g., ketoconazole, <e2>itraconazole</e2>, voriconazole). ",False,negative
nelfinavir,voriconazole,217,226,298,309,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, <e1>nelfinavir</e1>, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, <e2>voriconazole</e2>). ",False,negative
delavirdine,azole antifungals,229,239,245,261,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, <e1>delavirdine</e1>) or <e2>azole antifungals</e2> (e.g., ketoconazole, itraconazole, voriconazole). ",False,negative
delavirdine,ketoconazole,229,239,270,281,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, <e1>delavirdine</e1>) or azole antifungals (e.g., <e2>ketoconazole</e2>, itraconazole, voriconazole). ",False,negative
delavirdine,itraconazole,229,239,284,295,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, <e1>delavirdine</e1>) or azole antifungals (e.g., ketoconazole, <e2>itraconazole</e2>, voriconazole). ",False,negative
delavirdine,voriconazole,229,239,298,309,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, <e1>delavirdine</e1>) or azole antifungals (e.g., ketoconazole, itraconazole, <e2>voriconazole</e2>). ",False,negative
azole antifungals,ketoconazole,245,261,270,281,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or <e1>azole antifungals</e1> (e.g., <e2>ketoconazole</e2>, itraconazole, voriconazole). ",False,negative
azole antifungals,itraconazole,245,261,284,295,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or <e1>azole antifungals</e1> (e.g., ketoconazole, <e2>itraconazole</e2>, voriconazole). ",False,negative
azole antifungals,voriconazole,245,261,298,309,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or <e1>azole antifungals</e1> (e.g., ketoconazole, itraconazole, <e2>voriconazole</e2>). ",False,negative
ketoconazole,itraconazole,270,281,284,295,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., <e1>ketoconazole</e1>, <e2>itraconazole</e2>, voriconazole). ",False,negative
ketoconazole,voriconazole,270,281,298,309,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., <e1>ketoconazole</e1>, itraconazole, <e2>voriconazole</e2>). ",False,negative
itraconazole,voriconazole,284,295,298,309,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, <e1>itraconazole</e1>, <e2>voriconazole</e2>). ",False,negative
saquinavir,nefazodone,31,40,43,52,"Less potent inhibitors include <e1>saquinavir</e1>, <e2>nefazodone</e2>, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",False,negative
saquinavir,fluconazole,31,40,55,65,"Less potent inhibitors include <e1>saquinavir</e1>, nefazodone, <e2>fluconazole</e2>, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",False,negative
saquinavir,fluoxetine,31,40,86,95,"Less potent inhibitors include <e1>saquinavir</e1>, nefazodone, fluconazole, grapefruit juice, <e2>fluoxetine</e2>, fluvoxamine, zileuton, and clotrimazole. ",False,negative
saquinavir,fluvoxamine,31,40,98,108,"Less potent inhibitors include <e1>saquinavir</e1>, nefazodone, fluconazole, grapefruit juice, fluoxetine, <e2>fluvoxamine</e2>, zileuton, and clotrimazole. ",False,negative
saquinavir,zileuton,31,40,111,118,"Less potent inhibitors include <e1>saquinavir</e1>, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, <e2>zileuton</e2>, and clotrimazole. ",False,negative
saquinavir,clotrimazole,31,40,125,136,"Less potent inhibitors include <e1>saquinavir</e1>, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and <e2>clotrimazole</e2>. ",False,negative
nefazodone,fluconazole,43,52,55,65,"Less potent inhibitors include saquinavir, <e1>nefazodone</e1>, <e2>fluconazole</e2>, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",False,negative
nefazodone,fluoxetine,43,52,86,95,"Less potent inhibitors include saquinavir, <e1>nefazodone</e1>, fluconazole, grapefruit juice, <e2>fluoxetine</e2>, fluvoxamine, zileuton, and clotrimazole. ",False,negative
nefazodone,fluvoxamine,43,52,98,108,"Less potent inhibitors include saquinavir, <e1>nefazodone</e1>, fluconazole, grapefruit juice, fluoxetine, <e2>fluvoxamine</e2>, zileuton, and clotrimazole. ",False,negative
nefazodone,zileuton,43,52,111,118,"Less potent inhibitors include saquinavir, <e1>nefazodone</e1>, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, <e2>zileuton</e2>, and clotrimazole. ",False,negative
nefazodone,clotrimazole,43,52,125,136,"Less potent inhibitors include saquinavir, <e1>nefazodone</e1>, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and <e2>clotrimazole</e2>. ",False,negative
fluconazole,fluoxetine,55,65,86,95,"Less potent inhibitors include saquinavir, nefazodone, <e1>fluconazole</e1>, grapefruit juice, <e2>fluoxetine</e2>, fluvoxamine, zileuton, and clotrimazole. ",False,negative
fluconazole,fluvoxamine,55,65,98,108,"Less potent inhibitors include saquinavir, nefazodone, <e1>fluconazole</e1>, grapefruit juice, fluoxetine, <e2>fluvoxamine</e2>, zileuton, and clotrimazole. ",False,negative
fluconazole,zileuton,55,65,111,118,"Less potent inhibitors include saquinavir, nefazodone, <e1>fluconazole</e1>, grapefruit juice, fluoxetine, fluvoxamine, <e2>zileuton</e2>, and clotrimazole. ",False,negative
fluconazole,clotrimazole,55,65,125,136,"Less potent inhibitors include saquinavir, nefazodone, <e1>fluconazole</e1>, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and <e2>clotrimazole</e2>. ",False,negative
fluoxetine,fluvoxamine,86,95,98,108,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, <e1>fluoxetine</e1>, <e2>fluvoxamine</e2>, zileuton, and clotrimazole. ",False,negative
fluoxetine,zileuton,86,95,111,118,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, <e1>fluoxetine</e1>, fluvoxamine, <e2>zileuton</e2>, and clotrimazole. ",False,negative
fluoxetine,clotrimazole,86,95,125,136,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, <e1>fluoxetine</e1>, fluvoxamine, zileuton, and <e2>clotrimazole</e2>. ",False,negative
fluvoxamine,zileuton,98,108,111,118,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, <e1>fluvoxamine</e1>, <e2>zileuton</e2>, and clotrimazole. ",False,negative
fluvoxamine,clotrimazole,98,108,125,136,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, <e1>fluvoxamine</e1>, zileuton, and <e2>clotrimazole</e2>. ",False,negative
zileuton,clotrimazole,111,118,125,136,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, <e1>zileuton</e1>, and <e2>clotrimazole</e2>. ",False,negative
Methergine,methylergonovine maleate,33,42,48,71,Caution should be exercised when <e1>Methergine</e1>    (<e2>methylergonovine maleate</e2>) is used concurrently with other vasoconstrictors or ergot alkaloids.,False,negative
Methergine,vasoconstrictors,33,42,106,121,Caution should be exercised when <e1>Methergine</e1>    (methylergonovine maleate) is used concurrently with other <e2>vasoconstrictors</e2> or ergot alkaloids.,True,advise
Methergine,ergot alkaloids,33,42,126,140,Caution should be exercised when <e1>Methergine</e1>    (methylergonovine maleate) is used concurrently with other vasoconstrictors or <e2>ergot alkaloids</e2>.,True,advise
methylergonovine maleate,vasoconstrictors,48,71,106,121,Caution should be exercised when Methergine    (<e1>methylergonovine maleate</e1>) is used concurrently with other <e2>vasoconstrictors</e2> or ergot alkaloids.,True,advise
methylergonovine maleate,ergot alkaloids,48,71,126,140,Caution should be exercised when Methergine    (<e1>methylergonovine maleate</e1>) is used concurrently with other vasoconstrictors or <e2>ergot alkaloids</e2>.,False,negative
vasoconstrictors,ergot alkaloids,106,121,126,140,Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other <e1>vasoconstrictors</e1> or <e2>ergot alkaloids</e2>.,False,negative
Ritalin,guanethidine,0,6,47,58,<e1>Ritalin</e1> may decrease the hypotensive effect of <e2>guanethidine</e2>. ,True,effect
Ritalin,coumarin anticoagulants,44,50,82,104,"Human pharmacologic studies have shown that <e1>Ritalin</e1> may inhibit the metabolism of <e2>coumarin anticoagulants</e2>, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",True,mechanism
Ritalin,anticonvulsants,44,50,107,121,"Human pharmacologic studies have shown that <e1>Ritalin</e1> may inhibit the metabolism of coumarin anticoagulants, <e2>anticonvulsants</e2> (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",True,mechanism
Ritalin,phenobarbital,44,50,124,136,"Human pharmacologic studies have shown that <e1>Ritalin</e1> may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (<e2>phenobarbital</e2>, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",True,mechanism
Ritalin,diphenylhydantoin,44,50,139,155,"Human pharmacologic studies have shown that <e1>Ritalin</e1> may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, <e2>diphenylhydantoin</e2>, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",True,mechanism
Ritalin,primidone,44,50,158,166,"Human pharmacologic studies have shown that <e1>Ritalin</e1> may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, <e2>primidone</e2>), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",True,mechanism
Ritalin,phenylbutazone,44,50,170,183,"Human pharmacologic studies have shown that <e1>Ritalin</e1> may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), <e2>phenylbutazone</e2>, and tricyclic drugs (imipramine, clomipramine, desipramine). ",True,mechanism
Ritalin,tricyclic drugs,44,50,190,204,"Human pharmacologic studies have shown that <e1>Ritalin</e1> may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and <e2>tricyclic drugs</e2> (imipramine, clomipramine, desipramine). ",True,mechanism
Ritalin,imipramine,44,50,207,216,"Human pharmacologic studies have shown that <e1>Ritalin</e1> may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (<e2>imipramine</e2>, clomipramine, desipramine). ",True,mechanism
Ritalin,clomipramine,44,50,219,230,"Human pharmacologic studies have shown that <e1>Ritalin</e1> may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, <e2>clomipramine</e2>, desipramine). ",True,mechanism
Ritalin,desipramine,44,50,233,243,"Human pharmacologic studies have shown that <e1>Ritalin</e1> may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, <e2>desipramine</e2>). ",True,mechanism
coumarin anticoagulants,anticonvulsants,82,104,107,121,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of <e1>coumarin anticoagulants</e1>, <e2>anticonvulsants</e2> (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",False,negative
coumarin anticoagulants,phenobarbital,82,104,124,136,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of <e1>coumarin anticoagulants</e1>, anticonvulsants (<e2>phenobarbital</e2>, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",False,negative
coumarin anticoagulants,diphenylhydantoin,82,104,139,155,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of <e1>coumarin anticoagulants</e1>, anticonvulsants (phenobarbital, <e2>diphenylhydantoin</e2>, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",False,negative
coumarin anticoagulants,primidone,82,104,158,166,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of <e1>coumarin anticoagulants</e1>, anticonvulsants (phenobarbital, diphenylhydantoin, <e2>primidone</e2>), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",False,negative
coumarin anticoagulants,phenylbutazone,82,104,170,183,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of <e1>coumarin anticoagulants</e1>, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), <e2>phenylbutazone</e2>, and tricyclic drugs (imipramine, clomipramine, desipramine). ",False,negative
coumarin anticoagulants,tricyclic drugs,82,104,190,204,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of <e1>coumarin anticoagulants</e1>, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and <e2>tricyclic drugs</e2> (imipramine, clomipramine, desipramine). ",False,negative
coumarin anticoagulants,imipramine,82,104,207,216,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of <e1>coumarin anticoagulants</e1>, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (<e2>imipramine</e2>, clomipramine, desipramine). ",False,negative
coumarin anticoagulants,clomipramine,82,104,219,230,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of <e1>coumarin anticoagulants</e1>, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, <e2>clomipramine</e2>, desipramine). ",False,negative
coumarin anticoagulants,desipramine,82,104,233,243,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of <e1>coumarin anticoagulants</e1>, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, <e2>desipramine</e2>). ",False,negative
anticonvulsants,phenobarbital,107,121,124,136,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, <e1>anticonvulsants</e1> (<e2>phenobarbital</e2>, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",False,negative
anticonvulsants,diphenylhydantoin,107,121,139,155,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, <e1>anticonvulsants</e1> (phenobarbital, <e2>diphenylhydantoin</e2>, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",False,negative
anticonvulsants,primidone,107,121,158,166,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, <e1>anticonvulsants</e1> (phenobarbital, diphenylhydantoin, <e2>primidone</e2>), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",False,negative
anticonvulsants,phenylbutazone,107,121,170,183,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, <e1>anticonvulsants</e1> (phenobarbital, diphenylhydantoin, primidone), <e2>phenylbutazone</e2>, and tricyclic drugs (imipramine, clomipramine, desipramine). ",False,negative
anticonvulsants,tricyclic drugs,107,121,190,204,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, <e1>anticonvulsants</e1> (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and <e2>tricyclic drugs</e2> (imipramine, clomipramine, desipramine). ",False,negative
anticonvulsants,imipramine,107,121,207,216,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, <e1>anticonvulsants</e1> (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (<e2>imipramine</e2>, clomipramine, desipramine). ",False,negative
anticonvulsants,clomipramine,107,121,219,230,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, <e1>anticonvulsants</e1> (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, <e2>clomipramine</e2>, desipramine). ",False,negative
anticonvulsants,desipramine,107,121,233,243,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, <e1>anticonvulsants</e1> (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, <e2>desipramine</e2>). ",False,negative
phenobarbital,diphenylhydantoin,124,136,139,155,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (<e1>phenobarbital</e1>, <e2>diphenylhydantoin</e2>, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",False,negative
phenobarbital,primidone,124,136,158,166,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (<e1>phenobarbital</e1>, diphenylhydantoin, <e2>primidone</e2>), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",False,negative
phenobarbital,phenylbutazone,124,136,170,183,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (<e1>phenobarbital</e1>, diphenylhydantoin, primidone), <e2>phenylbutazone</e2>, and tricyclic drugs (imipramine, clomipramine, desipramine). ",False,negative
phenobarbital,tricyclic drugs,124,136,190,204,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (<e1>phenobarbital</e1>, diphenylhydantoin, primidone), phenylbutazone, and <e2>tricyclic drugs</e2> (imipramine, clomipramine, desipramine). ",False,negative
phenobarbital,imipramine,124,136,207,216,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (<e1>phenobarbital</e1>, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (<e2>imipramine</e2>, clomipramine, desipramine). ",False,negative
phenobarbital,clomipramine,124,136,219,230,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (<e1>phenobarbital</e1>, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, <e2>clomipramine</e2>, desipramine). ",False,negative
phenobarbital,desipramine,124,136,233,243,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (<e1>phenobarbital</e1>, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, <e2>desipramine</e2>). ",False,negative
diphenylhydantoin,primidone,139,155,158,166,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, <e1>diphenylhydantoin</e1>, <e2>primidone</e2>), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",False,negative
diphenylhydantoin,phenylbutazone,139,155,170,183,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, <e1>diphenylhydantoin</e1>, primidone), <e2>phenylbutazone</e2>, and tricyclic drugs (imipramine, clomipramine, desipramine). ",False,negative
diphenylhydantoin,tricyclic drugs,139,155,190,204,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, <e1>diphenylhydantoin</e1>, primidone), phenylbutazone, and <e2>tricyclic drugs</e2> (imipramine, clomipramine, desipramine). ",False,negative
diphenylhydantoin,imipramine,139,155,207,216,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, <e1>diphenylhydantoin</e1>, primidone), phenylbutazone, and tricyclic drugs (<e2>imipramine</e2>, clomipramine, desipramine). ",False,negative
diphenylhydantoin,clomipramine,139,155,219,230,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, <e1>diphenylhydantoin</e1>, primidone), phenylbutazone, and tricyclic drugs (imipramine, <e2>clomipramine</e2>, desipramine). ",False,negative
diphenylhydantoin,desipramine,139,155,233,243,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, <e1>diphenylhydantoin</e1>, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, <e2>desipramine</e2>). ",False,negative
primidone,phenylbutazone,158,166,170,183,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, <e1>primidone</e1>), <e2>phenylbutazone</e2>, and tricyclic drugs (imipramine, clomipramine, desipramine). ",False,negative
primidone,tricyclic drugs,158,166,190,204,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, <e1>primidone</e1>), phenylbutazone, and <e2>tricyclic drugs</e2> (imipramine, clomipramine, desipramine). ",False,negative
primidone,imipramine,158,166,207,216,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, <e1>primidone</e1>), phenylbutazone, and tricyclic drugs (<e2>imipramine</e2>, clomipramine, desipramine). ",False,negative
primidone,clomipramine,158,166,219,230,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, <e1>primidone</e1>), phenylbutazone, and tricyclic drugs (imipramine, <e2>clomipramine</e2>, desipramine). ",False,negative
primidone,desipramine,158,166,233,243,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, <e1>primidone</e1>), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, <e2>desipramine</e2>). ",False,negative
phenylbutazone,tricyclic drugs,170,183,190,204,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), <e1>phenylbutazone</e1>, and <e2>tricyclic drugs</e2> (imipramine, clomipramine, desipramine). ",False,negative
phenylbutazone,imipramine,170,183,207,216,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), <e1>phenylbutazone</e1>, and tricyclic drugs (<e2>imipramine</e2>, clomipramine, desipramine). ",False,negative
phenylbutazone,clomipramine,170,183,219,230,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), <e1>phenylbutazone</e1>, and tricyclic drugs (imipramine, <e2>clomipramine</e2>, desipramine). ",False,negative
phenylbutazone,desipramine,170,183,233,243,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), <e1>phenylbutazone</e1>, and tricyclic drugs (imipramine, clomipramine, <e2>desipramine</e2>). ",False,negative
tricyclic drugs,imipramine,190,204,207,216,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and <e1>tricyclic drugs</e1> (<e2>imipramine</e2>, clomipramine, desipramine). ",False,negative
tricyclic drugs,clomipramine,190,204,219,230,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and <e1>tricyclic drugs</e1> (imipramine, <e2>clomipramine</e2>, desipramine). ",False,negative
tricyclic drugs,desipramine,190,204,233,243,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and <e1>tricyclic drugs</e1> (imipramine, clomipramine, <e2>desipramine</e2>). ",False,negative
imipramine,clomipramine,207,216,219,230,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (<e1>imipramine</e1>, <e2>clomipramine</e2>, desipramine). ",False,negative
imipramine,desipramine,207,216,233,243,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (<e1>imipramine</e1>, clomipramine, <e2>desipramine</e2>). ",False,negative
clomipramine,desipramine,219,230,233,243,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, <e1>clomipramine</e1>, <e2>desipramine</e2>). ",False,negative
methylphenidate,clonidine,20,34,56,64,The safety of using <e1>methylphenidate</e1> in combination with <e2>clonidine</e2> or other centrally acting alpha-2 agonists has not been systemically evaluated.    ,False,negative
methylphenidate,alpha-2 agonists,20,34,92,107,The safety of using <e1>methylphenidate</e1> in combination with clonidine or other centrally acting <e2>alpha-2 agonists</e2> has not been systemically evaluated.    ,False,negative
clonidine,alpha-2 agonists,56,64,92,107,The safety of using methylphenidate in combination with <e1>clonidine</e1> or other centrally acting <e2>alpha-2 agonists</e2> has not been systemically evaluated.    ,False,negative
cyclosporin,methylprednisolone,62,72,78,95,Mutual inhibition of metabolism occurs with concurrent use of <e1>cyclosporin</e1> and <e2>methylprednisolone</e2>; ,True,mechanism
methylprednisolone,cyclosporin,54,71,77,87,convulsions have been reported with concurrent use of <e1>methylprednisolone</e1> and <e2>cyclosporin</e2>. ,True,effect
phenobarbital,phenytoin,42,54,57,65,"Drugs that induce hepatic enzymes such as <e1>phenobarbital</e1>, <e2>phenytoin</e2>, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",False,negative
phenobarbital,rifampin,42,54,72,79,"Drugs that induce hepatic enzymes such as <e1>phenobarbital</e1>, phenytoin, and <e2>rifampin</e2> may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",False,negative
phenobarbital,methylprednisolone,42,54,111,128,"Drugs that induce hepatic enzymes such as <e1>phenobarbital</e1>, phenytoin, and rifampin may increase the clearance of <e2>methylprednisolone</e2> and may require increased in methylprednisolone dose to achieve the desired response. ",True,mechanism
phenobarbital,methylprednisolone,42,54,159,176,"Drugs that induce hepatic enzymes such as <e1>phenobarbital</e1>, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in <e2>methylprednisolone</e2> dose to achieve the desired response. ",True,advise
phenytoin,rifampin,57,65,72,79,"Drugs that induce hepatic enzymes such as phenobarbital, <e1>phenytoin</e1>, and <e2>rifampin</e2> may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",False,negative
phenytoin,methylprednisolone,57,65,111,128,"Drugs that induce hepatic enzymes such as phenobarbital, <e1>phenytoin</e1>, and rifampin may increase the clearance of <e2>methylprednisolone</e2> and may require increased in methylprednisolone dose to achieve the desired response. ",True,mechanism
phenytoin,methylprednisolone,57,65,159,176,"Drugs that induce hepatic enzymes such as phenobarbital, <e1>phenytoin</e1>, and rifampin may increase the clearance of methylprednisolone and may require increased in <e2>methylprednisolone</e2> dose to achieve the desired response. ",True,advise
rifampin,methylprednisolone,72,79,111,128,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and <e1>rifampin</e1> may increase the clearance of <e2>methylprednisolone</e2> and may require increased in methylprednisolone dose to achieve the desired response. ",True,mechanism
rifampin,methylprednisolone,72,79,159,176,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and <e1>rifampin</e1> may increase the clearance of methylprednisolone and may require increased in <e2>methylprednisolone</e2> dose to achieve the desired response. ",True,advise
methylprednisolone,methylprednisolone,111,128,159,176,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of <e1>methylprednisolone</e1> and may require increased in <e2>methylprednisolone</e2> dose to achieve the desired response. ",False,negative
troleandomycin,ketoconazole,14,27,33,44,Drugs such as <e1>troleandomycin</e1> and <e2>ketoconazole</e2> may inhibit the metabolism of methylprednisolone and thus decrease its clearance. ,False,negative
troleandomycin,methylprednisolone,14,27,76,93,Drugs such as <e1>troleandomycin</e1> and ketoconazole may inhibit the metabolism of <e2>methylprednisolone</e2> and thus decrease its clearance. ,True,mechanism
ketoconazole,methylprednisolone,33,44,76,93,Drugs such as troleandomycin and <e1>ketoconazole</e1> may inhibit the metabolism of <e2>methylprednisolone</e2> and thus decrease its clearance. ,True,mechanism
Methylprednisolone,aspirin,0,17,67,73,<e1>Methylprednisolone</e1> may increase the clearance of chronic high dose <e2>aspirin</e2>. ,True,mechanism
salicylate,salicylate,29,38,77,86,This could lead to decreased <e1>salicylate</e1> serum levels or increase the risk of <e2>salicylate</e2> toxicity when methylprednisolone is withdrawn. ,False,negative
salicylate,methylprednisolone,29,38,102,119,This could lead to decreased <e1>salicylate</e1> serum levels or increase the risk of salicylate toxicity when <e2>methylprednisolone</e2> is withdrawn. ,False,negative
salicylate,methylprednisolone,77,86,102,119,This could lead to decreased salicylate serum levels or increase the risk of <e1>salicylate</e1> toxicity when <e2>methylprednisolone</e2> is withdrawn. ,True,effect
Aspirin,corticosteroids,0,6,54,68,<e1>Aspirin</e1> should be used cautiously in conjunction with <e2>corticosteroids</e2> in patients suffering from hypoprothrombinemia. ,True,advise
methylprednisolone,anticoagulants,14,31,41,54,The effect of <e1>methylprednisolone</e1> on oral <e2>anticoagulants</e2> is variable. ,False,negative
anticoagulant,corticosteroids,63,75,106,120,There are reports of enhanced as well as diminished effects of <e1>anticoagulant</e1> when given concurrently with <e2>corticosteroids</e2>. ,True,effect
Methscopolamine,antidepressants,0,14,34,48,"<e1>Methscopolamine</e1> may interact with <e2>antidepressants</e2> (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
Methscopolamine,tricyclic,0,14,51,59,"<e1>Methscopolamine</e1> may interact with antidepressants (<e2>tricyclic</e2> type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",True,int
Methscopolamine,MAO inhibitors,0,14,68,81,"<e1>Methscopolamine</e1> may interact with antidepressants (tricyclic type), <e2>MAO inhibitors</e2> (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",True,int
Methscopolamine,phenelzine,0,14,90,99,"<e1>Methscopolamine</e1> may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., <e2>phenelzine</e2>, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",True,int
Methscopolamine,linezolid,0,14,102,110,"<e1>Methscopolamine</e1> may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, <e2>linezolid</e2>, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",True,int
Methscopolamine,tranylcypromine,0,14,113,127,"<e1>Methscopolamine</e1> may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, <e2>tranylcypromine</e2>, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",True,int
Methscopolamine,isocarboxazid,0,14,130,142,"<e1>Methscopolamine</e1> may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, <e2>isocarboxazid</e2>, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",True,int
Methscopolamine,selegiline,0,14,145,154,"<e1>Methscopolamine</e1> may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, <e2>selegiline</e2>, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",True,int
Methscopolamine,furazolidone,0,14,157,168,"<e1>Methscopolamine</e1> may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, <e2>furazolidone</e2>), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",True,int
Methscopolamine,quinidine,0,14,172,180,"<e1>Methscopolamine</e1> may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), <e2>quinidine</e2>, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",True,int
Methscopolamine,amantadine,0,14,183,192,"<e1>Methscopolamine</e1> may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, <e2>amantadine</e2>, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",True,int
Methscopolamine,antihistamines,0,14,195,208,"<e1>Methscopolamine</e1> may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, <e2>antihistamines</e2> (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",True,int
Methscopolamine,diphenhydramine,0,14,217,231,"<e1>Methscopolamine</e1> may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., <e2>diphenhydramine</e2>), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",True,int
Methscopolamine,anticholinergics,0,14,241,256,"<e1>Methscopolamine</e1> may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other <e2>anticholinergics</e2>, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",True,int
Methscopolamine,potassium chloride,0,14,259,276,"<e1>Methscopolamine</e1> may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, <e2>potassium chloride</e2> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",True,int
Methscopolamine,antacids,0,14,291,298,"<e1>Methscopolamine</e1> may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, <e2>antacids</e2>, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",True,int
Methscopolamine,absorbent-type anti-diarrhea medicines,0,14,301,338,"<e1>Methscopolamine</e1> may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, <e2>absorbent-type anti-diarrhea medicines</e2> (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",True,int
Methscopolamine,kaolin,0,14,347,352,"<e1>Methscopolamine</e1> may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e2>kaolin</e2>-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",True,int
Methscopolamine,pectin,0,14,354,359,"<e1>Methscopolamine</e1> may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-<e2>pectin</e2>), phenothiazines (e.g., chlorpromazine, promethazine).",True,int
Methscopolamine,phenothiazines,0,14,363,376,"<e1>Methscopolamine</e1> may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), <e2>phenothiazines</e2> (e.g., chlorpromazine, promethazine).",True,int
Methscopolamine,chlorpromazine,0,14,385,398,"<e1>Methscopolamine</e1> may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., <e2>chlorpromazine</e2>, promethazine).",True,int
Methscopolamine,promethazine,0,14,401,412,"<e1>Methscopolamine</e1> may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, <e2>promethazine</e2>).",True,int
antidepressants,tricyclic,34,48,51,59,"Methscopolamine may interact with <e1>antidepressants</e1> (<e2>tricyclic</e2> type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
antidepressants,MAO inhibitors,34,48,68,81,"Methscopolamine may interact with <e1>antidepressants</e1> (tricyclic type), <e2>MAO inhibitors</e2> (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
antidepressants,phenelzine,34,48,90,99,"Methscopolamine may interact with <e1>antidepressants</e1> (tricyclic type), MAO inhibitors (e.g., <e2>phenelzine</e2>, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
antidepressants,linezolid,34,48,102,110,"Methscopolamine may interact with <e1>antidepressants</e1> (tricyclic type), MAO inhibitors (e.g., phenelzine, <e2>linezolid</e2>, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
antidepressants,tranylcypromine,34,48,113,127,"Methscopolamine may interact with <e1>antidepressants</e1> (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, <e2>tranylcypromine</e2>, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
antidepressants,isocarboxazid,34,48,130,142,"Methscopolamine may interact with <e1>antidepressants</e1> (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, <e2>isocarboxazid</e2>, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
antidepressants,selegiline,34,48,145,154,"Methscopolamine may interact with <e1>antidepressants</e1> (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, <e2>selegiline</e2>, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
antidepressants,furazolidone,34,48,157,168,"Methscopolamine may interact with <e1>antidepressants</e1> (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, <e2>furazolidone</e2>), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
antidepressants,quinidine,34,48,172,180,"Methscopolamine may interact with <e1>antidepressants</e1> (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), <e2>quinidine</e2>, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
antidepressants,amantadine,34,48,183,192,"Methscopolamine may interact with <e1>antidepressants</e1> (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, <e2>amantadine</e2>, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
antidepressants,antihistamines,34,48,195,208,"Methscopolamine may interact with <e1>antidepressants</e1> (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, <e2>antihistamines</e2> (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
antidepressants,diphenhydramine,34,48,217,231,"Methscopolamine may interact with <e1>antidepressants</e1> (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., <e2>diphenhydramine</e2>), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
antidepressants,anticholinergics,34,48,241,256,"Methscopolamine may interact with <e1>antidepressants</e1> (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other <e2>anticholinergics</e2>, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
antidepressants,potassium chloride,34,48,259,276,"Methscopolamine may interact with <e1>antidepressants</e1> (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, <e2>potassium chloride</e2> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
antidepressants,antacids,34,48,291,298,"Methscopolamine may interact with <e1>antidepressants</e1> (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, <e2>antacids</e2>, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
antidepressants,absorbent-type anti-diarrhea medicines,34,48,301,338,"Methscopolamine may interact with <e1>antidepressants</e1> (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, <e2>absorbent-type anti-diarrhea medicines</e2> (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
antidepressants,kaolin,34,48,347,352,"Methscopolamine may interact with <e1>antidepressants</e1> (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e2>kaolin</e2>-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
antidepressants,pectin,34,48,354,359,"Methscopolamine may interact with <e1>antidepressants</e1> (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-<e2>pectin</e2>), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
antidepressants,phenothiazines,34,48,363,376,"Methscopolamine may interact with <e1>antidepressants</e1> (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), <e2>phenothiazines</e2> (e.g., chlorpromazine, promethazine).",False,negative
antidepressants,chlorpromazine,34,48,385,398,"Methscopolamine may interact with <e1>antidepressants</e1> (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., <e2>chlorpromazine</e2>, promethazine).",False,negative
antidepressants,promethazine,34,48,401,412,"Methscopolamine may interact with <e1>antidepressants</e1> (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, <e2>promethazine</e2>).",False,negative
tricyclic,MAO inhibitors,51,59,68,81,"Methscopolamine may interact with antidepressants (<e1>tricyclic</e1> type), <e2>MAO inhibitors</e2> (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
tricyclic,phenelzine,51,59,90,99,"Methscopolamine may interact with antidepressants (<e1>tricyclic</e1> type), MAO inhibitors (e.g., <e2>phenelzine</e2>, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
tricyclic,linezolid,51,59,102,110,"Methscopolamine may interact with antidepressants (<e1>tricyclic</e1> type), MAO inhibitors (e.g., phenelzine, <e2>linezolid</e2>, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
tricyclic,tranylcypromine,51,59,113,127,"Methscopolamine may interact with antidepressants (<e1>tricyclic</e1> type), MAO inhibitors (e.g., phenelzine, linezolid, <e2>tranylcypromine</e2>, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
tricyclic,isocarboxazid,51,59,130,142,"Methscopolamine may interact with antidepressants (<e1>tricyclic</e1> type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, <e2>isocarboxazid</e2>, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
tricyclic,selegiline,51,59,145,154,"Methscopolamine may interact with antidepressants (<e1>tricyclic</e1> type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, <e2>selegiline</e2>, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
tricyclic,furazolidone,51,59,157,168,"Methscopolamine may interact with antidepressants (<e1>tricyclic</e1> type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, <e2>furazolidone</e2>), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
tricyclic,quinidine,51,59,172,180,"Methscopolamine may interact with antidepressants (<e1>tricyclic</e1> type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), <e2>quinidine</e2>, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
tricyclic,amantadine,51,59,183,192,"Methscopolamine may interact with antidepressants (<e1>tricyclic</e1> type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, <e2>amantadine</e2>, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
tricyclic,antihistamines,51,59,195,208,"Methscopolamine may interact with antidepressants (<e1>tricyclic</e1> type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, <e2>antihistamines</e2> (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
tricyclic,diphenhydramine,51,59,217,231,"Methscopolamine may interact with antidepressants (<e1>tricyclic</e1> type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., <e2>diphenhydramine</e2>), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
tricyclic,anticholinergics,51,59,241,256,"Methscopolamine may interact with antidepressants (<e1>tricyclic</e1> type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other <e2>anticholinergics</e2>, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
tricyclic,potassium chloride,51,59,259,276,"Methscopolamine may interact with antidepressants (<e1>tricyclic</e1> type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, <e2>potassium chloride</e2> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
tricyclic,antacids,51,59,291,298,"Methscopolamine may interact with antidepressants (<e1>tricyclic</e1> type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, <e2>antacids</e2>, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
tricyclic,absorbent-type anti-diarrhea medicines,51,59,301,338,"Methscopolamine may interact with antidepressants (<e1>tricyclic</e1> type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, <e2>absorbent-type anti-diarrhea medicines</e2> (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
tricyclic,kaolin,51,59,347,352,"Methscopolamine may interact with antidepressants (<e1>tricyclic</e1> type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e2>kaolin</e2>-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
tricyclic,pectin,51,59,354,359,"Methscopolamine may interact with antidepressants (<e1>tricyclic</e1> type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-<e2>pectin</e2>), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
tricyclic,phenothiazines,51,59,363,376,"Methscopolamine may interact with antidepressants (<e1>tricyclic</e1> type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), <e2>phenothiazines</e2> (e.g., chlorpromazine, promethazine).",False,negative
tricyclic,chlorpromazine,51,59,385,398,"Methscopolamine may interact with antidepressants (<e1>tricyclic</e1> type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., <e2>chlorpromazine</e2>, promethazine).",False,negative
tricyclic,promethazine,51,59,401,412,"Methscopolamine may interact with antidepressants (<e1>tricyclic</e1> type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, <e2>promethazine</e2>).",False,negative
MAO inhibitors,phenelzine,68,81,90,99,"Methscopolamine may interact with antidepressants (tricyclic type), <e1>MAO inhibitors</e1> (e.g., <e2>phenelzine</e2>, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
MAO inhibitors,linezolid,68,81,102,110,"Methscopolamine may interact with antidepressants (tricyclic type), <e1>MAO inhibitors</e1> (e.g., phenelzine, <e2>linezolid</e2>, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
MAO inhibitors,tranylcypromine,68,81,113,127,"Methscopolamine may interact with antidepressants (tricyclic type), <e1>MAO inhibitors</e1> (e.g., phenelzine, linezolid, <e2>tranylcypromine</e2>, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
MAO inhibitors,isocarboxazid,68,81,130,142,"Methscopolamine may interact with antidepressants (tricyclic type), <e1>MAO inhibitors</e1> (e.g., phenelzine, linezolid, tranylcypromine, <e2>isocarboxazid</e2>, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
MAO inhibitors,selegiline,68,81,145,154,"Methscopolamine may interact with antidepressants (tricyclic type), <e1>MAO inhibitors</e1> (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, <e2>selegiline</e2>, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
MAO inhibitors,furazolidone,68,81,157,168,"Methscopolamine may interact with antidepressants (tricyclic type), <e1>MAO inhibitors</e1> (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, <e2>furazolidone</e2>), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
MAO inhibitors,quinidine,68,81,172,180,"Methscopolamine may interact with antidepressants (tricyclic type), <e1>MAO inhibitors</e1> (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), <e2>quinidine</e2>, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
MAO inhibitors,amantadine,68,81,183,192,"Methscopolamine may interact with antidepressants (tricyclic type), <e1>MAO inhibitors</e1> (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, <e2>amantadine</e2>, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
MAO inhibitors,antihistamines,68,81,195,208,"Methscopolamine may interact with antidepressants (tricyclic type), <e1>MAO inhibitors</e1> (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, <e2>antihistamines</e2> (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
MAO inhibitors,diphenhydramine,68,81,217,231,"Methscopolamine may interact with antidepressants (tricyclic type), <e1>MAO inhibitors</e1> (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., <e2>diphenhydramine</e2>), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
MAO inhibitors,anticholinergics,68,81,241,256,"Methscopolamine may interact with antidepressants (tricyclic type), <e1>MAO inhibitors</e1> (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other <e2>anticholinergics</e2>, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
MAO inhibitors,potassium chloride,68,81,259,276,"Methscopolamine may interact with antidepressants (tricyclic type), <e1>MAO inhibitors</e1> (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, <e2>potassium chloride</e2> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
MAO inhibitors,antacids,68,81,291,298,"Methscopolamine may interact with antidepressants (tricyclic type), <e1>MAO inhibitors</e1> (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, <e2>antacids</e2>, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
MAO inhibitors,absorbent-type anti-diarrhea medicines,68,81,301,338,"Methscopolamine may interact with antidepressants (tricyclic type), <e1>MAO inhibitors</e1> (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, <e2>absorbent-type anti-diarrhea medicines</e2> (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
MAO inhibitors,kaolin,68,81,347,352,"Methscopolamine may interact with antidepressants (tricyclic type), <e1>MAO inhibitors</e1> (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e2>kaolin</e2>-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
MAO inhibitors,pectin,68,81,354,359,"Methscopolamine may interact with antidepressants (tricyclic type), <e1>MAO inhibitors</e1> (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-<e2>pectin</e2>), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
MAO inhibitors,phenothiazines,68,81,363,376,"Methscopolamine may interact with antidepressants (tricyclic type), <e1>MAO inhibitors</e1> (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), <e2>phenothiazines</e2> (e.g., chlorpromazine, promethazine).",False,negative
MAO inhibitors,chlorpromazine,68,81,385,398,"Methscopolamine may interact with antidepressants (tricyclic type), <e1>MAO inhibitors</e1> (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., <e2>chlorpromazine</e2>, promethazine).",False,negative
MAO inhibitors,promethazine,68,81,401,412,"Methscopolamine may interact with antidepressants (tricyclic type), <e1>MAO inhibitors</e1> (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, <e2>promethazine</e2>).",False,negative
phenelzine,linezolid,90,99,102,110,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., <e1>phenelzine</e1>, <e2>linezolid</e2>, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
phenelzine,tranylcypromine,90,99,113,127,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., <e1>phenelzine</e1>, linezolid, <e2>tranylcypromine</e2>, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
phenelzine,isocarboxazid,90,99,130,142,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., <e1>phenelzine</e1>, linezolid, tranylcypromine, <e2>isocarboxazid</e2>, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
phenelzine,selegiline,90,99,145,154,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., <e1>phenelzine</e1>, linezolid, tranylcypromine, isocarboxazid, <e2>selegiline</e2>, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
phenelzine,furazolidone,90,99,157,168,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., <e1>phenelzine</e1>, linezolid, tranylcypromine, isocarboxazid, selegiline, <e2>furazolidone</e2>), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
phenelzine,quinidine,90,99,172,180,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., <e1>phenelzine</e1>, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), <e2>quinidine</e2>, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
phenelzine,amantadine,90,99,183,192,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., <e1>phenelzine</e1>, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, <e2>amantadine</e2>, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
phenelzine,antihistamines,90,99,195,208,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., <e1>phenelzine</e1>, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, <e2>antihistamines</e2> (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
phenelzine,diphenhydramine,90,99,217,231,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., <e1>phenelzine</e1>, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., <e2>diphenhydramine</e2>), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
phenelzine,anticholinergics,90,99,241,256,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., <e1>phenelzine</e1>, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other <e2>anticholinergics</e2>, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
phenelzine,potassium chloride,90,99,259,276,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., <e1>phenelzine</e1>, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, <e2>potassium chloride</e2> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
phenelzine,antacids,90,99,291,298,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., <e1>phenelzine</e1>, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, <e2>antacids</e2>, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
phenelzine,absorbent-type anti-diarrhea medicines,90,99,301,338,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., <e1>phenelzine</e1>, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, <e2>absorbent-type anti-diarrhea medicines</e2> (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
phenelzine,kaolin,90,99,347,352,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., <e1>phenelzine</e1>, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e2>kaolin</e2>-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
phenelzine,pectin,90,99,354,359,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., <e1>phenelzine</e1>, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-<e2>pectin</e2>), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
phenelzine,phenothiazines,90,99,363,376,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., <e1>phenelzine</e1>, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), <e2>phenothiazines</e2> (e.g., chlorpromazine, promethazine).",False,negative
phenelzine,chlorpromazine,90,99,385,398,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., <e1>phenelzine</e1>, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., <e2>chlorpromazine</e2>, promethazine).",False,negative
phenelzine,promethazine,90,99,401,412,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., <e1>phenelzine</e1>, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, <e2>promethazine</e2>).",False,negative
linezolid,tranylcypromine,102,110,113,127,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, <e1>linezolid</e1>, <e2>tranylcypromine</e2>, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
linezolid,isocarboxazid,102,110,130,142,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, <e1>linezolid</e1>, tranylcypromine, <e2>isocarboxazid</e2>, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
linezolid,selegiline,102,110,145,154,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, <e1>linezolid</e1>, tranylcypromine, isocarboxazid, <e2>selegiline</e2>, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
linezolid,furazolidone,102,110,157,168,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, <e1>linezolid</e1>, tranylcypromine, isocarboxazid, selegiline, <e2>furazolidone</e2>), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
linezolid,quinidine,102,110,172,180,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, <e1>linezolid</e1>, tranylcypromine, isocarboxazid, selegiline, furazolidone), <e2>quinidine</e2>, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
linezolid,amantadine,102,110,183,192,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, <e1>linezolid</e1>, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, <e2>amantadine</e2>, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
linezolid,antihistamines,102,110,195,208,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, <e1>linezolid</e1>, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, <e2>antihistamines</e2> (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
linezolid,diphenhydramine,102,110,217,231,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, <e1>linezolid</e1>, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., <e2>diphenhydramine</e2>), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
linezolid,anticholinergics,102,110,241,256,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, <e1>linezolid</e1>, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other <e2>anticholinergics</e2>, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
linezolid,potassium chloride,102,110,259,276,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, <e1>linezolid</e1>, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, <e2>potassium chloride</e2> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
linezolid,antacids,102,110,291,298,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, <e1>linezolid</e1>, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, <e2>antacids</e2>, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
linezolid,absorbent-type anti-diarrhea medicines,102,110,301,338,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, <e1>linezolid</e1>, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, <e2>absorbent-type anti-diarrhea medicines</e2> (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
linezolid,kaolin,102,110,347,352,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, <e1>linezolid</e1>, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e2>kaolin</e2>-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
linezolid,pectin,102,110,354,359,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, <e1>linezolid</e1>, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-<e2>pectin</e2>), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
linezolid,phenothiazines,102,110,363,376,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, <e1>linezolid</e1>, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), <e2>phenothiazines</e2> (e.g., chlorpromazine, promethazine).",False,negative
linezolid,chlorpromazine,102,110,385,398,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, <e1>linezolid</e1>, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., <e2>chlorpromazine</e2>, promethazine).",False,negative
linezolid,promethazine,102,110,401,412,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, <e1>linezolid</e1>, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, <e2>promethazine</e2>).",False,negative
tranylcypromine,isocarboxazid,113,127,130,142,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, <e1>tranylcypromine</e1>, <e2>isocarboxazid</e2>, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
tranylcypromine,selegiline,113,127,145,154,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, <e1>tranylcypromine</e1>, isocarboxazid, <e2>selegiline</e2>, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
tranylcypromine,furazolidone,113,127,157,168,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, <e1>tranylcypromine</e1>, isocarboxazid, selegiline, <e2>furazolidone</e2>), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
tranylcypromine,quinidine,113,127,172,180,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, <e1>tranylcypromine</e1>, isocarboxazid, selegiline, furazolidone), <e2>quinidine</e2>, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
tranylcypromine,amantadine,113,127,183,192,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, <e1>tranylcypromine</e1>, isocarboxazid, selegiline, furazolidone), quinidine, <e2>amantadine</e2>, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
tranylcypromine,antihistamines,113,127,195,208,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, <e1>tranylcypromine</e1>, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, <e2>antihistamines</e2> (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
tranylcypromine,diphenhydramine,113,127,217,231,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, <e1>tranylcypromine</e1>, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., <e2>diphenhydramine</e2>), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
tranylcypromine,anticholinergics,113,127,241,256,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, <e1>tranylcypromine</e1>, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other <e2>anticholinergics</e2>, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
tranylcypromine,potassium chloride,113,127,259,276,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, <e1>tranylcypromine</e1>, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, <e2>potassium chloride</e2> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
tranylcypromine,antacids,113,127,291,298,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, <e1>tranylcypromine</e1>, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, <e2>antacids</e2>, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
tranylcypromine,absorbent-type anti-diarrhea medicines,113,127,301,338,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, <e1>tranylcypromine</e1>, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, <e2>absorbent-type anti-diarrhea medicines</e2> (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
tranylcypromine,kaolin,113,127,347,352,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, <e1>tranylcypromine</e1>, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e2>kaolin</e2>-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
tranylcypromine,pectin,113,127,354,359,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, <e1>tranylcypromine</e1>, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-<e2>pectin</e2>), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
tranylcypromine,phenothiazines,113,127,363,376,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, <e1>tranylcypromine</e1>, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), <e2>phenothiazines</e2> (e.g., chlorpromazine, promethazine).",False,negative
tranylcypromine,chlorpromazine,113,127,385,398,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, <e1>tranylcypromine</e1>, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., <e2>chlorpromazine</e2>, promethazine).",False,negative
tranylcypromine,promethazine,113,127,401,412,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, <e1>tranylcypromine</e1>, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, <e2>promethazine</e2>).",False,negative
isocarboxazid,selegiline,130,142,145,154,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, <e1>isocarboxazid</e1>, <e2>selegiline</e2>, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
isocarboxazid,furazolidone,130,142,157,168,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, <e1>isocarboxazid</e1>, selegiline, <e2>furazolidone</e2>), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
isocarboxazid,quinidine,130,142,172,180,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, <e1>isocarboxazid</e1>, selegiline, furazolidone), <e2>quinidine</e2>, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
isocarboxazid,amantadine,130,142,183,192,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, <e1>isocarboxazid</e1>, selegiline, furazolidone), quinidine, <e2>amantadine</e2>, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
isocarboxazid,antihistamines,130,142,195,208,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, <e1>isocarboxazid</e1>, selegiline, furazolidone), quinidine, amantadine, <e2>antihistamines</e2> (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
isocarboxazid,diphenhydramine,130,142,217,231,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, <e1>isocarboxazid</e1>, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., <e2>diphenhydramine</e2>), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
isocarboxazid,anticholinergics,130,142,241,256,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, <e1>isocarboxazid</e1>, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other <e2>anticholinergics</e2>, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
isocarboxazid,potassium chloride,130,142,259,276,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, <e1>isocarboxazid</e1>, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, <e2>potassium chloride</e2> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
isocarboxazid,antacids,130,142,291,298,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, <e1>isocarboxazid</e1>, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, <e2>antacids</e2>, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
isocarboxazid,absorbent-type anti-diarrhea medicines,130,142,301,338,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, <e1>isocarboxazid</e1>, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, <e2>absorbent-type anti-diarrhea medicines</e2> (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
isocarboxazid,kaolin,130,142,347,352,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, <e1>isocarboxazid</e1>, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e2>kaolin</e2>-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
isocarboxazid,pectin,130,142,354,359,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, <e1>isocarboxazid</e1>, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-<e2>pectin</e2>), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
isocarboxazid,phenothiazines,130,142,363,376,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, <e1>isocarboxazid</e1>, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), <e2>phenothiazines</e2> (e.g., chlorpromazine, promethazine).",False,negative
isocarboxazid,chlorpromazine,130,142,385,398,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, <e1>isocarboxazid</e1>, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., <e2>chlorpromazine</e2>, promethazine).",False,negative
isocarboxazid,promethazine,130,142,401,412,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, <e1>isocarboxazid</e1>, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, <e2>promethazine</e2>).",False,negative
selegiline,furazolidone,145,154,157,168,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, <e1>selegiline</e1>, <e2>furazolidone</e2>), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
selegiline,quinidine,145,154,172,180,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, <e1>selegiline</e1>, furazolidone), <e2>quinidine</e2>, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
selegiline,amantadine,145,154,183,192,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, <e1>selegiline</e1>, furazolidone), quinidine, <e2>amantadine</e2>, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
selegiline,antihistamines,145,154,195,208,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, <e1>selegiline</e1>, furazolidone), quinidine, amantadine, <e2>antihistamines</e2> (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
selegiline,diphenhydramine,145,154,217,231,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, <e1>selegiline</e1>, furazolidone), quinidine, amantadine, antihistamines (e.g., <e2>diphenhydramine</e2>), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
selegiline,anticholinergics,145,154,241,256,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, <e1>selegiline</e1>, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other <e2>anticholinergics</e2>, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
selegiline,potassium chloride,145,154,259,276,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, <e1>selegiline</e1>, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, <e2>potassium chloride</e2> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
selegiline,antacids,145,154,291,298,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, <e1>selegiline</e1>, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, <e2>antacids</e2>, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
selegiline,absorbent-type anti-diarrhea medicines,145,154,301,338,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, <e1>selegiline</e1>, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, <e2>absorbent-type anti-diarrhea medicines</e2> (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
selegiline,kaolin,145,154,347,352,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, <e1>selegiline</e1>, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e2>kaolin</e2>-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
selegiline,pectin,145,154,354,359,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, <e1>selegiline</e1>, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-<e2>pectin</e2>), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
selegiline,phenothiazines,145,154,363,376,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, <e1>selegiline</e1>, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), <e2>phenothiazines</e2> (e.g., chlorpromazine, promethazine).",False,negative
selegiline,chlorpromazine,145,154,385,398,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, <e1>selegiline</e1>, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., <e2>chlorpromazine</e2>, promethazine).",False,negative
selegiline,promethazine,145,154,401,412,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, <e1>selegiline</e1>, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, <e2>promethazine</e2>).",False,negative
furazolidone,quinidine,157,168,172,180,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, <e1>furazolidone</e1>), <e2>quinidine</e2>, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
furazolidone,amantadine,157,168,183,192,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, <e1>furazolidone</e1>), quinidine, <e2>amantadine</e2>, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
furazolidone,antihistamines,157,168,195,208,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, <e1>furazolidone</e1>), quinidine, amantadine, <e2>antihistamines</e2> (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
furazolidone,diphenhydramine,157,168,217,231,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, <e1>furazolidone</e1>), quinidine, amantadine, antihistamines (e.g., <e2>diphenhydramine</e2>), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
furazolidone,anticholinergics,157,168,241,256,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, <e1>furazolidone</e1>), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other <e2>anticholinergics</e2>, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
furazolidone,potassium chloride,157,168,259,276,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, <e1>furazolidone</e1>), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, <e2>potassium chloride</e2> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
furazolidone,antacids,157,168,291,298,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, <e1>furazolidone</e1>), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, <e2>antacids</e2>, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
furazolidone,absorbent-type anti-diarrhea medicines,157,168,301,338,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, <e1>furazolidone</e1>), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, <e2>absorbent-type anti-diarrhea medicines</e2> (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
furazolidone,kaolin,157,168,347,352,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, <e1>furazolidone</e1>), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e2>kaolin</e2>-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
furazolidone,pectin,157,168,354,359,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, <e1>furazolidone</e1>), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-<e2>pectin</e2>), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
furazolidone,phenothiazines,157,168,363,376,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, <e1>furazolidone</e1>), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), <e2>phenothiazines</e2> (e.g., chlorpromazine, promethazine).",False,negative
furazolidone,chlorpromazine,157,168,385,398,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, <e1>furazolidone</e1>), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., <e2>chlorpromazine</e2>, promethazine).",False,negative
furazolidone,promethazine,157,168,401,412,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, <e1>furazolidone</e1>), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, <e2>promethazine</e2>).",False,negative
quinidine,amantadine,172,180,183,192,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), <e1>quinidine</e1>, <e2>amantadine</e2>, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
quinidine,antihistamines,172,180,195,208,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), <e1>quinidine</e1>, amantadine, <e2>antihistamines</e2> (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
quinidine,diphenhydramine,172,180,217,231,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), <e1>quinidine</e1>, amantadine, antihistamines (e.g., <e2>diphenhydramine</e2>), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
quinidine,anticholinergics,172,180,241,256,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), <e1>quinidine</e1>, amantadine, antihistamines (e.g., diphenhydramine), other <e2>anticholinergics</e2>, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
quinidine,potassium chloride,172,180,259,276,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), <e1>quinidine</e1>, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, <e2>potassium chloride</e2> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
quinidine,antacids,172,180,291,298,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), <e1>quinidine</e1>, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, <e2>antacids</e2>, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
quinidine,absorbent-type anti-diarrhea medicines,172,180,301,338,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), <e1>quinidine</e1>, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, <e2>absorbent-type anti-diarrhea medicines</e2> (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
quinidine,kaolin,172,180,347,352,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), <e1>quinidine</e1>, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e2>kaolin</e2>-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
quinidine,pectin,172,180,354,359,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), <e1>quinidine</e1>, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-<e2>pectin</e2>), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
quinidine,phenothiazines,172,180,363,376,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), <e1>quinidine</e1>, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), <e2>phenothiazines</e2> (e.g., chlorpromazine, promethazine).",False,negative
quinidine,chlorpromazine,172,180,385,398,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), <e1>quinidine</e1>, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., <e2>chlorpromazine</e2>, promethazine).",False,negative
quinidine,promethazine,172,180,401,412,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), <e1>quinidine</e1>, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, <e2>promethazine</e2>).",False,negative
amantadine,antihistamines,183,192,195,208,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, <e1>amantadine</e1>, <e2>antihistamines</e2> (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
amantadine,diphenhydramine,183,192,217,231,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, <e1>amantadine</e1>, antihistamines (e.g., <e2>diphenhydramine</e2>), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
amantadine,anticholinergics,183,192,241,256,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, <e1>amantadine</e1>, antihistamines (e.g., diphenhydramine), other <e2>anticholinergics</e2>, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
amantadine,potassium chloride,183,192,259,276,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, <e1>amantadine</e1>, antihistamines (e.g., diphenhydramine), other anticholinergics, <e2>potassium chloride</e2> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
amantadine,antacids,183,192,291,298,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, <e1>amantadine</e1>, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, <e2>antacids</e2>, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
amantadine,absorbent-type anti-diarrhea medicines,183,192,301,338,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, <e1>amantadine</e1>, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, <e2>absorbent-type anti-diarrhea medicines</e2> (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
amantadine,kaolin,183,192,347,352,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, <e1>amantadine</e1>, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e2>kaolin</e2>-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
amantadine,pectin,183,192,354,359,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, <e1>amantadine</e1>, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-<e2>pectin</e2>), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
amantadine,phenothiazines,183,192,363,376,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, <e1>amantadine</e1>, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), <e2>phenothiazines</e2> (e.g., chlorpromazine, promethazine).",False,negative
amantadine,chlorpromazine,183,192,385,398,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, <e1>amantadine</e1>, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., <e2>chlorpromazine</e2>, promethazine).",False,negative
amantadine,promethazine,183,192,401,412,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, <e1>amantadine</e1>, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, <e2>promethazine</e2>).",False,negative
antihistamines,diphenhydramine,195,208,217,231,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, <e1>antihistamines</e1> (e.g., <e2>diphenhydramine</e2>), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
antihistamines,anticholinergics,195,208,241,256,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, <e1>antihistamines</e1> (e.g., diphenhydramine), other <e2>anticholinergics</e2>, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
antihistamines,potassium chloride,195,208,259,276,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, <e1>antihistamines</e1> (e.g., diphenhydramine), other anticholinergics, <e2>potassium chloride</e2> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
antihistamines,antacids,195,208,291,298,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, <e1>antihistamines</e1> (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, <e2>antacids</e2>, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
antihistamines,absorbent-type anti-diarrhea medicines,195,208,301,338,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, <e1>antihistamines</e1> (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, <e2>absorbent-type anti-diarrhea medicines</e2> (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
antihistamines,kaolin,195,208,347,352,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, <e1>antihistamines</e1> (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e2>kaolin</e2>-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
antihistamines,pectin,195,208,354,359,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, <e1>antihistamines</e1> (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-<e2>pectin</e2>), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
antihistamines,phenothiazines,195,208,363,376,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, <e1>antihistamines</e1> (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), <e2>phenothiazines</e2> (e.g., chlorpromazine, promethazine).",False,negative
antihistamines,chlorpromazine,195,208,385,398,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, <e1>antihistamines</e1> (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., <e2>chlorpromazine</e2>, promethazine).",False,negative
antihistamines,promethazine,195,208,401,412,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, <e1>antihistamines</e1> (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, <e2>promethazine</e2>).",False,negative
diphenhydramine,anticholinergics,217,231,241,256,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., <e1>diphenhydramine</e1>), other <e2>anticholinergics</e2>, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
diphenhydramine,potassium chloride,217,231,259,276,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., <e1>diphenhydramine</e1>), other anticholinergics, <e2>potassium chloride</e2> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
diphenhydramine,antacids,217,231,291,298,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., <e1>diphenhydramine</e1>), other anticholinergics, potassium chloride supplements, <e2>antacids</e2>, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
diphenhydramine,absorbent-type anti-diarrhea medicines,217,231,301,338,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., <e1>diphenhydramine</e1>), other anticholinergics, potassium chloride supplements, antacids, <e2>absorbent-type anti-diarrhea medicines</e2> (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
diphenhydramine,kaolin,217,231,347,352,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., <e1>diphenhydramine</e1>), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e2>kaolin</e2>-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
diphenhydramine,pectin,217,231,354,359,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., <e1>diphenhydramine</e1>), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-<e2>pectin</e2>), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
diphenhydramine,phenothiazines,217,231,363,376,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., <e1>diphenhydramine</e1>), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), <e2>phenothiazines</e2> (e.g., chlorpromazine, promethazine).",False,negative
diphenhydramine,chlorpromazine,217,231,385,398,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., <e1>diphenhydramine</e1>), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., <e2>chlorpromazine</e2>, promethazine).",False,negative
diphenhydramine,promethazine,217,231,401,412,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., <e1>diphenhydramine</e1>), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, <e2>promethazine</e2>).",False,negative
anticholinergics,potassium chloride,241,256,259,276,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other <e1>anticholinergics</e1>, <e2>potassium chloride</e2> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
anticholinergics,antacids,241,256,291,298,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other <e1>anticholinergics</e1>, potassium chloride supplements, <e2>antacids</e2>, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
anticholinergics,absorbent-type anti-diarrhea medicines,241,256,301,338,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other <e1>anticholinergics</e1>, potassium chloride supplements, antacids, <e2>absorbent-type anti-diarrhea medicines</e2> (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
anticholinergics,kaolin,241,256,347,352,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other <e1>anticholinergics</e1>, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e2>kaolin</e2>-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
anticholinergics,pectin,241,256,354,359,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other <e1>anticholinergics</e1>, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-<e2>pectin</e2>), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
anticholinergics,phenothiazines,241,256,363,376,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other <e1>anticholinergics</e1>, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), <e2>phenothiazines</e2> (e.g., chlorpromazine, promethazine).",False,negative
anticholinergics,chlorpromazine,241,256,385,398,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other <e1>anticholinergics</e1>, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., <e2>chlorpromazine</e2>, promethazine).",False,negative
anticholinergics,promethazine,241,256,401,412,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other <e1>anticholinergics</e1>, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, <e2>promethazine</e2>).",False,negative
potassium chloride,antacids,259,276,291,298,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, <e1>potassium chloride</e1> supplements, <e2>antacids</e2>, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
potassium chloride,absorbent-type anti-diarrhea medicines,259,276,301,338,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, <e1>potassium chloride</e1> supplements, antacids, <e2>absorbent-type anti-diarrhea medicines</e2> (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
potassium chloride,kaolin,259,276,347,352,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, <e1>potassium chloride</e1> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e2>kaolin</e2>-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
potassium chloride,pectin,259,276,354,359,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, <e1>potassium chloride</e1> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-<e2>pectin</e2>), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
potassium chloride,phenothiazines,259,276,363,376,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, <e1>potassium chloride</e1> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), <e2>phenothiazines</e2> (e.g., chlorpromazine, promethazine).",False,negative
potassium chloride,chlorpromazine,259,276,385,398,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, <e1>potassium chloride</e1> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., <e2>chlorpromazine</e2>, promethazine).",False,negative
potassium chloride,promethazine,259,276,401,412,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, <e1>potassium chloride</e1> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, <e2>promethazine</e2>).",False,negative
antacids,absorbent-type anti-diarrhea medicines,291,298,301,338,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, <e1>antacids</e1>, <e2>absorbent-type anti-diarrhea medicines</e2> (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
antacids,kaolin,291,298,347,352,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, <e1>antacids</e1>, absorbent-type anti-diarrhea medicines (e.g., <e2>kaolin</e2>-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
antacids,pectin,291,298,354,359,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, <e1>antacids</e1>, absorbent-type anti-diarrhea medicines (e.g., kaolin-<e2>pectin</e2>), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
antacids,phenothiazines,291,298,363,376,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, <e1>antacids</e1>, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), <e2>phenothiazines</e2> (e.g., chlorpromazine, promethazine).",False,negative
antacids,chlorpromazine,291,298,385,398,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, <e1>antacids</e1>, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., <e2>chlorpromazine</e2>, promethazine).",False,negative
antacids,promethazine,291,298,401,412,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, <e1>antacids</e1>, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, <e2>promethazine</e2>).",False,negative
absorbent-type anti-diarrhea medicines,kaolin,301,338,347,352,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, <e1>absorbent-type anti-diarrhea medicines</e1> (e.g., <e2>kaolin</e2>-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
absorbent-type anti-diarrhea medicines,pectin,301,338,354,359,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, <e1>absorbent-type anti-diarrhea medicines</e1> (e.g., kaolin-<e2>pectin</e2>), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
absorbent-type anti-diarrhea medicines,phenothiazines,301,338,363,376,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, <e1>absorbent-type anti-diarrhea medicines</e1> (e.g., kaolin-pectin), <e2>phenothiazines</e2> (e.g., chlorpromazine, promethazine).",False,negative
absorbent-type anti-diarrhea medicines,chlorpromazine,301,338,385,398,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, <e1>absorbent-type anti-diarrhea medicines</e1> (e.g., kaolin-pectin), phenothiazines (e.g., <e2>chlorpromazine</e2>, promethazine).",False,negative
absorbent-type anti-diarrhea medicines,promethazine,301,338,401,412,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, <e1>absorbent-type anti-diarrhea medicines</e1> (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, <e2>promethazine</e2>).",False,negative
kaolin,pectin,347,352,354,359,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e1>kaolin</e1>-<e2>pectin</e2>), phenothiazines (e.g., chlorpromazine, promethazine).",False,negative
kaolin,phenothiazines,347,352,363,376,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e1>kaolin</e1>-pectin), <e2>phenothiazines</e2> (e.g., chlorpromazine, promethazine).",False,negative
kaolin,chlorpromazine,347,352,385,398,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e1>kaolin</e1>-pectin), phenothiazines (e.g., <e2>chlorpromazine</e2>, promethazine).",False,negative
kaolin,promethazine,347,352,401,412,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e1>kaolin</e1>-pectin), phenothiazines (e.g., chlorpromazine, <e2>promethazine</e2>).",False,negative
pectin,phenothiazines,354,359,363,376,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-<e1>pectin</e1>), <e2>phenothiazines</e2> (e.g., chlorpromazine, promethazine).",False,negative
pectin,chlorpromazine,354,359,385,398,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-<e1>pectin</e1>), phenothiazines (e.g., <e2>chlorpromazine</e2>, promethazine).",False,negative
pectin,promethazine,354,359,401,412,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-<e1>pectin</e1>), phenothiazines (e.g., chlorpromazine, <e2>promethazine</e2>).",False,negative
phenothiazines,chlorpromazine,363,376,385,398,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), <e1>phenothiazines</e1> (e.g., <e2>chlorpromazine</e2>, promethazine).",False,negative
phenothiazines,promethazine,363,376,401,412,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), <e1>phenothiazines</e1> (e.g., chlorpromazine, <e2>promethazine</e2>).",False,negative
chlorpromazine,promethazine,385,398,401,412,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., <e1>chlorpromazine</e1>, <e2>promethazine</e2>).",False,negative
alcohol,CNS depression-producing drugs,18,24,36,65,Concurrent use of <e1>alcohol</e1> and other <e2>CNS depression-producing drugs</e2> may increase the CNS depressant effects of methyprylon or these other medications.,False,negative
alcohol,methyprylon,18,24,110,120,Concurrent use of <e1>alcohol</e1> and other CNS depression-producing drugs may increase the CNS depressant effects of <e2>methyprylon</e2> or these other medications.,True,effect
CNS depression-producing drugs,methyprylon,36,65,110,120,Concurrent use of alcohol and other <e1>CNS depression-producing drugs</e1> may increase the CNS depressant effects of <e2>methyprylon</e2> or these other medications.,True,effect
Methysergide,narcotic analgesics,0,11,51,69,<e1>Methysergide</e1> may reverse the analgesic activity of <e2>narcotic analgesics</e2>. ,True,effect
vasoconstrictor agents,ergot alkaloids,20,41,53,67,"Concurrent use with <e1>vasoconstrictor agents</e1> including <e2>ergot alkaloids</e2>, sumatriptan, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.",False,negative
vasoconstrictor agents,sumatriptan,20,41,70,80,"Concurrent use with <e1>vasoconstrictor agents</e1> including ergot alkaloids, <e2>sumatriptan</e2>, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.",False,negative
vasoconstrictor agents,nicotine,20,41,87,94,"Concurrent use with <e1>vasoconstrictor agents</e1> including ergot alkaloids, sumatriptan, and <e2>nicotine</e2> (e.g. smoking) may result in enhanced vasoconstriction.",False,negative
ergot alkaloids,sumatriptan,53,67,70,80,"Concurrent use with vasoconstrictor agents including <e1>ergot alkaloids</e1>, <e2>sumatriptan</e2>, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.",False,negative
ergot alkaloids,nicotine,53,67,87,94,"Concurrent use with vasoconstrictor agents including <e1>ergot alkaloids</e1>, sumatriptan, and <e2>nicotine</e2> (e.g. smoking) may result in enhanced vasoconstriction.",False,negative
sumatriptan,nicotine,70,80,87,94,"Concurrent use with vasoconstrictor agents including ergot alkaloids, <e1>sumatriptan</e1>, and <e2>nicotine</e2> (e.g. smoking) may result in enhanced vasoconstriction.",False,negative
metoclopramide,anticholinergic drugs,15,28,78,98,The effects of <e1>metoclopramide</e1> on gastrointestinal motility are antagonized by <e2>anticholinergic drugs</e2> and narcotic analgesics. ,True,effect
metoclopramide,narcotic analgesics,15,28,104,122,The effects of <e1>metoclopramide</e1> on gastrointestinal motility are antagonized by anticholinergic drugs and <e2>narcotic analgesics</e2>. ,True,effect
anticholinergic drugs,narcotic analgesics,78,98,104,122,The effects of metoclopramide on gastrointestinal motility are antagonized by <e1>anticholinergic drugs</e1> and <e2>narcotic analgesics</e2>. ,False,negative
metoclopramide,alcohol,41,54,70,76,"Additive sedative effects can occur when <e1>metoclopramide</e1> is given with <e2>alcohol</e2>, sedatives, hypnotics, narcotics, or tranquilizers. ",True,effect
metoclopramide,sedatives,41,54,79,87,"Additive sedative effects can occur when <e1>metoclopramide</e1> is given with alcohol, <e2>sedatives</e2>, hypnotics, narcotics, or tranquilizers. ",True,effect
metoclopramide,hypnotics,41,54,90,98,"Additive sedative effects can occur when <e1>metoclopramide</e1> is given with alcohol, sedatives, <e2>hypnotics</e2>, narcotics, or tranquilizers. ",True,effect
metoclopramide,narcotics,41,54,101,109,"Additive sedative effects can occur when <e1>metoclopramide</e1> is given with alcohol, sedatives, hypnotics, <e2>narcotics</e2>, or tranquilizers. ",True,effect
metoclopramide,tranquilizers,41,54,115,127,"Additive sedative effects can occur when <e1>metoclopramide</e1> is given with alcohol, sedatives, hypnotics, narcotics, or <e2>tranquilizers</e2>. ",True,effect
alcohol,sedatives,70,76,79,87,"Additive sedative effects can occur when metoclopramide is given with <e1>alcohol</e1>, <e2>sedatives</e2>, hypnotics, narcotics, or tranquilizers. ",False,negative
alcohol,hypnotics,70,76,90,98,"Additive sedative effects can occur when metoclopramide is given with <e1>alcohol</e1>, sedatives, <e2>hypnotics</e2>, narcotics, or tranquilizers. ",False,negative
alcohol,narcotics,70,76,101,109,"Additive sedative effects can occur when metoclopramide is given with <e1>alcohol</e1>, sedatives, hypnotics, <e2>narcotics</e2>, or tranquilizers. ",False,negative
alcohol,tranquilizers,70,76,115,127,"Additive sedative effects can occur when metoclopramide is given with <e1>alcohol</e1>, sedatives, hypnotics, narcotics, or <e2>tranquilizers</e2>. ",False,negative
sedatives,hypnotics,79,87,90,98,"Additive sedative effects can occur when metoclopramide is given with alcohol, <e1>sedatives</e1>, <e2>hypnotics</e2>, narcotics, or tranquilizers. ",False,negative
sedatives,narcotics,79,87,101,109,"Additive sedative effects can occur when metoclopramide is given with alcohol, <e1>sedatives</e1>, hypnotics, <e2>narcotics</e2>, or tranquilizers. ",False,negative
sedatives,tranquilizers,79,87,115,127,"Additive sedative effects can occur when metoclopramide is given with alcohol, <e1>sedatives</e1>, hypnotics, narcotics, or <e2>tranquilizers</e2>. ",False,negative
hypnotics,narcotics,90,98,101,109,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, <e1>hypnotics</e1>, <e2>narcotics</e2>, or tranquilizers. ",False,negative
hypnotics,tranquilizers,90,98,115,127,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, <e1>hypnotics</e1>, narcotics, or <e2>tranquilizers</e2>. ",False,negative
narcotics,tranquilizers,101,109,115,127,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, <e1>narcotics</e1>, or <e2>tranquilizers</e2>. ",False,negative
metoclopramide,monoamine oxi-dase inhibitors,17,30,173,201,"The finding that <e1>metoclopramide</e1> releases catecholamines in patients with essential hypertension suggests that it should be used cautiously, if at all, in patients receiving <e2>monoamine oxi-dase inhibitors</e2>. ",True,advise
digoxin,metoclopramide,62,68,74,87,"Absorption of drugs from the stomach may be diminished (e.g., <e1>digoxin</e1>) by <e2>metoclopramide</e2>, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",True,mechanism
digoxin,acetaminophen,62,68,189,201,"Absorption of drugs from the stomach may be diminished (e.g., <e1>digoxin</e1>) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., <e2>acetaminophen</e2>, tetracycline, levodopa, ethanol, cyclosporine). ",False,negative
digoxin,tetracycline,62,68,204,215,"Absorption of drugs from the stomach may be diminished (e.g., <e1>digoxin</e1>) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, <e2>tetracycline</e2>, levodopa, ethanol, cyclosporine). ",False,negative
digoxin,levodopa,62,68,218,225,"Absorption of drugs from the stomach may be diminished (e.g., <e1>digoxin</e1>) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, <e2>levodopa</e2>, ethanol, cyclosporine). ",False,negative
digoxin,ethanol,62,68,228,234,"Absorption of drugs from the stomach may be diminished (e.g., <e1>digoxin</e1>) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, <e2>ethanol</e2>, cyclosporine). ",False,negative
digoxin,cyclosporine,62,68,237,248,"Absorption of drugs from the stomach may be diminished (e.g., <e1>digoxin</e1>) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, <e2>cyclosporine</e2>). ",False,negative
metoclopramide,acetaminophen,74,87,189,201,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by <e1>metoclopramide</e1>, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., <e2>acetaminophen</e2>, tetracycline, levodopa, ethanol, cyclosporine). ",True,mechanism
metoclopramide,tetracycline,74,87,204,215,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by <e1>metoclopramide</e1>, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, <e2>tetracycline</e2>, levodopa, ethanol, cyclosporine). ",False,negative
metoclopramide,levodopa,74,87,218,225,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by <e1>metoclopramide</e1>, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, <e2>levodopa</e2>, ethanol, cyclosporine). ",False,negative
metoclopramide,ethanol,74,87,228,234,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by <e1>metoclopramide</e1>, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, <e2>ethanol</e2>, cyclosporine). ",False,negative
metoclopramide,cyclosporine,74,87,237,248,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by <e1>metoclopramide</e1>, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, <e2>cyclosporine</e2>). ",False,negative
acetaminophen,tetracycline,189,201,204,215,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., <e1>acetaminophen</e1>, <e2>tetracycline</e2>, levodopa, ethanol, cyclosporine). ",False,negative
acetaminophen,levodopa,189,201,218,225,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., <e1>acetaminophen</e1>, tetracycline, <e2>levodopa</e2>, ethanol, cyclosporine). ",False,negative
acetaminophen,ethanol,189,201,228,234,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., <e1>acetaminophen</e1>, tetracycline, levodopa, <e2>ethanol</e2>, cyclosporine). ",False,negative
acetaminophen,cyclosporine,189,201,237,248,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., <e1>acetaminophen</e1>, tetracycline, levodopa, ethanol, <e2>cyclosporine</e2>). ",False,negative
tetracycline,levodopa,204,215,218,225,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, <e1>tetracycline</e1>, <e2>levodopa</e2>, ethanol, cyclosporine). ",False,negative
tetracycline,ethanol,204,215,228,234,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, <e1>tetracycline</e1>, levodopa, <e2>ethanol</e2>, cyclosporine). ",False,negative
tetracycline,cyclosporine,204,215,237,248,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, <e1>tetracycline</e1>, levodopa, ethanol, <e2>cyclosporine</e2>). ",False,negative
levodopa,ethanol,218,225,228,234,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, <e1>levodopa</e1>, <e2>ethanol</e2>, cyclosporine). ",False,negative
levodopa,cyclosporine,218,225,237,248,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, <e1>levodopa</e1>, ethanol, <e2>cyclosporine</e2>). ",False,negative
ethanol,cyclosporine,228,234,237,248,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, <e1>ethanol</e1>, <e2>cyclosporine</e2>). ",False,negative
metoclopramide,insulin,22,35,124,130,"Because the action of <e1>metoclopramide</e1> will influence the delivery of food to the intestines and thus the rate of absorption, <e2>insulin</e2> dosage or timing of dosage may require adjustment.",True,advise
Diuretics,Furosemide,0,8,11,20,<e1>Diuretics</e1>: <e2>Furosemide</e2> and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes. ,False,negative
Diuretics,loop diuretics,0,8,41,54,<e1>Diuretics</e1>: Furosemide and probably other <e2>loop diuretics</e2> given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes. ,False,negative
Diuretics,metolazone,0,8,81,90,<e1>Diuretics</e1>: Furosemide and probably other loop diuretics given concomitantly with <e2>metolazone</e2> can cause unusually large or prolonged losses of fluid and electrolytes. ,False,negative
Furosemide,loop diuretics,11,20,41,54,Diuretics: <e1>Furosemide</e1> and probably other <e2>loop diuretics</e2> given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes. ,False,negative
Furosemide,metolazone,11,20,81,90,Diuretics: <e1>Furosemide</e1> and probably other loop diuretics given concomitantly with <e2>metolazone</e2> can cause unusually large or prolonged losses of fluid and electrolytes. ,True,effect
loop diuretics,metolazone,41,54,81,90,Diuretics: Furosemide and probably other <e1>loop diuretics</e1> given concomitantly with <e2>metolazone</e2> can cause unusually large or prolonged losses of fluid and electrolytes. ,True,effect
Antihypertensives,MYKROX,6,22,30,35,"Other <e1>Antihypertensives</e1>: When <e2>MYKROX</e2> Tablets are used with other antihypertensive drugs, care must be taken, especially during initial therapy. ",False,negative
Antihypertensives,antihypertensive drugs,6,22,65,86,"Other <e1>Antihypertensives</e1>: When MYKROX Tablets are used with other <e2>antihypertensive drugs</e2>, care must be taken, especially during initial therapy. ",False,negative
MYKROX,antihypertensive drugs,30,35,65,86,"Other Antihypertensives: When <e1>MYKROX</e1> Tablets are used with other <e2>antihypertensive drugs</e2>, care must be taken, especially during initial therapy. ",True,advise
Alcohol,Barbiturates,0,6,9,20,"<e1>Alcohol</e1>, <e2>Barbiturates</e2>, and Narcotics: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy. ",False,negative
Alcohol,Narcotics,0,6,27,35,"<e1>Alcohol</e1>, Barbiturates, and <e2>Narcotics</e2>: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy. ",False,negative
Alcohol,metolazone,0,6,150,159,"<e1>Alcohol</e1>, Barbiturates, and Narcotics: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with <e2>metolazone</e2> therapy. ",False,negative
Barbiturates,Narcotics,9,20,27,35,"Alcohol, <e1>Barbiturates</e1>, and <e2>Narcotics</e2>: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy. ",False,negative
Barbiturates,metolazone,9,20,150,159,"Alcohol, <e1>Barbiturates</e1>, and Narcotics: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with <e2>metolazone</e2> therapy. ",False,negative
Narcotics,metolazone,27,35,150,159,"Alcohol, Barbiturates, and <e1>Narcotics</e1>: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with <e2>metolazone</e2> therapy. ",False,negative
Digitalis Glycosides,Diuretic,0,19,22,29,<e1>Digitalis Glycosides</e1>: <e2>Diuretic</e2>-induced hypokalemia can increase the sensitivity of the myocardium to digitalis. ,False,negative
Digitalis Glycosides,digitalis,0,19,101,109,<e1>Digitalis Glycosides</e1>: Diuretic-induced hypokalemia can increase the sensitivity of the myocardium to <e2>digitalis</e2>. ,False,negative
Diuretic,digitalis,22,29,101,109,Digitalis Glycosides: <e1>Diuretic</e1>-induced hypokalemia can increase the sensitivity of the myocardium to <e2>digitalis</e2>. ,True,effect
Corticosteroids,ACTH,0,14,19,22,<e1>Corticosteroids</e1> or <e2>ACTH</e2>: May increase the risk of hypokalemia and increase salt and water retention. ,False,negative
Lithium,lithium,0,6,15,21,<e1>Lithium</e1>: Serum <e2>lithium</e2> levels may increase. ,False,negative
Curariform Drugs,Diuretic,0,15,18,25,<e1>Curariform Drugs</e1>: <e2>Diuretic</e2>-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea. ,False,negative
Curariform Drugs,curariform drugs,0,15,93,108,<e1>Curariform Drugs</e1>: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of <e2>curariform drugs</e2> (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea. ,False,negative
Curariform Drugs,tubocurarine,0,15,119,130,<e1>Curariform Drugs</e1>: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as <e2>tubocurarine</e2>) the most serious effect would be respiratory depression which could proceed to apnea. ,False,negative
Diuretic,curariform drugs,18,25,93,108,Curariform Drugs: <e1>Diuretic</e1>-induced hypokalemia may enhance neuromuscular blocking effects of <e2>curariform drugs</e2> (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea. ,True,effect
Diuretic,tubocurarine,18,25,119,130,Curariform Drugs: <e1>Diuretic</e1>-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as <e2>tubocurarine</e2>) the most serious effect would be respiratory depression which could proceed to apnea. ,True,effect
curariform drugs,tubocurarine,93,108,119,130,Curariform Drugs: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of <e1>curariform drugs</e1> (such as <e2>tubocurarine</e2>) the most serious effect would be respiratory depression which could proceed to apnea. ,False,negative
Salicylates,Non-Steroidal Anti-Inflammatory Drugs,0,10,22,58,<e1>Salicylates</e1> and Other <e2>Non-Steroidal Anti-Inflammatory Drugs</e2>: May decrease the antihypertensive effects of MYKROX Tablets. ,False,negative
Salicylates,MYKROX,0,10,106,111,<e1>Salicylates</e1> and Other Non-Steroidal Anti-Inflammatory Drugs: May decrease the antihypertensive effects of <e2>MYKROX</e2> Tablets. ,True,effect
Non-Steroidal Anti-Inflammatory Drugs,MYKROX,22,58,106,111,Salicylates and Other <e1>Non-Steroidal Anti-Inflammatory Drugs</e1>: May decrease the antihypertensive effects of <e2>MYKROX</e2> Tablets. ,True,effect
Sympathomimetics,Metolazone,0,15,18,27,"<e1>Sympathomimetics</e1>: <e2>Metolazone</e2> may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. ",False,negative
Sympathomimetics,norepinephrine,0,15,69,82,"<e1>Sympathomimetics</e1>: Metolazone may decrease arterial responsiveness to <e2>norepinephrine</e2>, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. ",False,negative
Metolazone,norepinephrine,18,27,69,82,"Sympathomimetics: <e1>Metolazone</e1> may decrease arterial responsiveness to <e2>norepinephrine</e2>, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. ",True,effect
Methenamine,metolazone,0,10,75,84,<e1>Methenamine</e1>: Efficacy may be decreased due to urinary alkalizing effect of <e2>metolazone</e2>. ,True,effect
Anticoagulants,Metolazone,0,13,16,25,"<e1>Anticoagulants</e1>: <e2>Metolazone</e2>, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to anticoagulants; ",False,negative
Anticoagulants,thiazide-like diuretics,0,13,45,67,"<e1>Anticoagulants</e1>: Metolazone, as well as other <e2>thiazide-like diuretics</e2>, may affect the hypoprothrombinemic response to anticoagulants; ",False,negative
Anticoagulants,anticoagulants,0,13,117,130,"<e1>Anticoagulants</e1>: Metolazone, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to <e2>anticoagulants</e2>; ",False,negative
Metolazone,thiazide-like diuretics,16,25,45,67,"Anticoagulants: <e1>Metolazone</e1>, as well as other <e2>thiazide-like diuretics</e2>, may affect the hypoprothrombinemic response to anticoagulants; ",False,negative
Metolazone,anticoagulants,16,25,117,130,"Anticoagulants: <e1>Metolazone</e1>, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to <e2>anticoagulants</e2>; ",True,effect
thiazide-like diuretics,anticoagulants,45,67,117,130,"Anticoagulants: Metolazone, as well as other <e1>thiazide-like diuretics</e1>, may affect the hypoprothrombinemic response to <e2>anticoagulants</e2>; ",False,negative
reserpine,beta-blocking agents,37,45,92,111,"Catecholamine-depleting drugs (e.g., <e1>reserpine</e1>) may have an additive effect when given with <e2>beta-blocking agents</e2>. ",True,effect
metronidazole,coumarin,5,17,79,86,"Oral <e1>metronidazole</e1> has been reported to potentiate the anticoagulant effect of <e2>coumarin</e2> and warfarin, resulting in a prolongation of prothrombin time. ",True,effect
metronidazole,warfarin,5,17,92,99,"Oral <e1>metronidazole</e1> has been reported to potentiate the anticoagulant effect of coumarin and <e2>warfarin</e2>, resulting in a prolongation of prothrombin time. ",True,effect
coumarin,warfarin,79,86,92,99,"Oral metronidazole has been reported to potentiate the anticoagulant effect of <e1>coumarin</e1> and <e2>warfarin</e2>, resulting in a prolongation of prothrombin time. ",False,negative
METROGEL,metronidazole,46,53,56,68,"Drug interactions should be kept in mind when <e1>METROGEL</e1> (<e2>metronidazole</e2> gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical metronidazole administration because of low absorption.    ",False,negative
METROGEL,metronidazole,46,53,201,213,"Drug interactions should be kept in mind when <e1>METROGEL</e1> (metronidazole gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical <e2>metronidazole</e2> administration because of low absorption.    ",False,negative
metronidazole,metronidazole,56,68,201,213,"Drug interactions should be kept in mind when METROGEL (<e1>metronidazole</e1> gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical <e2>metronidazole</e2> administration because of low absorption.    ",False,negative
Metopirone,phenytoin,18,27,47,55,The metabolism of <e1>Metopirone</e1> is accelerated by <e2>phenytoin</e2>; ,True,mechanism
Metopirone,acetaminophen,0,9,43,55,<e1>Metopirone</e1> inhibits the glucuronidation of <e2>acetaminophen</e2> and could possibly potentiate acetaminophen toxicity.,True,mechanism
Metopirone,acetaminophen,0,9,87,99,<e1>Metopirone</e1> inhibits the glucuronidation of acetaminophen and could possibly potentiate <e2>acetaminophen</e2> toxicity.,True,effect
acetaminophen,acetaminophen,43,55,87,99,Metopirone inhibits the glucuronidation of <e1>acetaminophen</e1> and could possibly potentiate <e2>acetaminophen</e2> toxicity.,False,negative
DEMSER,phenothiazines,44,49,73,86,Caution should be observed in administering <e1>DEMSER</e1> to patients receiving <e2>phenothiazines</e2> or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. ,True,advise
DEMSER,haloperidol,44,49,91,101,Caution should be observed in administering <e1>DEMSER</e1> to patients receiving phenothiazines or <e2>haloperidol</e2> because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. ,True,advise
phenothiazines,haloperidol,73,86,91,101,Caution should be observed in administering DEMSER to patients receiving <e1>phenothiazines</e1> or <e2>haloperidol</e2> because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. ,False,negative
DEMSER,alcohol,18,23,30,36,Concurrent use of <e1>DEMSER</e1> with <e2>alcohol</e2> or other CNS depressants can increase their sedative effects.,True,effect
DEMSER,CNS depressants,18,23,47,61,Concurrent use of <e1>DEMSER</e1> with alcohol or other <e2>CNS depressants</e2> can increase their sedative effects.,True,effect
alcohol,CNS depressants,30,36,47,61,Concurrent use of DEMSER with <e1>alcohol</e1> or other <e2>CNS depressants</e2> can increase their sedative effects.,False,negative
MEXITIL,mexiletine,6,12,171,180,"Since <e1>MEXITIL</e1> is a substrate for the metabolic pathways involving CYP2D6 and CYP1A2 enzymes, inhibition or induction of either of these enzymes would be expected to alter <e2>mexiletine</e2> plasma concentrations. ",False,negative
mexiletine,fluvoxamine,74,83,140,150,"In a formal, single-dose interaction study (n = 6 males) the clearance of <e1>mexiletine</e1> was decreased by 38% following the coadministration of <e2>fluvoxamine</e2>, an inhibitor of CYP1A2. ",True,mechanism
propafenone,mexiletine,101,111,143,152,"In another formal study (n = 8 extensive and n = 7 poor metabolizers of CYP2D6), coadministration of <e1>propafenone</e1> did not alter the kinetics of <e2>mexiletine</e2> in the poor CYP2D6 metabolizer group. ",False,negative
propafenone,mexiletine,62,72,137,146,"In this crossover steady state study, the pharmacokinetics of <e1>propafenone</e1> were unaffected in either phenotype by the coadministration of <e2>mexiletine</e2>. ",False,negative
mexiletine,propafenone,12,21,26,36,"Addition of <e1>mexiletine</e1> to <e2>propafenone</e2> did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than propafenone alone. ",False,negative
mexiletine,propafenone,12,21,141,151,"Addition of <e1>mexiletine</e1> to propafenone did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than <e2>propafenone</e2> alone. ",False,negative
propafenone,propafenone,26,36,141,151,"Addition of mexiletine to <e1>propafenone</e1> did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than <e2>propafenone</e2> alone. ",False,negative
mexiletine,mexiletine,66,75,103,112,"When concomitant administration of either of these two drugs with <e1>mexiletine</e1> is initiated, the dose of <e2>mexiletine</e2> should be slowly titrated to desired effect. ",False,negative
Mexitil,antihypertensive,37,43,111,126,"In a large compassionate use program <e1>Mexitil</e1>    has been used concurrently with commonly employed antianginal, <e2>antihypertensive</e2>, and anticoagulant drugs without observed interactions. ",False,negative
Mexitil,anticoagulant drugs,37,43,133,151,"In a large compassionate use program <e1>Mexitil</e1>    has been used concurrently with commonly employed antianginal, antihypertensive, and <e2>anticoagulant drugs</e2> without observed interactions. ",False,negative
antihypertensive,anticoagulant drugs,111,126,133,151,"In a large compassionate use program Mexitil    has been used concurrently with commonly employed antianginal, <e1>antihypertensive</e1>, and <e2>anticoagulant drugs</e2> without observed interactions. ",False,negative
antiarrhythmics,quinidine,13,27,37,45,"A variety of <e1>antiarrhythmics</e1> such as <e2>quinidine</e2> or propranolol were also added, sometimes with improved control of ventricular ectopy. ",False,negative
antiarrhythmics,propranolol,13,27,50,60,"A variety of <e1>antiarrhythmics</e1> such as quinidine or <e2>propranolol</e2> were also added, sometimes with improved control of ventricular ectopy. ",False,negative
quinidine,propranolol,37,45,50,60,"A variety of antiarrhythmics such as <e1>quinidine</e1> or <e2>propranolol</e2> were also added, sometimes with improved control of ventricular ectopy. ",False,negative
phenytoin,rifampin,5,13,56,63,"When <e1>phenytoin</e1> or other hepatic enzyme inducers such as <e2>rifampin</e2> and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. ",False,negative
phenytoin,phenobarbital,5,13,69,81,"When <e1>phenytoin</e1> or other hepatic enzyme inducers such as rifampin and <e2>phenobarbital</e2> have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. ",False,negative
phenytoin,Mexitil,5,13,117,123,"When <e1>phenytoin</e1> or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with <e2>Mexitil</e2>   , lowered Mexitil    plasma levels have been reported. ",True,mechanism
phenytoin,Mexitil,5,13,137,143,"When <e1>phenytoin</e1> or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered <e2>Mexitil</e2>    plasma levels have been reported. ",False,negative
rifampin,phenobarbital,56,63,69,81,"When phenytoin or other hepatic enzyme inducers such as <e1>rifampin</e1> and <e2>phenobarbital</e2> have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. ",False,negative
rifampin,Mexitil,56,63,117,123,"When phenytoin or other hepatic enzyme inducers such as <e1>rifampin</e1> and phenobarbital have been taken concurrently with <e2>Mexitil</e2>   , lowered Mexitil    plasma levels have been reported. ",True,mechanism
rifampin,Mexitil,56,63,137,143,"When phenytoin or other hepatic enzyme inducers such as <e1>rifampin</e1> and phenobarbital have been taken concurrently with Mexitil   , lowered <e2>Mexitil</e2>    plasma levels have been reported. ",False,negative
phenobarbital,Mexitil,69,81,117,123,"When phenytoin or other hepatic enzyme inducers such as rifampin and <e1>phenobarbital</e1> have been taken concurrently with <e2>Mexitil</e2>   , lowered Mexitil    plasma levels have been reported. ",True,mechanism
phenobarbital,Mexitil,69,81,137,143,"When phenytoin or other hepatic enzyme inducers such as rifampin and <e1>phenobarbital</e1> have been taken concurrently with Mexitil   , lowered <e2>Mexitil</e2>    plasma levels have been reported. ",False,negative
Mexitil,Mexitil,117,123,137,143,"When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with <e1>Mexitil</e1>   , lowered <e2>Mexitil</e2>    plasma levels have been reported. ",False,negative
benzodiazepines,Mexitil,19,33,60,66,"In a formal study, <e1>benzodiazepines</e1> were shown not to affect <e2>Mexitil</e2>    plasma concentrations. ",False,negative
Mexitil,digoxin,64,70,79,85,"ECG intervals (PR, QRS, and QT) were not affected by concurrent <e1>Mexitil</e1>    and <e2>digoxin</e2>, diuretics, or propranolol. ",False,negative
Mexitil,diuretics,64,70,88,96,"ECG intervals (PR, QRS, and QT) were not affected by concurrent <e1>Mexitil</e1>    and digoxin, <e2>diuretics</e2>, or propranolol. ",False,negative
Mexitil,propranolol,64,70,102,112,"ECG intervals (PR, QRS, and QT) were not affected by concurrent <e1>Mexitil</e1>    and digoxin, diuretics, or <e2>propranolol</e2>. ",False,negative
digoxin,diuretics,79,85,88,96,"ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and <e1>digoxin</e1>, <e2>diuretics</e2>, or propranolol. ",False,negative
digoxin,propranolol,79,85,102,112,"ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and <e1>digoxin</e1>, diuretics, or <e2>propranolol</e2>. ",False,negative
diuretics,propranolol,88,96,102,112,"ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and digoxin, <e1>diuretics</e1>, or <e2>propranolol</e2>. ",False,negative
cimetidine,Mexitil,29,38,44,50,"Concurrent administration of <e1>cimetidine</e1> and <e2>Mexitil</e2>    has been reported to increase, decrease, or leave unchanged Mexitil    plasma levels; ",True,mechanism
cimetidine,Mexitil,29,38,115,121,"Concurrent administration of <e1>cimetidine</e1> and Mexitil    has been reported to increase, decrease, or leave unchanged <e2>Mexitil</e2>    plasma levels; ",False,negative
Mexitil,Mexitil,44,50,115,121,"Concurrent administration of cimetidine and <e1>Mexitil</e1>    has been reported to increase, decrease, or leave unchanged <e2>Mexitil</e2>    plasma levels; ",False,negative
Mexitil,digoxin,0,6,32,38,"<e1>Mexitil</e1>    does not alter serum <e2>digoxin</e2> levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. ",False,negative
Mexitil,magnesium-aluminum hydroxide,0,6,51,78,"<e1>Mexitil</e1>    does not alter serum digoxin levels but <e2>magnesium-aluminum hydroxide</e2>, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. ",False,negative
Mexitil,Mexitil,0,6,133,139,"<e1>Mexitil</e1>    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to <e2>Mexitil</e2>   , has been reported to lower serum digoxin levels. ",False,negative
Mexitil,digoxin,0,6,178,184,"<e1>Mexitil</e1>    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum <e2>digoxin</e2> levels. ",False,negative
digoxin,magnesium-aluminum hydroxide,32,38,51,78,"Mexitil    does not alter serum <e1>digoxin</e1> levels but <e2>magnesium-aluminum hydroxide</e2>, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. ",False,negative
digoxin,Mexitil,32,38,133,139,"Mexitil    does not alter serum <e1>digoxin</e1> levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to <e2>Mexitil</e2>   , has been reported to lower serum digoxin levels. ",False,negative
digoxin,digoxin,32,38,178,184,"Mexitil    does not alter serum <e1>digoxin</e1> levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum <e2>digoxin</e2> levels. ",False,negative
magnesium-aluminum hydroxide,Mexitil,51,78,133,139,"Mexitil    does not alter serum digoxin levels but <e1>magnesium-aluminum hydroxide</e1>, when used to treat gastrointestinal symptoms due to <e2>Mexitil</e2>   , has been reported to lower serum digoxin levels. ",False,negative
magnesium-aluminum hydroxide,digoxin,51,78,178,184,"Mexitil    does not alter serum digoxin levels but <e1>magnesium-aluminum hydroxide</e1>, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum <e2>digoxin</e2> levels. ",True,mechanism
Mexitil,digoxin,133,139,178,184,"Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to <e1>Mexitil</e1>   , has been reported to lower serum <e2>digoxin</e2> levels. ",False,negative
Mexitil,theophylline,18,24,33,44,Concurrent use of <e1>Mexitil</e1>    and <e2>theophylline</e2> may lead to increased plasma theophylline levels. ,True,mechanism
Mexitil,theophylline,18,24,75,86,Concurrent use of <e1>Mexitil</e1>    and theophylline may lead to increased plasma <e2>theophylline</e2> levels. ,False,negative
theophylline,theophylline,33,44,75,86,Concurrent use of Mexitil    and <e1>theophylline</e1> may lead to increased plasma <e2>theophylline</e2> levels. ,False,negative
Mexitil,Theophylline,91,97,103,114,"This increase was observed at the first test point which was the second day after starting <e1>Mexitil</e1>   . <e2>Theophylline</e2> plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",False,negative
Mexitil,Mexitil,91,97,146,152,"This increase was observed at the first test point which was the second day after starting <e1>Mexitil</e1>   . Theophylline plasma levels returned to pre-<e2>Mexitil</e2>    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",False,negative
Mexitil,Mexitil,91,97,200,206,"This increase was observed at the first test point which was the second day after starting <e1>Mexitil</e1>   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing <e2>Mexitil</e2>   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",False,negative
Mexitil,Mexitil,91,97,215,221,"This increase was observed at the first test point which was the second day after starting <e1>Mexitil</e1>   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If <e2>Mexitil</e2> and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",False,negative
Mexitil,theophylline,91,97,227,238,"This increase was observed at the first test point which was the second day after starting <e1>Mexitil</e1>   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and <e2>theophylline</e2> are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",False,negative
Mexitil,theophylline,91,97,269,280,"This increase was observed at the first test point which was the second day after starting <e1>Mexitil</e1>   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, <e2>theophylline</e2> blood levels should be monitored, particularly when the Mexitil    dose is changed. ",False,negative
Mexitil,Mexitil,91,97,338,344,"This increase was observed at the first test point which was the second day after starting <e1>Mexitil</e1>   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the <e2>Mexitil</e2>    dose is changed. ",False,negative
Theophylline,Mexitil,103,114,146,152,"This increase was observed at the first test point which was the second day after starting Mexitil   . <e1>Theophylline</e1> plasma levels returned to pre-<e2>Mexitil</e2>    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",False,negative
Theophylline,Mexitil,103,114,200,206,"This increase was observed at the first test point which was the second day after starting Mexitil   . <e1>Theophylline</e1> plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing <e2>Mexitil</e2>   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",True,mechanism
Theophylline,Mexitil,103,114,215,221,"This increase was observed at the first test point which was the second day after starting Mexitil   . <e1>Theophylline</e1> plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If <e2>Mexitil</e2> and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",False,negative
Theophylline,theophylline,103,114,227,238,"This increase was observed at the first test point which was the second day after starting Mexitil   . <e1>Theophylline</e1> plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and <e2>theophylline</e2> are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",False,negative
Theophylline,theophylline,103,114,269,280,"This increase was observed at the first test point which was the second day after starting Mexitil   . <e1>Theophylline</e1> plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, <e2>theophylline</e2> blood levels should be monitored, particularly when the Mexitil    dose is changed. ",False,negative
Theophylline,Mexitil,103,114,338,344,"This increase was observed at the first test point which was the second day after starting Mexitil   . <e1>Theophylline</e1> plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the <e2>Mexitil</e2>    dose is changed. ",False,negative
Mexitil,Mexitil,146,152,200,206,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-<e1>Mexitil</e1>    values within 48 hours after discontinuing <e2>Mexitil</e2>   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",False,negative
Mexitil,Mexitil,146,152,215,221,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-<e1>Mexitil</e1>    values within 48 hours after discontinuing Mexitil   . If <e2>Mexitil</e2> and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",False,negative
Mexitil,theophylline,146,152,227,238,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-<e1>Mexitil</e1>    values within 48 hours after discontinuing Mexitil   . If Mexitil and <e2>theophylline</e2> are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",False,negative
Mexitil,theophylline,146,152,269,280,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-<e1>Mexitil</e1>    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, <e2>theophylline</e2> blood levels should be monitored, particularly when the Mexitil    dose is changed. ",False,negative
Mexitil,Mexitil,146,152,338,344,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-<e1>Mexitil</e1>    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the <e2>Mexitil</e2>    dose is changed. ",False,negative
Mexitil,Mexitil,200,206,215,221,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing <e1>Mexitil</e1>   . If <e2>Mexitil</e2> and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",False,negative
Mexitil,theophylline,200,206,227,238,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing <e1>Mexitil</e1>   . If Mexitil and <e2>theophylline</e2> are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",False,negative
Mexitil,theophylline,200,206,269,280,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing <e1>Mexitil</e1>   . If Mexitil and theophylline are to be used concurrently, <e2>theophylline</e2> blood levels should be monitored, particularly when the Mexitil    dose is changed. ",False,negative
Mexitil,Mexitil,200,206,338,344,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing <e1>Mexitil</e1>   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the <e2>Mexitil</e2>    dose is changed. ",False,negative
Mexitil,theophylline,215,221,227,238,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If <e1>Mexitil</e1> and <e2>theophylline</e2> are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",True,advise
Mexitil,theophylline,215,221,269,280,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If <e1>Mexitil</e1> and theophylline are to be used concurrently, <e2>theophylline</e2> blood levels should be monitored, particularly when the Mexitil    dose is changed. ",False,negative
Mexitil,Mexitil,215,221,338,344,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If <e1>Mexitil</e1> and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the <e2>Mexitil</e2>    dose is changed. ",False,negative
theophylline,theophylline,227,238,269,280,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and <e1>theophylline</e1> are to be used concurrently, <e2>theophylline</e2> blood levels should be monitored, particularly when the Mexitil    dose is changed. ",False,negative
theophylline,Mexitil,227,238,338,344,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and <e1>theophylline</e1> are to be used concurrently, theophylline blood levels should be monitored, particularly when the <e2>Mexitil</e2>    dose is changed. ",False,negative
theophylline,Mexitil,269,280,338,344,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, <e1>theophylline</e1> blood levels should be monitored, particularly when the <e2>Mexitil</e2>    dose is changed. ",False,negative
caffeine,Mexitil,99,106,158,164,"Additionally, in one controlled study in five normal subjects and seven patients, the clearance of <e1>caffeine</e1> was decreased 50% following the administration of <e2>Mexitil</e2>   .",True,mechanism
Posicor,terfenadine,0,6,78,88,"<e1>Posicor</e1> inhibits some of the liver's ability to metabolize some other drugs - <e2>terfenadine</e2>, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",True,mechanism
Posicor,astemizole,0,6,91,100,"<e1>Posicor</e1> inhibits some of the liver's ability to metabolize some other drugs - terfenadine, <e2>astemizole</e2>, cisapride, cyclosporine, and tricyclic antidepressants. ",True,mechanism
Posicor,cisapride,0,6,103,111,"<e1>Posicor</e1> inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, <e2>cisapride</e2>, cyclosporine, and tricyclic antidepressants. ",True,mechanism
Posicor,cyclosporine,0,6,114,125,"<e1>Posicor</e1> inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, <e2>cyclosporine</e2>, and tricyclic antidepressants. ",True,mechanism
Posicor,tricyclic antidepressants,0,6,132,156,"<e1>Posicor</e1> inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and <e2>tricyclic antidepressants</e2>. ",True,mechanism
terfenadine,astemizole,78,88,91,100,"Posicor inhibits some of the liver's ability to metabolize some other drugs - <e1>terfenadine</e1>, <e2>astemizole</e2>, cisapride, cyclosporine, and tricyclic antidepressants. ",False,negative
terfenadine,cisapride,78,88,103,111,"Posicor inhibits some of the liver's ability to metabolize some other drugs - <e1>terfenadine</e1>, astemizole, <e2>cisapride</e2>, cyclosporine, and tricyclic antidepressants. ",False,negative
terfenadine,cyclosporine,78,88,114,125,"Posicor inhibits some of the liver's ability to metabolize some other drugs - <e1>terfenadine</e1>, astemizole, cisapride, <e2>cyclosporine</e2>, and tricyclic antidepressants. ",False,negative
terfenadine,tricyclic antidepressants,78,88,132,156,"Posicor inhibits some of the liver's ability to metabolize some other drugs - <e1>terfenadine</e1>, astemizole, cisapride, cyclosporine, and <e2>tricyclic antidepressants</e2>. ",False,negative
astemizole,cisapride,91,100,103,111,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, <e1>astemizole</e1>, <e2>cisapride</e2>, cyclosporine, and tricyclic antidepressants. ",False,negative
astemizole,cyclosporine,91,100,114,125,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, <e1>astemizole</e1>, cisapride, <e2>cyclosporine</e2>, and tricyclic antidepressants. ",False,negative
astemizole,tricyclic antidepressants,91,100,132,156,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, <e1>astemizole</e1>, cisapride, cyclosporine, and <e2>tricyclic antidepressants</e2>. ",False,negative
cisapride,cyclosporine,103,111,114,125,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, <e1>cisapride</e1>, <e2>cyclosporine</e2>, and tricyclic antidepressants. ",False,negative
cisapride,tricyclic antidepressants,103,111,132,156,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, <e1>cisapride</e1>, cyclosporine, and <e2>tricyclic antidepressants</e2>. ",False,negative
cyclosporine,tricyclic antidepressants,114,125,132,156,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, <e1>cyclosporine</e1>, and <e2>tricyclic antidepressants</e2>. ",False,negative
MYCAMINE,mycophenolate mofetil,140,147,153,173,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between <e1>MYCAMINE</e1> and <e2>mycophenolate mofetil</e2>, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",False,negative
MYCAMINE,cyclosporine,140,147,176,187,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between <e1>MYCAMINE</e1> and mycophenolate mofetil, <e2>cyclosporine</e2>, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",False,negative
MYCAMINE,tacrolimus,140,147,190,199,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between <e1>MYCAMINE</e1> and mycophenolate mofetil, cyclosporine, <e2>tacrolimus</e2>, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",False,negative
MYCAMINE,prednisolone,140,147,202,213,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between <e1>MYCAMINE</e1> and mycophenolate mofetil, cyclosporine, tacrolimus, <e2>prednisolone</e2>, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",False,negative
MYCAMINE,sirolimus,140,147,216,224,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between <e1>MYCAMINE</e1> and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, <e2>sirolimus</e2>, nifedipine, fluconazole, ritonavir, and rifampin. ",False,negative
MYCAMINE,nifedipine,140,147,227,236,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between <e1>MYCAMINE</e1> and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, <e2>nifedipine</e2>, fluconazole, ritonavir, and rifampin. ",False,negative
MYCAMINE,fluconazole,140,147,239,249,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between <e1>MYCAMINE</e1> and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, <e2>fluconazole</e2>, ritonavir, and rifampin. ",False,negative
MYCAMINE,ritonavir,140,147,252,260,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between <e1>MYCAMINE</e1> and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, <e2>ritonavir</e2>, and rifampin. ",False,negative
MYCAMINE,rifampin,140,147,267,274,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between <e1>MYCAMINE</e1> and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and <e2>rifampin</e2>. ",False,negative
mycophenolate mofetil,cyclosporine,153,173,176,187,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and <e1>mycophenolate mofetil</e1>, <e2>cyclosporine</e2>, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",False,negative
mycophenolate mofetil,tacrolimus,153,173,190,199,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and <e1>mycophenolate mofetil</e1>, cyclosporine, <e2>tacrolimus</e2>, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",False,negative
mycophenolate mofetil,prednisolone,153,173,202,213,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and <e1>mycophenolate mofetil</e1>, cyclosporine, tacrolimus, <e2>prednisolone</e2>, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",False,negative
mycophenolate mofetil,sirolimus,153,173,216,224,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and <e1>mycophenolate mofetil</e1>, cyclosporine, tacrolimus, prednisolone, <e2>sirolimus</e2>, nifedipine, fluconazole, ritonavir, and rifampin. ",False,negative
mycophenolate mofetil,nifedipine,153,173,227,236,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and <e1>mycophenolate mofetil</e1>, cyclosporine, tacrolimus, prednisolone, sirolimus, <e2>nifedipine</e2>, fluconazole, ritonavir, and rifampin. ",False,negative
mycophenolate mofetil,fluconazole,153,173,239,249,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and <e1>mycophenolate mofetil</e1>, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, <e2>fluconazole</e2>, ritonavir, and rifampin. ",False,negative
mycophenolate mofetil,ritonavir,153,173,252,260,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and <e1>mycophenolate mofetil</e1>, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, <e2>ritonavir</e2>, and rifampin. ",False,negative
mycophenolate mofetil,rifampin,153,173,267,274,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and <e1>mycophenolate mofetil</e1>, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and <e2>rifampin</e2>. ",False,negative
cyclosporine,tacrolimus,176,187,190,199,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, <e1>cyclosporine</e1>, <e2>tacrolimus</e2>, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",False,negative
cyclosporine,prednisolone,176,187,202,213,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, <e1>cyclosporine</e1>, tacrolimus, <e2>prednisolone</e2>, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",False,negative
cyclosporine,sirolimus,176,187,216,224,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, <e1>cyclosporine</e1>, tacrolimus, prednisolone, <e2>sirolimus</e2>, nifedipine, fluconazole, ritonavir, and rifampin. ",False,negative
cyclosporine,nifedipine,176,187,227,236,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, <e1>cyclosporine</e1>, tacrolimus, prednisolone, sirolimus, <e2>nifedipine</e2>, fluconazole, ritonavir, and rifampin. ",False,negative
cyclosporine,fluconazole,176,187,239,249,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, <e1>cyclosporine</e1>, tacrolimus, prednisolone, sirolimus, nifedipine, <e2>fluconazole</e2>, ritonavir, and rifampin. ",False,negative
cyclosporine,ritonavir,176,187,252,260,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, <e1>cyclosporine</e1>, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, <e2>ritonavir</e2>, and rifampin. ",False,negative
cyclosporine,rifampin,176,187,267,274,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, <e1>cyclosporine</e1>, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and <e2>rifampin</e2>. ",False,negative
tacrolimus,prednisolone,190,199,202,213,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, <e1>tacrolimus</e1>, <e2>prednisolone</e2>, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",False,negative
tacrolimus,sirolimus,190,199,216,224,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, <e1>tacrolimus</e1>, prednisolone, <e2>sirolimus</e2>, nifedipine, fluconazole, ritonavir, and rifampin. ",False,negative
tacrolimus,nifedipine,190,199,227,236,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, <e1>tacrolimus</e1>, prednisolone, sirolimus, <e2>nifedipine</e2>, fluconazole, ritonavir, and rifampin. ",False,negative
tacrolimus,fluconazole,190,199,239,249,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, <e1>tacrolimus</e1>, prednisolone, sirolimus, nifedipine, <e2>fluconazole</e2>, ritonavir, and rifampin. ",False,negative
tacrolimus,ritonavir,190,199,252,260,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, <e1>tacrolimus</e1>, prednisolone, sirolimus, nifedipine, fluconazole, <e2>ritonavir</e2>, and rifampin. ",False,negative
tacrolimus,rifampin,190,199,267,274,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, <e1>tacrolimus</e1>, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and <e2>rifampin</e2>. ",False,negative
prednisolone,sirolimus,202,213,216,224,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, <e1>prednisolone</e1>, <e2>sirolimus</e2>, nifedipine, fluconazole, ritonavir, and rifampin. ",False,negative
prednisolone,nifedipine,202,213,227,236,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, <e1>prednisolone</e1>, sirolimus, <e2>nifedipine</e2>, fluconazole, ritonavir, and rifampin. ",False,negative
prednisolone,fluconazole,202,213,239,249,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, <e1>prednisolone</e1>, sirolimus, nifedipine, <e2>fluconazole</e2>, ritonavir, and rifampin. ",False,negative
prednisolone,ritonavir,202,213,252,260,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, <e1>prednisolone</e1>, sirolimus, nifedipine, fluconazole, <e2>ritonavir</e2>, and rifampin. ",False,negative
prednisolone,rifampin,202,213,267,274,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, <e1>prednisolone</e1>, sirolimus, nifedipine, fluconazole, ritonavir, and <e2>rifampin</e2>. ",False,negative
sirolimus,nifedipine,216,224,227,236,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, <e1>sirolimus</e1>, <e2>nifedipine</e2>, fluconazole, ritonavir, and rifampin. ",False,negative
sirolimus,fluconazole,216,224,239,249,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, <e1>sirolimus</e1>, nifedipine, <e2>fluconazole</e2>, ritonavir, and rifampin. ",False,negative
sirolimus,ritonavir,216,224,252,260,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, <e1>sirolimus</e1>, nifedipine, fluconazole, <e2>ritonavir</e2>, and rifampin. ",False,negative
sirolimus,rifampin,216,224,267,274,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, <e1>sirolimus</e1>, nifedipine, fluconazole, ritonavir, and <e2>rifampin</e2>. ",False,negative
nifedipine,fluconazole,227,236,239,249,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, <e1>nifedipine</e1>, <e2>fluconazole</e2>, ritonavir, and rifampin. ",False,negative
nifedipine,ritonavir,227,236,252,260,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, <e1>nifedipine</e1>, fluconazole, <e2>ritonavir</e2>, and rifampin. ",False,negative
nifedipine,rifampin,227,236,267,274,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, <e1>nifedipine</e1>, fluconazole, ritonavir, and <e2>rifampin</e2>. ",False,negative
fluconazole,ritonavir,239,249,252,260,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, <e1>fluconazole</e1>, <e2>ritonavir</e2>, and rifampin. ",False,negative
fluconazole,rifampin,239,249,267,274,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, <e1>fluconazole</e1>, ritonavir, and <e2>rifampin</e2>. ",False,negative
ritonavir,rifampin,252,260,267,274,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, <e1>ritonavir</e1>, and <e2>rifampin</e2>. ",False,negative
MYCAMINE,mycophenolate mofetil,58,65,70,90,"There was no effect of a single dose or multiple doses of <e1>MYCAMINE</e1> on <e2>mycophenolate mofetil</e2>, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. ",False,negative
MYCAMINE,cyclosporine,58,65,93,104,"There was no effect of a single dose or multiple doses of <e1>MYCAMINE</e1> on mycophenolate mofetil, <e2>cyclosporine</e2>, tacrolimus, prednisolone, and fluconazole pharmacokinetics. ",False,negative
MYCAMINE,tacrolimus,58,65,107,116,"There was no effect of a single dose or multiple doses of <e1>MYCAMINE</e1> on mycophenolate mofetil, cyclosporine, <e2>tacrolimus</e2>, prednisolone, and fluconazole pharmacokinetics. ",False,negative
MYCAMINE,prednisolone,58,65,119,130,"There was no effect of a single dose or multiple doses of <e1>MYCAMINE</e1> on mycophenolate mofetil, cyclosporine, tacrolimus, <e2>prednisolone</e2>, and fluconazole pharmacokinetics. ",False,negative
MYCAMINE,fluconazole,58,65,137,147,"There was no effect of a single dose or multiple doses of <e1>MYCAMINE</e1> on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and <e2>fluconazole</e2> pharmacokinetics. ",False,negative
mycophenolate mofetil,cyclosporine,70,90,93,104,"There was no effect of a single dose or multiple doses of MYCAMINE on <e1>mycophenolate mofetil</e1>, <e2>cyclosporine</e2>, tacrolimus, prednisolone, and fluconazole pharmacokinetics. ",False,negative
mycophenolate mofetil,tacrolimus,70,90,107,116,"There was no effect of a single dose or multiple doses of MYCAMINE on <e1>mycophenolate mofetil</e1>, cyclosporine, <e2>tacrolimus</e2>, prednisolone, and fluconazole pharmacokinetics. ",False,negative
mycophenolate mofetil,prednisolone,70,90,119,130,"There was no effect of a single dose or multiple doses of MYCAMINE on <e1>mycophenolate mofetil</e1>, cyclosporine, tacrolimus, <e2>prednisolone</e2>, and fluconazole pharmacokinetics. ",False,negative
mycophenolate mofetil,fluconazole,70,90,137,147,"There was no effect of a single dose or multiple doses of MYCAMINE on <e1>mycophenolate mofetil</e1>, cyclosporine, tacrolimus, prednisolone, and <e2>fluconazole</e2> pharmacokinetics. ",False,negative
cyclosporine,tacrolimus,93,104,107,116,"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, <e1>cyclosporine</e1>, <e2>tacrolimus</e2>, prednisolone, and fluconazole pharmacokinetics. ",False,negative
cyclosporine,prednisolone,93,104,119,130,"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, <e1>cyclosporine</e1>, tacrolimus, <e2>prednisolone</e2>, and fluconazole pharmacokinetics. ",False,negative
cyclosporine,fluconazole,93,104,137,147,"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, <e1>cyclosporine</e1>, tacrolimus, prednisolone, and <e2>fluconazole</e2> pharmacokinetics. ",False,negative
tacrolimus,prednisolone,107,116,119,130,"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, <e1>tacrolimus</e1>, <e2>prednisolone</e2>, and fluconazole pharmacokinetics. ",False,negative
tacrolimus,fluconazole,107,116,137,147,"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, <e1>tacrolimus</e1>, prednisolone, and <e2>fluconazole</e2> pharmacokinetics. ",False,negative
prednisolone,fluconazole,119,130,137,147,"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, <e1>prednisolone</e1>, and <e2>fluconazole</e2> pharmacokinetics. ",False,negative
Sirolimus,MYCAMINE,0,8,90,97,<e1>Sirolimus</e1> AUC was increased by 21% with no effect on Cmax in the presence of steady-state <e2>MYCAMINE</e2> compared with sirolimus alone. ,True,mechanism
Sirolimus,sirolimus,0,8,113,121,<e1>Sirolimus</e1> AUC was increased by 21% with no effect on Cmax in the presence of steady-state MYCAMINE compared with <e2>sirolimus</e2> alone. ,False,negative
MYCAMINE,sirolimus,90,97,113,121,Sirolimus AUC was increased by 21% with no effect on Cmax in the presence of steady-state <e1>MYCAMINE</e1> compared with <e2>sirolimus</e2> alone. ,False,negative
Nifedipine,MYCAMINE,0,9,101,108,"<e1>Nifedipine</e1> AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state <e2>MYCAMINE</e2> compared with nifedipine alone. ",True,mechanism
Nifedipine,nifedipine,0,9,124,133,"<e1>Nifedipine</e1> AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state MYCAMINE compared with <e2>nifedipine</e2> alone. ",False,negative
MYCAMINE,nifedipine,101,108,124,133,"Nifedipine AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state <e1>MYCAMINE</e1> compared with <e2>nifedipine</e2> alone. ",False,negative
sirolimus,nifedipine,19,27,32,41,Patients receiving <e1>sirolimus</e1> or <e2>nifedipine</e2> in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,False,negative
sirolimus,MYCAMINE,19,27,63,70,Patients receiving <e1>sirolimus</e1> or nifedipine in combination with <e2>MYCAMINE</e2> should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,True,advise
sirolimus,sirolimus,19,27,96,104,Patients receiving <e1>sirolimus</e1> or nifedipine in combination with MYCAMINE should be monitored for <e2>sirolimus</e2> or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,False,negative
sirolimus,nifedipine,19,27,109,118,Patients receiving <e1>sirolimus</e1> or nifedipine in combination with MYCAMINE should be monitored for sirolimus or <e2>nifedipine</e2> toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,False,negative
sirolimus,sirolimus,19,27,133,141,Patients receiving <e1>sirolimus</e1> or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and <e2>sirolimus</e2> or nifedipine dosage should be reduced if necessary. ,False,negative
sirolimus,nifedipine,19,27,146,155,Patients receiving <e1>sirolimus</e1> or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or <e2>nifedipine</e2> dosage should be reduced if necessary. ,False,negative
nifedipine,MYCAMINE,32,41,63,70,Patients receiving sirolimus or <e1>nifedipine</e1> in combination with <e2>MYCAMINE</e2> should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,True,advise
nifedipine,sirolimus,32,41,96,104,Patients receiving sirolimus or <e1>nifedipine</e1> in combination with MYCAMINE should be monitored for <e2>sirolimus</e2> or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,False,negative
nifedipine,nifedipine,32,41,109,118,Patients receiving sirolimus or <e1>nifedipine</e1> in combination with MYCAMINE should be monitored for sirolimus or <e2>nifedipine</e2> toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,False,negative
nifedipine,sirolimus,32,41,133,141,Patients receiving sirolimus or <e1>nifedipine</e1> in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and <e2>sirolimus</e2> or nifedipine dosage should be reduced if necessary. ,False,negative
nifedipine,nifedipine,32,41,146,155,Patients receiving sirolimus or <e1>nifedipine</e1> in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or <e2>nifedipine</e2> dosage should be reduced if necessary. ,False,negative
MYCAMINE,sirolimus,63,70,96,104,Patients receiving sirolimus or nifedipine in combination with <e1>MYCAMINE</e1> should be monitored for <e2>sirolimus</e2> or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,False,negative
MYCAMINE,nifedipine,63,70,109,118,Patients receiving sirolimus or nifedipine in combination with <e1>MYCAMINE</e1> should be monitored for sirolimus or <e2>nifedipine</e2> toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,False,negative
MYCAMINE,sirolimus,63,70,133,141,Patients receiving sirolimus or nifedipine in combination with <e1>MYCAMINE</e1> should be monitored for sirolimus or nifedipine toxicity and <e2>sirolimus</e2> or nifedipine dosage should be reduced if necessary. ,False,negative
MYCAMINE,nifedipine,63,70,146,155,Patients receiving sirolimus or nifedipine in combination with <e1>MYCAMINE</e1> should be monitored for sirolimus or nifedipine toxicity and sirolimus or <e2>nifedipine</e2> dosage should be reduced if necessary. ,False,negative
sirolimus,nifedipine,96,104,109,118,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for <e1>sirolimus</e1> or <e2>nifedipine</e2> toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,False,negative
sirolimus,sirolimus,96,104,133,141,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for <e1>sirolimus</e1> or nifedipine toxicity and <e2>sirolimus</e2> or nifedipine dosage should be reduced if necessary. ,False,negative
sirolimus,nifedipine,96,104,146,155,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for <e1>sirolimus</e1> or nifedipine toxicity and sirolimus or <e2>nifedipine</e2> dosage should be reduced if necessary. ,False,negative
nifedipine,sirolimus,109,118,133,141,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or <e1>nifedipine</e1> toxicity and <e2>sirolimus</e2> or nifedipine dosage should be reduced if necessary. ,False,negative
nifedipine,nifedipine,109,118,146,155,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or <e1>nifedipine</e1> toxicity and sirolimus or <e2>nifedipine</e2> dosage should be reduced if necessary. ,False,negative
sirolimus,nifedipine,133,141,146,155,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and <e1>sirolimus</e1> or <e2>nifedipine</e2> dosage should be reduced if necessary. ,False,negative
midazolam,azole antimycotics,74,82,228,245,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when <e1>midazolam</e1> is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of <e2>azole antimycotics</e2>, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ",True,advise
midazolam,protease inhibitors,74,82,248,266,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when <e1>midazolam</e1> is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, <e2>protease inhibitors</e2>, calcium channel antagonists, and macrolide antibiotics). ",True,advise
midazolam,calcium channel antagonists,74,82,269,295,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when <e1>midazolam</e1> is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, <e2>calcium channel antagonists</e2>, and macrolide antibiotics). ",True,advise
midazolam,macrolide antibiotics,74,82,302,322,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when <e1>midazolam</e1> is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and <e2>macrolide antibiotics</e2>). ",True,advise
azole antimycotics,protease inhibitors,228,245,248,266,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of <e1>azole antimycotics</e1>, <e2>protease inhibitors</e2>, calcium channel antagonists, and macrolide antibiotics). ",False,negative
azole antimycotics,calcium channel antagonists,228,245,269,295,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of <e1>azole antimycotics</e1>, protease inhibitors, <e2>calcium channel antagonists</e2>, and macrolide antibiotics). ",False,negative
azole antimycotics,macrolide antibiotics,228,245,302,322,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of <e1>azole antimycotics</e1>, protease inhibitors, calcium channel antagonists, and <e2>macrolide antibiotics</e2>). ",False,negative
protease inhibitors,calcium channel antagonists,248,266,269,295,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, <e1>protease inhibitors</e1>, <e2>calcium channel antagonists</e2>, and macrolide antibiotics). ",False,negative
protease inhibitors,macrolide antibiotics,248,266,302,322,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, <e1>protease inhibitors</e1>, calcium channel antagonists, and <e2>macrolide antibiotics</e2>). ",False,negative
calcium channel antagonists,macrolide antibiotics,269,295,302,322,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, <e1>calcium channel antagonists</e1>, and <e2>macrolide antibiotics</e2>). ",False,negative
erythromycin,diltiazem,14,25,28,36,"Drugs such as <e1>erythromycin</e1>, <e2>diltiazem</e2>, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",False,negative
erythromycin,verapamil,14,25,39,47,"Drugs such as <e1>erythromycin</e1>, diltiazem, <e2>verapamil</e2>, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",False,negative
erythromycin,ketoconazole,14,25,50,61,"Drugs such as <e1>erythromycin</e1>, diltiazem, verapamil, <e2>ketoconazole</e2>, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",False,negative
erythromycin,fluconazole,14,25,64,74,"Drugs such as <e1>erythromycin</e1>, diltiazem, verapamil, ketoconazole, <e2>fluconazole</e2> and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",False,negative
erythromycin,itraconazole,14,25,80,91,"Drugs such as <e1>erythromycin</e1>, diltiazem, verapamil, ketoconazole, fluconazole and <e2>itraconazole</e2> were shown to significantly increase the C max and AUC of orally administered midazolam. ",False,negative
erythromycin,midazolam,14,25,171,179,"Drugs such as <e1>erythromycin</e1>, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered <e2>midazolam</e2>. ",True,mechanism
diltiazem,verapamil,28,36,39,47,"Drugs such as erythromycin, <e1>diltiazem</e1>, <e2>verapamil</e2>, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",False,negative
diltiazem,ketoconazole,28,36,50,61,"Drugs such as erythromycin, <e1>diltiazem</e1>, verapamil, <e2>ketoconazole</e2>, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",False,negative
diltiazem,fluconazole,28,36,64,74,"Drugs such as erythromycin, <e1>diltiazem</e1>, verapamil, ketoconazole, <e2>fluconazole</e2> and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",False,negative
diltiazem,itraconazole,28,36,80,91,"Drugs such as erythromycin, <e1>diltiazem</e1>, verapamil, ketoconazole, fluconazole and <e2>itraconazole</e2> were shown to significantly increase the C max and AUC of orally administered midazolam. ",False,negative
diltiazem,midazolam,28,36,171,179,"Drugs such as erythromycin, <e1>diltiazem</e1>, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered <e2>midazolam</e2>. ",True,mechanism
verapamil,ketoconazole,39,47,50,61,"Drugs such as erythromycin, diltiazem, <e1>verapamil</e1>, <e2>ketoconazole</e2>, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",False,negative
verapamil,fluconazole,39,47,64,74,"Drugs such as erythromycin, diltiazem, <e1>verapamil</e1>, ketoconazole, <e2>fluconazole</e2> and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",False,negative
verapamil,itraconazole,39,47,80,91,"Drugs such as erythromycin, diltiazem, <e1>verapamil</e1>, ketoconazole, fluconazole and <e2>itraconazole</e2> were shown to significantly increase the C max and AUC of orally administered midazolam. ",False,negative
verapamil,midazolam,39,47,171,179,"Drugs such as erythromycin, diltiazem, <e1>verapamil</e1>, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered <e2>midazolam</e2>. ",True,mechanism
ketoconazole,fluconazole,50,61,64,74,"Drugs such as erythromycin, diltiazem, verapamil, <e1>ketoconazole</e1>, <e2>fluconazole</e2> and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",False,negative
ketoconazole,itraconazole,50,61,80,91,"Drugs such as erythromycin, diltiazem, verapamil, <e1>ketoconazole</e1>, fluconazole and <e2>itraconazole</e2> were shown to significantly increase the C max and AUC of orally administered midazolam. ",False,negative
ketoconazole,midazolam,50,61,171,179,"Drugs such as erythromycin, diltiazem, verapamil, <e1>ketoconazole</e1>, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered <e2>midazolam</e2>. ",True,mechanism
fluconazole,itraconazole,64,74,80,91,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, <e1>fluconazole</e1> and <e2>itraconazole</e2> were shown to significantly increase the C max and AUC of orally administered midazolam. ",False,negative
fluconazole,midazolam,64,74,171,179,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, <e1>fluconazole</e1> and itraconazole were shown to significantly increase the C max and AUC of orally administered <e2>midazolam</e2>. ",True,mechanism
itraconazole,midazolam,80,91,171,179,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and <e1>itraconazole</e1> were shown to significantly increase the C max and AUC of orally administered <e2>midazolam</e2>. ",True,mechanism
ritonavir,nelfinavir,64,72,78,87,"Although not studied, the potent cytochrome P450 3A4 inhibitors <e1>ritonavir</e1> and <e2>nelfinavir</e2> may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam. ",False,negative
ritonavir,midazolam,64,72,198,206,"Although not studied, the potent cytochrome P450 3A4 inhibitors <e1>ritonavir</e1> and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of <e2>midazolam</e2>. ",True,mechanism
nelfinavir,midazolam,78,87,198,206,"Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and <e1>nelfinavir</e1> may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of <e2>midazolam</e2>. ",True,mechanism
rifampin,carbamazepine,63,70,73,85,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as <e1>rifampin</e1>, <e2>carbamazepine</e2>, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. ",False,negative
rifampin,phenytoin,63,70,92,100,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as <e1>rifampin</e1>, carbamazepine, and <e2>phenytoin</e2>, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. ",False,negative
rifampin,midazolam,63,70,175,183,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as <e1>rifampin</e1>, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral <e2>midazolam</e2> in adult studies. ",True,mechanism
carbamazepine,phenytoin,73,85,92,100,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, <e1>carbamazepine</e1>, and <e2>phenytoin</e2>, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. ",False,negative
carbamazepine,midazolam,73,85,175,183,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, <e1>carbamazepine</e1>, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral <e2>midazolam</e2> in adult studies. ",True,mechanism
phenytoin,midazolam,92,100,175,183,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and <e1>phenytoin</e1>, induce metabolism and caused a markedly decreased C max and AUC of oral <e2>midazolam</e2> in adult studies. ",True,mechanism
sedatives,methylphenidate,102,110,178,192,The difficulty in achieving adequate sedation may have been the result of decreased absorption of the <e1>sedatives</e1> due to both the gastrointestinal effects and stimulant effects of <e2>methylphenidate</e2>. ,False,negative
VERSED Syrup,narcotics,23,34,153,161,"The sedative effect of <e1>VERSED Syrup</e1> is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly <e2>narcotics</e2> (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",True,effect
VERSED Syrup,morphine,23,34,168,175,"The sedative effect of <e1>VERSED Syrup</e1> is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, <e2>morphine</e2>, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",True,effect
VERSED Syrup,meperidine,23,34,178,187,"The sedative effect of <e1>VERSED Syrup</e1> is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, <e2>meperidine</e2> and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",True,effect
VERSED Syrup,fentanyl,23,34,193,200,"The sedative effect of <e1>VERSED Syrup</e1> is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and <e2>fentanyl</e2>), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",True,effect
VERSED Syrup,propofol,23,34,204,211,"The sedative effect of <e1>VERSED Syrup</e1> is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), <e2>propofol</e2>, ketamine, nitrous oxide, secobarbital and droperidol. ",True,effect
VERSED Syrup,ketamine,23,34,214,221,"The sedative effect of <e1>VERSED Syrup</e1> is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, <e2>ketamine</e2>, nitrous oxide, secobarbital and droperidol. ",True,effect
VERSED Syrup,nitrous oxide,23,34,224,236,"The sedative effect of <e1>VERSED Syrup</e1> is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, <e2>nitrous oxide</e2>, secobarbital and droperidol. ",True,effect
VERSED Syrup,secobarbital,23,34,239,250,"The sedative effect of <e1>VERSED Syrup</e1> is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, <e2>secobarbital</e2> and droperidol. ",True,effect
VERSED Syrup,droperidol,23,34,256,265,"The sedative effect of <e1>VERSED Syrup</e1> is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and <e2>droperidol</e2>. ",True,effect
narcotics,morphine,153,161,168,175,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly <e1>narcotics</e1> (eg, <e2>morphine</e2>, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",False,negative
narcotics,meperidine,153,161,178,187,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly <e1>narcotics</e1> (eg, morphine, <e2>meperidine</e2> and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",False,negative
narcotics,fentanyl,153,161,193,200,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly <e1>narcotics</e1> (eg, morphine, meperidine and <e2>fentanyl</e2>), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",False,negative
narcotics,propofol,153,161,204,211,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly <e1>narcotics</e1> (eg, morphine, meperidine and fentanyl), <e2>propofol</e2>, ketamine, nitrous oxide, secobarbital and droperidol. ",False,negative
narcotics,ketamine,153,161,214,221,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly <e1>narcotics</e1> (eg, morphine, meperidine and fentanyl), propofol, <e2>ketamine</e2>, nitrous oxide, secobarbital and droperidol. ",False,negative
narcotics,nitrous oxide,153,161,224,236,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly <e1>narcotics</e1> (eg, morphine, meperidine and fentanyl), propofol, ketamine, <e2>nitrous oxide</e2>, secobarbital and droperidol. ",False,negative
narcotics,secobarbital,153,161,239,250,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly <e1>narcotics</e1> (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, <e2>secobarbital</e2> and droperidol. ",False,negative
narcotics,droperidol,153,161,256,265,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly <e1>narcotics</e1> (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and <e2>droperidol</e2>. ",False,negative
morphine,meperidine,168,175,178,187,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, <e1>morphine</e1>, <e2>meperidine</e2> and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",False,negative
morphine,fentanyl,168,175,193,200,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, <e1>morphine</e1>, meperidine and <e2>fentanyl</e2>), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",False,negative
morphine,propofol,168,175,204,211,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, <e1>morphine</e1>, meperidine and fentanyl), <e2>propofol</e2>, ketamine, nitrous oxide, secobarbital and droperidol. ",False,negative
morphine,ketamine,168,175,214,221,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, <e1>morphine</e1>, meperidine and fentanyl), propofol, <e2>ketamine</e2>, nitrous oxide, secobarbital and droperidol. ",False,negative
morphine,nitrous oxide,168,175,224,236,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, <e1>morphine</e1>, meperidine and fentanyl), propofol, ketamine, <e2>nitrous oxide</e2>, secobarbital and droperidol. ",False,negative
morphine,secobarbital,168,175,239,250,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, <e1>morphine</e1>, meperidine and fentanyl), propofol, ketamine, nitrous oxide, <e2>secobarbital</e2> and droperidol. ",False,negative
morphine,droperidol,168,175,256,265,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, <e1>morphine</e1>, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and <e2>droperidol</e2>. ",False,negative
meperidine,fentanyl,178,187,193,200,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, <e1>meperidine</e1> and <e2>fentanyl</e2>), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",False,negative
meperidine,propofol,178,187,204,211,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, <e1>meperidine</e1> and fentanyl), <e2>propofol</e2>, ketamine, nitrous oxide, secobarbital and droperidol. ",False,negative
meperidine,ketamine,178,187,214,221,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, <e1>meperidine</e1> and fentanyl), propofol, <e2>ketamine</e2>, nitrous oxide, secobarbital and droperidol. ",False,negative
meperidine,nitrous oxide,178,187,224,236,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, <e1>meperidine</e1> and fentanyl), propofol, ketamine, <e2>nitrous oxide</e2>, secobarbital and droperidol. ",False,negative
meperidine,secobarbital,178,187,239,250,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, <e1>meperidine</e1> and fentanyl), propofol, ketamine, nitrous oxide, <e2>secobarbital</e2> and droperidol. ",False,negative
meperidine,droperidol,178,187,256,265,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, <e1>meperidine</e1> and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and <e2>droperidol</e2>. ",False,negative
fentanyl,propofol,193,200,204,211,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and <e1>fentanyl</e1>), <e2>propofol</e2>, ketamine, nitrous oxide, secobarbital and droperidol. ",False,negative
fentanyl,ketamine,193,200,214,221,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and <e1>fentanyl</e1>), propofol, <e2>ketamine</e2>, nitrous oxide, secobarbital and droperidol. ",False,negative
fentanyl,nitrous oxide,193,200,224,236,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and <e1>fentanyl</e1>), propofol, ketamine, <e2>nitrous oxide</e2>, secobarbital and droperidol. ",False,negative
fentanyl,secobarbital,193,200,239,250,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and <e1>fentanyl</e1>), propofol, ketamine, nitrous oxide, <e2>secobarbital</e2> and droperidol. ",False,negative
fentanyl,droperidol,193,200,256,265,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and <e1>fentanyl</e1>), propofol, ketamine, nitrous oxide, secobarbital and <e2>droperidol</e2>. ",False,negative
propofol,ketamine,204,211,214,221,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), <e1>propofol</e1>, <e2>ketamine</e2>, nitrous oxide, secobarbital and droperidol. ",False,negative
propofol,nitrous oxide,204,211,224,236,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), <e1>propofol</e1>, ketamine, <e2>nitrous oxide</e2>, secobarbital and droperidol. ",False,negative
propofol,secobarbital,204,211,239,250,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), <e1>propofol</e1>, ketamine, nitrous oxide, <e2>secobarbital</e2> and droperidol. ",False,negative
propofol,droperidol,204,211,256,265,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), <e1>propofol</e1>, ketamine, nitrous oxide, secobarbital and <e2>droperidol</e2>. ",False,negative
ketamine,nitrous oxide,214,221,224,236,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, <e1>ketamine</e1>, <e2>nitrous oxide</e2>, secobarbital and droperidol. ",False,negative
ketamine,secobarbital,214,221,239,250,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, <e1>ketamine</e1>, nitrous oxide, <e2>secobarbital</e2> and droperidol. ",False,negative
ketamine,droperidol,214,221,256,265,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, <e1>ketamine</e1>, nitrous oxide, secobarbital and <e2>droperidol</e2>. ",False,negative
nitrous oxide,secobarbital,224,236,239,250,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, <e1>nitrous oxide</e1>, <e2>secobarbital</e2> and droperidol. ",False,negative
nitrous oxide,droperidol,224,236,256,265,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, <e1>nitrous oxide</e1>, secobarbital and <e2>droperidol</e2>. ",False,negative
secobarbital,droperidol,239,250,256,265,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, <e1>secobarbital</e1> and <e2>droperidol</e2>. ",False,negative
atropine,scopolamine,72,79,82,92,"No significant adverse interactions with common premedications (such as <e1>atropine</e1>, <e2>scopolamine</e2>, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",False,negative
atropine,glycopyrrolate,72,79,95,108,"No significant adverse interactions with common premedications (such as <e1>atropine</e1>, scopolamine, <e2>glycopyrrolate</e2>, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",False,negative
atropine,diazepam,72,79,111,118,"No significant adverse interactions with common premedications (such as <e1>atropine</e1>, scopolamine, glycopyrrolate, <e2>diazepam</e2>, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",False,negative
atropine,hydroxyzine,72,79,121,131,"No significant adverse interactions with common premedications (such as <e1>atropine</e1>, scopolamine, glycopyrrolate, diazepam, <e2>hydroxyzine</e2>, and other muscle relaxants) or local anesthetics have been observed.",False,negative
atropine,muscle relaxants,72,79,144,159,"No significant adverse interactions with common premedications (such as <e1>atropine</e1>, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other <e2>muscle relaxants</e2>) or local anesthetics have been observed.",False,negative
atropine,anesthetics,72,79,171,181,"No significant adverse interactions with common premedications (such as <e1>atropine</e1>, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local <e2>anesthetics</e2> have been observed.",False,negative
scopolamine,glycopyrrolate,82,92,95,108,"No significant adverse interactions with common premedications (such as atropine, <e1>scopolamine</e1>, <e2>glycopyrrolate</e2>, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",False,negative
scopolamine,diazepam,82,92,111,118,"No significant adverse interactions with common premedications (such as atropine, <e1>scopolamine</e1>, glycopyrrolate, <e2>diazepam</e2>, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",False,negative
scopolamine,hydroxyzine,82,92,121,131,"No significant adverse interactions with common premedications (such as atropine, <e1>scopolamine</e1>, glycopyrrolate, diazepam, <e2>hydroxyzine</e2>, and other muscle relaxants) or local anesthetics have been observed.",False,negative
scopolamine,muscle relaxants,82,92,144,159,"No significant adverse interactions with common premedications (such as atropine, <e1>scopolamine</e1>, glycopyrrolate, diazepam, hydroxyzine, and other <e2>muscle relaxants</e2>) or local anesthetics have been observed.",False,negative
scopolamine,anesthetics,82,92,171,181,"No significant adverse interactions with common premedications (such as atropine, <e1>scopolamine</e1>, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local <e2>anesthetics</e2> have been observed.",False,negative
glycopyrrolate,diazepam,95,108,111,118,"No significant adverse interactions with common premedications (such as atropine, scopolamine, <e1>glycopyrrolate</e1>, <e2>diazepam</e2>, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",False,negative
glycopyrrolate,hydroxyzine,95,108,121,131,"No significant adverse interactions with common premedications (such as atropine, scopolamine, <e1>glycopyrrolate</e1>, diazepam, <e2>hydroxyzine</e2>, and other muscle relaxants) or local anesthetics have been observed.",False,negative
glycopyrrolate,muscle relaxants,95,108,144,159,"No significant adverse interactions with common premedications (such as atropine, scopolamine, <e1>glycopyrrolate</e1>, diazepam, hydroxyzine, and other <e2>muscle relaxants</e2>) or local anesthetics have been observed.",False,negative
glycopyrrolate,anesthetics,95,108,171,181,"No significant adverse interactions with common premedications (such as atropine, scopolamine, <e1>glycopyrrolate</e1>, diazepam, hydroxyzine, and other muscle relaxants) or local <e2>anesthetics</e2> have been observed.",False,negative
diazepam,hydroxyzine,111,118,121,131,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, <e1>diazepam</e1>, <e2>hydroxyzine</e2>, and other muscle relaxants) or local anesthetics have been observed.",False,negative
diazepam,muscle relaxants,111,118,144,159,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, <e1>diazepam</e1>, hydroxyzine, and other <e2>muscle relaxants</e2>) or local anesthetics have been observed.",False,negative
diazepam,anesthetics,111,118,171,181,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, <e1>diazepam</e1>, hydroxyzine, and other muscle relaxants) or local <e2>anesthetics</e2> have been observed.",False,negative
hydroxyzine,muscle relaxants,121,131,144,159,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, <e1>hydroxyzine</e1>, and other <e2>muscle relaxants</e2>) or local anesthetics have been observed.",False,negative
hydroxyzine,anesthetics,121,131,171,181,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, <e1>hydroxyzine</e1>, and other muscle relaxants) or local <e2>anesthetics</e2> have been observed.",False,negative
muscle relaxants,anesthetics,144,159,171,181,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other <e1>muscle relaxants</e1>) or local <e2>anesthetics</e2> have been observed.",False,negative
ProAmatine,cardiac glycosides,37,46,52,69,"When administered concomitantly with <e1>ProAmatine</e1>   , <e2>cardiac glycosides</e2> may enhance or precipitate bradycardia, A.V. ",True,effect
phenylephrine,pseudoephedrine,66,78,81,95,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., <e1>phenylephrine</e1>, <e2>pseudoephedrine</e2>, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",False,negative
phenylephrine,ephedrine,66,78,98,106,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., <e1>phenylephrine</e1>, pseudoephedrine, <e2>ephedrine</e2>, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",False,negative
phenylephrine,phenylpropanolamine,66,78,109,127,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., <e1>phenylephrine</e1>, pseudoephedrine, ephedrine, <e2>phenylpropanolamine</e2> or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",False,negative
phenylephrine,dihydroergotamine,66,78,132,148,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., <e1>phenylephrine</e1>, pseudoephedrine, ephedrine, phenylpropanolamine or <e2>dihydroergotamine</e2>) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",False,negative
phenylephrine,ProAmatine,66,78,200,209,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., <e1>phenylephrine</e1>, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of <e2>ProAmatine</e2>   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",True,effect
phenylephrine,ProAmatine,66,78,254,263,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., <e1>phenylephrine</e1>, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when <e2>ProAmatine</e2>    is administered concomitantly with agents that cause vasoconstriction. ",False,negative
pseudoephedrine,ephedrine,81,95,98,106,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, <e1>pseudoephedrine</e1>, <e2>ephedrine</e2>, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",False,negative
pseudoephedrine,phenylpropanolamine,81,95,109,127,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, <e1>pseudoephedrine</e1>, ephedrine, <e2>phenylpropanolamine</e2> or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",False,negative
pseudoephedrine,dihydroergotamine,81,95,132,148,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, <e1>pseudoephedrine</e1>, ephedrine, phenylpropanolamine or <e2>dihydroergotamine</e2>) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",False,negative
pseudoephedrine,ProAmatine,81,95,200,209,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, <e1>pseudoephedrine</e1>, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of <e2>ProAmatine</e2>   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",True,effect
pseudoephedrine,ProAmatine,81,95,254,263,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, <e1>pseudoephedrine</e1>, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when <e2>ProAmatine</e2>    is administered concomitantly with agents that cause vasoconstriction. ",False,negative
ephedrine,phenylpropanolamine,98,106,109,127,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, <e1>ephedrine</e1>, <e2>phenylpropanolamine</e2> or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",False,negative
ephedrine,dihydroergotamine,98,106,132,148,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, <e1>ephedrine</e1>, phenylpropanolamine or <e2>dihydroergotamine</e2>) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",False,negative
ephedrine,ProAmatine,98,106,200,209,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, <e1>ephedrine</e1>, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of <e2>ProAmatine</e2>   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",True,effect
ephedrine,ProAmatine,98,106,254,263,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, <e1>ephedrine</e1>, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when <e2>ProAmatine</e2>    is administered concomitantly with agents that cause vasoconstriction. ",False,negative
phenylpropanolamine,dihydroergotamine,109,127,132,148,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, <e1>phenylpropanolamine</e1> or <e2>dihydroergotamine</e2>) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",False,negative
phenylpropanolamine,ProAmatine,109,127,200,209,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, <e1>phenylpropanolamine</e1> or dihydroergotamine) may enhance or potentiate the pressor effects of <e2>ProAmatine</e2>   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",True,effect
phenylpropanolamine,ProAmatine,109,127,254,263,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, <e1>phenylpropanolamine</e1> or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when <e2>ProAmatine</e2>    is administered concomitantly with agents that cause vasoconstriction. ",False,negative
dihydroergotamine,ProAmatine,132,148,200,209,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or <e1>dihydroergotamine</e1>) may enhance or potentiate the pressor effects of <e2>ProAmatine</e2>   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",True,effect
dihydroergotamine,ProAmatine,132,148,254,263,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or <e1>dihydroergotamine</e1>) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when <e2>ProAmatine</e2>    is administered concomitantly with agents that cause vasoconstriction. ",False,negative
ProAmatine,ProAmatine,200,209,254,263,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of <e1>ProAmatine</e1>   . Therefore, caution should be used when <e2>ProAmatine</e2>    is administered concomitantly with agents that cause vasoconstriction. ",False,negative
ProAmatine,fludrocortisone acetate,0,9,105,127,"<e1>ProAmatine</e1>    has been used in patients concomitantly treated with salt-retaining steroid therapy (i.e., <e2>fludrocortisone acetate</e2>), with or without salt supplementation. ",False,negative
ProAmatine,Alpha-adrenergic blocking agents,0,9,12,43,"<e1>ProAmatine</e1>. <e2>Alpha-adrenergic blocking agents</e2>, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",False,negative
ProAmatine,prazosin,0,9,54,61,"<e1>ProAmatine</e1>. Alpha-adrenergic blocking agents, such as <e2>prazosin</e2>, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",False,negative
ProAmatine,terazosin,0,9,64,72,"<e1>ProAmatine</e1>. Alpha-adrenergic blocking agents, such as prazosin, <e2>terazosin</e2>, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",False,negative
ProAmatine,doxazosin,0,9,79,87,"<e1>ProAmatine</e1>. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and <e2>doxazosin</e2>, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",False,negative
ProAmatine,ProAmatine,0,9,120,129,"<e1>ProAmatine</e1>. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of <e2>ProAmatine</e2>. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",False,negative
ProAmatine,desglymidodrine,0,9,274,288,"<e1>ProAmatine</e1>. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e2>desglymidodrine</e2> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",False,negative
ProAmatine,metformin,0,9,415,423,"<e1>ProAmatine</e1>. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e2>metformin</e2>, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",False,negative
ProAmatine,cimetidine,0,9,426,435,"<e1>ProAmatine</e1>. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, <e2>cimetidine</e2>, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",False,negative
ProAmatine,ranitidine,0,9,438,447,"<e1>ProAmatine</e1>. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, <e2>ranitidine</e2>, procainamide, triamterene, flecainide, and quinidine. ",False,negative
ProAmatine,procainamide,0,9,450,461,"<e1>ProAmatine</e1>. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, <e2>procainamide</e2>, triamterene, flecainide, and quinidine. ",False,negative
ProAmatine,triamterene,0,9,464,474,"<e1>ProAmatine</e1>. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, <e2>triamterene</e2>, flecainide, and quinidine. ",False,negative
ProAmatine,flecainide,0,9,477,486,"<e1>ProAmatine</e1>. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, <e2>flecainide</e2>, and quinidine. ",False,negative
ProAmatine,quinidine,0,9,493,501,"<e1>ProAmatine</e1>. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and <e2>quinidine</e2>. ",False,negative
Alpha-adrenergic blocking agents,prazosin,12,43,54,61,"ProAmatine. <e1>Alpha-adrenergic blocking agents</e1>, such as <e2>prazosin</e2>, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",False,negative
Alpha-adrenergic blocking agents,terazosin,12,43,64,72,"ProAmatine. <e1>Alpha-adrenergic blocking agents</e1>, such as prazosin, <e2>terazosin</e2>, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",False,negative
Alpha-adrenergic blocking agents,doxazosin,12,43,79,87,"ProAmatine. <e1>Alpha-adrenergic blocking agents</e1>, such as prazosin, terazosin, and <e2>doxazosin</e2>, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",False,negative
Alpha-adrenergic blocking agents,ProAmatine,12,43,120,129,"ProAmatine. <e1>Alpha-adrenergic blocking agents</e1>, such as prazosin, terazosin, and doxazosin, can antagonize the effects of <e2>ProAmatine</e2>. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",True,effect
Alpha-adrenergic blocking agents,desglymidodrine,12,43,274,288,"ProAmatine. <e1>Alpha-adrenergic blocking agents</e1>, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e2>desglymidodrine</e2> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",False,negative
Alpha-adrenergic blocking agents,metformin,12,43,415,423,"ProAmatine. <e1>Alpha-adrenergic blocking agents</e1>, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e2>metformin</e2>, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",False,negative
Alpha-adrenergic blocking agents,cimetidine,12,43,426,435,"ProAmatine. <e1>Alpha-adrenergic blocking agents</e1>, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, <e2>cimetidine</e2>, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",False,negative
Alpha-adrenergic blocking agents,ranitidine,12,43,438,447,"ProAmatine. <e1>Alpha-adrenergic blocking agents</e1>, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, <e2>ranitidine</e2>, procainamide, triamterene, flecainide, and quinidine. ",False,negative
Alpha-adrenergic blocking agents,procainamide,12,43,450,461,"ProAmatine. <e1>Alpha-adrenergic blocking agents</e1>, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, <e2>procainamide</e2>, triamterene, flecainide, and quinidine. ",False,negative
Alpha-adrenergic blocking agents,triamterene,12,43,464,474,"ProAmatine. <e1>Alpha-adrenergic blocking agents</e1>, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, <e2>triamterene</e2>, flecainide, and quinidine. ",False,negative
Alpha-adrenergic blocking agents,flecainide,12,43,477,486,"ProAmatine. <e1>Alpha-adrenergic blocking agents</e1>, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, <e2>flecainide</e2>, and quinidine. ",False,negative
Alpha-adrenergic blocking agents,quinidine,12,43,493,501,"ProAmatine. <e1>Alpha-adrenergic blocking agents</e1>, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and <e2>quinidine</e2>. ",False,negative
prazosin,terazosin,54,61,64,72,"ProAmatine. Alpha-adrenergic blocking agents, such as <e1>prazosin</e1>, <e2>terazosin</e2>, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",False,negative
prazosin,doxazosin,54,61,79,87,"ProAmatine. Alpha-adrenergic blocking agents, such as <e1>prazosin</e1>, terazosin, and <e2>doxazosin</e2>, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",False,negative
prazosin,ProAmatine,54,61,120,129,"ProAmatine. Alpha-adrenergic blocking agents, such as <e1>prazosin</e1>, terazosin, and doxazosin, can antagonize the effects of <e2>ProAmatine</e2>. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",True,effect
prazosin,desglymidodrine,54,61,274,288,"ProAmatine. Alpha-adrenergic blocking agents, such as <e1>prazosin</e1>, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e2>desglymidodrine</e2> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",False,negative
prazosin,metformin,54,61,415,423,"ProAmatine. Alpha-adrenergic blocking agents, such as <e1>prazosin</e1>, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e2>metformin</e2>, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",False,negative
prazosin,cimetidine,54,61,426,435,"ProAmatine. Alpha-adrenergic blocking agents, such as <e1>prazosin</e1>, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, <e2>cimetidine</e2>, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",False,negative
prazosin,ranitidine,54,61,438,447,"ProAmatine. Alpha-adrenergic blocking agents, such as <e1>prazosin</e1>, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, <e2>ranitidine</e2>, procainamide, triamterene, flecainide, and quinidine. ",False,negative
prazosin,procainamide,54,61,450,461,"ProAmatine. Alpha-adrenergic blocking agents, such as <e1>prazosin</e1>, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, <e2>procainamide</e2>, triamterene, flecainide, and quinidine. ",False,negative
prazosin,triamterene,54,61,464,474,"ProAmatine. Alpha-adrenergic blocking agents, such as <e1>prazosin</e1>, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, <e2>triamterene</e2>, flecainide, and quinidine. ",False,negative
prazosin,flecainide,54,61,477,486,"ProAmatine. Alpha-adrenergic blocking agents, such as <e1>prazosin</e1>, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, <e2>flecainide</e2>, and quinidine. ",False,negative
prazosin,quinidine,54,61,493,501,"ProAmatine. Alpha-adrenergic blocking agents, such as <e1>prazosin</e1>, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and <e2>quinidine</e2>. ",False,negative
terazosin,doxazosin,64,72,79,87,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, <e1>terazosin</e1>, and <e2>doxazosin</e2>, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",False,negative
terazosin,ProAmatine,64,72,120,129,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, <e1>terazosin</e1>, and doxazosin, can antagonize the effects of <e2>ProAmatine</e2>. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",True,effect
terazosin,desglymidodrine,64,72,274,288,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, <e1>terazosin</e1>, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e2>desglymidodrine</e2> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",False,negative
terazosin,metformin,64,72,415,423,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, <e1>terazosin</e1>, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e2>metformin</e2>, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",False,negative
terazosin,cimetidine,64,72,426,435,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, <e1>terazosin</e1>, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, <e2>cimetidine</e2>, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",False,negative
terazosin,ranitidine,64,72,438,447,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, <e1>terazosin</e1>, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, <e2>ranitidine</e2>, procainamide, triamterene, flecainide, and quinidine. ",False,negative
terazosin,procainamide,64,72,450,461,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, <e1>terazosin</e1>, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, <e2>procainamide</e2>, triamterene, flecainide, and quinidine. ",False,negative
terazosin,triamterene,64,72,464,474,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, <e1>terazosin</e1>, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, <e2>triamterene</e2>, flecainide, and quinidine. ",False,negative
terazosin,flecainide,64,72,477,486,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, <e1>terazosin</e1>, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, <e2>flecainide</e2>, and quinidine. ",False,negative
terazosin,quinidine,64,72,493,501,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, <e1>terazosin</e1>, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and <e2>quinidine</e2>. ",False,negative
doxazosin,ProAmatine,79,87,120,129,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and <e1>doxazosin</e1>, can antagonize the effects of <e2>ProAmatine</e2>. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",True,effect
doxazosin,desglymidodrine,79,87,274,288,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and <e1>doxazosin</e1>, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e2>desglymidodrine</e2> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",False,negative
doxazosin,metformin,79,87,415,423,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and <e1>doxazosin</e1>, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e2>metformin</e2>, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",False,negative
doxazosin,cimetidine,79,87,426,435,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and <e1>doxazosin</e1>, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, <e2>cimetidine</e2>, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",False,negative
doxazosin,ranitidine,79,87,438,447,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and <e1>doxazosin</e1>, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, <e2>ranitidine</e2>, procainamide, triamterene, flecainide, and quinidine. ",False,negative
doxazosin,procainamide,79,87,450,461,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and <e1>doxazosin</e1>, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, <e2>procainamide</e2>, triamterene, flecainide, and quinidine. ",False,negative
doxazosin,triamterene,79,87,464,474,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and <e1>doxazosin</e1>, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, <e2>triamterene</e2>, flecainide, and quinidine. ",False,negative
doxazosin,flecainide,79,87,477,486,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and <e1>doxazosin</e1>, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, <e2>flecainide</e2>, and quinidine. ",False,negative
doxazosin,quinidine,79,87,493,501,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and <e1>doxazosin</e1>, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and <e2>quinidine</e2>. ",False,negative
ProAmatine,desglymidodrine,120,129,274,288,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of <e1>ProAmatine</e1>. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e2>desglymidodrine</e2> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",False,negative
ProAmatine,metformin,120,129,415,423,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of <e1>ProAmatine</e1>. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e2>metformin</e2>, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",False,negative
ProAmatine,cimetidine,120,129,426,435,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of <e1>ProAmatine</e1>. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, <e2>cimetidine</e2>, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",False,negative
ProAmatine,ranitidine,120,129,438,447,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of <e1>ProAmatine</e1>. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, <e2>ranitidine</e2>, procainamide, triamterene, flecainide, and quinidine. ",False,negative
ProAmatine,procainamide,120,129,450,461,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of <e1>ProAmatine</e1>. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, <e2>procainamide</e2>, triamterene, flecainide, and quinidine. ",False,negative
ProAmatine,triamterene,120,129,464,474,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of <e1>ProAmatine</e1>. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, <e2>triamterene</e2>, flecainide, and quinidine. ",False,negative
ProAmatine,flecainide,120,129,477,486,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of <e1>ProAmatine</e1>. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, <e2>flecainide</e2>, and quinidine. ",False,negative
ProAmatine,quinidine,120,129,493,501,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of <e1>ProAmatine</e1>. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and <e2>quinidine</e2>. ",False,negative
desglymidodrine,metformin,274,288,415,423,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e1>desglymidodrine</e1> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e2>metformin</e2>, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",True,mechanism
desglymidodrine,cimetidine,274,288,426,435,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e1>desglymidodrine</e1> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, <e2>cimetidine</e2>, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",True,mechanism
desglymidodrine,ranitidine,274,288,438,447,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e1>desglymidodrine</e1> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, <e2>ranitidine</e2>, procainamide, triamterene, flecainide, and quinidine. ",True,mechanism
desglymidodrine,procainamide,274,288,450,461,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e1>desglymidodrine</e1> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, <e2>procainamide</e2>, triamterene, flecainide, and quinidine. ",True,mechanism
desglymidodrine,triamterene,274,288,464,474,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e1>desglymidodrine</e1> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, <e2>triamterene</e2>, flecainide, and quinidine. ",True,mechanism
desglymidodrine,flecainide,274,288,477,486,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e1>desglymidodrine</e1> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, <e2>flecainide</e2>, and quinidine. ",True,mechanism
desglymidodrine,quinidine,274,288,493,501,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e1>desglymidodrine</e1> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and <e2>quinidine</e2>. ",True,mechanism
metformin,cimetidine,415,423,426,435,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e1>metformin</e1>, <e2>cimetidine</e2>, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",False,negative
metformin,ranitidine,415,423,438,447,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e1>metformin</e1>, cimetidine, <e2>ranitidine</e2>, procainamide, triamterene, flecainide, and quinidine. ",False,negative
metformin,procainamide,415,423,450,461,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e1>metformin</e1>, cimetidine, ranitidine, <e2>procainamide</e2>, triamterene, flecainide, and quinidine. ",False,negative
metformin,triamterene,415,423,464,474,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e1>metformin</e1>, cimetidine, ranitidine, procainamide, <e2>triamterene</e2>, flecainide, and quinidine. ",False,negative
metformin,flecainide,415,423,477,486,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e1>metformin</e1>, cimetidine, ranitidine, procainamide, triamterene, <e2>flecainide</e2>, and quinidine. ",False,negative
metformin,quinidine,415,423,493,501,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e1>metformin</e1>, cimetidine, ranitidine, procainamide, triamterene, flecainide, and <e2>quinidine</e2>. ",False,negative
cimetidine,ranitidine,426,435,438,447,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, <e1>cimetidine</e1>, <e2>ranitidine</e2>, procainamide, triamterene, flecainide, and quinidine. ",False,negative
cimetidine,procainamide,426,435,450,461,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, <e1>cimetidine</e1>, ranitidine, <e2>procainamide</e2>, triamterene, flecainide, and quinidine. ",False,negative
cimetidine,triamterene,426,435,464,474,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, <e1>cimetidine</e1>, ranitidine, procainamide, <e2>triamterene</e2>, flecainide, and quinidine. ",False,negative
cimetidine,flecainide,426,435,477,486,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, <e1>cimetidine</e1>, ranitidine, procainamide, triamterene, <e2>flecainide</e2>, and quinidine. ",False,negative
cimetidine,quinidine,426,435,493,501,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, <e1>cimetidine</e1>, ranitidine, procainamide, triamterene, flecainide, and <e2>quinidine</e2>. ",False,negative
ranitidine,procainamide,438,447,450,461,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, <e1>ranitidine</e1>, <e2>procainamide</e2>, triamterene, flecainide, and quinidine. ",False,negative
ranitidine,triamterene,438,447,464,474,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, <e1>ranitidine</e1>, procainamide, <e2>triamterene</e2>, flecainide, and quinidine. ",False,negative
ranitidine,flecainide,438,447,477,486,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, <e1>ranitidine</e1>, procainamide, triamterene, <e2>flecainide</e2>, and quinidine. ",False,negative
ranitidine,quinidine,438,447,493,501,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, <e1>ranitidine</e1>, procainamide, triamterene, flecainide, and <e2>quinidine</e2>. ",False,negative
procainamide,triamterene,450,461,464,474,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, <e1>procainamide</e1>, <e2>triamterene</e2>, flecainide, and quinidine. ",False,negative
procainamide,flecainide,450,461,477,486,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, <e1>procainamide</e1>, triamterene, <e2>flecainide</e2>, and quinidine. ",False,negative
procainamide,quinidine,450,461,493,501,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, <e1>procainamide</e1>, triamterene, flecainide, and <e2>quinidine</e2>. ",False,negative
triamterene,flecainide,464,474,477,486,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, <e1>triamterene</e1>, <e2>flecainide</e2>, and quinidine. ",False,negative
triamterene,quinidine,464,474,493,501,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, <e1>triamterene</e1>, flecainide, and <e2>quinidine</e2>. ",False,negative
flecainide,quinidine,477,486,493,501,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, <e1>flecainide</e1>, and <e2>quinidine</e2>. ",False,negative
mifepristone,ketoconazole,49,60,158,169,"Although specific drug or food interactions with <e1>mifepristone</e1> have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that <e2>ketoconazole</e2>, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",False,negative
mifepristone,itraconazole,49,60,172,183,"Although specific drug or food interactions with <e1>mifepristone</e1> have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, <e2>itraconazole</e2>, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",False,negative
mifepristone,erythromycin,49,60,186,197,"Although specific drug or food interactions with <e1>mifepristone</e1> have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, <e2>erythromycin</e2>, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",False,negative
mifepristone,mifepristone,49,60,276,287,"Although specific drug or food interactions with <e1>mifepristone</e1> have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of <e2>mifepristone</e2>). ",False,negative
ketoconazole,itraconazole,158,169,172,183,"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that <e1>ketoconazole</e1>, <e2>itraconazole</e2>, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",False,negative
ketoconazole,erythromycin,158,169,186,197,"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that <e1>ketoconazole</e1>, itraconazole, <e2>erythromycin</e2>, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",False,negative
ketoconazole,mifepristone,158,169,276,287,"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that <e1>ketoconazole</e1>, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of <e2>mifepristone</e2>). ",True,mechanism
itraconazole,erythromycin,172,183,186,197,"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, <e1>itraconazole</e1>, <e2>erythromycin</e2>, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",False,negative
itraconazole,mifepristone,172,183,276,287,"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, <e1>itraconazole</e1>, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of <e2>mifepristone</e2>). ",True,mechanism
erythromycin,mifepristone,186,197,276,287,"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, <e1>erythromycin</e1>, and grapefruit juice may inhibit its metabolism (increasing serum levels of <e2>mifepristone</e2>). ",True,mechanism
rifampin,dexamethasone,13,20,23,35,"Furthermore, <e1>rifampin</e1>, <e2>dexamethasone</e2>, St. ",False,negative
anticonvulsants,phenytoin,27,41,44,52,"John   s Wort, and certain <e1>anticonvulsants</e1> (<e2>phenytoin</e2>, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",False,negative
anticonvulsants,phenobarbital,27,41,55,67,"John   s Wort, and certain <e1>anticonvulsants</e1> (phenytoin, <e2>phenobarbital</e2>, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",False,negative
anticonvulsants,carbamazepine,27,41,70,82,"John   s Wort, and certain <e1>anticonvulsants</e1> (phenytoin, phenobarbital, <e2>carbamazepine</e2>) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",False,negative
anticonvulsants,mifepristone,27,41,96,107,"John   s Wort, and certain <e1>anticonvulsants</e1> (phenytoin, phenobarbital, carbamazepine) may induce <e2>mifepristone</e2> metabolism (lowering serum levels of mifepristone). ",True,mechanism
anticonvulsants,mifepristone,27,41,146,157,"John   s Wort, and certain <e1>anticonvulsants</e1> (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of <e2>mifepristone</e2>). ",False,negative
phenytoin,phenobarbital,44,52,55,67,"John   s Wort, and certain anticonvulsants (<e1>phenytoin</e1>, <e2>phenobarbital</e2>, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",False,negative
phenytoin,carbamazepine,44,52,70,82,"John   s Wort, and certain anticonvulsants (<e1>phenytoin</e1>, phenobarbital, <e2>carbamazepine</e2>) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",False,negative
phenytoin,mifepristone,44,52,96,107,"John   s Wort, and certain anticonvulsants (<e1>phenytoin</e1>, phenobarbital, carbamazepine) may induce <e2>mifepristone</e2> metabolism (lowering serum levels of mifepristone). ",True,mechanism
phenytoin,mifepristone,44,52,146,157,"John   s Wort, and certain anticonvulsants (<e1>phenytoin</e1>, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of <e2>mifepristone</e2>). ",False,negative
phenobarbital,carbamazepine,55,67,70,82,"John   s Wort, and certain anticonvulsants (phenytoin, <e1>phenobarbital</e1>, <e2>carbamazepine</e2>) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",False,negative
phenobarbital,mifepristone,55,67,96,107,"John   s Wort, and certain anticonvulsants (phenytoin, <e1>phenobarbital</e1>, carbamazepine) may induce <e2>mifepristone</e2> metabolism (lowering serum levels of mifepristone). ",True,mechanism
phenobarbital,mifepristone,55,67,146,157,"John   s Wort, and certain anticonvulsants (phenytoin, <e1>phenobarbital</e1>, carbamazepine) may induce mifepristone metabolism (lowering serum levels of <e2>mifepristone</e2>). ",False,negative
carbamazepine,mifepristone,70,82,96,107,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, <e1>carbamazepine</e1>) may induce <e2>mifepristone</e2> metabolism (lowering serum levels of mifepristone). ",True,mechanism
carbamazepine,mifepristone,70,82,146,157,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, <e1>carbamazepine</e1>) may induce mifepristone metabolism (lowering serum levels of <e2>mifepristone</e2>). ",False,negative
mifepristone,mifepristone,96,107,146,157,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce <e1>mifepristone</e1> metabolism (lowering serum levels of <e2>mifepristone</e2>). ",False,negative
ZAVESCA,Cerezyme,27,33,76,83,"While co-administration of <e1>ZAVESCA</e1>    appeared to increase the clearance of <e2>Cerezyme</e2> by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme. ",True,mechanism
ZAVESCA,Cerezyme,27,33,218,225,"While co-administration of <e1>ZAVESCA</e1>    appeared to increase the clearance of Cerezyme by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of <e2>Cerezyme</e2>. ",False,negative
Cerezyme,Cerezyme,76,83,218,225,"While co-administration of ZAVESCA    appeared to increase the clearance of <e1>Cerezyme</e1> by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of <e2>Cerezyme</e2>. ",False,negative
Cerezyme,imiglucerase,25,32,38,49,Combination therapy with <e1>Cerezyme</e1>    (<e2>imiglucerase</e2>) and ZAVESCA    is not indicated.,False,negative
Cerezyme,ZAVESCA,25,32,56,62,Combination therapy with <e1>Cerezyme</e1>    (imiglucerase) and <e2>ZAVESCA</e2>    is not indicated.,True,advise
imiglucerase,ZAVESCA,38,49,56,62,Combination therapy with Cerezyme    (<e1>imiglucerase</e1>) and <e2>ZAVESCA</e2>    is not indicated.,True,advise
tetracyclines,anticoagulant,8,20,98,110,"Because <e1>tetracyclines</e1> have been shown to depress plasma prothrombin activity, patients who are on <e2>anticoagulant</e2> therapy may require downward adjustment of their anticoagulant dosage. ",True,advise
tetracyclines,anticoagulant,8,20,161,173,"Because <e1>tetracyclines</e1> have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their <e2>anticoagulant</e2> dosage. ",False,negative
anticoagulant,anticoagulant,98,110,161,173,"Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on <e1>anticoagulant</e1> therapy may require downward adjustment of their <e2>anticoagulant</e2> dosage. ",False,negative
penicillin,tetracycline class drugs,73,82,117,140,"Since bacteriostatic drugs may interfere with the bactericidal action of <e1>penicillin</e1>, it is advisable to avoid giving <e2>tetracycline class drugs</e2> in conjunction with penicillin. ",False,negative
penicillin,penicillin,73,82,162,171,"Since bacteriostatic drugs may interfere with the bactericidal action of <e1>penicillin</e1>, it is advisable to avoid giving tetracycline class drugs in conjunction with <e2>penicillin</e2>. ",False,negative
tetracycline class drugs,penicillin,117,140,162,171,"Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving <e1>tetracycline class drugs</e1> in conjunction with <e2>penicillin</e2>. ",True,advise
tetracyclines,antacids,14,26,43,50,"Absorption of <e1>tetracyclines</e1> is impaired by <e2>antacids</e2> containing aluminum, calcium or magnesium, and iron-containing preparations. ",False,negative
tetracyclines,aluminum,14,26,63,70,"Absorption of <e1>tetracyclines</e1> is impaired by antacids containing <e2>aluminum</e2>, calcium or magnesium, and iron-containing preparations. ",True,mechanism
tetracyclines,calcium,14,26,73,79,"Absorption of <e1>tetracyclines</e1> is impaired by antacids containing aluminum, <e2>calcium</e2> or magnesium, and iron-containing preparations. ",True,mechanism
tetracyclines,magnesium,14,26,84,92,"Absorption of <e1>tetracyclines</e1> is impaired by antacids containing aluminum, calcium or <e2>magnesium</e2>, and iron-containing preparations. ",True,mechanism
tetracyclines,iron,14,26,99,102,"Absorption of <e1>tetracyclines</e1> is impaired by antacids containing aluminum, calcium or magnesium, and <e2>iron</e2>-containing preparations. ",True,mechanism
antacids,aluminum,43,50,63,70,"Absorption of tetracyclines is impaired by <e1>antacids</e1> containing <e2>aluminum</e2>, calcium or magnesium, and iron-containing preparations. ",False,negative
antacids,calcium,43,50,73,79,"Absorption of tetracyclines is impaired by <e1>antacids</e1> containing aluminum, <e2>calcium</e2> or magnesium, and iron-containing preparations. ",False,negative
antacids,magnesium,43,50,84,92,"Absorption of tetracyclines is impaired by <e1>antacids</e1> containing aluminum, calcium or <e2>magnesium</e2>, and iron-containing preparations. ",False,negative
antacids,iron,43,50,99,102,"Absorption of tetracyclines is impaired by <e1>antacids</e1> containing aluminum, calcium or magnesium, and <e2>iron</e2>-containing preparations. ",False,negative
aluminum,calcium,63,70,73,79,"Absorption of tetracyclines is impaired by antacids containing <e1>aluminum</e1>, <e2>calcium</e2> or magnesium, and iron-containing preparations. ",False,negative
aluminum,magnesium,63,70,84,92,"Absorption of tetracyclines is impaired by antacids containing <e1>aluminum</e1>, calcium or <e2>magnesium</e2>, and iron-containing preparations. ",False,negative
aluminum,iron,63,70,99,102,"Absorption of tetracyclines is impaired by antacids containing <e1>aluminum</e1>, calcium or magnesium, and <e2>iron</e2>-containing preparations. ",False,negative
calcium,magnesium,73,79,84,92,"Absorption of tetracyclines is impaired by antacids containing aluminum, <e1>calcium</e1> or <e2>magnesium</e2>, and iron-containing preparations. ",False,negative
calcium,iron,73,79,99,102,"Absorption of tetracyclines is impaired by antacids containing aluminum, <e1>calcium</e1> or magnesium, and <e2>iron</e2>-containing preparations. ",False,negative
magnesium,iron,84,92,99,102,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or <e1>magnesium</e1>, and <e2>iron</e2>-containing preparations. ",False,negative
tetracycline,methoxyflurane,22,33,39,52,The concurrent use of <e1>tetracycline</e1> and <e2>methoxyflurane</e2> has been reported to result in fatal renal toxicity. ,True,effect
tetracyclines,contraceptives,18,30,42,55,Concurrent use of <e1>tetracyclines</e1> with oral <e2>contraceptives</e2> may render oral contraceptives less effective.,True,effect
tetracyclines,contraceptives,18,30,73,86,Concurrent use of <e1>tetracyclines</e1> with oral contraceptives may render oral <e2>contraceptives</e2> less effective.,False,negative
contraceptives,contraceptives,42,55,73,86,Concurrent use of tetracyclines with oral <e1>contraceptives</e1> may render oral <e2>contraceptives</e2> less effective.,False,negative
Guanethidine,minoxidil,17,28,40,48,"Interaction with <e1>Guanethidine</e1>: Although <e2>minoxidil</e2> does not itself cause orthostatic hypotension, its administration to patients already receiving guanethidine can result in profound orthostatic effects. ",False,negative
Guanethidine,guanethidine,17,28,146,157,"Interaction with <e1>Guanethidine</e1>: Although minoxidil does not itself cause orthostatic hypotension, its administration to patients already receiving <e2>guanethidine</e2> can result in profound orthostatic effects. ",False,negative
minoxidil,guanethidine,40,48,146,157,"Interaction with Guanethidine: Although <e1>minoxidil</e1> does not itself cause orthostatic hypotension, its administration to patients already receiving <e2>guanethidine</e2> can result in profound orthostatic effects. ",True,effect
guanethidine,minoxidil,19,30,67,75,If at all possible <e1>guanethidine</e1> should be discontinued well before <e2>minoxidil</e2> is begun. ,True,advise
REMERON SolTab,mirtazapine,74,87,93,103,Drugs Affecting Hepatic Metabolism The metabolism and pharmacokinetics of <e1>REMERON SolTab</e1>    (<e2>mirtazapine</e2>) Orally Disintegrating Tablets may be affected by the induction or inhibition of drug-metab-olizing enzymes. ,False,negative
mirtazapine,mirtazapine,39,49,121,131,"While in vitro studies have shown that <e1>mirtazapine</e1> is not a potent inhibitor of any of these enzymes, an indication that <e2>mirtazapine</e2> is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of REMERON SolTab with most other drugs metabolized by these enzymes has not been formally studied. ",False,negative
mirtazapine,REMERON SolTab,39,49,309,322,"While in vitro studies have shown that <e1>mirtazapine</e1> is not a potent inhibitor of any of these enzymes, an indication that mirtazapine is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of <e2>REMERON SolTab</e2> with most other drugs metabolized by these enzymes has not been formally studied. ",False,negative
mirtazapine,REMERON SolTab,121,131,309,322,"While in vitro studies have shown that mirtazapine is not a potent inhibitor of any of these enzymes, an indication that <e1>mirtazapine</e1> is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of <e2>REMERON SolTab</e2> with most other drugs metabolized by these enzymes has not been formally studied. ",False,negative
Alcohol,alcohol,0,6,39,45,<e1>Alcohol</e1>: Concomitant administration of <e2>alcohol</e2> (equivalent to 60 g) had a minimal effect on plasma levels of mirtazapine (15 mg) in 6 healthy male subjects. ,False,negative
Alcohol,mirtazapine,0,6,109,119,<e1>Alcohol</e1>: Concomitant administration of alcohol (equivalent to 60 g) had a minimal effect on plasma levels of <e2>mirtazapine</e2> (15 mg) in 6 healthy male subjects. ,False,negative
alcohol,mirtazapine,39,45,109,119,Alcohol: Concomitant administration of <e1>alcohol</e1> (equivalent to 60 g) had a minimal effect on plasma levels of <e2>mirtazapine</e2> (15 mg) in 6 healthy male subjects. ,True,mechanism
REMERON,alcohol,66,72,126,132,"However, the impairment of cognitive and motor skills produced by <e1>REMERON</e1>    were shown to be additive with those produced by <e2>alcohol</e2>. ",True,effect
alcohol,REMERON SolTab,49,55,70,83,"Accordingly, patients should be advised to avoid <e1>alcohol</e1> while taking <e2>REMERON SolTab</e2>. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",True,advise
alcohol,Diazepam,49,55,86,93,"Accordingly, patients should be advised to avoid <e1>alcohol</e1> while taking REMERON SolTab. <e2>Diazepam</e2>: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",False,negative
alcohol,diazepam,49,55,126,133,"Accordingly, patients should be advised to avoid <e1>alcohol</e1> while taking REMERON SolTab. Diazepam: Concomitant administration of <e2>diazepam</e2> (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",False,negative
alcohol,mirtazapine,49,55,184,194,"Accordingly, patients should be advised to avoid <e1>alcohol</e1> while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of <e2>mirtazapine</e2> (15 mg) in 12 healthy subjects. ",False,negative
REMERON SolTab,Diazepam,70,83,86,93,"Accordingly, patients should be advised to avoid alcohol while taking <e1>REMERON SolTab</e1>. <e2>Diazepam</e2>: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",False,negative
REMERON SolTab,diazepam,70,83,126,133,"Accordingly, patients should be advised to avoid alcohol while taking <e1>REMERON SolTab</e1>. Diazepam: Concomitant administration of <e2>diazepam</e2> (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",False,negative
REMERON SolTab,mirtazapine,70,83,184,194,"Accordingly, patients should be advised to avoid alcohol while taking <e1>REMERON SolTab</e1>. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of <e2>mirtazapine</e2> (15 mg) in 12 healthy subjects. ",False,negative
Diazepam,diazepam,86,93,126,133,"Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. <e1>Diazepam</e1>: Concomitant administration of <e2>diazepam</e2> (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",False,negative
Diazepam,mirtazapine,86,93,184,194,"Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. <e1>Diazepam</e1>: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of <e2>mirtazapine</e2> (15 mg) in 12 healthy subjects. ",False,negative
diazepam,mirtazapine,126,133,184,194,"Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of <e1>diazepam</e1> (15 mg) had a minimal effect on plasma levels of <e2>mirtazapine</e2> (15 mg) in 12 healthy subjects. ",True,mechanism
REMERON,diazepam,52,58,111,118,"However, the impairment of motor skills produced by <e1>REMERON</e1> has been shown to be additive with those caused by <e2>diazepam</e2>. ",True,effect
diazepam,REMERON SolTab,49,56,95,108,"Accordingly, patients should be advised to avoid <e1>diazepam</e1> and other similar drugs while taking <e2>REMERON SolTab</e2>.",True,advise
Mitotane,warfarin,0,7,59,66,"<e1>Mitotane</e1> has been reported to accelerate the metabolism of <e2>warfarin</e2> by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for warfarin. ",True,mechanism
Mitotane,warfarin,0,7,175,182,"<e1>Mitotane</e1> has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for <e2>warfarin</e2>. ",False,negative
warfarin,warfarin,59,66,175,182,"Mitotane has been reported to accelerate the metabolism of <e1>warfarin</e1> by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for <e2>warfarin</e2>. ",False,negative
anticoagulant,Mitotane,70,82,123,130,"Therefore, physicians should closely monitor patients for a change in <e1>anticoagulant</e1> dosage requirements when administering <e2>Mitotane</e2> to patients on coumarin-type anticoagulants. ",False,negative
anticoagulant,coumarin-type anticoagulants,70,82,147,174,"Therefore, physicians should closely monitor patients for a change in <e1>anticoagulant</e1> dosage requirements when administering Mitotane to patients on <e2>coumarin-type anticoagulants</e2>. ",False,negative
Mitotane,coumarin-type anticoagulants,123,130,147,174,"Therefore, physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering <e1>Mitotane</e1> to patients on <e2>coumarin-type anticoagulants</e2>. ",True,advise
MIVACRON,MIVACRON,9,16,165,172,"Although <e1>MIVACRON</e1> (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between <e2>MIVACRON</e2> and succinylcholine has not been systematically studied. ",False,negative
MIVACRON,succinylcholine,9,16,178,192,"Although <e1>MIVACRON</e1> (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between MIVACRON and <e2>succinylcholine</e2> has not been systematically studied. ",False,negative
MIVACRON,succinylcholine,165,172,178,192,"Although MIVACRON (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between <e1>MIVACRON</e1> and <e2>succinylcholine</e2> has not been systematically studied. ",False,negative
succinylcholine,nondepolarizing agents,24,38,93,114,Prior administration of <e1>succinylcholine</e1> can potentiate the neuromuscular blocking effects of <e2>nondepolarizing agents</e2>. ,True,effect
succinylcholine,MIVACRON,38,52,102,109,Evidence of spontaneous recovery from <e1>succinylcholine</e1> should be observed before the administration of <e2>MIVACRON</e2>. ,True,advise
MIVACRON,succinylcholine,11,18,27,41,The use of <e1>MIVACRON</e1> before <e2>succinylcholine</e2> to attenuate some of the side effects of succinylcholine has not been studied. ,False,negative
MIVACRON,succinylcholine,11,18,84,98,The use of <e1>MIVACRON</e1> before succinylcholine to attenuate some of the side effects of <e2>succinylcholine</e2> has not been studied. ,False,negative
succinylcholine,succinylcholine,27,41,84,98,The use of MIVACRON before <e1>succinylcholine</e1> to attenuate some of the side effects of <e2>succinylcholine</e2> has not been studied. ,False,negative
MIVACRON,nondepolarizing neuromuscular blocking agents,41,48,61,105,There are no clinical data on the use of <e1>MIVACRON</e1> with other <e2>nondepolarizing neuromuscular blocking agents</e2>. ,False,negative
Isoflurane,enflurane,0,9,15,23,<e1>Isoflurane</e1> and <e2>enflurane</e2> (administered with nitrous oxide/oxygen to achieve 1.25 M.C. ,False,negative
Isoflurane,nitrous oxide,0,9,44,56,<e1>Isoflurane</e1> and enflurane (administered with <e2>nitrous oxide</e2>/oxygen to achieve 1.25 M.C. ,False,negative
Isoflurane,oxygen,0,9,58,63,<e1>Isoflurane</e1> and enflurane (administered with nitrous oxide/<e2>oxygen</e2> to achieve 1.25 M.C. ,False,negative
enflurane,nitrous oxide,15,23,44,56,Isoflurane and <e1>enflurane</e1> (administered with <e2>nitrous oxide</e2>/oxygen to achieve 1.25 M.C. ,False,negative
enflurane,oxygen,15,23,58,63,Isoflurane and <e1>enflurane</e1> (administered with nitrous oxide/<e2>oxygen</e2> to achieve 1.25 M.C. ,False,negative
nitrous oxide,oxygen,44,56,58,63,Isoflurane and enflurane (administered with <e1>nitrous oxide</e1>/<e2>oxygen</e2> to achieve 1.25 M.C. ,False,negative
MIVACRON,enflurane,64,71,119,127,A greater potentiation of the neuromuscular blocking effects of <e1>MIVACRON</e1> may be expected with higher concentrations of <e2>enflurane</e2> or isoflurane. ,False,negative
MIVACRON,isoflurane,64,71,132,141,A greater potentiation of the neuromuscular blocking effects of <e1>MIVACRON</e1> may be expected with higher concentrations of enflurane or <e2>isoflurane</e2>. ,False,negative
enflurane,isoflurane,119,127,132,141,A greater potentiation of the neuromuscular blocking effects of MIVACRON may be expected with higher concentrations of <e1>enflurane</e1> or <e2>isoflurane</e2>. ,False,negative
nondepolarizing agents,MIVACRON,67,88,98,105,"Other drugs which may enhance the neuromuscular blocking action of <e1>nondepolarizing agents</e1> such as <e2>MIVACRON</e2> include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
nondepolarizing agents,antibiotics,67,88,123,133,"Other drugs which may enhance the neuromuscular blocking action of <e1>nondepolarizing agents</e1> such as MIVACRON include certain <e2>antibiotics</e2> (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",True,int
nondepolarizing agents,aminoglycosides,67,88,142,156,"Other drugs which may enhance the neuromuscular blocking action of <e1>nondepolarizing agents</e1> such as MIVACRON include certain antibiotics (e.g., <e2>aminoglycosides</e2>, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",True,int
nondepolarizing agents,tetracyclines,67,88,159,171,"Other drugs which may enhance the neuromuscular blocking action of <e1>nondepolarizing agents</e1> such as MIVACRON include certain antibiotics (e.g., aminoglycosides, <e2>tetracyclines</e2>, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",True,int
nondepolarizing agents,bacitracin,67,88,174,183,"Other drugs which may enhance the neuromuscular blocking action of <e1>nondepolarizing agents</e1> such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, <e2>bacitracin</e2>, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",True,int
nondepolarizing agents,polymyxins,67,88,186,195,"Other drugs which may enhance the neuromuscular blocking action of <e1>nondepolarizing agents</e1> such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, <e2>polymyxins</e2>, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",True,int
nondepolarizing agents,lincomycin,67,88,198,207,"Other drugs which may enhance the neuromuscular blocking action of <e1>nondepolarizing agents</e1> such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, <e2>lincomycin</e2>, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",True,int
nondepolarizing agents,clindamycin,67,88,210,220,"Other drugs which may enhance the neuromuscular blocking action of <e1>nondepolarizing agents</e1> such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, <e2>clindamycin</e2>, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",True,int
nondepolarizing agents,colistin,67,88,223,230,"Other drugs which may enhance the neuromuscular blocking action of <e1>nondepolarizing agents</e1> such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, <e2>colistin</e2>, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",True,int
nondepolarizing agents,sodium colistimethate,67,88,237,257,"Other drugs which may enhance the neuromuscular blocking action of <e1>nondepolarizing agents</e1> such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and <e2>sodium colistimethate</e2>), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",True,int
nondepolarizing agents,magnesium,67,88,261,269,"Other drugs which may enhance the neuromuscular blocking action of <e1>nondepolarizing agents</e1> such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), <e2>magnesium</e2> salts, lithium, local anesthetics, procainamide, and quinidine. ",True,int
nondepolarizing agents,lithium,67,88,278,284,"Other drugs which may enhance the neuromuscular blocking action of <e1>nondepolarizing agents</e1> such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, <e2>lithium</e2>, local anesthetics, procainamide, and quinidine. ",True,int
nondepolarizing agents,anesthetics,67,88,293,303,"Other drugs which may enhance the neuromuscular blocking action of <e1>nondepolarizing agents</e1> such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local <e2>anesthetics</e2>, procainamide, and quinidine. ",True,int
nondepolarizing agents,procainamide,67,88,306,317,"Other drugs which may enhance the neuromuscular blocking action of <e1>nondepolarizing agents</e1> such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, <e2>procainamide</e2>, and quinidine. ",True,int
nondepolarizing agents,quinidine,67,88,324,332,"Other drugs which may enhance the neuromuscular blocking action of <e1>nondepolarizing agents</e1> such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and <e2>quinidine</e2>. ",True,int
MIVACRON,antibiotics,98,105,123,133,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1>MIVACRON</e1> include certain <e2>antibiotics</e2> (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",True,int
MIVACRON,aminoglycosides,98,105,142,156,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1>MIVACRON</e1> include certain antibiotics (e.g., <e2>aminoglycosides</e2>, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",True,int
MIVACRON,tetracyclines,98,105,159,171,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1>MIVACRON</e1> include certain antibiotics (e.g., aminoglycosides, <e2>tetracyclines</e2>, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",True,int
MIVACRON,bacitracin,98,105,174,183,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1>MIVACRON</e1> include certain antibiotics (e.g., aminoglycosides, tetracyclines, <e2>bacitracin</e2>, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",True,int
MIVACRON,polymyxins,98,105,186,195,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1>MIVACRON</e1> include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, <e2>polymyxins</e2>, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",True,int
MIVACRON,lincomycin,98,105,198,207,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1>MIVACRON</e1> include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, <e2>lincomycin</e2>, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",True,int
MIVACRON,clindamycin,98,105,210,220,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1>MIVACRON</e1> include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, <e2>clindamycin</e2>, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",True,int
MIVACRON,colistin,98,105,223,230,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1>MIVACRON</e1> include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, <e2>colistin</e2>, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",True,int
MIVACRON,sodium colistimethate,98,105,237,257,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1>MIVACRON</e1> include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and <e2>sodium colistimethate</e2>), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",True,int
MIVACRON,magnesium,98,105,261,269,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1>MIVACRON</e1> include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), <e2>magnesium</e2> salts, lithium, local anesthetics, procainamide, and quinidine. ",True,int
MIVACRON,lithium,98,105,278,284,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1>MIVACRON</e1> include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, <e2>lithium</e2>, local anesthetics, procainamide, and quinidine. ",True,int
MIVACRON,anesthetics,98,105,293,303,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1>MIVACRON</e1> include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local <e2>anesthetics</e2>, procainamide, and quinidine. ",True,int
MIVACRON,procainamide,98,105,306,317,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1>MIVACRON</e1> include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, <e2>procainamide</e2>, and quinidine. ",True,int
MIVACRON,quinidine,98,105,324,332,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1>MIVACRON</e1> include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and <e2>quinidine</e2>. ",True,int
antibiotics,aminoglycosides,123,133,142,156,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain <e1>antibiotics</e1> (e.g., <e2>aminoglycosides</e2>, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
antibiotics,tetracyclines,123,133,159,171,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain <e1>antibiotics</e1> (e.g., aminoglycosides, <e2>tetracyclines</e2>, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
antibiotics,bacitracin,123,133,174,183,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain <e1>antibiotics</e1> (e.g., aminoglycosides, tetracyclines, <e2>bacitracin</e2>, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
antibiotics,polymyxins,123,133,186,195,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain <e1>antibiotics</e1> (e.g., aminoglycosides, tetracyclines, bacitracin, <e2>polymyxins</e2>, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
antibiotics,lincomycin,123,133,198,207,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain <e1>antibiotics</e1> (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, <e2>lincomycin</e2>, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
antibiotics,clindamycin,123,133,210,220,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain <e1>antibiotics</e1> (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, <e2>clindamycin</e2>, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
antibiotics,colistin,123,133,223,230,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain <e1>antibiotics</e1> (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, <e2>colistin</e2>, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
antibiotics,sodium colistimethate,123,133,237,257,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain <e1>antibiotics</e1> (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and <e2>sodium colistimethate</e2>), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
antibiotics,magnesium,123,133,261,269,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain <e1>antibiotics</e1> (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), <e2>magnesium</e2> salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
antibiotics,lithium,123,133,278,284,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain <e1>antibiotics</e1> (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, <e2>lithium</e2>, local anesthetics, procainamide, and quinidine. ",False,negative
antibiotics,anesthetics,123,133,293,303,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain <e1>antibiotics</e1> (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local <e2>anesthetics</e2>, procainamide, and quinidine. ",False,negative
antibiotics,procainamide,123,133,306,317,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain <e1>antibiotics</e1> (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, <e2>procainamide</e2>, and quinidine. ",False,negative
antibiotics,quinidine,123,133,324,332,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain <e1>antibiotics</e1> (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and <e2>quinidine</e2>. ",False,negative
aminoglycosides,tetracyclines,142,156,159,171,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., <e1>aminoglycosides</e1>, <e2>tetracyclines</e2>, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
aminoglycosides,bacitracin,142,156,174,183,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., <e1>aminoglycosides</e1>, tetracyclines, <e2>bacitracin</e2>, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
aminoglycosides,polymyxins,142,156,186,195,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., <e1>aminoglycosides</e1>, tetracyclines, bacitracin, <e2>polymyxins</e2>, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
aminoglycosides,lincomycin,142,156,198,207,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., <e1>aminoglycosides</e1>, tetracyclines, bacitracin, polymyxins, <e2>lincomycin</e2>, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
aminoglycosides,clindamycin,142,156,210,220,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., <e1>aminoglycosides</e1>, tetracyclines, bacitracin, polymyxins, lincomycin, <e2>clindamycin</e2>, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
aminoglycosides,colistin,142,156,223,230,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., <e1>aminoglycosides</e1>, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, <e2>colistin</e2>, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
aminoglycosides,sodium colistimethate,142,156,237,257,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., <e1>aminoglycosides</e1>, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and <e2>sodium colistimethate</e2>), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
aminoglycosides,magnesium,142,156,261,269,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., <e1>aminoglycosides</e1>, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), <e2>magnesium</e2> salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
aminoglycosides,lithium,142,156,278,284,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., <e1>aminoglycosides</e1>, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, <e2>lithium</e2>, local anesthetics, procainamide, and quinidine. ",False,negative
aminoglycosides,anesthetics,142,156,293,303,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., <e1>aminoglycosides</e1>, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local <e2>anesthetics</e2>, procainamide, and quinidine. ",False,negative
aminoglycosides,procainamide,142,156,306,317,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., <e1>aminoglycosides</e1>, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, <e2>procainamide</e2>, and quinidine. ",False,negative
aminoglycosides,quinidine,142,156,324,332,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., <e1>aminoglycosides</e1>, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and <e2>quinidine</e2>. ",False,negative
tetracyclines,bacitracin,159,171,174,183,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, <e1>tetracyclines</e1>, <e2>bacitracin</e2>, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
tetracyclines,polymyxins,159,171,186,195,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, <e1>tetracyclines</e1>, bacitracin, <e2>polymyxins</e2>, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
tetracyclines,lincomycin,159,171,198,207,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, <e1>tetracyclines</e1>, bacitracin, polymyxins, <e2>lincomycin</e2>, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
tetracyclines,clindamycin,159,171,210,220,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, <e1>tetracyclines</e1>, bacitracin, polymyxins, lincomycin, <e2>clindamycin</e2>, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
tetracyclines,colistin,159,171,223,230,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, <e1>tetracyclines</e1>, bacitracin, polymyxins, lincomycin, clindamycin, <e2>colistin</e2>, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
tetracyclines,sodium colistimethate,159,171,237,257,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, <e1>tetracyclines</e1>, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and <e2>sodium colistimethate</e2>), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
tetracyclines,magnesium,159,171,261,269,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, <e1>tetracyclines</e1>, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), <e2>magnesium</e2> salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
tetracyclines,lithium,159,171,278,284,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, <e1>tetracyclines</e1>, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, <e2>lithium</e2>, local anesthetics, procainamide, and quinidine. ",False,negative
tetracyclines,anesthetics,159,171,293,303,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, <e1>tetracyclines</e1>, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local <e2>anesthetics</e2>, procainamide, and quinidine. ",False,negative
tetracyclines,procainamide,159,171,306,317,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, <e1>tetracyclines</e1>, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, <e2>procainamide</e2>, and quinidine. ",False,negative
tetracyclines,quinidine,159,171,324,332,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, <e1>tetracyclines</e1>, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and <e2>quinidine</e2>. ",False,negative
bacitracin,polymyxins,174,183,186,195,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, <e1>bacitracin</e1>, <e2>polymyxins</e2>, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
bacitracin,lincomycin,174,183,198,207,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, <e1>bacitracin</e1>, polymyxins, <e2>lincomycin</e2>, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
bacitracin,clindamycin,174,183,210,220,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, <e1>bacitracin</e1>, polymyxins, lincomycin, <e2>clindamycin</e2>, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
bacitracin,colistin,174,183,223,230,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, <e1>bacitracin</e1>, polymyxins, lincomycin, clindamycin, <e2>colistin</e2>, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
bacitracin,sodium colistimethate,174,183,237,257,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, <e1>bacitracin</e1>, polymyxins, lincomycin, clindamycin, colistin, and <e2>sodium colistimethate</e2>), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
bacitracin,magnesium,174,183,261,269,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, <e1>bacitracin</e1>, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), <e2>magnesium</e2> salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
bacitracin,lithium,174,183,278,284,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, <e1>bacitracin</e1>, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, <e2>lithium</e2>, local anesthetics, procainamide, and quinidine. ",False,negative
bacitracin,anesthetics,174,183,293,303,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, <e1>bacitracin</e1>, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local <e2>anesthetics</e2>, procainamide, and quinidine. ",False,negative
bacitracin,procainamide,174,183,306,317,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, <e1>bacitracin</e1>, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, <e2>procainamide</e2>, and quinidine. ",False,negative
bacitracin,quinidine,174,183,324,332,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, <e1>bacitracin</e1>, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and <e2>quinidine</e2>. ",False,negative
polymyxins,lincomycin,186,195,198,207,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, <e1>polymyxins</e1>, <e2>lincomycin</e2>, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
polymyxins,clindamycin,186,195,210,220,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, <e1>polymyxins</e1>, lincomycin, <e2>clindamycin</e2>, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
polymyxins,colistin,186,195,223,230,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, <e1>polymyxins</e1>, lincomycin, clindamycin, <e2>colistin</e2>, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
polymyxins,sodium colistimethate,186,195,237,257,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, <e1>polymyxins</e1>, lincomycin, clindamycin, colistin, and <e2>sodium colistimethate</e2>), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
polymyxins,magnesium,186,195,261,269,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, <e1>polymyxins</e1>, lincomycin, clindamycin, colistin, and sodium colistimethate), <e2>magnesium</e2> salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
polymyxins,lithium,186,195,278,284,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, <e1>polymyxins</e1>, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, <e2>lithium</e2>, local anesthetics, procainamide, and quinidine. ",False,negative
polymyxins,anesthetics,186,195,293,303,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, <e1>polymyxins</e1>, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local <e2>anesthetics</e2>, procainamide, and quinidine. ",False,negative
polymyxins,procainamide,186,195,306,317,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, <e1>polymyxins</e1>, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, <e2>procainamide</e2>, and quinidine. ",False,negative
polymyxins,quinidine,186,195,324,332,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, <e1>polymyxins</e1>, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and <e2>quinidine</e2>. ",False,negative
lincomycin,clindamycin,198,207,210,220,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, <e1>lincomycin</e1>, <e2>clindamycin</e2>, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
lincomycin,colistin,198,207,223,230,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, <e1>lincomycin</e1>, clindamycin, <e2>colistin</e2>, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
lincomycin,sodium colistimethate,198,207,237,257,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, <e1>lincomycin</e1>, clindamycin, colistin, and <e2>sodium colistimethate</e2>), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
lincomycin,magnesium,198,207,261,269,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, <e1>lincomycin</e1>, clindamycin, colistin, and sodium colistimethate), <e2>magnesium</e2> salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
lincomycin,lithium,198,207,278,284,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, <e1>lincomycin</e1>, clindamycin, colistin, and sodium colistimethate), magnesium salts, <e2>lithium</e2>, local anesthetics, procainamide, and quinidine. ",False,negative
lincomycin,anesthetics,198,207,293,303,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, <e1>lincomycin</e1>, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local <e2>anesthetics</e2>, procainamide, and quinidine. ",False,negative
lincomycin,procainamide,198,207,306,317,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, <e1>lincomycin</e1>, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, <e2>procainamide</e2>, and quinidine. ",False,negative
lincomycin,quinidine,198,207,324,332,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, <e1>lincomycin</e1>, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and <e2>quinidine</e2>. ",False,negative
clindamycin,colistin,210,220,223,230,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, <e1>clindamycin</e1>, <e2>colistin</e2>, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
clindamycin,sodium colistimethate,210,220,237,257,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, <e1>clindamycin</e1>, colistin, and <e2>sodium colistimethate</e2>), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
clindamycin,magnesium,210,220,261,269,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, <e1>clindamycin</e1>, colistin, and sodium colistimethate), <e2>magnesium</e2> salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
clindamycin,lithium,210,220,278,284,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, <e1>clindamycin</e1>, colistin, and sodium colistimethate), magnesium salts, <e2>lithium</e2>, local anesthetics, procainamide, and quinidine. ",False,negative
clindamycin,anesthetics,210,220,293,303,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, <e1>clindamycin</e1>, colistin, and sodium colistimethate), magnesium salts, lithium, local <e2>anesthetics</e2>, procainamide, and quinidine. ",False,negative
clindamycin,procainamide,210,220,306,317,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, <e1>clindamycin</e1>, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, <e2>procainamide</e2>, and quinidine. ",False,negative
clindamycin,quinidine,210,220,324,332,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, <e1>clindamycin</e1>, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and <e2>quinidine</e2>. ",False,negative
colistin,sodium colistimethate,223,230,237,257,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, <e1>colistin</e1>, and <e2>sodium colistimethate</e2>), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
colistin,magnesium,223,230,261,269,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, <e1>colistin</e1>, and sodium colistimethate), <e2>magnesium</e2> salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
colistin,lithium,223,230,278,284,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, <e1>colistin</e1>, and sodium colistimethate), magnesium salts, <e2>lithium</e2>, local anesthetics, procainamide, and quinidine. ",False,negative
colistin,anesthetics,223,230,293,303,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, <e1>colistin</e1>, and sodium colistimethate), magnesium salts, lithium, local <e2>anesthetics</e2>, procainamide, and quinidine. ",False,negative
colistin,procainamide,223,230,306,317,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, <e1>colistin</e1>, and sodium colistimethate), magnesium salts, lithium, local anesthetics, <e2>procainamide</e2>, and quinidine. ",False,negative
colistin,quinidine,223,230,324,332,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, <e1>colistin</e1>, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and <e2>quinidine</e2>. ",False,negative
sodium colistimethate,magnesium,237,257,261,269,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and <e1>sodium colistimethate</e1>), <e2>magnesium</e2> salts, lithium, local anesthetics, procainamide, and quinidine. ",False,negative
sodium colistimethate,lithium,237,257,278,284,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and <e1>sodium colistimethate</e1>), magnesium salts, <e2>lithium</e2>, local anesthetics, procainamide, and quinidine. ",False,negative
sodium colistimethate,anesthetics,237,257,293,303,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and <e1>sodium colistimethate</e1>), magnesium salts, lithium, local <e2>anesthetics</e2>, procainamide, and quinidine. ",False,negative
sodium colistimethate,procainamide,237,257,306,317,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and <e1>sodium colistimethate</e1>), magnesium salts, lithium, local anesthetics, <e2>procainamide</e2>, and quinidine. ",False,negative
sodium colistimethate,quinidine,237,257,324,332,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and <e1>sodium colistimethate</e1>), magnesium salts, lithium, local anesthetics, procainamide, and <e2>quinidine</e2>. ",False,negative
magnesium,lithium,261,269,278,284,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), <e1>magnesium</e1> salts, <e2>lithium</e2>, local anesthetics, procainamide, and quinidine. ",False,negative
magnesium,anesthetics,261,269,293,303,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), <e1>magnesium</e1> salts, lithium, local <e2>anesthetics</e2>, procainamide, and quinidine. ",False,negative
magnesium,procainamide,261,269,306,317,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), <e1>magnesium</e1> salts, lithium, local anesthetics, <e2>procainamide</e2>, and quinidine. ",False,negative
magnesium,quinidine,261,269,324,332,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), <e1>magnesium</e1> salts, lithium, local anesthetics, procainamide, and <e2>quinidine</e2>. ",False,negative
lithium,anesthetics,278,284,293,303,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, <e1>lithium</e1>, local <e2>anesthetics</e2>, procainamide, and quinidine. ",False,negative
lithium,procainamide,278,284,306,317,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, <e1>lithium</e1>, local anesthetics, <e2>procainamide</e2>, and quinidine. ",False,negative
lithium,quinidine,278,284,324,332,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, <e1>lithium</e1>, local anesthetics, procainamide, and <e2>quinidine</e2>. ",False,negative
anesthetics,procainamide,293,303,306,317,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local <e1>anesthetics</e1>, <e2>procainamide</e2>, and quinidine. ",False,negative
anesthetics,quinidine,293,303,324,332,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local <e1>anesthetics</e1>, procainamide, and <e2>quinidine</e2>. ",False,negative
procainamide,quinidine,306,317,324,332,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, <e1>procainamide</e1>, and <e2>quinidine</e2>. ",False,negative
MIVACRON,contraceptives,37,44,151,164,"The neuromuscular blocking effect of <e1>MIVACRON</e1> may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral <e2>contraceptives</e2>, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",True,effect
MIVACRON,glucocorticoids,37,44,167,181,"The neuromuscular blocking effect of <e1>MIVACRON</e1> may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, <e2>glucocorticoids</e2>, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",True,effect
MIVACRON,monoamine oxidase inhibitors,37,44,195,222,"The neuromuscular blocking effect of <e1>MIVACRON</e1> may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain <e2>monoamine oxidase inhibitors</e2>) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",True,effect
MIVACRON,neuromuscular blocking agents,37,44,354,382,"The neuromuscular blocking effect of <e1>MIVACRON</e1> may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing <e2>neuromuscular blocking agents</e2> has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",False,negative
MIVACRON,phenytoin,37,44,443,451,"The neuromuscular blocking effect of <e1>MIVACRON</e1> may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered <e2>phenytoin</e2> or carbamazepine. ",False,negative
MIVACRON,carbamazepine,37,44,456,468,"The neuromuscular blocking effect of <e1>MIVACRON</e1> may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or <e2>carbamazepine</e2>. ",False,negative
contraceptives,glucocorticoids,151,164,167,181,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral <e1>contraceptives</e1>, <e2>glucocorticoids</e2>, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",False,negative
contraceptives,monoamine oxidase inhibitors,151,164,195,222,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral <e1>contraceptives</e1>, glucocorticoids, or certain <e2>monoamine oxidase inhibitors</e2>) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",False,negative
contraceptives,neuromuscular blocking agents,151,164,354,382,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral <e1>contraceptives</e1>, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing <e2>neuromuscular blocking agents</e2> has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",False,negative
contraceptives,phenytoin,151,164,443,451,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral <e1>contraceptives</e1>, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered <e2>phenytoin</e2> or carbamazepine. ",False,negative
contraceptives,carbamazepine,151,164,456,468,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral <e1>contraceptives</e1>, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or <e2>carbamazepine</e2>. ",False,negative
glucocorticoids,monoamine oxidase inhibitors,167,181,195,222,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, <e1>glucocorticoids</e1>, or certain <e2>monoamine oxidase inhibitors</e2>) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",False,negative
glucocorticoids,neuromuscular blocking agents,167,181,354,382,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, <e1>glucocorticoids</e1>, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing <e2>neuromuscular blocking agents</e2> has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",False,negative
glucocorticoids,phenytoin,167,181,443,451,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, <e1>glucocorticoids</e1>, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered <e2>phenytoin</e2> or carbamazepine. ",False,negative
glucocorticoids,carbamazepine,167,181,456,468,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, <e1>glucocorticoids</e1>, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or <e2>carbamazepine</e2>. ",False,negative
monoamine oxidase inhibitors,neuromuscular blocking agents,195,222,354,382,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain <e1>monoamine oxidase inhibitors</e1>) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing <e2>neuromuscular blocking agents</e2> has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",False,negative
monoamine oxidase inhibitors,phenytoin,195,222,443,451,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain <e1>monoamine oxidase inhibitors</e1>) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered <e2>phenytoin</e2> or carbamazepine. ",False,negative
monoamine oxidase inhibitors,carbamazepine,195,222,456,468,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain <e1>monoamine oxidase inhibitors</e1>) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or <e2>carbamazepine</e2>. ",False,negative
neuromuscular blocking agents,phenytoin,354,382,443,451,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing <e1>neuromuscular blocking agents</e1> has been demonstrated in patients chronically administered <e2>phenytoin</e2> or carbamazepine. ",True,effect
neuromuscular blocking agents,carbamazepine,354,382,456,468,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing <e1>neuromuscular blocking agents</e1> has been demonstrated in patients chronically administered phenytoin or <e2>carbamazepine</e2>. ",True,effect
phenytoin,carbamazepine,443,451,456,468,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered <e1>phenytoin</e1> or <e2>carbamazepine</e2>. ",False,negative
phenytoin,carbamazepine,29,37,42,54,"While the effects of chronic <e1>phenytoin</e1> or <e2>carbamazepine</e2> therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. ",False,negative
phenytoin,MIVACRON,29,37,81,88,"While the effects of chronic <e1>phenytoin</e1> or carbamazepine therapy on the action of <e2>MIVACRON</e2> are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. ",True,effect
carbamazepine,MIVACRON,42,54,81,88,"While the effects of chronic phenytoin or <e1>carbamazepine</e1> therapy on the action of <e2>MIVACRON</e2> are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. ",True,effect
corticosteroids,phenytoin,53,67,176,184,Some drug interactions are:  - birth control pills - <e1>corticosteroids</e1> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e2>phenytoin</e2> or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
corticosteroids,carbamazepine,53,67,189,201,Some drug interactions are:  - birth control pills - <e1>corticosteroids</e1> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e2>carbamazepine</e2> - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
corticosteroids,antibiotics,53,67,213,223,Some drug interactions are:  - birth control pills - <e1>corticosteroids</e1> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e2>antibiotics</e2> given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
corticosteroids,cisplatin,53,67,246,254,Some drug interactions are:  - birth control pills - <e1>corticosteroids</e1> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - <e2>cisplatin</e2> - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
corticosteroids,edrophonium,53,67,258,268,Some drug interactions are:  - birth control pills - <e1>corticosteroids</e1> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - <e2>edrophonium</e2> - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
corticosteroids,neostigmine,53,67,272,282,Some drug interactions are:  - birth control pills - <e1>corticosteroids</e1> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - <e2>neostigmine</e2> - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
corticosteroids,polymyxin B,53,67,286,296,Some drug interactions are:  - birth control pills - <e1>corticosteroids</e1> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - <e2>polymyxin B</e2> or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
corticosteroids,bacitracin,53,67,301,310,Some drug interactions are:  - birth control pills - <e1>corticosteroids</e1> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or <e2>bacitracin</e2> - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
corticosteroids,anesthetics,53,67,320,330,Some drug interactions are:  - birth control pills - <e1>corticosteroids</e1> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local <e2>anesthetics</e2> such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
corticosteroids,procaine,53,67,340,347,Some drug interactions are:  - birth control pills - <e1>corticosteroids</e1> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as <e2>procaine</e2> - general anesthetics - succinylcholine or other muscle relaxants,False,negative
corticosteroids,anesthetics,53,67,359,369,Some drug interactions are:  - birth control pills - <e1>corticosteroids</e1> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general <e2>anesthetics</e2> - succinylcholine or other muscle relaxants,False,negative
corticosteroids,succinylcholine,53,67,373,387,Some drug interactions are:  - birth control pills - <e1>corticosteroids</e1> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - <e2>succinylcholine</e2> or other muscle relaxants,False,negative
corticosteroids,muscle relaxants,53,67,398,413,Some drug interactions are:  - birth control pills - <e1>corticosteroids</e1> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other <e2>muscle relaxants</e2>,False,negative
phenytoin,carbamazepine,176,184,189,201,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e1>phenytoin</e1> or <e2>carbamazepine</e2> - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
phenytoin,antibiotics,176,184,213,223,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e1>phenytoin</e1> or carbamazepine - certain <e2>antibiotics</e2> given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
phenytoin,cisplatin,176,184,246,254,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e1>phenytoin</e1> or carbamazepine - certain antibiotics given by injection - <e2>cisplatin</e2> - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
phenytoin,edrophonium,176,184,258,268,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e1>phenytoin</e1> or carbamazepine - certain antibiotics given by injection - cisplatin - <e2>edrophonium</e2> - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
phenytoin,neostigmine,176,184,272,282,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e1>phenytoin</e1> or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - <e2>neostigmine</e2> - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
phenytoin,polymyxin B,176,184,286,296,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e1>phenytoin</e1> or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - <e2>polymyxin B</e2> or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
phenytoin,bacitracin,176,184,301,310,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e1>phenytoin</e1> or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or <e2>bacitracin</e2> - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
phenytoin,anesthetics,176,184,320,330,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e1>phenytoin</e1> or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local <e2>anesthetics</e2> such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
phenytoin,procaine,176,184,340,347,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e1>phenytoin</e1> or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as <e2>procaine</e2> - general anesthetics - succinylcholine or other muscle relaxants,False,negative
phenytoin,anesthetics,176,184,359,369,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e1>phenytoin</e1> or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general <e2>anesthetics</e2> - succinylcholine or other muscle relaxants,False,negative
phenytoin,succinylcholine,176,184,373,387,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e1>phenytoin</e1> or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - <e2>succinylcholine</e2> or other muscle relaxants,False,negative
phenytoin,muscle relaxants,176,184,398,413,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e1>phenytoin</e1> or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other <e2>muscle relaxants</e2>,False,negative
carbamazepine,antibiotics,189,201,213,223,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e1>carbamazepine</e1> - certain <e2>antibiotics</e2> given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
carbamazepine,cisplatin,189,201,246,254,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e1>carbamazepine</e1> - certain antibiotics given by injection - <e2>cisplatin</e2> - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
carbamazepine,edrophonium,189,201,258,268,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e1>carbamazepine</e1> - certain antibiotics given by injection - cisplatin - <e2>edrophonium</e2> - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
carbamazepine,neostigmine,189,201,272,282,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e1>carbamazepine</e1> - certain antibiotics given by injection - cisplatin - edrophonium - <e2>neostigmine</e2> - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
carbamazepine,polymyxin B,189,201,286,296,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e1>carbamazepine</e1> - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - <e2>polymyxin B</e2> or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
carbamazepine,bacitracin,189,201,301,310,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e1>carbamazepine</e1> - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or <e2>bacitracin</e2> - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
carbamazepine,anesthetics,189,201,320,330,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e1>carbamazepine</e1> - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local <e2>anesthetics</e2> such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
carbamazepine,procaine,189,201,340,347,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e1>carbamazepine</e1> - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as <e2>procaine</e2> - general anesthetics - succinylcholine or other muscle relaxants,False,negative
carbamazepine,anesthetics,189,201,359,369,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e1>carbamazepine</e1> - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general <e2>anesthetics</e2> - succinylcholine or other muscle relaxants,False,negative
carbamazepine,succinylcholine,189,201,373,387,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e1>carbamazepine</e1> - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - <e2>succinylcholine</e2> or other muscle relaxants,False,negative
carbamazepine,muscle relaxants,189,201,398,413,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e1>carbamazepine</e1> - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other <e2>muscle relaxants</e2>,False,negative
antibiotics,cisplatin,213,223,246,254,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e1>antibiotics</e1> given by injection - <e2>cisplatin</e2> - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
antibiotics,edrophonium,213,223,258,268,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e1>antibiotics</e1> given by injection - cisplatin - <e2>edrophonium</e2> - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
antibiotics,neostigmine,213,223,272,282,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e1>antibiotics</e1> given by injection - cisplatin - edrophonium - <e2>neostigmine</e2> - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
antibiotics,polymyxin B,213,223,286,296,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e1>antibiotics</e1> given by injection - cisplatin - edrophonium - neostigmine - <e2>polymyxin B</e2> or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
antibiotics,bacitracin,213,223,301,310,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e1>antibiotics</e1> given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or <e2>bacitracin</e2> - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
antibiotics,anesthetics,213,223,320,330,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e1>antibiotics</e1> given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local <e2>anesthetics</e2> such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
antibiotics,procaine,213,223,340,347,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e1>antibiotics</e1> given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as <e2>procaine</e2> - general anesthetics - succinylcholine or other muscle relaxants,False,negative
antibiotics,anesthetics,213,223,359,369,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e1>antibiotics</e1> given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general <e2>anesthetics</e2> - succinylcholine or other muscle relaxants,False,negative
antibiotics,succinylcholine,213,223,373,387,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e1>antibiotics</e1> given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - <e2>succinylcholine</e2> or other muscle relaxants,False,negative
antibiotics,muscle relaxants,213,223,398,413,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e1>antibiotics</e1> given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other <e2>muscle relaxants</e2>,False,negative
cisplatin,edrophonium,246,254,258,268,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - <e1>cisplatin</e1> - <e2>edrophonium</e2> - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
cisplatin,neostigmine,246,254,272,282,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - <e1>cisplatin</e1> - edrophonium - <e2>neostigmine</e2> - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
cisplatin,polymyxin B,246,254,286,296,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - <e1>cisplatin</e1> - edrophonium - neostigmine - <e2>polymyxin B</e2> or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
cisplatin,bacitracin,246,254,301,310,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - <e1>cisplatin</e1> - edrophonium - neostigmine - polymyxin B or <e2>bacitracin</e2> - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
cisplatin,anesthetics,246,254,320,330,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - <e1>cisplatin</e1> - edrophonium - neostigmine - polymyxin B or bacitracin - local <e2>anesthetics</e2> such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
cisplatin,procaine,246,254,340,347,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - <e1>cisplatin</e1> - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as <e2>procaine</e2> - general anesthetics - succinylcholine or other muscle relaxants,False,negative
cisplatin,anesthetics,246,254,359,369,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - <e1>cisplatin</e1> - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general <e2>anesthetics</e2> - succinylcholine or other muscle relaxants,False,negative
cisplatin,succinylcholine,246,254,373,387,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - <e1>cisplatin</e1> - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - <e2>succinylcholine</e2> or other muscle relaxants,False,negative
cisplatin,muscle relaxants,246,254,398,413,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - <e1>cisplatin</e1> - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other <e2>muscle relaxants</e2>,False,negative
edrophonium,neostigmine,258,268,272,282,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - <e1>edrophonium</e1> - <e2>neostigmine</e2> - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
edrophonium,polymyxin B,258,268,286,296,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - <e1>edrophonium</e1> - neostigmine - <e2>polymyxin B</e2> or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
edrophonium,bacitracin,258,268,301,310,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - <e1>edrophonium</e1> - neostigmine - polymyxin B or <e2>bacitracin</e2> - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
edrophonium,anesthetics,258,268,320,330,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - <e1>edrophonium</e1> - neostigmine - polymyxin B or bacitracin - local <e2>anesthetics</e2> such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
edrophonium,procaine,258,268,340,347,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - <e1>edrophonium</e1> - neostigmine - polymyxin B or bacitracin - local anesthetics such as <e2>procaine</e2> - general anesthetics - succinylcholine or other muscle relaxants,False,negative
edrophonium,anesthetics,258,268,359,369,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - <e1>edrophonium</e1> - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general <e2>anesthetics</e2> - succinylcholine or other muscle relaxants,False,negative
edrophonium,succinylcholine,258,268,373,387,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - <e1>edrophonium</e1> - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - <e2>succinylcholine</e2> or other muscle relaxants,False,negative
edrophonium,muscle relaxants,258,268,398,413,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - <e1>edrophonium</e1> - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other <e2>muscle relaxants</e2>,False,negative
neostigmine,polymyxin B,272,282,286,296,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - <e1>neostigmine</e1> - <e2>polymyxin B</e2> or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
neostigmine,bacitracin,272,282,301,310,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - <e1>neostigmine</e1> - polymyxin B or <e2>bacitracin</e2> - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
neostigmine,anesthetics,272,282,320,330,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - <e1>neostigmine</e1> - polymyxin B or bacitracin - local <e2>anesthetics</e2> such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
neostigmine,procaine,272,282,340,347,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - <e1>neostigmine</e1> - polymyxin B or bacitracin - local anesthetics such as <e2>procaine</e2> - general anesthetics - succinylcholine or other muscle relaxants,False,negative
neostigmine,anesthetics,272,282,359,369,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - <e1>neostigmine</e1> - polymyxin B or bacitracin - local anesthetics such as procaine - general <e2>anesthetics</e2> - succinylcholine or other muscle relaxants,False,negative
neostigmine,succinylcholine,272,282,373,387,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - <e1>neostigmine</e1> - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - <e2>succinylcholine</e2> or other muscle relaxants,False,negative
neostigmine,muscle relaxants,272,282,398,413,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - <e1>neostigmine</e1> - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other <e2>muscle relaxants</e2>,False,negative
polymyxin B,bacitracin,286,296,301,310,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - <e1>polymyxin B</e1> or <e2>bacitracin</e2> - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
polymyxin B,anesthetics,286,296,320,330,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - <e1>polymyxin B</e1> or bacitracin - local <e2>anesthetics</e2> such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
polymyxin B,procaine,286,296,340,347,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - <e1>polymyxin B</e1> or bacitracin - local anesthetics such as <e2>procaine</e2> - general anesthetics - succinylcholine or other muscle relaxants,False,negative
polymyxin B,anesthetics,286,296,359,369,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - <e1>polymyxin B</e1> or bacitracin - local anesthetics such as procaine - general <e2>anesthetics</e2> - succinylcholine or other muscle relaxants,False,negative
polymyxin B,succinylcholine,286,296,373,387,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - <e1>polymyxin B</e1> or bacitracin - local anesthetics such as procaine - general anesthetics - <e2>succinylcholine</e2> or other muscle relaxants,False,negative
polymyxin B,muscle relaxants,286,296,398,413,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - <e1>polymyxin B</e1> or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other <e2>muscle relaxants</e2>,False,negative
bacitracin,anesthetics,301,310,320,330,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or <e1>bacitracin</e1> - local <e2>anesthetics</e2> such as procaine - general anesthetics - succinylcholine or other muscle relaxants,False,negative
bacitracin,procaine,301,310,340,347,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or <e1>bacitracin</e1> - local anesthetics such as <e2>procaine</e2> - general anesthetics - succinylcholine or other muscle relaxants,False,negative
bacitracin,anesthetics,301,310,359,369,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or <e1>bacitracin</e1> - local anesthetics such as procaine - general <e2>anesthetics</e2> - succinylcholine or other muscle relaxants,False,negative
bacitracin,succinylcholine,301,310,373,387,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or <e1>bacitracin</e1> - local anesthetics such as procaine - general anesthetics - <e2>succinylcholine</e2> or other muscle relaxants,False,negative
bacitracin,muscle relaxants,301,310,398,413,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or <e1>bacitracin</e1> - local anesthetics such as procaine - general anesthetics - succinylcholine or other <e2>muscle relaxants</e2>,False,negative
anesthetics,procaine,320,330,340,347,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local <e1>anesthetics</e1> such as <e2>procaine</e2> - general anesthetics - succinylcholine or other muscle relaxants,False,negative
anesthetics,anesthetics,320,330,359,369,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local <e1>anesthetics</e1> such as procaine - general <e2>anesthetics</e2> - succinylcholine or other muscle relaxants,False,negative
anesthetics,succinylcholine,320,330,373,387,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local <e1>anesthetics</e1> such as procaine - general anesthetics - <e2>succinylcholine</e2> or other muscle relaxants,False,negative
anesthetics,muscle relaxants,320,330,398,413,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local <e1>anesthetics</e1> such as procaine - general anesthetics - succinylcholine or other <e2>muscle relaxants</e2>,False,negative
procaine,anesthetics,340,347,359,369,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as <e1>procaine</e1> - general <e2>anesthetics</e2> - succinylcholine or other muscle relaxants,False,negative
procaine,succinylcholine,340,347,373,387,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as <e1>procaine</e1> - general anesthetics - <e2>succinylcholine</e2> or other muscle relaxants,False,negative
procaine,muscle relaxants,340,347,398,413,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as <e1>procaine</e1> - general anesthetics - succinylcholine or other <e2>muscle relaxants</e2>,False,negative
anesthetics,succinylcholine,359,369,373,387,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general <e1>anesthetics</e1> - <e2>succinylcholine</e2> or other muscle relaxants,False,negative
anesthetics,muscle relaxants,359,369,398,413,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general <e1>anesthetics</e1> - succinylcholine or other <e2>muscle relaxants</e2>,False,negative
succinylcholine,muscle relaxants,373,387,398,413,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - <e1>succinylcholine</e1> or other <e2>muscle relaxants</e2>,False,negative
Diuretics,ACE inhibitors,0,8,97,110,<e1>Diuretics</e1>: Excessive reductions in blood pressure may occur in patients on diuretic therapy when <e2>ACE inhibitors</e2> are started. ,False,negative
UNIVASC,UNIVASC,44,50,196,202,"The possibility of hypotensive effects with <e1>UNIVASC</e1>    can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with <e2>UNIVASC</e2>   . If this is not possible, the starting dose of moexpril should be reduced.. ",False,negative
UNIVASC,moexpril,44,50,254,261,"The possibility of hypotensive effects with <e1>UNIVASC</e1>    can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with UNIVASC   . If this is not possible, the starting dose of <e2>moexpril</e2> should be reduced.. ",False,negative
UNIVASC,moexpril,196,202,254,261,"The possibility of hypotensive effects with UNIVASC    can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with <e1>UNIVASC</e1>   . If this is not possible, the starting dose of <e2>moexpril</e2> should be reduced.. ",False,negative
Potassium,Potassium-Sparing Diuretics,0,8,26,52,<e1>Potassium</e1> Supplements and <e2>Potassium-Sparing Diuretics</e2>: UNIVASC    can increase serum potassium because it decreases aldosterone secretion. ,False,negative
Potassium,UNIVASC,0,8,55,61,<e1>Potassium</e1> Supplements and Potassium-Sparing Diuretics: <e2>UNIVASC</e2>    can increase serum potassium because it decreases aldosterone secretion. ,False,negative
Potassium-Sparing Diuretics,UNIVASC,26,52,55,61,Potassium Supplements and <e1>Potassium-Sparing Diuretics</e1>: <e2>UNIVASC</e2>    can increase serum potassium because it decreases aldosterone secretion. ,False,negative
potassium-sparing diuretics,spironolactone,7,33,36,49,"Use of <e1>potassium-sparing diuretics</e1> (<e2>spironolactone</e2>, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",False,negative
potassium-sparing diuretics,triamterene,7,33,52,62,"Use of <e1>potassium-sparing diuretics</e1> (spironolactone, <e2>triamterene</e2>, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",False,negative
potassium-sparing diuretics,amiloride,7,33,65,73,"Use of <e1>potassium-sparing diuretics</e1> (spironolactone, triamterene, <e2>amiloride</e2>) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",False,negative
potassium-sparing diuretics,potassium,7,33,79,87,"Use of <e1>potassium-sparing diuretics</e1> (spironolactone, triamterene, amiloride) or <e2>potassium</e2> supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",False,negative
potassium-sparing diuretics,ACE inhibitors,7,33,120,133,"Use of <e1>potassium-sparing diuretics</e1> (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with <e2>ACE inhibitors</e2> can increase the risk of hyperkalemia. ",True,effect
spironolactone,triamterene,36,49,52,62,"Use of potassium-sparing diuretics (<e1>spironolactone</e1>, <e2>triamterene</e2>, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",False,negative
spironolactone,amiloride,36,49,65,73,"Use of potassium-sparing diuretics (<e1>spironolactone</e1>, triamterene, <e2>amiloride</e2>) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",False,negative
spironolactone,potassium,36,49,79,87,"Use of potassium-sparing diuretics (<e1>spironolactone</e1>, triamterene, amiloride) or <e2>potassium</e2> supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",False,negative
spironolactone,ACE inhibitors,36,49,120,133,"Use of potassium-sparing diuretics (<e1>spironolactone</e1>, triamterene, amiloride) or potassium supplements concomitantly with <e2>ACE inhibitors</e2> can increase the risk of hyperkalemia. ",True,effect
triamterene,amiloride,52,62,65,73,"Use of potassium-sparing diuretics (spironolactone, <e1>triamterene</e1>, <e2>amiloride</e2>) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",False,negative
triamterene,potassium,52,62,79,87,"Use of potassium-sparing diuretics (spironolactone, <e1>triamterene</e1>, amiloride) or <e2>potassium</e2> supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",False,negative
triamterene,ACE inhibitors,52,62,120,133,"Use of potassium-sparing diuretics (spironolactone, <e1>triamterene</e1>, amiloride) or potassium supplements concomitantly with <e2>ACE inhibitors</e2> can increase the risk of hyperkalemia. ",True,effect
amiloride,potassium,65,73,79,87,"Use of potassium-sparing diuretics (spironolactone, triamterene, <e1>amiloride</e1>) or <e2>potassium</e2> supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",False,negative
amiloride,ACE inhibitors,65,73,120,133,"Use of potassium-sparing diuretics (spironolactone, triamterene, <e1>amiloride</e1>) or potassium supplements concomitantly with <e2>ACE inhibitors</e2> can increase the risk of hyperkalemia. ",True,effect
potassium,ACE inhibitors,79,87,120,133,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or <e1>potassium</e1> supplements concomitantly with <e2>ACE inhibitors</e2> can increase the risk of hyperkalemia. ",True,effect
Anticoagulants,warfarin,5,18,46,53,Oral <e1>Anticoagulants</e1>: Interaction studies with <e2>warfarin</e2> failed to identify any clinically important effect on the serum concentrations of the anticoagulant or on its anticoagulant effect. ,False,negative
Anticoagulants,anticoagulant,5,18,141,153,Oral <e1>Anticoagulants</e1>: Interaction studies with warfarin failed to identify any clinically important effect on the serum concentrations of the <e2>anticoagulant</e2> or on its anticoagulant effect. ,False,negative
warfarin,anticoagulant,46,53,141,153,Oral Anticoagulants: Interaction studies with <e1>warfarin</e1> failed to identify any clinically important effect on the serum concentrations of the <e2>anticoagulant</e2> or on its anticoagulant effect. ,False,negative
Lithium,lithium,0,6,25,31,<e1>Lithium</e1>: Increased serum <e2>lithium</e2> levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. ,False,negative
Lithium,lithium,0,6,56,62,<e1>Lithium</e1>: Increased serum lithium levels and symptoms of <e2>lithium</e2> toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. ,False,negative
Lithium,ACE inhibitors,0,6,114,127,<e1>Lithium</e1>: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving <e2>ACE inhibitors</e2> during therapy with lithium. ,False,negative
Lithium,lithium,0,6,149,155,<e1>Lithium</e1>: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with <e2>lithium</e2>. ,False,negative
lithium,lithium,25,31,56,62,Lithium: Increased serum <e1>lithium</e1> levels and symptoms of <e2>lithium</e2> toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. ,False,negative
lithium,ACE inhibitors,25,31,114,127,Lithium: Increased serum <e1>lithium</e1> levels and symptoms of lithium toxicity have been reported in patients receiving <e2>ACE inhibitors</e2> during therapy with lithium. ,False,negative
lithium,lithium,25,31,149,155,Lithium: Increased serum <e1>lithium</e1> levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with <e2>lithium</e2>. ,False,negative
lithium,ACE inhibitors,56,62,114,127,Lithium: Increased serum lithium levels and symptoms of <e1>lithium</e1> toxicity have been reported in patients receiving <e2>ACE inhibitors</e2> during therapy with lithium. ,False,negative
lithium,lithium,56,62,149,155,Lithium: Increased serum lithium levels and symptoms of <e1>lithium</e1> toxicity have been reported in patients receiving ACE inhibitors during therapy with <e2>lithium</e2>. ,False,negative
ACE inhibitors,lithium,114,127,149,155,Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving <e1>ACE inhibitors</e1> during therapy with <e2>lithium</e2>. ,True,effect
diuretic,lithium,5,12,40,46,"If a <e1>diuretic</e1> is also used, the risk of <e2>lithium</e2> toxicity may be increased. ",True,effect
UNIVASC,hydrochlorothiazide,81,87,128,146,"Other Agents: No clinically important pharmacokinetic interactions occurred when <e1>UNIVASC</e1>    was administered concomitantly with <e2>hydrochlorothiazide</e2>, digoxin, or cimetidine. ",False,negative
UNIVASC,digoxin,81,87,149,155,"Other Agents: No clinically important pharmacokinetic interactions occurred when <e1>UNIVASC</e1>    was administered concomitantly with hydrochlorothiazide, <e2>digoxin</e2>, or cimetidine. ",False,negative
UNIVASC,cimetidine,81,87,161,170,"Other Agents: No clinically important pharmacokinetic interactions occurred when <e1>UNIVASC</e1>    was administered concomitantly with hydrochlorothiazide, digoxin, or <e2>cimetidine</e2>. ",False,negative
hydrochlorothiazide,digoxin,128,146,149,155,"Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC    was administered concomitantly with <e1>hydrochlorothiazide</e1>, <e2>digoxin</e2>, or cimetidine. ",False,negative
hydrochlorothiazide,cimetidine,128,146,161,170,"Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC    was administered concomitantly with <e1>hydrochlorothiazide</e1>, digoxin, or <e2>cimetidine</e2>. ",False,negative
digoxin,cimetidine,149,155,161,170,"Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC    was administered concomitantly with hydrochlorothiazide, <e1>digoxin</e1>, or <e2>cimetidine</e2>. ",False,negative
UNIVASC,calcium-channel-blocking agents,0,6,63,93,"<e1>UNIVASC</e1>    has been used in clinical trials concomitantly with <e2>calcium-channel-blocking agents</e2>, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",False,negative
UNIVASC,diuretics,0,6,96,104,"<e1>UNIVASC</e1>    has been used in clinical trials concomitantly with calcium-channel-blocking agents, <e2>diuretics</e2>, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",False,negative
UNIVASC,H2 blockers,0,6,107,117,"<e1>UNIVASC</e1>    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, <e2>H2 blockers</e2>, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",False,negative
UNIVASC,digoxin,0,6,120,126,"<e1>UNIVASC</e1>    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, <e2>digoxin</e2>, oral hypoglycemic agents, and cholesterol-lowering agents. ",False,negative
UNIVASC,hypoglycemic agents,0,6,134,152,"<e1>UNIVASC</e1>    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral <e2>hypoglycemic agents</e2>, and cholesterol-lowering agents. ",False,negative
calcium-channel-blocking agents,diuretics,63,93,96,104,"UNIVASC    has been used in clinical trials concomitantly with <e1>calcium-channel-blocking agents</e1>, <e2>diuretics</e2>, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",False,negative
calcium-channel-blocking agents,H2 blockers,63,93,107,117,"UNIVASC    has been used in clinical trials concomitantly with <e1>calcium-channel-blocking agents</e1>, diuretics, <e2>H2 blockers</e2>, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",False,negative
calcium-channel-blocking agents,digoxin,63,93,120,126,"UNIVASC    has been used in clinical trials concomitantly with <e1>calcium-channel-blocking agents</e1>, diuretics, H2 blockers, <e2>digoxin</e2>, oral hypoglycemic agents, and cholesterol-lowering agents. ",False,negative
calcium-channel-blocking agents,hypoglycemic agents,63,93,134,152,"UNIVASC    has been used in clinical trials concomitantly with <e1>calcium-channel-blocking agents</e1>, diuretics, H2 blockers, digoxin, oral <e2>hypoglycemic agents</e2>, and cholesterol-lowering agents. ",False,negative
diuretics,H2 blockers,96,104,107,117,"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, <e1>diuretics</e1>, <e2>H2 blockers</e2>, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",False,negative
diuretics,digoxin,96,104,120,126,"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, <e1>diuretics</e1>, H2 blockers, <e2>digoxin</e2>, oral hypoglycemic agents, and cholesterol-lowering agents. ",False,negative
diuretics,hypoglycemic agents,96,104,134,152,"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, <e1>diuretics</e1>, H2 blockers, digoxin, oral <e2>hypoglycemic agents</e2>, and cholesterol-lowering agents. ",False,negative
H2 blockers,digoxin,107,117,120,126,"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, <e1>H2 blockers</e1>, <e2>digoxin</e2>, oral hypoglycemic agents, and cholesterol-lowering agents. ",False,negative
H2 blockers,hypoglycemic agents,107,117,134,152,"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, <e1>H2 blockers</e1>, digoxin, oral <e2>hypoglycemic agents</e2>, and cholesterol-lowering agents. ",False,negative
digoxin,hypoglycemic agents,120,126,134,152,"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, <e1>digoxin</e1>, oral <e2>hypoglycemic agents</e2>, and cholesterol-lowering agents. ",False,negative
ketoconazole,mometasone furoate,9,20,96,113,"However, <e1>ketoconazole</e1>, a potent inhibitor of cytochrome P450 3A4, may increase plasma levels of <e2>mometasone furoate</e2> during concomitant dosing.",True,mechanism
Montelukast,theophylline,0,10,176,187,<e1>Montelukast</e1> at a Dose of 10 mg Once Daily Dosed to Pharmacokinetic Steady State  - did not cause clinically significant changes in the kinetics of a single intravenous dose of <e2>theophylline</e2> (predominantly a cytochrome P450 1A2 substrate). ,False,negative
warfarin,warfarin,48,55,158,165,- did not change the pharmacokinetic profile of <e1>warfarin</e1> (a substrate of cytochromes P450 2A6 and 2C9) or influence the effect of a single 30-mg oral dose of <e2>warfarin</e2> on prothrombin time or the INR (International Normalized Ratio). ,False,negative
terfenadine,fexofenadine,53,63,105,116,"- did not change the plasma concentration profile of <e1>terfenadine</e1> (a substrate of cytochrome P450 3A4) or <e2>fexofenadine</e2>, its carboxylated metabolite, and did not prolong the QTc interval following co-administration with terfenadine 60 mg twice daily. ",False,negative
terfenadine,terfenadine,53,63,218,228,"- did not change the plasma concentration profile of <e1>terfenadine</e1> (a substrate of cytochrome P450 3A4) or fexofenadine, its carboxylated metabolite, and did not prolong the QTc interval following co-administration with <e2>terfenadine</e2> 60 mg twice daily. ",False,negative
fexofenadine,terfenadine,105,116,218,228,"- did not change the plasma concentration profile of terfenadine (a substrate of cytochrome P450 3A4) or <e1>fexofenadine</e1>, its carboxylated metabolite, and did not prolong the QTc interval following co-administration with <e2>terfenadine</e2> 60 mg twice daily. ",False,negative
Montelukast,contraceptive,0,10,167,179,<e1>Montelukast</e1> at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral <e2>contraceptive</e2> containing norethindrone 1 mg/ethinyl estradiol 35 mcg. ,False,negative
Montelukast,norethindrone,0,10,192,204,<e1>Montelukast</e1> at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing <e2>norethindrone</e2> 1 mg/ethinyl estradiol 35 mcg. ,False,negative
Montelukast,estradiol,0,10,219,227,<e1>Montelukast</e1> at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl <e2>estradiol</e2> 35 mcg. ,False,negative
contraceptive,norethindrone,167,179,192,204,Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral <e1>contraceptive</e1> containing <e2>norethindrone</e2> 1 mg/ethinyl estradiol 35 mcg. ,False,negative
contraceptive,estradiol,167,179,219,227,Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral <e1>contraceptive</e1> containing norethindrone 1 mg/ethinyl <e2>estradiol</e2> 35 mcg. ,False,negative
norethindrone,estradiol,192,204,219,227,Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing <e1>norethindrone</e1> 1 mg/ethinyl <e2>estradiol</e2> 35 mcg. ,False,negative
prednisone,prednisolone,72,81,86,97,- did not cause any clinically significant change in plasma profiles of <e1>prednisone</e1> or <e2>prednisolone</e2> following administration of either oral prednisone or intravenous prednisolone.  ,False,negative
prednisone,prednisone,72,81,139,148,- did not cause any clinically significant change in plasma profiles of <e1>prednisone</e1> or prednisolone following administration of either oral <e2>prednisone</e2> or intravenous prednisolone.  ,False,negative
prednisone,prednisolone,72,81,165,176,- did not cause any clinically significant change in plasma profiles of <e1>prednisone</e1> or prednisolone following administration of either oral prednisone or intravenous <e2>prednisolone</e2>.  ,False,negative
prednisolone,prednisone,86,97,139,148,- did not cause any clinically significant change in plasma profiles of prednisone or <e1>prednisolone</e1> following administration of either oral <e2>prednisone</e2> or intravenous prednisolone.  ,False,negative
prednisolone,prednisolone,86,97,165,176,- did not cause any clinically significant change in plasma profiles of prednisone or <e1>prednisolone</e1> following administration of either oral prednisone or intravenous <e2>prednisolone</e2>.  ,False,negative
prednisone,prednisolone,139,148,165,176,- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral <e1>prednisone</e1> or intravenous <e2>prednisolone</e2>.  ,False,negative
Phenobarbital,montelukast,0,12,70,80,"<e1>Phenobarbital</e1>, which induces hepatic metabolism, decreased the AUC of <e2>montelukast</e2> approximately 40% following a single 10-mg dose of montelukast. ",False,negative
Phenobarbital,montelukast,0,12,133,143,"<e1>Phenobarbital</e1>, which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of <e2>montelukast</e2>. ",False,negative
montelukast,montelukast,70,80,133,143,"Phenobarbital, which induces hepatic metabolism, decreased the AUC of <e1>montelukast</e1> approximately 40% following a single 10-mg dose of <e2>montelukast</e2>. ",False,negative
phenobarbital,rifampin,112,124,129,136,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as <e1>phenobarbital</e1> or <e2>rifampin</e2>, are co-administered with montelukast. ",False,negative
phenobarbital,montelukast,112,124,164,174,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as <e1>phenobarbital</e1> or rifampin, are co-administered with <e2>montelukast</e2>. ",True,advise
rifampin,montelukast,129,136,164,174,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or <e1>rifampin</e1>, are co-administered with <e2>montelukast</e2>. ",True,advise
montelukast,theophylline,62,72,164,175,"In drug-interaction studies, the recommended clinical dose of <e1>montelukast</e1> did not have clinically important effects on the pharmacokinetics of the following drugs: <e2>theophylline</e2>, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",False,negative
montelukast,prednisone,62,72,178,187,"In drug-interaction studies, the recommended clinical dose of <e1>montelukast</e1> did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, <e2>prednisone</e2>, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",False,negative
montelukast,prednisolone,62,72,190,201,"In drug-interaction studies, the recommended clinical dose of <e1>montelukast</e1> did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, <e2>prednisolone</e2>, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",False,negative
montelukast,contraceptives,62,72,209,222,"In drug-interaction studies, the recommended clinical dose of <e1>montelukast</e1> did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral <e2>contraceptives</e2> (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",False,negative
montelukast,norethindrone,62,72,225,237,"In drug-interaction studies, the recommended clinical dose of <e1>montelukast</e1> did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (<e2>norethindrone</e2> 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",False,negative
montelukast,ethinyl estradiol,62,72,244,260,"In drug-interaction studies, the recommended clinical dose of <e1>montelukast</e1> did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/<e2>ethinyl estradiol</e2> 35 mcg), terfenadine, digoxin, and warfarin. ",False,negative
montelukast,terfenadine,62,72,271,281,"In drug-interaction studies, the recommended clinical dose of <e1>montelukast</e1> did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), <e2>terfenadine</e2>, digoxin, and warfarin. ",False,negative
montelukast,digoxin,62,72,284,290,"In drug-interaction studies, the recommended clinical dose of <e1>montelukast</e1> did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, <e2>digoxin</e2>, and warfarin. ",False,negative
montelukast,warfarin,62,72,297,304,"In drug-interaction studies, the recommended clinical dose of <e1>montelukast</e1> did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and <e2>warfarin</e2>. ",False,negative
theophylline,prednisone,164,175,178,187,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: <e1>theophylline</e1>, <e2>prednisone</e2>, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",False,negative
theophylline,prednisolone,164,175,190,201,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: <e1>theophylline</e1>, prednisone, <e2>prednisolone</e2>, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",False,negative
theophylline,contraceptives,164,175,209,222,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: <e1>theophylline</e1>, prednisone, prednisolone, oral <e2>contraceptives</e2> (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",False,negative
theophylline,norethindrone,164,175,225,237,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: <e1>theophylline</e1>, prednisone, prednisolone, oral contraceptives (<e2>norethindrone</e2> 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",False,negative
theophylline,ethinyl estradiol,164,175,244,260,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: <e1>theophylline</e1>, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/<e2>ethinyl estradiol</e2> 35 mcg), terfenadine, digoxin, and warfarin. ",False,negative
theophylline,terfenadine,164,175,271,281,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: <e1>theophylline</e1>, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), <e2>terfenadine</e2>, digoxin, and warfarin. ",False,negative
theophylline,digoxin,164,175,284,290,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: <e1>theophylline</e1>, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, <e2>digoxin</e2>, and warfarin. ",False,negative
theophylline,warfarin,164,175,297,304,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: <e1>theophylline</e1>, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and <e2>warfarin</e2>. ",False,negative
prednisone,prednisolone,178,187,190,201,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, <e1>prednisone</e1>, <e2>prednisolone</e2>, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",False,negative
prednisone,contraceptives,178,187,209,222,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, <e1>prednisone</e1>, prednisolone, oral <e2>contraceptives</e2> (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",False,negative
prednisone,norethindrone,178,187,225,237,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, <e1>prednisone</e1>, prednisolone, oral contraceptives (<e2>norethindrone</e2> 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",False,negative
prednisone,ethinyl estradiol,178,187,244,260,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, <e1>prednisone</e1>, prednisolone, oral contraceptives (norethindrone 1 mg/<e2>ethinyl estradiol</e2> 35 mcg), terfenadine, digoxin, and warfarin. ",False,negative
prednisone,terfenadine,178,187,271,281,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, <e1>prednisone</e1>, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), <e2>terfenadine</e2>, digoxin, and warfarin. ",False,negative
prednisone,digoxin,178,187,284,290,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, <e1>prednisone</e1>, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, <e2>digoxin</e2>, and warfarin. ",False,negative
prednisone,warfarin,178,187,297,304,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, <e1>prednisone</e1>, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and <e2>warfarin</e2>. ",False,negative
prednisolone,contraceptives,190,201,209,222,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, <e1>prednisolone</e1>, oral <e2>contraceptives</e2> (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",False,negative
prednisolone,norethindrone,190,201,225,237,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, <e1>prednisolone</e1>, oral contraceptives (<e2>norethindrone</e2> 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",False,negative
prednisolone,ethinyl estradiol,190,201,244,260,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, <e1>prednisolone</e1>, oral contraceptives (norethindrone 1 mg/<e2>ethinyl estradiol</e2> 35 mcg), terfenadine, digoxin, and warfarin. ",False,negative
prednisolone,terfenadine,190,201,271,281,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, <e1>prednisolone</e1>, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), <e2>terfenadine</e2>, digoxin, and warfarin. ",False,negative
prednisolone,digoxin,190,201,284,290,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, <e1>prednisolone</e1>, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, <e2>digoxin</e2>, and warfarin. ",False,negative
prednisolone,warfarin,190,201,297,304,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, <e1>prednisolone</e1>, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and <e2>warfarin</e2>. ",False,negative
contraceptives,norethindrone,209,222,225,237,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral <e1>contraceptives</e1> (<e2>norethindrone</e2> 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",False,negative
contraceptives,ethinyl estradiol,209,222,244,260,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral <e1>contraceptives</e1> (norethindrone 1 mg/<e2>ethinyl estradiol</e2> 35 mcg), terfenadine, digoxin, and warfarin. ",False,negative
contraceptives,terfenadine,209,222,271,281,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral <e1>contraceptives</e1> (norethindrone 1 mg/ethinyl estradiol 35 mcg), <e2>terfenadine</e2>, digoxin, and warfarin. ",False,negative
contraceptives,digoxin,209,222,284,290,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral <e1>contraceptives</e1> (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, <e2>digoxin</e2>, and warfarin. ",False,negative
contraceptives,warfarin,209,222,297,304,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral <e1>contraceptives</e1> (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and <e2>warfarin</e2>. ",False,negative
norethindrone,ethinyl estradiol,225,237,244,260,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (<e1>norethindrone</e1> 1 mg/<e2>ethinyl estradiol</e2> 35 mcg), terfenadine, digoxin, and warfarin. ",False,negative
norethindrone,terfenadine,225,237,271,281,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (<e1>norethindrone</e1> 1 mg/ethinyl estradiol 35 mcg), <e2>terfenadine</e2>, digoxin, and warfarin. ",False,negative
norethindrone,digoxin,225,237,284,290,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (<e1>norethindrone</e1> 1 mg/ethinyl estradiol 35 mcg), terfenadine, <e2>digoxin</e2>, and warfarin. ",False,negative
norethindrone,warfarin,225,237,297,304,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (<e1>norethindrone</e1> 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and <e2>warfarin</e2>. ",False,negative
ethinyl estradiol,terfenadine,244,260,271,281,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/<e1>ethinyl estradiol</e1> 35 mcg), <e2>terfenadine</e2>, digoxin, and warfarin. ",False,negative
ethinyl estradiol,digoxin,244,260,284,290,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/<e1>ethinyl estradiol</e1> 35 mcg), terfenadine, <e2>digoxin</e2>, and warfarin. ",False,negative
ethinyl estradiol,warfarin,244,260,297,304,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/<e1>ethinyl estradiol</e1> 35 mcg), terfenadine, digoxin, and <e2>warfarin</e2>. ",False,negative
terfenadine,digoxin,271,281,284,290,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), <e1>terfenadine</e1>, <e2>digoxin</e2>, and warfarin. ",False,negative
terfenadine,warfarin,271,281,297,304,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), <e1>terfenadine</e1>, digoxin, and <e2>warfarin</e2>. ",False,negative
digoxin,warfarin,284,290,297,304,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, <e1>digoxin</e1>, and <e2>warfarin</e2>. ",False,negative
thyroid hormones,sedative hypnotics,27,42,45,62,"These medications included <e1>thyroid hormones</e1>, <e2>sedative hypnotics</e2>, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants. ",False,negative
thyroid hormones,non-steroidal anti-inflammatory agents,27,42,65,102,"These medications included <e1>thyroid hormones</e1>, sedative hypnotics, <e2>non-steroidal anti-inflammatory agents</e2>, benzodiazepines, and decongestants. ",False,negative
thyroid hormones,benzodiazepines,27,42,105,119,"These medications included <e1>thyroid hormones</e1>, sedative hypnotics, non-steroidal anti-inflammatory agents, <e2>benzodiazepines</e2>, and decongestants. ",False,negative
thyroid hormones,decongestants,27,42,126,138,"These medications included <e1>thyroid hormones</e1>, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and <e2>decongestants</e2>. ",False,negative
sedative hypnotics,non-steroidal anti-inflammatory agents,45,62,65,102,"These medications included thyroid hormones, <e1>sedative hypnotics</e1>, <e2>non-steroidal anti-inflammatory agents</e2>, benzodiazepines, and decongestants. ",False,negative
sedative hypnotics,benzodiazepines,45,62,105,119,"These medications included thyroid hormones, <e1>sedative hypnotics</e1>, non-steroidal anti-inflammatory agents, <e2>benzodiazepines</e2>, and decongestants. ",False,negative
sedative hypnotics,decongestants,45,62,126,138,"These medications included thyroid hormones, <e1>sedative hypnotics</e1>, non-steroidal anti-inflammatory agents, benzodiazepines, and <e2>decongestants</e2>. ",False,negative
non-steroidal anti-inflammatory agents,benzodiazepines,65,102,105,119,"These medications included thyroid hormones, sedative hypnotics, <e1>non-steroidal anti-inflammatory agents</e1>, <e2>benzodiazepines</e2>, and decongestants. ",False,negative
non-steroidal anti-inflammatory agents,decongestants,65,102,126,138,"These medications included thyroid hormones, sedative hypnotics, <e1>non-steroidal anti-inflammatory agents</e1>, benzodiazepines, and <e2>decongestants</e2>. ",False,negative
benzodiazepines,decongestants,105,119,126,138,"These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, <e1>benzodiazepines</e1>, and <e2>decongestants</e2>. ",False,negative
Phenobarbital,montelukast,0,12,70,80,"<e1>Phenobarbital</e1>, which induces hepatic metabolism, decreased the AUC of <e2>montelukast</e2> approximately 40% following a single 10-mg dose of montelukast. ",False,negative
Phenobarbital,montelukast,0,12,133,143,"<e1>Phenobarbital</e1>, which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of <e2>montelukast</e2>. ",False,negative
montelukast,montelukast,70,80,133,143,"Phenobarbital, which induces hepatic metabolism, decreased the AUC of <e1>montelukast</e1> approximately 40% following a single 10-mg dose of <e2>montelukast</e2>. ",False,negative
phenobarbital,rifampin,112,124,129,136,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as <e1>phenobarbital</e1> or <e2>rifampin</e2>, are co-administered with montelukast.",False,negative
phenobarbital,montelukast,112,124,164,174,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as <e1>phenobarbital</e1> or rifampin, are co-administered with <e2>montelukast</e2>.",True,advise
rifampin,montelukast,129,136,164,174,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or <e1>rifampin</e1>, are co-administered with <e2>montelukast</e2>.",True,advise
Central Nervous System Depressants,morphine,15,48,77,84,"Use with Other <e1>Central Nervous System Depressants</e1>: The depressant effects of <e2>morphine</e2> are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",False,negative
Central Nervous System Depressants,CNS depressants,15,48,127,141,"Use with Other <e1>Central Nervous System Depressants</e1>: The depressant effects of morphine are potentiated by the presence of other <e2>CNS depressants</e2> such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",False,negative
Central Nervous System Depressants,alcohol,15,48,151,157,"Use with Other <e1>Central Nervous System Depressants</e1>: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as <e2>alcohol</e2>, sedatives, antihistaminics, or psychotropic drugs. ",False,negative
Central Nervous System Depressants,sedatives,15,48,160,168,"Use with Other <e1>Central Nervous System Depressants</e1>: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, <e2>sedatives</e2>, antihistaminics, or psychotropic drugs. ",False,negative
Central Nervous System Depressants,antihistaminics,15,48,171,185,"Use with Other <e1>Central Nervous System Depressants</e1>: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, <e2>antihistaminics</e2>, or psychotropic drugs. ",False,negative
Central Nervous System Depressants,psychotropic drugs,15,48,191,208,"Use with Other <e1>Central Nervous System Depressants</e1>: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or <e2>psychotropic drugs</e2>. ",False,negative
morphine,CNS depressants,77,84,127,141,"Use with Other Central Nervous System Depressants: The depressant effects of <e1>morphine</e1> are potentiated by the presence of other <e2>CNS depressants</e2> such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",True,effect
morphine,alcohol,77,84,151,157,"Use with Other Central Nervous System Depressants: The depressant effects of <e1>morphine</e1> are potentiated by the presence of other CNS depressants such as <e2>alcohol</e2>, sedatives, antihistaminics, or psychotropic drugs. ",True,effect
morphine,sedatives,77,84,160,168,"Use with Other Central Nervous System Depressants: The depressant effects of <e1>morphine</e1> are potentiated by the presence of other CNS depressants such as alcohol, <e2>sedatives</e2>, antihistaminics, or psychotropic drugs. ",True,effect
morphine,antihistaminics,77,84,171,185,"Use with Other Central Nervous System Depressants: The depressant effects of <e1>morphine</e1> are potentiated by the presence of other CNS depressants such as alcohol, sedatives, <e2>antihistaminics</e2>, or psychotropic drugs. ",True,effect
morphine,psychotropic drugs,77,84,191,208,"Use with Other Central Nervous System Depressants: The depressant effects of <e1>morphine</e1> are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or <e2>psychotropic drugs</e2>. ",True,effect
CNS depressants,alcohol,127,141,151,157,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other <e1>CNS depressants</e1> such as <e2>alcohol</e2>, sedatives, antihistaminics, or psychotropic drugs. ",False,negative
CNS depressants,sedatives,127,141,160,168,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other <e1>CNS depressants</e1> such as alcohol, <e2>sedatives</e2>, antihistaminics, or psychotropic drugs. ",False,negative
CNS depressants,antihistaminics,127,141,171,185,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other <e1>CNS depressants</e1> such as alcohol, sedatives, <e2>antihistaminics</e2>, or psychotropic drugs. ",False,negative
CNS depressants,psychotropic drugs,127,141,191,208,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other <e1>CNS depressants</e1> such as alcohol, sedatives, antihistaminics, or <e2>psychotropic drugs</e2>. ",False,negative
alcohol,sedatives,151,157,160,168,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as <e1>alcohol</e1>, <e2>sedatives</e2>, antihistaminics, or psychotropic drugs. ",False,negative
alcohol,antihistaminics,151,157,171,185,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as <e1>alcohol</e1>, sedatives, <e2>antihistaminics</e2>, or psychotropic drugs. ",False,negative
alcohol,psychotropic drugs,151,157,191,208,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as <e1>alcohol</e1>, sedatives, antihistaminics, or <e2>psychotropic drugs</e2>. ",False,negative
sedatives,antihistaminics,160,168,171,185,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, <e1>sedatives</e1>, <e2>antihistaminics</e2>, or psychotropic drugs. ",False,negative
sedatives,psychotropic drugs,160,168,191,208,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, <e1>sedatives</e1>, antihistaminics, or <e2>psychotropic drugs</e2>. ",False,negative
antihistaminics,psychotropic drugs,171,185,191,208,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, <e1>antihistaminics</e1>, or <e2>psychotropic drugs</e2>. ",False,negative
neuroleptics,morphine,7,18,45,52,"Use of <e1>neuroleptics</e1> in conjunction with oral <e2>morphine</e2> may increase the risk of respiratory depression, hypotension and profound sedation or coma. ",True,effect
Mixed Agonist/Antagonist Opioid Analgesics,Agonist/antagonist analgesics,17,58,61,89,"Interaction with <e1>Mixed Agonist/Antagonist Opioid Analgesics</e1>: <e2>Agonist/antagonist analgesics</e2> (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",False,negative
Mixed Agonist/Antagonist Opioid Analgesics,pentazocine,17,58,98,108,"Interaction with <e1>Mixed Agonist/Antagonist Opioid Analgesics</e1>: Agonist/antagonist analgesics (i.e., <e2>pentazocine</e2>, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",False,negative
Mixed Agonist/Antagonist Opioid Analgesics,nalbuphine,17,58,111,120,"Interaction with <e1>Mixed Agonist/Antagonist Opioid Analgesics</e1>: Agonist/antagonist analgesics (i.e., pentazocine, <e2>nalbuphine</e2>, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",False,negative
Mixed Agonist/Antagonist Opioid Analgesics,butorphanol,17,58,123,133,"Interaction with <e1>Mixed Agonist/Antagonist Opioid Analgesics</e1>: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, <e2>butorphanol</e2>, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",False,negative
Mixed Agonist/Antagonist Opioid Analgesics,buprenorphine,17,58,139,151,"Interaction with <e1>Mixed Agonist/Antagonist Opioid Analgesics</e1>: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or <e2>buprenorphine</e2>) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",False,negative
Mixed Agonist/Antagonist Opioid Analgesics,opioid agonist analgesic,17,58,261,284,"Interaction with <e1>Mixed Agonist/Antagonist Opioid Analgesics</e1>: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof <e2>opioid agonist analgesic</e2>. ",False,negative
Agonist/antagonist analgesics,pentazocine,61,89,98,108,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: <e1>Agonist/antagonist analgesics</e1> (i.e., <e2>pentazocine</e2>, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",False,negative
Agonist/antagonist analgesics,nalbuphine,61,89,111,120,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: <e1>Agonist/antagonist analgesics</e1> (i.e., pentazocine, <e2>nalbuphine</e2>, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",False,negative
Agonist/antagonist analgesics,butorphanol,61,89,123,133,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: <e1>Agonist/antagonist analgesics</e1> (i.e., pentazocine, nalbuphine, <e2>butorphanol</e2>, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",False,negative
Agonist/antagonist analgesics,buprenorphine,61,89,139,151,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: <e1>Agonist/antagonist analgesics</e1> (i.e., pentazocine, nalbuphine, butorphanol, or <e2>buprenorphine</e2>) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",False,negative
Agonist/antagonist analgesics,opioid agonist analgesic,61,89,261,284,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: <e1>Agonist/antagonist analgesics</e1> (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof <e2>opioid agonist analgesic</e2>. ",True,advise
pentazocine,nalbuphine,98,108,111,120,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., <e1>pentazocine</e1>, <e2>nalbuphine</e2>, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",False,negative
pentazocine,butorphanol,98,108,123,133,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., <e1>pentazocine</e1>, nalbuphine, <e2>butorphanol</e2>, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",False,negative
pentazocine,buprenorphine,98,108,139,151,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., <e1>pentazocine</e1>, nalbuphine, butorphanol, or <e2>buprenorphine</e2>) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",False,negative
pentazocine,opioid agonist analgesic,98,108,261,284,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., <e1>pentazocine</e1>, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof <e2>opioid agonist analgesic</e2>. ",True,advise
nalbuphine,butorphanol,111,120,123,133,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, <e1>nalbuphine</e1>, <e2>butorphanol</e2>, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",False,negative
nalbuphine,buprenorphine,111,120,139,151,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, <e1>nalbuphine</e1>, butorphanol, or <e2>buprenorphine</e2>) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",False,negative
nalbuphine,opioid agonist analgesic,111,120,261,284,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, <e1>nalbuphine</e1>, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof <e2>opioid agonist analgesic</e2>. ",True,advise
butorphanol,buprenorphine,123,133,139,151,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, <e1>butorphanol</e1>, or <e2>buprenorphine</e2>) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",False,negative
butorphanol,opioid agonist analgesic,123,133,261,284,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, <e1>butorphanol</e1>, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof <e2>opioid agonist analgesic</e2>. ",True,advise
buprenorphine,opioid agonist analgesic,139,151,261,284,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or <e1>buprenorphine</e1>) should NOT be administered to patients who have received or are receiving a course of therapy with a proof <e2>opioid agonist analgesic</e2>. ",True,advise
Antacids,Myfortic,0,7,41,48,"<e1>Antacids</e1>: Absorption of a single dose of <e2>Myfortic</e2> was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",False,negative
Antacids,magnesium,0,7,133,141,"<e1>Antacids</e1>: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking <e2>magnesium</e2>-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",False,negative
Antacids,aluminum,0,7,143,150,"<e1>Antacids</e1>: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-<e2>aluminum</e2> containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",False,negative
Antacids,antacids,0,7,163,170,"<e1>Antacids</e1>: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing <e2>antacids</e2> (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",False,negative
Antacids,Myfortic,0,7,271,278,"<e1>Antacids</e1>: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when <e2>Myfortic</e2> was administered alone under fasting conditions. ",False,negative
Myfortic,magnesium,41,48,133,141,"Antacids: Absorption of a single dose of <e1>Myfortic</e1> was decreased when administered to 12 stable renal transplant patients also taking <e2>magnesium</e2>-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",True,mechanism
Myfortic,aluminum,41,48,143,150,"Antacids: Absorption of a single dose of <e1>Myfortic</e1> was decreased when administered to 12 stable renal transplant patients also taking magnesium-<e2>aluminum</e2> containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",True,mechanism
Myfortic,antacids,41,48,163,170,"Antacids: Absorption of a single dose of <e1>Myfortic</e1> was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing <e2>antacids</e2> (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",False,negative
Myfortic,Myfortic,41,48,271,278,"Antacids: Absorption of a single dose of <e1>Myfortic</e1> was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when <e2>Myfortic</e2> was administered alone under fasting conditions. ",False,negative
magnesium,aluminum,133,141,143,150,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking <e1>magnesium</e1>-<e2>aluminum</e2> containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",False,negative
magnesium,antacids,133,141,163,170,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking <e1>magnesium</e1>-aluminum containing <e2>antacids</e2> (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",False,negative
magnesium,Myfortic,133,141,271,278,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking <e1>magnesium</e1>-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when <e2>Myfortic</e2> was administered alone under fasting conditions. ",False,negative
aluminum,antacids,143,150,163,170,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-<e1>aluminum</e1> containing <e2>antacids</e2> (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",False,negative
aluminum,Myfortic,143,150,271,278,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-<e1>aluminum</e1> containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when <e2>Myfortic</e2> was administered alone under fasting conditions. ",False,negative
antacids,Myfortic,163,170,271,278,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing <e1>antacids</e1> (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when <e2>Myfortic</e2> was administered alone under fasting conditions. ",False,negative
Myfortic,antacids,23,30,36,43,It is recommended that <e1>Myfortic</e1> and <e2>antacids</e2> not be administered simultaneously. ,True,advise
Cyclosporine,cyclosporine,0,11,64,75,"<e1>Cyclosporine</e1>: When studied in stable renal transplant patients, <e2>cyclosporine</e2>, USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of Myfortic. ",False,negative
Cyclosporine,Myfortic,0,11,152,159,"<e1>Cyclosporine</e1>: When studied in stable renal transplant patients, cyclosporine, USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of <e2>Myfortic</e2>. ",False,negative
cyclosporine,Myfortic,64,75,152,159,"Cyclosporine: When studied in stable renal transplant patients, <e1>cyclosporine</e1>, USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of <e2>Myfortic</e2>. ",False,negative
Acyclovir,Ganciclovir,0,8,10,20,<e1>Acyclovir</e1>/<e2>Ganciclovir</e2>: may be taken with Myfortic; ,False,negative
Acyclovir,Myfortic,0,8,41,48,<e1>Acyclovir</e1>/Ganciclovir: may be taken with <e2>Myfortic</e2>; ,False,negative
Ganciclovir,Myfortic,10,20,41,48,Acyclovir/<e1>Ganciclovir</e1>: may be taken with <e2>Myfortic</e2>; ,False,negative
acyclovir,ganciclovir,5,13,15,25,"Both <e1>acyclovir</e1>/<e2>ganciclovir</e2> and MPAG concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two. ",False,negative
acyclovir,MPAG,5,13,31,34,"Both <e1>acyclovir</e1>/ganciclovir and <e2>MPAG</e2> concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two. ",False,negative
ganciclovir,MPAG,15,25,31,34,"Both acyclovir/<e1>ganciclovir</e1> and <e2>MPAG</e2> concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two. ",False,negative
Azathioprine,Mycophenolate Mofetil,0,11,13,33,"<e1>Azathioprine</e1>/<e2>Mycophenolate Mofetil</e2>: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",False,negative
Azathioprine,azathioprine,0,11,47,58,"<e1>Azathioprine</e1>/Mycophenolate Mofetil: Given that <e2>azathioprine</e2> and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",False,negative
Azathioprine,mycophenolate mofetil,0,11,64,84,"<e1>Azathioprine</e1>/Mycophenolate Mofetil: Given that azathioprine and <e2>mycophenolate mofetil</e2> inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",False,negative
Azathioprine,Myfortic,0,11,136,143,"<e1>Azathioprine</e1>/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that <e2>Myfortic</e2> not be administered concomitantly with azathioprine or mycophenolate mofetil. ",False,negative
Azathioprine,azathioprine,0,11,184,195,"<e1>Azathioprine</e1>/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with <e2>azathioprine</e2> or mycophenolate mofetil. ",False,negative
Azathioprine,mycophenolate mofetil,0,11,200,220,"<e1>Azathioprine</e1>/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or <e2>mycophenolate mofetil</e2>. ",False,negative
Mycophenolate Mofetil,azathioprine,13,33,47,58,"Azathioprine/<e1>Mycophenolate Mofetil</e1>: Given that <e2>azathioprine</e2> and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",False,negative
Mycophenolate Mofetil,mycophenolate mofetil,13,33,64,84,"Azathioprine/<e1>Mycophenolate Mofetil</e1>: Given that azathioprine and <e2>mycophenolate mofetil</e2> inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",False,negative
Mycophenolate Mofetil,Myfortic,13,33,136,143,"Azathioprine/<e1>Mycophenolate Mofetil</e1>: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that <e2>Myfortic</e2> not be administered concomitantly with azathioprine or mycophenolate mofetil. ",False,negative
Mycophenolate Mofetil,azathioprine,13,33,184,195,"Azathioprine/<e1>Mycophenolate Mofetil</e1>: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with <e2>azathioprine</e2> or mycophenolate mofetil. ",False,negative
Mycophenolate Mofetil,mycophenolate mofetil,13,33,200,220,"Azathioprine/<e1>Mycophenolate Mofetil</e1>: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or <e2>mycophenolate mofetil</e2>. ",False,negative
azathioprine,mycophenolate mofetil,47,58,64,84,"Azathioprine/Mycophenolate Mofetil: Given that <e1>azathioprine</e1> and <e2>mycophenolate mofetil</e2> inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",False,negative
azathioprine,Myfortic,47,58,136,143,"Azathioprine/Mycophenolate Mofetil: Given that <e1>azathioprine</e1> and mycophenolate mofetil inhibit purine metabolism, it is recommended that <e2>Myfortic</e2> not be administered concomitantly with azathioprine or mycophenolate mofetil. ",False,negative
azathioprine,azathioprine,47,58,184,195,"Azathioprine/Mycophenolate Mofetil: Given that <e1>azathioprine</e1> and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with <e2>azathioprine</e2> or mycophenolate mofetil. ",False,negative
azathioprine,mycophenolate mofetil,47,58,200,220,"Azathioprine/Mycophenolate Mofetil: Given that <e1>azathioprine</e1> and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or <e2>mycophenolate mofetil</e2>. ",False,negative
mycophenolate mofetil,Myfortic,64,84,136,143,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and <e1>mycophenolate mofetil</e1> inhibit purine metabolism, it is recommended that <e2>Myfortic</e2> not be administered concomitantly with azathioprine or mycophenolate mofetil. ",False,negative
mycophenolate mofetil,azathioprine,64,84,184,195,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and <e1>mycophenolate mofetil</e1> inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with <e2>azathioprine</e2> or mycophenolate mofetil. ",False,negative
mycophenolate mofetil,mycophenolate mofetil,64,84,200,220,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and <e1>mycophenolate mofetil</e1> inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or <e2>mycophenolate mofetil</e2>. ",False,negative
Myfortic,azathioprine,136,143,184,195,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that <e1>Myfortic</e1> not be administered concomitantly with <e2>azathioprine</e2> or mycophenolate mofetil. ",True,advise
Myfortic,mycophenolate mofetil,136,143,200,220,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that <e1>Myfortic</e1> not be administered concomitantly with azathioprine or <e2>mycophenolate mofetil</e2>. ",True,advise
azathioprine,mycophenolate mofetil,184,195,200,220,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with <e1>azathioprine</e1> or <e2>mycophenolate mofetil</e2>. ",False,negative
Cholestyramine,MPA,0,13,108,110,<e1>Cholestyramine</e1> and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce <e2>MPA</e2> exposure when coadministered with mycophenolate mofetil. ,False,negative
Cholestyramine,mycophenolate mofetil,0,13,146,166,<e1>Cholestyramine</e1> and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce MPA exposure when coadministered with <e2>mycophenolate mofetil</e2>. ,False,negative
MPA,mycophenolate mofetil,108,110,146,166,Cholestyramine and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce <e1>MPA</e1> exposure when coadministered with <e2>mycophenolate mofetil</e2>. ,False,negative
Myfortic,cholestyramine,29,36,43,56,"Therefore, do not administer <e1>Myfortic</e1> with <e2>cholestyramine</e2> or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic. ",True,advise
Myfortic,activated charcoal,29,36,204,221,"Therefore, do not administer <e1>Myfortic</e1> with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral <e2>activated charcoal</e2>, because of the potential to reduce the efficacy of Myfortic. ",True,advise
Myfortic,Myfortic,29,36,275,282,"Therefore, do not administer <e1>Myfortic</e1> with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of <e2>Myfortic</e2>. ",False,negative
cholestyramine,activated charcoal,43,56,204,221,"Therefore, do not administer Myfortic with <e1>cholestyramine</e1> or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral <e2>activated charcoal</e2>, because of the potential to reduce the efficacy of Myfortic. ",False,negative
cholestyramine,Myfortic,43,56,275,282,"Therefore, do not administer Myfortic with <e1>cholestyramine</e1> or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of <e2>Myfortic</e2>. ",False,negative
activated charcoal,Myfortic,204,221,275,282,"Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral <e1>activated charcoal</e1>, because of the potential to reduce the efficacy of <e2>Myfortic</e2>. ",False,negative
Contraceptives,Myfortic,5,18,55,62,"Oral <e1>Contraceptives</e1>: Given the different metabolism of <e2>Myfortic</e2> and oral contraceptives, no drug interaction between these two classes of drug is expected. ",False,negative
Contraceptives,contraceptives,5,18,73,86,"Oral <e1>Contraceptives</e1>: Given the different metabolism of Myfortic and oral <e2>contraceptives</e2>, no drug interaction between these two classes of drug is expected. ",False,negative
Myfortic,contraceptives,55,62,73,86,"Oral Contraceptives: Given the different metabolism of <e1>Myfortic</e1> and oral <e2>contraceptives</e2>, no drug interaction between these two classes of drug is expected. ",False,negative
levonorgesterol,mycophenolate mofetil,48,62,114,134,"However, in a drug-drug interaction study, mean <e1>levonorgesterol</e1> AUC was decreased by 15% when coadministered with <e2>mycophenolate mofetil</e2>. ",True,mechanism
contraceptives,Myfortic,39,52,80,87,"Therefore, it is recommended that oral <e1>contraceptives</e1> are co- administered with <e2>Myfortic</e2> with caution and additional birth control methods be considered. ",True,advise
Live Vaccines,Myfortic,0,12,37,44,"<e1>Live Vaccines</e1>: During treatment with <e2>Myfortic</e2>, the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective. ",False,negative
Live Vaccines,live attenuated vaccines,0,12,58,81,"<e1>Live Vaccines</e1>: During treatment with Myfortic, the use of <e2>live attenuated vaccines</e2> should be avoided and patients should be advised that vaccinations may be less effective. ",False,negative
Myfortic,live attenuated vaccines,37,44,58,81,"Live Vaccines: During treatment with <e1>Myfortic</e1>, the use of <e2>live attenuated vaccines</e2> should be avoided and patients should be advised that vaccinations may be less effective. ",True,advise
MPAG,MPA,16,19,49,51,Interference of <e1>MPAG</e1> hydrolysis may lead to less <e2>MPA</e2> available for absorption.,False,negative
ondansetron,ondansetron,8,18,209,219,"Because <e1>ondansetron</e1> is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes (CYP3A4, CYP2D6, CYP1A2), inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of <e2>ondansetron</e2>. ",False,negative
Phenytoin,Carbamazepine,0,8,11,23,"<e1>Phenytoin</e1>, <e2>Carbamazepine</e2>, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",False,negative
Phenytoin,Rifampicin,0,8,30,39,"<e1>Phenytoin</e1>, Carbamazepine, and <e2>Rifampicin</e2>: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",False,negative
Phenytoin,phenytoin,0,8,100,108,"<e1>Phenytoin</e1>, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., <e2>phenytoin</e2>, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",False,negative
Phenytoin,carbamazepine,0,8,111,123,"<e1>Phenytoin</e1>, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, <e2>carbamazepine</e2>, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",False,negative
Phenytoin,rifampicin,0,8,130,139,"<e1>Phenytoin</e1>, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and <e2>rifampicin</e2>), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",False,negative
Phenytoin,ondansetron,0,8,160,170,"<e1>Phenytoin</e1>, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of <e2>ondansetron</e2> was significantly increased and ondansetron blood concentrations were decreased. ",False,negative
Phenytoin,ondansetron,0,8,204,214,"<e1>Phenytoin</e1>, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and <e2>ondansetron</e2> blood concentrations were decreased. ",False,negative
Carbamazepine,Rifampicin,11,23,30,39,"Phenytoin, <e1>Carbamazepine</e1>, and <e2>Rifampicin</e2>: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",False,negative
Carbamazepine,phenytoin,11,23,100,108,"Phenytoin, <e1>Carbamazepine</e1>, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., <e2>phenytoin</e2>, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",False,negative
Carbamazepine,carbamazepine,11,23,111,123,"Phenytoin, <e1>Carbamazepine</e1>, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, <e2>carbamazepine</e2>, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",False,negative
Carbamazepine,rifampicin,11,23,130,139,"Phenytoin, <e1>Carbamazepine</e1>, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and <e2>rifampicin</e2>), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",False,negative
Carbamazepine,ondansetron,11,23,160,170,"Phenytoin, <e1>Carbamazepine</e1>, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of <e2>ondansetron</e2> was significantly increased and ondansetron blood concentrations were decreased. ",False,negative
Carbamazepine,ondansetron,11,23,204,214,"Phenytoin, <e1>Carbamazepine</e1>, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and <e2>ondansetron</e2> blood concentrations were decreased. ",False,negative
Rifampicin,phenytoin,30,39,100,108,"Phenytoin, Carbamazepine, and <e1>Rifampicin</e1>: In patients treated with potent inducers of CYP3A4 (i.e., <e2>phenytoin</e2>, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",False,negative
Rifampicin,carbamazepine,30,39,111,123,"Phenytoin, Carbamazepine, and <e1>Rifampicin</e1>: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, <e2>carbamazepine</e2>, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",False,negative
Rifampicin,rifampicin,30,39,130,139,"Phenytoin, Carbamazepine, and <e1>Rifampicin</e1>: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and <e2>rifampicin</e2>), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",False,negative
Rifampicin,ondansetron,30,39,160,170,"Phenytoin, Carbamazepine, and <e1>Rifampicin</e1>: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of <e2>ondansetron</e2> was significantly increased and ondansetron blood concentrations were decreased. ",False,negative
Rifampicin,ondansetron,30,39,204,214,"Phenytoin, Carbamazepine, and <e1>Rifampicin</e1>: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and <e2>ondansetron</e2> blood concentrations were decreased. ",False,negative
phenytoin,carbamazepine,100,108,111,123,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., <e1>phenytoin</e1>, <e2>carbamazepine</e2>, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",False,negative
phenytoin,rifampicin,100,108,130,139,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., <e1>phenytoin</e1>, carbamazepine, and <e2>rifampicin</e2>), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",False,negative
phenytoin,ondansetron,100,108,160,170,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., <e1>phenytoin</e1>, carbamazepine, and rifampicin), the clearance of <e2>ondansetron</e2> was significantly increased and ondansetron blood concentrations were decreased. ",True,mechanism
phenytoin,ondansetron,100,108,204,214,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., <e1>phenytoin</e1>, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and <e2>ondansetron</e2> blood concentrations were decreased. ",True,mechanism
carbamazepine,rifampicin,111,123,130,139,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, <e1>carbamazepine</e1>, and <e2>rifampicin</e2>), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",False,negative
carbamazepine,ondansetron,111,123,160,170,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, <e1>carbamazepine</e1>, and rifampicin), the clearance of <e2>ondansetron</e2> was significantly increased and ondansetron blood concentrations were decreased. ",True,mechanism
carbamazepine,ondansetron,111,123,204,214,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, <e1>carbamazepine</e1>, and rifampicin), the clearance of ondansetron was significantly increased and <e2>ondansetron</e2> blood concentrations were decreased. ",True,mechanism
rifampicin,ondansetron,130,139,160,170,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and <e1>rifampicin</e1>), the clearance of <e2>ondansetron</e2> was significantly increased and ondansetron blood concentrations were decreased. ",True,mechanism
rifampicin,ondansetron,130,139,204,214,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and <e1>rifampicin</e1>), the clearance of ondansetron was significantly increased and <e2>ondansetron</e2> blood concentrations were decreased. ",True,mechanism
ondansetron,ondansetron,160,170,204,214,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of <e1>ondansetron</e1> was significantly increased and <e2>ondansetron</e2> blood concentrations were decreased. ",False,negative
ondansetron,Tramadol,66,76,126,133,"However, on the basis of available data, no dosage adjustment for <e1>ondansetron</e1> is recommended for patients on these drugs.1,3  <e2>Tramadol</e2>: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",False,negative
ondansetron,ondansetron,66,76,189,199,"However, on the basis of available data, no dosage adjustment for <e1>ondansetron</e1> is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between <e2>ondansetron</e2> and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",False,negative
ondansetron,tramadol,66,76,205,212,"However, on the basis of available data, no dosage adjustment for <e1>ondansetron</e1> is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and <e2>tramadol</e2> has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",False,negative
ondansetron,ondansetron,66,76,273,283,"However, on the basis of available data, no dosage adjustment for <e1>ondansetron</e1> is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that <e2>ondansetron</e2> may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",False,negative
ondansetron,tramadol,66,76,360,367,"However, on the basis of available data, no dosage adjustment for <e1>ondansetron</e1> is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of <e2>tramadol</e2>.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",False,negative
ondansetron,ondansetron,66,76,472,482,"However, on the basis of available data, no dosage adjustment for <e1>ondansetron</e1> is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by <e2>ondansetron</e2>. ",False,negative
Tramadol,ondansetron,126,133,189,199,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  <e1>Tramadol</e1>: Although no pharmacokinetic drug interaction between <e2>ondansetron</e2> and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",False,negative
Tramadol,tramadol,126,133,205,212,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  <e1>Tramadol</e1>: Although no pharmacokinetic drug interaction between ondansetron and <e2>tramadol</e2> has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",False,negative
Tramadol,ondansetron,126,133,273,283,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  <e1>Tramadol</e1>: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that <e2>ondansetron</e2> may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",False,negative
Tramadol,tramadol,126,133,360,367,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  <e1>Tramadol</e1>: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of <e2>tramadol</e2>.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",False,negative
Tramadol,ondansetron,126,133,472,482,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  <e1>Tramadol</e1>: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by <e2>ondansetron</e2>. ",False,negative
ondansetron,tramadol,189,199,205,212,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between <e1>ondansetron</e1> and <e2>tramadol</e2> has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",False,negative
ondansetron,ondansetron,189,199,273,283,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between <e1>ondansetron</e1> and tramadol has been observed, data from 2 small studies indicate that <e2>ondansetron</e2> may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",False,negative
ondansetron,tramadol,189,199,360,367,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between <e1>ondansetron</e1> and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of <e2>tramadol</e2>.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",False,negative
ondansetron,ondansetron,189,199,472,482,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between <e1>ondansetron</e1> and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by <e2>ondansetron</e2>. ",False,negative
tramadol,ondansetron,205,212,273,283,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and <e1>tramadol</e1> has been observed, data from 2 small studies indicate that <e2>ondansetron</e2> may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",False,negative
tramadol,tramadol,205,212,360,367,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and <e1>tramadol</e1> has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of <e2>tramadol</e2>.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",False,negative
tramadol,ondansetron,205,212,472,482,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and <e1>tramadol</e1> has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by <e2>ondansetron</e2>. ",False,negative
ondansetron,tramadol,273,283,360,367,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that <e1>ondansetron</e1> may be associated with an increase in patient controlled administration of <e2>tramadol</e2>.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",True,effect
ondansetron,ondansetron,273,283,472,482,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that <e1>ondansetron</e1> may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by <e2>ondansetron</e2>. ",False,negative
tramadol,ondansetron,360,367,472,482,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of <e1>tramadol</e1>.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by <e2>ondansetron</e2>. ",False,negative
carmustine,etoposide,11,20,23,31,"In humans, <e1>carmustine</e1>, <e2>etoposide</e2>, and cisplatin do not affect the pharmacokinetics of ondansetron.  ",False,negative
carmustine,cisplatin,11,20,38,46,"In humans, <e1>carmustine</e1>, etoposide, and <e2>cisplatin</e2> do not affect the pharmacokinetics of ondansetron.  ",False,negative
carmustine,ondansetron,11,20,86,96,"In humans, <e1>carmustine</e1>, etoposide, and cisplatin do not affect the pharmacokinetics of <e2>ondansetron</e2>.  ",False,negative
etoposide,cisplatin,23,31,38,46,"In humans, carmustine, <e1>etoposide</e1>, and <e2>cisplatin</e2> do not affect the pharmacokinetics of ondansetron.  ",False,negative
etoposide,ondansetron,23,31,86,96,"In humans, carmustine, <e1>etoposide</e1>, and cisplatin do not affect the pharmacokinetics of <e2>ondansetron</e2>.  ",False,negative
cisplatin,ondansetron,38,46,86,96,"In humans, carmustine, etoposide, and <e1>cisplatin</e1> do not affect the pharmacokinetics of <e2>ondansetron</e2>.  ",False,negative
ondansetron,methotrexate,0,10,55,66,<e1>ondansetron</e1> did not increase blood levels of high-dose <e2>methotrexate</e2>.,False,negative
beta adrenergic aerosol bronchodilators,Alupent,6,44,84,90,Other <e1>beta adrenergic aerosol bronchodilators</e1> should not be used concomitantly with <e2>Alupent</e2>    (metaproterenol sulfate USP) because they may have additive effects. ,True,advise
beta adrenergic aerosol bronchodilators,metaproterenol sulfate,6,44,96,117,Other <e1>beta adrenergic aerosol bronchodilators</e1> should not be used concomitantly with Alupent    (<e2>metaproterenol sulfate</e2> USP) because they may have additive effects. ,True,advise
Alupent,metaproterenol sulfate,84,90,96,117,Other beta adrenergic aerosol bronchodilators should not be used concomitantly with <e1>Alupent</e1>    (<e2>metaproterenol sulfate</e2> USP) because they may have additive effects. ,False,negative
Beta adrenergic agonists,monoamine oxidase inhibitors,0,23,92,119,"<e1>Beta adrenergic agonists</e1> should be administered with caution to patients being treated with <e2>monoamine oxidase inhibitors</e2> or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.",True,advise
Beta adrenergic agonists,tricyclic antidepressants,0,23,124,148,"<e1>Beta adrenergic agonists</e1> should be administered with caution to patients being treated with monoamine oxidase inhibitors or <e2>tricyclic antidepressants</e2>, since the action of beta adrenergic agonists on the vascular system may be potentiated.",True,advise
Beta adrenergic agonists,beta adrenergic agonists,0,23,171,194,"<e1>Beta adrenergic agonists</e1> should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of <e2>beta adrenergic agonists</e2> on the vascular system may be potentiated.",False,negative
monoamine oxidase inhibitors,tricyclic antidepressants,92,119,124,148,"Beta adrenergic agonists should be administered with caution to patients being treated with <e1>monoamine oxidase inhibitors</e1> or <e2>tricyclic antidepressants</e2>, since the action of beta adrenergic agonists on the vascular system may be potentiated.",False,negative
monoamine oxidase inhibitors,beta adrenergic agonists,92,119,171,194,"Beta adrenergic agonists should be administered with caution to patients being treated with <e1>monoamine oxidase inhibitors</e1> or tricyclic antidepressants, since the action of <e2>beta adrenergic agonists</e2> on the vascular system may be potentiated.",False,negative
tricyclic antidepressants,beta adrenergic agonists,124,148,171,194,"Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or <e1>tricyclic antidepressants</e1>, since the action of <e2>beta adrenergic agonists</e2> on the vascular system may be potentiated.",False,negative
Alcohol,XENICAL,0,6,84,90,"<e1>Alcohol</e1>: In a multiple-dose study in 30 normal weight subjects, coadministration of <e2>XENICAL</e2> and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",False,negative
Alcohol,alcohol,0,6,108,114,"<e1>Alcohol</e1>: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of <e2>alcohol</e2> (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",False,negative
Alcohol,alcohol,0,6,188,194,"<e1>Alcohol</e1>: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of <e2>alcohol</e2> pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",False,negative
Alcohol,orlistat,0,6,214,221,"<e1>Alcohol</e1>: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, <e2>orlistat</e2> pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",False,negative
Alcohol,orlistat,0,6,287,294,"<e1>Alcohol</e1>: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to <e2>orlistat</e2>. ",False,negative
XENICAL,alcohol,84,90,108,114,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of <e1>XENICAL</e1> and 40 grams of <e2>alcohol</e2> (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",False,negative
XENICAL,alcohol,84,90,188,194,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of <e1>XENICAL</e1> and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of <e2>alcohol</e2> pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",False,negative
XENICAL,orlistat,84,90,214,221,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of <e1>XENICAL</e1> and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, <e2>orlistat</e2> pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",False,negative
XENICAL,orlistat,84,90,287,294,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of <e1>XENICAL</e1> and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to <e2>orlistat</e2>. ",False,negative
alcohol,alcohol,108,114,188,194,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of <e1>alcohol</e1> (e.g., approximately 3 glasses of wine) did not result in alteration of <e2>alcohol</e2> pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",False,negative
alcohol,orlistat,108,114,214,221,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of <e1>alcohol</e1> (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, <e2>orlistat</e2> pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",False,negative
alcohol,orlistat,108,114,287,294,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of <e1>alcohol</e1> (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to <e2>orlistat</e2>. ",False,negative
alcohol,orlistat,188,194,214,221,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of <e1>alcohol</e1> pharmacokinetics, <e2>orlistat</e2> pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",False,negative
alcohol,orlistat,188,194,287,294,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of <e1>alcohol</e1> pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to <e2>orlistat</e2>. ",False,negative
orlistat,orlistat,214,221,287,294,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, <e1>orlistat</e1> pharmacodynamics (fecal fat excretion), or systemic exposure to <e2>orlistat</e2>. ",False,negative
Cyclosporine,XENICAL,0,11,38,44,<e1>Cyclosporine</e1>: Preliminary data from a <e2>XENICAL</e2> and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ,False,negative
Cyclosporine,cyclosporine,0,11,50,61,<e1>Cyclosporine</e1>: Preliminary data from a XENICAL and <e2>cyclosporine</e2> drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ,False,negative
Cyclosporine,cyclosporine,0,11,110,121,<e1>Cyclosporine</e1>: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in <e2>cyclosporine</e2> plasma levels when XENICAL was coadministered with cyclosporine. ,False,negative
Cyclosporine,XENICAL,0,11,142,148,<e1>Cyclosporine</e1>: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when <e2>XENICAL</e2> was coadministered with cyclosporine. ,False,negative
Cyclosporine,cyclosporine,0,11,174,185,<e1>Cyclosporine</e1>: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with <e2>cyclosporine</e2>. ,False,negative
XENICAL,cyclosporine,38,44,50,61,Cyclosporine: Preliminary data from a <e1>XENICAL</e1> and <e2>cyclosporine</e2> drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ,False,negative
XENICAL,cyclosporine,38,44,110,121,Cyclosporine: Preliminary data from a <e1>XENICAL</e1> and cyclosporine drug interaction study indicate a reduction in <e2>cyclosporine</e2> plasma levels when XENICAL was coadministered with cyclosporine. ,False,negative
XENICAL,XENICAL,38,44,142,148,Cyclosporine: Preliminary data from a <e1>XENICAL</e1> and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when <e2>XENICAL</e2> was coadministered with cyclosporine. ,False,negative
XENICAL,cyclosporine,38,44,174,185,Cyclosporine: Preliminary data from a <e1>XENICAL</e1> and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with <e2>cyclosporine</e2>. ,False,negative
cyclosporine,cyclosporine,50,61,110,121,Cyclosporine: Preliminary data from a XENICAL and <e1>cyclosporine</e1> drug interaction study indicate a reduction in <e2>cyclosporine</e2> plasma levels when XENICAL was coadministered with cyclosporine. ,False,negative
cyclosporine,XENICAL,50,61,142,148,Cyclosporine: Preliminary data from a XENICAL and <e1>cyclosporine</e1> drug interaction study indicate a reduction in cyclosporine plasma levels when <e2>XENICAL</e2> was coadministered with cyclosporine. ,False,negative
cyclosporine,cyclosporine,50,61,174,185,Cyclosporine: Preliminary data from a XENICAL and <e1>cyclosporine</e1> drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with <e2>cyclosporine</e2>. ,False,negative
cyclosporine,XENICAL,110,121,142,148,Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in <e1>cyclosporine</e1> plasma levels when <e2>XENICAL</e2> was coadministered with cyclosporine. ,False,negative
cyclosporine,cyclosporine,110,121,174,185,Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in <e1>cyclosporine</e1> plasma levels when XENICAL was coadministered with <e2>cyclosporine</e2>. ,False,negative
XENICAL,cyclosporine,142,148,174,185,Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when <e1>XENICAL</e1> was coadministered with <e2>cyclosporine</e2>. ,True,mechanism
Digoxin,XENICAL,0,6,48,54,"<e1>Digoxin</e1>: In 12 normal-weight subjects receiving <e2>XENICAL</e2> 120 mg three times a day for 6 days, XENICAL did not alter the pharmacokinetics of a single dose of digoxin. ",False,negative
Digoxin,XENICAL,0,6,93,99,"<e1>Digoxin</e1>: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, <e2>XENICAL</e2> did not alter the pharmacokinetics of a single dose of digoxin. ",False,negative
Digoxin,digoxin,0,6,156,162,"<e1>Digoxin</e1>: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the pharmacokinetics of a single dose of <e2>digoxin</e2>. ",False,negative
XENICAL,XENICAL,48,54,93,99,"Digoxin: In 12 normal-weight subjects receiving <e1>XENICAL</e1> 120 mg three times a day for 6 days, <e2>XENICAL</e2> did not alter the pharmacokinetics of a single dose of digoxin. ",False,negative
XENICAL,digoxin,48,54,156,162,"Digoxin: In 12 normal-weight subjects receiving <e1>XENICAL</e1> 120 mg three times a day for 6 days, XENICAL did not alter the pharmacokinetics of a single dose of <e2>digoxin</e2>. ",False,negative
XENICAL,digoxin,93,99,156,162,"Digoxin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, <e1>XENICAL</e1> did not alter the pharmacokinetics of a single dose of <e2>digoxin</e2>. ",False,negative
Fat-soluble Vitamin Supplements,beta-carotene,0,30,109,121,<e1>Fat-soluble Vitamin Supplements</e1> and Analogues: A pharmacokinetic interaction study showed a 30% reduction in <e2>beta-carotene</e2> supplement absorption when concomitantly administered with XENICAL. ,False,negative
Fat-soluble Vitamin Supplements,XENICAL,0,30,182,188,<e1>Fat-soluble Vitamin Supplements</e1> and Analogues: A pharmacokinetic interaction study showed a 30% reduction in beta-carotene supplement absorption when concomitantly administered with <e2>XENICAL</e2>. ,False,negative
beta-carotene,XENICAL,109,121,182,188,Fat-soluble Vitamin Supplements and Analogues: A pharmacokinetic interaction study showed a 30% reduction in <e1>beta-carotene</e1> supplement absorption when concomitantly administered with <e2>XENICAL</e2>. ,True,mechanism
XENICAL,vitamin E acetate,0,6,34,50,<e1>XENICAL</e1> inhibited absorption of a <e2>vitamin E acetate</e2> supplement by approximately 60%. ,True,mechanism
orlistat,vitamin D,14,21,57,65,"The effect of <e1>orlistat</e1> on the absorption of supplemental <e2>vitamin D</e2>, vitamin A, and nutritionally-derived vitamin K is not known at this time. ",False,negative
orlistat,vitamin A,14,21,68,76,"The effect of <e1>orlistat</e1> on the absorption of supplemental vitamin D, <e2>vitamin A</e2>, and nutritionally-derived vitamin K is not known at this time. ",False,negative
orlistat,vitamin K,14,21,105,113,"The effect of <e1>orlistat</e1> on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived <e2>vitamin K</e2> is not known at this time. ",False,negative
vitamin D,vitamin A,57,65,68,76,"The effect of orlistat on the absorption of supplemental <e1>vitamin D</e1>, <e2>vitamin A</e2>, and nutritionally-derived vitamin K is not known at this time. ",False,negative
vitamin D,vitamin K,57,65,105,113,"The effect of orlistat on the absorption of supplemental <e1>vitamin D</e1>, vitamin A, and nutritionally-derived <e2>vitamin K</e2> is not known at this time. ",False,negative
vitamin A,vitamin K,68,76,105,113,"The effect of orlistat on the absorption of supplemental vitamin D, <e1>vitamin A</e1>, and nutritionally-derived <e2>vitamin K</e2> is not known at this time. ",False,negative
Glyburide,orlistat,0,8,50,57,"<e1>Glyburide</e1>: In 12 normal-weight subjects receiving <e2>orlistat</e2> 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide. ",False,negative
Glyburide,orlistat,0,8,95,102,"<e1>Glyburide</e1>: In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, <e2>orlistat</e2> did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide. ",False,negative
Glyburide,glyburide,0,8,187,195,"<e1>Glyburide</e1>: In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of <e2>glyburide</e2>. ",False,negative
orlistat,orlistat,50,57,95,102,"Glyburide: In 12 normal-weight subjects receiving <e1>orlistat</e1> 80 mg three times a day for 5 days, <e2>orlistat</e2> did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide. ",False,negative
orlistat,glyburide,50,57,187,195,"Glyburide: In 12 normal-weight subjects receiving <e1>orlistat</e1> 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of <e2>glyburide</e2>. ",False,negative
orlistat,glyburide,95,102,187,195,"Glyburide: In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, <e1>orlistat</e1> did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of <e2>glyburide</e2>. ",False,negative
Nifedipine,XENICAL,0,9,78,84,"<e1>Nifedipine</e1> (extended-release tablets): In 17 normal-weight subjects receiving <e2>XENICAL</e2> 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of nifedipine (extended-release tablets). ",False,negative
Nifedipine,XENICAL,0,9,123,129,"<e1>Nifedipine</e1> (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, <e2>XENICAL</e2> did not alter the bioavailability of nifedipine (extended-release tablets). ",False,negative
Nifedipine,nifedipine,0,9,168,177,"<e1>Nifedipine</e1> (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of <e2>nifedipine</e2> (extended-release tablets). ",False,negative
XENICAL,XENICAL,78,84,123,129,"Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving <e1>XENICAL</e1> 120 mg three times a day for 6 days, <e2>XENICAL</e2> did not alter the bioavailability of nifedipine (extended-release tablets). ",False,negative
XENICAL,nifedipine,78,84,168,177,"Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving <e1>XENICAL</e1> 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of <e2>nifedipine</e2> (extended-release tablets). ",False,negative
XENICAL,nifedipine,123,129,168,177,"Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, <e1>XENICAL</e1> did not alter the bioavailability of <e2>nifedipine</e2> (extended-release tablets). ",False,negative
Contraceptives,XENICAL,5,18,75,81,"Oral <e1>Contraceptives</e1>: In 20 normal-weight female subjects, the treatment of <e2>XENICAL</e2> 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral contraceptives. ",False,negative
Contraceptives,contraceptives,5,18,187,200,"Oral <e1>Contraceptives</e1>: In 20 normal-weight female subjects, the treatment of XENICAL 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral <e2>contraceptives</e2>. ",False,negative
XENICAL,contraceptives,75,81,187,200,"Oral Contraceptives: In 20 normal-weight female subjects, the treatment of <e1>XENICAL</e1> 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral <e2>contraceptives</e2>. ",False,negative
Phenytoin,XENICAL,0,8,50,56,"<e1>Phenytoin</e1>: In 12 normal-weight subjects receiving <e2>XENICAL</e2> 120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of phenytoin. ",False,negative
Phenytoin,XENICAL,0,8,95,101,"<e1>Phenytoin</e1>: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days, <e2>XENICAL</e2> did not alter the pharmacokinetics of a single 300-mg dose of phenytoin. ",False,negative
Phenytoin,phenytoin,0,8,165,173,"<e1>Phenytoin</e1>: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of <e2>phenytoin</e2>. ",False,negative
XENICAL,XENICAL,50,56,95,101,"Phenytoin: In 12 normal-weight subjects receiving <e1>XENICAL</e1> 120 mg three times a day for 7 days, <e2>XENICAL</e2> did not alter the pharmacokinetics of a single 300-mg dose of phenytoin. ",False,negative
XENICAL,phenytoin,50,56,165,173,"Phenytoin: In 12 normal-weight subjects receiving <e1>XENICAL</e1> 120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of <e2>phenytoin</e2>. ",False,negative
XENICAL,phenytoin,95,101,165,173,"Phenytoin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days, <e1>XENICAL</e1> did not alter the pharmacokinetics of a single 300-mg dose of <e2>phenytoin</e2>. ",False,negative
Pravastatin,XENICAL,0,10,108,114,"<e1>Pravastatin</e1>: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving <e2>XENICAL</e2> 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of pravastatin. ",False,negative
Pravastatin,XENICAL,0,10,153,159,"<e1>Pravastatin</e1>: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, <e2>XENICAL</e2> did not affect the pharmacokinetics of pravastatin. ",False,negative
Pravastatin,pravastatin,0,10,200,210,"<e1>Pravastatin</e1>: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of <e2>pravastatin</e2>. ",False,negative
XENICAL,XENICAL,108,114,153,159,"Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving <e1>XENICAL</e1> 120 mg three times a day for 6 days, <e2>XENICAL</e2> did not affect the pharmacokinetics of pravastatin. ",False,negative
XENICAL,pravastatin,108,114,200,210,"Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving <e1>XENICAL</e1> 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of <e2>pravastatin</e2>. ",False,negative
XENICAL,pravastatin,153,159,200,210,"Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, <e1>XENICAL</e1> did not affect the pharmacokinetics of <e2>pravastatin</e2>. ",False,negative
Warfarin,XENICAL,0,7,58,64,"<e1>Warfarin</e1>: In 12 normal-weight subjects, administration of <e2>XENICAL</e2> 120 mg three times a day for 16 days did not result in any change in either warfarin pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII). ",False,negative
Warfarin,warfarin,0,7,142,149,"<e1>Warfarin</e1>: In 12 normal-weight subjects, administration of XENICAL 120 mg three times a day for 16 days did not result in any change in either <e2>warfarin</e2> pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII). ",False,negative
XENICAL,warfarin,58,64,142,149,"Warfarin: In 12 normal-weight subjects, administration of <e1>XENICAL</e1> 120 mg three times a day for 16 days did not result in any change in either <e2>warfarin</e2> pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII). ",False,negative
XENICAL,XENICAL,101,107,179,185,"Although undercarboxylated osteocalcin, a marker of vitamin K nutritional status, was unaltered with <e1>XENICAL</e1> administration, vitamin K levels tended to decline in subjects taking <e2>XENICAL</e2>. ",False,negative
vitamin K,XENICAL,14,22,57,63,"Therefore, as <e1>vitamin K</e1> absorption may be decreased with <e2>XENICAL</e2>, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.",True,mechanism
vitamin K,warfarin,14,22,102,109,"Therefore, as <e1>vitamin K</e1> absorption may be decreased with XENICAL, patients on chronic stable doses of <e2>warfarin</e2> who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.",False,negative
vitamin K,XENICAL,14,22,130,136,"Therefore, as <e1>vitamin K</e1> absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed <e2>XENICAL</e2> should be monitored closely for changes in coagulation parameters.",False,negative
XENICAL,warfarin,57,63,102,109,"Therefore, as vitamin K absorption may be decreased with <e1>XENICAL</e1>, patients on chronic stable doses of <e2>warfarin</e2> who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.",False,negative
XENICAL,XENICAL,57,63,130,136,"Therefore, as vitamin K absorption may be decreased with <e1>XENICAL</e1>, patients on chronic stable doses of warfarin who are prescribed <e2>XENICAL</e2> should be monitored closely for changes in coagulation parameters.",False,negative
warfarin,XENICAL,102,109,130,136,"Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of <e1>warfarin</e1> who are prescribed <e2>XENICAL</e2> should be monitored closely for changes in coagulation parameters.",True,advise
Tetracycline,antibiotic,0,11,31,40,"<e1>Tetracycline</e1>, a bacteriostatic <e2>antibiotic</e2>, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.",False,negative
Tetracycline,penicillin,0,11,85,94,"<e1>Tetracycline</e1>, a bacteriostatic antibiotic, may antagonize the bactericidal effect of <e2>penicillin</e2> and concurrent use of these drugs should be avoided.",True,effect
antibiotic,penicillin,31,40,85,94,"Tetracycline, a bacteriostatic <e1>antibiotic</e1>, may antagonize the bactericidal effect of <e2>penicillin</e2> and concurrent use of these drugs should be avoided.",False,negative
ELOXATIN,5-FU,48,55,72,75,No pharmacokinetic interaction between 85 mg/m2 <e1>ELOXATIN</e1> and infusional <e2>5-FU</e2> has been observed in patients treated every 2 weeks. ,False,negative
5-FU,ELOXATIN,13,16,104,111,Increases of <e1>5-FU</e1> plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2 <e2>ELOXATIN</e2> dosed every 3 weeks. ,True,mechanism
Anticoagulants,Anabolic steroids,0,13,15,31,<e1>Anticoagulants</e1> <e2>Anabolic steroids</e2> may increase sensitivity to oral anticoagulants. ,False,negative
Anticoagulants,anticoagulants,0,13,66,79,<e1>Anticoagulants</e1> Anabolic steroids may increase sensitivity to oral <e2>anticoagulants</e2>. ,False,negative
Anabolic steroids,anticoagulants,15,31,66,79,Anticoagulants <e1>Anabolic steroids</e1> may increase sensitivity to oral <e2>anticoagulants</e2>. ,True,effect
Warfarin,oxandrolone,0,7,31,41,"<e1>Warfarin</e1>: A multidose study of <e2>oxandrolone</e2>, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. ",False,negative
Warfarin,warfarin,0,7,117,124,"<e1>Warfarin</e1>: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with <e2>warfarin</e2>, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. ",False,negative
Warfarin,S-warfarin,0,7,158,167,"<e1>Warfarin</e1>: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in <e2>S-warfarin</e2> half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. ",False,negative
Warfarin,R-warfarin,0,7,257,266,"<e1>Warfarin</e1>: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in <e2>R-warfarin</e2> half-life and AUC were also detected. ",False,negative
oxandrolone,warfarin,31,41,117,124,"Warfarin: A multidose study of <e1>oxandrolone</e1>, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with <e2>warfarin</e2>, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. ",True,mechanism
oxandrolone,S-warfarin,31,41,158,167,"Warfarin: A multidose study of <e1>oxandrolone</e1>, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in <e2>S-warfarin</e2> half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. ",False,negative
oxandrolone,R-warfarin,31,41,257,266,"Warfarin: A multidose study of <e1>oxandrolone</e1>, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in <e2>R-warfarin</e2> half-life and AUC were also detected. ",False,negative
warfarin,S-warfarin,117,124,158,167,"Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with <e1>warfarin</e1>, resulted in a mean increase in <e2>S-warfarin</e2> half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. ",False,negative
warfarin,R-warfarin,117,124,257,266,"Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with <e1>warfarin</e1>, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in <e2>R-warfarin</e2> half-life and AUC were also detected. ",False,negative
S-warfarin,R-warfarin,158,167,257,266,"Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in <e1>S-warfarin</e1> half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in <e2>R-warfarin</e2> half-life and AUC were also detected. ",False,negative
warfarin,warfarin,32,39,113,120,"A 5.5-fold decrease in the mean <e1>warfarin</e1> dose from 6.13 mg/day to 1.13 mg/day (approximately 80-85% reduction of <e2>warfarin</e2> dose), was necessary to maintain a target INR of 1.5. ",False,negative
oxandrolone,warfarin,5,15,84,91,"When <e1>oxandrolone</e1> therapy is initiated in a patient already receiving treatment with <e2>warfarin</e2>, the INR or prothrombin time (PT) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target INR or PT has been achieved. ",True,advise
oxandrolone,warfarin,5,15,171,178,"When <e1>oxandrolone</e1> therapy is initiated in a patient already receiving treatment with warfarin, the INR or prothrombin time (PT) should be monitored closely and the dose of <e2>warfarin</e2> adjusted as necessary until a stable target INR or PT has been achieved. ",False,negative
warfarin,warfarin,84,91,171,178,"When oxandrolone therapy is initiated in a patient already receiving treatment with <e1>warfarin</e1>, the INR or prothrombin time (PT) should be monitored closely and the dose of <e2>warfarin</e2> adjusted as necessary until a stable target INR or PT has been achieved. ",False,negative
warfarin,oxandrolone,106,113,160,170,"Furthermore, in patients receiving both drugs, careful monitoring of the INR or PT, and adjustment of the <e1>warfarin</e1> dosage if indicated are recommended when the <e2>oxandrolone</e2> dose is changed or discontinued. ",True,advise
hypoglycemic agents,Oxandrolone,5,23,25,35,Oral <e1>hypoglycemic agents</e1> <e2>Oxandrolone</e2> may inhibit the metabolism of oral hypoglycemic agents. ,False,negative
hypoglycemic agents,hypoglycemic agents,5,23,72,90,Oral <e1>hypoglycemic agents</e1> Oxandrolone may inhibit the metabolism of oral <e2>hypoglycemic agents</e2>. ,False,negative
Oxandrolone,hypoglycemic agents,25,35,72,90,Oral hypoglycemic agents <e1>Oxandrolone</e1> may inhibit the metabolism of oral <e2>hypoglycemic agents</e2>. ,True,mechanism
Adrenal steroids,ACTH,0,15,20,23,"<e1>Adrenal steroids</e1> or <e2>ACTH</e2> In patients with edema, concomitant administration with adrenal cortical steroids or ACTH may increase the edema. ",False,negative
Adrenal steroids,adrenal cortical steroids,0,15,81,105,"<e1>Adrenal steroids</e1> or ACTH In patients with edema, concomitant administration with <e2>adrenal cortical steroids</e2> or ACTH may increase the edema. ",False,negative
Adrenal steroids,ACTH,0,15,110,113,"<e1>Adrenal steroids</e1> or ACTH In patients with edema, concomitant administration with adrenal cortical steroids or <e2>ACTH</e2> may increase the edema. ",False,negative
ACTH,adrenal cortical steroids,20,23,81,105,"Adrenal steroids or <e1>ACTH</e1> In patients with edema, concomitant administration with <e2>adrenal cortical steroids</e2> or ACTH may increase the edema. ",False,negative
ACTH,ACTH,20,23,110,113,"Adrenal steroids or <e1>ACTH</e1> In patients with edema, concomitant administration with adrenal cortical steroids or <e2>ACTH</e2> may increase the edema. ",False,negative
adrenal cortical steroids,ACTH,81,105,110,113,"Adrenal steroids or ACTH In patients with edema, concomitant administration with <e1>adrenal cortical steroids</e1> or <e2>ACTH</e2> may increase the edema. ",False,negative
oxybutynin,anticholinergic drugs,23,32,45,65,"The concomitant use of <e1>oxybutynin</e1> with other <e2>anticholinergic drugs</e2> or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects. ",True,effect
oxybutynin chloride,DITROPAN XL,5,23,85,95,"Mean <e1>oxybutynin chloride</e1> plasma concentrations were approximately 2 fold higher when <e2>DITROPAN XL</e2> was administered with ketoconazole, a potent CYP3A4 inhibitor. ",False,negative
oxybutynin chloride,ketoconazole,5,23,119,130,"Mean <e1>oxybutynin chloride</e1> plasma concentrations were approximately 2 fold higher when DITROPAN XL was administered with <e2>ketoconazole</e2>, a potent CYP3A4 inhibitor. ",False,negative
DITROPAN XL,ketoconazole,85,95,119,130,"Mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when <e1>DITROPAN XL</e1> was administered with <e2>ketoconazole</e2>, a potent CYP3A4 inhibitor. ",True,mechanism
antimycotic agents,itraconazole,67,84,93,104,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as <e1>antimycotic agents</e1> (e.g., <e2>itraconazole</e2> and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",False,negative
antimycotic agents,miconazole,67,84,110,119,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as <e1>antimycotic agents</e1> (e.g., itraconazole and <e2>miconazole</e2>) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",False,negative
antimycotic agents,macrolide antibiotics,67,84,125,145,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as <e1>antimycotic agents</e1> (e.g., itraconazole and miconazole) or <e2>macrolide antibiotics</e2> (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",False,negative
antimycotic agents,erythromycin,67,84,154,165,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as <e1>antimycotic agents</e1> (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., <e2>erythromycin</e2> and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",False,negative
antimycotic agents,clarithromycin,67,84,171,184,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as <e1>antimycotic agents</e1> (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and <e2>clarithromycin</e2>), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",False,negative
antimycotic agents,oxybutynin,67,84,198,207,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as <e1>antimycotic agents</e1> (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter <e2>oxybutynin</e2> mean pharmacokinetic parameters (i.e., Cmax and AUC). ",True,mechanism
itraconazole,miconazole,93,104,110,119,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., <e1>itraconazole</e1> and <e2>miconazole</e2>) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",False,negative
itraconazole,macrolide antibiotics,93,104,125,145,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., <e1>itraconazole</e1> and miconazole) or <e2>macrolide antibiotics</e2> (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",False,negative
itraconazole,erythromycin,93,104,154,165,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., <e1>itraconazole</e1> and miconazole) or macrolide antibiotics (e.g., <e2>erythromycin</e2> and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",False,negative
itraconazole,clarithromycin,93,104,171,184,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., <e1>itraconazole</e1> and miconazole) or macrolide antibiotics (e.g., erythromycin and <e2>clarithromycin</e2>), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",False,negative
itraconazole,oxybutynin,93,104,198,207,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., <e1>itraconazole</e1> and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter <e2>oxybutynin</e2> mean pharmacokinetic parameters (i.e., Cmax and AUC). ",True,mechanism
miconazole,macrolide antibiotics,110,119,125,145,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and <e1>miconazole</e1>) or <e2>macrolide antibiotics</e2> (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",False,negative
miconazole,erythromycin,110,119,154,165,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and <e1>miconazole</e1>) or macrolide antibiotics (e.g., <e2>erythromycin</e2> and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",False,negative
miconazole,clarithromycin,110,119,171,184,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and <e1>miconazole</e1>) or macrolide antibiotics (e.g., erythromycin and <e2>clarithromycin</e2>), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",False,negative
miconazole,oxybutynin,110,119,198,207,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and <e1>miconazole</e1>) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter <e2>oxybutynin</e2> mean pharmacokinetic parameters (i.e., Cmax and AUC). ",True,mechanism
macrolide antibiotics,erythromycin,125,145,154,165,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or <e1>macrolide antibiotics</e1> (e.g., <e2>erythromycin</e2> and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",False,negative
macrolide antibiotics,clarithromycin,125,145,171,184,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or <e1>macrolide antibiotics</e1> (e.g., erythromycin and <e2>clarithromycin</e2>), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",False,negative
macrolide antibiotics,oxybutynin,125,145,198,207,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or <e1>macrolide antibiotics</e1> (e.g., erythromycin and clarithromycin), may alter <e2>oxybutynin</e2> mean pharmacokinetic parameters (i.e., Cmax and AUC). ",True,mechanism
erythromycin,clarithromycin,154,165,171,184,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., <e1>erythromycin</e1> and <e2>clarithromycin</e2>), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",False,negative
erythromycin,oxybutynin,154,165,198,207,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., <e1>erythromycin</e1> and clarithromycin), may alter <e2>oxybutynin</e2> mean pharmacokinetic parameters (i.e., Cmax and AUC). ",True,mechanism
clarithromycin,oxybutynin,171,184,198,207,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and <e1>clarithromycin</e1>), may alter <e2>oxybutynin</e2> mean pharmacokinetic parameters (i.e., Cmax and AUC). ",True,mechanism
antacid,antacid,24,30,42,48,"Concurrent ingestion of <e1>antacid</e1> (20 mL of <e2>antacid</e2> containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",False,negative
antacid,aluminum hydroxide,24,30,61,78,"Concurrent ingestion of <e1>antacid</e1> (20 mL of antacid containing <e2>aluminum hydroxide</e2>, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",False,negative
antacid,magnesium hydroxide,24,30,81,99,"Concurrent ingestion of <e1>antacid</e1> (20 mL of antacid containing aluminum hydroxide, <e2>magnesium hydroxide</e2>, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",False,negative
antacid,simethicone,24,30,106,116,"Concurrent ingestion of <e1>antacid</e1> (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and <e2>simethicone</e2>) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",False,negative
antacid,oxybutynin,24,30,164,173,"Concurrent ingestion of <e1>antacid</e1> (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of <e2>oxybutynin</e2> or desethyloxybutynin.    ",False,negative
antacid,desethyloxybutynin,24,30,178,195,"Concurrent ingestion of <e1>antacid</e1> (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or <e2>desethyloxybutynin</e2>.    ",False,negative
antacid,aluminum hydroxide,42,48,61,78,"Concurrent ingestion of antacid (20 mL of <e1>antacid</e1> containing <e2>aluminum hydroxide</e2>, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",False,negative
antacid,magnesium hydroxide,42,48,81,99,"Concurrent ingestion of antacid (20 mL of <e1>antacid</e1> containing aluminum hydroxide, <e2>magnesium hydroxide</e2>, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",False,negative
antacid,simethicone,42,48,106,116,"Concurrent ingestion of antacid (20 mL of <e1>antacid</e1> containing aluminum hydroxide, magnesium hydroxide, and <e2>simethicone</e2>) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",False,negative
antacid,oxybutynin,42,48,164,173,"Concurrent ingestion of antacid (20 mL of <e1>antacid</e1> containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of <e2>oxybutynin</e2> or desethyloxybutynin.    ",False,negative
antacid,desethyloxybutynin,42,48,178,195,"Concurrent ingestion of antacid (20 mL of <e1>antacid</e1> containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or <e2>desethyloxybutynin</e2>.    ",False,negative
aluminum hydroxide,magnesium hydroxide,61,78,81,99,"Concurrent ingestion of antacid (20 mL of antacid containing <e1>aluminum hydroxide</e1>, <e2>magnesium hydroxide</e2>, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",False,negative
aluminum hydroxide,simethicone,61,78,106,116,"Concurrent ingestion of antacid (20 mL of antacid containing <e1>aluminum hydroxide</e1>, magnesium hydroxide, and <e2>simethicone</e2>) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",False,negative
aluminum hydroxide,oxybutynin,61,78,164,173,"Concurrent ingestion of antacid (20 mL of antacid containing <e1>aluminum hydroxide</e1>, magnesium hydroxide, and simethicone) did not significantly affect the exposure of <e2>oxybutynin</e2> or desethyloxybutynin.    ",False,negative
aluminum hydroxide,desethyloxybutynin,61,78,178,195,"Concurrent ingestion of antacid (20 mL of antacid containing <e1>aluminum hydroxide</e1>, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or <e2>desethyloxybutynin</e2>.    ",False,negative
magnesium hydroxide,simethicone,81,99,106,116,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, <e1>magnesium hydroxide</e1>, and <e2>simethicone</e2>) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",False,negative
magnesium hydroxide,oxybutynin,81,99,164,173,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, <e1>magnesium hydroxide</e1>, and simethicone) did not significantly affect the exposure of <e2>oxybutynin</e2> or desethyloxybutynin.    ",False,negative
magnesium hydroxide,desethyloxybutynin,81,99,178,195,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, <e1>magnesium hydroxide</e1>, and simethicone) did not significantly affect the exposure of oxybutynin or <e2>desethyloxybutynin</e2>.    ",False,negative
simethicone,oxybutynin,106,116,164,173,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and <e1>simethicone</e1>) did not significantly affect the exposure of <e2>oxybutynin</e2> or desethyloxybutynin.    ",False,negative
simethicone,desethyloxybutynin,106,116,178,195,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and <e1>simethicone</e1>) did not significantly affect the exposure of oxybutynin or <e2>desethyloxybutynin</e2>.    ",False,negative
oxybutynin,desethyloxybutynin,164,173,178,195,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of <e1>oxybutynin</e1> or <e2>desethyloxybutynin</e2>.    ",False,negative
oxycodone hydrochloride,CNS depressants,30,52,89,103,The CNS depressant effects of <e1>oxycodone hydrochloride</e1> may be additive with that of other <e2>CNS depressants</e2>..,True,effect
CNS depressants,sedatives,29,43,55,63,"The concomitant use of other <e1>CNS depressants</e1> including <e2>sedatives</e2>, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",False,negative
CNS depressants,hypnotics,29,43,66,74,"The concomitant use of other <e1>CNS depressants</e1> including sedatives, <e2>hypnotics</e2>, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",False,negative
CNS depressants,tranquilizers,29,43,77,89,"The concomitant use of other <e1>CNS depressants</e1> including sedatives, hypnotics, <e2>tranquilizers</e2>, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",False,negative
CNS depressants,anesthetics,29,43,100,110,"The concomitant use of other <e1>CNS depressants</e1> including sedatives, hypnotics, tranquilizers, general <e2>anesthetics</e2>, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",False,negative
CNS depressants,phenothiazines,29,43,113,126,"The concomitant use of other <e1>CNS depressants</e1> including sedatives, hypnotics, tranquilizers, general anesthetics, <e2>phenothiazines</e2>, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",False,negative
CNS depressants,opioids,29,43,135,141,"The concomitant use of other <e1>CNS depressants</e1> including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other <e2>opioids</e2>, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",False,negative
CNS depressants,tricyclic antidepressants,29,43,144,168,"The concomitant use of other <e1>CNS depressants</e1> including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, <e2>tricyclic antidepressants</e2>, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",False,negative
CNS depressants,monoamine oxidase (MAO) inhibitors,29,43,171,204,"The concomitant use of other <e1>CNS depressants</e1> including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, <e2>monoamine oxidase (MAO) inhibitors</e2>, and alcohol may produce additive CNS depressant effects. ",False,negative
CNS depressants,alcohol,29,43,211,217,"The concomitant use of other <e1>CNS depressants</e1> including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and <e2>alcohol</e2> may produce additive CNS depressant effects. ",False,negative
sedatives,hypnotics,55,63,66,74,"The concomitant use of other CNS depressants including <e1>sedatives</e1>, <e2>hypnotics</e2>, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",False,negative
sedatives,tranquilizers,55,63,77,89,"The concomitant use of other CNS depressants including <e1>sedatives</e1>, hypnotics, <e2>tranquilizers</e2>, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",False,negative
sedatives,anesthetics,55,63,100,110,"The concomitant use of other CNS depressants including <e1>sedatives</e1>, hypnotics, tranquilizers, general <e2>anesthetics</e2>, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",False,negative
sedatives,phenothiazines,55,63,113,126,"The concomitant use of other CNS depressants including <e1>sedatives</e1>, hypnotics, tranquilizers, general anesthetics, <e2>phenothiazines</e2>, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",False,negative
sedatives,opioids,55,63,135,141,"The concomitant use of other CNS depressants including <e1>sedatives</e1>, hypnotics, tranquilizers, general anesthetics, phenothiazines, other <e2>opioids</e2>, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",False,negative
sedatives,tricyclic antidepressants,55,63,144,168,"The concomitant use of other CNS depressants including <e1>sedatives</e1>, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, <e2>tricyclic antidepressants</e2>, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",False,negative
sedatives,monoamine oxidase (MAO) inhibitors,55,63,171,204,"The concomitant use of other CNS depressants including <e1>sedatives</e1>, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, <e2>monoamine oxidase (MAO) inhibitors</e2>, and alcohol may produce additive CNS depressant effects. ",False,negative
sedatives,alcohol,55,63,211,217,"The concomitant use of other CNS depressants including <e1>sedatives</e1>, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and <e2>alcohol</e2> may produce additive CNS depressant effects. ",False,negative
hypnotics,tranquilizers,66,74,77,89,"The concomitant use of other CNS depressants including sedatives, <e1>hypnotics</e1>, <e2>tranquilizers</e2>, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",False,negative
hypnotics,anesthetics,66,74,100,110,"The concomitant use of other CNS depressants including sedatives, <e1>hypnotics</e1>, tranquilizers, general <e2>anesthetics</e2>, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",False,negative
hypnotics,phenothiazines,66,74,113,126,"The concomitant use of other CNS depressants including sedatives, <e1>hypnotics</e1>, tranquilizers, general anesthetics, <e2>phenothiazines</e2>, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",False,negative
hypnotics,opioids,66,74,135,141,"The concomitant use of other CNS depressants including sedatives, <e1>hypnotics</e1>, tranquilizers, general anesthetics, phenothiazines, other <e2>opioids</e2>, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",False,negative
hypnotics,tricyclic antidepressants,66,74,144,168,"The concomitant use of other CNS depressants including sedatives, <e1>hypnotics</e1>, tranquilizers, general anesthetics, phenothiazines, other opioids, <e2>tricyclic antidepressants</e2>, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",False,negative
hypnotics,monoamine oxidase (MAO) inhibitors,66,74,171,204,"The concomitant use of other CNS depressants including sedatives, <e1>hypnotics</e1>, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, <e2>monoamine oxidase (MAO) inhibitors</e2>, and alcohol may produce additive CNS depressant effects. ",False,negative
hypnotics,alcohol,66,74,211,217,"The concomitant use of other CNS depressants including sedatives, <e1>hypnotics</e1>, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and <e2>alcohol</e2> may produce additive CNS depressant effects. ",False,negative
tranquilizers,anesthetics,77,89,100,110,"The concomitant use of other CNS depressants including sedatives, hypnotics, <e1>tranquilizers</e1>, general <e2>anesthetics</e2>, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",False,negative
tranquilizers,phenothiazines,77,89,113,126,"The concomitant use of other CNS depressants including sedatives, hypnotics, <e1>tranquilizers</e1>, general anesthetics, <e2>phenothiazines</e2>, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",False,negative
tranquilizers,opioids,77,89,135,141,"The concomitant use of other CNS depressants including sedatives, hypnotics, <e1>tranquilizers</e1>, general anesthetics, phenothiazines, other <e2>opioids</e2>, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",False,negative
tranquilizers,tricyclic antidepressants,77,89,144,168,"The concomitant use of other CNS depressants including sedatives, hypnotics, <e1>tranquilizers</e1>, general anesthetics, phenothiazines, other opioids, <e2>tricyclic antidepressants</e2>, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",False,negative
tranquilizers,monoamine oxidase (MAO) inhibitors,77,89,171,204,"The concomitant use of other CNS depressants including sedatives, hypnotics, <e1>tranquilizers</e1>, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, <e2>monoamine oxidase (MAO) inhibitors</e2>, and alcohol may produce additive CNS depressant effects. ",False,negative
tranquilizers,alcohol,77,89,211,217,"The concomitant use of other CNS depressants including sedatives, hypnotics, <e1>tranquilizers</e1>, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and <e2>alcohol</e2> may produce additive CNS depressant effects. ",False,negative
anesthetics,phenothiazines,100,110,113,126,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general <e1>anesthetics</e1>, <e2>phenothiazines</e2>, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",False,negative
anesthetics,opioids,100,110,135,141,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general <e1>anesthetics</e1>, phenothiazines, other <e2>opioids</e2>, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",False,negative
anesthetics,tricyclic antidepressants,100,110,144,168,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general <e1>anesthetics</e1>, phenothiazines, other opioids, <e2>tricyclic antidepressants</e2>, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",False,negative
anesthetics,monoamine oxidase (MAO) inhibitors,100,110,171,204,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general <e1>anesthetics</e1>, phenothiazines, other opioids, tricyclic antidepressants, <e2>monoamine oxidase (MAO) inhibitors</e2>, and alcohol may produce additive CNS depressant effects. ",False,negative
anesthetics,alcohol,100,110,211,217,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general <e1>anesthetics</e1>, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and <e2>alcohol</e2> may produce additive CNS depressant effects. ",False,negative
phenothiazines,opioids,113,126,135,141,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, <e1>phenothiazines</e1>, other <e2>opioids</e2>, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",False,negative
phenothiazines,tricyclic antidepressants,113,126,144,168,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, <e1>phenothiazines</e1>, other opioids, <e2>tricyclic antidepressants</e2>, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",False,negative
phenothiazines,monoamine oxidase (MAO) inhibitors,113,126,171,204,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, <e1>phenothiazines</e1>, other opioids, tricyclic antidepressants, <e2>monoamine oxidase (MAO) inhibitors</e2>, and alcohol may produce additive CNS depressant effects. ",False,negative
phenothiazines,alcohol,113,126,211,217,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, <e1>phenothiazines</e1>, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and <e2>alcohol</e2> may produce additive CNS depressant effects. ",False,negative
opioids,tricyclic antidepressants,135,141,144,168,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other <e1>opioids</e1>, <e2>tricyclic antidepressants</e2>, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",False,negative
opioids,monoamine oxidase (MAO) inhibitors,135,141,171,204,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other <e1>opioids</e1>, tricyclic antidepressants, <e2>monoamine oxidase (MAO) inhibitors</e2>, and alcohol may produce additive CNS depressant effects. ",False,negative
opioids,alcohol,135,141,211,217,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other <e1>opioids</e1>, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and <e2>alcohol</e2> may produce additive CNS depressant effects. ",False,negative
tricyclic antidepressants,monoamine oxidase (MAO) inhibitors,144,168,171,204,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, <e1>tricyclic antidepressants</e1>, <e2>monoamine oxidase (MAO) inhibitors</e2>, and alcohol may produce additive CNS depressant effects. ",False,negative
tricyclic antidepressants,alcohol,144,168,211,217,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, <e1>tricyclic antidepressants</e1>, monoamine oxidase (MAO) inhibitors, and <e2>alcohol</e2> may produce additive CNS depressant effects. ",False,negative
monoamine oxidase (MAO) inhibitors,alcohol,171,204,211,217,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, <e1>monoamine oxidase (MAO) inhibitors</e1>, and <e2>alcohol</e2> may produce additive CNS depressant effects. ",False,negative
Anticholinergics,opioid analgesics,0,15,96,112,"<e1>Anticholinergics</e1> or other medications with anticholinergic activity when used concurrently with <e2>opioid analgesics</e2> may result in increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. ",True,effect
oxymorphone,propofol,74,84,104,111,It has been reported that the incidence of bradycardia was increased when <e1>oxymorphone</e1> was combined with <e2>propofol</e2> for induction of anesthesia. ,True,effect
cimetidine,opioid analgesics,143,152,159,175,"In addition, CNS toxicity has been reported (confusion, disorientation, respiratory depression, apnea, seizures) following coadministration of <e1>cimetidine</e1> with <e2>opioid analgesics</e2>; ",True,effect
INVEGA,Paliperidone,14,19,46,57,Potential for <e1>INVEGA</e1>    to Affect Other Drugs <e2>Paliperidone</e2> is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. ,False,negative
paliperidone,INVEGA,33,44,47,52,"Given the primary CNS effects of <e1>paliperidone</e1>, <e2>INVEGA</e2>    should be used with caution in combination with other centrally acting drugs and alcohol. ",False,negative
paliperidone,centrally acting drugs,33,44,111,132,"Given the primary CNS effects of <e1>paliperidone</e1>, INVEGA    should be used with caution in combination with other <e2>centrally acting drugs</e2> and alcohol. ",True,advise
paliperidone,alcohol,33,44,138,144,"Given the primary CNS effects of <e1>paliperidone</e1>, INVEGA    should be used with caution in combination with other centrally acting drugs and <e2>alcohol</e2>. ",True,advise
INVEGA,centrally acting drugs,47,52,111,132,"Given the primary CNS effects of paliperidone, <e1>INVEGA</e1>    should be used with caution in combination with other <e2>centrally acting drugs</e2> and alcohol. ",True,advise
INVEGA,alcohol,47,52,138,144,"Given the primary CNS effects of paliperidone, <e1>INVEGA</e1>    should be used with caution in combination with other centrally acting drugs and <e2>alcohol</e2>. ",True,advise
centrally acting drugs,alcohol,111,132,138,144,"Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other <e1>centrally acting drugs</e1> and <e2>alcohol</e2>. ",False,negative
Paliperidone,levodopa,0,11,42,49,<e1>Paliperidone</e1> may antagonize the effect of <e2>levodopa</e2> and other dopamine agonists. ,True,effect
Paliperidone,dopamine agonists,0,11,61,77,<e1>Paliperidone</e1> may antagonize the effect of levodopa and other <e2>dopamine agonists</e2>. ,True,effect
levodopa,dopamine agonists,42,49,61,77,Paliperidone may antagonize the effect of <e1>levodopa</e1> and other <e2>dopamine agonists</e2>. ,False,negative
INVEGA,Paliperidone,36,41,46,57,"Potential for Other Drugs to Affect <e1>INVEGA</e1>    <e2>Paliperidone</e2> is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely. ",False,negative
pantoprazole,theophylline,53,64,154,165,"Based on studies evaluating possible interactions of <e1>pantoprazole</e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: <e2>theophylline</e2>, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
pantoprazole,cisapride,53,64,168,176,"Based on studies evaluating possible interactions of <e1>pantoprazole</e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e2>cisapride</e2>, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
pantoprazole,antipyrine,53,64,179,188,"Based on studies evaluating possible interactions of <e1>pantoprazole</e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e2>antipyrine</e2>, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
pantoprazole,caffeine,53,64,191,198,"Based on studies evaluating possible interactions of <e1>pantoprazole</e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e2>caffeine</e2>, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
pantoprazole,carbamazepine,53,64,201,213,"Based on studies evaluating possible interactions of <e1>pantoprazole</e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e2>carbamazepine</e2>, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
pantoprazole,diazepam,53,64,216,223,"Based on studies evaluating possible interactions of <e1>pantoprazole</e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, <e2>diazepam</e2> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
pantoprazole,desmethyldiazepam,53,64,253,269,"Based on studies evaluating possible interactions of <e1>pantoprazole</e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e2>desmethyldiazepam</e2>), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
pantoprazole,diclofenac,53,64,273,282,"Based on studies evaluating possible interactions of <e1>pantoprazole</e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e2>diclofenac</e2>, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
pantoprazole,naproxen,53,64,285,292,"Based on studies evaluating possible interactions of <e1>pantoprazole</e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e2>naproxen</e2>, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
pantoprazole,piroxicam,53,64,295,303,"Based on studies evaluating possible interactions of <e1>pantoprazole</e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e2>piroxicam</e2>, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
pantoprazole,digoxin,53,64,306,312,"Based on studies evaluating possible interactions of <e1>pantoprazole</e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e2>digoxin</e2>, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
pantoprazole,ethanol,53,64,315,321,"Based on studies evaluating possible interactions of <e1>pantoprazole</e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, <e2>ethanol</e2>, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
pantoprazole,glyburide,53,64,324,332,"Based on studies evaluating possible interactions of <e1>pantoprazole</e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, <e2>glyburide</e2>, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
pantoprazole,contraceptive,53,64,343,355,"Based on studies evaluating possible interactions of <e1>pantoprazole</e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral <e2>contraceptive</e2> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
pantoprazole,levonorgestrel,53,64,358,371,"Based on studies evaluating possible interactions of <e1>pantoprazole</e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (<e2>levonorgestrel</e2>/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
pantoprazole,ethinyl estradiol,53,64,373,389,"Based on studies evaluating possible interactions of <e1>pantoprazole</e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/<e2>ethinyl estradiol</e2>), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
pantoprazole,metoprolol,53,64,393,402,"Based on studies evaluating possible interactions of <e1>pantoprazole</e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e2>metoprolol</e2>, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
pantoprazole,nifedipine,53,64,405,414,"Based on studies evaluating possible interactions of <e1>pantoprazole</e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e2>nifedipine</e2>, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
pantoprazole,phenytoin,53,64,417,425,"Based on studies evaluating possible interactions of <e1>pantoprazole</e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e2>phenytoin</e2>, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
pantoprazole,warfarin,53,64,428,435,"Based on studies evaluating possible interactions of <e1>pantoprazole</e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e2>warfarin</e2>, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
pantoprazole,midazolam,53,64,438,446,"Based on studies evaluating possible interactions of <e1>pantoprazole</e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, <e2>midazolam</e2>, clarithromycin, metronidazole, or amoxicillin. ",False,negative
pantoprazole,clarithromycin,53,64,449,462,"Based on studies evaluating possible interactions of <e1>pantoprazole</e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, <e2>clarithromycin</e2>, metronidazole, or amoxicillin. ",False,negative
pantoprazole,metronidazole,53,64,465,477,"Based on studies evaluating possible interactions of <e1>pantoprazole</e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, <e2>metronidazole</e2>, or amoxicillin. ",False,negative
pantoprazole,amoxicillin,53,64,483,493,"Based on studies evaluating possible interactions of <e1>pantoprazole</e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or <e2>amoxicillin</e2>. ",False,negative
theophylline,cisapride,154,165,168,176,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1>theophylline</e1>, <e2>cisapride</e2>, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
theophylline,antipyrine,154,165,179,188,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1>theophylline</e1>, cisapride, <e2>antipyrine</e2>, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
theophylline,caffeine,154,165,191,198,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1>theophylline</e1>, cisapride, antipyrine, <e2>caffeine</e2>, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
theophylline,carbamazepine,154,165,201,213,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1>theophylline</e1>, cisapride, antipyrine, caffeine, <e2>carbamazepine</e2>, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
theophylline,diazepam,154,165,216,223,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1>theophylline</e1>, cisapride, antipyrine, caffeine, carbamazepine, <e2>diazepam</e2> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
theophylline,desmethyldiazepam,154,165,253,269,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1>theophylline</e1>, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e2>desmethyldiazepam</e2>), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
theophylline,diclofenac,154,165,273,282,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1>theophylline</e1>, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e2>diclofenac</e2>, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
theophylline,naproxen,154,165,285,292,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1>theophylline</e1>, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e2>naproxen</e2>, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
theophylline,piroxicam,154,165,295,303,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1>theophylline</e1>, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e2>piroxicam</e2>, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
theophylline,digoxin,154,165,306,312,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1>theophylline</e1>, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e2>digoxin</e2>, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
theophylline,ethanol,154,165,315,321,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1>theophylline</e1>, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, <e2>ethanol</e2>, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
theophylline,glyburide,154,165,324,332,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1>theophylline</e1>, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, <e2>glyburide</e2>, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
theophylline,contraceptive,154,165,343,355,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1>theophylline</e1>, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral <e2>contraceptive</e2> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
theophylline,levonorgestrel,154,165,358,371,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1>theophylline</e1>, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (<e2>levonorgestrel</e2>/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
theophylline,ethinyl estradiol,154,165,373,389,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1>theophylline</e1>, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/<e2>ethinyl estradiol</e2>), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
theophylline,metoprolol,154,165,393,402,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1>theophylline</e1>, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e2>metoprolol</e2>, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
theophylline,nifedipine,154,165,405,414,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1>theophylline</e1>, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e2>nifedipine</e2>, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
theophylline,phenytoin,154,165,417,425,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1>theophylline</e1>, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e2>phenytoin</e2>, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
theophylline,warfarin,154,165,428,435,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1>theophylline</e1>, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e2>warfarin</e2>, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
theophylline,midazolam,154,165,438,446,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1>theophylline</e1>, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, <e2>midazolam</e2>, clarithromycin, metronidazole, or amoxicillin. ",False,negative
theophylline,clarithromycin,154,165,449,462,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1>theophylline</e1>, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, <e2>clarithromycin</e2>, metronidazole, or amoxicillin. ",False,negative
theophylline,metronidazole,154,165,465,477,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1>theophylline</e1>, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, <e2>metronidazole</e2>, or amoxicillin. ",False,negative
theophylline,amoxicillin,154,165,483,493,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1>theophylline</e1>, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or <e2>amoxicillin</e2>. ",False,negative
cisapride,antipyrine,168,176,179,188,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1>cisapride</e1>, <e2>antipyrine</e2>, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
cisapride,caffeine,168,176,191,198,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1>cisapride</e1>, antipyrine, <e2>caffeine</e2>, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
cisapride,carbamazepine,168,176,201,213,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1>cisapride</e1>, antipyrine, caffeine, <e2>carbamazepine</e2>, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
cisapride,diazepam,168,176,216,223,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1>cisapride</e1>, antipyrine, caffeine, carbamazepine, <e2>diazepam</e2> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
cisapride,desmethyldiazepam,168,176,253,269,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1>cisapride</e1>, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e2>desmethyldiazepam</e2>), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
cisapride,diclofenac,168,176,273,282,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1>cisapride</e1>, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e2>diclofenac</e2>, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
cisapride,naproxen,168,176,285,292,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1>cisapride</e1>, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e2>naproxen</e2>, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
cisapride,piroxicam,168,176,295,303,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1>cisapride</e1>, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e2>piroxicam</e2>, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
cisapride,digoxin,168,176,306,312,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1>cisapride</e1>, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e2>digoxin</e2>, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
cisapride,ethanol,168,176,315,321,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1>cisapride</e1>, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, <e2>ethanol</e2>, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
cisapride,glyburide,168,176,324,332,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1>cisapride</e1>, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, <e2>glyburide</e2>, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
cisapride,contraceptive,168,176,343,355,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1>cisapride</e1>, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral <e2>contraceptive</e2> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
cisapride,levonorgestrel,168,176,358,371,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1>cisapride</e1>, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (<e2>levonorgestrel</e2>/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
cisapride,ethinyl estradiol,168,176,373,389,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1>cisapride</e1>, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/<e2>ethinyl estradiol</e2>), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
cisapride,metoprolol,168,176,393,402,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1>cisapride</e1>, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e2>metoprolol</e2>, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
cisapride,nifedipine,168,176,405,414,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1>cisapride</e1>, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e2>nifedipine</e2>, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
cisapride,phenytoin,168,176,417,425,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1>cisapride</e1>, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e2>phenytoin</e2>, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
cisapride,warfarin,168,176,428,435,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1>cisapride</e1>, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e2>warfarin</e2>, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
cisapride,midazolam,168,176,438,446,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1>cisapride</e1>, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, <e2>midazolam</e2>, clarithromycin, metronidazole, or amoxicillin. ",False,negative
cisapride,clarithromycin,168,176,449,462,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1>cisapride</e1>, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, <e2>clarithromycin</e2>, metronidazole, or amoxicillin. ",False,negative
cisapride,metronidazole,168,176,465,477,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1>cisapride</e1>, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, <e2>metronidazole</e2>, or amoxicillin. ",False,negative
cisapride,amoxicillin,168,176,483,493,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1>cisapride</e1>, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or <e2>amoxicillin</e2>. ",False,negative
antipyrine,caffeine,179,188,191,198,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1>antipyrine</e1>, <e2>caffeine</e2>, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
antipyrine,carbamazepine,179,188,201,213,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1>antipyrine</e1>, caffeine, <e2>carbamazepine</e2>, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
antipyrine,diazepam,179,188,216,223,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1>antipyrine</e1>, caffeine, carbamazepine, <e2>diazepam</e2> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
antipyrine,desmethyldiazepam,179,188,253,269,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1>antipyrine</e1>, caffeine, carbamazepine, diazepam (and its active metabolite, <e2>desmethyldiazepam</e2>), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
antipyrine,diclofenac,179,188,273,282,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1>antipyrine</e1>, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e2>diclofenac</e2>, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
antipyrine,naproxen,179,188,285,292,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1>antipyrine</e1>, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e2>naproxen</e2>, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
antipyrine,piroxicam,179,188,295,303,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1>antipyrine</e1>, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e2>piroxicam</e2>, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
antipyrine,digoxin,179,188,306,312,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1>antipyrine</e1>, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e2>digoxin</e2>, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
antipyrine,ethanol,179,188,315,321,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1>antipyrine</e1>, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, <e2>ethanol</e2>, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
antipyrine,glyburide,179,188,324,332,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1>antipyrine</e1>, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, <e2>glyburide</e2>, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
antipyrine,contraceptive,179,188,343,355,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1>antipyrine</e1>, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral <e2>contraceptive</e2> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
antipyrine,levonorgestrel,179,188,358,371,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1>antipyrine</e1>, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (<e2>levonorgestrel</e2>/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
antipyrine,ethinyl estradiol,179,188,373,389,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1>antipyrine</e1>, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/<e2>ethinyl estradiol</e2>), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
antipyrine,metoprolol,179,188,393,402,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1>antipyrine</e1>, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e2>metoprolol</e2>, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
antipyrine,nifedipine,179,188,405,414,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1>antipyrine</e1>, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e2>nifedipine</e2>, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
antipyrine,phenytoin,179,188,417,425,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1>antipyrine</e1>, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e2>phenytoin</e2>, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
antipyrine,warfarin,179,188,428,435,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1>antipyrine</e1>, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e2>warfarin</e2>, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
antipyrine,midazolam,179,188,438,446,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1>antipyrine</e1>, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, <e2>midazolam</e2>, clarithromycin, metronidazole, or amoxicillin. ",False,negative
antipyrine,clarithromycin,179,188,449,462,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1>antipyrine</e1>, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, <e2>clarithromycin</e2>, metronidazole, or amoxicillin. ",False,negative
antipyrine,metronidazole,179,188,465,477,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1>antipyrine</e1>, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, <e2>metronidazole</e2>, or amoxicillin. ",False,negative
antipyrine,amoxicillin,179,188,483,493,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1>antipyrine</e1>, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or <e2>amoxicillin</e2>. ",False,negative
caffeine,carbamazepine,191,198,201,213,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1>caffeine</e1>, <e2>carbamazepine</e2>, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
caffeine,diazepam,191,198,216,223,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1>caffeine</e1>, carbamazepine, <e2>diazepam</e2> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
caffeine,desmethyldiazepam,191,198,253,269,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1>caffeine</e1>, carbamazepine, diazepam (and its active metabolite, <e2>desmethyldiazepam</e2>), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
caffeine,diclofenac,191,198,273,282,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1>caffeine</e1>, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e2>diclofenac</e2>, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
caffeine,naproxen,191,198,285,292,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1>caffeine</e1>, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e2>naproxen</e2>, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
caffeine,piroxicam,191,198,295,303,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1>caffeine</e1>, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e2>piroxicam</e2>, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
caffeine,digoxin,191,198,306,312,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1>caffeine</e1>, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e2>digoxin</e2>, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
caffeine,ethanol,191,198,315,321,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1>caffeine</e1>, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, <e2>ethanol</e2>, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
caffeine,glyburide,191,198,324,332,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1>caffeine</e1>, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, <e2>glyburide</e2>, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
caffeine,contraceptive,191,198,343,355,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1>caffeine</e1>, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral <e2>contraceptive</e2> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
caffeine,levonorgestrel,191,198,358,371,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1>caffeine</e1>, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (<e2>levonorgestrel</e2>/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
caffeine,ethinyl estradiol,191,198,373,389,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1>caffeine</e1>, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/<e2>ethinyl estradiol</e2>), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
caffeine,metoprolol,191,198,393,402,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1>caffeine</e1>, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e2>metoprolol</e2>, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
caffeine,nifedipine,191,198,405,414,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1>caffeine</e1>, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e2>nifedipine</e2>, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
caffeine,phenytoin,191,198,417,425,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1>caffeine</e1>, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e2>phenytoin</e2>, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
caffeine,warfarin,191,198,428,435,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1>caffeine</e1>, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e2>warfarin</e2>, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
caffeine,midazolam,191,198,438,446,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1>caffeine</e1>, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, <e2>midazolam</e2>, clarithromycin, metronidazole, or amoxicillin. ",False,negative
caffeine,clarithromycin,191,198,449,462,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1>caffeine</e1>, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, <e2>clarithromycin</e2>, metronidazole, or amoxicillin. ",False,negative
caffeine,metronidazole,191,198,465,477,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1>caffeine</e1>, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, <e2>metronidazole</e2>, or amoxicillin. ",False,negative
caffeine,amoxicillin,191,198,483,493,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1>caffeine</e1>, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or <e2>amoxicillin</e2>. ",False,negative
carbamazepine,diazepam,201,213,216,223,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e1>carbamazepine</e1>, <e2>diazepam</e2> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
carbamazepine,desmethyldiazepam,201,213,253,269,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e1>carbamazepine</e1>, diazepam (and its active metabolite, <e2>desmethyldiazepam</e2>), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
carbamazepine,diclofenac,201,213,273,282,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e1>carbamazepine</e1>, diazepam (and its active metabolite, desmethyldiazepam), <e2>diclofenac</e2>, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
carbamazepine,naproxen,201,213,285,292,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e1>carbamazepine</e1>, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e2>naproxen</e2>, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
carbamazepine,piroxicam,201,213,295,303,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e1>carbamazepine</e1>, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e2>piroxicam</e2>, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
carbamazepine,digoxin,201,213,306,312,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e1>carbamazepine</e1>, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e2>digoxin</e2>, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
carbamazepine,ethanol,201,213,315,321,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e1>carbamazepine</e1>, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, <e2>ethanol</e2>, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
carbamazepine,glyburide,201,213,324,332,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e1>carbamazepine</e1>, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, <e2>glyburide</e2>, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
carbamazepine,contraceptive,201,213,343,355,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e1>carbamazepine</e1>, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral <e2>contraceptive</e2> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
carbamazepine,levonorgestrel,201,213,358,371,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e1>carbamazepine</e1>, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (<e2>levonorgestrel</e2>/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
carbamazepine,ethinyl estradiol,201,213,373,389,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e1>carbamazepine</e1>, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/<e2>ethinyl estradiol</e2>), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
carbamazepine,metoprolol,201,213,393,402,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e1>carbamazepine</e1>, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e2>metoprolol</e2>, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
carbamazepine,nifedipine,201,213,405,414,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e1>carbamazepine</e1>, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e2>nifedipine</e2>, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
carbamazepine,phenytoin,201,213,417,425,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e1>carbamazepine</e1>, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e2>phenytoin</e2>, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
carbamazepine,warfarin,201,213,428,435,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e1>carbamazepine</e1>, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e2>warfarin</e2>, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
carbamazepine,midazolam,201,213,438,446,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e1>carbamazepine</e1>, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, <e2>midazolam</e2>, clarithromycin, metronidazole, or amoxicillin. ",False,negative
carbamazepine,clarithromycin,201,213,449,462,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e1>carbamazepine</e1>, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, <e2>clarithromycin</e2>, metronidazole, or amoxicillin. ",False,negative
carbamazepine,metronidazole,201,213,465,477,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e1>carbamazepine</e1>, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, <e2>metronidazole</e2>, or amoxicillin. ",False,negative
carbamazepine,amoxicillin,201,213,483,493,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e1>carbamazepine</e1>, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or <e2>amoxicillin</e2>. ",False,negative
diazepam,desmethyldiazepam,216,223,253,269,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, <e1>diazepam</e1> (and its active metabolite, <e2>desmethyldiazepam</e2>), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
diazepam,diclofenac,216,223,273,282,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, <e1>diazepam</e1> (and its active metabolite, desmethyldiazepam), <e2>diclofenac</e2>, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
diazepam,naproxen,216,223,285,292,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, <e1>diazepam</e1> (and its active metabolite, desmethyldiazepam), diclofenac, <e2>naproxen</e2>, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
diazepam,piroxicam,216,223,295,303,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, <e1>diazepam</e1> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e2>piroxicam</e2>, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
diazepam,digoxin,216,223,306,312,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, <e1>diazepam</e1> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e2>digoxin</e2>, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
diazepam,ethanol,216,223,315,321,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, <e1>diazepam</e1> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, <e2>ethanol</e2>, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
diazepam,glyburide,216,223,324,332,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, <e1>diazepam</e1> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, <e2>glyburide</e2>, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
diazepam,contraceptive,216,223,343,355,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, <e1>diazepam</e1> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral <e2>contraceptive</e2> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
diazepam,levonorgestrel,216,223,358,371,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, <e1>diazepam</e1> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (<e2>levonorgestrel</e2>/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
diazepam,ethinyl estradiol,216,223,373,389,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, <e1>diazepam</e1> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/<e2>ethinyl estradiol</e2>), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
diazepam,metoprolol,216,223,393,402,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, <e1>diazepam</e1> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e2>metoprolol</e2>, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
diazepam,nifedipine,216,223,405,414,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, <e1>diazepam</e1> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e2>nifedipine</e2>, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
diazepam,phenytoin,216,223,417,425,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, <e1>diazepam</e1> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e2>phenytoin</e2>, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
diazepam,warfarin,216,223,428,435,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, <e1>diazepam</e1> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e2>warfarin</e2>, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
diazepam,midazolam,216,223,438,446,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, <e1>diazepam</e1> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, <e2>midazolam</e2>, clarithromycin, metronidazole, or amoxicillin. ",False,negative
diazepam,clarithromycin,216,223,449,462,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, <e1>diazepam</e1> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, <e2>clarithromycin</e2>, metronidazole, or amoxicillin. ",False,negative
diazepam,metronidazole,216,223,465,477,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, <e1>diazepam</e1> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, <e2>metronidazole</e2>, or amoxicillin. ",False,negative
diazepam,amoxicillin,216,223,483,493,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, <e1>diazepam</e1> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or <e2>amoxicillin</e2>. ",False,negative
desmethyldiazepam,diclofenac,253,269,273,282,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e1>desmethyldiazepam</e1>), <e2>diclofenac</e2>, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
desmethyldiazepam,naproxen,253,269,285,292,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e1>desmethyldiazepam</e1>), diclofenac, <e2>naproxen</e2>, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
desmethyldiazepam,piroxicam,253,269,295,303,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e1>desmethyldiazepam</e1>), diclofenac, naproxen, <e2>piroxicam</e2>, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
desmethyldiazepam,digoxin,253,269,306,312,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e1>desmethyldiazepam</e1>), diclofenac, naproxen, piroxicam, <e2>digoxin</e2>, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
desmethyldiazepam,ethanol,253,269,315,321,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e1>desmethyldiazepam</e1>), diclofenac, naproxen, piroxicam, digoxin, <e2>ethanol</e2>, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
desmethyldiazepam,glyburide,253,269,324,332,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e1>desmethyldiazepam</e1>), diclofenac, naproxen, piroxicam, digoxin, ethanol, <e2>glyburide</e2>, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
desmethyldiazepam,contraceptive,253,269,343,355,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e1>desmethyldiazepam</e1>), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral <e2>contraceptive</e2> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
desmethyldiazepam,levonorgestrel,253,269,358,371,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e1>desmethyldiazepam</e1>), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (<e2>levonorgestrel</e2>/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
desmethyldiazepam,ethinyl estradiol,253,269,373,389,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e1>desmethyldiazepam</e1>), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/<e2>ethinyl estradiol</e2>), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
desmethyldiazepam,metoprolol,253,269,393,402,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e1>desmethyldiazepam</e1>), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e2>metoprolol</e2>, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
desmethyldiazepam,nifedipine,253,269,405,414,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e1>desmethyldiazepam</e1>), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e2>nifedipine</e2>, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
desmethyldiazepam,phenytoin,253,269,417,425,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e1>desmethyldiazepam</e1>), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e2>phenytoin</e2>, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
desmethyldiazepam,warfarin,253,269,428,435,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e1>desmethyldiazepam</e1>), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e2>warfarin</e2>, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
desmethyldiazepam,midazolam,253,269,438,446,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e1>desmethyldiazepam</e1>), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, <e2>midazolam</e2>, clarithromycin, metronidazole, or amoxicillin. ",False,negative
desmethyldiazepam,clarithromycin,253,269,449,462,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e1>desmethyldiazepam</e1>), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, <e2>clarithromycin</e2>, metronidazole, or amoxicillin. ",False,negative
desmethyldiazepam,metronidazole,253,269,465,477,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e1>desmethyldiazepam</e1>), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, <e2>metronidazole</e2>, or amoxicillin. ",False,negative
desmethyldiazepam,amoxicillin,253,269,483,493,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e1>desmethyldiazepam</e1>), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or <e2>amoxicillin</e2>. ",False,negative
diclofenac,naproxen,273,282,285,292,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e1>diclofenac</e1>, <e2>naproxen</e2>, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
diclofenac,piroxicam,273,282,295,303,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e1>diclofenac</e1>, naproxen, <e2>piroxicam</e2>, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
diclofenac,digoxin,273,282,306,312,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e1>diclofenac</e1>, naproxen, piroxicam, <e2>digoxin</e2>, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
diclofenac,ethanol,273,282,315,321,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e1>diclofenac</e1>, naproxen, piroxicam, digoxin, <e2>ethanol</e2>, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
diclofenac,glyburide,273,282,324,332,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e1>diclofenac</e1>, naproxen, piroxicam, digoxin, ethanol, <e2>glyburide</e2>, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
diclofenac,contraceptive,273,282,343,355,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e1>diclofenac</e1>, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral <e2>contraceptive</e2> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
diclofenac,levonorgestrel,273,282,358,371,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e1>diclofenac</e1>, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (<e2>levonorgestrel</e2>/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
diclofenac,ethinyl estradiol,273,282,373,389,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e1>diclofenac</e1>, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/<e2>ethinyl estradiol</e2>), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
diclofenac,metoprolol,273,282,393,402,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e1>diclofenac</e1>, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e2>metoprolol</e2>, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
diclofenac,nifedipine,273,282,405,414,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e1>diclofenac</e1>, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e2>nifedipine</e2>, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
diclofenac,phenytoin,273,282,417,425,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e1>diclofenac</e1>, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e2>phenytoin</e2>, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
diclofenac,warfarin,273,282,428,435,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e1>diclofenac</e1>, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e2>warfarin</e2>, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
diclofenac,midazolam,273,282,438,446,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e1>diclofenac</e1>, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, <e2>midazolam</e2>, clarithromycin, metronidazole, or amoxicillin. ",False,negative
diclofenac,clarithromycin,273,282,449,462,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e1>diclofenac</e1>, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, <e2>clarithromycin</e2>, metronidazole, or amoxicillin. ",False,negative
diclofenac,metronidazole,273,282,465,477,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e1>diclofenac</e1>, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, <e2>metronidazole</e2>, or amoxicillin. ",False,negative
diclofenac,amoxicillin,273,282,483,493,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e1>diclofenac</e1>, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or <e2>amoxicillin</e2>. ",False,negative
naproxen,piroxicam,285,292,295,303,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e1>naproxen</e1>, <e2>piroxicam</e2>, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
naproxen,digoxin,285,292,306,312,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e1>naproxen</e1>, piroxicam, <e2>digoxin</e2>, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
naproxen,ethanol,285,292,315,321,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e1>naproxen</e1>, piroxicam, digoxin, <e2>ethanol</e2>, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
naproxen,glyburide,285,292,324,332,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e1>naproxen</e1>, piroxicam, digoxin, ethanol, <e2>glyburide</e2>, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
naproxen,contraceptive,285,292,343,355,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e1>naproxen</e1>, piroxicam, digoxin, ethanol, glyburide, an oral <e2>contraceptive</e2> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
naproxen,levonorgestrel,285,292,358,371,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e1>naproxen</e1>, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (<e2>levonorgestrel</e2>/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
naproxen,ethinyl estradiol,285,292,373,389,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e1>naproxen</e1>, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/<e2>ethinyl estradiol</e2>), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
naproxen,metoprolol,285,292,393,402,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e1>naproxen</e1>, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e2>metoprolol</e2>, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
naproxen,nifedipine,285,292,405,414,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e1>naproxen</e1>, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e2>nifedipine</e2>, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
naproxen,phenytoin,285,292,417,425,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e1>naproxen</e1>, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e2>phenytoin</e2>, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
naproxen,warfarin,285,292,428,435,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e1>naproxen</e1>, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e2>warfarin</e2>, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
naproxen,midazolam,285,292,438,446,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e1>naproxen</e1>, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, <e2>midazolam</e2>, clarithromycin, metronidazole, or amoxicillin. ",False,negative
naproxen,clarithromycin,285,292,449,462,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e1>naproxen</e1>, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, <e2>clarithromycin</e2>, metronidazole, or amoxicillin. ",False,negative
naproxen,metronidazole,285,292,465,477,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e1>naproxen</e1>, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, <e2>metronidazole</e2>, or amoxicillin. ",False,negative
naproxen,amoxicillin,285,292,483,493,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e1>naproxen</e1>, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or <e2>amoxicillin</e2>. ",False,negative
piroxicam,digoxin,295,303,306,312,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e1>piroxicam</e1>, <e2>digoxin</e2>, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
piroxicam,ethanol,295,303,315,321,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e1>piroxicam</e1>, digoxin, <e2>ethanol</e2>, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
piroxicam,glyburide,295,303,324,332,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e1>piroxicam</e1>, digoxin, ethanol, <e2>glyburide</e2>, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
piroxicam,contraceptive,295,303,343,355,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e1>piroxicam</e1>, digoxin, ethanol, glyburide, an oral <e2>contraceptive</e2> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
piroxicam,levonorgestrel,295,303,358,371,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e1>piroxicam</e1>, digoxin, ethanol, glyburide, an oral contraceptive (<e2>levonorgestrel</e2>/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
piroxicam,ethinyl estradiol,295,303,373,389,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e1>piroxicam</e1>, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/<e2>ethinyl estradiol</e2>), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
piroxicam,metoprolol,295,303,393,402,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e1>piroxicam</e1>, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e2>metoprolol</e2>, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
piroxicam,nifedipine,295,303,405,414,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e1>piroxicam</e1>, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e2>nifedipine</e2>, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
piroxicam,phenytoin,295,303,417,425,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e1>piroxicam</e1>, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e2>phenytoin</e2>, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
piroxicam,warfarin,295,303,428,435,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e1>piroxicam</e1>, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e2>warfarin</e2>, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
piroxicam,midazolam,295,303,438,446,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e1>piroxicam</e1>, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, <e2>midazolam</e2>, clarithromycin, metronidazole, or amoxicillin. ",False,negative
piroxicam,clarithromycin,295,303,449,462,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e1>piroxicam</e1>, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, <e2>clarithromycin</e2>, metronidazole, or amoxicillin. ",False,negative
piroxicam,metronidazole,295,303,465,477,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e1>piroxicam</e1>, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, <e2>metronidazole</e2>, or amoxicillin. ",False,negative
piroxicam,amoxicillin,295,303,483,493,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e1>piroxicam</e1>, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or <e2>amoxicillin</e2>. ",False,negative
digoxin,ethanol,306,312,315,321,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e1>digoxin</e1>, <e2>ethanol</e2>, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
digoxin,glyburide,306,312,324,332,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e1>digoxin</e1>, ethanol, <e2>glyburide</e2>, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
digoxin,contraceptive,306,312,343,355,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e1>digoxin</e1>, ethanol, glyburide, an oral <e2>contraceptive</e2> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
digoxin,levonorgestrel,306,312,358,371,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e1>digoxin</e1>, ethanol, glyburide, an oral contraceptive (<e2>levonorgestrel</e2>/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
digoxin,ethinyl estradiol,306,312,373,389,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e1>digoxin</e1>, ethanol, glyburide, an oral contraceptive (levonorgestrel/<e2>ethinyl estradiol</e2>), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
digoxin,metoprolol,306,312,393,402,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e1>digoxin</e1>, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e2>metoprolol</e2>, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
digoxin,nifedipine,306,312,405,414,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e1>digoxin</e1>, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e2>nifedipine</e2>, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
digoxin,phenytoin,306,312,417,425,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e1>digoxin</e1>, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e2>phenytoin</e2>, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
digoxin,warfarin,306,312,428,435,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e1>digoxin</e1>, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e2>warfarin</e2>, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
digoxin,midazolam,306,312,438,446,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e1>digoxin</e1>, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, <e2>midazolam</e2>, clarithromycin, metronidazole, or amoxicillin. ",False,negative
digoxin,clarithromycin,306,312,449,462,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e1>digoxin</e1>, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, <e2>clarithromycin</e2>, metronidazole, or amoxicillin. ",False,negative
digoxin,metronidazole,306,312,465,477,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e1>digoxin</e1>, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, <e2>metronidazole</e2>, or amoxicillin. ",False,negative
digoxin,amoxicillin,306,312,483,493,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e1>digoxin</e1>, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or <e2>amoxicillin</e2>. ",False,negative
ethanol,glyburide,315,321,324,332,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, <e1>ethanol</e1>, <e2>glyburide</e2>, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
ethanol,contraceptive,315,321,343,355,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, <e1>ethanol</e1>, glyburide, an oral <e2>contraceptive</e2> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
ethanol,levonorgestrel,315,321,358,371,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, <e1>ethanol</e1>, glyburide, an oral contraceptive (<e2>levonorgestrel</e2>/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
ethanol,ethinyl estradiol,315,321,373,389,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, <e1>ethanol</e1>, glyburide, an oral contraceptive (levonorgestrel/<e2>ethinyl estradiol</e2>), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
ethanol,metoprolol,315,321,393,402,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, <e1>ethanol</e1>, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e2>metoprolol</e2>, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
ethanol,nifedipine,315,321,405,414,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, <e1>ethanol</e1>, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e2>nifedipine</e2>, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
ethanol,phenytoin,315,321,417,425,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, <e1>ethanol</e1>, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e2>phenytoin</e2>, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
ethanol,warfarin,315,321,428,435,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, <e1>ethanol</e1>, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e2>warfarin</e2>, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
ethanol,midazolam,315,321,438,446,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, <e1>ethanol</e1>, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, <e2>midazolam</e2>, clarithromycin, metronidazole, or amoxicillin. ",False,negative
ethanol,clarithromycin,315,321,449,462,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, <e1>ethanol</e1>, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, <e2>clarithromycin</e2>, metronidazole, or amoxicillin. ",False,negative
ethanol,metronidazole,315,321,465,477,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, <e1>ethanol</e1>, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, <e2>metronidazole</e2>, or amoxicillin. ",False,negative
ethanol,amoxicillin,315,321,483,493,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, <e1>ethanol</e1>, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or <e2>amoxicillin</e2>. ",False,negative
glyburide,contraceptive,324,332,343,355,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, <e1>glyburide</e1>, an oral <e2>contraceptive</e2> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
glyburide,levonorgestrel,324,332,358,371,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, <e1>glyburide</e1>, an oral contraceptive (<e2>levonorgestrel</e2>/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
glyburide,ethinyl estradiol,324,332,373,389,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, <e1>glyburide</e1>, an oral contraceptive (levonorgestrel/<e2>ethinyl estradiol</e2>), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
glyburide,metoprolol,324,332,393,402,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, <e1>glyburide</e1>, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e2>metoprolol</e2>, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
glyburide,nifedipine,324,332,405,414,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, <e1>glyburide</e1>, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e2>nifedipine</e2>, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
glyburide,phenytoin,324,332,417,425,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, <e1>glyburide</e1>, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e2>phenytoin</e2>, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
glyburide,warfarin,324,332,428,435,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, <e1>glyburide</e1>, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e2>warfarin</e2>, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
glyburide,midazolam,324,332,438,446,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, <e1>glyburide</e1>, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, <e2>midazolam</e2>, clarithromycin, metronidazole, or amoxicillin. ",False,negative
glyburide,clarithromycin,324,332,449,462,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, <e1>glyburide</e1>, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, <e2>clarithromycin</e2>, metronidazole, or amoxicillin. ",False,negative
glyburide,metronidazole,324,332,465,477,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, <e1>glyburide</e1>, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, <e2>metronidazole</e2>, or amoxicillin. ",False,negative
glyburide,amoxicillin,324,332,483,493,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, <e1>glyburide</e1>, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or <e2>amoxicillin</e2>. ",False,negative
contraceptive,levonorgestrel,343,355,358,371,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral <e1>contraceptive</e1> (<e2>levonorgestrel</e2>/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
contraceptive,ethinyl estradiol,343,355,373,389,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral <e1>contraceptive</e1> (levonorgestrel/<e2>ethinyl estradiol</e2>), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
contraceptive,metoprolol,343,355,393,402,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral <e1>contraceptive</e1> (levonorgestrel/ethinyl estradiol), <e2>metoprolol</e2>, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
contraceptive,nifedipine,343,355,405,414,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral <e1>contraceptive</e1> (levonorgestrel/ethinyl estradiol), metoprolol, <e2>nifedipine</e2>, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
contraceptive,phenytoin,343,355,417,425,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral <e1>contraceptive</e1> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e2>phenytoin</e2>, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
contraceptive,warfarin,343,355,428,435,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral <e1>contraceptive</e1> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e2>warfarin</e2>, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
contraceptive,midazolam,343,355,438,446,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral <e1>contraceptive</e1> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, <e2>midazolam</e2>, clarithromycin, metronidazole, or amoxicillin. ",False,negative
contraceptive,clarithromycin,343,355,449,462,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral <e1>contraceptive</e1> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, <e2>clarithromycin</e2>, metronidazole, or amoxicillin. ",False,negative
contraceptive,metronidazole,343,355,465,477,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral <e1>contraceptive</e1> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, <e2>metronidazole</e2>, or amoxicillin. ",False,negative
contraceptive,amoxicillin,343,355,483,493,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral <e1>contraceptive</e1> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or <e2>amoxicillin</e2>. ",False,negative
levonorgestrel,ethinyl estradiol,358,371,373,389,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (<e1>levonorgestrel</e1>/<e2>ethinyl estradiol</e2>), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
levonorgestrel,metoprolol,358,371,393,402,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (<e1>levonorgestrel</e1>/ethinyl estradiol), <e2>metoprolol</e2>, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
levonorgestrel,nifedipine,358,371,405,414,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (<e1>levonorgestrel</e1>/ethinyl estradiol), metoprolol, <e2>nifedipine</e2>, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
levonorgestrel,phenytoin,358,371,417,425,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (<e1>levonorgestrel</e1>/ethinyl estradiol), metoprolol, nifedipine, <e2>phenytoin</e2>, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
levonorgestrel,warfarin,358,371,428,435,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (<e1>levonorgestrel</e1>/ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e2>warfarin</e2>, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
levonorgestrel,midazolam,358,371,438,446,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (<e1>levonorgestrel</e1>/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, <e2>midazolam</e2>, clarithromycin, metronidazole, or amoxicillin. ",False,negative
levonorgestrel,clarithromycin,358,371,449,462,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (<e1>levonorgestrel</e1>/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, <e2>clarithromycin</e2>, metronidazole, or amoxicillin. ",False,negative
levonorgestrel,metronidazole,358,371,465,477,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (<e1>levonorgestrel</e1>/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, <e2>metronidazole</e2>, or amoxicillin. ",False,negative
levonorgestrel,amoxicillin,358,371,483,493,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (<e1>levonorgestrel</e1>/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or <e2>amoxicillin</e2>. ",False,negative
ethinyl estradiol,metoprolol,373,389,393,402,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/<e1>ethinyl estradiol</e1>), <e2>metoprolol</e2>, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
ethinyl estradiol,nifedipine,373,389,405,414,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/<e1>ethinyl estradiol</e1>), metoprolol, <e2>nifedipine</e2>, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
ethinyl estradiol,phenytoin,373,389,417,425,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/<e1>ethinyl estradiol</e1>), metoprolol, nifedipine, <e2>phenytoin</e2>, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
ethinyl estradiol,warfarin,373,389,428,435,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/<e1>ethinyl estradiol</e1>), metoprolol, nifedipine, phenytoin, <e2>warfarin</e2>, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
ethinyl estradiol,midazolam,373,389,438,446,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/<e1>ethinyl estradiol</e1>), metoprolol, nifedipine, phenytoin, warfarin, <e2>midazolam</e2>, clarithromycin, metronidazole, or amoxicillin. ",False,negative
ethinyl estradiol,clarithromycin,373,389,449,462,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/<e1>ethinyl estradiol</e1>), metoprolol, nifedipine, phenytoin, warfarin, midazolam, <e2>clarithromycin</e2>, metronidazole, or amoxicillin. ",False,negative
ethinyl estradiol,metronidazole,373,389,465,477,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/<e1>ethinyl estradiol</e1>), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, <e2>metronidazole</e2>, or amoxicillin. ",False,negative
ethinyl estradiol,amoxicillin,373,389,483,493,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/<e1>ethinyl estradiol</e1>), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or <e2>amoxicillin</e2>. ",False,negative
metoprolol,nifedipine,393,402,405,414,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e1>metoprolol</e1>, <e2>nifedipine</e2>, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
metoprolol,phenytoin,393,402,417,425,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e1>metoprolol</e1>, nifedipine, <e2>phenytoin</e2>, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
metoprolol,warfarin,393,402,428,435,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e1>metoprolol</e1>, nifedipine, phenytoin, <e2>warfarin</e2>, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
metoprolol,midazolam,393,402,438,446,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e1>metoprolol</e1>, nifedipine, phenytoin, warfarin, <e2>midazolam</e2>, clarithromycin, metronidazole, or amoxicillin. ",False,negative
metoprolol,clarithromycin,393,402,449,462,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e1>metoprolol</e1>, nifedipine, phenytoin, warfarin, midazolam, <e2>clarithromycin</e2>, metronidazole, or amoxicillin. ",False,negative
metoprolol,metronidazole,393,402,465,477,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e1>metoprolol</e1>, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, <e2>metronidazole</e2>, or amoxicillin. ",False,negative
metoprolol,amoxicillin,393,402,483,493,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e1>metoprolol</e1>, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or <e2>amoxicillin</e2>. ",False,negative
nifedipine,phenytoin,405,414,417,425,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e1>nifedipine</e1>, <e2>phenytoin</e2>, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
nifedipine,warfarin,405,414,428,435,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e1>nifedipine</e1>, phenytoin, <e2>warfarin</e2>, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
nifedipine,midazolam,405,414,438,446,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e1>nifedipine</e1>, phenytoin, warfarin, <e2>midazolam</e2>, clarithromycin, metronidazole, or amoxicillin. ",False,negative
nifedipine,clarithromycin,405,414,449,462,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e1>nifedipine</e1>, phenytoin, warfarin, midazolam, <e2>clarithromycin</e2>, metronidazole, or amoxicillin. ",False,negative
nifedipine,metronidazole,405,414,465,477,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e1>nifedipine</e1>, phenytoin, warfarin, midazolam, clarithromycin, <e2>metronidazole</e2>, or amoxicillin. ",False,negative
nifedipine,amoxicillin,405,414,483,493,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e1>nifedipine</e1>, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or <e2>amoxicillin</e2>. ",False,negative
phenytoin,warfarin,417,425,428,435,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e1>phenytoin</e1>, <e2>warfarin</e2>, midazolam, clarithromycin, metronidazole, or amoxicillin. ",False,negative
phenytoin,midazolam,417,425,438,446,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e1>phenytoin</e1>, warfarin, <e2>midazolam</e2>, clarithromycin, metronidazole, or amoxicillin. ",False,negative
phenytoin,clarithromycin,417,425,449,462,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e1>phenytoin</e1>, warfarin, midazolam, <e2>clarithromycin</e2>, metronidazole, or amoxicillin. ",False,negative
phenytoin,metronidazole,417,425,465,477,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e1>phenytoin</e1>, warfarin, midazolam, clarithromycin, <e2>metronidazole</e2>, or amoxicillin. ",False,negative
phenytoin,amoxicillin,417,425,483,493,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e1>phenytoin</e1>, warfarin, midazolam, clarithromycin, metronidazole, or <e2>amoxicillin</e2>. ",False,negative
warfarin,midazolam,428,435,438,446,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e1>warfarin</e1>, <e2>midazolam</e2>, clarithromycin, metronidazole, or amoxicillin. ",False,negative
warfarin,clarithromycin,428,435,449,462,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e1>warfarin</e1>, midazolam, <e2>clarithromycin</e2>, metronidazole, or amoxicillin. ",False,negative
warfarin,metronidazole,428,435,465,477,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e1>warfarin</e1>, midazolam, clarithromycin, <e2>metronidazole</e2>, or amoxicillin. ",False,negative
warfarin,amoxicillin,428,435,483,493,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e1>warfarin</e1>, midazolam, clarithromycin, metronidazole, or <e2>amoxicillin</e2>. ",False,negative
midazolam,clarithromycin,438,446,449,462,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, <e1>midazolam</e1>, <e2>clarithromycin</e2>, metronidazole, or amoxicillin. ",False,negative
midazolam,metronidazole,438,446,465,477,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, <e1>midazolam</e1>, clarithromycin, <e2>metronidazole</e2>, or amoxicillin. ",False,negative
midazolam,amoxicillin,438,446,483,493,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, <e1>midazolam</e1>, clarithromycin, metronidazole, or <e2>amoxicillin</e2>. ",False,negative
clarithromycin,metronidazole,449,462,465,477,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, <e1>clarithromycin</e1>, <e2>metronidazole</e2>, or amoxicillin. ",False,negative
clarithromycin,amoxicillin,449,462,483,493,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, <e1>clarithromycin</e1>, metronidazole, or <e2>amoxicillin</e2>. ",False,negative
metronidazole,amoxicillin,465,477,483,493,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, <e1>metronidazole</e1>, or <e2>amoxicillin</e2>. ",False,negative
pantoprazole,pantoprazole,36,47,78,89,"Therefore, when coadministered with <e1>pantoprazole</e1>, adjustment of the dosage of <e2>pantoprazole</e2> or of such drugs may not be necessary. ",False,negative
proton pump inhibitors,pantoprazole,98,119,132,143,"There have been postmarketing reports of increased INR and prothrombin time in patients receiving <e1>proton pump inhibitors</e1>, including <e2>pantoprazole</e2>, and warfarin concomitantly. ",False,negative
proton pump inhibitors,warfarin,98,119,150,157,"There have been postmarketing reports of increased INR and prothrombin time in patients receiving <e1>proton pump inhibitors</e1>, including pantoprazole, and <e2>warfarin</e2> concomitantly. ",True,effect
pantoprazole,warfarin,132,143,150,157,"There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including <e1>pantoprazole</e1>, and <e2>warfarin</e2> concomitantly. ",True,effect
proton pump inhibitors,warfarin,22,43,49,56,Patients treated with <e1>proton pump inhibitors</e1> and <e2>warfarin</e2> concomitantly should be monitored for increases in INR and prothrombin time. ,True,advise
pantoprazole,ketoconazole,75,86,202,213,"Because of profound and long lasting inhibition of gastric acid secretion, <e1>pantoprazole</e1> may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, <e2>ketoconazole</e2>, ampicillin esters, and iron salts). ",True,mechanism
pantoprazole,ampicillin,75,86,216,225,"Because of profound and long lasting inhibition of gastric acid secretion, <e1>pantoprazole</e1> may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, <e2>ampicillin</e2> esters, and iron salts). ",True,mechanism
pantoprazole,iron,75,86,239,242,"Because of profound and long lasting inhibition of gastric acid secretion, <e1>pantoprazole</e1> may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and <e2>iron</e2> salts). ",True,mechanism
ketoconazole,ampicillin,202,213,216,225,"Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, <e1>ketoconazole</e1>, <e2>ampicillin</e2> esters, and iron salts). ",False,negative
ketoconazole,iron,202,213,239,242,"Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, <e1>ketoconazole</e1>, ampicillin esters, and <e2>iron</e2> salts). ",False,negative
ampicillin,iron,216,225,239,242,"Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, <e1>ampicillin</e1> esters, and <e2>iron</e2> salts). ",False,negative
tetrahydrocannabinol,THC,85,104,107,109,"Laboratory Tests There have been reports of false-positive urine screening tests for <e1>tetrahydrocannabinol</e1> (<e2>THC</e2>) in patients receiving most proton pump inhibitors, including pantoprazole. ",False,negative
tetrahydrocannabinol,proton pump inhibitors,85,104,139,160,"Laboratory Tests There have been reports of false-positive urine screening tests for <e1>tetrahydrocannabinol</e1> (THC) in patients receiving most <e2>proton pump inhibitors</e2>, including pantoprazole. ",False,negative
tetrahydrocannabinol,pantoprazole,85,104,173,184,"Laboratory Tests There have been reports of false-positive urine screening tests for <e1>tetrahydrocannabinol</e1> (THC) in patients receiving most proton pump inhibitors, including <e2>pantoprazole</e2>. ",False,negative
THC,proton pump inhibitors,107,109,139,160,"Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol (<e1>THC</e1>) in patients receiving most <e2>proton pump inhibitors</e2>, including pantoprazole. ",False,negative
THC,pantoprazole,107,109,173,184,"Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol (<e1>THC</e1>) in patients receiving most proton pump inhibitors, including <e2>pantoprazole</e2>. ",False,negative
proton pump inhibitors,pantoprazole,139,160,173,184,"Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving most <e1>proton pump inhibitors</e1>, including <e2>pantoprazole</e2>. ",False,negative
ketoconazole,paricalcitol,62,73,97,108,"A multiple dose drug-drug interaction study demonstrated that <e1>ketoconazole</e1> approximately doubled <e2>paricalcitol</e2> AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",True,mechanism
ketoconazole,paricalcitol,62,73,126,137,"A multiple dose drug-drug interaction study demonstrated that <e1>ketoconazole</e1> approximately doubled paricalcitol AUC0-   . Since <e2>paricalcitol</e2> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
ketoconazole,ketoconazole,62,73,177,188,"A multiple dose drug-drug interaction study demonstrated that <e1>ketoconazole</e1> approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and <e2>ketoconazole</e2> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
ketoconazole,paricalcitol,62,73,291,302,"A multiple dose drug-drug interaction study demonstrated that <e1>ketoconazole</e1> approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e2>paricalcitol</e2> with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
ketoconazole,ketoconazole,62,73,309,320,"A multiple dose drug-drug interaction study demonstrated that <e1>ketoconazole</e1> approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with <e2>ketoconazole</e2> and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
ketoconazole,atazanavir,62,73,368,377,"A multiple dose drug-drug interaction study demonstrated that <e1>ketoconazole</e1> approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including <e2>atazanavir</e2>, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
ketoconazole,clarithromycin,62,73,380,393,"A multiple dose drug-drug interaction study demonstrated that <e1>ketoconazole</e1> approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, <e2>clarithromycin</e2>, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
ketoconazole,indinavir,62,73,396,404,"A multiple dose drug-drug interaction study demonstrated that <e1>ketoconazole</e1> approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, <e2>indinavir</e2>, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
ketoconazole,itraconazole,62,73,407,418,"A multiple dose drug-drug interaction study demonstrated that <e1>ketoconazole</e1> approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, <e2>itraconazole</e2>, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
ketoconazole,nefazodone,62,73,421,430,"A multiple dose drug-drug interaction study demonstrated that <e1>ketoconazole</e1> approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, <e2>nefazodone</e2>, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
ketoconazole,nelfinavir,62,73,433,442,"A multiple dose drug-drug interaction study demonstrated that <e1>ketoconazole</e1> approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, <e2>nelfinavir</e2>, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
ketoconazole,ritonavir,62,73,445,453,"A multiple dose drug-drug interaction study demonstrated that <e1>ketoconazole</e1> approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, <e2>ritonavir</e2>, saquinavir, telithromycin or voriconazole. ",False,negative
ketoconazole,saquinavir,62,73,456,465,"A multiple dose drug-drug interaction study demonstrated that <e1>ketoconazole</e1> approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, <e2>saquinavir</e2>, telithromycin or voriconazole. ",False,negative
ketoconazole,telithromycin,62,73,468,480,"A multiple dose drug-drug interaction study demonstrated that <e1>ketoconazole</e1> approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, <e2>telithromycin</e2> or voriconazole. ",False,negative
ketoconazole,voriconazole,62,73,485,496,"A multiple dose drug-drug interaction study demonstrated that <e1>ketoconazole</e1> approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or <e2>voriconazole</e2>. ",False,negative
paricalcitol,paricalcitol,97,108,126,137,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled <e1>paricalcitol</e1> AUC0-   . Since <e2>paricalcitol</e2> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
paricalcitol,ketoconazole,97,108,177,188,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled <e1>paricalcitol</e1> AUC0-   . Since paricalcitol is partially metabolized by CYP3A and <e2>ketoconazole</e2> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
paricalcitol,paricalcitol,97,108,291,302,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled <e1>paricalcitol</e1> AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e2>paricalcitol</e2> with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
paricalcitol,ketoconazole,97,108,309,320,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled <e1>paricalcitol</e1> AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with <e2>ketoconazole</e2> and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
paricalcitol,atazanavir,97,108,368,377,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled <e1>paricalcitol</e1> AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including <e2>atazanavir</e2>, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
paricalcitol,clarithromycin,97,108,380,393,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled <e1>paricalcitol</e1> AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, <e2>clarithromycin</e2>, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
paricalcitol,indinavir,97,108,396,404,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled <e1>paricalcitol</e1> AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, <e2>indinavir</e2>, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
paricalcitol,itraconazole,97,108,407,418,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled <e1>paricalcitol</e1> AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, <e2>itraconazole</e2>, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
paricalcitol,nefazodone,97,108,421,430,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled <e1>paricalcitol</e1> AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, <e2>nefazodone</e2>, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
paricalcitol,nelfinavir,97,108,433,442,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled <e1>paricalcitol</e1> AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, <e2>nelfinavir</e2>, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
paricalcitol,ritonavir,97,108,445,453,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled <e1>paricalcitol</e1> AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, <e2>ritonavir</e2>, saquinavir, telithromycin or voriconazole. ",False,negative
paricalcitol,saquinavir,97,108,456,465,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled <e1>paricalcitol</e1> AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, <e2>saquinavir</e2>, telithromycin or voriconazole. ",False,negative
paricalcitol,telithromycin,97,108,468,480,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled <e1>paricalcitol</e1> AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, <e2>telithromycin</e2> or voriconazole. ",False,negative
paricalcitol,voriconazole,97,108,485,496,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled <e1>paricalcitol</e1> AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or <e2>voriconazole</e2>. ",False,negative
paricalcitol,ketoconazole,126,137,177,188,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since <e1>paricalcitol</e1> is partially metabolized by CYP3A and <e2>ketoconazole</e2> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
paricalcitol,paricalcitol,126,137,291,302,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since <e1>paricalcitol</e1> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e2>paricalcitol</e2> with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
paricalcitol,ketoconazole,126,137,309,320,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since <e1>paricalcitol</e1> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with <e2>ketoconazole</e2> and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
paricalcitol,atazanavir,126,137,368,377,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since <e1>paricalcitol</e1> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including <e2>atazanavir</e2>, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
paricalcitol,clarithromycin,126,137,380,393,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since <e1>paricalcitol</e1> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, <e2>clarithromycin</e2>, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
paricalcitol,indinavir,126,137,396,404,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since <e1>paricalcitol</e1> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, <e2>indinavir</e2>, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
paricalcitol,itraconazole,126,137,407,418,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since <e1>paricalcitol</e1> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, <e2>itraconazole</e2>, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
paricalcitol,nefazodone,126,137,421,430,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since <e1>paricalcitol</e1> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, <e2>nefazodone</e2>, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
paricalcitol,nelfinavir,126,137,433,442,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since <e1>paricalcitol</e1> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, <e2>nelfinavir</e2>, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
paricalcitol,ritonavir,126,137,445,453,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since <e1>paricalcitol</e1> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, <e2>ritonavir</e2>, saquinavir, telithromycin or voriconazole. ",False,negative
paricalcitol,saquinavir,126,137,456,465,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since <e1>paricalcitol</e1> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, <e2>saquinavir</e2>, telithromycin or voriconazole. ",False,negative
paricalcitol,telithromycin,126,137,468,480,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since <e1>paricalcitol</e1> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, <e2>telithromycin</e2> or voriconazole. ",False,negative
paricalcitol,voriconazole,126,137,485,496,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since <e1>paricalcitol</e1> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or <e2>voriconazole</e2>. ",False,negative
ketoconazole,paricalcitol,177,188,291,302,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and <e1>ketoconazole</e1> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e2>paricalcitol</e2> with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
ketoconazole,ketoconazole,177,188,309,320,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and <e1>ketoconazole</e1> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with <e2>ketoconazole</e2> and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
ketoconazole,atazanavir,177,188,368,377,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and <e1>ketoconazole</e1> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including <e2>atazanavir</e2>, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
ketoconazole,clarithromycin,177,188,380,393,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and <e1>ketoconazole</e1> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, <e2>clarithromycin</e2>, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
ketoconazole,indinavir,177,188,396,404,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and <e1>ketoconazole</e1> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, <e2>indinavir</e2>, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
ketoconazole,itraconazole,177,188,407,418,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and <e1>ketoconazole</e1> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, <e2>itraconazole</e2>, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
ketoconazole,nefazodone,177,188,421,430,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and <e1>ketoconazole</e1> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, <e2>nefazodone</e2>, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
ketoconazole,nelfinavir,177,188,433,442,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and <e1>ketoconazole</e1> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, <e2>nelfinavir</e2>, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
ketoconazole,ritonavir,177,188,445,453,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and <e1>ketoconazole</e1> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, <e2>ritonavir</e2>, saquinavir, telithromycin or voriconazole. ",False,negative
ketoconazole,saquinavir,177,188,456,465,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and <e1>ketoconazole</e1> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, <e2>saquinavir</e2>, telithromycin or voriconazole. ",False,negative
ketoconazole,telithromycin,177,188,468,480,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and <e1>ketoconazole</e1> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, <e2>telithromycin</e2> or voriconazole. ",False,negative
ketoconazole,voriconazole,177,188,485,496,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and <e1>ketoconazole</e1> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or <e2>voriconazole</e2>. ",False,negative
paricalcitol,ketoconazole,291,302,309,320,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e1>paricalcitol</e1> with <e2>ketoconazole</e2> and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",True,advise
paricalcitol,atazanavir,291,302,368,377,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e1>paricalcitol</e1> with ketoconazole and other strong P450 3A inhibitors including <e2>atazanavir</e2>, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",True,advise
paricalcitol,clarithromycin,291,302,380,393,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e1>paricalcitol</e1> with ketoconazole and other strong P450 3A inhibitors including atazanavir, <e2>clarithromycin</e2>, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",True,advise
paricalcitol,indinavir,291,302,396,404,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e1>paricalcitol</e1> with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, <e2>indinavir</e2>, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",True,advise
paricalcitol,itraconazole,291,302,407,418,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e1>paricalcitol</e1> with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, <e2>itraconazole</e2>, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",True,advise
paricalcitol,nefazodone,291,302,421,430,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e1>paricalcitol</e1> with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, <e2>nefazodone</e2>, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",True,advise
paricalcitol,nelfinavir,291,302,433,442,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e1>paricalcitol</e1> with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, <e2>nelfinavir</e2>, ritonavir, saquinavir, telithromycin or voriconazole. ",True,advise
paricalcitol,ritonavir,291,302,445,453,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e1>paricalcitol</e1> with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, <e2>ritonavir</e2>, saquinavir, telithromycin or voriconazole. ",True,advise
paricalcitol,saquinavir,291,302,456,465,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e1>paricalcitol</e1> with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, <e2>saquinavir</e2>, telithromycin or voriconazole. ",True,advise
paricalcitol,telithromycin,291,302,468,480,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e1>paricalcitol</e1> with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, <e2>telithromycin</e2> or voriconazole. ",True,advise
paricalcitol,voriconazole,291,302,485,496,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e1>paricalcitol</e1> with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or <e2>voriconazole</e2>. ",True,advise
ketoconazole,atazanavir,309,320,368,377,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with <e1>ketoconazole</e1> and other strong P450 3A inhibitors including <e2>atazanavir</e2>, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
ketoconazole,clarithromycin,309,320,380,393,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with <e1>ketoconazole</e1> and other strong P450 3A inhibitors including atazanavir, <e2>clarithromycin</e2>, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
ketoconazole,indinavir,309,320,396,404,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with <e1>ketoconazole</e1> and other strong P450 3A inhibitors including atazanavir, clarithromycin, <e2>indinavir</e2>, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
ketoconazole,itraconazole,309,320,407,418,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with <e1>ketoconazole</e1> and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, <e2>itraconazole</e2>, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
ketoconazole,nefazodone,309,320,421,430,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with <e1>ketoconazole</e1> and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, <e2>nefazodone</e2>, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
ketoconazole,nelfinavir,309,320,433,442,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with <e1>ketoconazole</e1> and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, <e2>nelfinavir</e2>, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
ketoconazole,ritonavir,309,320,445,453,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with <e1>ketoconazole</e1> and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, <e2>ritonavir</e2>, saquinavir, telithromycin or voriconazole. ",False,negative
ketoconazole,saquinavir,309,320,456,465,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with <e1>ketoconazole</e1> and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, <e2>saquinavir</e2>, telithromycin or voriconazole. ",False,negative
ketoconazole,telithromycin,309,320,468,480,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with <e1>ketoconazole</e1> and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, <e2>telithromycin</e2> or voriconazole. ",False,negative
ketoconazole,voriconazole,309,320,485,496,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with <e1>ketoconazole</e1> and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or <e2>voriconazole</e2>. ",False,negative
atazanavir,clarithromycin,368,377,380,393,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including <e1>atazanavir</e1>, <e2>clarithromycin</e2>, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
atazanavir,indinavir,368,377,396,404,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including <e1>atazanavir</e1>, clarithromycin, <e2>indinavir</e2>, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
atazanavir,itraconazole,368,377,407,418,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including <e1>atazanavir</e1>, clarithromycin, indinavir, <e2>itraconazole</e2>, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
atazanavir,nefazodone,368,377,421,430,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including <e1>atazanavir</e1>, clarithromycin, indinavir, itraconazole, <e2>nefazodone</e2>, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
atazanavir,nelfinavir,368,377,433,442,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including <e1>atazanavir</e1>, clarithromycin, indinavir, itraconazole, nefazodone, <e2>nelfinavir</e2>, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
atazanavir,ritonavir,368,377,445,453,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including <e1>atazanavir</e1>, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, <e2>ritonavir</e2>, saquinavir, telithromycin or voriconazole. ",False,negative
atazanavir,saquinavir,368,377,456,465,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including <e1>atazanavir</e1>, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, <e2>saquinavir</e2>, telithromycin or voriconazole. ",False,negative
atazanavir,telithromycin,368,377,468,480,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including <e1>atazanavir</e1>, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, <e2>telithromycin</e2> or voriconazole. ",False,negative
atazanavir,voriconazole,368,377,485,496,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including <e1>atazanavir</e1>, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or <e2>voriconazole</e2>. ",False,negative
clarithromycin,indinavir,380,393,396,404,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, <e1>clarithromycin</e1>, <e2>indinavir</e2>, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
clarithromycin,itraconazole,380,393,407,418,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, <e1>clarithromycin</e1>, indinavir, <e2>itraconazole</e2>, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
clarithromycin,nefazodone,380,393,421,430,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, <e1>clarithromycin</e1>, indinavir, itraconazole, <e2>nefazodone</e2>, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
clarithromycin,nelfinavir,380,393,433,442,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, <e1>clarithromycin</e1>, indinavir, itraconazole, nefazodone, <e2>nelfinavir</e2>, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
clarithromycin,ritonavir,380,393,445,453,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, <e1>clarithromycin</e1>, indinavir, itraconazole, nefazodone, nelfinavir, <e2>ritonavir</e2>, saquinavir, telithromycin or voriconazole. ",False,negative
clarithromycin,saquinavir,380,393,456,465,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, <e1>clarithromycin</e1>, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, <e2>saquinavir</e2>, telithromycin or voriconazole. ",False,negative
clarithromycin,telithromycin,380,393,468,480,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, <e1>clarithromycin</e1>, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, <e2>telithromycin</e2> or voriconazole. ",False,negative
clarithromycin,voriconazole,380,393,485,496,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, <e1>clarithromycin</e1>, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or <e2>voriconazole</e2>. ",False,negative
indinavir,itraconazole,396,404,407,418,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, <e1>indinavir</e1>, <e2>itraconazole</e2>, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
indinavir,nefazodone,396,404,421,430,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, <e1>indinavir</e1>, itraconazole, <e2>nefazodone</e2>, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
indinavir,nelfinavir,396,404,433,442,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, <e1>indinavir</e1>, itraconazole, nefazodone, <e2>nelfinavir</e2>, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
indinavir,ritonavir,396,404,445,453,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, <e1>indinavir</e1>, itraconazole, nefazodone, nelfinavir, <e2>ritonavir</e2>, saquinavir, telithromycin or voriconazole. ",False,negative
indinavir,saquinavir,396,404,456,465,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, <e1>indinavir</e1>, itraconazole, nefazodone, nelfinavir, ritonavir, <e2>saquinavir</e2>, telithromycin or voriconazole. ",False,negative
indinavir,telithromycin,396,404,468,480,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, <e1>indinavir</e1>, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, <e2>telithromycin</e2> or voriconazole. ",False,negative
indinavir,voriconazole,396,404,485,496,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, <e1>indinavir</e1>, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or <e2>voriconazole</e2>. ",False,negative
itraconazole,nefazodone,407,418,421,430,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, <e1>itraconazole</e1>, <e2>nefazodone</e2>, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
itraconazole,nelfinavir,407,418,433,442,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, <e1>itraconazole</e1>, nefazodone, <e2>nelfinavir</e2>, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
itraconazole,ritonavir,407,418,445,453,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, <e1>itraconazole</e1>, nefazodone, nelfinavir, <e2>ritonavir</e2>, saquinavir, telithromycin or voriconazole. ",False,negative
itraconazole,saquinavir,407,418,456,465,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, <e1>itraconazole</e1>, nefazodone, nelfinavir, ritonavir, <e2>saquinavir</e2>, telithromycin or voriconazole. ",False,negative
itraconazole,telithromycin,407,418,468,480,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, <e1>itraconazole</e1>, nefazodone, nelfinavir, ritonavir, saquinavir, <e2>telithromycin</e2> or voriconazole. ",False,negative
itraconazole,voriconazole,407,418,485,496,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, <e1>itraconazole</e1>, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or <e2>voriconazole</e2>. ",False,negative
nefazodone,nelfinavir,421,430,433,442,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, <e1>nefazodone</e1>, <e2>nelfinavir</e2>, ritonavir, saquinavir, telithromycin or voriconazole. ",False,negative
nefazodone,ritonavir,421,430,445,453,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, <e1>nefazodone</e1>, nelfinavir, <e2>ritonavir</e2>, saquinavir, telithromycin or voriconazole. ",False,negative
nefazodone,saquinavir,421,430,456,465,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, <e1>nefazodone</e1>, nelfinavir, ritonavir, <e2>saquinavir</e2>, telithromycin or voriconazole. ",False,negative
nefazodone,telithromycin,421,430,468,480,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, <e1>nefazodone</e1>, nelfinavir, ritonavir, saquinavir, <e2>telithromycin</e2> or voriconazole. ",False,negative
nefazodone,voriconazole,421,430,485,496,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, <e1>nefazodone</e1>, nelfinavir, ritonavir, saquinavir, telithromycin or <e2>voriconazole</e2>. ",False,negative
nelfinavir,ritonavir,433,442,445,453,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, <e1>nelfinavir</e1>, <e2>ritonavir</e2>, saquinavir, telithromycin or voriconazole. ",False,negative
nelfinavir,saquinavir,433,442,456,465,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, <e1>nelfinavir</e1>, ritonavir, <e2>saquinavir</e2>, telithromycin or voriconazole. ",False,negative
nelfinavir,telithromycin,433,442,468,480,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, <e1>nelfinavir</e1>, ritonavir, saquinavir, <e2>telithromycin</e2> or voriconazole. ",False,negative
nelfinavir,voriconazole,433,442,485,496,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, <e1>nelfinavir</e1>, ritonavir, saquinavir, telithromycin or <e2>voriconazole</e2>. ",False,negative
ritonavir,saquinavir,445,453,456,465,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, <e1>ritonavir</e1>, <e2>saquinavir</e2>, telithromycin or voriconazole. ",False,negative
ritonavir,telithromycin,445,453,468,480,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, <e1>ritonavir</e1>, saquinavir, <e2>telithromycin</e2> or voriconazole. ",False,negative
ritonavir,voriconazole,445,453,485,496,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, <e1>ritonavir</e1>, saquinavir, telithromycin or <e2>voriconazole</e2>. ",False,negative
saquinavir,telithromycin,456,465,468,480,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, <e1>saquinavir</e1>, <e2>telithromycin</e2> or voriconazole. ",False,negative
saquinavir,voriconazole,456,465,485,496,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, <e1>saquinavir</e1>, telithromycin or <e2>voriconazole</e2>. ",False,negative
telithromycin,voriconazole,468,480,485,496,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, <e1>telithromycin</e1> or <e2>voriconazole</e2>. ",False,negative
Zemplar,ketoconazole,19,25,209,220,"Dose adjustment of <e1>Zemplar</e1> Capsules may be required, and iPTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor such as <e2>ketoconazole</e2>. ",True,advise
fat-soluble vitamins,cholestyramine,43,62,73,86,"Drugs that impair intestinal absorption of <e1>fat-soluble vitamins</e1>, such as <e2>cholestyramine</e2>, may interfere with the absorption of Zemplar Capsules.",True,mechanism
fat-soluble vitamins,Zemplar,43,62,126,132,"Drugs that impair intestinal absorption of <e1>fat-soluble vitamins</e1>, such as cholestyramine, may interfere with the absorption of <e2>Zemplar</e2> Capsules.",False,negative
cholestyramine,Zemplar,73,86,126,132,"Drugs that impair intestinal absorption of fat-soluble vitamins, such as <e1>cholestyramine</e1>, may interfere with the absorption of <e2>Zemplar</e2> Capsules.",True,mechanism
lithium,Neulasta,19,25,31,38,patients receiving <e1>lithium</e1> and <e2>Neulasta</e2> should have more frequent monitoring of neutrophil counts.,True,advise
methadone,PEG-Intron,86,94,112,121,"In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving <e1>methadone</e1>, treatment with <e2>PEG-Intron</e2> once weekly for 4 weeks was associated with a mean increase of 16% in methadone AUC; ",True,mechanism
methadone,methadone,86,94,193,201,"In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving <e1>methadone</e1>, treatment with PEG-Intron once weekly for 4 weeks was associated with a mean increase of 16% in <e2>methadone</e2> AUC; ",False,negative
PEG-Intron,methadone,112,121,193,201,"In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving methadone, treatment with <e1>PEG-Intron</e1> once weekly for 4 weeks was associated with a mean increase of 16% in <e2>methadone</e2> AUC; ",False,negative
insulin,hypoglycemic,63,69,83,94,Acromegalic patients with diabetes mellitus being treated with <e1>insulin</e1> and/or oral <e2>hypoglycemic</e2> agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT. ,False,negative
insulin,SOMAVERT,63,69,196,203,Acromegalic patients with diabetes mellitus being treated with <e1>insulin</e1> and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with <e2>SOMAVERT</e2>. ,True,advise
hypoglycemic,SOMAVERT,83,94,196,203,Acromegalic patients with diabetes mellitus being treated with insulin and/or oral <e1>hypoglycemic</e1> agents may require dose reductions of these therapeutic agents after the initiation of therapy with <e2>SOMAVERT</e2>. ,True,advise
opioids,pegvisomant,33,39,67,77,"In clinical studies, patients on <e1>opioids</e1> often needed higher serum <e2>pegvisomant</e2> concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids. ",True,mechanism
opioids,opioids,33,39,172,178,"In clinical studies, patients on <e1>opioids</e1> often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving <e2>opioids</e2>. ",False,negative
pegvisomant,opioids,67,77,172,178,"In clinical studies, patients on opioids often needed higher serum <e1>pegvisomant</e1> concentrations to achieve appropriate IGF-I suppression compared with patients not receiving <e2>opioids</e2>. ",False,negative
probenecid,ALIMTA,81,90,142,147,"Concomitant administration of substances that are also tubularly secreted (e.g., <e1>probenecid</e1>) could potentially result in delayed clearance of <e2>ALIMTA</e2>. ",True,mechanism
ibuprofen,ALIMTA,9,17,57,62,"Although <e1>ibuprofen</e1> (400 mg qid) can be administered with <e2>ALIMTA</e2> in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering ibuprofen concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). ",False,negative
ibuprofen,ibuprofen,9,17,182,190,"Although <e1>ibuprofen</e1> (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering <e2>ibuprofen</e2> concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). ",False,negative
ibuprofen,ALIMTA,9,17,210,215,"Although <e1>ibuprofen</e1> (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering ibuprofen concurrently with <e2>ALIMTA</e2> to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). ",False,negative
ALIMTA,ibuprofen,57,62,182,190,"Although ibuprofen (400 mg qid) can be administered with <e1>ALIMTA</e1> in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering <e2>ibuprofen</e2> concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). ",False,negative
ALIMTA,ALIMTA,57,62,210,215,"Although ibuprofen (400 mg qid) can be administered with <e1>ALIMTA</e1> in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering ibuprofen concurrently with <e2>ALIMTA</e2> to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). ",False,negative
ibuprofen,ALIMTA,182,190,210,215,"Although ibuprofen (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering <e1>ibuprofen</e1> concurrently with <e2>ALIMTA</e2> to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). ",True,advise
NSAIDs,ALIMTA,71,76,194,199,"Patients with mild to moderate renal insufficiency should avoid taking <e1>NSAIDs</e1> with short elimination half-lives for a period of 2 days before, the day of, and 2 days following administration of <e2>ALIMTA</e2>. ",True,advise
ALIMTA,NSAIDs,63,68,74,79,"In the absence of data regarding potential interaction between <e1>ALIMTA</e1> and <e2>NSAIDs</e2> with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least 5 days before, the day of, and 2 days following ALIMTA administration. ",False,negative
ALIMTA,NSAIDs,63,68,131,136,"In the absence of data regarding potential interaction between <e1>ALIMTA</e1> and NSAIDs with longer half-lives, all patients taking these <e2>NSAIDs</e2> should interrupt dosing for at least 5 days before, the day of, and 2 days following ALIMTA administration. ",False,negative
ALIMTA,ALIMTA,63,68,223,228,"In the absence of data regarding potential interaction between <e1>ALIMTA</e1> and NSAIDs with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least 5 days before, the day of, and 2 days following <e2>ALIMTA</e2> administration. ",False,negative
NSAIDs,NSAIDs,74,79,131,136,"In the absence of data regarding potential interaction between ALIMTA and <e1>NSAIDs</e1> with longer half-lives, all patients taking these <e2>NSAIDs</e2> should interrupt dosing for at least 5 days before, the day of, and 2 days following ALIMTA administration. ",False,negative
NSAIDs,ALIMTA,74,79,223,228,"In the absence of data regarding potential interaction between ALIMTA and <e1>NSAIDs</e1> with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least 5 days before, the day of, and 2 days following <e2>ALIMTA</e2> administration. ",False,negative
NSAIDs,ALIMTA,131,136,223,228,"In the absence of data regarding potential interaction between ALIMTA and NSAIDs with longer half-lives, all patients taking these <e1>NSAIDs</e1> should interrupt dosing for at least 5 days before, the day of, and 2 days following <e2>ALIMTA</e2> administration. ",True,advise
CYLERT,pemoline,19,24,27,34,The interaction of <e1>CYLERT</e1> (<e2>pemoline</e2>) with other drugs has not been studied in humans. ,False,negative
CYLERT,antiepileptic medications,68,73,94,118,Decreased seizure threshold has been reported in patients receiving <e1>CYLERT</e1> concomitantly with <e2>antiepileptic medications</e2>.,True,effect
bacteriostatic antibiotics,erythromycin,29,54,63,74,"Concurrent administration of <e1>bacteriostatic antibiotics</e1> (e.g., <e2>erythromycin</e2>, tetracycline) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth. ",False,negative
bacteriostatic antibiotics,tetracycline,29,54,77,88,"Concurrent administration of <e1>bacteriostatic antibiotics</e1> (e.g., erythromycin, <e2>tetracycline</e2>) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth. ",False,negative
bacteriostatic antibiotics,penicillins,29,54,132,142,"Concurrent administration of <e1>bacteriostatic antibiotics</e1> (e.g., erythromycin, tetracycline) may diminish the bactericidal effects of <e2>penicillins</e2> by slowing the rate of bacterial growth. ",True,effect
erythromycin,tetracycline,63,74,77,88,"Concurrent administration of bacteriostatic antibiotics (e.g., <e1>erythromycin</e1>, <e2>tetracycline</e2>) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth. ",False,negative
erythromycin,penicillins,63,74,132,142,"Concurrent administration of bacteriostatic antibiotics (e.g., <e1>erythromycin</e1>, tetracycline) may diminish the bactericidal effects of <e2>penicillins</e2> by slowing the rate of bacterial growth. ",True,effect
tetracycline,penicillins,77,88,132,142,"Concurrent administration of bacteriostatic antibiotics (e.g., erythromycin, <e1>tetracycline</e1>) may diminish the bactericidal effects of <e2>penicillins</e2> by slowing the rate of bacterial growth. ",True,effect
Penicillin,probenecid,0,9,73,82,<e1>Penicillin</e1> blood levels may be prolonged by concurrent administration of <e2>probenecid</e2> which blocks the renal tubular secretion of penicillins. ,True,mechanism
Penicillin,penicillins,0,9,128,138,<e1>Penicillin</e1> blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of <e2>penicillins</e2>. ,False,negative
probenecid,penicillins,73,82,128,138,Penicillin blood levels may be prolonged by concurrent administration of <e1>probenecid</e1> which blocks the renal tubular secretion of <e2>penicillins</e2>. ,False,negative
penicillin,penicillin,16,25,92,101,Displacement of <e1>penicillin</e1> from plasma protein binding sites will elevate the level of free <e2>penicillin</e2> in the serum.,False,negative
Alcohol,alcohol,11,17,80,86,"Usage with <e1>Alcohol</e1>: Due to the potential for increased CNS depressants effects, <e2>alcohol</e2> should be used with caution in patients who are currently receiving pentazocine.",False,negative
Alcohol,pentazocine,11,17,156,166,"Usage with <e1>Alcohol</e1>: Due to the potential for increased CNS depressants effects, alcohol should be used with caution in patients who are currently receiving <e2>pentazocine</e2>.",False,negative
alcohol,pentazocine,80,86,156,166,"Usage with Alcohol: Due to the potential for increased CNS depressants effects, <e1>alcohol</e1> should be used with caution in patients who are currently receiving <e2>pentazocine</e2>.",True,advise
TRENTAL,anticoagulants,152,158,177,190,"Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with <e1>TRENTAL</e1> with and without <e2>anticoagulants</e2> or platelet aggregation inhibitors. ",True,effect
TRENTAL,platelet aggregation inhibitors,152,158,195,225,"Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with <e1>TRENTAL</e1> with and without anticoagulants or <e2>platelet aggregation inhibitors</e2>. ",True,effect
anticoagulants,platelet aggregation inhibitors,177,190,195,225,"Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without <e1>anticoagulants</e1> or <e2>platelet aggregation inhibitors</e2>. ",False,negative
TRENTAL,theophylline,30,36,42,53,Concomitant administration of <e1>TRENTAL</e1> and <e2>theophylline</e2>-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. ,True,mechanism
TRENTAL,theophylline,30,36,91,102,Concomitant administration of <e1>TRENTAL</e1> and theophylline-containing drugs leads to increased <e2>theophylline</e2> levels and theophylline toxicity in some individuals. ,False,negative
TRENTAL,theophylline,30,36,115,126,Concomitant administration of <e1>TRENTAL</e1> and theophylline-containing drugs leads to increased theophylline levels and <e2>theophylline</e2> toxicity in some individuals. ,False,negative
theophylline,theophylline,42,53,91,102,Concomitant administration of TRENTAL and <e1>theophylline</e1>-containing drugs leads to increased <e2>theophylline</e2> levels and theophylline toxicity in some individuals. ,False,negative
theophylline,theophylline,42,53,115,126,Concomitant administration of TRENTAL and <e1>theophylline</e1>-containing drugs leads to increased theophylline levels and <e2>theophylline</e2> toxicity in some individuals. ,False,negative
theophylline,theophylline,91,102,115,126,Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased <e1>theophylline</e1> levels and <e2>theophylline</e2> toxicity in some individuals. ,False,negative
TRENTAL,antihypertensive drugs,0,6,40,61,"<e1>TRENTAL</e1> has been used concurrently with <e2>antihypertensive drugs</e2>, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",False,negative
TRENTAL,beta blockers,0,6,64,76,"<e1>TRENTAL</e1> has been used concurrently with antihypertensive drugs, <e2>beta blockers</e2>, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",False,negative
TRENTAL,digitalis,0,6,79,87,"<e1>TRENTAL</e1> has been used concurrently with antihypertensive drugs, beta blockers, <e2>digitalis</e2>, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",False,negative
TRENTAL,diuretics,0,6,90,98,"<e1>TRENTAL</e1> has been used concurrently with antihypertensive drugs, beta blockers, digitalis, <e2>diuretics</e2>, antidiabetic agents, and antiarrhythmics, without observed problems. ",False,negative
TRENTAL,antidiabetic agents,0,6,101,119,"<e1>TRENTAL</e1> has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, <e2>antidiabetic agents</e2>, and antiarrhythmics, without observed problems. ",False,negative
TRENTAL,antiarrhythmics,0,6,126,140,"<e1>TRENTAL</e1> has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and <e2>antiarrhythmics</e2>, without observed problems. ",False,negative
antihypertensive drugs,beta blockers,40,61,64,76,"TRENTAL has been used concurrently with <e1>antihypertensive drugs</e1>, <e2>beta blockers</e2>, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",False,negative
antihypertensive drugs,digitalis,40,61,79,87,"TRENTAL has been used concurrently with <e1>antihypertensive drugs</e1>, beta blockers, <e2>digitalis</e2>, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",False,negative
antihypertensive drugs,diuretics,40,61,90,98,"TRENTAL has been used concurrently with <e1>antihypertensive drugs</e1>, beta blockers, digitalis, <e2>diuretics</e2>, antidiabetic agents, and antiarrhythmics, without observed problems. ",False,negative
antihypertensive drugs,antidiabetic agents,40,61,101,119,"TRENTAL has been used concurrently with <e1>antihypertensive drugs</e1>, beta blockers, digitalis, diuretics, <e2>antidiabetic agents</e2>, and antiarrhythmics, without observed problems. ",False,negative
antihypertensive drugs,antiarrhythmics,40,61,126,140,"TRENTAL has been used concurrently with <e1>antihypertensive drugs</e1>, beta blockers, digitalis, diuretics, antidiabetic agents, and <e2>antiarrhythmics</e2>, without observed problems. ",False,negative
beta blockers,digitalis,64,76,79,87,"TRENTAL has been used concurrently with antihypertensive drugs, <e1>beta blockers</e1>, <e2>digitalis</e2>, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",False,negative
beta blockers,diuretics,64,76,90,98,"TRENTAL has been used concurrently with antihypertensive drugs, <e1>beta blockers</e1>, digitalis, <e2>diuretics</e2>, antidiabetic agents, and antiarrhythmics, without observed problems. ",False,negative
beta blockers,antidiabetic agents,64,76,101,119,"TRENTAL has been used concurrently with antihypertensive drugs, <e1>beta blockers</e1>, digitalis, diuretics, <e2>antidiabetic agents</e2>, and antiarrhythmics, without observed problems. ",False,negative
beta blockers,antiarrhythmics,64,76,126,140,"TRENTAL has been used concurrently with antihypertensive drugs, <e1>beta blockers</e1>, digitalis, diuretics, antidiabetic agents, and <e2>antiarrhythmics</e2>, without observed problems. ",False,negative
digitalis,diuretics,79,87,90,98,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, <e1>digitalis</e1>, <e2>diuretics</e2>, antidiabetic agents, and antiarrhythmics, without observed problems. ",False,negative
digitalis,antidiabetic agents,79,87,101,119,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, <e1>digitalis</e1>, diuretics, <e2>antidiabetic agents</e2>, and antiarrhythmics, without observed problems. ",False,negative
digitalis,antiarrhythmics,79,87,126,140,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, <e1>digitalis</e1>, diuretics, antidiabetic agents, and <e2>antiarrhythmics</e2>, without observed problems. ",False,negative
diuretics,antidiabetic agents,90,98,101,119,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, <e1>diuretics</e1>, <e2>antidiabetic agents</e2>, and antiarrhythmics, without observed problems. ",False,negative
diuretics,antiarrhythmics,90,98,126,140,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, <e1>diuretics</e1>, antidiabetic agents, and <e2>antiarrhythmics</e2>, without observed problems. ",False,negative
antidiabetic agents,antiarrhythmics,101,119,126,140,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, <e1>antidiabetic agents</e1>, and <e2>antiarrhythmics</e2>, without observed problems. ",False,negative
Dopamine antagonists,neuroleptics,0,19,34,45,"<e1>Dopamine antagonists</e1>, such as the <e2>neuroleptics</e2> (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",False,negative
Dopamine antagonists,phenothiazines,0,19,48,61,"<e1>Dopamine antagonists</e1>, such as the neuroleptics (<e2>phenothiazines</e2>, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",False,negative
Dopamine antagonists,butyrophenones,0,19,64,77,"<e1>Dopamine antagonists</e1>, such as the neuroleptics (phenothiazines, <e2>butyrophenones</e2>, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",False,negative
Dopamine antagonists,thioxanthines,0,19,80,92,"<e1>Dopamine antagonists</e1>, such as the neuroleptics (phenothiazines, butyrophenones, <e2>thioxanthines</e2> ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",False,negative
Dopamine antagonists,metoclopramide,0,19,99,112,"<e1>Dopamine antagonists</e1>, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or <e2>metoclopramide</e2>, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",False,negative
Dopamine antagonists,Permax,0,19,171,176,"<e1>Dopamine antagonists</e1>, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with <e2>Permax</e2> (a dopamine agonist); ",True,advise
Dopamine antagonists,dopamine agonist,0,19,181,196,"<e1>Dopamine antagonists</e1>, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a <e2>dopamine agonist</e2>); ",False,negative
neuroleptics,phenothiazines,34,45,48,61,"Dopamine antagonists, such as the <e1>neuroleptics</e1> (<e2>phenothiazines</e2>, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",False,negative
neuroleptics,butyrophenones,34,45,64,77,"Dopamine antagonists, such as the <e1>neuroleptics</e1> (phenothiazines, <e2>butyrophenones</e2>, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",False,negative
neuroleptics,thioxanthines,34,45,80,92,"Dopamine antagonists, such as the <e1>neuroleptics</e1> (phenothiazines, butyrophenones, <e2>thioxanthines</e2> ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",False,negative
neuroleptics,metoclopramide,34,45,99,112,"Dopamine antagonists, such as the <e1>neuroleptics</e1> (phenothiazines, butyrophenones, thioxanthines ) or <e2>metoclopramide</e2>, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",False,negative
neuroleptics,Permax,34,45,171,176,"Dopamine antagonists, such as the <e1>neuroleptics</e1> (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with <e2>Permax</e2> (a dopamine agonist); ",True,advise
neuroleptics,dopamine agonist,34,45,181,196,"Dopamine antagonists, such as the <e1>neuroleptics</e1> (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a <e2>dopamine agonist</e2>); ",False,negative
phenothiazines,butyrophenones,48,61,64,77,"Dopamine antagonists, such as the neuroleptics (<e1>phenothiazines</e1>, <e2>butyrophenones</e2>, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",False,negative
phenothiazines,thioxanthines,48,61,80,92,"Dopamine antagonists, such as the neuroleptics (<e1>phenothiazines</e1>, butyrophenones, <e2>thioxanthines</e2> ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",False,negative
phenothiazines,metoclopramide,48,61,99,112,"Dopamine antagonists, such as the neuroleptics (<e1>phenothiazines</e1>, butyrophenones, thioxanthines ) or <e2>metoclopramide</e2>, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",False,negative
phenothiazines,Permax,48,61,171,176,"Dopamine antagonists, such as the neuroleptics (<e1>phenothiazines</e1>, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with <e2>Permax</e2> (a dopamine agonist); ",True,advise
phenothiazines,dopamine agonist,48,61,181,196,"Dopamine antagonists, such as the neuroleptics (<e1>phenothiazines</e1>, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a <e2>dopamine agonist</e2>); ",False,negative
butyrophenones,thioxanthines,64,77,80,92,"Dopamine antagonists, such as the neuroleptics (phenothiazines, <e1>butyrophenones</e1>, <e2>thioxanthines</e2> ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",False,negative
butyrophenones,metoclopramide,64,77,99,112,"Dopamine antagonists, such as the neuroleptics (phenothiazines, <e1>butyrophenones</e1>, thioxanthines ) or <e2>metoclopramide</e2>, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",False,negative
butyrophenones,Permax,64,77,171,176,"Dopamine antagonists, such as the neuroleptics (phenothiazines, <e1>butyrophenones</e1>, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with <e2>Permax</e2> (a dopamine agonist); ",True,advise
butyrophenones,dopamine agonist,64,77,181,196,"Dopamine antagonists, such as the neuroleptics (phenothiazines, <e1>butyrophenones</e1>, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a <e2>dopamine agonist</e2>); ",False,negative
thioxanthines,metoclopramide,80,92,99,112,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, <e1>thioxanthines</e1> ) or <e2>metoclopramide</e2>, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",False,negative
thioxanthines,Permax,80,92,171,176,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, <e1>thioxanthines</e1> ) or metoclopramide, ordinarily should not be administered concurrently with <e2>Permax</e2> (a dopamine agonist); ",True,advise
thioxanthines,dopamine agonist,80,92,181,196,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, <e1>thioxanthines</e1> ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a <e2>dopamine agonist</e2>); ",False,negative
metoclopramide,Permax,99,112,171,176,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or <e1>metoclopramide</e1>, ordinarily should not be administered concurrently with <e2>Permax</e2> (a dopamine agonist); ",True,advise
metoclopramide,dopamine agonist,99,112,181,196,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or <e1>metoclopramide</e1>, ordinarily should not be administered concurrently with Permax (a <e2>dopamine agonist</e2>); ",False,negative
Permax,dopamine agonist,171,176,181,196,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with <e1>Permax</e1> (a <e2>dopamine agonist</e2>); ",False,negative
pergolide mesylate,pergolide mesylate,8,25,105,122,"Because <e1>pergolide mesylate</e1> is approximately 90% bound to plasma proteins, caution should be exercised if <e2>pergolide mesylate</e2> is coadministered with other drugs known to affect protein binding.",False,negative
Diuretics,diuretics,0,8,23,31,"<e1>Diuretics</e1>: Patients on <e2>diuretics</e2>, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of ACEON    Tablets therapy. ",False,negative
Diuretics,ACEON,0,8,162,166,"<e1>Diuretics</e1>: Patients on diuretics, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of <e2>ACEON</e2>    Tablets therapy. ",False,negative
diuretics,ACEON,23,31,162,166,"Diuretics: Patients on <e1>diuretics</e1>, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of <e2>ACEON</e2>    Tablets therapy. ",True,effect
diuretic,perindopril,84,91,161,171,The possibility of hypotensive effects can be minimized by either discontinuing the <e1>diuretic</e1> or increasing the salt intake prior to initiation of treatment with <e2>perindopril</e2>. ,True,effect
diuretics,ACEON,3,11,104,108,"If <e1>diuretics</e1> cannot be interrupted, close medical supervision should be provided with the first dose of <e2>ACEON</e2>    Tablets, for at least two hours and until blood pressure has stabilized for another hour. ",True,advise
perindopril,diuretics,23,33,94,102,The rate and extent of <e1>perindopril</e1> absorption and elimination are not affected by concomitant <e2>diuretics</e2>. ,False,negative
perindoprilat,diuretics,23,35,52,60,"The bioavailability of <e1>perindoprilat</e1> was reduced by <e2>diuretics</e2>, however, and this was associated with a decrease in plasma ACE inhibition. ",False,negative
Potassium,Potassium-Sparing Diuretics,0,8,26,52,<e1>Potassium</e1> Supplements and <e2>Potassium-Sparing Diuretics</e2>: ACEON    Tablets may increase serum potassium because of its potential to decrease aldosterone production. ,False,negative
Potassium,ACEON,0,8,55,59,<e1>Potassium</e1> Supplements and Potassium-Sparing Diuretics: <e2>ACEON</e2>    Tablets may increase serum potassium because of its potential to decrease aldosterone production. ,False,negative
Potassium-Sparing Diuretics,ACEON,26,52,55,59,Potassium Supplements and <e1>Potassium-Sparing Diuretics</e1>: <e2>ACEON</e2>    Tablets may increase serum potassium because of its potential to decrease aldosterone production. ,False,negative
potassium-sparing diuretics,spironolactone,7,33,36,49,"Use of <e1>potassium-sparing diuretics</e1> (<e2>spironolactone</e2>, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",False,negative
potassium-sparing diuretics,amiloride,7,33,52,60,"Use of <e1>potassium-sparing diuretics</e1> (spironolactone, <e2>amiloride</e2>, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",False,negative
potassium-sparing diuretics,triamterene,7,33,63,73,"Use of <e1>potassium-sparing diuretics</e1> (spironolactone, amiloride, <e2>triamterene</e2> and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",False,negative
potassium-sparing diuretics,potassium,7,33,88,96,"Use of <e1>potassium-sparing diuretics</e1> (spironolactone, amiloride, triamterene and others), <e2>potassium</e2> supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",False,negative
potassium-sparing diuretics,indomethacin,7,33,164,175,"Use of <e1>potassium-sparing diuretics</e1> (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (<e2>indomethacin</e2>, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",False,negative
potassium-sparing diuretics,heparin,7,33,178,184,"Use of <e1>potassium-sparing diuretics</e1> (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, <e2>heparin</e2>, cyclosporine and others) can increase the risk of hyperkalemia. ",False,negative
potassium-sparing diuretics,cyclosporine,7,33,187,198,"Use of <e1>potassium-sparing diuretics</e1> (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, <e2>cyclosporine</e2> and others) can increase the risk of hyperkalemia. ",False,negative
spironolactone,amiloride,36,49,52,60,"Use of potassium-sparing diuretics (<e1>spironolactone</e1>, <e2>amiloride</e2>, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",False,negative
spironolactone,triamterene,36,49,63,73,"Use of potassium-sparing diuretics (<e1>spironolactone</e1>, amiloride, <e2>triamterene</e2> and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",False,negative
spironolactone,potassium,36,49,88,96,"Use of potassium-sparing diuretics (<e1>spironolactone</e1>, amiloride, triamterene and others), <e2>potassium</e2> supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",False,negative
spironolactone,indomethacin,36,49,164,175,"Use of potassium-sparing diuretics (<e1>spironolactone</e1>, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (<e2>indomethacin</e2>, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",False,negative
spironolactone,heparin,36,49,178,184,"Use of potassium-sparing diuretics (<e1>spironolactone</e1>, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, <e2>heparin</e2>, cyclosporine and others) can increase the risk of hyperkalemia. ",False,negative
spironolactone,cyclosporine,36,49,187,198,"Use of potassium-sparing diuretics (<e1>spironolactone</e1>, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, <e2>cyclosporine</e2> and others) can increase the risk of hyperkalemia. ",False,negative
amiloride,triamterene,52,60,63,73,"Use of potassium-sparing diuretics (spironolactone, <e1>amiloride</e1>, <e2>triamterene</e2> and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",False,negative
amiloride,potassium,52,60,88,96,"Use of potassium-sparing diuretics (spironolactone, <e1>amiloride</e1>, triamterene and others), <e2>potassium</e2> supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",False,negative
amiloride,indomethacin,52,60,164,175,"Use of potassium-sparing diuretics (spironolactone, <e1>amiloride</e1>, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (<e2>indomethacin</e2>, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",False,negative
amiloride,heparin,52,60,178,184,"Use of potassium-sparing diuretics (spironolactone, <e1>amiloride</e1>, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, <e2>heparin</e2>, cyclosporine and others) can increase the risk of hyperkalemia. ",False,negative
amiloride,cyclosporine,52,60,187,198,"Use of potassium-sparing diuretics (spironolactone, <e1>amiloride</e1>, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, <e2>cyclosporine</e2> and others) can increase the risk of hyperkalemia. ",False,negative
triamterene,potassium,63,73,88,96,"Use of potassium-sparing diuretics (spironolactone, amiloride, <e1>triamterene</e1> and others), <e2>potassium</e2> supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",False,negative
triamterene,indomethacin,63,73,164,175,"Use of potassium-sparing diuretics (spironolactone, amiloride, <e1>triamterene</e1> and others), potassium supplements or other drugs capable of increasing serum potassium (<e2>indomethacin</e2>, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",False,negative
triamterene,heparin,63,73,178,184,"Use of potassium-sparing diuretics (spironolactone, amiloride, <e1>triamterene</e1> and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, <e2>heparin</e2>, cyclosporine and others) can increase the risk of hyperkalemia. ",False,negative
triamterene,cyclosporine,63,73,187,198,"Use of potassium-sparing diuretics (spironolactone, amiloride, <e1>triamterene</e1> and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, <e2>cyclosporine</e2> and others) can increase the risk of hyperkalemia. ",False,negative
potassium,indomethacin,88,96,164,175,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), <e1>potassium</e1> supplements or other drugs capable of increasing serum potassium (<e2>indomethacin</e2>, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",False,negative
potassium,heparin,88,96,178,184,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), <e1>potassium</e1> supplements or other drugs capable of increasing serum potassium (indomethacin, <e2>heparin</e2>, cyclosporine and others) can increase the risk of hyperkalemia. ",False,negative
potassium,cyclosporine,88,96,187,198,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), <e1>potassium</e1> supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, <e2>cyclosporine</e2> and others) can increase the risk of hyperkalemia. ",False,negative
indomethacin,heparin,164,175,178,184,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (<e1>indomethacin</e1>, <e2>heparin</e2>, cyclosporine and others) can increase the risk of hyperkalemia. ",False,negative
indomethacin,cyclosporine,164,175,187,198,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (<e1>indomethacin</e1>, heparin, <e2>cyclosporine</e2> and others) can increase the risk of hyperkalemia. ",False,negative
heparin,cyclosporine,178,184,187,198,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, <e1>heparin</e1>, <e2>cyclosporine</e2> and others) can increase the risk of hyperkalemia. ",False,negative
Lithium,lithium,0,6,25,31,<e1>Lithium</e1>: Increased serum <e2>lithium</e2> and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. ,False,negative
Lithium,lithium,0,6,49,55,<e1>Lithium</e1>: Increased serum lithium and symptoms of <e2>lithium</e2> toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. ,False,negative
Lithium,lithium,0,6,119,125,<e1>Lithium</e1>: Increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant <e2>lithium</e2> and ACE inhibitor therapy. ,False,negative
lithium,lithium,25,31,49,55,Lithium: Increased serum <e1>lithium</e1> and symptoms of <e2>lithium</e2> toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. ,False,negative
lithium,lithium,25,31,119,125,Lithium: Increased serum <e1>lithium</e1> and symptoms of lithium toxicity have been reported in patients receiving concomitant <e2>lithium</e2> and ACE inhibitor therapy. ,False,negative
lithium,lithium,49,55,119,125,Lithium: Increased serum lithium and symptoms of <e1>lithium</e1> toxicity have been reported in patients receiving concomitant <e2>lithium</e2> and ACE inhibitor therapy. ,False,negative
diuretic,lithium,9,16,51,57,Use of a <e1>diuretic</e1> may further increase the risk of <e2>lithium</e2> toxicity. ,False,negative
Digoxin,digoxin,0,6,74,80,"<e1>Digoxin</e1>: A controlled pharmacokinetic study has shown no effect on plasma <e2>digoxin</e2> concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",False,negative
Digoxin,ACEON,0,6,122,126,"<e1>Digoxin</e1>: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with <e2>ACEON</e2>    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",False,negative
Digoxin,digoxin,0,6,157,163,"<e1>Digoxin</e1>: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of <e2>digoxin</e2> on the plasma concentration of perindopril/perindoprilat has not been excluded. ",False,negative
Digoxin,perindopril,0,6,196,206,"<e1>Digoxin</e1>: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of <e2>perindopril</e2>/perindoprilat has not been excluded. ",False,negative
Digoxin,perindoprilat,0,6,208,220,"<e1>Digoxin</e1>: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/<e2>perindoprilat</e2> has not been excluded. ",False,negative
digoxin,ACEON,74,80,122,126,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma <e1>digoxin</e1> concentrations when coadministered with <e2>ACEON</e2>    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",False,negative
digoxin,digoxin,74,80,157,163,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma <e1>digoxin</e1> concentrations when coadministered with ACEON    Tablets, but an effect of <e2>digoxin</e2> on the plasma concentration of perindopril/perindoprilat has not been excluded. ",False,negative
digoxin,perindopril,74,80,196,206,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma <e1>digoxin</e1> concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of <e2>perindopril</e2>/perindoprilat has not been excluded. ",False,negative
digoxin,perindoprilat,74,80,208,220,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma <e1>digoxin</e1> concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/<e2>perindoprilat</e2> has not been excluded. ",False,negative
ACEON,digoxin,122,126,157,163,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with <e1>ACEON</e1>    Tablets, but an effect of <e2>digoxin</e2> on the plasma concentration of perindopril/perindoprilat has not been excluded. ",False,negative
ACEON,perindopril,122,126,196,206,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with <e1>ACEON</e1>    Tablets, but an effect of digoxin on the plasma concentration of <e2>perindopril</e2>/perindoprilat has not been excluded. ",False,negative
ACEON,perindoprilat,122,126,208,220,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with <e1>ACEON</e1>    Tablets, but an effect of digoxin on the plasma concentration of perindopril/<e2>perindoprilat</e2> has not been excluded. ",False,negative
digoxin,perindopril,157,163,196,206,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of <e1>digoxin</e1> on the plasma concentration of <e2>perindopril</e2>/perindoprilat has not been excluded. ",True,mechanism
digoxin,perindoprilat,157,163,208,220,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of <e1>digoxin</e1> on the plasma concentration of perindopril/<e2>perindoprilat</e2> has not been excluded. ",True,mechanism
perindopril,perindoprilat,196,206,208,220,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of <e1>perindopril</e1>/<e2>perindoprilat</e2> has not been excluded. ",False,negative
Gentamicin,perindopril,0,9,78,88,<e1>Gentamicin</e1>: Animal data have suggested the possibility of interaction between <e2>perindopril</e2> and gentamicin. ,False,negative
Gentamicin,gentamicin,0,9,94,103,<e1>Gentamicin</e1>: Animal data have suggested the possibility of interaction between perindopril and <e2>gentamicin</e2>. ,False,negative
perindopril,gentamicin,78,88,94,103,Gentamicin: Animal data have suggested the possibility of interaction between <e1>perindopril</e1> and <e2>gentamicin</e2>. ,True,int
ACEON,perindopril,41,45,119,129,Food Interaction: Oral administration of <e1>ACEON</e1>    Tablets with food does not significantly lower the rate or extent of <e2>perindopril</e2> absorption relative to the fasted state. ,False,negative
perindopril,perindoprilat,44,54,82,94,"However, the extent of biotransformation of <e1>perindopril</e1> to the active metabolite, <e2>perindoprilat</e2>, is reduced approximately 43%, resulting in a reduction in the plasma ACE inhibition curve of approximately 20%, probably clinically insignificant. ",False,negative
alcohol,phentermine hydrochloride,19,25,32,56,Concomitant use of <e1>alcohol</e1> with <e2>phentermine hydrochloride</e2> may result in an adverse drug interaction.,True,int
Vasopressors,metaraminol,0,11,27,37,"<e1>Vasopressors</e1>, particularly <e2>metaraminol</e2>, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. ",False,negative
Vasopressors,halothane,0,11,85,93,"<e1>Vasopressors</e1>, particularly metaraminol, may cause serious cardiac arrhythmias during <e2>halothane</e2> anesthesia and therefore should be used only with great caution or not at all. ",True,effect
metaraminol,halothane,27,37,85,93,"Vasopressors, particularly <e1>metaraminol</e1>, may cause serious cardiac arrhythmias during <e2>halothane</e2> anesthesia and therefore should be used only with great caution or not at all. ",True,effect
MAO Inhibitors,sympathomimetic pressor amines,0,13,38,67,<e1>MAO Inhibitors</e1>: The pressor effect of <e2>sympathomimetic pressor amines</e2> is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,False,negative
MAO Inhibitors,monoamine oxidase inhibitors,0,13,115,142,<e1>MAO Inhibitors</e1>: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving <e2>monoamine oxidase inhibitors</e2> (MAOI). ,False,negative
MAO Inhibitors,MAOI,0,13,145,148,<e1>MAO Inhibitors</e1>: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (<e2>MAOI</e2>). ,False,negative
sympathomimetic pressor amines,monoamine oxidase inhibitors,38,67,115,142,MAO Inhibitors: The pressor effect of <e1>sympathomimetic pressor amines</e1> is markedly potentiated in patients receiving <e2>monoamine oxidase inhibitors</e2> (MAOI). ,True,effect
sympathomimetic pressor amines,MAOI,38,67,145,148,MAO Inhibitors: The pressor effect of <e1>sympathomimetic pressor amines</e1> is markedly potentiated in patients receiving monoamine oxidase inhibitors (<e2>MAOI</e2>). ,True,effect
monoamine oxidase inhibitors,MAOI,115,142,145,148,MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving <e1>monoamine oxidase inhibitors</e1> (<e2>MAOI</e2>). ,False,negative
adrenergic agents,tricyclic antidepressants,24,40,69,93,The pressor response of <e1>adrenergic agents</e1> may also be potentiated by <e2>tricyclic antidepressants</e2>.,True,effect
Vasopressors,metaraminol,0,11,27,37,"<e1>Vasopressors</e1>, particularly <e2>metaraminol</e2>, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. ",False,negative
Vasopressors,halothane,0,11,85,93,"<e1>Vasopressors</e1>, particularly metaraminol, may cause serious cardiac arrhythmias during <e2>halothane</e2> anesthesia and therefore should be used only with great caution or not at all. ",True,effect
metaraminol,halothane,27,37,85,93,"Vasopressors, particularly <e1>metaraminol</e1>, may cause serious cardiac arrhythmias during <e2>halothane</e2> anesthesia and therefore should be used only with great caution or not at all. ",True,effect
MAO Inhibitors,sympathomimetic pressor amines,0,13,39,68,<e1>MAO Inhibitors</e1> - The pressor effect of <e2>sympathomimetic pressor amines</e2> is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,False,negative
MAO Inhibitors,monoamine oxidase inhibitors,0,13,116,143,<e1>MAO Inhibitors</e1> - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving <e2>monoamine oxidase inhibitors</e2> (MAOI). ,False,negative
MAO Inhibitors,MAOI,0,13,146,149,<e1>MAO Inhibitors</e1> - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (<e2>MAOI</e2>). ,False,negative
sympathomimetic pressor amines,monoamine oxidase inhibitors,39,68,116,143,MAO Inhibitors - The pressor effect of <e1>sympathomimetic pressor amines</e1> is markedly potentiated in patients receiving <e2>monoamine oxidase inhibitors</e2> (MAOI). ,True,effect
sympathomimetic pressor amines,MAOI,39,68,146,149,MAO Inhibitors - The pressor effect of <e1>sympathomimetic pressor amines</e1> is markedly potentiated in patients receiving monoamine oxidase inhibitors (<e2>MAOI</e2>). ,True,effect
monoamine oxidase inhibitors,MAOI,116,143,146,149,MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving <e1>monoamine oxidase inhibitors</e1> (<e2>MAOI</e2>). ,False,negative
adrenergic agents,tricyclic antidepressants,24,40,69,93,The pressor response of <e1>adrenergic agents</e1> may also be potentiated by <e2>tricyclic antidepressants</e2>.,True,effect
Pilocarpine,beta adrenergic antagonists,0,10,67,93,<e1>Pilocarpine</e1> should be administered with caution to patients taking <e2>beta adrenergic antagonists</e2> because of the possibility of conduction disturbances. ,True,advise
atropine,ipratropium,146,153,164,174,"These effects should be considered when anticholinergic properties may be contributing to the therapeutic effect of concomitant medication (e.g., <e1>atropine</e1>, inhaled <e2>ipratropium</e2>). ",False,negative
acetylsalicylic acid,calcium,179,198,219,225,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: <e1>acetylsalicylic acid</e1>, artificial tears, <e2>calcium</e2>, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",False,negative
acetylsalicylic acid,conjugated estrogens,179,198,228,247,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: <e1>acetylsalicylic acid</e1>, artificial tears, calcium, <e2>conjugated estrogens</e2>, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",False,negative
acetylsalicylic acid,hydroxychloroquine sulfate,179,198,250,275,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: <e1>acetylsalicylic acid</e1>, artificial tears, calcium, conjugated estrogens, <e2>hydroxychloroquine sulfate</e2>, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",False,negative
acetylsalicylic acid,ibuprofen,179,198,278,286,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: <e1>acetylsalicylic acid</e1>, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, <e2>ibuprofen</e2>, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",False,negative
acetylsalicylic acid,levothyroxine sodium,179,198,289,308,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: <e1>acetylsalicylic acid</e1>, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, <e2>levothyroxine sodium</e2>, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",False,negative
acetylsalicylic acid,medroxyprogesterone acetate,179,198,311,337,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: <e1>acetylsalicylic acid</e1>, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, <e2>medroxyprogesterone acetate</e2>, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",False,negative
acetylsalicylic acid,methotrexate,179,198,340,351,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: <e1>acetylsalicylic acid</e1>, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, <e2>methotrexate</e2>, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",False,negative
acetylsalicylic acid,multivitamins,179,198,354,366,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: <e1>acetylsalicylic acid</e1>, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, <e2>multivitamins</e2>, naproxen, omeprazole, paracetamol, and prednisone.",False,negative
acetylsalicylic acid,naproxen,179,198,369,376,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: <e1>acetylsalicylic acid</e1>, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, <e2>naproxen</e2>, omeprazole, paracetamol, and prednisone.",False,negative
acetylsalicylic acid,omeprazole,179,198,379,388,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: <e1>acetylsalicylic acid</e1>, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, <e2>omeprazole</e2>, paracetamol, and prednisone.",False,negative
acetylsalicylic acid,paracetamol,179,198,391,401,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: <e1>acetylsalicylic acid</e1>, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, <e2>paracetamol</e2>, and prednisone.",False,negative
acetylsalicylic acid,prednisone,179,198,408,417,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: <e1>acetylsalicylic acid</e1>, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and <e2>prednisone</e2>.",False,negative
calcium,conjugated estrogens,219,225,228,247,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, <e1>calcium</e1>, <e2>conjugated estrogens</e2>, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",False,negative
calcium,hydroxychloroquine sulfate,219,225,250,275,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, <e1>calcium</e1>, conjugated estrogens, <e2>hydroxychloroquine sulfate</e2>, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",False,negative
calcium,ibuprofen,219,225,278,286,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, <e1>calcium</e1>, conjugated estrogens, hydroxychloroquine sulfate, <e2>ibuprofen</e2>, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",False,negative
calcium,levothyroxine sodium,219,225,289,308,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, <e1>calcium</e1>, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, <e2>levothyroxine sodium</e2>, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",False,negative
calcium,medroxyprogesterone acetate,219,225,311,337,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, <e1>calcium</e1>, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, <e2>medroxyprogesterone acetate</e2>, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",False,negative
calcium,methotrexate,219,225,340,351,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, <e1>calcium</e1>, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, <e2>methotrexate</e2>, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",False,negative
calcium,multivitamins,219,225,354,366,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, <e1>calcium</e1>, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, <e2>multivitamins</e2>, naproxen, omeprazole, paracetamol, and prednisone.",False,negative
calcium,naproxen,219,225,369,376,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, <e1>calcium</e1>, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, <e2>naproxen</e2>, omeprazole, paracetamol, and prednisone.",False,negative
calcium,omeprazole,219,225,379,388,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, <e1>calcium</e1>, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, <e2>omeprazole</e2>, paracetamol, and prednisone.",False,negative
calcium,paracetamol,219,225,391,401,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, <e1>calcium</e1>, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, <e2>paracetamol</e2>, and prednisone.",False,negative
calcium,prednisone,219,225,408,417,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, <e1>calcium</e1>, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and <e2>prednisone</e2>.",False,negative
conjugated estrogens,hydroxychloroquine sulfate,228,247,250,275,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, <e1>conjugated estrogens</e1>, <e2>hydroxychloroquine sulfate</e2>, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",False,negative
conjugated estrogens,ibuprofen,228,247,278,286,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, <e1>conjugated estrogens</e1>, hydroxychloroquine sulfate, <e2>ibuprofen</e2>, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",False,negative
conjugated estrogens,levothyroxine sodium,228,247,289,308,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, <e1>conjugated estrogens</e1>, hydroxychloroquine sulfate, ibuprofen, <e2>levothyroxine sodium</e2>, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",False,negative
conjugated estrogens,medroxyprogesterone acetate,228,247,311,337,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, <e1>conjugated estrogens</e1>, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, <e2>medroxyprogesterone acetate</e2>, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",False,negative
conjugated estrogens,methotrexate,228,247,340,351,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, <e1>conjugated estrogens</e1>, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, <e2>methotrexate</e2>, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",False,negative
conjugated estrogens,multivitamins,228,247,354,366,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, <e1>conjugated estrogens</e1>, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, <e2>multivitamins</e2>, naproxen, omeprazole, paracetamol, and prednisone.",False,negative
conjugated estrogens,naproxen,228,247,369,376,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, <e1>conjugated estrogens</e1>, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, <e2>naproxen</e2>, omeprazole, paracetamol, and prednisone.",False,negative
conjugated estrogens,omeprazole,228,247,379,388,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, <e1>conjugated estrogens</e1>, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, <e2>omeprazole</e2>, paracetamol, and prednisone.",False,negative
conjugated estrogens,paracetamol,228,247,391,401,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, <e1>conjugated estrogens</e1>, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, <e2>paracetamol</e2>, and prednisone.",False,negative
conjugated estrogens,prednisone,228,247,408,417,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, <e1>conjugated estrogens</e1>, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and <e2>prednisone</e2>.",False,negative
hydroxychloroquine sulfate,ibuprofen,250,275,278,286,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, <e1>hydroxychloroquine sulfate</e1>, <e2>ibuprofen</e2>, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",False,negative
hydroxychloroquine sulfate,levothyroxine sodium,250,275,289,308,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, <e1>hydroxychloroquine sulfate</e1>, ibuprofen, <e2>levothyroxine sodium</e2>, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",False,negative
hydroxychloroquine sulfate,medroxyprogesterone acetate,250,275,311,337,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, <e1>hydroxychloroquine sulfate</e1>, ibuprofen, levothyroxine sodium, <e2>medroxyprogesterone acetate</e2>, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",False,negative
hydroxychloroquine sulfate,methotrexate,250,275,340,351,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, <e1>hydroxychloroquine sulfate</e1>, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, <e2>methotrexate</e2>, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",False,negative
hydroxychloroquine sulfate,multivitamins,250,275,354,366,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, <e1>hydroxychloroquine sulfate</e1>, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, <e2>multivitamins</e2>, naproxen, omeprazole, paracetamol, and prednisone.",False,negative
hydroxychloroquine sulfate,naproxen,250,275,369,376,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, <e1>hydroxychloroquine sulfate</e1>, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, <e2>naproxen</e2>, omeprazole, paracetamol, and prednisone.",False,negative
hydroxychloroquine sulfate,omeprazole,250,275,379,388,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, <e1>hydroxychloroquine sulfate</e1>, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, <e2>omeprazole</e2>, paracetamol, and prednisone.",False,negative
hydroxychloroquine sulfate,paracetamol,250,275,391,401,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, <e1>hydroxychloroquine sulfate</e1>, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, <e2>paracetamol</e2>, and prednisone.",False,negative
hydroxychloroquine sulfate,prednisone,250,275,408,417,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, <e1>hydroxychloroquine sulfate</e1>, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and <e2>prednisone</e2>.",False,negative
ibuprofen,levothyroxine sodium,278,286,289,308,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, <e1>ibuprofen</e1>, <e2>levothyroxine sodium</e2>, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",False,negative
ibuprofen,medroxyprogesterone acetate,278,286,311,337,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, <e1>ibuprofen</e1>, levothyroxine sodium, <e2>medroxyprogesterone acetate</e2>, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",False,negative
ibuprofen,methotrexate,278,286,340,351,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, <e1>ibuprofen</e1>, levothyroxine sodium, medroxyprogesterone acetate, <e2>methotrexate</e2>, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",False,negative
ibuprofen,multivitamins,278,286,354,366,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, <e1>ibuprofen</e1>, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, <e2>multivitamins</e2>, naproxen, omeprazole, paracetamol, and prednisone.",False,negative
ibuprofen,naproxen,278,286,369,376,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, <e1>ibuprofen</e1>, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, <e2>naproxen</e2>, omeprazole, paracetamol, and prednisone.",False,negative
ibuprofen,omeprazole,278,286,379,388,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, <e1>ibuprofen</e1>, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, <e2>omeprazole</e2>, paracetamol, and prednisone.",False,negative
ibuprofen,paracetamol,278,286,391,401,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, <e1>ibuprofen</e1>, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, <e2>paracetamol</e2>, and prednisone.",False,negative
ibuprofen,prednisone,278,286,408,417,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, <e1>ibuprofen</e1>, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and <e2>prednisone</e2>.",False,negative
levothyroxine sodium,medroxyprogesterone acetate,289,308,311,337,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, <e1>levothyroxine sodium</e1>, <e2>medroxyprogesterone acetate</e2>, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",False,negative
levothyroxine sodium,methotrexate,289,308,340,351,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, <e1>levothyroxine sodium</e1>, medroxyprogesterone acetate, <e2>methotrexate</e2>, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",False,negative
levothyroxine sodium,multivitamins,289,308,354,366,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, <e1>levothyroxine sodium</e1>, medroxyprogesterone acetate, methotrexate, <e2>multivitamins</e2>, naproxen, omeprazole, paracetamol, and prednisone.",False,negative
levothyroxine sodium,naproxen,289,308,369,376,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, <e1>levothyroxine sodium</e1>, medroxyprogesterone acetate, methotrexate, multivitamins, <e2>naproxen</e2>, omeprazole, paracetamol, and prednisone.",False,negative
levothyroxine sodium,omeprazole,289,308,379,388,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, <e1>levothyroxine sodium</e1>, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, <e2>omeprazole</e2>, paracetamol, and prednisone.",False,negative
levothyroxine sodium,paracetamol,289,308,391,401,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, <e1>levothyroxine sodium</e1>, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, <e2>paracetamol</e2>, and prednisone.",False,negative
levothyroxine sodium,prednisone,289,308,408,417,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, <e1>levothyroxine sodium</e1>, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and <e2>prednisone</e2>.",False,negative
medroxyprogesterone acetate,methotrexate,311,337,340,351,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, <e1>medroxyprogesterone acetate</e1>, <e2>methotrexate</e2>, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",False,negative
medroxyprogesterone acetate,multivitamins,311,337,354,366,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, <e1>medroxyprogesterone acetate</e1>, methotrexate, <e2>multivitamins</e2>, naproxen, omeprazole, paracetamol, and prednisone.",False,negative
medroxyprogesterone acetate,naproxen,311,337,369,376,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, <e1>medroxyprogesterone acetate</e1>, methotrexate, multivitamins, <e2>naproxen</e2>, omeprazole, paracetamol, and prednisone.",False,negative
medroxyprogesterone acetate,omeprazole,311,337,379,388,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, <e1>medroxyprogesterone acetate</e1>, methotrexate, multivitamins, naproxen, <e2>omeprazole</e2>, paracetamol, and prednisone.",False,negative
medroxyprogesterone acetate,paracetamol,311,337,391,401,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, <e1>medroxyprogesterone acetate</e1>, methotrexate, multivitamins, naproxen, omeprazole, <e2>paracetamol</e2>, and prednisone.",False,negative
medroxyprogesterone acetate,prednisone,311,337,408,417,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, <e1>medroxyprogesterone acetate</e1>, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and <e2>prednisone</e2>.",False,negative
methotrexate,multivitamins,340,351,354,366,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, <e1>methotrexate</e1>, <e2>multivitamins</e2>, naproxen, omeprazole, paracetamol, and prednisone.",False,negative
methotrexate,naproxen,340,351,369,376,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, <e1>methotrexate</e1>, multivitamins, <e2>naproxen</e2>, omeprazole, paracetamol, and prednisone.",False,negative
methotrexate,omeprazole,340,351,379,388,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, <e1>methotrexate</e1>, multivitamins, naproxen, <e2>omeprazole</e2>, paracetamol, and prednisone.",False,negative
methotrexate,paracetamol,340,351,391,401,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, <e1>methotrexate</e1>, multivitamins, naproxen, omeprazole, <e2>paracetamol</e2>, and prednisone.",False,negative
methotrexate,prednisone,340,351,408,417,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, <e1>methotrexate</e1>, multivitamins, naproxen, omeprazole, paracetamol, and <e2>prednisone</e2>.",False,negative
multivitamins,naproxen,354,366,369,376,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, <e1>multivitamins</e1>, <e2>naproxen</e2>, omeprazole, paracetamol, and prednisone.",False,negative
multivitamins,omeprazole,354,366,379,388,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, <e1>multivitamins</e1>, naproxen, <e2>omeprazole</e2>, paracetamol, and prednisone.",False,negative
multivitamins,paracetamol,354,366,391,401,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, <e1>multivitamins</e1>, naproxen, omeprazole, <e2>paracetamol</e2>, and prednisone.",False,negative
multivitamins,prednisone,354,366,408,417,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, <e1>multivitamins</e1>, naproxen, omeprazole, paracetamol, and <e2>prednisone</e2>.",False,negative
naproxen,omeprazole,369,376,379,388,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, <e1>naproxen</e1>, <e2>omeprazole</e2>, paracetamol, and prednisone.",False,negative
naproxen,paracetamol,369,376,391,401,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, <e1>naproxen</e1>, omeprazole, <e2>paracetamol</e2>, and prednisone.",False,negative
naproxen,prednisone,369,376,408,417,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, <e1>naproxen</e1>, omeprazole, paracetamol, and <e2>prednisone</e2>.",False,negative
omeprazole,paracetamol,379,388,391,401,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, <e1>omeprazole</e1>, <e2>paracetamol</e2>, and prednisone.",False,negative
omeprazole,prednisone,379,388,408,417,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, <e1>omeprazole</e1>, paracetamol, and <e2>prednisone</e2>.",False,negative
paracetamol,prednisone,391,401,408,417,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, <e1>paracetamol</e1>, and <e2>prednisone</e2>.",False,negative
reserpine,beta-blocking agents,37,45,92,111,"Catecholamine-depleting drugs (e.g., <e1>reserpine</e1>) may have an additive effect when given with <e2>beta-blocking agents</e2>. ",True,effect
Pindolol,antihypertensive agents,0,7,41,63,"<e1>Pindolol</e1> has been used with a variety of <e2>antihypertensive agents</e2>, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions. ",False,negative
Pindolol,hydrochlorothiazide,0,7,76,94,"<e1>Pindolol</e1> has been used with a variety of antihypertensive agents, including <e2>hydrochlorothiazide</e2>, hydralazine, and guanethidine without unexpected adverse interactions. ",False,negative
Pindolol,hydralazine,0,7,97,107,"<e1>Pindolol</e1> has been used with a variety of antihypertensive agents, including hydrochlorothiazide, <e2>hydralazine</e2>, and guanethidine without unexpected adverse interactions. ",False,negative
Pindolol,guanethidine,0,7,114,125,"<e1>Pindolol</e1> has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and <e2>guanethidine</e2> without unexpected adverse interactions. ",False,negative
antihypertensive agents,hydrochlorothiazide,41,63,76,94,"Pindolol has been used with a variety of <e1>antihypertensive agents</e1>, including <e2>hydrochlorothiazide</e2>, hydralazine, and guanethidine without unexpected adverse interactions. ",False,negative
antihypertensive agents,hydralazine,41,63,97,107,"Pindolol has been used with a variety of <e1>antihypertensive agents</e1>, including hydrochlorothiazide, <e2>hydralazine</e2>, and guanethidine without unexpected adverse interactions. ",False,negative
antihypertensive agents,guanethidine,41,63,114,125,"Pindolol has been used with a variety of <e1>antihypertensive agents</e1>, including hydrochlorothiazide, hydralazine, and <e2>guanethidine</e2> without unexpected adverse interactions. ",False,negative
hydrochlorothiazide,hydralazine,76,94,97,107,"Pindolol has been used with a variety of antihypertensive agents, including <e1>hydrochlorothiazide</e1>, <e2>hydralazine</e2>, and guanethidine without unexpected adverse interactions. ",False,negative
hydrochlorothiazide,guanethidine,76,94,114,125,"Pindolol has been used with a variety of antihypertensive agents, including <e1>hydrochlorothiazide</e1>, hydralazine, and <e2>guanethidine</e2> without unexpected adverse interactions. ",False,negative
hydralazine,guanethidine,97,107,114,125,"Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, <e1>hydralazine</e1>, and <e2>guanethidine</e2> without unexpected adverse interactions. ",False,negative
Pindolol,thioridazine,0,7,42,53,<e1>Pindolol</e1> has been shown to increase serum <e2>thioridazine</e2> levels when both drugs are co-administered. ,True,mechanism
short-acting beta adrenergic aerosol bronchodilators,MAXAIR AUTOHALER,6,57,97,112,Other <e1>short-acting beta adrenergic aerosol bronchodilators</e1> should not be used concomitantly with <e2>MAXAIR AUTOHALER</e2> because they may have additive effects.,True,advise
coumarin-type anticoagulants,coumarin-type anticoagulants,56,83,104,131,"Although this has not occurred in in vitro studies with <e1>coumarin-type anticoagulants</e1>, interactions with <e2>coumarin-type anticoagulants</e2> have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ",False,negative
coumarin-type anticoagulants,FELDENE,56,83,157,163,"Although this has not occurred in in vitro studies with <e1>coumarin-type anticoagulants</e1>, interactions with coumarin-type anticoagulants have been reported with <e2>FELDENE</e2> since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ",False,negative
coumarin-type anticoagulants,FELDENE,56,83,291,297,"Although this has not occurred in in vitro studies with <e1>coumarin-type anticoagulants</e1>, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering <e2>FELDENE</e2> to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ",False,negative
coumarin-type anticoagulants,coumarin-type anticoagulants,56,83,314,341,"Although this has not occurred in in vitro studies with <e1>coumarin-type anticoagulants</e1>, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on <e2>coumarin-type anticoagulants</e2> and other highly protein-bound drugs. ",False,negative
coumarin-type anticoagulants,FELDENE,104,131,157,163,"Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with <e1>coumarin-type anticoagulants</e1> have been reported with <e2>FELDENE</e2> since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ",True,int
coumarin-type anticoagulants,FELDENE,104,131,291,297,"Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with <e1>coumarin-type anticoagulants</e1> have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering <e2>FELDENE</e2> to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ",False,negative
coumarin-type anticoagulants,coumarin-type anticoagulants,104,131,314,341,"Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with <e1>coumarin-type anticoagulants</e1> have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on <e2>coumarin-type anticoagulants</e2> and other highly protein-bound drugs. ",False,negative
FELDENE,FELDENE,157,163,291,297,"Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with <e1>FELDENE</e1> since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering <e2>FELDENE</e2> to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ",False,negative
FELDENE,coumarin-type anticoagulants,157,163,314,341,"Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with <e1>FELDENE</e1> since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on <e2>coumarin-type anticoagulants</e2> and other highly protein-bound drugs. ",False,negative
FELDENE,coumarin-type anticoagulants,291,297,314,341,"Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering <e1>FELDENE</e1> to patients on <e2>coumarin-type anticoagulants</e2> and other highly protein-bound drugs. ",True,advise
piroxicam,FELDENE,17,25,90,96,"Plasma levels of <e1>piroxicam</e1> are depressed to approximately 80% of their normal values when <e2>FELDENE</e2> is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",False,negative
piroxicam,aspirin,17,25,134,140,"Plasma levels of <e1>piroxicam</e1> are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with <e2>aspirin</e2> (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",False,negative
piroxicam,antacids,17,25,191,198,"Plasma levels of <e1>piroxicam</e1> are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of <e2>antacids</e2> has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",False,negative
piroxicam,piroxicam,17,25,217,225,"Plasma levels of <e1>piroxicam</e1> are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on <e2>piroxicam</e2> plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",False,negative
piroxicam,Nonsteroidal anti-inflammatory agents,17,25,243,279,"Plasma levels of <e1>piroxicam</e1> are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . <e2>Nonsteroidal anti-inflammatory agents</e2>, including FELDENE, have been reported to increase steady state plasma lithium levels. ",False,negative
piroxicam,FELDENE,17,25,292,298,"Plasma levels of <e1>piroxicam</e1> are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including <e2>FELDENE</e2>, have been reported to increase steady state plasma lithium levels. ",False,negative
piroxicam,lithium,17,25,352,358,"Plasma levels of <e1>piroxicam</e1> are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma <e2>lithium</e2> levels. ",False,negative
FELDENE,aspirin,90,96,134,140,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when <e1>FELDENE</e1> is administered in conjunction with <e2>aspirin</e2> (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",True,mechanism
FELDENE,antacids,90,96,191,198,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when <e1>FELDENE</e1> is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of <e2>antacids</e2> has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",False,negative
FELDENE,piroxicam,90,96,217,225,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when <e1>FELDENE</e1> is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on <e2>piroxicam</e2> plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",False,negative
FELDENE,Nonsteroidal anti-inflammatory agents,90,96,243,279,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when <e1>FELDENE</e1> is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . <e2>Nonsteroidal anti-inflammatory agents</e2>, including FELDENE, have been reported to increase steady state plasma lithium levels. ",False,negative
FELDENE,FELDENE,90,96,292,298,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when <e1>FELDENE</e1> is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including <e2>FELDENE</e2>, have been reported to increase steady state plasma lithium levels. ",False,negative
FELDENE,lithium,90,96,352,358,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when <e1>FELDENE</e1> is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma <e2>lithium</e2> levels. ",False,negative
aspirin,antacids,134,140,191,198,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with <e1>aspirin</e1> (3900 mg/day), but concomitant administration of <e2>antacids</e2> has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",False,negative
aspirin,piroxicam,134,140,217,225,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with <e1>aspirin</e1> (3900 mg/day), but concomitant administration of antacids has no effect on <e2>piroxicam</e2> plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",False,negative
aspirin,Nonsteroidal anti-inflammatory agents,134,140,243,279,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with <e1>aspirin</e1> (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . <e2>Nonsteroidal anti-inflammatory agents</e2>, including FELDENE, have been reported to increase steady state plasma lithium levels. ",False,negative
aspirin,FELDENE,134,140,292,298,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with <e1>aspirin</e1> (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including <e2>FELDENE</e2>, have been reported to increase steady state plasma lithium levels. ",False,negative
aspirin,lithium,134,140,352,358,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with <e1>aspirin</e1> (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma <e2>lithium</e2> levels. ",False,negative
antacids,piroxicam,191,198,217,225,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of <e1>antacids</e1> has no effect on <e2>piroxicam</e2> plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",False,negative
antacids,Nonsteroidal anti-inflammatory agents,191,198,243,279,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of <e1>antacids</e1> has no effect on piroxicam plasma levels . <e2>Nonsteroidal anti-inflammatory agents</e2>, including FELDENE, have been reported to increase steady state plasma lithium levels. ",False,negative
antacids,FELDENE,191,198,292,298,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of <e1>antacids</e1> has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including <e2>FELDENE</e2>, have been reported to increase steady state plasma lithium levels. ",False,negative
antacids,lithium,191,198,352,358,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of <e1>antacids</e1> has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma <e2>lithium</e2> levels. ",False,negative
piroxicam,Nonsteroidal anti-inflammatory agents,217,225,243,279,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on <e1>piroxicam</e1> plasma levels . <e2>Nonsteroidal anti-inflammatory agents</e2>, including FELDENE, have been reported to increase steady state plasma lithium levels. ",False,negative
piroxicam,FELDENE,217,225,292,298,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on <e1>piroxicam</e1> plasma levels . Nonsteroidal anti-inflammatory agents, including <e2>FELDENE</e2>, have been reported to increase steady state plasma lithium levels. ",False,negative
piroxicam,lithium,217,225,352,358,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on <e1>piroxicam</e1> plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma <e2>lithium</e2> levels. ",False,negative
Nonsteroidal anti-inflammatory agents,FELDENE,243,279,292,298,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . <e1>Nonsteroidal anti-inflammatory agents</e1>, including <e2>FELDENE</e2>, have been reported to increase steady state plasma lithium levels. ",False,negative
Nonsteroidal anti-inflammatory agents,lithium,243,279,352,358,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . <e1>Nonsteroidal anti-inflammatory agents</e1>, including FELDENE, have been reported to increase steady state plasma <e2>lithium</e2> levels. ",True,mechanism
FELDENE,lithium,292,298,352,358,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including <e1>FELDENE</e1>, have been reported to increase steady state plasma <e2>lithium</e2> levels. ",True,mechanism
lithium,FELDENE,30,36,103,109,"It is recommended that plasma <e1>lithium</e1> levels be monitored when initiating, adjusting and discontinuing <e2>FELDENE</e2>.",True,advise
atropine,pralidoxime,5,12,18,28,"When <e1>atropine</e1> and <e2>pralidoxime</e2> are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone. ",True,effect
atropine,atropine,5,12,189,196,"When <e1>atropine</e1> and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when <e2>atropine</e2> is used alone. ",False,negative
pralidoxime,atropine,18,28,189,196,"When atropine and <e1>pralidoxime</e1> are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when <e2>atropine</e2> is used alone. ",False,negative
atropine,pralidoxime,45,52,95,105,This is especially true if the total dose of <e1>atropine</e1> has been large and the administration of <e2>pralidoxime</e2> has been delayed. ,False,negative
pralidoxime,barbiturates,154,164,173,184,"2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of <e1>pralidoxime</e1>: since <e2>barbiturates</e2> are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions; ",False,negative
pralidoxime,anticholinesterases,154,164,209,227,"2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of <e1>pralidoxime</e1>: since barbiturates are potentiated by the <e2>anticholinesterases</e2>, they should be used cautiously in the treatment of convulsions; ",False,negative
barbiturates,anticholinesterases,173,184,209,227,"2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of pralidoxime: since <e1>barbiturates</e1> are potentiated by the <e2>anticholinesterases</e2>, they should be used cautiously in the treatment of convulsions; ",True,effect
morphine,theophylline,0,7,10,21,"<e1>morphine</e1>, <e2>theophylline</e2>, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",False,negative
morphine,aminophylline,0,7,24,36,"<e1>morphine</e1>, theophylline, <e2>aminophylline</e2>, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",False,negative
morphine,succinylcholine,0,7,39,53,"<e1>morphine</e1>, theophylline, aminophylline, <e2>succinylcholine</e2>, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",False,negative
morphine,reserpine,0,7,56,64,"<e1>morphine</e1>, theophylline, aminophylline, succinylcholine, <e2>reserpine</e2>, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",False,negative
morphine,phenothiazine-type tranquilizers,0,7,71,102,"<e1>morphine</e1>, theophylline, aminophylline, succinylcholine, reserpine, and <e2>phenothiazine-type tranquilizers</e2> should be avoided in patients with organophosphate poisoning.",False,negative
theophylline,aminophylline,10,21,24,36,"morphine, <e1>theophylline</e1>, <e2>aminophylline</e2>, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",False,negative
theophylline,succinylcholine,10,21,39,53,"morphine, <e1>theophylline</e1>, aminophylline, <e2>succinylcholine</e2>, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",False,negative
theophylline,reserpine,10,21,56,64,"morphine, <e1>theophylline</e1>, aminophylline, succinylcholine, <e2>reserpine</e2>, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",False,negative
theophylline,phenothiazine-type tranquilizers,10,21,71,102,"morphine, <e1>theophylline</e1>, aminophylline, succinylcholine, reserpine, and <e2>phenothiazine-type tranquilizers</e2> should be avoided in patients with organophosphate poisoning.",False,negative
aminophylline,succinylcholine,24,36,39,53,"morphine, theophylline, <e1>aminophylline</e1>, <e2>succinylcholine</e2>, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",False,negative
aminophylline,reserpine,24,36,56,64,"morphine, theophylline, <e1>aminophylline</e1>, succinylcholine, <e2>reserpine</e2>, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",False,negative
aminophylline,phenothiazine-type tranquilizers,24,36,71,102,"morphine, theophylline, <e1>aminophylline</e1>, succinylcholine, reserpine, and <e2>phenothiazine-type tranquilizers</e2> should be avoided in patients with organophosphate poisoning.",False,negative
succinylcholine,reserpine,39,53,56,64,"morphine, theophylline, aminophylline, <e1>succinylcholine</e1>, <e2>reserpine</e2>, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",False,negative
succinylcholine,phenothiazine-type tranquilizers,39,53,71,102,"morphine, theophylline, aminophylline, <e1>succinylcholine</e1>, reserpine, and <e2>phenothiazine-type tranquilizers</e2> should be avoided in patients with organophosphate poisoning.",False,negative
reserpine,phenothiazine-type tranquilizers,56,64,71,102,"morphine, theophylline, aminophylline, succinylcholine, <e1>reserpine</e1>, and <e2>phenothiazine-type tranquilizers</e2> should be avoided in patients with organophosphate poisoning.",False,negative
Carbidopa,Levodopa,0,8,10,17,<e1>Carbidopa</e1>/<e2>Levodopa</e2>: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). ,False,negative
Carbidopa,Carbidopa,0,8,20,28,<e1>Carbidopa</e1>/Levodopa: <e2>Carbidopa</e2>/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). ,False,negative
Carbidopa,Levodopa,0,8,30,37,<e1>Carbidopa</e1>/Levodopa: Carbidopa/<e2>Levodopa</e2> does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). ,False,negative
Carbidopa,pramipexole,0,8,82,92,<e1>Carbidopa</e1>/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of <e2>pramipexole</e2> in healthy volunteers (N= 10). ,False,negative
Levodopa,Carbidopa,10,17,20,28,Carbidopa/<e1>Levodopa</e1>: <e2>Carbidopa</e2>/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). ,False,negative
Levodopa,Levodopa,10,17,30,37,Carbidopa/<e1>Levodopa</e1>: Carbidopa/<e2>Levodopa</e2> does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). ,False,negative
Levodopa,pramipexole,10,17,82,92,Carbidopa/<e1>Levodopa</e1>: Carbidopa/Levodopa does not influence the pharmacokinetics of <e2>pramipexole</e2> in healthy volunteers (N= 10). ,False,negative
Carbidopa,Levodopa,20,28,30,37,Carbidopa/Levodopa: <e1>Carbidopa</e1>/<e2>Levodopa</e2> does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). ,False,negative
Carbidopa,pramipexole,20,28,82,92,Carbidopa/Levodopa: <e1>Carbidopa</e1>/Levodopa does not influence the pharmacokinetics of <e2>pramipexole</e2> in healthy volunteers (N= 10). ,False,negative
Levodopa,pramipexole,30,37,82,92,Carbidopa/Levodopa: Carbidopa/<e1>Levodopa</e1> does not influence the pharmacokinetics of <e2>pramipexole</e2> in healthy volunteers (N= 10). ,False,negative
Selegiline,selegiline,0,9,43,52,"<e1>Selegiline</e1>: In healthy volunteers (N= 11), <e2>selegiline</e2> did not influence the pharmacokinetics of pramipexole. ",False,negative
Selegiline,pramipexole,0,9,96,106,"<e1>Selegiline</e1>: In healthy volunteers (N= 11), selegiline did not influence the pharmacokinetics of <e2>pramipexole</e2>. ",False,negative
selegiline,pramipexole,43,52,96,106,"Selegiline: In healthy volunteers (N= 11), <e1>selegiline</e1> did not influence the pharmacokinetics of <e2>pramipexole</e2>. ",False,negative
Amantadine,amantadine,0,9,62,71,<e1>Amantadine</e1>: Population pharmacokinetic analysis suggests that <e2>amantadine</e2> is unlikely to alter the oral clearance of pramipexole (N= 54). ,False,negative
Amantadine,pramipexole,0,9,116,126,<e1>Amantadine</e1>: Population pharmacokinetic analysis suggests that amantadine is unlikely to alter the oral clearance of <e2>pramipexole</e2> (N= 54). ,False,negative
amantadine,pramipexole,62,71,116,126,Amantadine: Population pharmacokinetic analysis suggests that <e1>amantadine</e1> is unlikely to alter the oral clearance of <e2>pramipexole</e2> (N= 54). ,False,negative
Cimetidine,Cimetidine,0,9,12,21,"<e1>Cimetidine</e1>: <e2>Cimetidine</e2>, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in pramipexole AUC and a 40% increase in half-life (N= 12). ",False,negative
Cimetidine,pramipexole,0,9,146,156,"<e1>Cimetidine</e1>: Cimetidine, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in <e2>pramipexole</e2> AUC and a 40% increase in half-life (N= 12). ",False,negative
Cimetidine,pramipexole,12,21,146,156,"Cimetidine: <e1>Cimetidine</e1>, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in <e2>pramipexole</e2> AUC and a 40% increase in half-life (N= 12). ",True,mechanism
Probenecid,Probenecid,0,9,12,21,"<e1>Probenecid</e1>: <e2>Probenecid</e2>, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence pramipexole pharmacokinetics (N= 12). ",False,negative
Probenecid,pramipexole,0,9,144,154,"<e1>Probenecid</e1>: Probenecid, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence <e2>pramipexole</e2> pharmacokinetics (N= 12). ",False,negative
Probenecid,pramipexole,12,21,144,154,"Probenecid: <e1>Probenecid</e1>, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence <e2>pramipexole</e2> pharmacokinetics (N= 12). ",False,negative
cimetidine,ranitidine,178,187,190,199,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., <e1>cimetidine</e1>, <e2>ranitidine</e2>, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
cimetidine,diltiazem,178,187,202,210,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., <e1>cimetidine</e1>, ranitidine, <e2>diltiazem</e2>, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
cimetidine,triamterene,178,187,213,223,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., <e1>cimetidine</e1>, ranitidine, diltiazem, <e2>triamterene</e2>, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
cimetidine,verapamil,178,187,226,234,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., <e1>cimetidine</e1>, ranitidine, diltiazem, triamterene, <e2>verapamil</e2>, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
cimetidine,quinidine,178,187,237,245,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., <e1>cimetidine</e1>, ranitidine, diltiazem, triamterene, verapamil, <e2>quinidine</e2>, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
cimetidine,quinine,178,187,252,258,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., <e1>cimetidine</e1>, ranitidine, diltiazem, triamterene, verapamil, quinidine, and <e2>quinine</e2>) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
cimetidine,pramipexole,178,187,293,303,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., <e1>cimetidine</e1>, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of <e2>pramipexole</e2> by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",True,mechanism
cimetidine,cephalosporins,178,187,379,392,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., <e1>cimetidine</e1>, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., <e2>cephalosporins</e2>, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
cimetidine,penicillins,178,187,395,405,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., <e1>cimetidine</e1>, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, <e2>penicillins</e2>, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
cimetidine,indomethacin,178,187,408,419,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., <e1>cimetidine</e1>, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, <e2>indomethacin</e2>, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
cimetidine,hydrochlorothiazide,178,187,422,440,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., <e1>cimetidine</e1>, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, <e2>hydrochlorothiazide</e2>, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
cimetidine,chlorpropamide,178,187,447,460,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., <e1>cimetidine</e1>, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and <e2>chlorpropamide</e2>) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
cimetidine,pramipexole,178,187,521,531,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., <e1>cimetidine</e1>, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of <e2>pramipexole</e2>. ",False,negative
ranitidine,diltiazem,190,199,202,210,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, <e1>ranitidine</e1>, <e2>diltiazem</e2>, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
ranitidine,triamterene,190,199,213,223,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, <e1>ranitidine</e1>, diltiazem, <e2>triamterene</e2>, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
ranitidine,verapamil,190,199,226,234,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, <e1>ranitidine</e1>, diltiazem, triamterene, <e2>verapamil</e2>, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
ranitidine,quinidine,190,199,237,245,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, <e1>ranitidine</e1>, diltiazem, triamterene, verapamil, <e2>quinidine</e2>, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
ranitidine,quinine,190,199,252,258,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, <e1>ranitidine</e1>, diltiazem, triamterene, verapamil, quinidine, and <e2>quinine</e2>) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
ranitidine,pramipexole,190,199,293,303,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, <e1>ranitidine</e1>, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of <e2>pramipexole</e2> by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",True,mechanism
ranitidine,cephalosporins,190,199,379,392,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, <e1>ranitidine</e1>, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., <e2>cephalosporins</e2>, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
ranitidine,penicillins,190,199,395,405,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, <e1>ranitidine</e1>, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, <e2>penicillins</e2>, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
ranitidine,indomethacin,190,199,408,419,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, <e1>ranitidine</e1>, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, <e2>indomethacin</e2>, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
ranitidine,hydrochlorothiazide,190,199,422,440,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, <e1>ranitidine</e1>, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, <e2>hydrochlorothiazide</e2>, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
ranitidine,chlorpropamide,190,199,447,460,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, <e1>ranitidine</e1>, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and <e2>chlorpropamide</e2>) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
ranitidine,pramipexole,190,199,521,531,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, <e1>ranitidine</e1>, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of <e2>pramipexole</e2>. ",False,negative
diltiazem,triamterene,202,210,213,223,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, <e1>diltiazem</e1>, <e2>triamterene</e2>, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
diltiazem,verapamil,202,210,226,234,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, <e1>diltiazem</e1>, triamterene, <e2>verapamil</e2>, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
diltiazem,quinidine,202,210,237,245,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, <e1>diltiazem</e1>, triamterene, verapamil, <e2>quinidine</e2>, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
diltiazem,quinine,202,210,252,258,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, <e1>diltiazem</e1>, triamterene, verapamil, quinidine, and <e2>quinine</e2>) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
diltiazem,pramipexole,202,210,293,303,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, <e1>diltiazem</e1>, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of <e2>pramipexole</e2> by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",True,mechanism
diltiazem,cephalosporins,202,210,379,392,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, <e1>diltiazem</e1>, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., <e2>cephalosporins</e2>, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
diltiazem,penicillins,202,210,395,405,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, <e1>diltiazem</e1>, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, <e2>penicillins</e2>, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
diltiazem,indomethacin,202,210,408,419,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, <e1>diltiazem</e1>, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, <e2>indomethacin</e2>, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
diltiazem,hydrochlorothiazide,202,210,422,440,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, <e1>diltiazem</e1>, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, <e2>hydrochlorothiazide</e2>, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
diltiazem,chlorpropamide,202,210,447,460,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, <e1>diltiazem</e1>, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and <e2>chlorpropamide</e2>) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
diltiazem,pramipexole,202,210,521,531,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, <e1>diltiazem</e1>, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of <e2>pramipexole</e2>. ",False,negative
triamterene,verapamil,213,223,226,234,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, <e1>triamterene</e1>, <e2>verapamil</e2>, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
triamterene,quinidine,213,223,237,245,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, <e1>triamterene</e1>, verapamil, <e2>quinidine</e2>, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
triamterene,quinine,213,223,252,258,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, <e1>triamterene</e1>, verapamil, quinidine, and <e2>quinine</e2>) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
triamterene,pramipexole,213,223,293,303,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, <e1>triamterene</e1>, verapamil, quinidine, and quinine) decreases the oral clearance of <e2>pramipexole</e2> by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",True,mechanism
triamterene,cephalosporins,213,223,379,392,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, <e1>triamterene</e1>, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., <e2>cephalosporins</e2>, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
triamterene,penicillins,213,223,395,405,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, <e1>triamterene</e1>, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, <e2>penicillins</e2>, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
triamterene,indomethacin,213,223,408,419,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, <e1>triamterene</e1>, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, <e2>indomethacin</e2>, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
triamterene,hydrochlorothiazide,213,223,422,440,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, <e1>triamterene</e1>, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, <e2>hydrochlorothiazide</e2>, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
triamterene,chlorpropamide,213,223,447,460,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, <e1>triamterene</e1>, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and <e2>chlorpropamide</e2>) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
triamterene,pramipexole,213,223,521,531,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, <e1>triamterene</e1>, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of <e2>pramipexole</e2>. ",False,negative
verapamil,quinidine,226,234,237,245,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, <e1>verapamil</e1>, <e2>quinidine</e2>, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
verapamil,quinine,226,234,252,258,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, <e1>verapamil</e1>, quinidine, and <e2>quinine</e2>) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
verapamil,pramipexole,226,234,293,303,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, <e1>verapamil</e1>, quinidine, and quinine) decreases the oral clearance of <e2>pramipexole</e2> by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",True,mechanism
verapamil,cephalosporins,226,234,379,392,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, <e1>verapamil</e1>, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., <e2>cephalosporins</e2>, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
verapamil,penicillins,226,234,395,405,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, <e1>verapamil</e1>, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, <e2>penicillins</e2>, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
verapamil,indomethacin,226,234,408,419,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, <e1>verapamil</e1>, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, <e2>indomethacin</e2>, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
verapamil,hydrochlorothiazide,226,234,422,440,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, <e1>verapamil</e1>, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, <e2>hydrochlorothiazide</e2>, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
verapamil,chlorpropamide,226,234,447,460,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, <e1>verapamil</e1>, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and <e2>chlorpropamide</e2>) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
verapamil,pramipexole,226,234,521,531,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, <e1>verapamil</e1>, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of <e2>pramipexole</e2>. ",False,negative
quinidine,quinine,237,245,252,258,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, <e1>quinidine</e1>, and <e2>quinine</e2>) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
quinidine,pramipexole,237,245,293,303,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, <e1>quinidine</e1>, and quinine) decreases the oral clearance of <e2>pramipexole</e2> by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",True,mechanism
quinidine,cephalosporins,237,245,379,392,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, <e1>quinidine</e1>, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., <e2>cephalosporins</e2>, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
quinidine,penicillins,237,245,395,405,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, <e1>quinidine</e1>, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, <e2>penicillins</e2>, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
quinidine,indomethacin,237,245,408,419,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, <e1>quinidine</e1>, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, <e2>indomethacin</e2>, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
quinidine,hydrochlorothiazide,237,245,422,440,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, <e1>quinidine</e1>, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, <e2>hydrochlorothiazide</e2>, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
quinidine,chlorpropamide,237,245,447,460,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, <e1>quinidine</e1>, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and <e2>chlorpropamide</e2>) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
quinidine,pramipexole,237,245,521,531,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, <e1>quinidine</e1>, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of <e2>pramipexole</e2>. ",False,negative
quinine,pramipexole,252,258,293,303,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and <e1>quinine</e1>) decreases the oral clearance of <e2>pramipexole</e2> by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",True,mechanism
quinine,cephalosporins,252,258,379,392,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and <e1>quinine</e1>) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., <e2>cephalosporins</e2>, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
quinine,penicillins,252,258,395,405,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and <e1>quinine</e1>) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, <e2>penicillins</e2>, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
quinine,indomethacin,252,258,408,419,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and <e1>quinine</e1>) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, <e2>indomethacin</e2>, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
quinine,hydrochlorothiazide,252,258,422,440,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and <e1>quinine</e1>) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, <e2>hydrochlorothiazide</e2>, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
quinine,chlorpropamide,252,258,447,460,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and <e1>quinine</e1>) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and <e2>chlorpropamide</e2>) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
quinine,pramipexole,252,258,521,531,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and <e1>quinine</e1>) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of <e2>pramipexole</e2>. ",False,negative
pramipexole,cephalosporins,293,303,379,392,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of <e1>pramipexole</e1> by about 20%, while those secreted by the anionic transport system (e.g., <e2>cephalosporins</e2>, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
pramipexole,penicillins,293,303,395,405,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of <e1>pramipexole</e1> by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, <e2>penicillins</e2>, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
pramipexole,indomethacin,293,303,408,419,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of <e1>pramipexole</e1> by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, <e2>indomethacin</e2>, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
pramipexole,hydrochlorothiazide,293,303,422,440,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of <e1>pramipexole</e1> by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, <e2>hydrochlorothiazide</e2>, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
pramipexole,chlorpropamide,293,303,447,460,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of <e1>pramipexole</e1> by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and <e2>chlorpropamide</e2>) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
pramipexole,pramipexole,293,303,521,531,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of <e1>pramipexole</e1> by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of <e2>pramipexole</e2>. ",False,negative
cephalosporins,penicillins,379,392,395,405,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., <e1>cephalosporins</e1>, <e2>penicillins</e2>, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
cephalosporins,indomethacin,379,392,408,419,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., <e1>cephalosporins</e1>, penicillins, <e2>indomethacin</e2>, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
cephalosporins,hydrochlorothiazide,379,392,422,440,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., <e1>cephalosporins</e1>, penicillins, indomethacin, <e2>hydrochlorothiazide</e2>, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
cephalosporins,chlorpropamide,379,392,447,460,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., <e1>cephalosporins</e1>, penicillins, indomethacin, hydrochlorothiazide, and <e2>chlorpropamide</e2>) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
cephalosporins,pramipexole,379,392,521,531,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., <e1>cephalosporins</e1>, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of <e2>pramipexole</e2>. ",True,mechanism
penicillins,indomethacin,395,405,408,419,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, <e1>penicillins</e1>, <e2>indomethacin</e2>, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
penicillins,hydrochlorothiazide,395,405,422,440,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, <e1>penicillins</e1>, indomethacin, <e2>hydrochlorothiazide</e2>, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
penicillins,chlorpropamide,395,405,447,460,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, <e1>penicillins</e1>, indomethacin, hydrochlorothiazide, and <e2>chlorpropamide</e2>) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
penicillins,pramipexole,395,405,521,531,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, <e1>penicillins</e1>, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of <e2>pramipexole</e2>. ",True,mechanism
indomethacin,hydrochlorothiazide,408,419,422,440,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, <e1>indomethacin</e1>, <e2>hydrochlorothiazide</e2>, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
indomethacin,chlorpropamide,408,419,447,460,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, <e1>indomethacin</e1>, hydrochlorothiazide, and <e2>chlorpropamide</e2>) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
indomethacin,pramipexole,408,419,521,531,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, <e1>indomethacin</e1>, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of <e2>pramipexole</e2>. ",True,mechanism
hydrochlorothiazide,chlorpropamide,422,440,447,460,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, <e1>hydrochlorothiazide</e1>, and <e2>chlorpropamide</e2>) are likely to have little effect on the oral clearance of pramipexole. ",False,negative
hydrochlorothiazide,pramipexole,422,440,521,531,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, <e1>hydrochlorothiazide</e1>, and chlorpropamide) are likely to have little effect on the oral clearance of <e2>pramipexole</e2>. ",True,mechanism
chlorpropamide,pramipexole,447,460,521,531,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and <e1>chlorpropamide</e1>) are likely to have little effect on the oral clearance of <e2>pramipexole</e2>. ",True,mechanism
pramipexole,pramipexole,88,98,120,130,CYP interactions: Inhibitors of cytochrome P450 enzymes would not be expected to affect <e1>pramipexole</e1> elimination because <e2>pramipexole</e2> is not appreciably metabolized by these enzymes in vivo or in vitro. ,False,negative
Dopamine antagonists,pramipexole,0,19,28,38,"<e1>Dopamine antagonists</e1>: Since <e2>pramipexole</e2> is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",False,negative
Dopamine antagonists,dopamine agonist,0,19,45,60,"<e1>Dopamine antagonists</e1>: Since pramipexole is a <e2>dopamine agonist</e2>, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",False,negative
Dopamine antagonists,dopamine antagonists,0,19,83,102,"<e1>Dopamine antagonists</e1>: Since pramipexole is a dopamine agonist, it is possible that <e2>dopamine antagonists</e2>, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",False,negative
Dopamine antagonists,neuroleptics,0,19,117,128,"<e1>Dopamine antagonists</e1>: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the <e2>neuroleptics</e2> (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",False,negative
Dopamine antagonists,phenothiazines,0,19,131,144,"<e1>Dopamine antagonists</e1>: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (<e2>phenothiazines</e2>, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",False,negative
Dopamine antagonists,butyrophenones,0,19,147,160,"<e1>Dopamine antagonists</e1>: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, <e2>butyrophenones</e2>, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",False,negative
Dopamine antagonists,thioxanthenes,0,19,163,175,"<e1>Dopamine antagonists</e1>: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, <e2>thioxanthenes</e2>) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",False,negative
Dopamine antagonists,metoclopramide,0,19,181,194,"<e1>Dopamine antagonists</e1>: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or <e2>metoclopramide</e2>, may diminish the effectiveness of MIRAPEX. ",False,negative
Dopamine antagonists,MIRAPEX,0,19,231,237,"<e1>Dopamine antagonists</e1>: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of <e2>MIRAPEX</e2>. ",False,negative
pramipexole,dopamine agonist,28,38,45,60,"Dopamine antagonists: Since <e1>pramipexole</e1> is a <e2>dopamine agonist</e2>, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",False,negative
pramipexole,dopamine antagonists,28,38,83,102,"Dopamine antagonists: Since <e1>pramipexole</e1> is a dopamine agonist, it is possible that <e2>dopamine antagonists</e2>, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",False,negative
pramipexole,neuroleptics,28,38,117,128,"Dopamine antagonists: Since <e1>pramipexole</e1> is a dopamine agonist, it is possible that dopamine antagonists, such as the <e2>neuroleptics</e2> (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",False,negative
pramipexole,phenothiazines,28,38,131,144,"Dopamine antagonists: Since <e1>pramipexole</e1> is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (<e2>phenothiazines</e2>, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",False,negative
pramipexole,butyrophenones,28,38,147,160,"Dopamine antagonists: Since <e1>pramipexole</e1> is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, <e2>butyrophenones</e2>, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",False,negative
pramipexole,thioxanthenes,28,38,163,175,"Dopamine antagonists: Since <e1>pramipexole</e1> is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, <e2>thioxanthenes</e2>) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",False,negative
pramipexole,metoclopramide,28,38,181,194,"Dopamine antagonists: Since <e1>pramipexole</e1> is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or <e2>metoclopramide</e2>, may diminish the effectiveness of MIRAPEX. ",False,negative
pramipexole,MIRAPEX,28,38,231,237,"Dopamine antagonists: Since <e1>pramipexole</e1> is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of <e2>MIRAPEX</e2>. ",False,negative
dopamine agonist,dopamine antagonists,45,60,83,102,"Dopamine antagonists: Since pramipexole is a <e1>dopamine agonist</e1>, it is possible that <e2>dopamine antagonists</e2>, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",False,negative
dopamine agonist,neuroleptics,45,60,117,128,"Dopamine antagonists: Since pramipexole is a <e1>dopamine agonist</e1>, it is possible that dopamine antagonists, such as the <e2>neuroleptics</e2> (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",False,negative
dopamine agonist,phenothiazines,45,60,131,144,"Dopamine antagonists: Since pramipexole is a <e1>dopamine agonist</e1>, it is possible that dopamine antagonists, such as the neuroleptics (<e2>phenothiazines</e2>, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",False,negative
dopamine agonist,butyrophenones,45,60,147,160,"Dopamine antagonists: Since pramipexole is a <e1>dopamine agonist</e1>, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, <e2>butyrophenones</e2>, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",False,negative
dopamine agonist,thioxanthenes,45,60,163,175,"Dopamine antagonists: Since pramipexole is a <e1>dopamine agonist</e1>, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, <e2>thioxanthenes</e2>) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",False,negative
dopamine agonist,metoclopramide,45,60,181,194,"Dopamine antagonists: Since pramipexole is a <e1>dopamine agonist</e1>, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or <e2>metoclopramide</e2>, may diminish the effectiveness of MIRAPEX. ",False,negative
dopamine agonist,MIRAPEX,45,60,231,237,"Dopamine antagonists: Since pramipexole is a <e1>dopamine agonist</e1>, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of <e2>MIRAPEX</e2>. ",False,negative
dopamine antagonists,neuroleptics,83,102,117,128,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that <e1>dopamine antagonists</e1>, such as the <e2>neuroleptics</e2> (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",False,negative
dopamine antagonists,phenothiazines,83,102,131,144,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that <e1>dopamine antagonists</e1>, such as the neuroleptics (<e2>phenothiazines</e2>, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",False,negative
dopamine antagonists,butyrophenones,83,102,147,160,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that <e1>dopamine antagonists</e1>, such as the neuroleptics (phenothiazines, <e2>butyrophenones</e2>, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",False,negative
dopamine antagonists,thioxanthenes,83,102,163,175,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that <e1>dopamine antagonists</e1>, such as the neuroleptics (phenothiazines, butyrophenones, <e2>thioxanthenes</e2>) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",False,negative
dopamine antagonists,metoclopramide,83,102,181,194,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that <e1>dopamine antagonists</e1>, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or <e2>metoclopramide</e2>, may diminish the effectiveness of MIRAPEX. ",False,negative
dopamine antagonists,MIRAPEX,83,102,231,237,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that <e1>dopamine antagonists</e1>, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of <e2>MIRAPEX</e2>. ",True,effect
neuroleptics,phenothiazines,117,128,131,144,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the <e1>neuroleptics</e1> (<e2>phenothiazines</e2>, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",False,negative
neuroleptics,butyrophenones,117,128,147,160,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the <e1>neuroleptics</e1> (phenothiazines, <e2>butyrophenones</e2>, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",False,negative
neuroleptics,thioxanthenes,117,128,163,175,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the <e1>neuroleptics</e1> (phenothiazines, butyrophenones, <e2>thioxanthenes</e2>) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",False,negative
neuroleptics,metoclopramide,117,128,181,194,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the <e1>neuroleptics</e1> (phenothiazines, butyrophenones, thioxanthenes) or <e2>metoclopramide</e2>, may diminish the effectiveness of MIRAPEX. ",False,negative
neuroleptics,MIRAPEX,117,128,231,237,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the <e1>neuroleptics</e1> (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of <e2>MIRAPEX</e2>. ",True,effect
phenothiazines,butyrophenones,131,144,147,160,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (<e1>phenothiazines</e1>, <e2>butyrophenones</e2>, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",False,negative
phenothiazines,thioxanthenes,131,144,163,175,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (<e1>phenothiazines</e1>, butyrophenones, <e2>thioxanthenes</e2>) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",False,negative
phenothiazines,metoclopramide,131,144,181,194,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (<e1>phenothiazines</e1>, butyrophenones, thioxanthenes) or <e2>metoclopramide</e2>, may diminish the effectiveness of MIRAPEX. ",False,negative
phenothiazines,MIRAPEX,131,144,231,237,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (<e1>phenothiazines</e1>, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of <e2>MIRAPEX</e2>. ",True,effect
butyrophenones,thioxanthenes,147,160,163,175,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, <e1>butyrophenones</e1>, <e2>thioxanthenes</e2>) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",False,negative
butyrophenones,metoclopramide,147,160,181,194,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, <e1>butyrophenones</e1>, thioxanthenes) or <e2>metoclopramide</e2>, may diminish the effectiveness of MIRAPEX. ",False,negative
butyrophenones,MIRAPEX,147,160,231,237,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, <e1>butyrophenones</e1>, thioxanthenes) or metoclopramide, may diminish the effectiveness of <e2>MIRAPEX</e2>. ",True,effect
thioxanthenes,metoclopramide,163,175,181,194,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, <e1>thioxanthenes</e1>) or <e2>metoclopramide</e2>, may diminish the effectiveness of MIRAPEX. ",False,negative
thioxanthenes,MIRAPEX,163,175,231,237,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, <e1>thioxanthenes</e1>) or metoclopramide, may diminish the effectiveness of <e2>MIRAPEX</e2>. ",True,effect
metoclopramide,MIRAPEX,181,194,231,237,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or <e1>metoclopramide</e1>, may diminish the effectiveness of <e2>MIRAPEX</e2>. ",True,effect
SYMLIN,anticholinergic agents,40,45,150,171,"Due to its effects on gastric emptying, <e1>SYMLIN</e1> therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., <e2>anticholinergic agents</e2> such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors). ",True,advise
SYMLIN,atropine,40,45,181,188,"Due to its effects on gastric emptying, <e1>SYMLIN</e1> therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as <e2>atropine</e2>) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors). ",True,advise
SYMLIN,alpha glucosidase inhibitors,40,45,258,285,"Due to its effects on gastric emptying, <e1>SYMLIN</e1> therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., <e2>alpha glucosidase inhibitors</e2>). ",True,advise
anticholinergic agents,atropine,150,171,181,188,"Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., <e1>anticholinergic agents</e1> such as <e2>atropine</e2>) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors). ",False,negative
anticholinergic agents,alpha glucosidase inhibitors,150,171,258,285,"Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., <e1>anticholinergic agents</e1> such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., <e2>alpha glucosidase inhibitors</e2>). ",False,negative
atropine,alpha glucosidase inhibitors,181,188,258,285,"Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as <e1>atropine</e1>) and agents that slow the intestinal absorption of nutrients (e.g., <e2>alpha glucosidase inhibitors</e2>). ",False,negative
analgesics,SYMLIN,116,125,204,209,"When the rapid onset of a concomitant orally administered agent is a critical determinant of effectiveness (such as <e1>analgesics</e1>), the agent should be administered at least 1 hour prior to or 2 hours after <e2>SYMLIN</e2> injection. ",True,advise
sulfonylureas,biguanides,43,55,60,69,"In clinical trials, the concomitant use of <e1>sulfonylureas</e1> or <e2>biguanides</e2> did not alter the adverse event profile of SYMLIN. ",False,negative
sulfonylureas,SYMLIN,43,55,114,119,"In clinical trials, the concomitant use of <e1>sulfonylureas</e1> or biguanides did not alter the adverse event profile of <e2>SYMLIN</e2>. ",False,negative
biguanides,SYMLIN,60,69,114,119,"In clinical trials, the concomitant use of sulfonylureas or <e1>biguanides</e1> did not alter the adverse event profile of <e2>SYMLIN</e2>. ",False,negative
SYMLIN,antidiabetic agents,74,79,105,123,No formal interaction studies have been performed to assess the effect of <e1>SYMLIN</e1> on the kinetics of oral <e2>antidiabetic agents</e2>. ,False,negative
SYMLIN,Insulin,7,12,18,24,"Mixing <e1>SYMLIN</e1> and <e2>Insulin</e2> The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection. ",False,negative
SYMLIN,SYMLIN,7,12,60,65,"Mixing <e1>SYMLIN</e1> and Insulin The pharmacokinetic parameters of <e2>SYMLIN</e2> were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection. ",False,negative
SYMLIN,human insulin,7,12,157,169,"Mixing <e1>SYMLIN</e1> and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant <e2>human insulin</e2> immediately prior to injection. ",False,negative
Insulin,SYMLIN,18,24,60,65,"Mixing SYMLIN and <e1>Insulin</e1> The pharmacokinetic parameters of <e2>SYMLIN</e2> were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection. ",False,negative
Insulin,human insulin,18,24,157,169,"Mixing SYMLIN and <e1>Insulin</e1> The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant <e2>human insulin</e2> immediately prior to injection. ",False,negative
SYMLIN,human insulin,60,65,157,169,"Mixing SYMLIN and Insulin The pharmacokinetic parameters of <e1>SYMLIN</e1> were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant <e2>human insulin</e2> immediately prior to injection. ",True,mechanism
SYMLIN,insulin,6,11,17,23,"Thus, <e1>SYMLIN</e1> and <e2>insulin</e2> should not be mixed and must be administered separately.",False,negative
phenobarbital,phenytoin,42,54,57,65,"Drugs that induce hepatic enzymes such as <e1>phenobarbital</e1>, <e2>phenytoin</e2> and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",False,negative
phenobarbital,rifampin,42,54,71,78,"Drugs that induce hepatic enzymes such as <e1>phenobarbital</e1>, phenytoin and <e2>rifampin</e2> may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",False,negative
phenobarbital,corticosteroids,42,54,110,124,"Drugs that induce hepatic enzymes such as <e1>phenobarbital</e1>, phenytoin and rifampin may increase the clearance of <e2>corticosteroids</e2> and may require increases in corticosteroid dose to achieve the desired response. ",True,mechanism
phenobarbital,corticosteroid,42,54,155,168,"Drugs that induce hepatic enzymes such as <e1>phenobarbital</e1>, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in <e2>corticosteroid</e2> dose to achieve the desired response. ",True,mechanism
phenytoin,rifampin,57,65,71,78,"Drugs that induce hepatic enzymes such as phenobarbital, <e1>phenytoin</e1> and <e2>rifampin</e2> may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",False,negative
phenytoin,corticosteroids,57,65,110,124,"Drugs that induce hepatic enzymes such as phenobarbital, <e1>phenytoin</e1> and rifampin may increase the clearance of <e2>corticosteroids</e2> and may require increases in corticosteroid dose to achieve the desired response. ",True,mechanism
phenytoin,corticosteroid,57,65,155,168,"Drugs that induce hepatic enzymes such as phenobarbital, <e1>phenytoin</e1> and rifampin may increase the clearance of corticosteroids and may require increases in <e2>corticosteroid</e2> dose to achieve the desired response. ",True,mechanism
rifampin,corticosteroids,71,78,110,124,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and <e1>rifampin</e1> may increase the clearance of <e2>corticosteroids</e2> and may require increases in corticosteroid dose to achieve the desired response. ",True,mechanism
rifampin,corticosteroid,71,78,155,168,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and <e1>rifampin</e1> may increase the clearance of corticosteroids and may require increases in <e2>corticosteroid</e2> dose to achieve the desired response. ",True,mechanism
corticosteroids,corticosteroid,110,124,155,168,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of <e1>corticosteroids</e1> and may require increases in <e2>corticosteroid</e2> dose to achieve the desired response. ",False,negative
troleandomycin,ketoconazole,14,27,33,44,Drugs such as <e1>troleandomycin</e1> and <e2>ketoconazole</e2> may inhibit the metabolism of corticosteroids and thus decrease their clearance. ,False,negative
troleandomycin,corticosteroids,14,27,76,90,Drugs such as <e1>troleandomycin</e1> and ketoconazole may inhibit the metabolism of <e2>corticosteroids</e2> and thus decrease their clearance. ,True,mechanism
ketoconazole,corticosteroids,33,44,76,90,Drugs such as troleandomycin and <e1>ketoconazole</e1> may inhibit the metabolism of <e2>corticosteroids</e2> and thus decrease their clearance. ,True,mechanism
Corticosteroids,aspirin,0,14,64,70,<e1>Corticosteroids</e1> may increase the clearance of chronic high dose <e2>aspirin</e2>. ,True,mechanism
salicylate,salicylate,29,38,77,86,This could lead to decreased <e1>salicylate</e1> serum levels or increase the risk of <e2>salicylate</e2> toxicity when corticosteroid is withdrawn. ,False,negative
salicylate,corticosteroid,29,38,102,115,This could lead to decreased <e1>salicylate</e1> serum levels or increase the risk of salicylate toxicity when <e2>corticosteroid</e2> is withdrawn. ,False,negative
salicylate,corticosteroid,77,86,102,115,This could lead to decreased salicylate serum levels or increase the risk of <e1>salicylate</e1> toxicity when <e2>corticosteroid</e2> is withdrawn. ,True,effect
Aspirin,corticosteroids,0,6,54,68,<e1>Aspirin</e1> should be used cautiously in conjunction with <e2>corticosteroids</e2> in patients suffering from hypoprothrombinemia. ,True,advise
corticosteroids,anticoagulants,14,28,38,51,The effect of <e1>corticosteroids</e1> on oral <e2>anticoagulants</e2> is variable. ,True,effect
anticoagulants,corticosteroids,63,76,107,121,There are reports of enhanced as well as diminished effects of <e1>anticoagulants</e1> when given concurrently with <e2>corticosteroids</e2>. ,True,effect
Anticholinesterases,procaine hydrochloride,0,18,39,60,<e1>Anticholinesterases</e1>: Concurrent use of <e2>procaine hydrochloride</e2> and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride. ,False,negative
Anticholinesterases,anticholinesterase agents,0,18,66,90,<e1>Anticholinesterases</e1>: Concurrent use of procaine hydrochloride and <e2>anticholinesterase agents</e2> may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride. ,False,negative
Anticholinesterases,anticholinesterases,0,18,140,158,<e1>Anticholinesterases</e1>: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since <e2>anticholinesterases</e2> inhibit the breakdown of procaine hydrochloride. ,False,negative
Anticholinesterases,procaine hydrochloride,0,18,185,206,<e1>Anticholinesterases</e1>: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of <e2>procaine hydrochloride</e2>. ,False,negative
procaine hydrochloride,anticholinesterase agents,39,60,66,90,Anticholinesterases: Concurrent use of <e1>procaine hydrochloride</e1> and <e2>anticholinesterase agents</e2> may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride. ,True,effect
procaine hydrochloride,anticholinesterases,39,60,140,158,Anticholinesterases: Concurrent use of <e1>procaine hydrochloride</e1> and anticholinesterase agents may result in increased systemic toxicity since <e2>anticholinesterases</e2> inhibit the breakdown of procaine hydrochloride. ,False,negative
procaine hydrochloride,procaine hydrochloride,39,60,185,206,Anticholinesterases: Concurrent use of <e1>procaine hydrochloride</e1> and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of <e2>procaine hydrochloride</e2>. ,False,negative
anticholinesterase agents,anticholinesterases,66,90,140,158,Anticholinesterases: Concurrent use of procaine hydrochloride and <e1>anticholinesterase agents</e1> may result in increased systemic toxicity since <e2>anticholinesterases</e2> inhibit the breakdown of procaine hydrochloride. ,False,negative
anticholinesterase agents,procaine hydrochloride,66,90,185,206,Anticholinesterases: Concurrent use of procaine hydrochloride and <e1>anticholinesterase agents</e1> may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of <e2>procaine hydrochloride</e2>. ,False,negative
anticholinesterases,procaine hydrochloride,140,158,185,206,Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since <e1>anticholinesterases</e1> inhibit the breakdown of <e2>procaine hydrochloride</e2>. ,True,mechanism
CNS depressant,procaine hydrochloride,0,13,46,67,<e1>CNS depressant</e1> medications: Concurrent use of <e2>procaine hydrochloride</e2> and CNS depressant medications may result in additive depressant effects. ,False,negative
CNS depressant,CNS depressant medications,0,13,73,98,<e1>CNS depressant</e1> medications: Concurrent use of procaine hydrochloride and <e2>CNS depressant medications</e2> may result in additive depressant effects. ,False,negative
procaine hydrochloride,CNS depressant medications,46,67,73,98,CNS depressant medications: Concurrent use of <e1>procaine hydrochloride</e1> and <e2>CNS depressant medications</e2> may result in additive depressant effects. ,True,effect
Hyaluronidase,Hyaluronidase,0,12,15,27,"<e1>Hyaluronidase</e1>: <e2>Hyaluronidase</e2> may increase the diffusion rate of procaine hydrochloride, resulting in a decreased time of onset, but an increase in systemic toxicity. ",False,negative
Hyaluronidase,procaine hydrochloride,0,12,64,85,"<e1>Hyaluronidase</e1>: Hyaluronidase may increase the diffusion rate of <e2>procaine hydrochloride</e2>, resulting in a decreased time of onset, but an increase in systemic toxicity. ",False,negative
Hyaluronidase,procaine hydrochloride,15,27,64,85,"Hyaluronidase: <e1>Hyaluronidase</e1> may increase the diffusion rate of <e2>procaine hydrochloride</e2>, resulting in a decreased time of onset, but an increase in systemic toxicity. ",True,mechanism
Neuromuscular blocking agents,suxamethonium chloride,0,28,39,60,<e1>Neuromuscular blocking agents</e1> (such as <e2>suxamethonium chloride</e2>): Concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade. ,False,negative
Neuromuscular blocking agents,procaine hydrochloride,0,28,82,103,<e1>Neuromuscular blocking agents</e1> (such as suxamethonium chloride): Concurrent use of <e2>procaine hydrochloride</e2> and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade. ,False,negative
Neuromuscular blocking agents,neuromuscular blocking agents,0,28,109,137,<e1>Neuromuscular blocking agents</e1> (such as suxamethonium chloride): Concurrent use of procaine hydrochloride and <e2>neuromuscular blocking agents</e2> may result in prolongation or enhancement of the neuromuscular blockade. ,False,negative
suxamethonium chloride,procaine hydrochloride,39,60,82,103,Neuromuscular blocking agents (such as <e1>suxamethonium chloride</e1>): Concurrent use of <e2>procaine hydrochloride</e2> and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade. ,False,negative
suxamethonium chloride,neuromuscular blocking agents,39,60,109,137,Neuromuscular blocking agents (such as <e1>suxamethonium chloride</e1>): Concurrent use of procaine hydrochloride and <e2>neuromuscular blocking agents</e2> may result in prolongation or enhancement of the neuromuscular blockade. ,False,negative
procaine hydrochloride,neuromuscular blocking agents,82,103,109,137,Neuromuscular blocking agents (such as suxamethonium chloride): Concurrent use of <e1>procaine hydrochloride</e1> and <e2>neuromuscular blocking agents</e2> may result in prolongation or enhancement of the neuromuscular blockade. ,True,effect
Sulfonamides,procaine hydrochloride,0,11,32,53,<e1>Sulfonamides</e1>: Concurrent use of <e2>procaine hydrochloride</e2> and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide. ,False,negative
Sulfonamides,sulfonamides,0,11,59,70,<e1>Sulfonamides</e1>: Concurrent use of procaine hydrochloride and <e2>sulfonamides</e2> may result in a reduction of the antibacterial action of the sulfonamide. ,False,negative
Sulfonamides,sulfonamide,0,11,133,143,<e1>Sulfonamides</e1>: Concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the <e2>sulfonamide</e2>. ,False,negative
procaine hydrochloride,sulfonamides,32,53,59,70,Sulfonamides: Concurrent use of <e1>procaine hydrochloride</e1> and <e2>sulfonamides</e2> may result in a reduction of the antibacterial action of the sulfonamide. ,True,effect
procaine hydrochloride,sulfonamide,32,53,133,143,Sulfonamides: Concurrent use of <e1>procaine hydrochloride</e1> and sulfonamides may result in a reduction of the antibacterial action of the <e2>sulfonamide</e2>. ,False,negative
sulfonamides,sulfonamide,59,70,133,143,Sulfonamides: Concurrent use of procaine hydrochloride and <e1>sulfonamides</e1> may result in a reduction of the antibacterial action of the <e2>sulfonamide</e2>. ,False,negative
Acetazolamide,acetazolamide,0,12,33,45,<e1>Acetazolamide</e1>: Concurrent use of <e2>acetazolamide</e2> and procaine hydrochloride may extend the plasma half-life of procaine.,False,negative
Acetazolamide,procaine hydrochloride,0,12,51,72,<e1>Acetazolamide</e1>: Concurrent use of acetazolamide and <e2>procaine hydrochloride</e2> may extend the plasma half-life of procaine.,False,negative
Acetazolamide,procaine,0,12,109,116,<e1>Acetazolamide</e1>: Concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of <e2>procaine</e2>.,False,negative
acetazolamide,procaine hydrochloride,33,45,51,72,Acetazolamide: Concurrent use of <e1>acetazolamide</e1> and <e2>procaine hydrochloride</e2> may extend the plasma half-life of procaine.,True,mechanism
acetazolamide,procaine,33,45,109,116,Acetazolamide: Concurrent use of <e1>acetazolamide</e1> and procaine hydrochloride may extend the plasma half-life of <e2>procaine</e2>.,False,negative
procaine hydrochloride,procaine,51,72,109,116,Acetazolamide: Concurrent use of acetazolamide and <e1>procaine hydrochloride</e1> may extend the plasma half-life of <e2>procaine</e2>.,False,negative
barbiturates,antihistamines,54,65,68,81,"To minimize CNS depression and possible potentiation, <e1>barbiturates</e1>, <e2>antihistamines</e2>, narcotics, hypotensive agents or phenothiazines should be used with caution. ",False,negative
barbiturates,narcotics,54,65,84,92,"To minimize CNS depression and possible potentiation, <e1>barbiturates</e1>, antihistamines, <e2>narcotics</e2>, hypotensive agents or phenothiazines should be used with caution. ",False,negative
barbiturates,hypotensive agents,54,65,95,112,"To minimize CNS depression and possible potentiation, <e1>barbiturates</e1>, antihistamines, narcotics, <e2>hypotensive agents</e2> or phenothiazines should be used with caution. ",False,negative
barbiturates,phenothiazines,54,65,117,130,"To minimize CNS depression and possible potentiation, <e1>barbiturates</e1>, antihistamines, narcotics, hypotensive agents or <e2>phenothiazines</e2> should be used with caution. ",False,negative
antihistamines,narcotics,68,81,84,92,"To minimize CNS depression and possible potentiation, barbiturates, <e1>antihistamines</e1>, <e2>narcotics</e2>, hypotensive agents or phenothiazines should be used with caution. ",False,negative
antihistamines,hypotensive agents,68,81,95,112,"To minimize CNS depression and possible potentiation, barbiturates, <e1>antihistamines</e1>, narcotics, <e2>hypotensive agents</e2> or phenothiazines should be used with caution. ",False,negative
antihistamines,phenothiazines,68,81,117,130,"To minimize CNS depression and possible potentiation, barbiturates, <e1>antihistamines</e1>, narcotics, hypotensive agents or <e2>phenothiazines</e2> should be used with caution. ",False,negative
narcotics,hypotensive agents,84,92,95,112,"To minimize CNS depression and possible potentiation, barbiturates, antihistamines, <e1>narcotics</e1>, <e2>hypotensive agents</e2> or phenothiazines should be used with caution. ",False,negative
narcotics,phenothiazines,84,92,117,130,"To minimize CNS depression and possible potentiation, barbiturates, antihistamines, <e1>narcotics</e1>, hypotensive agents or <e2>phenothiazines</e2> should be used with caution. ",False,negative
hypotensive agents,phenothiazines,95,112,117,130,"To minimize CNS depression and possible potentiation, barbiturates, antihistamines, narcotics, <e1>hypotensive agents</e1> or <e2>phenothiazines</e2> should be used with caution. ",False,negative
Matulane,sympathomimetic drugs,8,15,70,90,"Because <e1>Matulane</e1> exhibits some monoamine oxidase inhibitory activity, <e2>sympathomimetic drugs</e2>, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",True,advise
Matulane,tricyclic antidepressant,8,15,93,116,"Because <e1>Matulane</e1> exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, <e2>tricyclic antidepressant</e2> drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",True,advise
Matulane,amitriptyline HCl,8,15,131,147,"Because <e1>Matulane</e1> exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., <e2>amitriptyline HCl</e2>, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",True,advise
Matulane,imipramine HCl,8,15,150,163,"Because <e1>Matulane</e1> exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, <e2>imipramine HCl</e2>) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",True,advise
Matulane,tyramine,8,15,208,215,"Because <e1>Matulane</e1> exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high <e2>tyramine</e2> content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",True,advise
sympathomimetic drugs,tricyclic antidepressant,70,90,93,116,"Because Matulane exhibits some monoamine oxidase inhibitory activity, <e1>sympathomimetic drugs</e1>, <e2>tricyclic antidepressant</e2> drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",False,negative
sympathomimetic drugs,amitriptyline HCl,70,90,131,147,"Because Matulane exhibits some monoamine oxidase inhibitory activity, <e1>sympathomimetic drugs</e1>, tricyclic antidepressant drugs (e.g., <e2>amitriptyline HCl</e2>, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",False,negative
sympathomimetic drugs,imipramine HCl,70,90,150,163,"Because Matulane exhibits some monoamine oxidase inhibitory activity, <e1>sympathomimetic drugs</e1>, tricyclic antidepressant drugs (e.g., amitriptyline HCl, <e2>imipramine HCl</e2>) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",False,negative
sympathomimetic drugs,tyramine,70,90,208,215,"Because Matulane exhibits some monoamine oxidase inhibitory activity, <e1>sympathomimetic drugs</e1>, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high <e2>tyramine</e2> content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",False,negative
tricyclic antidepressant,amitriptyline HCl,93,116,131,147,"Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, <e1>tricyclic antidepressant</e1> drugs (e.g., <e2>amitriptyline HCl</e2>, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",False,negative
tricyclic antidepressant,imipramine HCl,93,116,150,163,"Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, <e1>tricyclic antidepressant</e1> drugs (e.g., amitriptyline HCl, <e2>imipramine HCl</e2>) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",False,negative
tricyclic antidepressant,tyramine,93,116,208,215,"Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, <e1>tricyclic antidepressant</e1> drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high <e2>tyramine</e2> content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",False,negative
amitriptyline HCl,imipramine HCl,131,147,150,163,"Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., <e1>amitriptyline HCl</e1>, <e2>imipramine HCl</e2>) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",False,negative
amitriptyline HCl,tyramine,131,147,208,215,"Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., <e1>amitriptyline HCl</e1>, imipramine HCl) and other drugs and foods with known high <e2>tyramine</e2> content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",False,negative
imipramine HCl,tyramine,150,163,208,215,"Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, <e1>imipramine HCl</e1>) and other drugs and foods with known high <e2>tyramine</e2> content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",False,negative
chemotherapeutic agents,steroids,31,53,72,79,"No cross-resistance with other <e1>chemotherapeutic agents</e1>, radiotherapy or <e2>steroids</e2> has been demonstrated.",False,negative
Thiazide diuretics,phenothiazines,0,17,82,95,<e1>Thiazide diuretics</e1> may accentuate the orthostatic hypotension that may occur with <e2>phenothiazines</e2>. ,True,effect
guanethidine,phenothiazines,28,39,88,101,Antihypertensive effects of <e1>guanethidine</e1> and related compounds may be counteracted when <e2>phenothiazines</e2> are used concomitantly. ,True,effect
propranolol,phenothiazines,30,40,47,60,Concomitant administration of <e1>propranolol</e1> with <e2>phenothiazines</e2> results in increased plasma levels of both drugs.,True,mechanism
DIPRIVAN,narcotics,35,42,158,166,"The induction dose requirements of <e1>DIPRIVAN</e1> Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with <e2>narcotics</e2> (eg, morphine, meperidine, and fentanyl, etc.) ",True,effect
DIPRIVAN,morphine,35,42,173,180,"The induction dose requirements of <e1>DIPRIVAN</e1> Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, <e2>morphine</e2>, meperidine, and fentanyl, etc.) ",True,effect
DIPRIVAN,meperidine,35,42,183,192,"The induction dose requirements of <e1>DIPRIVAN</e1> Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, <e2>meperidine</e2>, and fentanyl, etc.) ",True,effect
DIPRIVAN,fentanyl,35,42,199,206,"The induction dose requirements of <e1>DIPRIVAN</e1> Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and <e2>fentanyl</e2>, etc.) ",True,effect
narcotics,morphine,158,166,173,180,"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with <e1>narcotics</e1> (eg, <e2>morphine</e2>, meperidine, and fentanyl, etc.) ",False,negative
narcotics,meperidine,158,166,183,192,"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with <e1>narcotics</e1> (eg, morphine, <e2>meperidine</e2>, and fentanyl, etc.) ",False,negative
narcotics,fentanyl,158,166,199,206,"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with <e1>narcotics</e1> (eg, morphine, meperidine, and <e2>fentanyl</e2>, etc.) ",False,negative
morphine,meperidine,173,180,183,192,"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, <e1>morphine</e1>, <e2>meperidine</e2>, and fentanyl, etc.) ",False,negative
morphine,fentanyl,173,180,199,206,"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, <e1>morphine</e1>, meperidine, and <e2>fentanyl</e2>, etc.) ",False,negative
meperidine,fentanyl,183,192,199,206,"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, <e1>meperidine</e1>, and <e2>fentanyl</e2>, etc.) ",False,negative
opioids,sedatives,20,26,32,40,"and combinations of <e1>opioids</e1> and <e2>sedatives</e2> (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). ",False,negative
opioids,benzodiazepines,20,26,47,61,"and combinations of <e1>opioids</e1> and sedatives (eg, <e2>benzodiazepines</e2>, barbiturates, chloral hydrate, droperidol, etc.). ",False,negative
opioids,barbiturates,20,26,64,75,"and combinations of <e1>opioids</e1> and sedatives (eg, benzodiazepines, <e2>barbiturates</e2>, chloral hydrate, droperidol, etc.). ",False,negative
opioids,chloral hydrate,20,26,78,92,"and combinations of <e1>opioids</e1> and sedatives (eg, benzodiazepines, barbiturates, <e2>chloral hydrate</e2>, droperidol, etc.). ",False,negative
opioids,droperidol,20,26,95,104,"and combinations of <e1>opioids</e1> and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, <e2>droperidol</e2>, etc.). ",False,negative
sedatives,benzodiazepines,32,40,47,61,"and combinations of opioids and <e1>sedatives</e1> (eg, <e2>benzodiazepines</e2>, barbiturates, chloral hydrate, droperidol, etc.). ",False,negative
sedatives,barbiturates,32,40,64,75,"and combinations of opioids and <e1>sedatives</e1> (eg, benzodiazepines, <e2>barbiturates</e2>, chloral hydrate, droperidol, etc.). ",False,negative
sedatives,chloral hydrate,32,40,78,92,"and combinations of opioids and <e1>sedatives</e1> (eg, benzodiazepines, barbiturates, <e2>chloral hydrate</e2>, droperidol, etc.). ",False,negative
sedatives,droperidol,32,40,95,104,"and combinations of opioids and <e1>sedatives</e1> (eg, benzodiazepines, barbiturates, chloral hydrate, <e2>droperidol</e2>, etc.). ",False,negative
benzodiazepines,barbiturates,47,61,64,75,"and combinations of opioids and sedatives (eg, <e1>benzodiazepines</e1>, <e2>barbiturates</e2>, chloral hydrate, droperidol, etc.). ",False,negative
benzodiazepines,chloral hydrate,47,61,78,92,"and combinations of opioids and sedatives (eg, <e1>benzodiazepines</e1>, barbiturates, <e2>chloral hydrate</e2>, droperidol, etc.). ",False,negative
benzodiazepines,droperidol,47,61,95,104,"and combinations of opioids and sedatives (eg, <e1>benzodiazepines</e1>, barbiturates, chloral hydrate, <e2>droperidol</e2>, etc.). ",False,negative
barbiturates,chloral hydrate,64,75,78,92,"and combinations of opioids and sedatives (eg, benzodiazepines, <e1>barbiturates</e1>, <e2>chloral hydrate</e2>, droperidol, etc.). ",False,negative
barbiturates,droperidol,64,75,95,104,"and combinations of opioids and sedatives (eg, benzodiazepines, <e1>barbiturates</e1>, chloral hydrate, <e2>droperidol</e2>, etc.). ",False,negative
chloral hydrate,droperidol,78,92,95,104,"and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, <e1>chloral hydrate</e1>, <e2>droperidol</e2>, etc.). ",False,negative
DIPRIVAN,analgesic agents,58,65,229,244,"During maintenance of anesthesia or sedation, the rate of <e1>DIPRIVAN</e1> Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental <e2>analgesic agents</e2> (eg, nitrous oxide or opioids). ",True,advise
DIPRIVAN,nitrous oxide,58,65,251,263,"During maintenance of anesthesia or sedation, the rate of <e1>DIPRIVAN</e1> Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, <e2>nitrous oxide</e2> or opioids). ",True,advise
DIPRIVAN,opioids,58,65,268,274,"During maintenance of anesthesia or sedation, the rate of <e1>DIPRIVAN</e1> Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or <e2>opioids</e2>). ",True,advise
analgesic agents,nitrous oxide,229,244,251,263,"During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental <e1>analgesic agents</e1> (eg, <e2>nitrous oxide</e2> or opioids). ",False,negative
analgesic agents,opioids,229,244,268,274,"During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental <e1>analgesic agents</e1> (eg, nitrous oxide or <e2>opioids</e2>). ",False,negative
nitrous oxide,opioids,251,263,268,274,"During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, <e1>nitrous oxide</e1> or <e2>opioids</e2>). ",False,negative
isoflurane,enflurane,65,74,77,85,"The concurrent administration of potent inhalational agents (eg, <e1>isoflurane</e1>, <e2>enflurane</e2>, and halothane) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated. ",False,negative
isoflurane,halothane,65,74,92,100,"The concurrent administration of potent inhalational agents (eg, <e1>isoflurane</e1>, enflurane, and <e2>halothane</e2>) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated. ",False,negative
isoflurane,DIPRIVAN,65,74,127,134,"The concurrent administration of potent inhalational agents (eg, <e1>isoflurane</e1>, enflurane, and halothane) during maintenance with <e2>DIPRIVAN</e2> Injectable Emulsion has not been extensively evaluated. ",False,negative
enflurane,halothane,77,85,92,100,"The concurrent administration of potent inhalational agents (eg, isoflurane, <e1>enflurane</e1>, and <e2>halothane</e2>) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated. ",False,negative
enflurane,DIPRIVAN,77,85,127,134,"The concurrent administration of potent inhalational agents (eg, isoflurane, <e1>enflurane</e1>, and halothane) during maintenance with <e2>DIPRIVAN</e2> Injectable Emulsion has not been extensively evaluated. ",False,negative
halothane,DIPRIVAN,92,100,127,134,"The concurrent administration of potent inhalational agents (eg, isoflurane, enflurane, and <e1>halothane</e1>) during maintenance with <e2>DIPRIVAN</e2> Injectable Emulsion has not been extensively evaluated. ",False,negative
DIPRIVAN,neuromuscular blocking agents,0,7,140,168,"<e1>DIPRIVAN</e1> Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used <e2>neuromuscular blocking agents</e2> (eg, succinylcholine and nondepolarizing muscle relaxants). ",False,negative
DIPRIVAN,succinylcholine,0,7,175,189,"<e1>DIPRIVAN</e1> Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, <e2>succinylcholine</e2> and nondepolarizing muscle relaxants). ",False,negative
DIPRIVAN,nondepolarizing muscle relaxants,0,7,195,226,"<e1>DIPRIVAN</e1> Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, succinylcholine and <e2>nondepolarizing muscle relaxants</e2>). ",False,negative
neuromuscular blocking agents,succinylcholine,140,168,175,189,"DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used <e1>neuromuscular blocking agents</e1> (eg, <e2>succinylcholine</e2> and nondepolarizing muscle relaxants). ",False,negative
neuromuscular blocking agents,nondepolarizing muscle relaxants,140,168,195,226,"DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used <e1>neuromuscular blocking agents</e1> (eg, succinylcholine and <e2>nondepolarizing muscle relaxants</e2>). ",False,negative
succinylcholine,nondepolarizing muscle relaxants,175,189,195,226,"DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, <e1>succinylcholine</e1> and <e2>nondepolarizing muscle relaxants</e2>). ",False,negative
muscle relaxants,analgesic agents,136,151,175,190,"No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of <e1>muscle relaxants</e1>, inhalational agents, <e2>analgesic agents</e2>, and local anesthetic agents) have been observed.",False,negative
muscle relaxants,anesthetic agents,136,151,203,219,"No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of <e1>muscle relaxants</e1>, inhalational agents, analgesic agents, and local <e2>anesthetic agents</e2>) have been observed.",False,negative
analgesic agents,anesthetic agents,175,190,203,219,"No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of muscle relaxants, inhalational agents, <e1>analgesic agents</e1>, and local <e2>anesthetic agents</e2>) have been observed.",False,negative
propoxyphene,CNS depressants,29,40,73,87,"The CNS-depressant effect of <e1>propoxyphene</e1> is additive with that of other <e2>CNS depressants</e2>, including alcohol. ",True,effect
propoxyphene,alcohol,29,40,100,106,"The CNS-depressant effect of <e1>propoxyphene</e1> is additive with that of other CNS depressants, including <e2>alcohol</e2>. ",True,effect
CNS depressants,alcohol,73,87,100,106,"The CNS-depressant effect of propoxyphene is additive with that of other <e1>CNS depressants</e1>, including <e2>alcohol</e2>. ",False,negative
propoxyphene,antidepressants,41,52,86,100,"Such occurrences have been reported when <e1>propoxyphene</e1> was administered to patients on <e2>antidepressants</e2>, anticonvulsants, or warfarin-like drugs. ",False,negative
propoxyphene,anticonvulsants,41,52,103,117,"Such occurrences have been reported when <e1>propoxyphene</e1> was administered to patients on antidepressants, <e2>anticonvulsants</e2>, or warfarin-like drugs. ",False,negative
propoxyphene,warfarin,41,52,123,130,"Such occurrences have been reported when <e1>propoxyphene</e1> was administered to patients on antidepressants, anticonvulsants, or <e2>warfarin</e2>-like drugs. ",False,negative
antidepressants,anticonvulsants,86,100,103,117,"Such occurrences have been reported when propoxyphene was administered to patients on <e1>antidepressants</e1>, <e2>anticonvulsants</e2>, or warfarin-like drugs. ",False,negative
antidepressants,warfarin,86,100,123,130,"Such occurrences have been reported when propoxyphene was administered to patients on <e1>antidepressants</e1>, anticonvulsants, or <e2>warfarin</e2>-like drugs. ",False,negative
anticonvulsants,warfarin,103,117,123,130,"Such occurrences have been reported when propoxyphene was administered to patients on antidepressants, <e1>anticonvulsants</e1>, or <e2>warfarin</e2>-like drugs. ",False,negative
MAO inhibitors,beta adrenergic blockers,0,13,19,42,<e1>MAO inhibitors</e1> and <e2>beta adrenergic blockers</e2> increase the effects of pseudoephedrine. ,False,negative
MAO inhibitors,pseudoephedrine,0,13,68,82,<e1>MAO inhibitors</e1> and beta adrenergic blockers increase the effects of <e2>pseudoephedrine</e2>. ,True,effect
beta adrenergic blockers,pseudoephedrine,19,42,68,82,MAO inhibitors and <e1>beta adrenergic blockers</e1> increase the effects of <e2>pseudoephedrine</e2>. ,True,effect
Sympathomimetics,methyldopa,0,15,60,69,"<e1>Sympathomimetics</e1> may reduce the antihypertensive effects of <e2>methyldopa</e2>, mecamylamine, reserpine and veratrum alkaloids.",True,effect
Sympathomimetics,mecamylamine,0,15,72,83,"<e1>Sympathomimetics</e1> may reduce the antihypertensive effects of methyldopa, <e2>mecamylamine</e2>, reserpine and veratrum alkaloids.",True,effect
Sympathomimetics,reserpine,0,15,86,94,"<e1>Sympathomimetics</e1> may reduce the antihypertensive effects of methyldopa, mecamylamine, <e2>reserpine</e2> and veratrum alkaloids.",True,effect
Sympathomimetics,veratrum alkaloids,0,15,100,117,"<e1>Sympathomimetics</e1> may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and <e2>veratrum alkaloids</e2>.",True,effect
methyldopa,mecamylamine,60,69,72,83,"Sympathomimetics may reduce the antihypertensive effects of <e1>methyldopa</e1>, <e2>mecamylamine</e2>, reserpine and veratrum alkaloids.",False,negative
methyldopa,reserpine,60,69,86,94,"Sympathomimetics may reduce the antihypertensive effects of <e1>methyldopa</e1>, mecamylamine, <e2>reserpine</e2> and veratrum alkaloids.",False,negative
methyldopa,veratrum alkaloids,60,69,100,117,"Sympathomimetics may reduce the antihypertensive effects of <e1>methyldopa</e1>, mecamylamine, reserpine and <e2>veratrum alkaloids</e2>.",False,negative
mecamylamine,reserpine,72,83,86,94,"Sympathomimetics may reduce the antihypertensive effects of methyldopa, <e1>mecamylamine</e1>, <e2>reserpine</e2> and veratrum alkaloids.",False,negative
mecamylamine,veratrum alkaloids,72,83,100,117,"Sympathomimetics may reduce the antihypertensive effects of methyldopa, <e1>mecamylamine</e1>, reserpine and <e2>veratrum alkaloids</e2>.",False,negative
reserpine,veratrum alkaloids,86,94,100,117,"Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, <e1>reserpine</e1> and <e2>veratrum alkaloids</e2>.",False,negative
Pyrimethamine,sulfonamides,0,12,31,42,"<e1>Pyrimethamine</e1> may be used with <e2>sulfonamides</e2>, quinine and other antimalarials, and with other antibiotics. ",False,negative
Pyrimethamine,quinine,0,12,45,51,"<e1>Pyrimethamine</e1> may be used with sulfonamides, <e2>quinine</e2> and other antimalarials, and with other antibiotics. ",False,negative
Pyrimethamine,antimalarials,0,12,63,75,"<e1>Pyrimethamine</e1> may be used with sulfonamides, quinine and other <e2>antimalarials</e2>, and with other antibiotics. ",False,negative
Pyrimethamine,antibiotics,0,12,93,103,"<e1>Pyrimethamine</e1> may be used with sulfonamides, quinine and other antimalarials, and with other <e2>antibiotics</e2>. ",False,negative
sulfonamides,quinine,31,42,45,51,"Pyrimethamine may be used with <e1>sulfonamides</e1>, <e2>quinine</e2> and other antimalarials, and with other antibiotics. ",False,negative
sulfonamides,antimalarials,31,42,63,75,"Pyrimethamine may be used with <e1>sulfonamides</e1>, quinine and other <e2>antimalarials</e2>, and with other antibiotics. ",False,negative
sulfonamides,antibiotics,31,42,93,103,"Pyrimethamine may be used with <e1>sulfonamides</e1>, quinine and other antimalarials, and with other <e2>antibiotics</e2>. ",False,negative
quinine,antimalarials,45,51,63,75,"Pyrimethamine may be used with sulfonamides, <e1>quinine</e1> and other <e2>antimalarials</e2>, and with other antibiotics. ",False,negative
quinine,antibiotics,45,51,93,103,"Pyrimethamine may be used with sulfonamides, <e1>quinine</e1> and other antimalarials, and with other <e2>antibiotics</e2>. ",False,negative
antimalarials,antibiotics,63,75,93,103,"Pyrimethamine may be used with sulfonamides, quinine and other <e1>antimalarials</e1>, and with other <e2>antibiotics</e2>. ",False,negative
Folinic acid,leucovorin,0,11,14,23,<e1>Folinic acid</e1> (<e2>leucovorin</e2>) should be administered until normal hematopoiesis is restored. ,False,negative
lorazepam,pyrimethamine,60,68,74,86,Mild hepatotoxicity has been reported in some patients when <e1>lorazepam</e1> and <e2>pyrimethamine</e2> were administered concomitantly.,True,effect
Cholestyramine,Cholestyramine,0,13,16,29,<e1>Cholestyramine</e1>: <e2>Cholestyramine</e2> causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. ,False,negative
Cholestyramine,raloxifene,0,13,101,110,<e1>Cholestyramine</e1>: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of <e2>raloxifene</e2> and should not be coadministered with EVISTA. ,False,negative
Cholestyramine,EVISTA,0,13,150,155,<e1>Cholestyramine</e1>: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with <e2>EVISTA</e2>. ,False,negative
Cholestyramine,raloxifene,16,29,101,110,Cholestyramine: <e1>Cholestyramine</e1> causes a 60% reduction in the absorption and enterohepatic cycling of <e2>raloxifene</e2> and should not be coadministered with EVISTA. ,True,mechanism
Cholestyramine,EVISTA,16,29,150,155,Cholestyramine: <e1>Cholestyramine</e1> causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with <e2>EVISTA</e2>. ,True,advise
raloxifene,EVISTA,101,110,150,155,Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of <e1>raloxifene</e1> and should not be coadministered with <e2>EVISTA</e2>. ,False,negative
Warfarin,EVISTA,0,7,34,39,<e1>Warfarin</e1>: The coadministration of <e2>EVISTA</e2> and warfarin has not been assessed under chronic conditions. ,False,negative
Warfarin,warfarin,0,7,45,52,<e1>Warfarin</e1>: The coadministration of EVISTA and <e2>warfarin</e2> has not been assessed under chronic conditions. ,False,negative
EVISTA,warfarin,34,39,45,52,Warfarin: The coadministration of <e1>EVISTA</e1> and <e2>warfarin</e2> has not been assessed under chronic conditions. ,False,negative
EVISTA,warfarin,3,8,37,44,"If <e1>EVISTA</e1> is given concurrently with <e2>warfarin</e2>, prothrombin time should be monitored. ",True,advise
raloxifene,warfarin,10,19,51,58,"In vitro, <e1>raloxifene</e1> did not affect the binding of <e2>warfarin</e2>, phenytoin, or tamoxifen. ",False,negative
raloxifene,phenytoin,10,19,61,69,"In vitro, <e1>raloxifene</e1> did not affect the binding of warfarin, <e2>phenytoin</e2>, or tamoxifen. ",False,negative
raloxifene,tamoxifen,10,19,75,83,"In vitro, <e1>raloxifene</e1> did not affect the binding of warfarin, phenytoin, or <e2>tamoxifen</e2>. ",False,negative
warfarin,phenytoin,51,58,61,69,"In vitro, raloxifene did not affect the binding of <e1>warfarin</e1>, <e2>phenytoin</e2>, or tamoxifen. ",False,negative
warfarin,tamoxifen,51,58,75,83,"In vitro, raloxifene did not affect the binding of <e1>warfarin</e1>, phenytoin, or <e2>tamoxifen</e2>. ",False,negative
phenytoin,tamoxifen,61,69,75,83,"In vitro, raloxifene did not affect the binding of warfarin, <e1>phenytoin</e1>, or <e2>tamoxifen</e2>. ",False,negative
EVISTA,clofibrate,28,33,100,109,"Caution should be used when <e1>EVISTA</e1> is coadministered with other highly protein-bound drugs, such as <e2>clofibrate</e2>, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",True,advise
EVISTA,indomethacin,28,33,112,123,"Caution should be used when <e1>EVISTA</e1> is coadministered with other highly protein-bound drugs, such as clofibrate, <e2>indomethacin</e2>, naproxen, ibuprofen, diazepam, and diazoxide. ",True,advise
EVISTA,naproxen,28,33,126,133,"Caution should be used when <e1>EVISTA</e1> is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, <e2>naproxen</e2>, ibuprofen, diazepam, and diazoxide. ",True,advise
EVISTA,ibuprofen,28,33,136,144,"Caution should be used when <e1>EVISTA</e1> is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, <e2>ibuprofen</e2>, diazepam, and diazoxide. ",True,advise
EVISTA,diazepam,28,33,147,154,"Caution should be used when <e1>EVISTA</e1> is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, <e2>diazepam</e2>, and diazoxide. ",True,advise
EVISTA,diazoxide,28,33,161,169,"Caution should be used when <e1>EVISTA</e1> is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and <e2>diazoxide</e2>. ",True,advise
clofibrate,indomethacin,100,109,112,123,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as <e1>clofibrate</e1>, <e2>indomethacin</e2>, naproxen, ibuprofen, diazepam, and diazoxide. ",False,negative
clofibrate,naproxen,100,109,126,133,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as <e1>clofibrate</e1>, indomethacin, <e2>naproxen</e2>, ibuprofen, diazepam, and diazoxide. ",False,negative
clofibrate,ibuprofen,100,109,136,144,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as <e1>clofibrate</e1>, indomethacin, naproxen, <e2>ibuprofen</e2>, diazepam, and diazoxide. ",False,negative
clofibrate,diazepam,100,109,147,154,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as <e1>clofibrate</e1>, indomethacin, naproxen, ibuprofen, <e2>diazepam</e2>, and diazoxide. ",False,negative
clofibrate,diazoxide,100,109,161,169,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as <e1>clofibrate</e1>, indomethacin, naproxen, ibuprofen, diazepam, and <e2>diazoxide</e2>. ",False,negative
indomethacin,naproxen,112,123,126,133,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, <e1>indomethacin</e1>, <e2>naproxen</e2>, ibuprofen, diazepam, and diazoxide. ",False,negative
indomethacin,ibuprofen,112,123,136,144,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, <e1>indomethacin</e1>, naproxen, <e2>ibuprofen</e2>, diazepam, and diazoxide. ",False,negative
indomethacin,diazepam,112,123,147,154,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, <e1>indomethacin</e1>, naproxen, ibuprofen, <e2>diazepam</e2>, and diazoxide. ",False,negative
indomethacin,diazoxide,112,123,161,169,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, <e1>indomethacin</e1>, naproxen, ibuprofen, diazepam, and <e2>diazoxide</e2>. ",False,negative
naproxen,ibuprofen,126,133,136,144,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, <e1>naproxen</e1>, <e2>ibuprofen</e2>, diazepam, and diazoxide. ",False,negative
naproxen,diazepam,126,133,147,154,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, <e1>naproxen</e1>, ibuprofen, <e2>diazepam</e2>, and diazoxide. ",False,negative
naproxen,diazoxide,126,133,161,169,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, <e1>naproxen</e1>, ibuprofen, diazepam, and <e2>diazoxide</e2>. ",False,negative
ibuprofen,diazepam,136,144,147,154,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, <e1>ibuprofen</e1>, <e2>diazepam</e2>, and diazoxide. ",False,negative
ibuprofen,diazoxide,136,144,161,169,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, <e1>ibuprofen</e1>, diazepam, and <e2>diazoxide</e2>. ",False,negative
diazepam,diazoxide,147,154,161,169,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, <e1>diazepam</e1>, and <e2>diazoxide</e2>. ",False,negative
TRITEC,clarithromycin,20,25,32,45,"Coadministration of <e1>TRITEC</e1> with <e2>clarithromycin</e2> resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%). ",True,mechanism
TRITEC,ranitidine,20,25,76,85,"Coadministration of <e1>TRITEC</e1> with clarithromycin resulted in increased plasma <e2>ranitidine</e2> concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%). ",False,negative
TRITEC,14- hydroxy- clarithromycin,20,25,177,203,"Coadministration of <e1>TRITEC</e1> with clarithromycin resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased <e2>14- hydroxy- clarithromycin</e2> plasma concentrations (31%). ",False,negative
clarithromycin,ranitidine,32,45,76,85,"Coadministration of TRITEC with <e1>clarithromycin</e1> resulted in increased plasma <e2>ranitidine</e2> concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%). ",False,negative
clarithromycin,14- hydroxy- clarithromycin,32,45,177,203,"Coadministration of TRITEC with <e1>clarithromycin</e1> resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased <e2>14- hydroxy- clarithromycin</e2> plasma concentrations (31%). ",False,negative
ranitidine,14- hydroxy- clarithromycin,76,85,177,203,"Coadministration of TRITEC with clarithromycin resulted in increased plasma <e1>ranitidine</e1> concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased <e2>14- hydroxy- clarithromycin</e2> plasma concentrations (31%). ",False,negative
aspirin,salicylate,22,28,74,83,Coadministration with <e1>aspirin</e1> results in a slight decrease in the rate of <e2>salicylate</e2> absorption that is clinically unimportant. ,False,negative
antacid,ranitidine,37,43,109,118,Coadministration with a high dose of <e1>antacid</e1> (170 mEq) results in a 28% decrease in plasma concentrations of <e2>ranitidine</e2> and may decrease plasma concentrations of bismuth from TRITEC. ,True,mechanism
antacid,TRITEC,37,43,175,180,Coadministration with a high dose of <e1>antacid</e1> (170 mEq) results in a 28% decrease in plasma concentrations of ranitidine and may decrease plasma concentrations of bismuth from <e2>TRITEC</e2>. ,True,mechanism
ranitidine,TRITEC,109,118,175,180,Coadministration with a high dose of antacid (170 mEq) results in a 28% decrease in plasma concentrations of <e1>ranitidine</e1> and may decrease plasma concentrations of bismuth from <e2>TRITEC</e2>. ,False,negative
ranitidine,ZANTAC,53,62,78,83,"For information on drug interactions associated with <e1>ranitidine</e1>, refer to the <e2>ZANTAC</e2>     package insert.",False,negative
ketoconazole,retapamulin,26,37,68,78,"Co-administration of oral <e1>ketoconazole</e1> 200 mg twice daily increased <e2>retapamulin</e2> geometric mean AUC(0-24) and Cmax by 81% after topical application of retapamulin ointment, 1% on the abraded skin of healthy adult males. ",False,negative
ketoconazole,retapamulin,26,37,150,160,"Co-administration of oral <e1>ketoconazole</e1> 200 mg twice daily increased retapamulin geometric mean AUC(0-24) and Cmax by 81% after topical application of <e2>retapamulin</e2> ointment, 1% on the abraded skin of healthy adult males. ",True,mechanism
retapamulin,retapamulin,68,78,150,160,"Co-administration of oral ketoconazole 200 mg twice daily increased <e1>retapamulin</e1> geometric mean AUC(0-24) and Cmax by 81% after topical application of <e2>retapamulin</e2> ointment, 1% on the abraded skin of healthy adult males. ",False,negative
retapamulin,retapamulin,32,42,110,120,"Due to low systemic exposure to <e1>retapamulin</e1> following topical application in patients, dosage adjustments for <e2>retapamulin</e2> are unnecessary when co-administered with CYP3A4 inhibitors, such as ketoconazole. ",False,negative
retapamulin,ketoconazole,32,42,191,202,"Due to low systemic exposure to <e1>retapamulin</e1> following topical application in patients, dosage adjustments for retapamulin are unnecessary when co-administered with CYP3A4 inhibitors, such as <e2>ketoconazole</e2>. ",False,negative
retapamulin,ketoconazole,110,120,191,202,"Due to low systemic exposure to retapamulin following topical application in patients, dosage adjustments for <e1>retapamulin</e1> are unnecessary when co-administered with CYP3A4 inhibitors, such as <e2>ketoconazole</e2>. ",False,negative
ALTABAX,retapamulin,114,120,123,133,"Based on in vitro P450 inhibition studies and the low systemic exposure observed following topical application of <e1>ALTABAX</e1>, <e2>retapamulin</e2> is unlikely to affect the metabolism of other P450 substrates. ",False,negative
heparin,vitamin K antagonists,40,46,52,72,"In addition to bleeding associated with <e1>heparin</e1> and <e2>vitamin K antagonists</e2>, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.",False,negative
heparin,aspirin,40,46,119,125,"In addition to bleeding associated with <e1>heparin</e1> and vitamin K antagonists, drugs that alter platelet function (such as <e2>aspirin</e2>, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.",False,negative
heparin,dipyridamole,40,46,128,139,"In addition to bleeding associated with <e1>heparin</e1> and vitamin K antagonists, drugs that alter platelet function (such as aspirin, <e2>dipyridamole</e2>, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.",False,negative
heparin,abciximab,40,46,146,154,"In addition to bleeding associated with <e1>heparin</e1> and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and <e2>abciximab</e2>) may increase the risk of bleeding if administered prior to or after Retavase    therapy.",False,negative
heparin,Retavase,40,46,225,232,"In addition to bleeding associated with <e1>heparin</e1> and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after <e2>Retavase</e2>    therapy.",True,effect
vitamin K antagonists,aspirin,52,72,119,125,"In addition to bleeding associated with heparin and <e1>vitamin K antagonists</e1>, drugs that alter platelet function (such as <e2>aspirin</e2>, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.",False,negative
vitamin K antagonists,dipyridamole,52,72,128,139,"In addition to bleeding associated with heparin and <e1>vitamin K antagonists</e1>, drugs that alter platelet function (such as aspirin, <e2>dipyridamole</e2>, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.",False,negative
vitamin K antagonists,abciximab,52,72,146,154,"In addition to bleeding associated with heparin and <e1>vitamin K antagonists</e1>, drugs that alter platelet function (such as aspirin, dipyridamole, and <e2>abciximab</e2>) may increase the risk of bleeding if administered prior to or after Retavase    therapy.",False,negative
vitamin K antagonists,Retavase,52,72,225,232,"In addition to bleeding associated with heparin and <e1>vitamin K antagonists</e1>, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after <e2>Retavase</e2>    therapy.",True,effect
aspirin,dipyridamole,119,125,128,139,"In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as <e1>aspirin</e1>, <e2>dipyridamole</e2>, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.",False,negative
aspirin,abciximab,119,125,146,154,"In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as <e1>aspirin</e1>, dipyridamole, and <e2>abciximab</e2>) may increase the risk of bleeding if administered prior to or after Retavase    therapy.",False,negative
aspirin,Retavase,119,125,225,232,"In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as <e1>aspirin</e1>, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after <e2>Retavase</e2>    therapy.",True,effect
dipyridamole,abciximab,128,139,146,154,"In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, <e1>dipyridamole</e1>, and <e2>abciximab</e2>) may increase the risk of bleeding if administered prior to or after Retavase    therapy.",False,negative
dipyridamole,Retavase,128,139,225,232,"In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, <e1>dipyridamole</e1>, and abciximab) may increase the risk of bleeding if administered prior to or after <e2>Retavase</e2>    therapy.",True,effect
abciximab,Retavase,146,154,225,232,"In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and <e1>abciximab</e1>) may increase the risk of bleeding if administered prior to or after <e2>Retavase</e2>    therapy.",True,effect
Vitamin B2,Riboflavin,17,26,29,38,Interactions for <e1>Vitamin B2</e1> (<e2>Riboflavin</e2>):  Alcohol - impairs the intestinal absorption of riboflavin,False,negative
Vitamin B2,Alcohol,17,26,43,49,Interactions for <e1>Vitamin B2</e1> (Riboflavin):  <e2>Alcohol</e2> - impairs the intestinal absorption of riboflavin,False,negative
Vitamin B2,riboflavin,17,26,90,99,Interactions for <e1>Vitamin B2</e1> (Riboflavin):  Alcohol - impairs the intestinal absorption of <e2>riboflavin</e2>,False,negative
Riboflavin,Alcohol,29,38,43,49,Interactions for Vitamin B2 (<e1>Riboflavin</e1>):  <e2>Alcohol</e2> - impairs the intestinal absorption of riboflavin,False,negative
Riboflavin,riboflavin,29,38,90,99,Interactions for Vitamin B2 (<e1>Riboflavin</e1>):  Alcohol - impairs the intestinal absorption of <e2>riboflavin</e2>,False,negative
Alcohol,riboflavin,43,49,90,99,Interactions for Vitamin B2 (Riboflavin):  <e1>Alcohol</e1> - impairs the intestinal absorption of <e2>riboflavin</e2>,True,mechanism
Probenecid,riboflavin,0,9,69,78,<e1>Probenecid</e1> - concurrent use decreases gastrointestinal absorption of <e2>riboflavin</e2>; ,True,mechanism
riboflavin,probenecid,17,26,67,76,requirements for <e1>riboflavin</e1> may be increased in patients receiving <e2>probenecid</e2>.,True,effect
Cimetidine,cimetidine,0,9,35,44,<e1>Cimetidine</e1>: The effects of chronic <e2>cimetidine</e2> use on the metabolism of rimantadine are not known. ,False,negative
Cimetidine,rimantadine,0,9,71,81,<e1>Cimetidine</e1>: The effects of chronic cimetidine use on the metabolism of <e2>rimantadine</e2> are not known. ,False,negative
cimetidine,rimantadine,35,44,71,81,Cimetidine: The effects of chronic <e1>cimetidine</e1> use on the metabolism of <e2>rimantadine</e2> are not known. ,False,negative
rimantadine HCl,Cimetidine,29,43,95,104,"When a single 100 mg dose of <e1>rimantadine HCl</e1> was administered one hour after the initiation of <e2>Cimetidine</e2> (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). ",True,mechanism
rimantadine HCl,rimantadine,29,43,152,162,"When a single 100 mg dose of <e1>rimantadine HCl</e1> was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total <e2>rimantadine</e2> clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). ",False,negative
rimantadine HCl,rimantadine,29,43,270,280,"When a single 100 mg dose of <e1>rimantadine HCl</e1> was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total <e2>rimantadine</e2> clearance in the same subjects in the absence of cimetidine). ",False,negative
rimantadine HCl,cimetidine,29,43,331,340,"When a single 100 mg dose of <e1>rimantadine HCl</e1> was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of <e2>cimetidine</e2>). ",False,negative
Cimetidine,rimantadine,95,104,152,162,"When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of <e1>Cimetidine</e1> (300 mg four times a day), the apparent total <e2>rimantadine</e2> clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). ",False,negative
Cimetidine,rimantadine,95,104,270,280,"When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of <e1>Cimetidine</e1> (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total <e2>rimantadine</e2> clearance in the same subjects in the absence of cimetidine). ",False,negative
Cimetidine,cimetidine,95,104,331,340,"When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of <e1>Cimetidine</e1> (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of <e2>cimetidine</e2>). ",False,negative
rimantadine,rimantadine,152,162,270,280,"When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total <e1>rimantadine</e1> clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total <e2>rimantadine</e2> clearance in the same subjects in the absence of cimetidine). ",False,negative
rimantadine,cimetidine,152,162,331,340,"When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total <e1>rimantadine</e1> clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of <e2>cimetidine</e2>). ",False,negative
rimantadine,cimetidine,270,280,331,340,"When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total <e1>rimantadine</e1> clearance in the same subjects in the absence of <e2>cimetidine</e2>). ",False,negative
Acetaminophen,Rimantadine HCl,0,12,15,29,"<e1>Acetaminophen</e1>: <e2>Rimantadine HCl</e2>, 100 mg, was given twice daily for 13 days to 12 healthy volunteers. ",False,negative
acetaminophen,rimantadine,22,34,86,96,Coadministration with <e1>acetaminophen</e1> reduced the peak concentration and AUC values for <e2>rimantadine</e2> by approximately 11%. ,True,mechanism
Aspirin,Rimantadine HCl,0,6,9,23,"<e1>Aspirin</e1>: <e2>Rimantadine HCl</e2>, 100 mg, was given twice daily fro 13 days to 12 healthy volunteers. ",False,negative
rimantadine,aspirin,38,48,100,106,Peak plasma concentrations and AUC of <e1>rimantadine</e1> were reduced approximately 10% in the presence of <e2>aspirin</e2>.,True,mechanism
Exelon,rivastigmine tartrate,33,38,44,64,Drug-Drug Interactions Effect of <e1>Exelon</e1>    (<e2>rivastigmine tartrate</e2>) on the Metabolism of Other Drugs: Rivastigmine is primarily metabolized through hydrolysis by esterases. ,False,negative
Exelon,Rivastigmine,33,38,101,112,Drug-Drug Interactions Effect of <e1>Exelon</e1>    (rivastigmine tartrate) on the Metabolism of Other Drugs: <e2>Rivastigmine</e2> is primarily metabolized through hydrolysis by esterases. ,False,negative
rivastigmine tartrate,Rivastigmine,44,64,101,112,Drug-Drug Interactions Effect of Exelon    (<e1>rivastigmine tartrate</e1>) on the Metabolism of Other Drugs: <e2>Rivastigmine</e2> is primarily metabolized through hydrolysis by esterases. ,False,negative
rivastigmine,digoxin,52,63,69,75,"No pharmacokinetic interaction was observed between <e1>rivastigmine</e1> and <e2>digoxin</e2>, warfarin, diazepam, or fluoxetine in studies in healthy volunteers. ",False,negative
rivastigmine,warfarin,52,63,78,85,"No pharmacokinetic interaction was observed between <e1>rivastigmine</e1> and digoxin, <e2>warfarin</e2>, diazepam, or fluoxetine in studies in healthy volunteers. ",False,negative
rivastigmine,diazepam,52,63,88,95,"No pharmacokinetic interaction was observed between <e1>rivastigmine</e1> and digoxin, warfarin, <e2>diazepam</e2>, or fluoxetine in studies in healthy volunteers. ",False,negative
rivastigmine,fluoxetine,52,63,101,110,"No pharmacokinetic interaction was observed between <e1>rivastigmine</e1> and digoxin, warfarin, diazepam, or <e2>fluoxetine</e2> in studies in healthy volunteers. ",False,negative
digoxin,warfarin,69,75,78,85,"No pharmacokinetic interaction was observed between rivastigmine and <e1>digoxin</e1>, <e2>warfarin</e2>, diazepam, or fluoxetine in studies in healthy volunteers. ",False,negative
digoxin,diazepam,69,75,88,95,"No pharmacokinetic interaction was observed between rivastigmine and <e1>digoxin</e1>, warfarin, <e2>diazepam</e2>, or fluoxetine in studies in healthy volunteers. ",False,negative
digoxin,fluoxetine,69,75,101,110,"No pharmacokinetic interaction was observed between rivastigmine and <e1>digoxin</e1>, warfarin, diazepam, or <e2>fluoxetine</e2> in studies in healthy volunteers. ",False,negative
warfarin,diazepam,78,85,88,95,"No pharmacokinetic interaction was observed between rivastigmine and digoxin, <e1>warfarin</e1>, <e2>diazepam</e2>, or fluoxetine in studies in healthy volunteers. ",False,negative
warfarin,fluoxetine,78,85,101,110,"No pharmacokinetic interaction was observed between rivastigmine and digoxin, <e1>warfarin</e1>, diazepam, or <e2>fluoxetine</e2> in studies in healthy volunteers. ",False,negative
diazepam,fluoxetine,88,95,101,110,"No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, <e1>diazepam</e1>, or <e2>fluoxetine</e2> in studies in healthy volunteers. ",False,negative
warfarin,Exelon,45,52,91,96,The elevation of prothrombin time induced by <e1>warfarin</e1> is not affected by administration of <e2>Exelon</e2>. ,False,negative
Exelon,rivastigmine,43,48,142,153,Effect of Other Drugs on the Metabolism of <e1>Exelon</e1>: Drugs that induce or inhibit CYP450 metabolism are not expected to alter the metabolism of <e2>rivastigmine</e2>. ,False,negative
rivastigmine,digoxin,72,83,147,153,"Single dose pharmacokinetic studies demonstrated that the metabolism of <e1>rivastigmine</e1> is not significantly affected by concurrent administration of <e2>digoxin</e2>, warfarin, diazepam, or fluoxetine. ",False,negative
rivastigmine,warfarin,72,83,156,163,"Single dose pharmacokinetic studies demonstrated that the metabolism of <e1>rivastigmine</e1> is not significantly affected by concurrent administration of digoxin, <e2>warfarin</e2>, diazepam, or fluoxetine. ",False,negative
rivastigmine,diazepam,72,83,166,173,"Single dose pharmacokinetic studies demonstrated that the metabolism of <e1>rivastigmine</e1> is not significantly affected by concurrent administration of digoxin, warfarin, <e2>diazepam</e2>, or fluoxetine. ",False,negative
rivastigmine,fluoxetine,72,83,179,188,"Single dose pharmacokinetic studies demonstrated that the metabolism of <e1>rivastigmine</e1> is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or <e2>fluoxetine</e2>. ",False,negative
digoxin,warfarin,147,153,156,163,"Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of <e1>digoxin</e1>, <e2>warfarin</e2>, diazepam, or fluoxetine. ",False,negative
digoxin,diazepam,147,153,166,173,"Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of <e1>digoxin</e1>, warfarin, <e2>diazepam</e2>, or fluoxetine. ",False,negative
digoxin,fluoxetine,147,153,179,188,"Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of <e1>digoxin</e1>, warfarin, diazepam, or <e2>fluoxetine</e2>. ",False,negative
warfarin,diazepam,156,163,166,173,"Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, <e1>warfarin</e1>, <e2>diazepam</e2>, or fluoxetine. ",False,negative
warfarin,fluoxetine,156,163,179,188,"Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, <e1>warfarin</e1>, diazepam, or <e2>fluoxetine</e2>. ",False,negative
diazepam,fluoxetine,166,173,179,188,"Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, <e1>diazepam</e1>, or <e2>fluoxetine</e2>. ",False,negative
rivastigmine,antacids,91,102,167,174,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of <e1>rivastigmine</e1> were not influenced by commonly prescribed medications such as <e2>antacids</e2> (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",False,negative
rivastigmine,antihypertensives,91,102,184,200,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of <e1>rivastigmine</e1> were not influenced by commonly prescribed medications such as antacids (n=77), <e2>antihypertensives</e2> (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",False,negative
rivastigmine,calcium channel blockers,91,102,210,233,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of <e1>rivastigmine</e1> were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), <e2>calcium channel blockers</e2> (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",False,negative
rivastigmine,antidiabetics,91,102,243,255,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of <e1>rivastigmine</e1> were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), <e2>antidiabetics</e2> (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",False,negative
rivastigmine,nonsteroidal anti-inflammatory drugs,91,102,265,300,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of <e1>rivastigmine</e1> were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), <e2>nonsteroidal anti-inflammatory drugs</e2> (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",False,negative
rivastigmine,estrogens,91,102,310,318,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of <e1>rivastigmine</e1> were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), <e2>estrogens</e2> (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",False,negative
rivastigmine,salicylate analgesics,91,102,328,348,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of <e1>rivastigmine</e1> were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), <e2>salicylate analgesics</e2> (n=177), antianginals (n=35), and antihistamines (n=15). ",False,negative
rivastigmine,antianginals,91,102,359,370,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of <e1>rivastigmine</e1> were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), <e2>antianginals</e2> (n=35), and antihistamines (n=15). ",False,negative
rivastigmine,antihistamines,91,102,384,397,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of <e1>rivastigmine</e1> were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and <e2>antihistamines</e2> (n=15). ",False,negative
antacids,antihypertensives,167,174,184,200,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as <e1>antacids</e1> (n=77), <e2>antihypertensives</e2> (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",False,negative
antacids,calcium channel blockers,167,174,210,233,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as <e1>antacids</e1> (n=77), antihypertensives (n=72), <e2>calcium channel blockers</e2> (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",False,negative
antacids,antidiabetics,167,174,243,255,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as <e1>antacids</e1> (n=77), antihypertensives (n=72), calcium channel blockers (n=75), <e2>antidiabetics</e2> (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",False,negative
antacids,nonsteroidal anti-inflammatory drugs,167,174,265,300,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as <e1>antacids</e1> (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), <e2>nonsteroidal anti-inflammatory drugs</e2> (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",False,negative
antacids,estrogens,167,174,310,318,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as <e1>antacids</e1> (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), <e2>estrogens</e2> (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",False,negative
antacids,salicylate analgesics,167,174,328,348,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as <e1>antacids</e1> (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), <e2>salicylate analgesics</e2> (n=177), antianginals (n=35), and antihistamines (n=15). ",False,negative
antacids,antianginals,167,174,359,370,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as <e1>antacids</e1> (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), <e2>antianginals</e2> (n=35), and antihistamines (n=15). ",False,negative
antacids,antihistamines,167,174,384,397,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as <e1>antacids</e1> (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and <e2>antihistamines</e2> (n=15). ",False,negative
antihypertensives,calcium channel blockers,184,200,210,233,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), <e1>antihypertensives</e1> (n=72), <e2>calcium channel blockers</e2> (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",False,negative
antihypertensives,antidiabetics,184,200,243,255,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), <e1>antihypertensives</e1> (n=72), calcium channel blockers (n=75), <e2>antidiabetics</e2> (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",False,negative
antihypertensives,nonsteroidal anti-inflammatory drugs,184,200,265,300,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), <e1>antihypertensives</e1> (n=72), calcium channel blockers (n=75), antidiabetics (n=21), <e2>nonsteroidal anti-inflammatory drugs</e2> (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",False,negative
antihypertensives,estrogens,184,200,310,318,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), <e1>antihypertensives</e1> (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), <e2>estrogens</e2> (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",False,negative
antihypertensives,salicylate analgesics,184,200,328,348,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), <e1>antihypertensives</e1> (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), <e2>salicylate analgesics</e2> (n=177), antianginals (n=35), and antihistamines (n=15). ",False,negative
antihypertensives,antianginals,184,200,359,370,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), <e1>antihypertensives</e1> (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), <e2>antianginals</e2> (n=35), and antihistamines (n=15). ",False,negative
antihypertensives,antihistamines,184,200,384,397,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), <e1>antihypertensives</e1> (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and <e2>antihistamines</e2> (n=15). ",False,negative
calcium channel blockers,antidiabetics,210,233,243,255,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), <e1>calcium channel blockers</e1> (n=75), <e2>antidiabetics</e2> (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",False,negative
calcium channel blockers,nonsteroidal anti-inflammatory drugs,210,233,265,300,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), <e1>calcium channel blockers</e1> (n=75), antidiabetics (n=21), <e2>nonsteroidal anti-inflammatory drugs</e2> (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",False,negative
calcium channel blockers,estrogens,210,233,310,318,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), <e1>calcium channel blockers</e1> (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), <e2>estrogens</e2> (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",False,negative
calcium channel blockers,salicylate analgesics,210,233,328,348,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), <e1>calcium channel blockers</e1> (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), <e2>salicylate analgesics</e2> (n=177), antianginals (n=35), and antihistamines (n=15). ",False,negative
calcium channel blockers,antianginals,210,233,359,370,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), <e1>calcium channel blockers</e1> (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), <e2>antianginals</e2> (n=35), and antihistamines (n=15). ",False,negative
calcium channel blockers,antihistamines,210,233,384,397,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), <e1>calcium channel blockers</e1> (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and <e2>antihistamines</e2> (n=15). ",False,negative
antidiabetics,nonsteroidal anti-inflammatory drugs,243,255,265,300,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), <e1>antidiabetics</e1> (n=21), <e2>nonsteroidal anti-inflammatory drugs</e2> (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",False,negative
antidiabetics,estrogens,243,255,310,318,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), <e1>antidiabetics</e1> (n=21), nonsteroidal anti-inflammatory drugs (n=79), <e2>estrogens</e2> (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",False,negative
antidiabetics,salicylate analgesics,243,255,328,348,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), <e1>antidiabetics</e1> (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), <e2>salicylate analgesics</e2> (n=177), antianginals (n=35), and antihistamines (n=15). ",False,negative
antidiabetics,antianginals,243,255,359,370,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), <e1>antidiabetics</e1> (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), <e2>antianginals</e2> (n=35), and antihistamines (n=15). ",False,negative
antidiabetics,antihistamines,243,255,384,397,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), <e1>antidiabetics</e1> (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and <e2>antihistamines</e2> (n=15). ",False,negative
nonsteroidal anti-inflammatory drugs,estrogens,265,300,310,318,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), <e1>nonsteroidal anti-inflammatory drugs</e1> (n=79), <e2>estrogens</e2> (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",False,negative
nonsteroidal anti-inflammatory drugs,salicylate analgesics,265,300,328,348,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), <e1>nonsteroidal anti-inflammatory drugs</e1> (n=79), estrogens (n=70), <e2>salicylate analgesics</e2> (n=177), antianginals (n=35), and antihistamines (n=15). ",False,negative
nonsteroidal anti-inflammatory drugs,antianginals,265,300,359,370,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), <e1>nonsteroidal anti-inflammatory drugs</e1> (n=79), estrogens (n=70), salicylate analgesics (n=177), <e2>antianginals</e2> (n=35), and antihistamines (n=15). ",False,negative
nonsteroidal anti-inflammatory drugs,antihistamines,265,300,384,397,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), <e1>nonsteroidal anti-inflammatory drugs</e1> (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and <e2>antihistamines</e2> (n=15). ",False,negative
estrogens,salicylate analgesics,310,318,328,348,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), <e1>estrogens</e1> (n=70), <e2>salicylate analgesics</e2> (n=177), antianginals (n=35), and antihistamines (n=15). ",False,negative
estrogens,antianginals,310,318,359,370,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), <e1>estrogens</e1> (n=70), salicylate analgesics (n=177), <e2>antianginals</e2> (n=35), and antihistamines (n=15). ",False,negative
estrogens,antihistamines,310,318,384,397,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), <e1>estrogens</e1> (n=70), salicylate analgesics (n=177), antianginals (n=35), and <e2>antihistamines</e2> (n=15). ",False,negative
salicylate analgesics,antianginals,328,348,359,370,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), <e1>salicylate analgesics</e1> (n=177), <e2>antianginals</e2> (n=35), and antihistamines (n=15). ",False,negative
salicylate analgesics,antihistamines,328,348,384,397,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), <e1>salicylate analgesics</e1> (n=177), antianginals (n=35), and <e2>antihistamines</e2> (n=15). ",False,negative
antianginals,antihistamines,359,370,384,397,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), <e1>antianginals</e1> (n=35), and <e2>antihistamines</e2> (n=15). ",False,negative
Anticholinergics,cholinesterase inhibitors,9,24,65,89,"Use with <e1>Anticholinergics</e1>: Because of their mechanism of action, <e2>cholinesterase inhibitors</e2> have the potential to interfere with the activity of anticholinergic medications. ",False,negative
Anticholinergics,anticholinergic medications,9,24,144,170,"Use with <e1>Anticholinergics</e1>: Because of their mechanism of action, cholinesterase inhibitors have the potential to interfere with the activity of <e2>anticholinergic medications</e2>. ",False,negative
cholinesterase inhibitors,anticholinergic medications,65,89,144,170,"Use with Anticholinergics: Because of their mechanism of action, <e1>cholinesterase inhibitors</e1> have the potential to interfere with the activity of <e2>anticholinergic medications</e2>. ",True,int
Cholinomimetics,Cholinesterase Inhibitors,9,23,35,59,"Use with <e1>Cholinomimetics</e1> and Other <e2>Cholinesterase Inhibitors</e2>: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",False,negative
Cholinomimetics,cholinesterase inhibitors,9,23,104,128,"Use with <e1>Cholinomimetics</e1> and Other Cholinesterase Inhibitors: A synergistic effect may be expected when <e2>cholinesterase inhibitors</e2> are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",False,negative
Cholinomimetics,succinylcholine,9,23,158,172,"Use with <e1>Cholinomimetics</e1> and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with <e2>succinylcholine</e2>, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",False,negative
Cholinomimetics,neuromuscular blocking agents,9,23,183,211,"Use with <e1>Cholinomimetics</e1> and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar <e2>neuromuscular blocking agents</e2> or cholinergic agonists such as bethanechol.",False,negative
Cholinomimetics,cholinergic agonists,9,23,216,235,"Use with <e1>Cholinomimetics</e1> and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or <e2>cholinergic agonists</e2> such as bethanechol.",False,negative
Cholinomimetics,bethanechol,9,23,245,255,"Use with <e1>Cholinomimetics</e1> and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as <e2>bethanechol</e2>.",False,negative
Cholinesterase Inhibitors,cholinesterase inhibitors,35,59,104,128,"Use with Cholinomimetics and Other <e1>Cholinesterase Inhibitors</e1>: A synergistic effect may be expected when <e2>cholinesterase inhibitors</e2> are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",False,negative
Cholinesterase Inhibitors,succinylcholine,35,59,158,172,"Use with Cholinomimetics and Other <e1>Cholinesterase Inhibitors</e1>: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with <e2>succinylcholine</e2>, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",False,negative
Cholinesterase Inhibitors,neuromuscular blocking agents,35,59,183,211,"Use with Cholinomimetics and Other <e1>Cholinesterase Inhibitors</e1>: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar <e2>neuromuscular blocking agents</e2> or cholinergic agonists such as bethanechol.",False,negative
Cholinesterase Inhibitors,cholinergic agonists,35,59,216,235,"Use with Cholinomimetics and Other <e1>Cholinesterase Inhibitors</e1>: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or <e2>cholinergic agonists</e2> such as bethanechol.",False,negative
Cholinesterase Inhibitors,bethanechol,35,59,245,255,"Use with Cholinomimetics and Other <e1>Cholinesterase Inhibitors</e1>: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as <e2>bethanechol</e2>.",False,negative
cholinesterase inhibitors,succinylcholine,104,128,158,172,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when <e1>cholinesterase inhibitors</e1> are given concurrently with <e2>succinylcholine</e2>, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",True,effect
cholinesterase inhibitors,neuromuscular blocking agents,104,128,183,211,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when <e1>cholinesterase inhibitors</e1> are given concurrently with succinylcholine, similar <e2>neuromuscular blocking agents</e2> or cholinergic agonists such as bethanechol.",True,effect
cholinesterase inhibitors,cholinergic agonists,104,128,216,235,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when <e1>cholinesterase inhibitors</e1> are given concurrently with succinylcholine, similar neuromuscular blocking agents or <e2>cholinergic agonists</e2> such as bethanechol.",True,effect
cholinesterase inhibitors,bethanechol,104,128,245,255,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when <e1>cholinesterase inhibitors</e1> are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as <e2>bethanechol</e2>.",True,effect
succinylcholine,neuromuscular blocking agents,158,172,183,211,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with <e1>succinylcholine</e1>, similar <e2>neuromuscular blocking agents</e2> or cholinergic agonists such as bethanechol.",False,negative
succinylcholine,cholinergic agonists,158,172,216,235,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with <e1>succinylcholine</e1>, similar neuromuscular blocking agents or <e2>cholinergic agonists</e2> such as bethanechol.",False,negative
succinylcholine,bethanechol,158,172,245,255,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with <e1>succinylcholine</e1>, similar neuromuscular blocking agents or cholinergic agonists such as <e2>bethanechol</e2>.",False,negative
neuromuscular blocking agents,cholinergic agonists,183,211,216,235,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar <e1>neuromuscular blocking agents</e1> or <e2>cholinergic agonists</e2> such as bethanechol.",False,negative
neuromuscular blocking agents,bethanechol,183,211,245,255,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar <e1>neuromuscular blocking agents</e1> or cholinergic agonists such as <e2>bethanechol</e2>.",False,negative
cholinergic agonists,bethanechol,216,235,245,255,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or <e1>cholinergic agonists</e1> such as <e2>bethanechol</e2>.",False,negative
ZEMURON,rocuronium bromide,30,36,42,59,"Drug Interactions: The use of <e1>ZEMURON</e1>    (<e2>rocuronium bromide</e2>) Injection before succinylcholine, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied. ",False,negative
ZEMURON,succinylcholine,30,36,79,93,"Drug Interactions: The use of <e1>ZEMURON</e1>    (rocuronium bromide) Injection before <e2>succinylcholine</e2>, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied. ",False,negative
ZEMURON,succinylcholine,30,36,155,169,"Drug Interactions: The use of <e1>ZEMURON</e1>    (rocuronium bromide) Injection before succinylcholine, for the purpose of attenuating some of the side effects of <e2>succinylcholine</e2>, has not been studied. ",False,negative
rocuronium bromide,succinylcholine,42,59,79,93,"Drug Interactions: The use of ZEMURON    (<e1>rocuronium bromide</e1>) Injection before <e2>succinylcholine</e2>, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied. ",False,negative
rocuronium bromide,succinylcholine,42,59,155,169,"Drug Interactions: The use of ZEMURON    (<e1>rocuronium bromide</e1>) Injection before succinylcholine, for the purpose of attenuating some of the side effects of <e2>succinylcholine</e2>, has not been studied. ",False,negative
succinylcholine,succinylcholine,79,93,155,169,"Drug Interactions: The use of ZEMURON    (rocuronium bromide) Injection before <e1>succinylcholine</e1>, for the purpose of attenuating some of the side effects of <e2>succinylcholine</e2>, has not been studied. ",False,negative
ZEMURON,succinylcholine,3,9,58,72,"If <e1>ZEMURON</e1>    is administered following administration of <e2>succinylcholine</e2>, it should not be given until recovery from succinylcholine has been observed. ",True,advise
ZEMURON,succinylcholine,3,9,118,132,"If <e1>ZEMURON</e1>    is administered following administration of succinylcholine, it should not be given until recovery from <e2>succinylcholine</e2> has been observed. ",False,negative
succinylcholine,succinylcholine,58,72,118,132,"If ZEMURON    is administered following administration of <e1>succinylcholine</e1>, it should not be given until recovery from <e2>succinylcholine</e2> has been observed. ",False,negative
ZEMURON,succinylcholine,33,39,91,105,"The median duration of action of <e1>ZEMURON</e1>    0.6 mg/kg administered after a 1 mg/kg dose of <e2>succinylcholine</e2> when T 1 returned to 75% of control was 36 minutes (range 14-57, n=12) vs. ",False,negative
ZEMURON,nondepolarizing muscle relaxants,55,61,88,119,There are no controlled studies documenting the use of <e1>ZEMURON</e1>    before or after other <e2>nondepolarizing muscle relaxants</e2>. ,False,negative
Ropivacaine,anesthetics,0,10,74,84,"<e1>Ropivacaine</e1> should be used with caution in patients receiving other local <e2>anesthetics</e2> or agents structurally related to amide-type local anesthetics, since the toxic effects of these drugs are additive. ",True,advise
Ropivacaine,amide-type local anesthetics,0,10,120,147,"<e1>Ropivacaine</e1> should be used with caution in patients receiving other local anesthetics or agents structurally related to <e2>amide-type local anesthetics</e2>, since the toxic effects of these drugs are additive. ",False,negative
anesthetics,amide-type local anesthetics,74,84,120,147,"Ropivacaine should be used with caution in patients receiving other local <e1>anesthetics</e1> or agents structurally related to <e2>amide-type local anesthetics</e2>, since the toxic effects of these drugs are additive. ",False,negative
ropivacaine,fluvoxamine,33,43,91,101,"In vivo, the plasma clearance of <e1>ropivacaine</e1> was reduced by 70% during coadministration of <e2>fluvoxamine</e2> (25 mg bid for 2 days), a selective and potent CYP1A2 inhibitor. ",True,mechanism
fluvoxamine,Ropivacaine,54,64,112,122,"Thus strong inhibitors of cytochrome P4501A2, such as <e1>fluvoxamine</e1>, given concomitantly during administration of <e2>Ropivacaine</e2>, can interact with Ropivacaine leading to increased ropivacaine plasma levels. ",True,int
fluvoxamine,Ropivacaine,54,64,143,153,"Thus strong inhibitors of cytochrome P4501A2, such as <e1>fluvoxamine</e1>, given concomitantly during administration of Ropivacaine, can interact with <e2>Ropivacaine</e2> leading to increased ropivacaine plasma levels. ",False,negative
fluvoxamine,ropivacaine,54,64,176,186,"Thus strong inhibitors of cytochrome P4501A2, such as <e1>fluvoxamine</e1>, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased <e2>ropivacaine</e2> plasma levels. ",False,negative
Ropivacaine,Ropivacaine,112,122,143,153,"Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of <e1>Ropivacaine</e1>, can interact with <e2>Ropivacaine</e2> leading to increased ropivacaine plasma levels. ",False,negative
Ropivacaine,ropivacaine,112,122,176,186,"Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of <e1>Ropivacaine</e1>, can interact with Ropivacaine leading to increased <e2>ropivacaine</e2> plasma levels. ",False,negative
Ropivacaine,ropivacaine,143,153,176,186,"Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with <e1>Ropivacaine</e1> leading to increased <e2>ropivacaine</e2> plasma levels. ",False,negative
theophylline,imipramine,102,113,119,128,Possible interactions with drugs known to be metabolized by CYP1A2 via competitive inhibition such as <e1>theophylline</e1> and <e2>imipramine</e2> may also occur. ,False,negative
ketoconazole,ropivacaine,64,75,105,115,"Coadministration of a selective and potent inhibitor of CYP3A4, <e1>ketoconazole</e1> (100 mg bid for 2 days with <e2>ropivacaine</e2> infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.",False,negative
ketoconazole,ketoconazole,64,75,152,163,"Coadministration of a selective and potent inhibitor of CYP3A4, <e1>ketoconazole</e1> (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after <e2>ketoconazole</e2>) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.",False,negative
ketoconazole,ropivacaine,64,75,220,230,"Coadministration of a selective and potent inhibitor of CYP3A4, <e1>ketoconazole</e1> (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of <e2>ropivacaine</e2>.",True,mechanism
ropivacaine,ketoconazole,105,115,152,163,"Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with <e1>ropivacaine</e1> infusion administered 1 hour after <e2>ketoconazole</e2>) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.",False,negative
ropivacaine,ropivacaine,105,115,220,230,"Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with <e1>ropivacaine</e1> infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of <e2>ropivacaine</e2>.",False,negative
ketoconazole,ropivacaine,152,163,220,230,"Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after <e1>ketoconazole</e1>) caused a 15% reduction in in-vivo plasma clearance of <e2>ropivacaine</e2>.",False,negative
gemfibrozil,rosiglitazone,32,42,69,81,An inhibitor of CYP2C8 (such as <e1>gemfibrozil</e1>) may increase the AUC of <e2>rosiglitazone</e2> and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone. ,True,mechanism
gemfibrozil,rifampin,32,42,117,124,An inhibitor of CYP2C8 (such as <e1>gemfibrozil</e1>) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as <e2>rifampin</e2>) may decrease the AUC of rosiglitazone. ,False,negative
gemfibrozil,rosiglitazone,32,42,151,163,An inhibitor of CYP2C8 (such as <e1>gemfibrozil</e1>) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of <e2>rosiglitazone</e2>. ,False,negative
rosiglitazone,rifampin,69,81,117,124,An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of <e1>rosiglitazone</e1> and an inducer of CYP2C8 (such as <e2>rifampin</e2>) may decrease the AUC of rosiglitazone. ,False,negative
rosiglitazone,rosiglitazone,69,81,151,163,An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of <e1>rosiglitazone</e1> and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of <e2>rosiglitazone</e2>. ,False,negative
rifampin,rosiglitazone,117,124,151,163,An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as <e1>rifampin</e1>) may decrease the AUC of <e2>rosiglitazone</e2>. ,True,mechanism
Terfenadine,astemizole,48,58,64,73,Concomitant administrations not recommended:  - <e1>Terfenadine</e1> and <e2>astemizole</e2>: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ,False,negative
Terfenadine,macrolides,48,58,84,93,Concomitant administrations not recommended:  - <e1>Terfenadine</e1> and astemizole: Certain <e2>macrolides</e2> interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ,False,negative
Terfenadine,terfenadine,48,58,109,119,Concomitant administrations not recommended:  - <e1>Terfenadine</e1> and astemizole: Certain macrolides interact with <e2>terfenadine</e2> and astemizole leading to increased serum concentrations of the latter. ,False,negative
Terfenadine,astemizole,48,58,125,134,Concomitant administrations not recommended:  - <e1>Terfenadine</e1> and astemizole: Certain macrolides interact with terfenadine and <e2>astemizole</e2> leading to increased serum concentrations of the latter. ,False,negative
astemizole,macrolides,64,73,84,93,Concomitant administrations not recommended:  - Terfenadine and <e1>astemizole</e1>: Certain <e2>macrolides</e2> interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ,False,negative
astemizole,terfenadine,64,73,109,119,Concomitant administrations not recommended:  - Terfenadine and <e1>astemizole</e1>: Certain macrolides interact with <e2>terfenadine</e2> and astemizole leading to increased serum concentrations of the latter. ,False,negative
astemizole,astemizole,64,73,125,134,Concomitant administrations not recommended:  - Terfenadine and <e1>astemizole</e1>: Certain macrolides interact with terfenadine and <e2>astemizole</e2> leading to increased serum concentrations of the latter. ,False,negative
macrolides,terfenadine,84,93,109,119,Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain <e1>macrolides</e1> interact with <e2>terfenadine</e2> and astemizole leading to increased serum concentrations of the latter. ,True,int
macrolides,astemizole,84,93,125,134,Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain <e1>macrolides</e1> interact with terfenadine and <e2>astemizole</e2> leading to increased serum concentrations of the latter. ,True,int
terfenadine,astemizole,109,119,125,134,Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with <e1>terfenadine</e1> and <e2>astemizole</e2> leading to increased serum concentrations of the latter. ,False,negative
roxithromycin,roxithromycin,56,68,101,113,"Although such a reaction has not been demonstrated with <e1>roxithromycin</e1>, concomitant administration of <e2>roxithromycin</e2> with terfenadine or astemizole is not recommended. ",False,negative
roxithromycin,terfenadine,56,68,120,130,"Although such a reaction has not been demonstrated with <e1>roxithromycin</e1>, concomitant administration of roxithromycin with <e2>terfenadine</e2> or astemizole is not recommended. ",False,negative
roxithromycin,astemizole,56,68,135,144,"Although such a reaction has not been demonstrated with <e1>roxithromycin</e1>, concomitant administration of roxithromycin with terfenadine or <e2>astemizole</e2> is not recommended. ",False,negative
roxithromycin,terfenadine,101,113,120,130,"Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of <e1>roxithromycin</e1> with <e2>terfenadine</e2> or astemizole is not recommended. ",True,advise
roxithromycin,astemizole,101,113,135,144,"Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of <e1>roxithromycin</e1> with terfenadine or <e2>astemizole</e2> is not recommended. ",True,advise
terfenadine,astemizole,120,130,135,144,"Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with <e1>terfenadine</e1> or <e2>astemizole</e2> is not recommended. ",False,negative
Cisapride,pimozide,2,10,13,20,"- <e1>Cisapride</e1>, <e2>pimozide</e2>: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ",False,negative
Cisapride,cisapride,2,10,43,51,"- <e1>Cisapride</e1>, pimozide: Other drugs such as <e2>cisapride</e2> or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ",False,negative
Cisapride,pimozide,2,10,56,63,"- <e1>Cisapride</e1>, pimozide: Other drugs such as cisapride or <e2>pimozide</e2>, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ",False,negative
Cisapride,macrolide antibacterials,2,10,352,375,"- <e1>Cisapride</e1>, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some <e2>macrolide antibacterials</e2>. ",False,negative
pimozide,cisapride,13,20,43,51,"- Cisapride, <e1>pimozide</e1>: Other drugs such as <e2>cisapride</e2> or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ",False,negative
pimozide,pimozide,13,20,56,63,"- Cisapride, <e1>pimozide</e1>: Other drugs such as cisapride or <e2>pimozide</e2>, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ",False,negative
pimozide,macrolide antibacterials,13,20,352,375,"- Cisapride, <e1>pimozide</e1>: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some <e2>macrolide antibacterials</e2>. ",True,mechanism
cisapride,pimozide,43,51,56,63,"- Cisapride, pimozide: Other drugs such as <e1>cisapride</e1> or <e2>pimozide</e2>, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ",False,negative
cisapride,macrolide antibacterials,43,51,352,375,"- Cisapride, pimozide: Other drugs such as <e1>cisapride</e1> or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some <e2>macrolide antibacterials</e2>. ",True,mechanism
pimozide,macrolide antibacterials,56,63,352,375,"- Cisapride, pimozide: Other drugs such as cisapride or <e1>pimozide</e1>, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some <e2>macrolide antibacterials</e2>. ",False,negative
roxithromycin,roxithromycin,41,53,71,83,"Although such a risk is not verified for <e1>roxithromycin</e1>, combination of <e2>roxithromycin</e2> with such drugs is not recommended.",False,negative
diphosphonate,Calcitonin (salmon),48,60,116,134,"however, in patients with Paget's Disease prior <e1>diphosphonate</e1> use appears to reduce the anti-resorptive response to <e2>Calcitonin (salmon)</e2> nasal spray.",True,effect
ASPIRIN,SALICYLATE DRUGS,0,6,18,33,<e1>ASPIRIN</e1> AND OTHER <e2>SALICYLATE DRUGS</e2> WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. ,False,negative
ASPIRIN,DISALCID,0,6,55,62,<e1>ASPIRIN</e1> AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO <e2>DISALCID</e2> AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. ,True,effect
ASPIRIN,SALICYLIC ACID,0,6,106,119,<e1>ASPIRIN</e1> AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF <e2>SALICYLIC ACID</e2> TO TOXIC LEVELS. ,False,negative
SALICYLATE DRUGS,DISALCID,18,33,55,62,ASPIRIN AND OTHER <e1>SALICYLATE DRUGS</e1> WILL BE ADDITIVE TO <e2>DISALCID</e2> AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. ,True,effect
SALICYLATE DRUGS,SALICYLIC ACID,18,33,106,119,ASPIRIN AND OTHER <e1>SALICYLATE DRUGS</e1> WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF <e2>SALICYLIC ACID</e2> TO TOXIC LEVELS. ,False,negative
DISALCID,SALICYLIC ACID,55,62,106,119,ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO <e1>DISALCID</e1> AND MAY INCREASE PLASMA CONCENTRATIONS OF <e2>SALICYLIC ACID</e2> TO TOXIC LEVELS. ,False,negative
Salicylates,anticoagulant drugs,0,10,37,55,<e1>Salicylates</e1> given concomitantly with <e2>anticoagulant drugs</e2> may predispose to systemic bleeding. ,True,effect
Salicylates,antidiabetic drugs,0,10,56,73,<e1>Salicylates</e1> may enhance the hypoglycemic effect of oral <e2>antidiabetic drugs</e2> of the sulfonylurea class. ,True,effect
Salicylate,penicillin,0,9,78,87,"<e1>Salicylate</e1> competes with a number of drugs for protein binding sites, notably <e2>penicillin</e2>, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",True,mechanism
Salicylate,thiopental,0,9,90,99,"<e1>Salicylate</e1> competes with a number of drugs for protein binding sites, notably penicillin, <e2>thiopental</e2>, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",True,mechanism
Salicylate,thyroxine,0,9,102,110,"<e1>Salicylate</e1> competes with a number of drugs for protein binding sites, notably penicillin, thiopental, <e2>thyroxine</e2>, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",True,mechanism
Salicylate,triiodothyronine,0,9,113,128,"<e1>Salicylate</e1> competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, <e2>triiodothyronine</e2>, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",True,mechanism
Salicylate,phenytoin,0,9,131,139,"<e1>Salicylate</e1> competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, <e2>phenytoin</e2>, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",True,mechanism
Salicylate,sulfinpyrazone,0,9,142,155,"<e1>Salicylate</e1> competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, <e2>sulfinpyrazone</e2>, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",True,mechanism
Salicylate,naproxen,0,9,158,165,"<e1>Salicylate</e1> competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, <e2>naproxen</e2>, warfarin, methotrexate, and possibly corticosteroids. ",True,mechanism
Salicylate,warfarin,0,9,168,175,"<e1>Salicylate</e1> competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, <e2>warfarin</e2>, methotrexate, and possibly corticosteroids. ",True,mechanism
Salicylate,methotrexate,0,9,178,189,"<e1>Salicylate</e1> competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, <e2>methotrexate</e2>, and possibly corticosteroids. ",True,mechanism
Salicylate,corticosteroids,0,9,205,219,"<e1>Salicylate</e1> competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly <e2>corticosteroids</e2>. ",True,mechanism
penicillin,thiopental,78,87,90,99,"Salicylate competes with a number of drugs for protein binding sites, notably <e1>penicillin</e1>, <e2>thiopental</e2>, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",False,negative
penicillin,thyroxine,78,87,102,110,"Salicylate competes with a number of drugs for protein binding sites, notably <e1>penicillin</e1>, thiopental, <e2>thyroxine</e2>, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",False,negative
penicillin,triiodothyronine,78,87,113,128,"Salicylate competes with a number of drugs for protein binding sites, notably <e1>penicillin</e1>, thiopental, thyroxine, <e2>triiodothyronine</e2>, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",False,negative
penicillin,phenytoin,78,87,131,139,"Salicylate competes with a number of drugs for protein binding sites, notably <e1>penicillin</e1>, thiopental, thyroxine, triiodothyronine, <e2>phenytoin</e2>, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",False,negative
penicillin,sulfinpyrazone,78,87,142,155,"Salicylate competes with a number of drugs for protein binding sites, notably <e1>penicillin</e1>, thiopental, thyroxine, triiodothyronine, phenytoin, <e2>sulfinpyrazone</e2>, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",False,negative
penicillin,naproxen,78,87,158,165,"Salicylate competes with a number of drugs for protein binding sites, notably <e1>penicillin</e1>, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, <e2>naproxen</e2>, warfarin, methotrexate, and possibly corticosteroids. ",False,negative
penicillin,warfarin,78,87,168,175,"Salicylate competes with a number of drugs for protein binding sites, notably <e1>penicillin</e1>, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, <e2>warfarin</e2>, methotrexate, and possibly corticosteroids. ",False,negative
penicillin,methotrexate,78,87,178,189,"Salicylate competes with a number of drugs for protein binding sites, notably <e1>penicillin</e1>, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, <e2>methotrexate</e2>, and possibly corticosteroids. ",False,negative
penicillin,corticosteroids,78,87,205,219,"Salicylate competes with a number of drugs for protein binding sites, notably <e1>penicillin</e1>, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly <e2>corticosteroids</e2>. ",False,negative
thiopental,thyroxine,90,99,102,110,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, <e1>thiopental</e1>, <e2>thyroxine</e2>, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",False,negative
thiopental,triiodothyronine,90,99,113,128,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, <e1>thiopental</e1>, thyroxine, <e2>triiodothyronine</e2>, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",False,negative
thiopental,phenytoin,90,99,131,139,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, <e1>thiopental</e1>, thyroxine, triiodothyronine, <e2>phenytoin</e2>, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",False,negative
thiopental,sulfinpyrazone,90,99,142,155,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, <e1>thiopental</e1>, thyroxine, triiodothyronine, phenytoin, <e2>sulfinpyrazone</e2>, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",False,negative
thiopental,naproxen,90,99,158,165,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, <e1>thiopental</e1>, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, <e2>naproxen</e2>, warfarin, methotrexate, and possibly corticosteroids. ",False,negative
thiopental,warfarin,90,99,168,175,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, <e1>thiopental</e1>, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, <e2>warfarin</e2>, methotrexate, and possibly corticosteroids. ",False,negative
thiopental,methotrexate,90,99,178,189,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, <e1>thiopental</e1>, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, <e2>methotrexate</e2>, and possibly corticosteroids. ",False,negative
thiopental,corticosteroids,90,99,205,219,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, <e1>thiopental</e1>, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly <e2>corticosteroids</e2>. ",False,negative
thyroxine,triiodothyronine,102,110,113,128,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, <e1>thyroxine</e1>, <e2>triiodothyronine</e2>, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",False,negative
thyroxine,phenytoin,102,110,131,139,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, <e1>thyroxine</e1>, triiodothyronine, <e2>phenytoin</e2>, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",False,negative
thyroxine,sulfinpyrazone,102,110,142,155,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, <e1>thyroxine</e1>, triiodothyronine, phenytoin, <e2>sulfinpyrazone</e2>, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",False,negative
thyroxine,naproxen,102,110,158,165,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, <e1>thyroxine</e1>, triiodothyronine, phenytoin, sulfinpyrazone, <e2>naproxen</e2>, warfarin, methotrexate, and possibly corticosteroids. ",False,negative
thyroxine,warfarin,102,110,168,175,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, <e1>thyroxine</e1>, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, <e2>warfarin</e2>, methotrexate, and possibly corticosteroids. ",False,negative
thyroxine,methotrexate,102,110,178,189,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, <e1>thyroxine</e1>, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, <e2>methotrexate</e2>, and possibly corticosteroids. ",False,negative
thyroxine,corticosteroids,102,110,205,219,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, <e1>thyroxine</e1>, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly <e2>corticosteroids</e2>. ",False,negative
triiodothyronine,phenytoin,113,128,131,139,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, <e1>triiodothyronine</e1>, <e2>phenytoin</e2>, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",False,negative
triiodothyronine,sulfinpyrazone,113,128,142,155,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, <e1>triiodothyronine</e1>, phenytoin, <e2>sulfinpyrazone</e2>, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",False,negative
triiodothyronine,naproxen,113,128,158,165,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, <e1>triiodothyronine</e1>, phenytoin, sulfinpyrazone, <e2>naproxen</e2>, warfarin, methotrexate, and possibly corticosteroids. ",False,negative
triiodothyronine,warfarin,113,128,168,175,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, <e1>triiodothyronine</e1>, phenytoin, sulfinpyrazone, naproxen, <e2>warfarin</e2>, methotrexate, and possibly corticosteroids. ",False,negative
triiodothyronine,methotrexate,113,128,178,189,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, <e1>triiodothyronine</e1>, phenytoin, sulfinpyrazone, naproxen, warfarin, <e2>methotrexate</e2>, and possibly corticosteroids. ",False,negative
triiodothyronine,corticosteroids,113,128,205,219,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, <e1>triiodothyronine</e1>, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly <e2>corticosteroids</e2>. ",False,negative
phenytoin,sulfinpyrazone,131,139,142,155,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, <e1>phenytoin</e1>, <e2>sulfinpyrazone</e2>, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",False,negative
phenytoin,naproxen,131,139,158,165,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, <e1>phenytoin</e1>, sulfinpyrazone, <e2>naproxen</e2>, warfarin, methotrexate, and possibly corticosteroids. ",False,negative
phenytoin,warfarin,131,139,168,175,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, <e1>phenytoin</e1>, sulfinpyrazone, naproxen, <e2>warfarin</e2>, methotrexate, and possibly corticosteroids. ",False,negative
phenytoin,methotrexate,131,139,178,189,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, <e1>phenytoin</e1>, sulfinpyrazone, naproxen, warfarin, <e2>methotrexate</e2>, and possibly corticosteroids. ",False,negative
phenytoin,corticosteroids,131,139,205,219,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, <e1>phenytoin</e1>, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly <e2>corticosteroids</e2>. ",False,negative
sulfinpyrazone,naproxen,142,155,158,165,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, <e1>sulfinpyrazone</e1>, <e2>naproxen</e2>, warfarin, methotrexate, and possibly corticosteroids. ",False,negative
sulfinpyrazone,warfarin,142,155,168,175,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, <e1>sulfinpyrazone</e1>, naproxen, <e2>warfarin</e2>, methotrexate, and possibly corticosteroids. ",False,negative
sulfinpyrazone,methotrexate,142,155,178,189,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, <e1>sulfinpyrazone</e1>, naproxen, warfarin, <e2>methotrexate</e2>, and possibly corticosteroids. ",False,negative
sulfinpyrazone,corticosteroids,142,155,205,219,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, <e1>sulfinpyrazone</e1>, naproxen, warfarin, methotrexate, and possibly <e2>corticosteroids</e2>. ",False,negative
naproxen,warfarin,158,165,168,175,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, <e1>naproxen</e1>, <e2>warfarin</e2>, methotrexate, and possibly corticosteroids. ",False,negative
naproxen,methotrexate,158,165,178,189,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, <e1>naproxen</e1>, warfarin, <e2>methotrexate</e2>, and possibly corticosteroids. ",False,negative
naproxen,corticosteroids,158,165,205,219,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, <e1>naproxen</e1>, warfarin, methotrexate, and possibly <e2>corticosteroids</e2>. ",False,negative
warfarin,methotrexate,168,175,178,189,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, <e1>warfarin</e1>, <e2>methotrexate</e2>, and possibly corticosteroids. ",False,negative
warfarin,corticosteroids,168,175,205,219,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, <e1>warfarin</e1>, methotrexate, and possibly <e2>corticosteroids</e2>. ",False,negative
methotrexate,corticosteroids,178,189,205,219,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, <e1>methotrexate</e1>, and possibly <e2>corticosteroids</e2>. ",False,negative
Leukine,lithium,61,67,78,84,"Drugs which may potentiate the myeloproliferative effects of <e1>Leukine</e1>, such as <e2>lithium</e2> and corticosteroids, should be used with caution.",True,effect
Leukine,corticosteroids,61,67,90,104,"Drugs which may potentiate the myeloproliferative effects of <e1>Leukine</e1>, such as lithium and <e2>corticosteroids</e2>, should be used with caution.",True,effect
lithium,corticosteroids,78,84,90,104,"Drugs which may potentiate the myeloproliferative effects of Leukine, such as <e1>lithium</e1> and <e2>corticosteroids</e2>, should be used with caution.",False,negative
Scopolamine,sedatives,0,10,116,124,"<e1>Scopolamine</e1> should be used with care in patients taking other drugs that are capable of causing CNS effects such as <e2>sedatives</e2>, tranquilizers, or alcohol. ",True,advise
Scopolamine,tranquilizers,0,10,127,139,"<e1>Scopolamine</e1> should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, <e2>tranquilizers</e2>, or alcohol. ",True,advise
Scopolamine,alcohol,0,10,145,151,"<e1>Scopolamine</e1> should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or <e2>alcohol</e2>. ",True,advise
sedatives,tranquilizers,116,124,127,139,"Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as <e1>sedatives</e1>, <e2>tranquilizers</e2>, or alcohol. ",False,negative
sedatives,alcohol,116,124,145,151,"Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as <e1>sedatives</e1>, tranquilizers, or <e2>alcohol</e2>. ",False,negative
tranquilizers,alcohol,127,139,145,151,"Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, <e1>tranquilizers</e1>, or <e2>alcohol</e2>. ",False,negative
belladonna alkaloids,antihistamines,12,31,34,47,"e.g., other <e1>belladonna alkaloids</e1>, <e2>antihistamines</e2> (including meclizine), tricyclic antidepressants, and muscle relaxants. ",False,negative
belladonna alkaloids,meclizine,12,31,60,68,"e.g., other <e1>belladonna alkaloids</e1>, antihistamines (including <e2>meclizine</e2>), tricyclic antidepressants, and muscle relaxants. ",False,negative
belladonna alkaloids,tricyclic antidepressants,12,31,72,96,"e.g., other <e1>belladonna alkaloids</e1>, antihistamines (including meclizine), <e2>tricyclic antidepressants</e2>, and muscle relaxants. ",False,negative
belladonna alkaloids,muscle relaxants,12,31,103,118,"e.g., other <e1>belladonna alkaloids</e1>, antihistamines (including meclizine), tricyclic antidepressants, and <e2>muscle relaxants</e2>. ",False,negative
antihistamines,meclizine,34,47,60,68,"e.g., other belladonna alkaloids, <e1>antihistamines</e1> (including <e2>meclizine</e2>), tricyclic antidepressants, and muscle relaxants. ",False,negative
antihistamines,tricyclic antidepressants,34,47,72,96,"e.g., other belladonna alkaloids, <e1>antihistamines</e1> (including meclizine), <e2>tricyclic antidepressants</e2>, and muscle relaxants. ",False,negative
antihistamines,muscle relaxants,34,47,103,118,"e.g., other belladonna alkaloids, <e1>antihistamines</e1> (including meclizine), tricyclic antidepressants, and <e2>muscle relaxants</e2>. ",False,negative
meclizine,tricyclic antidepressants,60,68,72,96,"e.g., other belladonna alkaloids, antihistamines (including <e1>meclizine</e1>), <e2>tricyclic antidepressants</e2>, and muscle relaxants. ",False,negative
meclizine,muscle relaxants,60,68,103,118,"e.g., other belladonna alkaloids, antihistamines (including <e1>meclizine</e1>), tricyclic antidepressants, and <e2>muscle relaxants</e2>. ",False,negative
tricyclic antidepressants,muscle relaxants,72,96,103,118,"e.g., other belladonna alkaloids, antihistamines (including meclizine), <e1>tricyclic antidepressants</e1>, and <e2>muscle relaxants</e2>. ",False,negative
Barbiturates,contraceptives,0,11,52,65,"<e1>Barbiturates</e1> may decrease the effectiveness of oral <e2>contraceptives</e2>, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.",True,int
Barbiturates,antibiotics,0,11,76,86,"<e1>Barbiturates</e1> may decrease the effectiveness of oral contraceptives, certain <e2>antibiotics</e2>, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.",True,int
Barbiturates,quinidine,0,11,89,97,"<e1>Barbiturates</e1> may decrease the effectiveness of oral contraceptives, certain antibiotics, <e2>quinidine</e2>, theophylline, corticosteroids, anticoagulants, and beta blockers.",True,int
Barbiturates,theophylline,0,11,100,111,"<e1>Barbiturates</e1> may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, <e2>theophylline</e2>, corticosteroids, anticoagulants, and beta blockers.",True,int
Barbiturates,corticosteroids,0,11,114,128,"<e1>Barbiturates</e1> may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, <e2>corticosteroids</e2>, anticoagulants, and beta blockers.",True,int
Barbiturates,anticoagulants,0,11,131,144,"<e1>Barbiturates</e1> may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, <e2>anticoagulants</e2>, and beta blockers.",True,int
Barbiturates,beta blockers,0,11,151,163,"<e1>Barbiturates</e1> may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and <e2>beta blockers</e2>.",True,int
contraceptives,antibiotics,52,65,76,86,"Barbiturates may decrease the effectiveness of oral <e1>contraceptives</e1>, certain <e2>antibiotics</e2>, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.",False,negative
contraceptives,quinidine,52,65,89,97,"Barbiturates may decrease the effectiveness of oral <e1>contraceptives</e1>, certain antibiotics, <e2>quinidine</e2>, theophylline, corticosteroids, anticoagulants, and beta blockers.",False,negative
contraceptives,theophylline,52,65,100,111,"Barbiturates may decrease the effectiveness of oral <e1>contraceptives</e1>, certain antibiotics, quinidine, <e2>theophylline</e2>, corticosteroids, anticoagulants, and beta blockers.",False,negative
contraceptives,corticosteroids,52,65,114,128,"Barbiturates may decrease the effectiveness of oral <e1>contraceptives</e1>, certain antibiotics, quinidine, theophylline, <e2>corticosteroids</e2>, anticoagulants, and beta blockers.",False,negative
contraceptives,anticoagulants,52,65,131,144,"Barbiturates may decrease the effectiveness of oral <e1>contraceptives</e1>, certain antibiotics, quinidine, theophylline, corticosteroids, <e2>anticoagulants</e2>, and beta blockers.",False,negative
contraceptives,beta blockers,52,65,151,163,"Barbiturates may decrease the effectiveness of oral <e1>contraceptives</e1>, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and <e2>beta blockers</e2>.",False,negative
antibiotics,quinidine,76,86,89,97,"Barbiturates may decrease the effectiveness of oral contraceptives, certain <e1>antibiotics</e1>, <e2>quinidine</e2>, theophylline, corticosteroids, anticoagulants, and beta blockers.",False,negative
antibiotics,theophylline,76,86,100,111,"Barbiturates may decrease the effectiveness of oral contraceptives, certain <e1>antibiotics</e1>, quinidine, <e2>theophylline</e2>, corticosteroids, anticoagulants, and beta blockers.",False,negative
antibiotics,corticosteroids,76,86,114,128,"Barbiturates may decrease the effectiveness of oral contraceptives, certain <e1>antibiotics</e1>, quinidine, theophylline, <e2>corticosteroids</e2>, anticoagulants, and beta blockers.",False,negative
antibiotics,anticoagulants,76,86,131,144,"Barbiturates may decrease the effectiveness of oral contraceptives, certain <e1>antibiotics</e1>, quinidine, theophylline, corticosteroids, <e2>anticoagulants</e2>, and beta blockers.",False,negative
antibiotics,beta blockers,76,86,151,163,"Barbiturates may decrease the effectiveness of oral contraceptives, certain <e1>antibiotics</e1>, quinidine, theophylline, corticosteroids, anticoagulants, and <e2>beta blockers</e2>.",False,negative
quinidine,theophylline,89,97,100,111,"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, <e1>quinidine</e1>, <e2>theophylline</e2>, corticosteroids, anticoagulants, and beta blockers.",False,negative
quinidine,corticosteroids,89,97,114,128,"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, <e1>quinidine</e1>, theophylline, <e2>corticosteroids</e2>, anticoagulants, and beta blockers.",False,negative
quinidine,anticoagulants,89,97,131,144,"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, <e1>quinidine</e1>, theophylline, corticosteroids, <e2>anticoagulants</e2>, and beta blockers.",False,negative
quinidine,beta blockers,89,97,151,163,"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, <e1>quinidine</e1>, theophylline, corticosteroids, anticoagulants, and <e2>beta blockers</e2>.",False,negative
theophylline,corticosteroids,100,111,114,128,"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, <e1>theophylline</e1>, <e2>corticosteroids</e2>, anticoagulants, and beta blockers.",False,negative
theophylline,anticoagulants,100,111,131,144,"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, <e1>theophylline</e1>, corticosteroids, <e2>anticoagulants</e2>, and beta blockers.",False,negative
theophylline,beta blockers,100,111,151,163,"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, <e1>theophylline</e1>, corticosteroids, anticoagulants, and <e2>beta blockers</e2>.",False,negative
corticosteroids,anticoagulants,114,128,131,144,"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, <e1>corticosteroids</e1>, <e2>anticoagulants</e2>, and beta blockers.",False,negative
corticosteroids,beta blockers,114,128,151,163,"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, <e1>corticosteroids</e1>, anticoagulants, and <e2>beta blockers</e2>.",False,negative
anticoagulants,beta blockers,131,144,151,163,"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, <e1>anticoagulants</e1>, and <e2>beta blockers</e2>.",False,negative
selegiline,meperidine,152,161,167,176,"The occurrence of stupor, muscular rigidity, severe agitation, and elevated temperature has been reported in some patients receiving the combination of <e1>selegiline</e1> and <e2>meperidine</e2>. ",True,effect
meperidine,MAOIs,38,47,53,57,This is typical of the interaction of <e1>meperidine</e1> and <e2>MAOIs</e2>. ,True,int
tricyclic antidepressants,ELDEPRYL,80,104,110,117,Severe toxicity has also been reported in patients receiving the combination of <e1>tricyclic antidepressants</e1> and <e2>ELDEPRYL</e2> and selective serotonin reuptake inhibitors and ELDEPRYL. ,True,effect
tricyclic antidepressants,selective serotonin reuptake inhibitors,80,104,123,161,Severe toxicity has also been reported in patients receiving the combination of <e1>tricyclic antidepressants</e1> and ELDEPRYL and <e2>selective serotonin reuptake inhibitors</e2> and ELDEPRYL. ,False,negative
tricyclic antidepressants,ELDEPRYL,80,104,167,174,Severe toxicity has also been reported in patients receiving the combination of <e1>tricyclic antidepressants</e1> and ELDEPRYL and selective serotonin reuptake inhibitors and <e2>ELDEPRYL</e2>. ,False,negative
ELDEPRYL,selective serotonin reuptake inhibitors,110,117,123,161,Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and <e1>ELDEPRYL</e1> and <e2>selective serotonin reuptake inhibitors</e2> and ELDEPRYL. ,False,negative
ELDEPRYL,ELDEPRYL,110,117,167,174,Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and <e1>ELDEPRYL</e1> and selective serotonin reuptake inhibitors and <e2>ELDEPRYL</e2>. ,False,negative
selective serotonin reuptake inhibitors,ELDEPRYL,123,161,167,174,Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and <e1>selective serotonin reuptake inhibitors</e1> and <e2>ELDEPRYL</e2>. ,True,effect
selegiline,sympathomimetic medication,95,104,112,137,One case of hypertensive crisis has been reported in a patient taking the recommended doses of <e1>selegiline</e1> and a <e2>sympathomimetic medication</e2> (ephedrine).,True,effect
selegiline,ephedrine,95,104,140,148,One case of hypertensive crisis has been reported in a patient taking the recommended doses of <e1>selegiline</e1> and a sympathomimetic medication (<e2>ephedrine</e2>).,True,effect
sympathomimetic medication,ephedrine,112,137,140,148,One case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a <e1>sympathomimetic medication</e1> (<e2>ephedrine</e2>).,False,negative
Digoxin,digoxin,0,6,124,130,"<e1>Digoxin</e1>: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of <e2>digoxin</e2> with the co-administration of 100 mg sitagliptin for 10 days. ",False,negative
Digoxin,sitagliptin,0,6,169,179,"<e1>Digoxin</e1>: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg <e2>sitagliptin</e2> for 10 days. ",False,negative
digoxin,sitagliptin,124,130,169,179,"Digoxin: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of <e1>digoxin</e1> with the co-administration of 100 mg <e2>sitagliptin</e2> for 10 days. ",True,mechanism
digoxin,JANUVIA,24,30,35,41,No dosage adjustment of <e1>digoxin</e1> or <e2>JANUVIA</e2> is recommended.,False,negative
norepinephrine,dobutamine,0,13,19,28,<e1>norepinephrine</e1> and <e2>dobutamine</e2> are incompatible with sodium bicarbonate solution. ,False,negative
norepinephrine,sodium bicarbonate,0,13,52,69,<e1>norepinephrine</e1> and dobutamine are incompatible with <e2>sodium bicarbonate</e2> solution. ,True,int
dobutamine,sodium bicarbonate,19,28,52,69,norepinephrine and <e1>dobutamine</e1> are incompatible with <e2>sodium bicarbonate</e2> solution. ,True,int
sodium bicarbonate,calcium,16,33,70,76,"The addition of <e1>sodium bicarbonate</e1> to parenteral solutions containing <e2>calcium</e2> should be avoided, except where compatibility has been previously established. ",False,negative
VESIcare,ketoconazole,35,42,88,99,Do not exceed a 5 mg daily dose of <e1>VESIcare</e1> when administered with therapeutic doses of <e2>ketoconazole</e2> or other potent CYP3A4 inhibitors. ,True,advise
solifenacin,solifenacin,81,91,177,187,"Patients with Congenital or Acquired QT Prolongation In a study of the effect of <e1>solifenacin</e1> on the QT interval in 76 healthy women, the QT prolonging effect appeared less with <e2>solifenacin</e2> 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose. ",False,negative
solifenacin,solifenacin,81,91,273,283,"Patients with Congenital or Acquired QT Prolongation In a study of the effect of <e1>solifenacin</e1> on the QT interval in 76 healthy women, the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of <e2>solifenacin</e2> 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose. ",False,negative
solifenacin,moxifloxacin,81,91,347,358,"Patients with Congenital or Acquired QT Prolongation In a study of the effect of <e1>solifenacin</e1> on the QT interval in 76 healthy women, the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control <e2>moxifloxacin</e2> at its therapeutic dose. ",False,negative
solifenacin,solifenacin,177,187,273,283,"Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women, the QT prolonging effect appeared less with <e1>solifenacin</e1> 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of <e2>solifenacin</e2> 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose. ",False,negative
solifenacin,moxifloxacin,177,187,347,358,"Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women, the QT prolonging effect appeared less with <e1>solifenacin</e1> 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control <e2>moxifloxacin</e2> at its therapeutic dose. ",False,negative
solifenacin,moxifloxacin,273,283,347,358,"Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women, the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of <e1>solifenacin</e1> 30 mg did not appear as large as that of the positive control <e2>moxifloxacin</e2> at its therapeutic dose. ",False,negative
glucocorticoid,glucocorticoid,3,16,47,60,"If <e1>glucocorticoid</e1> replacement is required, the <e2>glucocorticoid</e2> dose should be carefully adjusted. ",False,negative
GH,antipyrine,37,38,93,102,Limited published data indicate that <e1>GH</e1> treatment increases cytochrome P450 (CP450) mediated <e2>antipyrine</e2> clearance in man. ,True,mechanism
GH,corticosteroids,24,25,133,147,"These data suggest that <e1>GH</e1> administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., <e2>corticosteroids</e2>, sex steroids, anticonvulsants, cyclosporin). ",True,mechanism
GH,sex steroids,24,25,150,161,"These data suggest that <e1>GH</e1> administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, <e2>sex steroids</e2>, anticonvulsants, cyclosporin). ",True,mechanism
GH,anticonvulsants,24,25,164,178,"These data suggest that <e1>GH</e1> administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, <e2>anticonvulsants</e2>, cyclosporin). ",True,mechanism
GH,cyclosporin,24,25,181,191,"These data suggest that <e1>GH</e1> administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, <e2>cyclosporin</e2>). ",True,mechanism
corticosteroids,sex steroids,133,147,150,161,"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., <e1>corticosteroids</e1>, <e2>sex steroids</e2>, anticonvulsants, cyclosporin). ",False,negative
corticosteroids,anticonvulsants,133,147,164,178,"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., <e1>corticosteroids</e1>, sex steroids, <e2>anticonvulsants</e2>, cyclosporin). ",False,negative
corticosteroids,cyclosporin,133,147,181,191,"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., <e1>corticosteroids</e1>, sex steroids, anticonvulsants, <e2>cyclosporin</e2>). ",False,negative
sex steroids,anticonvulsants,150,161,164,178,"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, <e1>sex steroids</e1>, <e2>anticonvulsants</e2>, cyclosporin). ",False,negative
sex steroids,cyclosporin,150,161,181,191,"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, <e1>sex steroids</e1>, anticonvulsants, <e2>cyclosporin</e2>). ",False,negative
anticonvulsants,cyclosporin,164,178,181,191,"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, <e1>anticonvulsants</e1>, <e2>cyclosporin</e2>). ",False,negative
NEXAVAR,irinotecan,42,48,139,148,Caution is recommended when administering <e1>NEXAVAR</e1> with compounds that are metabolized/eliminated predominantly by the UGT1A1 pathway (e.g. <e2>irinotecan</e2>). ,True,advise
NEXAVAR,doxorubicin,27,33,76,86,Concomitant treatment with <e1>NEXAVAR</e1> resulted in a 21% increase in the AUC of <e2>doxorubicin</e2>. ,True,mechanism
doxorubicin,NEXAVAR,42,52,59,65,Caution is recommended when administering <e1>doxorubicin</e1> with <e2>NEXAVAR</e2>. ,True,advise
Zidovudine,stavudine,0,9,71,79,<e1>Zidovudine</e1> competitively inhibits the intracellular phosphorylation of <e2>stavudine</e2>. ,True,effect
zidovudine,ZERIT,18,27,49,53,"Therefore, use of <e1>zidovudine</e1> in combination with <e2>ZERIT</e2> should be avoided. ",True,advise
stavudine,doxorubicin,51,59,109,119,In vitro data indicate that the phosphorylation of <e1>stavudine</e1> is also inhibited at relevant concentrations by <e2>doxorubicin</e2> and ribavirin. ,True,effect
stavudine,ribavirin,51,59,125,133,In vitro data indicate that the phosphorylation of <e1>stavudine</e1> is also inhibited at relevant concentrations by doxorubicin and <e2>ribavirin</e2>. ,True,effect
doxorubicin,ribavirin,109,119,125,133,In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by <e1>doxorubicin</e1> and <e2>ribavirin</e2>. ,False,negative
Streptase,Streptokinase,19,27,30,42,"The interaction of <e1>Streptase</e1>, <e2>Streptokinase</e2>, with other drugs has not been well studied. ",False,negative
Anticoagulants,Antiplatelet Agents,7,20,26,44,"Use of <e1>Anticoagulants</e1> and <e2>Antiplatelet Agents</e2> -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",False,negative
Anticoagulants,Streptase,7,20,49,57,"Use of <e1>Anticoagulants</e1> and Antiplatelet Agents -- <e2>Streptase</e2>, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",False,negative
Anticoagulants,Streptokinase,7,20,60,72,"Use of <e1>Anticoagulants</e1> and Antiplatelet Agents -- Streptase, <e2>Streptokinase</e2>, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",False,negative
Anticoagulants,antiplatelet agents,7,20,104,122,"Use of <e1>Anticoagulants</e1> and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with <e2>antiplatelet agents</e2> and anticoagulants, may cause bleeding complications. ",False,negative
Anticoagulants,anticoagulants,7,20,128,141,"Use of <e1>Anticoagulants</e1> and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and <e2>anticoagulants</e2>, may cause bleeding complications. ",False,negative
Antiplatelet Agents,Streptase,26,44,49,57,"Use of Anticoagulants and <e1>Antiplatelet Agents</e1> -- <e2>Streptase</e2>, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",False,negative
Antiplatelet Agents,Streptokinase,26,44,60,72,"Use of Anticoagulants and <e1>Antiplatelet Agents</e1> -- Streptase, <e2>Streptokinase</e2>, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",False,negative
Antiplatelet Agents,antiplatelet agents,26,44,104,122,"Use of Anticoagulants and <e1>Antiplatelet Agents</e1> -- Streptase, Streptokinase, alone or in combination with <e2>antiplatelet agents</e2> and anticoagulants, may cause bleeding complications. ",False,negative
Antiplatelet Agents,anticoagulants,26,44,128,141,"Use of Anticoagulants and <e1>Antiplatelet Agents</e1> -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and <e2>anticoagulants</e2>, may cause bleeding complications. ",False,negative
Streptase,Streptokinase,49,57,60,72,"Use of Anticoagulants and Antiplatelet Agents -- <e1>Streptase</e1>, <e2>Streptokinase</e2>, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",False,negative
Streptase,antiplatelet agents,49,57,104,122,"Use of Anticoagulants and Antiplatelet Agents -- <e1>Streptase</e1>, Streptokinase, alone or in combination with <e2>antiplatelet agents</e2> and anticoagulants, may cause bleeding complications. ",True,effect
Streptase,anticoagulants,49,57,128,141,"Use of Anticoagulants and Antiplatelet Agents -- <e1>Streptase</e1>, Streptokinase, alone or in combination with antiplatelet agents and <e2>anticoagulants</e2>, may cause bleeding complications. ",True,effect
Streptokinase,antiplatelet agents,60,72,104,122,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, <e1>Streptokinase</e1>, alone or in combination with <e2>antiplatelet agents</e2> and anticoagulants, may cause bleeding complications. ",True,effect
Streptokinase,anticoagulants,60,72,128,141,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, <e1>Streptokinase</e1>, alone or in combination with antiplatelet agents and <e2>anticoagulants</e2>, may cause bleeding complications. ",True,effect
antiplatelet agents,anticoagulants,104,122,128,141,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with <e1>antiplatelet agents</e1> and <e2>anticoagulants</e2>, may cause bleeding complications. ",False,negative
aspirin,Streptokinase,30,36,103,115,"In the treatment of acute MI, <e1>aspirin</e1>, when not otherwise contraindicated, should be administered with <e2>Streptokinase</e2> ( see below ). ",False,negative
Antiplatelets,aspirin,20,32,139,145,"Anticoagulation and <e1>Antiplatelets</e1> After Treatment for Myocardial Infarction -- In the treatment of acute myocardial infarction, the use of <e2>aspirin</e2> has been shown to reduce the incidence of reinfarction and stroke. ",False,negative
aspirin,Streptokinase,16,22,27,39,"The addition of <e1>aspirin</e1> to <e2>Streptokinase</e2> causes a minimal increase in the risk of minor bleeding (3.9% vs. 3.1%), but does not appear to increase the incidence of major bleeding (see",True,effect
Streptozocin,doxorubicin,0,11,71,81,<e1>Streptozocin</e1> has been reported to prolong the elimination half-life of <e2>doxorubicin</e2> and may lead to severe bone marrow suppression; ,True,mechanism
doxorubicin,ZANOSAR,19,29,81,87,a reduction of the <e1>doxorubicin</e1> dosage should be considered in patients receiving <e2>ZANOSAR</e2> concurrently. ,True,advise
streptozocin,phenytoin,22,33,39,47,The concurrent use of <e1>streptozocin</e1> and <e2>phenytoin</e2> has been reported in one case to result in reduced streptozocin cytotoxicity.    ,True,effect
streptozocin,streptozocin,22,33,100,111,The concurrent use of <e1>streptozocin</e1> and phenytoin has been reported in one case to result in reduced <e2>streptozocin</e2> cytotoxicity.    ,False,negative
phenytoin,streptozocin,39,47,100,111,The concurrent use of streptozocin and <e1>phenytoin</e1> has been reported in one case to result in reduced <e2>streptozocin</e2> cytotoxicity.    ,False,negative
CHEMET,iron,0,5,59,62,<e1>CHEMET</e1> is not known to interact with other drugs including <e2>iron</e2> supplements; ,False,negative
CHEMET,CaNa 2 EDTA,30,35,75,85,"Concomitant administration of <e1>CHEMET</e1> with other chelation therapy, such as <e2>CaNa 2 EDTA</e2> is not recommended. ",True,advise
Sulfamethizole,barbiturates,0,13,43,54,"<e1>Sulfamethizole</e1> may increase the effects of <e2>barbiturates</e2>, tolbutamide, and uricosurics. ",True,effect
Sulfamethizole,tolbutamide,0,13,57,67,"<e1>Sulfamethizole</e1> may increase the effects of barbiturates, <e2>tolbutamide</e2>, and uricosurics. ",True,effect
Sulfamethizole,uricosurics,0,13,74,84,"<e1>Sulfamethizole</e1> may increase the effects of barbiturates, tolbutamide, and <e2>uricosurics</e2>. ",True,effect
barbiturates,tolbutamide,43,54,57,67,"Sulfamethizole may increase the effects of <e1>barbiturates</e1>, <e2>tolbutamide</e2>, and uricosurics. ",False,negative
barbiturates,uricosurics,43,54,74,84,"Sulfamethizole may increase the effects of <e1>barbiturates</e1>, tolbutamide, and <e2>uricosurics</e2>. ",False,negative
tolbutamide,uricosurics,57,67,74,84,"Sulfamethizole may increase the effects of barbiturates, <e1>tolbutamide</e1>, and <e2>uricosurics</e2>. ",False,negative
thiazides,cyclosporine,26,34,66,77,"It may also interact with <e1>thiazides</e1> (increased thrombocytopenia), <e2>cyclosporine</e2> (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",False,negative
thiazides,sulfonylurea agents,26,34,107,125,"It may also interact with <e1>thiazides</e1> (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), <e2>sulfonylurea agents</e2> (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",False,negative
thiazides,warfarin,26,34,162,169,"It may also interact with <e1>thiazides</e1> (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), <e2>warfarin</e2> (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",False,negative
thiazides,methotrexate,26,34,205,216,"It may also interact with <e1>thiazides</e1> (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), <e2>methotrexate</e2> (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",False,negative
thiazides,methotrexate,26,34,248,259,"It may also interact with <e1>thiazides</e1> (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of <e2>methotrexate</e2>), phenytoin (decreased hepatic clearance of phenytoin).",False,negative
thiazides,phenytoin,26,34,263,271,"It may also interact with <e1>thiazides</e1> (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), <e2>phenytoin</e2> (decreased hepatic clearance of phenytoin).",False,negative
thiazides,phenytoin,26,34,305,313,"It may also interact with <e1>thiazides</e1> (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of <e2>phenytoin</e2>).",False,negative
cyclosporine,sulfonylurea agents,66,77,107,125,"It may also interact with thiazides (increased thrombocytopenia), <e1>cyclosporine</e1> (increased nephrotoxicity), <e2>sulfonylurea agents</e2> (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",False,negative
cyclosporine,warfarin,66,77,162,169,"It may also interact with thiazides (increased thrombocytopenia), <e1>cyclosporine</e1> (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), <e2>warfarin</e2> (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",False,negative
cyclosporine,methotrexate,66,77,205,216,"It may also interact with thiazides (increased thrombocytopenia), <e1>cyclosporine</e1> (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), <e2>methotrexate</e2> (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",False,negative
cyclosporine,methotrexate,66,77,248,259,"It may also interact with thiazides (increased thrombocytopenia), <e1>cyclosporine</e1> (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of <e2>methotrexate</e2>), phenytoin (decreased hepatic clearance of phenytoin).",False,negative
cyclosporine,phenytoin,66,77,263,271,"It may also interact with thiazides (increased thrombocytopenia), <e1>cyclosporine</e1> (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), <e2>phenytoin</e2> (decreased hepatic clearance of phenytoin).",False,negative
cyclosporine,phenytoin,66,77,305,313,"It may also interact with thiazides (increased thrombocytopenia), <e1>cyclosporine</e1> (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of <e2>phenytoin</e2>).",False,negative
sulfonylurea agents,warfarin,107,125,162,169,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), <e1>sulfonylurea agents</e1> (increased hypoglycemic response), <e2>warfarin</e2> (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",False,negative
sulfonylurea agents,methotrexate,107,125,205,216,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), <e1>sulfonylurea agents</e1> (increased hypoglycemic response), warfarin (increased anticoagulant effect), <e2>methotrexate</e2> (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",False,negative
sulfonylurea agents,methotrexate,107,125,248,259,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), <e1>sulfonylurea agents</e1> (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of <e2>methotrexate</e2>), phenytoin (decreased hepatic clearance of phenytoin).",False,negative
sulfonylurea agents,phenytoin,107,125,263,271,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), <e1>sulfonylurea agents</e1> (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), <e2>phenytoin</e2> (decreased hepatic clearance of phenytoin).",False,negative
sulfonylurea agents,phenytoin,107,125,305,313,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), <e1>sulfonylurea agents</e1> (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of <e2>phenytoin</e2>).",False,negative
warfarin,methotrexate,162,169,205,216,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), <e1>warfarin</e1> (increased anticoagulant effect), <e2>methotrexate</e2> (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",False,negative
warfarin,methotrexate,162,169,248,259,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), <e1>warfarin</e1> (increased anticoagulant effect), methotrexate (decreased renal excretion of <e2>methotrexate</e2>), phenytoin (decreased hepatic clearance of phenytoin).",False,negative
warfarin,phenytoin,162,169,263,271,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), <e1>warfarin</e1> (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), <e2>phenytoin</e2> (decreased hepatic clearance of phenytoin).",False,negative
warfarin,phenytoin,162,169,305,313,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), <e1>warfarin</e1> (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of <e2>phenytoin</e2>).",False,negative
methotrexate,methotrexate,205,216,248,259,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), <e1>methotrexate</e1> (decreased renal excretion of <e2>methotrexate</e2>), phenytoin (decreased hepatic clearance of phenytoin).",False,negative
methotrexate,phenytoin,205,216,263,271,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), <e1>methotrexate</e1> (decreased renal excretion of methotrexate), <e2>phenytoin</e2> (decreased hepatic clearance of phenytoin).",False,negative
methotrexate,phenytoin,205,216,305,313,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), <e1>methotrexate</e1> (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of <e2>phenytoin</e2>).",False,negative
methotrexate,phenytoin,248,259,263,271,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of <e1>methotrexate</e1>), <e2>phenytoin</e2> (decreased hepatic clearance of phenytoin).",False,negative
methotrexate,phenytoin,248,259,305,313,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of <e1>methotrexate</e1>), phenytoin (decreased hepatic clearance of <e2>phenytoin</e2>).",False,negative
phenytoin,phenytoin,263,271,305,313,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), <e1>phenytoin</e1> (decreased hepatic clearance of <e2>phenytoin</e2>).",False,negative
diuretics,thiazides,51,59,72,80,"In elderly patients concurrently receiving certain <e1>diuretics</e1>, primarily <e2>thiazides</e2>, an increased incidence of thrombopenia with purpura has been reported. ",False,negative
sulfamethoxazole,anticoagulant,26,41,110,122,It has been reported that <e1>sulfamethoxazole</e1> may prolong the prothrombin time in patients who are receiving the <e2>anticoagulant</e2> warfarin. ,False,negative
sulfamethoxazole,warfarin,26,41,124,131,It has been reported that <e1>sulfamethoxazole</e1> may prolong the prothrombin time in patients who are receiving the anticoagulant <e2>warfarin</e2>. ,True,effect
anticoagulant,warfarin,110,122,124,131,It has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the <e1>anticoagulant</e1> <e2>warfarin</e2>. ,False,negative
Sulfamethoxazole,phenytoin,0,15,55,63,<e1>Sulfamethoxazole</e1> may inhibit the hepatic metabolism of <e2>phenytoin</e2>. ,True,mechanism
sulfamethoxazole,phenytoin,17,32,97,105,"At a 1.6-g dose, <e1>sulfamethoxazole</e1> produced a slight but significant increase in the half-life of <e2>phenytoin</e2> but did not produce a corresponding decrease in the metabolic clearance rate. ",True,mechanism
Sulfonamides,methotrexate,0,11,31,42,"<e1>Sulfonamides</e1> can also displace <e2>methotrexate</e2> from plasma protein-binding sites, thus increasing free methotrexate concentrations. ",True,mechanism
Sulfonamides,methotrexate,0,11,100,111,"<e1>Sulfonamides</e1> can also displace methotrexate from plasma protein-binding sites, thus increasing free <e2>methotrexate</e2> concentrations. ",False,negative
methotrexate,methotrexate,31,42,100,111,"Sulfonamides can also displace <e1>methotrexate</e1> from plasma protein-binding sites, thus increasing free <e2>methotrexate</e2> concentrations. ",False,negative
folic acid,digoxin,22,31,37,43,Reduced absorption of <e1>folic acid</e1> and <e2>digoxin</e2> have been reported when those agents were administered concomitantly with sulfasalazine. ,False,negative
folic acid,sulfasalazine,22,31,119,131,Reduced absorption of <e1>folic acid</e1> and digoxin have been reported when those agents were administered concomitantly with <e2>sulfasalazine</e2>. ,True,mechanism
digoxin,sulfasalazine,37,43,119,131,Reduced absorption of folic acid and <e1>digoxin</e1> have been reported when those agents were administered concomitantly with <e2>sulfasalazine</e2>. ,True,mechanism
sulfasalazine,methotrexate,20,32,58,69,"When daily doses of <e1>sulfasalazine</e1> 2 g and weekly doses of <e2>methotrexate</e2> 7.5 mg were coadministered to 15 rheumatoid arthritis patients in a drug-drug interaction study, the pharmacokinetic disposition of the drugs was not altered. ",False,negative
sulfasalazine,methotrexate,15,27,67,78,Daily doses of <e1>sulfasalazine</e1> 2 g (maximum 3 g) and weekly doses of <e2>methotrexate</e2> 7.5 mg (maximum 15 mg) were administered alone or in combination to 310 rheumatoid arthritis patients in two controlled 52-week clinical studies. ,False,negative
Sulfoxone,barbiturates,0,8,38,49,"<e1>Sulfoxone</e1> may increase the effects of <e2>barbiturates</e2>, tolbutamide, and uricosurics. ",True,effect
Sulfoxone,tolbutamide,0,8,52,62,"<e1>Sulfoxone</e1> may increase the effects of barbiturates, <e2>tolbutamide</e2>, and uricosurics. ",True,effect
Sulfoxone,uricosurics,0,8,69,79,"<e1>Sulfoxone</e1> may increase the effects of barbiturates, tolbutamide, and <e2>uricosurics</e2>. ",True,effect
barbiturates,tolbutamide,38,49,52,62,"Sulfoxone may increase the effects of <e1>barbiturates</e1>, <e2>tolbutamide</e2>, and uricosurics. ",False,negative
barbiturates,uricosurics,38,49,69,79,"Sulfoxone may increase the effects of <e1>barbiturates</e1>, tolbutamide, and <e2>uricosurics</e2>. ",False,negative
tolbutamide,uricosurics,52,62,69,79,"Sulfoxone may increase the effects of barbiturates, <e1>tolbutamide</e1>, and <e2>uricosurics</e2>. ",False,negative
thiazides,cyclosporine,26,34,66,77,"It may also interact with <e1>thiazides</e1> (increased thrombocytopenia), <e2>cyclosporine</e2> (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",False,negative
thiazides,sulfonylurea agents,26,34,107,125,"It may also interact with <e1>thiazides</e1> (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), <e2>sulfonylurea agents</e2> (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",False,negative
thiazides,warfarin,26,34,162,169,"It may also interact with <e1>thiazides</e1> (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), <e2>warfarin</e2> (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",False,negative
thiazides,methotrexate,26,34,205,216,"It may also interact with <e1>thiazides</e1> (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), <e2>methotrexate</e2> (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",False,negative
thiazides,methotrexate,26,34,248,259,"It may also interact with <e1>thiazides</e1> (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of <e2>methotrexate</e2>), phenytoin (decreased hepatic clearance of phenytoin).",False,negative
thiazides,phenytoin,26,34,263,271,"It may also interact with <e1>thiazides</e1> (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), <e2>phenytoin</e2> (decreased hepatic clearance of phenytoin).",False,negative
thiazides,phenytoin,26,34,305,313,"It may also interact with <e1>thiazides</e1> (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of <e2>phenytoin</e2>).",False,negative
cyclosporine,sulfonylurea agents,66,77,107,125,"It may also interact with thiazides (increased thrombocytopenia), <e1>cyclosporine</e1> (increased nephrotoxicity), <e2>sulfonylurea agents</e2> (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",False,negative
cyclosporine,warfarin,66,77,162,169,"It may also interact with thiazides (increased thrombocytopenia), <e1>cyclosporine</e1> (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), <e2>warfarin</e2> (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",False,negative
cyclosporine,methotrexate,66,77,205,216,"It may also interact with thiazides (increased thrombocytopenia), <e1>cyclosporine</e1> (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), <e2>methotrexate</e2> (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",False,negative
cyclosporine,methotrexate,66,77,248,259,"It may also interact with thiazides (increased thrombocytopenia), <e1>cyclosporine</e1> (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of <e2>methotrexate</e2>), phenytoin (decreased hepatic clearance of phenytoin).",False,negative
cyclosporine,phenytoin,66,77,263,271,"It may also interact with thiazides (increased thrombocytopenia), <e1>cyclosporine</e1> (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), <e2>phenytoin</e2> (decreased hepatic clearance of phenytoin).",False,negative
cyclosporine,phenytoin,66,77,305,313,"It may also interact with thiazides (increased thrombocytopenia), <e1>cyclosporine</e1> (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of <e2>phenytoin</e2>).",False,negative
sulfonylurea agents,warfarin,107,125,162,169,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), <e1>sulfonylurea agents</e1> (increased hypoglycemic response), <e2>warfarin</e2> (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",False,negative
sulfonylurea agents,methotrexate,107,125,205,216,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), <e1>sulfonylurea agents</e1> (increased hypoglycemic response), warfarin (increased anticoagulant effect), <e2>methotrexate</e2> (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",False,negative
sulfonylurea agents,methotrexate,107,125,248,259,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), <e1>sulfonylurea agents</e1> (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of <e2>methotrexate</e2>), phenytoin (decreased hepatic clearance of phenytoin).",False,negative
sulfonylurea agents,phenytoin,107,125,263,271,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), <e1>sulfonylurea agents</e1> (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), <e2>phenytoin</e2> (decreased hepatic clearance of phenytoin).",False,negative
sulfonylurea agents,phenytoin,107,125,305,313,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), <e1>sulfonylurea agents</e1> (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of <e2>phenytoin</e2>).",False,negative
warfarin,methotrexate,162,169,205,216,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), <e1>warfarin</e1> (increased anticoagulant effect), <e2>methotrexate</e2> (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",False,negative
warfarin,methotrexate,162,169,248,259,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), <e1>warfarin</e1> (increased anticoagulant effect), methotrexate (decreased renal excretion of <e2>methotrexate</e2>), phenytoin (decreased hepatic clearance of phenytoin).",False,negative
warfarin,phenytoin,162,169,263,271,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), <e1>warfarin</e1> (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), <e2>phenytoin</e2> (decreased hepatic clearance of phenytoin).",False,negative
warfarin,phenytoin,162,169,305,313,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), <e1>warfarin</e1> (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of <e2>phenytoin</e2>).",False,negative
methotrexate,methotrexate,205,216,248,259,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), <e1>methotrexate</e1> (decreased renal excretion of <e2>methotrexate</e2>), phenytoin (decreased hepatic clearance of phenytoin).",False,negative
methotrexate,phenytoin,205,216,263,271,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), <e1>methotrexate</e1> (decreased renal excretion of methotrexate), <e2>phenytoin</e2> (decreased hepatic clearance of phenytoin).",False,negative
methotrexate,phenytoin,205,216,305,313,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), <e1>methotrexate</e1> (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of <e2>phenytoin</e2>).",False,negative
methotrexate,phenytoin,248,259,263,271,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of <e1>methotrexate</e1>), <e2>phenytoin</e2> (decreased hepatic clearance of phenytoin).",False,negative
methotrexate,phenytoin,248,259,305,313,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of <e1>methotrexate</e1>), phenytoin (decreased hepatic clearance of <e2>phenytoin</e2>).",False,negative
phenytoin,phenytoin,263,271,305,313,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), <e1>phenytoin</e1> (decreased hepatic clearance of <e2>phenytoin</e2>).",False,negative
ergotamine,ergot-type medications,80,89,105,126,"Because there is a theoretical basis that these effects may be additive, use of <e1>ergotamine</e1>-containing or <e2>ergot-type medications</e2> (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. ",False,negative
ergotamine,dihydroergotamine,80,89,134,150,"Because there is a theoretical basis that these effects may be additive, use of <e1>ergotamine</e1>-containing or ergot-type medications (like <e2>dihydroergotamine</e2> or methysergide) and sumatriptan within 24 hours of each other should be avoided. ",False,negative
ergotamine,methysergide,80,89,155,166,"Because there is a theoretical basis that these effects may be additive, use of <e1>ergotamine</e1>-containing or ergot-type medications (like dihydroergotamine or <e2>methysergide</e2>) and sumatriptan within 24 hours of each other should be avoided. ",False,negative
ergotamine,sumatriptan,80,89,173,183,"Because there is a theoretical basis that these effects may be additive, use of <e1>ergotamine</e1>-containing or ergot-type medications (like dihydroergotamine or methysergide) and <e2>sumatriptan</e2> within 24 hours of each other should be avoided. ",True,advise
ergot-type medications,dihydroergotamine,105,126,134,150,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or <e1>ergot-type medications</e1> (like <e2>dihydroergotamine</e2> or methysergide) and sumatriptan within 24 hours of each other should be avoided. ",False,negative
ergot-type medications,methysergide,105,126,155,166,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or <e1>ergot-type medications</e1> (like dihydroergotamine or <e2>methysergide</e2>) and sumatriptan within 24 hours of each other should be avoided. ",False,negative
ergot-type medications,sumatriptan,105,126,173,183,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or <e1>ergot-type medications</e1> (like dihydroergotamine or methysergide) and <e2>sumatriptan</e2> within 24 hours of each other should be avoided. ",True,advise
dihydroergotamine,methysergide,134,150,155,166,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like <e1>dihydroergotamine</e1> or <e2>methysergide</e2>) and sumatriptan within 24 hours of each other should be avoided. ",False,negative
dihydroergotamine,sumatriptan,134,150,173,183,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like <e1>dihydroergotamine</e1> or methysergide) and <e2>sumatriptan</e2> within 24 hours of each other should be avoided. ",True,advise
methysergide,sumatriptan,155,166,173,183,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or <e1>methysergide</e1>) and <e2>sumatriptan</e2> within 24 hours of each other should be avoided. ",True,advise
MAO-A inhibitors,sumatriptan,0,15,24,34,"<e1>MAO-A inhibitors</e1> reduce <e2>sumatriptan</e2> clearance, significantly increasing systemic exposure. ",True,mechanism
sumatriptan succinate,MAO-A inhibitors,22,42,74,89,"Therefore, the use of <e1>sumatriptan succinate</e1> tablets in patients receiving <e2>MAO-A inhibitors</e2> is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",True,advise
sumatriptan succinate,Selective serotonin reuptake inhibitors,22,42,112,150,"Therefore, the use of <e1>sumatriptan succinate</e1> tablets in patients receiving MAO-A inhibitors is contraindicated . <e2>Selective serotonin reuptake inhibitors</e2> (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",False,negative
sumatriptan succinate,SSRIs,22,42,153,157,"Therefore, the use of <e1>sumatriptan succinate</e1> tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (<e2>SSRIs</e2>) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",False,negative
sumatriptan succinate,fluoxetine,22,42,167,176,"Therefore, the use of <e1>sumatriptan succinate</e1> tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., <e2>fluoxetine</e2>, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",False,negative
sumatriptan succinate,fluvoxamine,22,42,179,189,"Therefore, the use of <e1>sumatriptan succinate</e1> tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, <e2>fluvoxamine</e2>, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",False,negative
sumatriptan succinate,paroxetine,22,42,192,201,"Therefore, the use of <e1>sumatriptan succinate</e1> tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, <e2>paroxetine</e2>, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",False,negative
sumatriptan succinate,sertraline,22,42,204,213,"Therefore, the use of <e1>sumatriptan succinate</e1> tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, <e2>sertraline</e2>) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",False,negative
sumatriptan succinate,sumatriptan,22,42,322,332,"Therefore, the use of <e1>sumatriptan succinate</e1> tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with <e2>sumatriptan</e2>. ",False,negative
MAO-A inhibitors,Selective serotonin reuptake inhibitors,74,89,112,150,"Therefore, the use of sumatriptan succinate tablets in patients receiving <e1>MAO-A inhibitors</e1> is contraindicated . <e2>Selective serotonin reuptake inhibitors</e2> (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",False,negative
MAO-A inhibitors,SSRIs,74,89,153,157,"Therefore, the use of sumatriptan succinate tablets in patients receiving <e1>MAO-A inhibitors</e1> is contraindicated . Selective serotonin reuptake inhibitors (<e2>SSRIs</e2>) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",False,negative
MAO-A inhibitors,fluoxetine,74,89,167,176,"Therefore, the use of sumatriptan succinate tablets in patients receiving <e1>MAO-A inhibitors</e1> is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., <e2>fluoxetine</e2>, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",False,negative
MAO-A inhibitors,fluvoxamine,74,89,179,189,"Therefore, the use of sumatriptan succinate tablets in patients receiving <e1>MAO-A inhibitors</e1> is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, <e2>fluvoxamine</e2>, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",False,negative
MAO-A inhibitors,paroxetine,74,89,192,201,"Therefore, the use of sumatriptan succinate tablets in patients receiving <e1>MAO-A inhibitors</e1> is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, <e2>paroxetine</e2>, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",False,negative
MAO-A inhibitors,sertraline,74,89,204,213,"Therefore, the use of sumatriptan succinate tablets in patients receiving <e1>MAO-A inhibitors</e1> is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, <e2>sertraline</e2>) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",False,negative
MAO-A inhibitors,sumatriptan,74,89,322,332,"Therefore, the use of sumatriptan succinate tablets in patients receiving <e1>MAO-A inhibitors</e1> is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with <e2>sumatriptan</e2>. ",False,negative
Selective serotonin reuptake inhibitors,SSRIs,112,150,153,157,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . <e1>Selective serotonin reuptake inhibitors</e1> (<e2>SSRIs</e2>) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",False,negative
Selective serotonin reuptake inhibitors,fluoxetine,112,150,167,176,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . <e1>Selective serotonin reuptake inhibitors</e1> (SSRIs) (e.g., <e2>fluoxetine</e2>, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",False,negative
Selective serotonin reuptake inhibitors,fluvoxamine,112,150,179,189,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . <e1>Selective serotonin reuptake inhibitors</e1> (SSRIs) (e.g., fluoxetine, <e2>fluvoxamine</e2>, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",False,negative
Selective serotonin reuptake inhibitors,paroxetine,112,150,192,201,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . <e1>Selective serotonin reuptake inhibitors</e1> (SSRIs) (e.g., fluoxetine, fluvoxamine, <e2>paroxetine</e2>, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",False,negative
Selective serotonin reuptake inhibitors,sertraline,112,150,204,213,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . <e1>Selective serotonin reuptake inhibitors</e1> (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, <e2>sertraline</e2>) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",False,negative
Selective serotonin reuptake inhibitors,sumatriptan,112,150,322,332,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . <e1>Selective serotonin reuptake inhibitors</e1> (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with <e2>sumatriptan</e2>. ",True,effect
SSRIs,fluoxetine,153,157,167,176,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (<e1>SSRIs</e1>) (e.g., <e2>fluoxetine</e2>, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",False,negative
SSRIs,fluvoxamine,153,157,179,189,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (<e1>SSRIs</e1>) (e.g., fluoxetine, <e2>fluvoxamine</e2>, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",False,negative
SSRIs,paroxetine,153,157,192,201,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (<e1>SSRIs</e1>) (e.g., fluoxetine, fluvoxamine, <e2>paroxetine</e2>, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",False,negative
SSRIs,sertraline,153,157,204,213,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (<e1>SSRIs</e1>) (e.g., fluoxetine, fluvoxamine, paroxetine, <e2>sertraline</e2>) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",False,negative
SSRIs,sumatriptan,153,157,322,332,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (<e1>SSRIs</e1>) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with <e2>sumatriptan</e2>. ",True,effect
fluoxetine,fluvoxamine,167,176,179,189,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., <e1>fluoxetine</e1>, <e2>fluvoxamine</e2>, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",False,negative
fluoxetine,paroxetine,167,176,192,201,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., <e1>fluoxetine</e1>, fluvoxamine, <e2>paroxetine</e2>, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",False,negative
fluoxetine,sertraline,167,176,204,213,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., <e1>fluoxetine</e1>, fluvoxamine, paroxetine, <e2>sertraline</e2>) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",False,negative
fluoxetine,sumatriptan,167,176,322,332,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., <e1>fluoxetine</e1>, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with <e2>sumatriptan</e2>. ",True,effect
fluvoxamine,paroxetine,179,189,192,201,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, <e1>fluvoxamine</e1>, <e2>paroxetine</e2>, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",False,negative
fluvoxamine,sertraline,179,189,204,213,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, <e1>fluvoxamine</e1>, paroxetine, <e2>sertraline</e2>) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",False,negative
fluvoxamine,sumatriptan,179,189,322,332,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, <e1>fluvoxamine</e1>, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with <e2>sumatriptan</e2>. ",True,effect
paroxetine,sertraline,192,201,204,213,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, <e1>paroxetine</e1>, <e2>sertraline</e2>) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",False,negative
paroxetine,sumatriptan,192,201,322,332,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, <e1>paroxetine</e1>, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with <e2>sumatriptan</e2>. ",True,effect
sertraline,sumatriptan,204,213,322,332,"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, <e1>sertraline</e1>) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with <e2>sumatriptan</e2>. ",True,effect
sumatriptan,SSRI,30,40,49,52,"If concomitant treatment with <e1>sumatriptan</e1> and an <e2>SSRI</e2> is clinically warranted, appropriate observation of the patient is advised.",True,advise
SUTENT,ketoconazole,21,26,79,90,"Co-administration of <e1>SUTENT</e1> with strong inhibitors of the CYP3A4 family (e.g., <e2>ketoconazole</e2>, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",True,mechanism
SUTENT,itraconazole,21,26,93,104,"Co-administration of <e1>SUTENT</e1> with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, <e2>itraconazole</e2>, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",True,mechanism
SUTENT,clarithromycin,21,26,107,120,"Co-administration of <e1>SUTENT</e1> with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, <e2>clarithromycin</e2>, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",True,mechanism
SUTENT,atazanavir,21,26,123,132,"Co-administration of <e1>SUTENT</e1> with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, <e2>atazanavir</e2>, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",True,mechanism
SUTENT,indinavir,21,26,135,143,"Co-administration of <e1>SUTENT</e1> with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, <e2>indinavir</e2>, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",True,mechanism
SUTENT,nefazodone,21,26,146,155,"Co-administration of <e1>SUTENT</e1> with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, <e2>nefazodone</e2>, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",True,mechanism
SUTENT,nelfinavir,21,26,158,167,"Co-administration of <e1>SUTENT</e1> with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, <e2>nelfinavir</e2>, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",True,mechanism
SUTENT,ritonavir,21,26,170,178,"Co-administration of <e1>SUTENT</e1> with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, <e2>ritonavir</e2>, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",True,mechanism
SUTENT,saquinavir,21,26,181,190,"Co-administration of <e1>SUTENT</e1> with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, <e2>saquinavir</e2>, telithromycin, voriconizole) may increases sunitinib concentrations. ",True,mechanism
SUTENT,telithromycin,21,26,193,205,"Co-administration of <e1>SUTENT</e1> with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, <e2>telithromycin</e2>, voriconizole) may increases sunitinib concentrations. ",True,mechanism
SUTENT,voriconizole,21,26,208,219,"Co-administration of <e1>SUTENT</e1> with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, <e2>voriconizole</e2>) may increases sunitinib concentrations. ",True,mechanism
SUTENT,sunitinib,21,26,236,244,"Co-administration of <e1>SUTENT</e1> with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases <e2>sunitinib</e2> concentrations. ",False,negative
ketoconazole,itraconazole,79,90,93,104,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., <e1>ketoconazole</e1>, <e2>itraconazole</e2>, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",False,negative
ketoconazole,clarithromycin,79,90,107,120,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., <e1>ketoconazole</e1>, itraconazole, <e2>clarithromycin</e2>, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",False,negative
ketoconazole,atazanavir,79,90,123,132,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., <e1>ketoconazole</e1>, itraconazole, clarithromycin, <e2>atazanavir</e2>, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",False,negative
ketoconazole,indinavir,79,90,135,143,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., <e1>ketoconazole</e1>, itraconazole, clarithromycin, atazanavir, <e2>indinavir</e2>, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",False,negative
ketoconazole,nefazodone,79,90,146,155,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., <e1>ketoconazole</e1>, itraconazole, clarithromycin, atazanavir, indinavir, <e2>nefazodone</e2>, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",False,negative
ketoconazole,nelfinavir,79,90,158,167,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., <e1>ketoconazole</e1>, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, <e2>nelfinavir</e2>, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",False,negative
ketoconazole,ritonavir,79,90,170,178,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., <e1>ketoconazole</e1>, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, <e2>ritonavir</e2>, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",False,negative
ketoconazole,saquinavir,79,90,181,190,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., <e1>ketoconazole</e1>, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, <e2>saquinavir</e2>, telithromycin, voriconizole) may increases sunitinib concentrations. ",False,negative
ketoconazole,telithromycin,79,90,193,205,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., <e1>ketoconazole</e1>, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, <e2>telithromycin</e2>, voriconizole) may increases sunitinib concentrations. ",False,negative
ketoconazole,voriconizole,79,90,208,219,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., <e1>ketoconazole</e1>, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, <e2>voriconizole</e2>) may increases sunitinib concentrations. ",False,negative
ketoconazole,sunitinib,79,90,236,244,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., <e1>ketoconazole</e1>, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases <e2>sunitinib</e2> concentrations. ",False,negative
itraconazole,clarithromycin,93,104,107,120,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, <e1>itraconazole</e1>, <e2>clarithromycin</e2>, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",False,negative
itraconazole,atazanavir,93,104,123,132,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, <e1>itraconazole</e1>, clarithromycin, <e2>atazanavir</e2>, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",False,negative
itraconazole,indinavir,93,104,135,143,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, <e1>itraconazole</e1>, clarithromycin, atazanavir, <e2>indinavir</e2>, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",False,negative
itraconazole,nefazodone,93,104,146,155,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, <e1>itraconazole</e1>, clarithromycin, atazanavir, indinavir, <e2>nefazodone</e2>, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",False,negative
itraconazole,nelfinavir,93,104,158,167,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, <e1>itraconazole</e1>, clarithromycin, atazanavir, indinavir, nefazodone, <e2>nelfinavir</e2>, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",False,negative
itraconazole,ritonavir,93,104,170,178,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, <e1>itraconazole</e1>, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, <e2>ritonavir</e2>, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",False,negative
itraconazole,saquinavir,93,104,181,190,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, <e1>itraconazole</e1>, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, <e2>saquinavir</e2>, telithromycin, voriconizole) may increases sunitinib concentrations. ",False,negative
itraconazole,telithromycin,93,104,193,205,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, <e1>itraconazole</e1>, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, <e2>telithromycin</e2>, voriconizole) may increases sunitinib concentrations. ",False,negative
itraconazole,voriconizole,93,104,208,219,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, <e1>itraconazole</e1>, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, <e2>voriconizole</e2>) may increases sunitinib concentrations. ",False,negative
itraconazole,sunitinib,93,104,236,244,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, <e1>itraconazole</e1>, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases <e2>sunitinib</e2> concentrations. ",False,negative
clarithromycin,atazanavir,107,120,123,132,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, <e1>clarithromycin</e1>, <e2>atazanavir</e2>, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",False,negative
clarithromycin,indinavir,107,120,135,143,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, <e1>clarithromycin</e1>, atazanavir, <e2>indinavir</e2>, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",False,negative
clarithromycin,nefazodone,107,120,146,155,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, <e1>clarithromycin</e1>, atazanavir, indinavir, <e2>nefazodone</e2>, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",False,negative
clarithromycin,nelfinavir,107,120,158,167,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, <e1>clarithromycin</e1>, atazanavir, indinavir, nefazodone, <e2>nelfinavir</e2>, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",False,negative
clarithromycin,ritonavir,107,120,170,178,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, <e1>clarithromycin</e1>, atazanavir, indinavir, nefazodone, nelfinavir, <e2>ritonavir</e2>, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",False,negative
clarithromycin,saquinavir,107,120,181,190,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, <e1>clarithromycin</e1>, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, <e2>saquinavir</e2>, telithromycin, voriconizole) may increases sunitinib concentrations. ",False,negative
clarithromycin,telithromycin,107,120,193,205,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, <e1>clarithromycin</e1>, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, <e2>telithromycin</e2>, voriconizole) may increases sunitinib concentrations. ",False,negative
clarithromycin,voriconizole,107,120,208,219,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, <e1>clarithromycin</e1>, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, <e2>voriconizole</e2>) may increases sunitinib concentrations. ",False,negative
clarithromycin,sunitinib,107,120,236,244,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, <e1>clarithromycin</e1>, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases <e2>sunitinib</e2> concentrations. ",False,negative
atazanavir,indinavir,123,132,135,143,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, <e1>atazanavir</e1>, <e2>indinavir</e2>, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",False,negative
atazanavir,nefazodone,123,132,146,155,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, <e1>atazanavir</e1>, indinavir, <e2>nefazodone</e2>, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",False,negative
atazanavir,nelfinavir,123,132,158,167,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, <e1>atazanavir</e1>, indinavir, nefazodone, <e2>nelfinavir</e2>, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",False,negative
atazanavir,ritonavir,123,132,170,178,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, <e1>atazanavir</e1>, indinavir, nefazodone, nelfinavir, <e2>ritonavir</e2>, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",False,negative
atazanavir,saquinavir,123,132,181,190,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, <e1>atazanavir</e1>, indinavir, nefazodone, nelfinavir, ritonavir, <e2>saquinavir</e2>, telithromycin, voriconizole) may increases sunitinib concentrations. ",False,negative
atazanavir,telithromycin,123,132,193,205,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, <e1>atazanavir</e1>, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, <e2>telithromycin</e2>, voriconizole) may increases sunitinib concentrations. ",False,negative
atazanavir,voriconizole,123,132,208,219,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, <e1>atazanavir</e1>, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, <e2>voriconizole</e2>) may increases sunitinib concentrations. ",False,negative
atazanavir,sunitinib,123,132,236,244,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, <e1>atazanavir</e1>, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases <e2>sunitinib</e2> concentrations. ",False,negative
indinavir,nefazodone,135,143,146,155,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, <e1>indinavir</e1>, <e2>nefazodone</e2>, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",False,negative
indinavir,nelfinavir,135,143,158,167,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, <e1>indinavir</e1>, nefazodone, <e2>nelfinavir</e2>, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",False,negative
indinavir,ritonavir,135,143,170,178,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, <e1>indinavir</e1>, nefazodone, nelfinavir, <e2>ritonavir</e2>, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",False,negative
indinavir,saquinavir,135,143,181,190,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, <e1>indinavir</e1>, nefazodone, nelfinavir, ritonavir, <e2>saquinavir</e2>, telithromycin, voriconizole) may increases sunitinib concentrations. ",False,negative
indinavir,telithromycin,135,143,193,205,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, <e1>indinavir</e1>, nefazodone, nelfinavir, ritonavir, saquinavir, <e2>telithromycin</e2>, voriconizole) may increases sunitinib concentrations. ",False,negative
indinavir,voriconizole,135,143,208,219,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, <e1>indinavir</e1>, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, <e2>voriconizole</e2>) may increases sunitinib concentrations. ",False,negative
indinavir,sunitinib,135,143,236,244,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, <e1>indinavir</e1>, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases <e2>sunitinib</e2> concentrations. ",False,negative
nefazodone,nelfinavir,146,155,158,167,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, <e1>nefazodone</e1>, <e2>nelfinavir</e2>, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",False,negative
nefazodone,ritonavir,146,155,170,178,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, <e1>nefazodone</e1>, nelfinavir, <e2>ritonavir</e2>, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",False,negative
nefazodone,saquinavir,146,155,181,190,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, <e1>nefazodone</e1>, nelfinavir, ritonavir, <e2>saquinavir</e2>, telithromycin, voriconizole) may increases sunitinib concentrations. ",False,negative
nefazodone,telithromycin,146,155,193,205,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, <e1>nefazodone</e1>, nelfinavir, ritonavir, saquinavir, <e2>telithromycin</e2>, voriconizole) may increases sunitinib concentrations. ",False,negative
nefazodone,voriconizole,146,155,208,219,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, <e1>nefazodone</e1>, nelfinavir, ritonavir, saquinavir, telithromycin, <e2>voriconizole</e2>) may increases sunitinib concentrations. ",False,negative
nefazodone,sunitinib,146,155,236,244,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, <e1>nefazodone</e1>, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases <e2>sunitinib</e2> concentrations. ",False,negative
nelfinavir,ritonavir,158,167,170,178,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, <e1>nelfinavir</e1>, <e2>ritonavir</e2>, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",False,negative
nelfinavir,saquinavir,158,167,181,190,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, <e1>nelfinavir</e1>, ritonavir, <e2>saquinavir</e2>, telithromycin, voriconizole) may increases sunitinib concentrations. ",False,negative
nelfinavir,telithromycin,158,167,193,205,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, <e1>nelfinavir</e1>, ritonavir, saquinavir, <e2>telithromycin</e2>, voriconizole) may increases sunitinib concentrations. ",False,negative
nelfinavir,voriconizole,158,167,208,219,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, <e1>nelfinavir</e1>, ritonavir, saquinavir, telithromycin, <e2>voriconizole</e2>) may increases sunitinib concentrations. ",False,negative
nelfinavir,sunitinib,158,167,236,244,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, <e1>nelfinavir</e1>, ritonavir, saquinavir, telithromycin, voriconizole) may increases <e2>sunitinib</e2> concentrations. ",False,negative
ritonavir,saquinavir,170,178,181,190,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, <e1>ritonavir</e1>, <e2>saquinavir</e2>, telithromycin, voriconizole) may increases sunitinib concentrations. ",False,negative
ritonavir,telithromycin,170,178,193,205,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, <e1>ritonavir</e1>, saquinavir, <e2>telithromycin</e2>, voriconizole) may increases sunitinib concentrations. ",False,negative
ritonavir,voriconizole,170,178,208,219,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, <e1>ritonavir</e1>, saquinavir, telithromycin, <e2>voriconizole</e2>) may increases sunitinib concentrations. ",False,negative
ritonavir,sunitinib,170,178,236,244,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, <e1>ritonavir</e1>, saquinavir, telithromycin, voriconizole) may increases <e2>sunitinib</e2> concentrations. ",False,negative
saquinavir,telithromycin,181,190,193,205,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, <e1>saquinavir</e1>, <e2>telithromycin</e2>, voriconizole) may increases sunitinib concentrations. ",False,negative
saquinavir,voriconizole,181,190,208,219,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, <e1>saquinavir</e1>, telithromycin, <e2>voriconizole</e2>) may increases sunitinib concentrations. ",False,negative
saquinavir,sunitinib,181,190,236,244,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, <e1>saquinavir</e1>, telithromycin, voriconizole) may increases <e2>sunitinib</e2> concentrations. ",False,negative
telithromycin,voriconizole,193,205,208,219,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, <e1>telithromycin</e1>, <e2>voriconizole</e2>) may increases sunitinib concentrations. ",False,negative
telithromycin,sunitinib,193,205,236,244,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, <e1>telithromycin</e1>, voriconizole) may increases <e2>sunitinib</e2> concentrations. ",False,negative
voriconizole,sunitinib,208,219,236,244,"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, <e1>voriconizole</e1>) may increases <e2>sunitinib</e2> concentrations. ",False,negative
SUTENT,dexamethasone,21,26,70,82,"Co-administration of <e1>SUTENT</e1> with inducers of the CYP3A4 family (e.g., <e2>dexamethasone</e2>, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",True,mechanism
SUTENT,phenytoin,21,26,85,93,"Co-administration of <e1>SUTENT</e1> with inducers of the CYP3A4 family (e.g., dexamethasone, <e2>phenytoin</e2>, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",True,mechanism
SUTENT,carbamazepine,21,26,96,108,"Co-administration of <e1>SUTENT</e1> with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, <e2>carbamazepine</e2>, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",True,mechanism
SUTENT,rifampin,21,26,111,118,"Co-administration of <e1>SUTENT</e1> with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, <e2>rifampin</e2>, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",True,mechanism
SUTENT,rifabutin,21,26,121,129,"Co-administration of <e1>SUTENT</e1> with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, <e2>rifabutin</e2>, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",True,mechanism
SUTENT,rifapentin,21,26,132,141,"Co-administration of <e1>SUTENT</e1> with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, <e2>rifapentin</e2>, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",True,mechanism
SUTENT,phenobarbital,21,26,144,156,"Co-administration of <e1>SUTENT</e1> with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, <e2>phenobarbital</e2>, St. Johns Wort) may decrease sunitinib concentrations. ",True,mechanism
SUTENT,sunitinib,21,26,188,196,"Co-administration of <e1>SUTENT</e1> with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease <e2>sunitinib</e2> concentrations. ",False,negative
dexamethasone,phenytoin,70,82,85,93,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., <e1>dexamethasone</e1>, <e2>phenytoin</e2>, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",False,negative
dexamethasone,carbamazepine,70,82,96,108,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., <e1>dexamethasone</e1>, phenytoin, <e2>carbamazepine</e2>, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",False,negative
dexamethasone,rifampin,70,82,111,118,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., <e1>dexamethasone</e1>, phenytoin, carbamazepine, <e2>rifampin</e2>, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",False,negative
dexamethasone,rifabutin,70,82,121,129,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., <e1>dexamethasone</e1>, phenytoin, carbamazepine, rifampin, <e2>rifabutin</e2>, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",False,negative
dexamethasone,rifapentin,70,82,132,141,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., <e1>dexamethasone</e1>, phenytoin, carbamazepine, rifampin, rifabutin, <e2>rifapentin</e2>, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",False,negative
dexamethasone,phenobarbital,70,82,144,156,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., <e1>dexamethasone</e1>, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, <e2>phenobarbital</e2>, St. Johns Wort) may decrease sunitinib concentrations. ",False,negative
dexamethasone,sunitinib,70,82,188,196,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., <e1>dexamethasone</e1>, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease <e2>sunitinib</e2> concentrations. ",False,negative
phenytoin,carbamazepine,85,93,96,108,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, <e1>phenytoin</e1>, <e2>carbamazepine</e2>, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",False,negative
phenytoin,rifampin,85,93,111,118,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, <e1>phenytoin</e1>, carbamazepine, <e2>rifampin</e2>, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",False,negative
phenytoin,rifabutin,85,93,121,129,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, <e1>phenytoin</e1>, carbamazepine, rifampin, <e2>rifabutin</e2>, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",False,negative
phenytoin,rifapentin,85,93,132,141,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, <e1>phenytoin</e1>, carbamazepine, rifampin, rifabutin, <e2>rifapentin</e2>, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",False,negative
phenytoin,phenobarbital,85,93,144,156,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, <e1>phenytoin</e1>, carbamazepine, rifampin, rifabutin, rifapentin, <e2>phenobarbital</e2>, St. Johns Wort) may decrease sunitinib concentrations. ",False,negative
phenytoin,sunitinib,85,93,188,196,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, <e1>phenytoin</e1>, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease <e2>sunitinib</e2> concentrations. ",False,negative
carbamazepine,rifampin,96,108,111,118,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, <e1>carbamazepine</e1>, <e2>rifampin</e2>, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",False,negative
carbamazepine,rifabutin,96,108,121,129,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, <e1>carbamazepine</e1>, rifampin, <e2>rifabutin</e2>, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",False,negative
carbamazepine,rifapentin,96,108,132,141,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, <e1>carbamazepine</e1>, rifampin, rifabutin, <e2>rifapentin</e2>, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",False,negative
carbamazepine,phenobarbital,96,108,144,156,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, <e1>carbamazepine</e1>, rifampin, rifabutin, rifapentin, <e2>phenobarbital</e2>, St. Johns Wort) may decrease sunitinib concentrations. ",False,negative
carbamazepine,sunitinib,96,108,188,196,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, <e1>carbamazepine</e1>, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease <e2>sunitinib</e2> concentrations. ",False,negative
rifampin,rifabutin,111,118,121,129,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, <e1>rifampin</e1>, <e2>rifabutin</e2>, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",False,negative
rifampin,rifapentin,111,118,132,141,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, <e1>rifampin</e1>, rifabutin, <e2>rifapentin</e2>, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",False,negative
rifampin,phenobarbital,111,118,144,156,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, <e1>rifampin</e1>, rifabutin, rifapentin, <e2>phenobarbital</e2>, St. Johns Wort) may decrease sunitinib concentrations. ",False,negative
rifampin,sunitinib,111,118,188,196,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, <e1>rifampin</e1>, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease <e2>sunitinib</e2> concentrations. ",False,negative
rifabutin,rifapentin,121,129,132,141,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, <e1>rifabutin</e1>, <e2>rifapentin</e2>, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",False,negative
rifabutin,phenobarbital,121,129,144,156,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, <e1>rifabutin</e1>, rifapentin, <e2>phenobarbital</e2>, St. Johns Wort) may decrease sunitinib concentrations. ",False,negative
rifabutin,sunitinib,121,129,188,196,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, <e1>rifabutin</e1>, rifapentin, phenobarbital, St. Johns Wort) may decrease <e2>sunitinib</e2> concentrations. ",False,negative
rifapentin,phenobarbital,132,141,144,156,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, <e1>rifapentin</e1>, <e2>phenobarbital</e2>, St. Johns Wort) may decrease sunitinib concentrations. ",False,negative
rifapentin,sunitinib,132,141,188,196,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, <e1>rifapentin</e1>, phenobarbital, St. Johns Wort) may decrease <e2>sunitinib</e2> concentrations. ",False,negative
phenobarbital,sunitinib,144,156,188,196,"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, <e1>phenobarbital</e1>, St. Johns Wort) may decrease <e2>sunitinib</e2> concentrations. ",False,negative
acetylcholine chloride,Miochol,39,60,63,69,"Other eye drops or medications such as <e1>acetylcholine chloride</e1> (<e2>Miochol</e2>) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.",False,negative
acetylcholine chloride,carbachol,39,60,76,84,"Other eye drops or medications such as <e1>acetylcholine chloride</e1> (Miochol) and <e2>carbachol</e2> (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.",False,negative
acetylcholine chloride,Carboptic,39,60,87,95,"Other eye drops or medications such as <e1>acetylcholine chloride</e1> (Miochol) and carbachol (<e2>Carboptic</e2>, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.",False,negative
acetylcholine chloride,Isopto Carbachol,39,60,98,113,"Other eye drops or medications such as <e1>acetylcholine chloride</e1> (Miochol) and carbachol (Carboptic, <e2>Isopto Carbachol</e2>) may decrease the effects of suprofen ophthalmic.",False,negative
acetylcholine chloride,suprofen,39,60,144,151,"Other eye drops or medications such as <e1>acetylcholine chloride</e1> (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of <e2>suprofen</e2> ophthalmic.",True,effect
Miochol,carbachol,63,69,76,84,"Other eye drops or medications such as acetylcholine chloride (<e1>Miochol</e1>) and <e2>carbachol</e2> (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.",False,negative
Miochol,Carboptic,63,69,87,95,"Other eye drops or medications such as acetylcholine chloride (<e1>Miochol</e1>) and carbachol (<e2>Carboptic</e2>, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.",False,negative
Miochol,Isopto Carbachol,63,69,98,113,"Other eye drops or medications such as acetylcholine chloride (<e1>Miochol</e1>) and carbachol (Carboptic, <e2>Isopto Carbachol</e2>) may decrease the effects of suprofen ophthalmic.",False,negative
Miochol,suprofen,63,69,144,151,"Other eye drops or medications such as acetylcholine chloride (<e1>Miochol</e1>) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of <e2>suprofen</e2> ophthalmic.",True,effect
carbachol,Carboptic,76,84,87,95,"Other eye drops or medications such as acetylcholine chloride (Miochol) and <e1>carbachol</e1> (<e2>Carboptic</e2>, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.",False,negative
carbachol,Isopto Carbachol,76,84,98,113,"Other eye drops or medications such as acetylcholine chloride (Miochol) and <e1>carbachol</e1> (Carboptic, <e2>Isopto Carbachol</e2>) may decrease the effects of suprofen ophthalmic.",False,negative
carbachol,suprofen,76,84,144,151,"Other eye drops or medications such as acetylcholine chloride (Miochol) and <e1>carbachol</e1> (Carboptic, Isopto Carbachol) may decrease the effects of <e2>suprofen</e2> ophthalmic.",True,effect
Carboptic,Isopto Carbachol,87,95,98,113,"Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (<e1>Carboptic</e1>, <e2>Isopto Carbachol</e2>) may decrease the effects of suprofen ophthalmic.",False,negative
Carboptic,suprofen,87,95,144,151,"Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (<e1>Carboptic</e1>, Isopto Carbachol) may decrease the effects of <e2>suprofen</e2> ophthalmic.",True,effect
Isopto Carbachol,suprofen,98,113,144,151,"Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, <e1>Isopto Carbachol</e1>) may decrease the effects of <e2>suprofen</e2> ophthalmic.",True,effect
FLOMAX,alpha-adrenergic blocking agents,85,90,111,142,Drug-Drug Interactions: The pharmacokinetic and pharmacodynamic interactions between <e1>FLOMAX</e1> capsules and other <e2>alpha-adrenergic blocking agents</e2> have not been determined. ,False,negative
FLOMAX,alpha-adrenergic blocking agents,42,47,103,134,"However, interactions may be expected and <e1>FLOMAX</e1> capsules should NOT be used in combination with other <e2>alpha-adrenergic blocking agents</e2>. ",True,advise
cimetidine,FLOMAX,40,49,55,60,The pharmacokinetic interaction between <e1>cimetidine</e1> and <e2>FLOMAX</e2> capsules was investigated. ,False,negative
FLOMAX,cimetidine,11,16,75,84,"Therefore, <e1>FLOMAX</e1> capsules should be used with caution in combination with <e2>cimetidine</e2>, particularly at doses higher than 0.4 mg. ",True,advise
tamsulosin HCI,warfarin,80,93,99,106,Results from limited in vitro and in vivo drug-drug interaction studies between <e1>tamsulosin HCI</e1> and <e2>warfarin</e2> are inconclusive. ,False,negative
warfarin,FLOMAX,74,81,87,92,"Therefore, caution should be exercised with concomitant administration of <e1>warfarin</e1> and <e2>FLOMAX</e2> capsules.        ",True,advise
valproic acid,temozolomide,18,30,60,71,Administration of <e1>valproic acid</e1> decreases oral clearance of <e2>temozolomide</e2> by about 5%. ,True,mechanism
TNKase,heparin,39,44,74,80,Patients studied in clinical trials of <e1>TNKase</e1> were routinely treated with <e2>heparin</e2> and aspirin. ,False,negative
TNKase,aspirin,39,44,86,92,Patients studied in clinical trials of <e1>TNKase</e1> were routinely treated with heparin and <e2>aspirin</e2>. ,False,negative
heparin,aspirin,74,80,86,92,Patients studied in clinical trials of TNKase were routinely treated with <e1>heparin</e1> and <e2>aspirin</e2>. ,False,negative
Anticoagulants,heparin,0,13,24,30,"<e1>Anticoagulants</e1> (such as <e2>heparin</e2> and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",False,negative
Anticoagulants,vitamin K antagonists,0,13,36,56,"<e1>Anticoagulants</e1> (such as heparin and <e2>vitamin K antagonists</e2>) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",False,negative
Anticoagulants,acetylsalicylic acid,0,13,107,126,"<e1>Anticoagulants</e1> (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as <e2>acetylsalicylic acid</e2>, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",False,negative
Anticoagulants,dipyridamole,0,13,129,140,"<e1>Anticoagulants</e1> (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, <e2>dipyridamole</e2>, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",False,negative
Anticoagulants,TNKase,0,13,248,253,"<e1>Anticoagulants</e1> (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after <e2>TNKase</e2> therapy. ",True,effect
heparin,vitamin K antagonists,24,30,36,56,"Anticoagulants (such as <e1>heparin</e1> and <e2>vitamin K antagonists</e2>) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",False,negative
heparin,acetylsalicylic acid,24,30,107,126,"Anticoagulants (such as <e1>heparin</e1> and vitamin K antagonists) and drugs that alter platelet function (such as <e2>acetylsalicylic acid</e2>, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",False,negative
heparin,dipyridamole,24,30,129,140,"Anticoagulants (such as <e1>heparin</e1> and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, <e2>dipyridamole</e2>, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",False,negative
heparin,TNKase,24,30,248,253,"Anticoagulants (such as <e1>heparin</e1> and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after <e2>TNKase</e2> therapy. ",True,effect
vitamin K antagonists,acetylsalicylic acid,36,56,107,126,"Anticoagulants (such as heparin and <e1>vitamin K antagonists</e1>) and drugs that alter platelet function (such as <e2>acetylsalicylic acid</e2>, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",False,negative
vitamin K antagonists,dipyridamole,36,56,129,140,"Anticoagulants (such as heparin and <e1>vitamin K antagonists</e1>) and drugs that alter platelet function (such as acetylsalicylic acid, <e2>dipyridamole</e2>, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",False,negative
vitamin K antagonists,TNKase,36,56,248,253,"Anticoagulants (such as heparin and <e1>vitamin K antagonists</e1>) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after <e2>TNKase</e2> therapy. ",True,effect
acetylsalicylic acid,dipyridamole,107,126,129,140,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as <e1>acetylsalicylic acid</e1>, <e2>dipyridamole</e2>, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",False,negative
acetylsalicylic acid,TNKase,107,126,248,253,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as <e1>acetylsalicylic acid</e1>, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after <e2>TNKase</e2> therapy. ",True,effect
dipyridamole,TNKase,129,140,248,253,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, <e1>dipyridamole</e1>, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after <e2>TNKase</e2> therapy. ",True,effect
tolbutamide,sodium salicylate,95,105,108,124,"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of <e1>tolbutamide</e1>, <e2>sodium salicylate</e2> and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. ",False,negative
tolbutamide,sulfamethizole,95,105,130,143,"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of <e1>tolbutamide</e1>, sodium salicylate and <e2>sulfamethizole</e2> displaced protein-bound teniposide in fresh human serum to a small but significant extent. ",False,negative
tolbutamide,teniposide,95,105,169,178,"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of <e1>tolbutamide</e1>, sodium salicylate and sulfamethizole displaced protein-bound <e2>teniposide</e2> in fresh human serum to a small but significant extent. ",True,mechanism
sodium salicylate,sulfamethizole,108,124,130,143,"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, <e1>sodium salicylate</e1> and <e2>sulfamethizole</e2> displaced protein-bound teniposide in fresh human serum to a small but significant extent. ",False,negative
sodium salicylate,teniposide,108,124,169,178,"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, <e1>sodium salicylate</e1> and sulfamethizole displaced protein-bound <e2>teniposide</e2> in fresh human serum to a small but significant extent. ",True,mechanism
sulfamethizole,teniposide,130,143,169,178,"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and <e1>sulfamethizole</e1> displaced protein-bound <e2>teniposide</e2> in fresh human serum to a small but significant extent. ",True,mechanism
VUMON,teniposide,51,55,58,67,"Therefore, caution should be used in administering <e1>VUMON</e1> (<e2>teniposide</e2> injection) to patients receiving these other agents. ",False,negative
teniposide,methotrexate,46,55,82,93,There was no change in the plasma kinetics of <e1>teniposide</e1> when coadministered with <e2>methotrexate</e2>. ,False,negative
methotrexate,teniposide,39,50,93,102,An increase in intracellular levels of <e1>methotrexate</e1> was observed in vitro in the presence of <e2>teniposide</e2>.,True,mechanism
terbinafine,tolbutamide,57,67,104,114,"In vitro studies with human liver microsomes showed that <e1>terbinafine</e1> does not inhibit the metabolism of <e2>tolbutamide</e2>, ethinylestradiol, ethoxycoumarin, and cyclosporine. ",False,negative
terbinafine,ethinylestradiol,57,67,117,132,"In vitro studies with human liver microsomes showed that <e1>terbinafine</e1> does not inhibit the metabolism of tolbutamide, <e2>ethinylestradiol</e2>, ethoxycoumarin, and cyclosporine. ",False,negative
terbinafine,ethoxycoumarin,57,67,135,148,"In vitro studies with human liver microsomes showed that <e1>terbinafine</e1> does not inhibit the metabolism of tolbutamide, ethinylestradiol, <e2>ethoxycoumarin</e2>, and cyclosporine. ",False,negative
terbinafine,cyclosporine,57,67,155,166,"In vitro studies with human liver microsomes showed that <e1>terbinafine</e1> does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and <e2>cyclosporine</e2>. ",False,negative
tolbutamide,ethinylestradiol,104,114,117,132,"In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of <e1>tolbutamide</e1>, <e2>ethinylestradiol</e2>, ethoxycoumarin, and cyclosporine. ",False,negative
tolbutamide,ethoxycoumarin,104,114,135,148,"In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of <e1>tolbutamide</e1>, ethinylestradiol, <e2>ethoxycoumarin</e2>, and cyclosporine. ",False,negative
tolbutamide,cyclosporine,104,114,155,166,"In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of <e1>tolbutamide</e1>, ethinylestradiol, ethoxycoumarin, and <e2>cyclosporine</e2>. ",False,negative
ethinylestradiol,ethoxycoumarin,117,132,135,148,"In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, <e1>ethinylestradiol</e1>, <e2>ethoxycoumarin</e2>, and cyclosporine. ",False,negative
ethinylestradiol,cyclosporine,117,132,155,166,"In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, <e1>ethinylestradiol</e1>, ethoxycoumarin, and <e2>cyclosporine</e2>. ",False,negative
ethoxycoumarin,cyclosporine,135,148,155,166,"In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, <e1>ethoxycoumarin</e1>, and <e2>cyclosporine</e2>. ",False,negative
tricyclic antidepressants,selective serotonin reuptake inhibitors,98,122,139,177,"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as <e1>tricyclic antidepressants</e1>,    -blockers, <e2>selective serotonin reuptake inhibitors</e2> (SSRIs), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window. ",False,negative
tricyclic antidepressants,SSRIs,98,122,180,184,"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as <e1>tricyclic antidepressants</e1>,    -blockers, selective serotonin reuptake inhibitors (<e2>SSRIs</e2>), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window. ",False,negative
tricyclic antidepressants,monoamine oxidase inhibitors (MAO-Is) Type B,98,122,192,235,"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as <e1>tricyclic antidepressants</e1>,    -blockers, selective serotonin reuptake inhibitors (SSRIs), and <e2>monoamine oxidase inhibitors (MAO-Is) Type B</e2>, if they have a narrow therapeutic window. ",False,negative
selective serotonin reuptake inhibitors,SSRIs,139,177,180,184,"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, <e1>selective serotonin reuptake inhibitors</e1> (<e2>SSRIs</e2>), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window. ",False,negative
selective serotonin reuptake inhibitors,monoamine oxidase inhibitors (MAO-Is) Type B,139,177,192,235,"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, <e1>selective serotonin reuptake inhibitors</e1> (SSRIs), and <e2>monoamine oxidase inhibitors (MAO-Is) Type B</e2>, if they have a narrow therapeutic window. ",False,negative
SSRIs,monoamine oxidase inhibitors (MAO-Is) Type B,180,184,192,235,"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, selective serotonin reuptake inhibitors (<e1>SSRIs</e1>), and <e2>monoamine oxidase inhibitors (MAO-Is) Type B</e2>, if they have a narrow therapeutic window. ",False,negative
terbinafine,antipyrine,89,99,134,143,In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that <e1>terbinafine</e1> does not affect the clearance of <e2>antipyrine</e2> or digoxin. ,False,negative
terbinafine,digoxin,89,99,148,154,In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that <e1>terbinafine</e1> does not affect the clearance of antipyrine or <e2>digoxin</e2>. ,False,negative
antipyrine,digoxin,134,143,148,154,In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that terbinafine does not affect the clearance of <e1>antipyrine</e1> or <e2>digoxin</e2>. ,False,negative
Terbinafine,caffeine,0,10,39,46,<e1>Terbinafine</e1> decreases the clearance of <e2>caffeine</e2> by 19%. ,True,mechanism
Terbinafine,cyclosporine,0,10,39,50,<e1>Terbinafine</e1> increases the clearance of <e2>cyclosporine</e2> by 15%. ,True,mechanism
terbinafine,warfarin,119,129,135,142,"There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral <e1>terbinafine</e1> and <e2>warfarin</e2>, however, a causal relationship between LAMISIL    Tablets and these changes has not been established. ",True,effect
terbinafine,LAMISIL,119,129,184,190,"There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral <e1>terbinafine</e1> and warfarin, however, a causal relationship between <e2>LAMISIL</e2>    Tablets and these changes has not been established. ",False,negative
warfarin,LAMISIL,135,142,184,190,"There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and <e1>warfarin</e1>, however, a causal relationship between <e2>LAMISIL</e2>    Tablets and these changes has not been established. ",False,negative
Terbinafine,rifampin,0,10,43,50,"<e1>Terbinafine</e1> clearance is increased 100% by <e2>rifampin</e2>, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor. ",True,mechanism
Terbinafine,cimetidine,0,10,99,108,"<e1>Terbinafine</e1> clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by <e2>cimetidine</e2>, a CyP450 enzyme inhibitor. ",True,mechanism
rifampin,cimetidine,43,50,99,108,"Terbinafine clearance is increased 100% by <e1>rifampin</e1>, a CyP450 enzyme inducer, and decreased 33% by <e2>cimetidine</e2>, a CyP450 enzyme inhibitor. ",False,negative
Terbinafine,cyclosporine,0,10,39,50,<e1>Terbinafine</e1> clearance is unaffected by <e2>cyclosporine</e2>. ,False,negative
contraceptives,hypoglycemics,120,133,167,179,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral <e1>contraceptives</e1>, hormone replacement therapies, <e2>hypoglycemics</e2>, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",False,negative
contraceptives,theophyllines,120,133,182,194,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral <e1>contraceptives</e1>, hormone replacement therapies, hypoglycemics, <e2>theophyllines</e2>, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",False,negative
contraceptives,phenytoins,120,133,197,206,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral <e1>contraceptives</e1>, hormone replacement therapies, hypoglycemics, theophyllines, <e2>phenytoins</e2>, thiazide diuretics, beta blockers, and calcium channel blockers.",False,negative
contraceptives,thiazide diuretics,120,133,209,226,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral <e1>contraceptives</e1>, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, <e2>thiazide diuretics</e2>, beta blockers, and calcium channel blockers.",False,negative
contraceptives,beta blockers,120,133,229,241,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral <e1>contraceptives</e1>, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, <e2>beta blockers</e2>, and calcium channel blockers.",False,negative
contraceptives,calcium channel blockers,120,133,248,271,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral <e1>contraceptives</e1>, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and <e2>calcium channel blockers</e2>.",False,negative
hypoglycemics,theophyllines,167,179,182,194,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, <e1>hypoglycemics</e1>, <e2>theophyllines</e2>, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",False,negative
hypoglycemics,phenytoins,167,179,197,206,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, <e1>hypoglycemics</e1>, theophyllines, <e2>phenytoins</e2>, thiazide diuretics, beta blockers, and calcium channel blockers.",False,negative
hypoglycemics,thiazide diuretics,167,179,209,226,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, <e1>hypoglycemics</e1>, theophyllines, phenytoins, <e2>thiazide diuretics</e2>, beta blockers, and calcium channel blockers.",False,negative
hypoglycemics,beta blockers,167,179,229,241,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, <e1>hypoglycemics</e1>, theophyllines, phenytoins, thiazide diuretics, <e2>beta blockers</e2>, and calcium channel blockers.",False,negative
hypoglycemics,calcium channel blockers,167,179,248,271,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, <e1>hypoglycemics</e1>, theophyllines, phenytoins, thiazide diuretics, beta blockers, and <e2>calcium channel blockers</e2>.",False,negative
theophyllines,phenytoins,182,194,197,206,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, <e1>theophyllines</e1>, <e2>phenytoins</e2>, thiazide diuretics, beta blockers, and calcium channel blockers.",False,negative
theophyllines,thiazide diuretics,182,194,209,226,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, <e1>theophyllines</e1>, phenytoins, <e2>thiazide diuretics</e2>, beta blockers, and calcium channel blockers.",False,negative
theophyllines,beta blockers,182,194,229,241,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, <e1>theophyllines</e1>, phenytoins, thiazide diuretics, <e2>beta blockers</e2>, and calcium channel blockers.",False,negative
theophyllines,calcium channel blockers,182,194,248,271,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, <e1>theophyllines</e1>, phenytoins, thiazide diuretics, beta blockers, and <e2>calcium channel blockers</e2>.",False,negative
phenytoins,thiazide diuretics,197,206,209,226,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, <e1>phenytoins</e1>, <e2>thiazide diuretics</e2>, beta blockers, and calcium channel blockers.",False,negative
phenytoins,beta blockers,197,206,229,241,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, <e1>phenytoins</e1>, thiazide diuretics, <e2>beta blockers</e2>, and calcium channel blockers.",False,negative
phenytoins,calcium channel blockers,197,206,248,271,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, <e1>phenytoins</e1>, thiazide diuretics, beta blockers, and <e2>calcium channel blockers</e2>.",False,negative
thiazide diuretics,beta blockers,209,226,229,241,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, <e1>thiazide diuretics</e1>, <e2>beta blockers</e2>, and calcium channel blockers.",False,negative
thiazide diuretics,calcium channel blockers,209,226,248,271,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, <e1>thiazide diuretics</e1>, beta blockers, and <e2>calcium channel blockers</e2>.",False,negative
beta blockers,calcium channel blockers,229,241,248,271,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, <e1>beta blockers</e1>, and <e2>calcium channel blockers</e2>.",False,negative
Ketoconazole,ketoconazole,0,11,82,93,"<e1>Ketoconazole</e1>: Spontaneous adverse reaction reports of patients taking concomitant <e2>ketoconazole</e2> with recommended doses of terfenadine demonstrate QT interval prolongation and rare serious cardiac events, e.g. ",False,negative
Ketoconazole,terfenadine,0,11,121,131,"<e1>Ketoconazole</e1>: Spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of <e2>terfenadine</e2> demonstrate QT interval prolongation and rare serious cardiac events, e.g. ",False,negative
ketoconazole,terfenadine,82,93,121,131,"Ketoconazole: Spontaneous adverse reaction reports of patients taking concomitant <e1>ketoconazole</e1> with recommended doses of <e2>terfenadine</e2> demonstrate QT interval prolongation and rare serious cardiac events, e.g. ",True,effect
ketoconazole,terfenadine,35,46,84,94,"Pharmacokinetic data indicate that <e1>ketoconazole</e1> markedly inhibits the metabolism of <e2>terfenadine</e2>, resulting in elevated plasma terfenadine levels. ",True,mechanism
ketoconazole,terfenadine,35,46,126,136,"Pharmacokinetic data indicate that <e1>ketoconazole</e1> markedly inhibits the metabolism of terfenadine, resulting in elevated plasma <e2>terfenadine</e2> levels. ",False,negative
terfenadine,terfenadine,84,94,126,136,"Pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of <e1>terfenadine</e1>, resulting in elevated plasma <e2>terfenadine</e2> levels. ",False,negative
ketoconazole,terfenadine,30,41,47,57,Concomitant administration of <e1>ketoconazole</e1> and <e2>terfenadine</e2> is contraindicated. ,True,advise
Itraconazole,terfenadine,0,11,54,64,<e1>Itraconazole</e1>: Torsades de pointes and elevated parent <e2>terfenadine</e2> levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. ,False,negative
Itraconazole,terfenadine,0,11,118,128,<e1>Itraconazole</e1>: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of <e2>terfenadine</e2> and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. ,False,negative
Itraconazole,itraconazole,0,11,134,145,<e1>Itraconazole</e1>: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and <e2>itraconazole</e2> in clinical trials of itraconazole and from foreign post-marketing sources. ,False,negative
Itraconazole,itraconazole,0,11,169,180,<e1>Itraconazole</e1>: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of <e2>itraconazole</e2> and from foreign post-marketing sources. ,False,negative
terfenadine,terfenadine,54,64,118,128,Itraconazole: Torsades de pointes and elevated parent <e1>terfenadine</e1> levels have been reported during concomitant use of <e2>terfenadine</e2> and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. ,False,negative
terfenadine,itraconazole,54,64,134,145,Itraconazole: Torsades de pointes and elevated parent <e1>terfenadine</e1> levels have been reported during concomitant use of terfenadine and <e2>itraconazole</e2> in clinical trials of itraconazole and from foreign post-marketing sources. ,False,negative
terfenadine,itraconazole,54,64,169,180,Itraconazole: Torsades de pointes and elevated parent <e1>terfenadine</e1> levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of <e2>itraconazole</e2> and from foreign post-marketing sources. ,False,negative
terfenadine,itraconazole,118,128,134,145,Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of <e1>terfenadine</e1> and <e2>itraconazole</e2> in clinical trials of itraconazole and from foreign post-marketing sources. ,True,mechanism
terfenadine,itraconazole,118,128,169,180,Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of <e1>terfenadine</e1> and itraconazole in clinical trials of <e2>itraconazole</e2> and from foreign post-marketing sources. ,False,negative
itraconazole,itraconazole,134,145,169,180,Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and <e1>itraconazole</e1> in clinical trials of <e2>itraconazole</e2> and from foreign post-marketing sources. ,False,negative
itraconazole,terfenadine,30,41,47,57,Concomitant administration of <e1>itraconazole</e1> and <e2>terfenadine</e2> is contraindicated. ,True,advise
azole-type antifungal agents,fluconazole,40,67,80,90,"Due to the chemical similarity of other <e1>azole-type antifungal agents</e1> (including <e2>fluconazole</e2>, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",False,negative
azole-type antifungal agents,metronidazole,40,67,93,105,"Due to the chemical similarity of other <e1>azole-type antifungal agents</e1> (including fluconazole, <e2>metronidazole</e2>, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",False,negative
azole-type antifungal agents,miconazole,40,67,112,121,"Due to the chemical similarity of other <e1>azole-type antifungal agents</e1> (including fluconazole, metronidazole, and <e2>miconazole</e2>) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",False,negative
azole-type antifungal agents,ketoconazole,40,67,127,138,"Due to the chemical similarity of other <e1>azole-type antifungal agents</e1> (including fluconazole, metronidazole, and miconazole) to <e2>ketoconazole</e2>, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",False,negative
azole-type antifungal agents,itraconazole,40,67,145,156,"Due to the chemical similarity of other <e1>azole-type antifungal agents</e1> (including fluconazole, metronidazole, and miconazole) to ketoconazole, and <e2>itraconazole</e2>, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",False,negative
azole-type antifungal agents,terfenadine,40,67,198,208,"Due to the chemical similarity of other <e1>azole-type antifungal agents</e1> (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with <e2>terfenadine</e2> is not recommended pending full examination of potential interactions. ",True,advise
fluconazole,metronidazole,80,90,93,105,"Due to the chemical similarity of other azole-type antifungal agents (including <e1>fluconazole</e1>, <e2>metronidazole</e2>, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",False,negative
fluconazole,miconazole,80,90,112,121,"Due to the chemical similarity of other azole-type antifungal agents (including <e1>fluconazole</e1>, metronidazole, and <e2>miconazole</e2>) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",False,negative
fluconazole,ketoconazole,80,90,127,138,"Due to the chemical similarity of other azole-type antifungal agents (including <e1>fluconazole</e1>, metronidazole, and miconazole) to <e2>ketoconazole</e2>, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",False,negative
fluconazole,itraconazole,80,90,145,156,"Due to the chemical similarity of other azole-type antifungal agents (including <e1>fluconazole</e1>, metronidazole, and miconazole) to ketoconazole, and <e2>itraconazole</e2>, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",False,negative
fluconazole,terfenadine,80,90,198,208,"Due to the chemical similarity of other azole-type antifungal agents (including <e1>fluconazole</e1>, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with <e2>terfenadine</e2> is not recommended pending full examination of potential interactions. ",True,advise
metronidazole,miconazole,93,105,112,121,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, <e1>metronidazole</e1>, and <e2>miconazole</e2>) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",False,negative
metronidazole,ketoconazole,93,105,127,138,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, <e1>metronidazole</e1>, and miconazole) to <e2>ketoconazole</e2>, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",False,negative
metronidazole,itraconazole,93,105,145,156,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, <e1>metronidazole</e1>, and miconazole) to ketoconazole, and <e2>itraconazole</e2>, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",False,negative
metronidazole,terfenadine,93,105,198,208,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, <e1>metronidazole</e1>, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with <e2>terfenadine</e2> is not recommended pending full examination of potential interactions. ",True,advise
miconazole,ketoconazole,112,121,127,138,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and <e1>miconazole</e1>) to <e2>ketoconazole</e2>, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",False,negative
miconazole,itraconazole,112,121,145,156,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and <e1>miconazole</e1>) to ketoconazole, and <e2>itraconazole</e2>, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",False,negative
miconazole,terfenadine,112,121,198,208,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and <e1>miconazole</e1>) to ketoconazole, and itraconazole, concomitant use of these products with <e2>terfenadine</e2> is not recommended pending full examination of potential interactions. ",True,advise
ketoconazole,itraconazole,127,138,145,156,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to <e1>ketoconazole</e1>, and <e2>itraconazole</e2>, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",False,negative
ketoconazole,terfenadine,127,138,198,208,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to <e1>ketoconazole</e1>, and itraconazole, concomitant use of these products with <e2>terfenadine</e2> is not recommended pending full examination of potential interactions. ",False,negative
itraconazole,terfenadine,145,156,198,208,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and <e1>itraconazole</e1>, concomitant use of these products with <e2>terfenadine</e2> is not recommended pending full examination of potential interactions. ",False,negative
Macrolides,erythromycin,0,9,60,71,"<e1>Macrolides</e1>: Clinical drug interaction studies indicate that <e2>erythromycin</e2> and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ",False,negative
Macrolides,clarithromycin,0,9,77,90,"<e1>Macrolides</e1>: Clinical drug interaction studies indicate that erythromycin and <e2>clarithromycin</e2> can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ",False,negative
Macrolides,terfenadine,0,9,115,125,"<e1>Macrolides</e1>: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on <e2>terfenadine</e2> metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ",False,negative
Macrolides,ketoconazole,0,9,185,196,"<e1>Macrolides</e1>: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of <e2>ketoconazole</e2>, but to a lesser extent. ",False,negative
erythromycin,clarithromycin,60,71,77,90,"Macrolides: Clinical drug interaction studies indicate that <e1>erythromycin</e1> and <e2>clarithromycin</e2> can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ",False,negative
erythromycin,terfenadine,60,71,115,125,"Macrolides: Clinical drug interaction studies indicate that <e1>erythromycin</e1> and clarithromycin can exert an effect on <e2>terfenadine</e2> metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ",True,mechanism
erythromycin,ketoconazole,60,71,185,196,"Macrolides: Clinical drug interaction studies indicate that <e1>erythromycin</e1> and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of <e2>ketoconazole</e2>, but to a lesser extent. ",False,negative
clarithromycin,terfenadine,77,90,115,125,"Macrolides: Clinical drug interaction studies indicate that erythromycin and <e1>clarithromycin</e1> can exert an effect on <e2>terfenadine</e2> metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ",True,mechanism
clarithromycin,ketoconazole,77,90,185,196,"Macrolides: Clinical drug interaction studies indicate that erythromycin and <e1>clarithromycin</e1> can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of <e2>ketoconazole</e2>, but to a lesser extent. ",False,negative
terfenadine,ketoconazole,115,125,185,196,"Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on <e1>terfenadine</e1> metabolism by a mechanism which may be similar to that of <e2>ketoconazole</e2>, but to a lesser extent. ",False,negative
erythromycin,troleandomycin,155,166,171,184,"A few spontaneous accounts of QT interval prolongation with ventricular arrhythmia including torsades de pointes, have been reported in patients receiving <e1>erythromycin</e1> or <e2>troleandomycin</e2>. ",False,negative
terfenadine,clarithromycin,30,40,47,60,"Concomitant administration of <e1>terfenadine</e1> with <e2>clarithromycin</e2>, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",True,advise
terfenadine,erythromycin,30,40,63,74,"Concomitant administration of <e1>terfenadine</e1> with clarithromycin, <e2>erythromycin</e2>, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",True,advise
terfenadine,troleandomycin,30,40,80,93,"Concomitant administration of <e1>terfenadine</e1> with clarithromycin, erythromycin, or <e2>troleandomycin</e2> is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",True,advise
terfenadine,terfenadine,30,40,202,212,"Concomitant administration of <e1>terfenadine</e1> with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of <e2>terfenadine</e2> with other macrolide antibiotics, including azithromycin, is not recommended. ",False,negative
terfenadine,macrolide antibiotics,30,40,225,245,"Concomitant administration of <e1>terfenadine</e1> with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other <e2>macrolide antibiotics</e2>, including azithromycin, is not recommended. ",False,negative
terfenadine,azithromycin,30,40,258,269,"Concomitant administration of <e1>terfenadine</e1> with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including <e2>azithromycin</e2>, is not recommended. ",False,negative
clarithromycin,erythromycin,47,60,63,74,"Concomitant administration of terfenadine with <e1>clarithromycin</e1>, <e2>erythromycin</e2>, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",False,negative
clarithromycin,troleandomycin,47,60,80,93,"Concomitant administration of terfenadine with <e1>clarithromycin</e1>, erythromycin, or <e2>troleandomycin</e2> is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",False,negative
clarithromycin,terfenadine,47,60,202,212,"Concomitant administration of terfenadine with <e1>clarithromycin</e1>, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of <e2>terfenadine</e2> with other macrolide antibiotics, including azithromycin, is not recommended. ",False,negative
clarithromycin,macrolide antibiotics,47,60,225,245,"Concomitant administration of terfenadine with <e1>clarithromycin</e1>, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other <e2>macrolide antibiotics</e2>, including azithromycin, is not recommended. ",False,negative
clarithromycin,azithromycin,47,60,258,269,"Concomitant administration of terfenadine with <e1>clarithromycin</e1>, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including <e2>azithromycin</e2>, is not recommended. ",False,negative
erythromycin,troleandomycin,63,74,80,93,"Concomitant administration of terfenadine with clarithromycin, <e1>erythromycin</e1>, or <e2>troleandomycin</e2> is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",False,negative
erythromycin,terfenadine,63,74,202,212,"Concomitant administration of terfenadine with clarithromycin, <e1>erythromycin</e1>, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of <e2>terfenadine</e2> with other macrolide antibiotics, including azithromycin, is not recommended. ",False,negative
erythromycin,macrolide antibiotics,63,74,225,245,"Concomitant administration of terfenadine with clarithromycin, <e1>erythromycin</e1>, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other <e2>macrolide antibiotics</e2>, including azithromycin, is not recommended. ",False,negative
erythromycin,azithromycin,63,74,258,269,"Concomitant administration of terfenadine with clarithromycin, <e1>erythromycin</e1>, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including <e2>azithromycin</e2>, is not recommended. ",False,negative
troleandomycin,terfenadine,80,93,202,212,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or <e1>troleandomycin</e1> is contraindicated: Pending full characterization of potential interactions, concomitant administration of <e2>terfenadine</e2> with other macrolide antibiotics, including azithromycin, is not recommended. ",False,negative
troleandomycin,macrolide antibiotics,80,93,225,245,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or <e1>troleandomycin</e1> is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other <e2>macrolide antibiotics</e2>, including azithromycin, is not recommended. ",False,negative
troleandomycin,azithromycin,80,93,258,269,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or <e1>troleandomycin</e1> is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including <e2>azithromycin</e2>, is not recommended. ",False,negative
terfenadine,macrolide antibiotics,202,212,225,245,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of <e1>terfenadine</e1> with other <e2>macrolide antibiotics</e2>, including azithromycin, is not recommended. ",True,advise
terfenadine,azithromycin,202,212,258,269,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of <e1>terfenadine</e1> with other macrolide antibiotics, including <e2>azithromycin</e2>, is not recommended. ",True,advise
macrolide antibiotics,azithromycin,225,245,258,269,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other <e1>macrolide antibiotics</e1>, including <e2>azithromycin</e2>, is not recommended. ",False,negative
terfenadine,azithromycin,46,56,63,74,Studies to evaluate potential interactions of <e1>terfenadine</e1> with <e2>azithromycin</e2> are in progress.,False,negative
testolactone,anticoagulants,32,43,78,91,"When administered concurrently, <e1>testolactone</e1> may increase the effects of oral <e2>anticoagulants</e2>; ",True,effect
Thalidomide,barbiturates,0,10,66,77,"<e1>Thalidomide</e1> has been reported to enhance the sedative activity of <e2>barbiturates</e2>, alcohol, chlorpromazine, and reserpine. ",True,effect
Thalidomide,alcohol,0,10,80,86,"<e1>Thalidomide</e1> has been reported to enhance the sedative activity of barbiturates, <e2>alcohol</e2>, chlorpromazine, and reserpine. ",False,negative
Thalidomide,chlorpromazine,0,10,89,102,"<e1>Thalidomide</e1> has been reported to enhance the sedative activity of barbiturates, alcohol, <e2>chlorpromazine</e2>, and reserpine. ",False,negative
Thalidomide,reserpine,0,10,109,117,"<e1>Thalidomide</e1> has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and <e2>reserpine</e2>. ",False,negative
barbiturates,alcohol,66,77,80,86,"Thalidomide has been reported to enhance the sedative activity of <e1>barbiturates</e1>, <e2>alcohol</e2>, chlorpromazine, and reserpine. ",False,negative
barbiturates,chlorpromazine,66,77,89,102,"Thalidomide has been reported to enhance the sedative activity of <e1>barbiturates</e1>, alcohol, <e2>chlorpromazine</e2>, and reserpine. ",False,negative
barbiturates,reserpine,66,77,109,117,"Thalidomide has been reported to enhance the sedative activity of <e1>barbiturates</e1>, alcohol, chlorpromazine, and <e2>reserpine</e2>. ",False,negative
alcohol,chlorpromazine,80,86,89,102,"Thalidomide has been reported to enhance the sedative activity of barbiturates, <e1>alcohol</e1>, <e2>chlorpromazine</e2>, and reserpine. ",False,negative
alcohol,reserpine,80,86,109,117,"Thalidomide has been reported to enhance the sedative activity of barbiturates, <e1>alcohol</e1>, chlorpromazine, and <e2>reserpine</e2>. ",False,negative
chlorpromazine,reserpine,89,102,109,117,"Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, <e1>chlorpromazine</e1>, and <e2>reserpine</e2>. ",False,negative
Contraceptives,norethindrone,5,18,74,86,"Oral <e1>Contraceptives</e1>: In 10 healthy women, the pharmacokinetic profiles of <e2>norethindrone</e2> and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. ",False,negative
Contraceptives,ethinyl estradiol,5,18,92,108,"Oral <e1>Contraceptives</e1>: In 10 healthy women, the pharmacokinetic profiles of norethindrone and <e2>ethinyl estradiol</e2> following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. ",False,negative
Contraceptives,norethindrone acetate,5,18,173,193,"Oral <e1>Contraceptives</e1>: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of <e2>norethindrone acetate</e2> and 75    g of ethinyl estradiol were studied. ",False,negative
Contraceptives,ethinyl estradiol,5,18,210,226,"Oral <e1>Contraceptives</e1>: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of <e2>ethinyl estradiol</e2> were studied. ",False,negative
norethindrone,ethinyl estradiol,74,86,92,108,"Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of <e1>norethindrone</e1> and <e2>ethinyl estradiol</e2> following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. ",False,negative
norethindrone,norethindrone acetate,74,86,173,193,"Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of <e1>norethindrone</e1> and ethinyl estradiol following administration of a single dose containing 1.0 mg of <e2>norethindrone acetate</e2> and 75    g of ethinyl estradiol were studied. ",False,negative
norethindrone,ethinyl estradiol,74,86,210,226,"Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of <e1>norethindrone</e1> and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of <e2>ethinyl estradiol</e2> were studied. ",False,negative
ethinyl estradiol,norethindrone acetate,92,108,173,193,"Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and <e1>ethinyl estradiol</e1> following administration of a single dose containing 1.0 mg of <e2>norethindrone acetate</e2> and 75    g of ethinyl estradiol were studied. ",False,negative
ethinyl estradiol,ethinyl estradiol,92,108,210,226,"Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and <e1>ethinyl estradiol</e1> following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of <e2>ethinyl estradiol</e2> were studied. ",False,negative
norethindrone acetate,ethinyl estradiol,173,193,210,226,"Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of <e1>norethindrone acetate</e1> and 75    g of <e2>ethinyl estradiol</e2> were studied. ",False,negative
Thalidomide,Hormonal Contraceptives,14,24,70,92,"Important Non-<e1>Thalidomide</e1> Drug Interactions Drugs That Interfere with <e2>Hormonal Contraceptives</e2>: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",False,negative
Thalidomide,HIV-protease inhibitors,14,24,114,136,"Important Non-<e1>Thalidomide</e1> Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of <e2>HIV-protease inhibitors</e2>, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",False,negative
Thalidomide,griseofulvin,14,24,139,150,"Important Non-<e1>Thalidomide</e1> Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, <e2>griseofulvin</e2>, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",False,negative
Thalidomide,modafinil,14,24,153,161,"Important Non-<e1>Thalidomide</e1> Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, <e2>modafinil</e2>, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",False,negative
Thalidomide,penicillins,14,24,164,174,"Important Non-<e1>Thalidomide</e1> Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, <e2>penicillins</e2>, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",False,negative
Thalidomide,rifampin,14,24,177,184,"Important Non-<e1>Thalidomide</e1> Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, <e2>rifampin</e2>, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",False,negative
Thalidomide,rifabutin,14,24,187,195,"Important Non-<e1>Thalidomide</e1> Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, <e2>rifabutin</e2>, phenytoin, carbamazepine, or certain herbal supplements such as St. ",False,negative
Thalidomide,phenytoin,14,24,198,206,"Important Non-<e1>Thalidomide</e1> Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, <e2>phenytoin</e2>, carbamazepine, or certain herbal supplements such as St. ",False,negative
Thalidomide,carbamazepine,14,24,209,221,"Important Non-<e1>Thalidomide</e1> Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, <e2>carbamazepine</e2>, or certain herbal supplements such as St. ",False,negative
Hormonal Contraceptives,HIV-protease inhibitors,70,92,114,136,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with <e1>Hormonal Contraceptives</e1>: Concomitant use of <e2>HIV-protease inhibitors</e2>, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",False,negative
Hormonal Contraceptives,griseofulvin,70,92,139,150,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with <e1>Hormonal Contraceptives</e1>: Concomitant use of HIV-protease inhibitors, <e2>griseofulvin</e2>, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",False,negative
Hormonal Contraceptives,modafinil,70,92,153,161,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with <e1>Hormonal Contraceptives</e1>: Concomitant use of HIV-protease inhibitors, griseofulvin, <e2>modafinil</e2>, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",False,negative
Hormonal Contraceptives,penicillins,70,92,164,174,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with <e1>Hormonal Contraceptives</e1>: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, <e2>penicillins</e2>, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",False,negative
Hormonal Contraceptives,rifampin,70,92,177,184,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with <e1>Hormonal Contraceptives</e1>: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, <e2>rifampin</e2>, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",False,negative
Hormonal Contraceptives,rifabutin,70,92,187,195,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with <e1>Hormonal Contraceptives</e1>: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, <e2>rifabutin</e2>, phenytoin, carbamazepine, or certain herbal supplements such as St. ",False,negative
Hormonal Contraceptives,phenytoin,70,92,198,206,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with <e1>Hormonal Contraceptives</e1>: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, <e2>phenytoin</e2>, carbamazepine, or certain herbal supplements such as St. ",False,negative
Hormonal Contraceptives,carbamazepine,70,92,209,221,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with <e1>Hormonal Contraceptives</e1>: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, <e2>carbamazepine</e2>, or certain herbal supplements such as St. ",False,negative
HIV-protease inhibitors,griseofulvin,114,136,139,150,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of <e1>HIV-protease inhibitors</e1>, <e2>griseofulvin</e2>, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",False,negative
HIV-protease inhibitors,modafinil,114,136,153,161,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of <e1>HIV-protease inhibitors</e1>, griseofulvin, <e2>modafinil</e2>, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",False,negative
HIV-protease inhibitors,penicillins,114,136,164,174,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of <e1>HIV-protease inhibitors</e1>, griseofulvin, modafinil, <e2>penicillins</e2>, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",False,negative
HIV-protease inhibitors,rifampin,114,136,177,184,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of <e1>HIV-protease inhibitors</e1>, griseofulvin, modafinil, penicillins, <e2>rifampin</e2>, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",False,negative
HIV-protease inhibitors,rifabutin,114,136,187,195,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of <e1>HIV-protease inhibitors</e1>, griseofulvin, modafinil, penicillins, rifampin, <e2>rifabutin</e2>, phenytoin, carbamazepine, or certain herbal supplements such as St. ",False,negative
HIV-protease inhibitors,phenytoin,114,136,198,206,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of <e1>HIV-protease inhibitors</e1>, griseofulvin, modafinil, penicillins, rifampin, rifabutin, <e2>phenytoin</e2>, carbamazepine, or certain herbal supplements such as St. ",False,negative
HIV-protease inhibitors,carbamazepine,114,136,209,221,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of <e1>HIV-protease inhibitors</e1>, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, <e2>carbamazepine</e2>, or certain herbal supplements such as St. ",False,negative
griseofulvin,modafinil,139,150,153,161,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, <e1>griseofulvin</e1>, <e2>modafinil</e2>, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",False,negative
griseofulvin,penicillins,139,150,164,174,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, <e1>griseofulvin</e1>, modafinil, <e2>penicillins</e2>, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",False,negative
griseofulvin,rifampin,139,150,177,184,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, <e1>griseofulvin</e1>, modafinil, penicillins, <e2>rifampin</e2>, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",False,negative
griseofulvin,rifabutin,139,150,187,195,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, <e1>griseofulvin</e1>, modafinil, penicillins, rifampin, <e2>rifabutin</e2>, phenytoin, carbamazepine, or certain herbal supplements such as St. ",False,negative
griseofulvin,phenytoin,139,150,198,206,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, <e1>griseofulvin</e1>, modafinil, penicillins, rifampin, rifabutin, <e2>phenytoin</e2>, carbamazepine, or certain herbal supplements such as St. ",False,negative
griseofulvin,carbamazepine,139,150,209,221,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, <e1>griseofulvin</e1>, modafinil, penicillins, rifampin, rifabutin, phenytoin, <e2>carbamazepine</e2>, or certain herbal supplements such as St. ",False,negative
modafinil,penicillins,153,161,164,174,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, <e1>modafinil</e1>, <e2>penicillins</e2>, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",False,negative
modafinil,rifampin,153,161,177,184,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, <e1>modafinil</e1>, penicillins, <e2>rifampin</e2>, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",False,negative
modafinil,rifabutin,153,161,187,195,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, <e1>modafinil</e1>, penicillins, rifampin, <e2>rifabutin</e2>, phenytoin, carbamazepine, or certain herbal supplements such as St. ",False,negative
modafinil,phenytoin,153,161,198,206,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, <e1>modafinil</e1>, penicillins, rifampin, rifabutin, <e2>phenytoin</e2>, carbamazepine, or certain herbal supplements such as St. ",False,negative
modafinil,carbamazepine,153,161,209,221,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, <e1>modafinil</e1>, penicillins, rifampin, rifabutin, phenytoin, <e2>carbamazepine</e2>, or certain herbal supplements such as St. ",False,negative
penicillins,rifampin,164,174,177,184,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, <e1>penicillins</e1>, <e2>rifampin</e2>, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",False,negative
penicillins,rifabutin,164,174,187,195,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, <e1>penicillins</e1>, rifampin, <e2>rifabutin</e2>, phenytoin, carbamazepine, or certain herbal supplements such as St. ",False,negative
penicillins,phenytoin,164,174,198,206,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, <e1>penicillins</e1>, rifampin, rifabutin, <e2>phenytoin</e2>, carbamazepine, or certain herbal supplements such as St. ",False,negative
penicillins,carbamazepine,164,174,209,221,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, <e1>penicillins</e1>, rifampin, rifabutin, phenytoin, <e2>carbamazepine</e2>, or certain herbal supplements such as St. ",False,negative
rifampin,rifabutin,177,184,187,195,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, <e1>rifampin</e1>, <e2>rifabutin</e2>, phenytoin, carbamazepine, or certain herbal supplements such as St. ",False,negative
rifampin,phenytoin,177,184,198,206,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, <e1>rifampin</e1>, rifabutin, <e2>phenytoin</e2>, carbamazepine, or certain herbal supplements such as St. ",False,negative
rifampin,carbamazepine,177,184,209,221,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, <e1>rifampin</e1>, rifabutin, phenytoin, <e2>carbamazepine</e2>, or certain herbal supplements such as St. ",False,negative
rifabutin,phenytoin,187,195,198,206,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, <e1>rifabutin</e1>, <e2>phenytoin</e2>, carbamazepine, or certain herbal supplements such as St. ",False,negative
rifabutin,carbamazepine,187,195,209,221,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, <e1>rifabutin</e1>, phenytoin, <e2>carbamazepine</e2>, or certain herbal supplements such as St. ",False,negative
phenytoin,carbamazepine,198,206,209,221,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, <e1>phenytoin</e1>, <e2>carbamazepine</e2>, or certain herbal supplements such as St. ",False,negative
John's Wort,hormonal contraceptive agents,0,10,17,45,<e1>John's Wort</e1> with <e2>hormonal contraceptive agents</e2> may reduce the effectiveness of the contraception and up to one month after discontinuation of these concomitant therapies. ,True,effect
Thiabendazole,theophylline,0,12,52,63,"<e1>Thiabendazole</e1> may compete with other drugs, such as <e2>theophylline</e2>, for sites of metabolism in the liver, thus elevating the serum levels of such compounds to potentially toxic levels. ",True,mechanism
thiabendazole,xanthine derivatives,35,47,53,72,"Therefore, when concomitant use of <e1>thiabendazole</e1> and <e2>xanthine derivatives</e2> is anticipated, it may be necessary to monitor blood levels and/or reduce the dosage of such compounds. ",True,advise
Vitamin B1,Thiamine,17,26,29,36,"Interactions for <e1>Vitamin B1</e1> (<e2>Thiamine</e2>):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",False,negative
Vitamin B1,Loop Diuretics,17,26,41,54,"Interactions for <e1>Vitamin B1</e1> (Thiamine):  <e2>Loop Diuretics</e2>, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",True,int
Vitamin B1,Contraceptives,17,26,62,75,"Interactions for <e1>Vitamin B1</e1> (Thiamine):  Loop Diuretics, Oral <e2>Contraceptives</e2>, Stavudine, Tricyclic Antidepressants",True,int
Vitamin B1,Stavudine,17,26,78,86,"Interactions for <e1>Vitamin B1</e1> (Thiamine):  Loop Diuretics, Oral Contraceptives, <e2>Stavudine</e2>, Tricyclic Antidepressants",True,int
Vitamin B1,Tricyclic Antidepressants,17,26,89,113,"Interactions for <e1>Vitamin B1</e1> (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, <e2>Tricyclic Antidepressants</e2>",True,int
Thiamine,Loop Diuretics,29,36,41,54,"Interactions for Vitamin B1 (<e1>Thiamine</e1>):  <e2>Loop Diuretics</e2>, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",True,int
Thiamine,Contraceptives,29,36,62,75,"Interactions for Vitamin B1 (<e1>Thiamine</e1>):  Loop Diuretics, Oral <e2>Contraceptives</e2>, Stavudine, Tricyclic Antidepressants",True,int
Thiamine,Stavudine,29,36,78,86,"Interactions for Vitamin B1 (<e1>Thiamine</e1>):  Loop Diuretics, Oral Contraceptives, <e2>Stavudine</e2>, Tricyclic Antidepressants",True,int
Thiamine,Tricyclic Antidepressants,29,36,89,113,"Interactions for Vitamin B1 (<e1>Thiamine</e1>):  Loop Diuretics, Oral Contraceptives, Stavudine, <e2>Tricyclic Antidepressants</e2>",True,int
Loop Diuretics,Contraceptives,41,54,62,75,"Interactions for Vitamin B1 (Thiamine):  <e1>Loop Diuretics</e1>, Oral <e2>Contraceptives</e2>, Stavudine, Tricyclic Antidepressants",False,negative
Loop Diuretics,Stavudine,41,54,78,86,"Interactions for Vitamin B1 (Thiamine):  <e1>Loop Diuretics</e1>, Oral Contraceptives, <e2>Stavudine</e2>, Tricyclic Antidepressants",False,negative
Loop Diuretics,Tricyclic Antidepressants,41,54,89,113,"Interactions for Vitamin B1 (Thiamine):  <e1>Loop Diuretics</e1>, Oral Contraceptives, Stavudine, <e2>Tricyclic Antidepressants</e2>",False,negative
Contraceptives,Stavudine,62,75,78,86,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral <e1>Contraceptives</e1>, <e2>Stavudine</e2>, Tricyclic Antidepressants",False,negative
Contraceptives,Tricyclic Antidepressants,62,75,89,113,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral <e1>Contraceptives</e1>, Stavudine, <e2>Tricyclic Antidepressants</e2>",False,negative
Stavudine,Tricyclic Antidepressants,78,86,89,113,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, <e1>Stavudine</e1>, <e2>Tricyclic Antidepressants</e2>",False,negative
Phenothiazines,CNS depressants,0,13,43,57,"<e1>Phenothiazines</e1> are capable of potentiating <e2>CNS depressants</e2> (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",True,effect
Phenothiazines,barbiturates,0,13,66,77,"<e1>Phenothiazines</e1> are capable of potentiating CNS depressants (e.g., <e2>barbiturates</e2>, anesthetics, opiates, alcohol, etc.) ",True,effect
Phenothiazines,anesthetics,0,13,80,90,"<e1>Phenothiazines</e1> are capable of potentiating CNS depressants (e.g., barbiturates, <e2>anesthetics</e2>, opiates, alcohol, etc.) ",True,effect
Phenothiazines,opiates,0,13,93,99,"<e1>Phenothiazines</e1> are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, <e2>opiates</e2>, alcohol, etc.) ",True,effect
Phenothiazines,alcohol,0,13,102,108,"<e1>Phenothiazines</e1> are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, <e2>alcohol</e2>, etc.) ",True,effect
CNS depressants,barbiturates,43,57,66,77,"Phenothiazines are capable of potentiating <e1>CNS depressants</e1> (e.g., <e2>barbiturates</e2>, anesthetics, opiates, alcohol, etc.) ",False,negative
CNS depressants,anesthetics,43,57,80,90,"Phenothiazines are capable of potentiating <e1>CNS depressants</e1> (e.g., barbiturates, <e2>anesthetics</e2>, opiates, alcohol, etc.) ",False,negative
CNS depressants,opiates,43,57,93,99,"Phenothiazines are capable of potentiating <e1>CNS depressants</e1> (e.g., barbiturates, anesthetics, <e2>opiates</e2>, alcohol, etc.) ",False,negative
CNS depressants,alcohol,43,57,102,108,"Phenothiazines are capable of potentiating <e1>CNS depressants</e1> (e.g., barbiturates, anesthetics, opiates, <e2>alcohol</e2>, etc.) ",False,negative
barbiturates,anesthetics,66,77,80,90,"Phenothiazines are capable of potentiating CNS depressants (e.g., <e1>barbiturates</e1>, <e2>anesthetics</e2>, opiates, alcohol, etc.) ",False,negative
barbiturates,opiates,66,77,93,99,"Phenothiazines are capable of potentiating CNS depressants (e.g., <e1>barbiturates</e1>, anesthetics, <e2>opiates</e2>, alcohol, etc.) ",False,negative
barbiturates,alcohol,66,77,102,108,"Phenothiazines are capable of potentiating CNS depressants (e.g., <e1>barbiturates</e1>, anesthetics, opiates, <e2>alcohol</e2>, etc.) ",False,negative
anesthetics,opiates,80,90,93,99,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, <e1>anesthetics</e1>, <e2>opiates</e2>, alcohol, etc.) ",False,negative
anesthetics,alcohol,80,90,102,108,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, <e1>anesthetics</e1>, opiates, <e2>alcohol</e2>, etc.) ",False,negative
opiates,alcohol,93,99,102,108,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, <e1>opiates</e1>, <e2>alcohol</e2>, etc.) ",False,negative
atropine,phosphorous insecticides,11,18,24,47,as well as <e1>atropine</e1> and <e2>phosphorous insecticides</e2>.,False,negative
PURINETHOL,mercaptopurine,51,60,63,76,There is usually complete cross-resistance between <e1>PURINETHOL</e1> (<e2>mercaptopurine</e2>) and TABLOID brand Thioguanine. ,False,negative
PURINETHOL,TABLOID,51,60,83,89,There is usually complete cross-resistance between <e1>PURINETHOL</e1> (mercaptopurine) and <e2>TABLOID</e2> brand Thioguanine. ,True,effect
PURINETHOL,Thioguanine,51,60,97,107,There is usually complete cross-resistance between <e1>PURINETHOL</e1> (mercaptopurine) and TABLOID brand <e2>Thioguanine</e2>. ,True,effect
mercaptopurine,TABLOID,63,76,83,89,There is usually complete cross-resistance between PURINETHOL (<e1>mercaptopurine</e1>) and <e2>TABLOID</e2> brand Thioguanine. ,True,effect
mercaptopurine,Thioguanine,63,76,97,107,There is usually complete cross-resistance between PURINETHOL (<e1>mercaptopurine</e1>) and TABLOID brand <e2>Thioguanine</e2>. ,True,effect
TABLOID,Thioguanine,83,89,97,107,There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and <e1>TABLOID</e1> brand <e2>Thioguanine</e2>. ,False,negative
aminosalicylate derivatives,olsalazine,35,61,70,79,"As there is in vitro evidence that <e1>aminosalicylate derivatives</e1> (e.g., <e2>olsalazine</e2>, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",False,negative
aminosalicylate derivatives,mesalazine,35,61,82,91,"As there is in vitro evidence that <e1>aminosalicylate derivatives</e1> (e.g., olsalazine, <e2>mesalazine</e2>, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",False,negative
aminosalicylate derivatives,sulphasalazine,35,61,97,110,"As there is in vitro evidence that <e1>aminosalicylate derivatives</e1> (e.g., olsalazine, mesalazine, or <e2>sulphasalazine</e2>) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",False,negative
aminosalicylate derivatives,thioguanine,35,61,212,222,"As there is in vitro evidence that <e1>aminosalicylate derivatives</e1> (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent <e2>thioguanine</e2> therapy.    ",True,mechanism
olsalazine,mesalazine,70,79,82,91,"As there is in vitro evidence that aminosalicylate derivatives (e.g., <e1>olsalazine</e1>, <e2>mesalazine</e2>, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",False,negative
olsalazine,sulphasalazine,70,79,97,110,"As there is in vitro evidence that aminosalicylate derivatives (e.g., <e1>olsalazine</e1>, mesalazine, or <e2>sulphasalazine</e2>) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",False,negative
olsalazine,thioguanine,70,79,212,222,"As there is in vitro evidence that aminosalicylate derivatives (e.g., <e1>olsalazine</e1>, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent <e2>thioguanine</e2> therapy.    ",True,mechanism
mesalazine,sulphasalazine,82,91,97,110,"As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, <e1>mesalazine</e1>, or <e2>sulphasalazine</e2>) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",False,negative
mesalazine,thioguanine,82,91,212,222,"As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, <e1>mesalazine</e1>, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent <e2>thioguanine</e2> therapy.    ",True,mechanism
sulphasalazine,thioguanine,97,110,212,222,"As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or <e1>sulphasalazine</e1>) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent <e2>thioguanine</e2> therapy.    ",True,mechanism
ZADAXIN,immunomodulating drugs,47,53,89,110,Caution should be exercised when administering <e1>ZADAXIN</e1> therapy in combination with other <e2>immunomodulating drugs</e2>. ,True,advise
tigecycline,warfarin,79,89,112,119,Prothrombin time or other suitable anticoagulation test should be monitored if <e1>tigecycline</e1> is administered with <e2>warfarin</e2>.   ,True,advise
antibacterial drugs,contraceptives,18,36,48,61,Concurrent use of <e1>antibacterial drugs</e1> with oral <e2>contraceptives</e2> may render oral contraceptives less effective.  ,True,effect
antibacterial drugs,contraceptives,18,36,79,92,Concurrent use of <e1>antibacterial drugs</e1> with oral contraceptives may render oral <e2>contraceptives</e2> less effective.  ,False,negative
contraceptives,contraceptives,48,61,79,92,Concurrent use of antibacterial drugs with oral <e1>contraceptives</e1> may render oral <e2>contraceptives</e2> less effective.  ,False,negative
SKELID,calcium,23,28,50,56,"The bioavailability of <e1>SKELID</e1> is decreased 80% by <e2>calcium</e2>, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",True,mechanism
SKELID,calcium,23,28,64,70,"The bioavailability of <e1>SKELID</e1> is decreased 80% by calcium, when <e2>calcium</e2> and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",False,negative
SKELID,SKELID,23,28,76,81,"The bioavailability of <e1>SKELID</e1> is decreased 80% by calcium, when calcium and <e2>SKELID</e2> are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",False,negative
SKELID,aluminum,23,28,134,141,"The bioavailability of <e1>SKELID</e1> is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some <e2>aluminum</e2>- or magnesium-containing antacids, when administered 1 hour before SKELID. ",False,negative
SKELID,magnesium,23,28,147,155,"The bioavailability of <e1>SKELID</e1> is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or <e2>magnesium</e2>-containing antacids, when administered 1 hour before SKELID. ",False,negative
SKELID,antacids,23,28,168,175,"The bioavailability of <e1>SKELID</e1> is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing <e2>antacids</e2>, when administered 1 hour before SKELID. ",False,negative
SKELID,SKELID,23,28,210,215,"The bioavailability of <e1>SKELID</e1> is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before <e2>SKELID</e2>. ",False,negative
calcium,calcium,50,56,64,70,"The bioavailability of SKELID is decreased 80% by <e1>calcium</e1>, when <e2>calcium</e2> and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",False,negative
calcium,SKELID,50,56,76,81,"The bioavailability of SKELID is decreased 80% by <e1>calcium</e1>, when calcium and <e2>SKELID</e2> are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",False,negative
calcium,aluminum,50,56,134,141,"The bioavailability of SKELID is decreased 80% by <e1>calcium</e1>, when calcium and SKELID are administered at the same time, and 60% by some <e2>aluminum</e2>- or magnesium-containing antacids, when administered 1 hour before SKELID. ",False,negative
calcium,magnesium,50,56,147,155,"The bioavailability of SKELID is decreased 80% by <e1>calcium</e1>, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or <e2>magnesium</e2>-containing antacids, when administered 1 hour before SKELID. ",False,negative
calcium,antacids,50,56,168,175,"The bioavailability of SKELID is decreased 80% by <e1>calcium</e1>, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing <e2>antacids</e2>, when administered 1 hour before SKELID. ",False,negative
calcium,SKELID,50,56,210,215,"The bioavailability of SKELID is decreased 80% by <e1>calcium</e1>, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before <e2>SKELID</e2>. ",False,negative
calcium,SKELID,64,70,76,81,"The bioavailability of SKELID is decreased 80% by calcium, when <e1>calcium</e1> and <e2>SKELID</e2> are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",False,negative
calcium,aluminum,64,70,134,141,"The bioavailability of SKELID is decreased 80% by calcium, when <e1>calcium</e1> and SKELID are administered at the same time, and 60% by some <e2>aluminum</e2>- or magnesium-containing antacids, when administered 1 hour before SKELID. ",False,negative
calcium,magnesium,64,70,147,155,"The bioavailability of SKELID is decreased 80% by calcium, when <e1>calcium</e1> and SKELID are administered at the same time, and 60% by some aluminum- or <e2>magnesium</e2>-containing antacids, when administered 1 hour before SKELID. ",False,negative
calcium,antacids,64,70,168,175,"The bioavailability of SKELID is decreased 80% by calcium, when <e1>calcium</e1> and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing <e2>antacids</e2>, when administered 1 hour before SKELID. ",False,negative
calcium,SKELID,64,70,210,215,"The bioavailability of SKELID is decreased 80% by calcium, when <e1>calcium</e1> and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before <e2>SKELID</e2>. ",False,negative
SKELID,aluminum,76,81,134,141,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and <e1>SKELID</e1> are administered at the same time, and 60% by some <e2>aluminum</e2>- or magnesium-containing antacids, when administered 1 hour before SKELID. ",False,negative
SKELID,magnesium,76,81,147,155,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and <e1>SKELID</e1> are administered at the same time, and 60% by some aluminum- or <e2>magnesium</e2>-containing antacids, when administered 1 hour before SKELID. ",False,negative
SKELID,antacids,76,81,168,175,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and <e1>SKELID</e1> are administered at the same time, and 60% by some aluminum- or magnesium-containing <e2>antacids</e2>, when administered 1 hour before SKELID. ",False,negative
SKELID,SKELID,76,81,210,215,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and <e1>SKELID</e1> are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before <e2>SKELID</e2>. ",False,negative
aluminum,magnesium,134,141,147,155,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some <e1>aluminum</e1>- or <e2>magnesium</e2>-containing antacids, when administered 1 hour before SKELID. ",False,negative
aluminum,antacids,134,141,168,175,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some <e1>aluminum</e1>- or magnesium-containing <e2>antacids</e2>, when administered 1 hour before SKELID. ",False,negative
aluminum,SKELID,134,141,210,215,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some <e1>aluminum</e1>- or magnesium-containing antacids, when administered 1 hour before <e2>SKELID</e2>. ",True,mechanism
magnesium,antacids,147,155,168,175,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or <e1>magnesium</e1>-containing <e2>antacids</e2>, when administered 1 hour before SKELID. ",False,negative
magnesium,SKELID,147,155,210,215,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or <e1>magnesium</e1>-containing antacids, when administered 1 hour before <e2>SKELID</e2>. ",True,mechanism
antacids,SKELID,168,175,210,215,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing <e1>antacids</e1>, when administered 1 hour before <e2>SKELID</e2>. ",False,negative
Aspirin,SKELID,0,6,40,45,<e1>Aspirin</e1> may decrease bioavailability of <e2>SKELID</e2> by up to 50% when taken 2 hours after SKELID. ,True,mechanism
Aspirin,SKELID,0,6,85,90,<e1>Aspirin</e1> may decrease bioavailability of SKELID by up to 50% when taken 2 hours after <e2>SKELID</e2>. ,False,negative
SKELID,SKELID,40,45,85,90,Aspirin may decrease bioavailability of <e1>SKELID</e1> by up to 50% when taken 2 hours after <e2>SKELID</e2>. ,False,negative
SKELID,indomethacin,23,28,55,66,The bioavailability of <e1>SKELID</e1> is increased 2-4 fold by <e2>indomethacin</e2> but is not significantly altered by coadministration of diclofenac. ,True,mechanism
SKELID,diclofenac,23,28,124,133,The bioavailability of <e1>SKELID</e1> is increased 2-4 fold by indomethacin but is not significantly altered by coadministration of <e2>diclofenac</e2>. ,False,negative
indomethacin,diclofenac,55,66,124,133,The bioavailability of SKELID is increased 2-4 fold by <e1>indomethacin</e1> but is not significantly altered by coadministration of <e2>diclofenac</e2>. ,False,negative
digoxin,SKELID,34,40,76,81,The pharmacokinetic parameters of <e1>digoxin</e1> are not significantly modified by <e2>SKELID</e2> coadministration. ,False,negative
tiludronate,warfarin,27,37,57,64,In vitro studies show that <e1>tiludronate</e1> does not displace <e2>warfarin</e2> from its binding site on protein.,False,negative
sympathomimetic bronchodilators,methylxanthines,14,44,47,61,"These include <e1>sympathomimetic bronchodilators</e1>, <e2>methylxanthines</e2>, and oral and inhaled steroids. ",False,negative
sympathomimetic bronchodilators,steroids,14,44,85,92,"These include <e1>sympathomimetic bronchodilators</e1>, methylxanthines, and oral and inhaled <e2>steroids</e2>. ",False,negative
methylxanthines,steroids,47,61,85,92,"These include sympathomimetic bronchodilators, <e1>methylxanthines</e1>, and oral and inhaled <e2>steroids</e2>. ",False,negative
SPIRIVA,anticholinergic,36,42,55,69,"However, the co   administration of <e1>SPIRIVA</e1> with other <e2>anticholinergic</e2>   containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended.",True,advise
SPIRIVA,ipratropium,36,42,97,107,"However, the co   administration of <e1>SPIRIVA</e1> with other anticholinergic   containing drugs (e.g., <e2>ipratropium</e2>) has not been studied and is therefore not recommended.",True,advise
anticholinergic,ipratropium,55,69,97,107,"However, the co   administration of SPIRIVA with other <e1>anticholinergic</e1>   containing drugs (e.g., <e2>ipratropium</e2>) has not been studied and is therefore not recommended.",False,negative
AGGRASTAT,aspirin,0,8,46,52,<e1>AGGRASTAT</e1> has been studied on a background of <e2>aspirin</e2> and heparin. ,False,negative
AGGRASTAT,heparin,0,8,58,64,<e1>AGGRASTAT</e1> has been studied on a background of aspirin and <e2>heparin</e2>. ,False,negative
aspirin,heparin,46,52,58,64,AGGRASTAT has been studied on a background of <e1>aspirin</e1> and <e2>heparin</e2>. ,False,negative
AGGRASTAT,heparin,11,19,42,48,"The use of <e1>AGGRASTAT</e1>, in combination with <e2>heparin</e2> and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see",True,effect
AGGRASTAT,aspirin,11,19,54,60,"The use of <e1>AGGRASTAT</e1>, in combination with heparin and <e2>aspirin</e2>, has been associated with an increase in bleeding compared to heparin and aspirin alone (see",True,effect
AGGRASTAT,heparin,11,19,124,130,"The use of <e1>AGGRASTAT</e1>, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to <e2>heparin</e2> and aspirin alone (see",False,negative
AGGRASTAT,aspirin,11,19,136,142,"The use of <e1>AGGRASTAT</e1>, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and <e2>aspirin</e2> alone (see",False,negative
heparin,aspirin,42,48,54,60,"The use of AGGRASTAT, in combination with <e1>heparin</e1> and <e2>aspirin</e2>, has been associated with an increase in bleeding compared to heparin and aspirin alone (see",False,negative
heparin,heparin,42,48,124,130,"The use of AGGRASTAT, in combination with <e1>heparin</e1> and aspirin, has been associated with an increase in bleeding compared to <e2>heparin</e2> and aspirin alone (see",False,negative
heparin,aspirin,42,48,136,142,"The use of AGGRASTAT, in combination with <e1>heparin</e1> and aspirin, has been associated with an increase in bleeding compared to heparin and <e2>aspirin</e2> alone (see",False,negative
aspirin,heparin,54,60,124,130,"The use of AGGRASTAT, in combination with heparin and <e1>aspirin</e1>, has been associated with an increase in bleeding compared to <e2>heparin</e2> and aspirin alone (see",False,negative
aspirin,aspirin,54,60,136,142,"The use of AGGRASTAT, in combination with heparin and <e1>aspirin</e1>, has been associated with an increase in bleeding compared to heparin and <e2>aspirin</e2> alone (see",False,negative
heparin,aspirin,124,130,136,142,"The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to <e1>heparin</e1> and <e2>aspirin</e2> alone (see",False,negative
TOBI,TOBI,23,26,45,48,"In clinical studies of <e1>TOBI</e1>, patients taking <e2>TOBI</e2> concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",False,negative
TOBI,dornase alfa,23,26,69,80,"In clinical studies of <e1>TOBI</e1>, patients taking TOBI concomitantly with <e2>dornase alfa</e2> (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",False,negative
TOBI,PULMOZYME,23,26,83,91,"In clinical studies of <e1>TOBI</e1>, patients taking TOBI concomitantly with dornase alfa (<e2>PULMOZYME</e2>   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",False,negative
TOBI,(beta)-agonists,23,26,109,123,"In clinical studies of <e1>TOBI</e1>, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), <e2>(beta)-agonists</e2>, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",False,negative
TOBI,corticosteroids,23,26,134,148,"In clinical studies of <e1>TOBI</e1>, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled <e2>corticosteroids</e2>, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",False,negative
TOBI,anti-pseudomonal antibiotics,23,26,157,184,"In clinical studies of <e1>TOBI</e1>, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other <e2>anti-pseudomonal antibiotics</e2>, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",False,negative
TOBI,aminoglycosides,23,26,201,215,"In clinical studies of <e1>TOBI</e1>, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral <e2>aminoglycosides</e2> demonstrated adverse experience profiles similar to the study population as a whole. ",False,negative
TOBI,dornase alfa,45,48,69,80,"In clinical studies of TOBI, patients taking <e1>TOBI</e1> concomitantly with <e2>dornase alfa</e2> (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",True,effect
TOBI,PULMOZYME,45,48,83,91,"In clinical studies of TOBI, patients taking <e1>TOBI</e1> concomitantly with dornase alfa (<e2>PULMOZYME</e2>   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",True,effect
TOBI,(beta)-agonists,45,48,109,123,"In clinical studies of TOBI, patients taking <e1>TOBI</e1> concomitantly with dornase alfa (PULMOZYME   , Genentech), <e2>(beta)-agonists</e2>, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",True,effect
TOBI,corticosteroids,45,48,134,148,"In clinical studies of TOBI, patients taking <e1>TOBI</e1> concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled <e2>corticosteroids</e2>, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",True,effect
TOBI,anti-pseudomonal antibiotics,45,48,157,184,"In clinical studies of TOBI, patients taking <e1>TOBI</e1> concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other <e2>anti-pseudomonal antibiotics</e2>, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",True,effect
TOBI,aminoglycosides,45,48,201,215,"In clinical studies of TOBI, patients taking <e1>TOBI</e1> concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral <e2>aminoglycosides</e2> demonstrated adverse experience profiles similar to the study population as a whole. ",True,effect
dornase alfa,PULMOZYME,69,80,83,91,"In clinical studies of TOBI, patients taking TOBI concomitantly with <e1>dornase alfa</e1> (<e2>PULMOZYME</e2>   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",False,negative
dornase alfa,(beta)-agonists,69,80,109,123,"In clinical studies of TOBI, patients taking TOBI concomitantly with <e1>dornase alfa</e1> (PULMOZYME   , Genentech), <e2>(beta)-agonists</e2>, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",False,negative
dornase alfa,corticosteroids,69,80,134,148,"In clinical studies of TOBI, patients taking TOBI concomitantly with <e1>dornase alfa</e1> (PULMOZYME   , Genentech), (beta)-agonists, inhaled <e2>corticosteroids</e2>, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",False,negative
dornase alfa,anti-pseudomonal antibiotics,69,80,157,184,"In clinical studies of TOBI, patients taking TOBI concomitantly with <e1>dornase alfa</e1> (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other <e2>anti-pseudomonal antibiotics</e2>, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",False,negative
dornase alfa,aminoglycosides,69,80,201,215,"In clinical studies of TOBI, patients taking TOBI concomitantly with <e1>dornase alfa</e1> (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral <e2>aminoglycosides</e2> demonstrated adverse experience profiles similar to the study population as a whole. ",False,negative
PULMOZYME,(beta)-agonists,83,91,109,123,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (<e1>PULMOZYME</e1>   , Genentech), <e2>(beta)-agonists</e2>, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",False,negative
PULMOZYME,corticosteroids,83,91,134,148,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (<e1>PULMOZYME</e1>   , Genentech), (beta)-agonists, inhaled <e2>corticosteroids</e2>, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",False,negative
PULMOZYME,anti-pseudomonal antibiotics,83,91,157,184,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (<e1>PULMOZYME</e1>   , Genentech), (beta)-agonists, inhaled corticosteroids, other <e2>anti-pseudomonal antibiotics</e2>, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",False,negative
PULMOZYME,aminoglycosides,83,91,201,215,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (<e1>PULMOZYME</e1>   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral <e2>aminoglycosides</e2> demonstrated adverse experience profiles similar to the study population as a whole. ",False,negative
(beta)-agonists,corticosteroids,109,123,134,148,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), <e1>(beta)-agonists</e1>, inhaled <e2>corticosteroids</e2>, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",False,negative
(beta)-agonists,anti-pseudomonal antibiotics,109,123,157,184,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), <e1>(beta)-agonists</e1>, inhaled corticosteroids, other <e2>anti-pseudomonal antibiotics</e2>, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",False,negative
(beta)-agonists,aminoglycosides,109,123,201,215,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), <e1>(beta)-agonists</e1>, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral <e2>aminoglycosides</e2> demonstrated adverse experience profiles similar to the study population as a whole. ",False,negative
corticosteroids,anti-pseudomonal antibiotics,134,148,157,184,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled <e1>corticosteroids</e1>, other <e2>anti-pseudomonal antibiotics</e2>, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",False,negative
corticosteroids,aminoglycosides,134,148,201,215,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled <e1>corticosteroids</e1>, other anti-pseudomonal antibiotics, or parenteral <e2>aminoglycosides</e2> demonstrated adverse experience profiles similar to the study population as a whole. ",False,negative
anti-pseudomonal antibiotics,aminoglycosides,157,184,201,215,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other <e1>anti-pseudomonal antibiotics</e1>, or parenteral <e2>aminoglycosides</e2> demonstrated adverse experience profiles similar to the study population as a whole. ",False,negative
diuretics,aminoglycoside,5,13,27,40,Some <e1>diuretics</e1> can enhance <e2>aminoglycoside</e2> toxicity by altering antibiotic concentrations in serum and tissue. ,True,effect
diuretics,antibiotic,5,13,63,72,Some <e1>diuretics</e1> can enhance aminoglycoside toxicity by altering <e2>antibiotic</e2> concentrations in serum and tissue. ,False,negative
aminoglycoside,antibiotic,27,40,63,72,Some diuretics can enhance <e1>aminoglycoside</e1> toxicity by altering <e2>antibiotic</e2> concentrations in serum and tissue. ,False,negative
TOBI,ethacrynic acid,0,3,51,65,"<e1>TOBI</e1> should not be administered concomitantly with <e2>ethacrynic acid</e2>, furosemide, urea, or mannitol.",True,advise
TOBI,furosemide,0,3,68,77,"<e1>TOBI</e1> should not be administered concomitantly with ethacrynic acid, <e2>furosemide</e2>, urea, or mannitol.",True,advise
TOBI,urea,0,3,80,83,"<e1>TOBI</e1> should not be administered concomitantly with ethacrynic acid, furosemide, <e2>urea</e2>, or mannitol.",True,advise
TOBI,mannitol,0,3,89,96,"<e1>TOBI</e1> should not be administered concomitantly with ethacrynic acid, furosemide, urea, or <e2>mannitol</e2>.",True,advise
ethacrynic acid,furosemide,51,65,68,77,"TOBI should not be administered concomitantly with <e1>ethacrynic acid</e1>, <e2>furosemide</e2>, urea, or mannitol.",False,negative
ethacrynic acid,urea,51,65,80,83,"TOBI should not be administered concomitantly with <e1>ethacrynic acid</e1>, furosemide, <e2>urea</e2>, or mannitol.",False,negative
ethacrynic acid,mannitol,51,65,89,96,"TOBI should not be administered concomitantly with <e1>ethacrynic acid</e1>, furosemide, urea, or <e2>mannitol</e2>.",False,negative
furosemide,urea,68,77,80,83,"TOBI should not be administered concomitantly with ethacrynic acid, <e1>furosemide</e1>, <e2>urea</e2>, or mannitol.",False,negative
furosemide,mannitol,68,77,89,96,"TOBI should not be administered concomitantly with ethacrynic acid, <e1>furosemide</e1>, urea, or <e2>mannitol</e2>.",False,negative
urea,mannitol,80,83,89,96,"TOBI should not be administered concomitantly with ethacrynic acid, furosemide, <e1>urea</e1>, or <e2>mannitol</e2>.",False,negative
warfarin,tolmetin,24,31,75,82,"The in vitro binding of <e1>warfarin</e1> to human plasma proteins is unaffected by <e2>tolmetin</e2>, and tolmetin does not alter the prothrombin time of normal volunteers. ",False,negative
warfarin,tolmetin,24,31,89,96,"The in vitro binding of <e1>warfarin</e1> to human plasma proteins is unaffected by tolmetin, and <e2>tolmetin</e2> does not alter the prothrombin time of normal volunteers. ",False,negative
tolmetin,tolmetin,75,82,89,96,"The in vitro binding of warfarin to human plasma proteins is unaffected by <e1>tolmetin</e1>, and <e2>tolmetin</e2> does not alter the prothrombin time of normal volunteers. ",False,negative
TOLECTIN,warfarin,95,102,108,115,"However, increased prothrombin time and bleeding have been reported in patients on concomitant <e1>TOLECTIN</e1> and <e2>warfarin</e2> therapy. ",True,effect
TOLECTIN,anticoagulants,58,65,82,95,"Therefore, caution should be exercised when administering <e1>TOLECTIN</e1> to patients on <e2>anticoagulants</e2>. ",True,advise
sulfonylureas,insulin,55,67,72,78,In adult diabetic patients under treatment with either <e1>sulfonylureas</e1> or <e2>insulin</e2> there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents. ,False,negative
sulfonylureas,TOLECTIN,55,67,133,140,In adult diabetic patients under treatment with either <e1>sulfonylureas</e1> or insulin there is no change in the clinical effects of either <e2>TOLECTIN</e2> or the hypoglycemic agents. ,False,negative
sulfonylureas,hypoglycemic agents,55,67,149,167,In adult diabetic patients under treatment with either <e1>sulfonylureas</e1> or insulin there is no change in the clinical effects of either TOLECTIN or the <e2>hypoglycemic agents</e2>. ,False,negative
insulin,TOLECTIN,72,78,133,140,In adult diabetic patients under treatment with either sulfonylureas or <e1>insulin</e1> there is no change in the clinical effects of either <e2>TOLECTIN</e2> or the hypoglycemic agents. ,False,negative
insulin,hypoglycemic agents,72,78,149,167,In adult diabetic patients under treatment with either sulfonylureas or <e1>insulin</e1> there is no change in the clinical effects of either TOLECTIN or the <e2>hypoglycemic agents</e2>. ,False,negative
TOLECTIN,hypoglycemic agents,133,140,149,167,In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either <e1>TOLECTIN</e1> or the <e2>hypoglycemic agents</e2>. ,False,negative
TOLECTIN,methotrexate,26,33,70,81,Caution should be used if <e1>TOLECTIN</e1> is administered concomitantly with <e2>methotrexate</e2>. ,True,advise
TOLECTIN,nonsteroidal anti-inflammatory drugs,0,7,19,54,"<e1>TOLECTIN</e1> and other <e2>nonsteroidal anti-inflammatory drugs</e2> have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. ",False,negative
TOLECTIN,methotrexate,0,7,110,121,"<e1>TOLECTIN</e1> and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of <e2>methotrexate</e2> in an animal model, possibly enhancing the toxicity of methotrexate. ",True,mechanism
TOLECTIN,methotrexate,0,7,178,189,"<e1>TOLECTIN</e1> and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of <e2>methotrexate</e2>. ",False,negative
nonsteroidal anti-inflammatory drugs,methotrexate,19,54,110,121,"TOLECTIN and other <e1>nonsteroidal anti-inflammatory drugs</e1> have been reported to reduce the tubular secretion of <e2>methotrexate</e2> in an animal model, possibly enhancing the toxicity of methotrexate. ",True,mechanism
nonsteroidal anti-inflammatory drugs,methotrexate,19,54,178,189,"TOLECTIN and other <e1>nonsteroidal anti-inflammatory drugs</e1> have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of <e2>methotrexate</e2>. ",False,negative
methotrexate,methotrexate,110,121,178,189,"TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of <e1>methotrexate</e1> in an animal model, possibly enhancing the toxicity of <e2>methotrexate</e2>. ",False,negative
Ketoconazole,tolterodine,19,30,135,145,"CYP3A4 Inhibitors: <e1>Ketoconazole</e1>, an inhibitor of the drug metabolizing enzyme CYP3A4, significantly increased plasma concentrations of <e2>tolterodine</e2> when coadministered to subjects who were poor metabolizers (see CLINICAL PHARMACOLOGY, Variability in Metabolism and Drug-Drug Interactions). ",True,mechanism
ketoconazole,azole antifungals,23,34,84,100,"For patients receiving <e1>ketoconazole</e1> or other potent CYP3A4 inhibitors such as other <e2>azole antifungals</e2> (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",False,negative
ketoconazole,itraconazole,23,34,107,118,"For patients receiving <e1>ketoconazole</e1> or other potent CYP3A4 inhibitors such as other azole antifungals (eg, <e2>itraconazole</e2>, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",False,negative
ketoconazole,miconazole,23,34,121,130,"For patients receiving <e1>ketoconazole</e1> or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, <e2>miconazole</e2>) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",False,negative
ketoconazole,macrolide antibiotics,23,34,136,156,"For patients receiving <e1>ketoconazole</e1> or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or <e2>macrolide antibiotics</e2> (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",False,negative
ketoconazole,erythromycin,23,34,163,174,"For patients receiving <e1>ketoconazole</e1> or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, <e2>erythromycin</e2>, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",False,negative
ketoconazole,clarithromycin,23,34,177,190,"For patients receiving <e1>ketoconazole</e1> or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, <e2>clarithromycin</e2>) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",False,negative
ketoconazole,cyclosporine,23,34,196,207,"For patients receiving <e1>ketoconazole</e1> or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or <e2>cyclosporine</e2> or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",False,negative
ketoconazole,vinblastine,23,34,212,222,"For patients receiving <e1>ketoconazole</e1> or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or <e2>vinblastine</e2>, the recommended dose of DETROL LA is 2 mg daily. ",False,negative
ketoconazole,DETROL LA,23,34,249,257,"For patients receiving <e1>ketoconazole</e1> or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of <e2>DETROL LA</e2> is 2 mg daily. ",True,advise
azole antifungals,itraconazole,84,100,107,118,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other <e1>azole antifungals</e1> (eg, <e2>itraconazole</e2>, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",False,negative
azole antifungals,miconazole,84,100,121,130,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other <e1>azole antifungals</e1> (eg, itraconazole, <e2>miconazole</e2>) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",False,negative
azole antifungals,macrolide antibiotics,84,100,136,156,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other <e1>azole antifungals</e1> (eg, itraconazole, miconazole) or <e2>macrolide antibiotics</e2> (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",False,negative
azole antifungals,erythromycin,84,100,163,174,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other <e1>azole antifungals</e1> (eg, itraconazole, miconazole) or macrolide antibiotics (eg, <e2>erythromycin</e2>, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",False,negative
azole antifungals,clarithromycin,84,100,177,190,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other <e1>azole antifungals</e1> (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, <e2>clarithromycin</e2>) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",False,negative
azole antifungals,cyclosporine,84,100,196,207,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other <e1>azole antifungals</e1> (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or <e2>cyclosporine</e2> or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",False,negative
azole antifungals,vinblastine,84,100,212,222,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other <e1>azole antifungals</e1> (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or <e2>vinblastine</e2>, the recommended dose of DETROL LA is 2 mg daily. ",False,negative
azole antifungals,DETROL LA,84,100,249,257,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other <e1>azole antifungals</e1> (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of <e2>DETROL LA</e2> is 2 mg daily. ",True,advise
itraconazole,miconazole,107,118,121,130,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, <e1>itraconazole</e1>, <e2>miconazole</e2>) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",False,negative
itraconazole,macrolide antibiotics,107,118,136,156,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, <e1>itraconazole</e1>, miconazole) or <e2>macrolide antibiotics</e2> (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",False,negative
itraconazole,erythromycin,107,118,163,174,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, <e1>itraconazole</e1>, miconazole) or macrolide antibiotics (eg, <e2>erythromycin</e2>, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",False,negative
itraconazole,clarithromycin,107,118,177,190,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, <e1>itraconazole</e1>, miconazole) or macrolide antibiotics (eg, erythromycin, <e2>clarithromycin</e2>) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",False,negative
itraconazole,cyclosporine,107,118,196,207,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, <e1>itraconazole</e1>, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or <e2>cyclosporine</e2> or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",False,negative
itraconazole,vinblastine,107,118,212,222,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, <e1>itraconazole</e1>, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or <e2>vinblastine</e2>, the recommended dose of DETROL LA is 2 mg daily. ",False,negative
itraconazole,DETROL LA,107,118,249,257,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, <e1>itraconazole</e1>, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of <e2>DETROL LA</e2> is 2 mg daily. ",True,advise
miconazole,macrolide antibiotics,121,130,136,156,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, <e1>miconazole</e1>) or <e2>macrolide antibiotics</e2> (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",False,negative
miconazole,erythromycin,121,130,163,174,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, <e1>miconazole</e1>) or macrolide antibiotics (eg, <e2>erythromycin</e2>, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",False,negative
miconazole,clarithromycin,121,130,177,190,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, <e1>miconazole</e1>) or macrolide antibiotics (eg, erythromycin, <e2>clarithromycin</e2>) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",False,negative
miconazole,cyclosporine,121,130,196,207,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, <e1>miconazole</e1>) or macrolide antibiotics (eg, erythromycin, clarithromycin) or <e2>cyclosporine</e2> or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",False,negative
miconazole,vinblastine,121,130,212,222,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, <e1>miconazole</e1>) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or <e2>vinblastine</e2>, the recommended dose of DETROL LA is 2 mg daily. ",False,negative
miconazole,DETROL LA,121,130,249,257,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, <e1>miconazole</e1>) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of <e2>DETROL LA</e2> is 2 mg daily. ",True,advise
macrolide antibiotics,erythromycin,136,156,163,174,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or <e1>macrolide antibiotics</e1> (eg, <e2>erythromycin</e2>, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",False,negative
macrolide antibiotics,clarithromycin,136,156,177,190,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or <e1>macrolide antibiotics</e1> (eg, erythromycin, <e2>clarithromycin</e2>) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",False,negative
macrolide antibiotics,cyclosporine,136,156,196,207,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or <e1>macrolide antibiotics</e1> (eg, erythromycin, clarithromycin) or <e2>cyclosporine</e2> or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",False,negative
macrolide antibiotics,vinblastine,136,156,212,222,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or <e1>macrolide antibiotics</e1> (eg, erythromycin, clarithromycin) or cyclosporine or <e2>vinblastine</e2>, the recommended dose of DETROL LA is 2 mg daily. ",False,negative
macrolide antibiotics,DETROL LA,136,156,249,257,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or <e1>macrolide antibiotics</e1> (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of <e2>DETROL LA</e2> is 2 mg daily. ",True,advise
erythromycin,clarithromycin,163,174,177,190,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, <e1>erythromycin</e1>, <e2>clarithromycin</e2>) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",False,negative
erythromycin,cyclosporine,163,174,196,207,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, <e1>erythromycin</e1>, clarithromycin) or <e2>cyclosporine</e2> or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",False,negative
erythromycin,vinblastine,163,174,212,222,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, <e1>erythromycin</e1>, clarithromycin) or cyclosporine or <e2>vinblastine</e2>, the recommended dose of DETROL LA is 2 mg daily. ",False,negative
erythromycin,DETROL LA,163,174,249,257,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, <e1>erythromycin</e1>, clarithromycin) or cyclosporine or vinblastine, the recommended dose of <e2>DETROL LA</e2> is 2 mg daily. ",True,advise
clarithromycin,cyclosporine,177,190,196,207,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, <e1>clarithromycin</e1>) or <e2>cyclosporine</e2> or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",False,negative
clarithromycin,vinblastine,177,190,212,222,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, <e1>clarithromycin</e1>) or cyclosporine or <e2>vinblastine</e2>, the recommended dose of DETROL LA is 2 mg daily. ",False,negative
clarithromycin,DETROL LA,177,190,249,257,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, <e1>clarithromycin</e1>) or cyclosporine or vinblastine, the recommended dose of <e2>DETROL LA</e2> is 2 mg daily. ",True,advise
cyclosporine,vinblastine,196,207,212,222,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or <e1>cyclosporine</e1> or <e2>vinblastine</e2>, the recommended dose of DETROL LA is 2 mg daily. ",False,negative
cyclosporine,DETROL LA,196,207,249,257,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or <e1>cyclosporine</e1> or vinblastine, the recommended dose of <e2>DETROL LA</e2> is 2 mg daily. ",True,advise
vinblastine,DETROL LA,212,222,249,257,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or <e1>vinblastine</e1>, the recommended dose of <e2>DETROL LA</e2> is 2 mg daily. ",True,advise
paclitaxel,HERCEPTIN,18,27,49,57,Administration of <e1>paclitaxel</e1> in combination with <e2>HERCEPTIN</e2> resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.,True,mechanism
paclitaxel,HERCEPTIN,18,27,94,102,Administration of <e1>paclitaxel</e1> in combination with HERCEPTIN resulted in a two-fold decrease in <e2>HERCEPTIN</e2> clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.,False,negative
paclitaxel,HERCEPTIN,18,27,173,181,Administration of <e1>paclitaxel</e1> in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in <e2>HERCEPTIN</e2> serum levels in clinical studies.,False,negative
HERCEPTIN,HERCEPTIN,49,57,94,102,Administration of paclitaxel in combination with <e1>HERCEPTIN</e1> resulted in a two-fold decrease in <e2>HERCEPTIN</e2> clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.,False,negative
HERCEPTIN,HERCEPTIN,49,57,173,181,Administration of paclitaxel in combination with <e1>HERCEPTIN</e1> resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in <e2>HERCEPTIN</e2> serum levels in clinical studies.,False,negative
HERCEPTIN,HERCEPTIN,94,102,173,181,Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in <e1>HERCEPTIN</e1> clearance in a non-human primate study and in a 1.5-fold increase in <e2>HERCEPTIN</e2> serum levels in clinical studies.,False,negative
Trilostane,aminoglutethimide,0,9,29,45,<e1>Trilostane</e1> may interact with <e2>aminoglutethimide</e2> or mitotane (causing too great a decrease in adrenal function).,True,int
Trilostane,mitotane,0,9,50,57,<e1>Trilostane</e1> may interact with aminoglutethimide or <e2>mitotane</e2> (causing too great a decrease in adrenal function).,True,int
aminoglutethimide,mitotane,29,45,50,57,Trilostane may interact with <e1>aminoglutethimide</e1> or <e2>mitotane</e2> (causing too great a decrease in adrenal function).,False,negative
Trimethoprim,phenytoin,0,11,51,59,<e1>Trimethoprim</e1> may inhibit the hepatic metabolism of <e2>phenytoin</e2>. ,True,mechanism
Trimethoprim,phenytoin,0,11,63,71,"<e1>Trimethoprim</e1>, given at a common clinical dosage, increased the <e2>phenytoin</e2> half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%. ",True,mechanism
Trimethoprim,phenytoin,0,11,108,116,"<e1>Trimethoprim</e1>, given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the <e2>phenytoin</e2> metabolic clearance rate by 30%. ",True,mechanism
phenytoin,phenytoin,63,71,108,116,"Trimethoprim, given at a common clinical dosage, increased the <e1>phenytoin</e1> half-life by 51% and decreased the <e2>phenytoin</e2> metabolic clearance rate by 30%. ",False,negative
trimetrexate,trimetrexate,6,17,184,195,"Since <e1>trimetrexate</e1> is metabolized by a P450 enzyme system, drugs that induce or inhibit this drug metabolizing enzyme system may elicit important drug-drug interactions that may alter <e2>trimetrexate</e2> plasma concentrations. ",False,negative
trimetrexate,erythromycin,41,52,133,144,"Agents that might be coadministered with <e1>trimetrexate</e1> in AIDS patients for other indications that could elicit this activity include <e2>erythromycin</e2>, rifampin, rifabutin, ketoconazole, and fluconazole. ",True,effect
trimetrexate,rifampin,41,52,147,154,"Agents that might be coadministered with <e1>trimetrexate</e1> in AIDS patients for other indications that could elicit this activity include erythromycin, <e2>rifampin</e2>, rifabutin, ketoconazole, and fluconazole. ",True,effect
trimetrexate,rifabutin,41,52,157,165,"Agents that might be coadministered with <e1>trimetrexate</e1> in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, <e2>rifabutin</e2>, ketoconazole, and fluconazole. ",True,effect
trimetrexate,ketoconazole,41,52,168,179,"Agents that might be coadministered with <e1>trimetrexate</e1> in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, <e2>ketoconazole</e2>, and fluconazole. ",True,effect
trimetrexate,fluconazole,41,52,186,196,"Agents that might be coadministered with <e1>trimetrexate</e1> in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and <e2>fluconazole</e2>. ",True,effect
erythromycin,rifampin,133,144,147,154,"Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include <e1>erythromycin</e1>, <e2>rifampin</e2>, rifabutin, ketoconazole, and fluconazole. ",False,negative
erythromycin,rifabutin,133,144,157,165,"Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include <e1>erythromycin</e1>, rifampin, <e2>rifabutin</e2>, ketoconazole, and fluconazole. ",False,negative
erythromycin,ketoconazole,133,144,168,179,"Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include <e1>erythromycin</e1>, rifampin, rifabutin, <e2>ketoconazole</e2>, and fluconazole. ",False,negative
erythromycin,fluconazole,133,144,186,196,"Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include <e1>erythromycin</e1>, rifampin, rifabutin, ketoconazole, and <e2>fluconazole</e2>. ",False,negative
rifampin,rifabutin,147,154,157,165,"Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, <e1>rifampin</e1>, <e2>rifabutin</e2>, ketoconazole, and fluconazole. ",False,negative
rifampin,ketoconazole,147,154,168,179,"Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, <e1>rifampin</e1>, rifabutin, <e2>ketoconazole</e2>, and fluconazole. ",False,negative
rifampin,fluconazole,147,154,186,196,"Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, <e1>rifampin</e1>, rifabutin, ketoconazole, and <e2>fluconazole</e2>. ",False,negative
rifabutin,ketoconazole,157,165,168,179,"Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, <e1>rifabutin</e1>, <e2>ketoconazole</e2>, and fluconazole. ",False,negative
rifabutin,fluconazole,157,165,186,196,"Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, <e1>rifabutin</e1>, ketoconazole, and <e2>fluconazole</e2>. ",False,negative
ketoconazole,fluconazole,168,179,186,196,"Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, <e1>ketoconazole</e1>, and <e2>fluconazole</e2>. ",False,negative
cimetidine,trimetrexate,56,65,101,112,In vitro perfusion of isolated rat liver has shown that <e1>cimetidine</e1> caused a significant reduction in <e2>trimetrexate</e2> metabolism and that acetaminophen altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites. ,True,mechanism
cimetidine,acetaminophen,56,65,134,146,In vitro perfusion of isolated rat liver has shown that <e1>cimetidine</e1> caused a significant reduction in trimetrexate metabolism and that <e2>acetaminophen</e2> altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites. ,False,negative
trimetrexate,acetaminophen,101,112,134,146,In vitro perfusion of isolated rat liver has shown that cimetidine caused a significant reduction in <e1>trimetrexate</e1> metabolism and that <e2>acetaminophen</e2> altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites. ,False,negative
imidazole drugs,clotrimazole,59,73,76,87,"Based on an in vitro rat liver model, nitrogen substituted <e1>imidazole drugs</e1> (<e2>clotrimazole</e2>, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. ",False,negative
imidazole drugs,ketoconazole,59,73,90,101,"Based on an in vitro rat liver model, nitrogen substituted <e1>imidazole drugs</e1> (clotrimazole, <e2>ketoconazole</e2>, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. ",False,negative
imidazole drugs,miconazole,59,73,104,113,"Based on an in vitro rat liver model, nitrogen substituted <e1>imidazole drugs</e1> (clotrimazole, ketoconazole, <e2>miconazole</e2>) were potent, non-competitive inhibitors of trimetrexate metabolism. ",False,negative
imidazole drugs,trimetrexate,59,73,159,170,"Based on an in vitro rat liver model, nitrogen substituted <e1>imidazole drugs</e1> (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of <e2>trimetrexate</e2> metabolism. ",True,mechanism
clotrimazole,ketoconazole,76,87,90,101,"Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (<e1>clotrimazole</e1>, <e2>ketoconazole</e2>, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. ",False,negative
clotrimazole,miconazole,76,87,104,113,"Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (<e1>clotrimazole</e1>, ketoconazole, <e2>miconazole</e2>) were potent, non-competitive inhibitors of trimetrexate metabolism. ",False,negative
clotrimazole,trimetrexate,76,87,159,170,"Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (<e1>clotrimazole</e1>, ketoconazole, miconazole) were potent, non-competitive inhibitors of <e2>trimetrexate</e2> metabolism. ",True,mechanism
ketoconazole,miconazole,90,101,104,113,"Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, <e1>ketoconazole</e1>, <e2>miconazole</e2>) were potent, non-competitive inhibitors of trimetrexate metabolism. ",False,negative
ketoconazole,trimetrexate,90,101,159,170,"Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, <e1>ketoconazole</e1>, miconazole) were potent, non-competitive inhibitors of <e2>trimetrexate</e2> metabolism. ",True,mechanism
miconazole,trimetrexate,104,113,159,170,"Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, <e1>miconazole</e1>) were potent, non-competitive inhibitors of <e2>trimetrexate</e2> metabolism. ",True,mechanism
Triprolidine,central nervous system depressants,0,11,49,82,"<e1>Triprolidine</e1> may enhance the sedative effects of <e2>central nervous system depressants</e2> including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",True,effect
Triprolidine,alcohol,0,11,94,100,"<e1>Triprolidine</e1> may enhance the sedative effects of central nervous system depressants including <e2>alcohol</e2>, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",True,effect
Triprolidine,barbiturates,0,11,103,114,"<e1>Triprolidine</e1> may enhance the sedative effects of central nervous system depressants including alcohol, <e2>barbiturates</e2>, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",True,effect
Triprolidine,hypnotics,0,11,117,125,"<e1>Triprolidine</e1> may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, <e2>hypnotics</e2>, narcotic analgesics, sedatives, and tranquillisers. ",True,effect
Triprolidine,narcotic analgesics,0,11,128,146,"<e1>Triprolidine</e1> may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, <e2>narcotic analgesics</e2>, sedatives, and tranquillisers. ",True,effect
Triprolidine,sedatives,0,11,149,157,"<e1>Triprolidine</e1> may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, <e2>sedatives</e2>, and tranquillisers. ",True,effect
Triprolidine,tranquillisers,0,11,164,177,"<e1>Triprolidine</e1> may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and <e2>tranquillisers</e2>. ",True,effect
central nervous system depressants,alcohol,49,82,94,100,"Triprolidine may enhance the sedative effects of <e1>central nervous system depressants</e1> including <e2>alcohol</e2>, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",False,negative
central nervous system depressants,barbiturates,49,82,103,114,"Triprolidine may enhance the sedative effects of <e1>central nervous system depressants</e1> including alcohol, <e2>barbiturates</e2>, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",False,negative
central nervous system depressants,hypnotics,49,82,117,125,"Triprolidine may enhance the sedative effects of <e1>central nervous system depressants</e1> including alcohol, barbiturates, <e2>hypnotics</e2>, narcotic analgesics, sedatives, and tranquillisers. ",False,negative
central nervous system depressants,narcotic analgesics,49,82,128,146,"Triprolidine may enhance the sedative effects of <e1>central nervous system depressants</e1> including alcohol, barbiturates, hypnotics, <e2>narcotic analgesics</e2>, sedatives, and tranquillisers. ",False,negative
central nervous system depressants,sedatives,49,82,149,157,"Triprolidine may enhance the sedative effects of <e1>central nervous system depressants</e1> including alcohol, barbiturates, hypnotics, narcotic analgesics, <e2>sedatives</e2>, and tranquillisers. ",False,negative
central nervous system depressants,tranquillisers,49,82,164,177,"Triprolidine may enhance the sedative effects of <e1>central nervous system depressants</e1> including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and <e2>tranquillisers</e2>. ",False,negative
alcohol,barbiturates,94,100,103,114,"Triprolidine may enhance the sedative effects of central nervous system depressants including <e1>alcohol</e1>, <e2>barbiturates</e2>, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",False,negative
alcohol,hypnotics,94,100,117,125,"Triprolidine may enhance the sedative effects of central nervous system depressants including <e1>alcohol</e1>, barbiturates, <e2>hypnotics</e2>, narcotic analgesics, sedatives, and tranquillisers. ",False,negative
alcohol,narcotic analgesics,94,100,128,146,"Triprolidine may enhance the sedative effects of central nervous system depressants including <e1>alcohol</e1>, barbiturates, hypnotics, <e2>narcotic analgesics</e2>, sedatives, and tranquillisers. ",False,negative
alcohol,sedatives,94,100,149,157,"Triprolidine may enhance the sedative effects of central nervous system depressants including <e1>alcohol</e1>, barbiturates, hypnotics, narcotic analgesics, <e2>sedatives</e2>, and tranquillisers. ",False,negative
alcohol,tranquillisers,94,100,164,177,"Triprolidine may enhance the sedative effects of central nervous system depressants including <e1>alcohol</e1>, barbiturates, hypnotics, narcotic analgesics, sedatives, and <e2>tranquillisers</e2>. ",False,negative
barbiturates,hypnotics,103,114,117,125,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, <e1>barbiturates</e1>, <e2>hypnotics</e2>, narcotic analgesics, sedatives, and tranquillisers. ",False,negative
barbiturates,narcotic analgesics,103,114,128,146,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, <e1>barbiturates</e1>, hypnotics, <e2>narcotic analgesics</e2>, sedatives, and tranquillisers. ",False,negative
barbiturates,sedatives,103,114,149,157,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, <e1>barbiturates</e1>, hypnotics, narcotic analgesics, <e2>sedatives</e2>, and tranquillisers. ",False,negative
barbiturates,tranquillisers,103,114,164,177,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, <e1>barbiturates</e1>, hypnotics, narcotic analgesics, sedatives, and <e2>tranquillisers</e2>. ",False,negative
hypnotics,narcotic analgesics,117,125,128,146,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, <e1>hypnotics</e1>, <e2>narcotic analgesics</e2>, sedatives, and tranquillisers. ",False,negative
hypnotics,sedatives,117,125,149,157,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, <e1>hypnotics</e1>, narcotic analgesics, <e2>sedatives</e2>, and tranquillisers. ",False,negative
hypnotics,tranquillisers,117,125,164,177,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, <e1>hypnotics</e1>, narcotic analgesics, sedatives, and <e2>tranquillisers</e2>. ",False,negative
narcotic analgesics,sedatives,128,146,149,157,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, <e1>narcotic analgesics</e1>, <e2>sedatives</e2>, and tranquillisers. ",False,negative
narcotic analgesics,tranquillisers,128,146,164,177,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, <e1>narcotic analgesics</e1>, sedatives, and <e2>tranquillisers</e2>. ",False,negative
sedatives,tranquillisers,149,157,164,177,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, <e1>sedatives</e1>, and <e2>tranquillisers</e2>. ",False,negative
anticholinergic drugs,atropine,15,35,46,53,"The effects of <e1>anticholinergic drugs</e1>, such as <e2>atropine</e2> and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. ",False,negative
anticholinergic drugs,tricyclic antidepressants,15,35,59,83,"The effects of <e1>anticholinergic drugs</e1>, such as atropine and <e2>tricyclic antidepressants</e2> may be enhanced by the concomitant administration of triprolidine. ",False,negative
anticholinergic drugs,triprolidine,15,35,138,149,"The effects of <e1>anticholinergic drugs</e1>, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of <e2>triprolidine</e2>. ",True,effect
atropine,tricyclic antidepressants,46,53,59,83,"The effects of anticholinergic drugs, such as <e1>atropine</e1> and <e2>tricyclic antidepressants</e2> may be enhanced by the concomitant administration of triprolidine. ",False,negative
atropine,triprolidine,46,53,138,149,"The effects of anticholinergic drugs, such as <e1>atropine</e1> and tricyclic antidepressants may be enhanced by the concomitant administration of <e2>triprolidine</e2>. ",True,effect
tricyclic antidepressants,triprolidine,59,83,138,149,"The effects of anticholinergic drugs, such as atropine and <e1>tricyclic antidepressants</e1> may be enhanced by the concomitant administration of <e2>triprolidine</e2>. ",True,effect
Sanctura,anticholinergic agents,23,30,43,64,"The concomitant use of <e1>Sanctura</e1> with other <e2>anticholinergic agents</e2> that produce dry mouth, constipation, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects. ",True,effect
Sanctura,Sanctura,101,108,135,142,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with <e1>Sanctura</e1> have not been conducted, <e2>Sanctura</e2> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",False,negative
Sanctura,digoxin,101,108,266,272,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with <e1>Sanctura</e1> have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. <e2>digoxin</e2>, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",False,negative
Sanctura,procainamide,101,108,275,286,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with <e1>Sanctura</e1> have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, <e2>procainamide</e2>, pancuronium, morphine, vancomycin, metformin and tenofovir). ",False,negative
Sanctura,pancuronium,101,108,289,299,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with <e1>Sanctura</e1> have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, <e2>pancuronium</e2>, morphine, vancomycin, metformin and tenofovir). ",False,negative
Sanctura,morphine,101,108,302,309,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with <e1>Sanctura</e1> have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, <e2>morphine</e2>, vancomycin, metformin and tenofovir). ",False,negative
Sanctura,vancomycin,101,108,312,321,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with <e1>Sanctura</e1> have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, <e2>vancomycin</e2>, metformin and tenofovir). ",False,negative
Sanctura,metformin,101,108,324,332,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with <e1>Sanctura</e1> have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, <e2>metformin</e2> and tenofovir). ",False,negative
Sanctura,tenofovir,101,108,338,346,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with <e1>Sanctura</e1> have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and <e2>tenofovir</e2>). ",False,negative
Sanctura,digoxin,135,142,266,272,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, <e1>Sanctura</e1> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. <e2>digoxin</e2>, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",True,mechanism
Sanctura,procainamide,135,142,275,286,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, <e1>Sanctura</e1> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, <e2>procainamide</e2>, pancuronium, morphine, vancomycin, metformin and tenofovir). ",True,mechanism
Sanctura,pancuronium,135,142,289,299,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, <e1>Sanctura</e1> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, <e2>pancuronium</e2>, morphine, vancomycin, metformin and tenofovir). ",True,mechanism
Sanctura,morphine,135,142,302,309,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, <e1>Sanctura</e1> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, <e2>morphine</e2>, vancomycin, metformin and tenofovir). ",True,mechanism
Sanctura,vancomycin,135,142,312,321,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, <e1>Sanctura</e1> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, <e2>vancomycin</e2>, metformin and tenofovir). ",True,mechanism
Sanctura,metformin,135,142,324,332,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, <e1>Sanctura</e1> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, <e2>metformin</e2> and tenofovir). ",True,mechanism
Sanctura,tenofovir,135,142,338,346,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, <e1>Sanctura</e1> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and <e2>tenofovir</e2>). ",True,mechanism
digoxin,procainamide,266,272,275,286,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. <e1>digoxin</e1>, <e2>procainamide</e2>, pancuronium, morphine, vancomycin, metformin and tenofovir). ",False,negative
digoxin,pancuronium,266,272,289,299,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. <e1>digoxin</e1>, procainamide, <e2>pancuronium</e2>, morphine, vancomycin, metformin and tenofovir). ",False,negative
digoxin,morphine,266,272,302,309,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. <e1>digoxin</e1>, procainamide, pancuronium, <e2>morphine</e2>, vancomycin, metformin and tenofovir). ",False,negative
digoxin,vancomycin,266,272,312,321,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. <e1>digoxin</e1>, procainamide, pancuronium, morphine, <e2>vancomycin</e2>, metformin and tenofovir). ",False,negative
digoxin,metformin,266,272,324,332,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. <e1>digoxin</e1>, procainamide, pancuronium, morphine, vancomycin, <e2>metformin</e2> and tenofovir). ",False,negative
digoxin,tenofovir,266,272,338,346,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. <e1>digoxin</e1>, procainamide, pancuronium, morphine, vancomycin, metformin and <e2>tenofovir</e2>). ",False,negative
procainamide,pancuronium,275,286,289,299,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, <e1>procainamide</e1>, <e2>pancuronium</e2>, morphine, vancomycin, metformin and tenofovir). ",False,negative
procainamide,morphine,275,286,302,309,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, <e1>procainamide</e1>, pancuronium, <e2>morphine</e2>, vancomycin, metformin and tenofovir). ",False,negative
procainamide,vancomycin,275,286,312,321,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, <e1>procainamide</e1>, pancuronium, morphine, <e2>vancomycin</e2>, metformin and tenofovir). ",False,negative
procainamide,metformin,275,286,324,332,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, <e1>procainamide</e1>, pancuronium, morphine, vancomycin, <e2>metformin</e2> and tenofovir). ",False,negative
procainamide,tenofovir,275,286,338,346,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, <e1>procainamide</e1>, pancuronium, morphine, vancomycin, metformin and <e2>tenofovir</e2>). ",False,negative
pancuronium,morphine,289,299,302,309,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, <e1>pancuronium</e1>, <e2>morphine</e2>, vancomycin, metformin and tenofovir). ",False,negative
pancuronium,vancomycin,289,299,312,321,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, <e1>pancuronium</e1>, morphine, <e2>vancomycin</e2>, metformin and tenofovir). ",False,negative
pancuronium,metformin,289,299,324,332,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, <e1>pancuronium</e1>, morphine, vancomycin, <e2>metformin</e2> and tenofovir). ",False,negative
pancuronium,tenofovir,289,299,338,346,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, <e1>pancuronium</e1>, morphine, vancomycin, metformin and <e2>tenofovir</e2>). ",False,negative
morphine,vancomycin,302,309,312,321,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, <e1>morphine</e1>, <e2>vancomycin</e2>, metformin and tenofovir). ",False,negative
morphine,metformin,302,309,324,332,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, <e1>morphine</e1>, vancomycin, <e2>metformin</e2> and tenofovir). ",False,negative
morphine,tenofovir,302,309,338,346,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, <e1>morphine</e1>, vancomycin, metformin and <e2>tenofovir</e2>). ",False,negative
vancomycin,metformin,312,321,324,332,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, <e1>vancomycin</e1>, <e2>metformin</e2> and tenofovir). ",False,negative
vancomycin,tenofovir,312,321,338,346,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, <e1>vancomycin</e1>, metformin and <e2>tenofovir</e2>). ",False,negative
metformin,tenofovir,324,332,338,346,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, <e1>metformin</e1> and <e2>tenofovir</e2>). ",False,negative
Sanctura,Sanctura,20,27,134,141,Coadministration of <e1>Sanctura</e1> with drugs that are eliminated by active renal tubular secretion may increase the serum concentration of <e2>Sanctura</e2> and/or the coadministered drug due to competition for this elimination pathway. ,False,negative
vancomycin,anesthetic agents,30,39,45,61,Concomitant administration of <e1>vancomycin</e1> and <e2>anesthetic agents</e2> has been associated with erythema and histamine-like flushing and anaphylactoid reactions. ,True,effect
amphotericin B,aminoglycosides,119,132,135,149,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as <e1>amphotericin B</e1>, <e2>aminoglycosides</e2>, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",False,negative
amphotericin B,bacitracin,119,132,152,161,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as <e1>amphotericin B</e1>, aminoglycosides, <e2>bacitracin</e2>, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",False,negative
amphotericin B,polymyxin B,119,132,164,174,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as <e1>amphotericin B</e1>, aminoglycosides, bacitracin, <e2>polymyxin B</e2>, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",False,negative
amphotericin B,colistin,119,132,177,184,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as <e1>amphotericin B</e1>, aminoglycosides, bacitracin, polymyxin B, <e2>colistin</e2>, viomycin, or cisplatin, when indicated, requires careful monitoring.",False,negative
amphotericin B,viomycin,119,132,187,194,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as <e1>amphotericin B</e1>, aminoglycosides, bacitracin, polymyxin B, colistin, <e2>viomycin</e2>, or cisplatin, when indicated, requires careful monitoring.",False,negative
amphotericin B,cisplatin,119,132,200,208,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as <e1>amphotericin B</e1>, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or <e2>cisplatin</e2>, when indicated, requires careful monitoring.",False,negative
aminoglycosides,bacitracin,135,149,152,161,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, <e1>aminoglycosides</e1>, <e2>bacitracin</e2>, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",False,negative
aminoglycosides,polymyxin B,135,149,164,174,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, <e1>aminoglycosides</e1>, bacitracin, <e2>polymyxin B</e2>, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",False,negative
aminoglycosides,colistin,135,149,177,184,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, <e1>aminoglycosides</e1>, bacitracin, polymyxin B, <e2>colistin</e2>, viomycin, or cisplatin, when indicated, requires careful monitoring.",False,negative
aminoglycosides,viomycin,135,149,187,194,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, <e1>aminoglycosides</e1>, bacitracin, polymyxin B, colistin, <e2>viomycin</e2>, or cisplatin, when indicated, requires careful monitoring.",False,negative
aminoglycosides,cisplatin,135,149,200,208,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, <e1>aminoglycosides</e1>, bacitracin, polymyxin B, colistin, viomycin, or <e2>cisplatin</e2>, when indicated, requires careful monitoring.",False,negative
bacitracin,polymyxin B,152,161,164,174,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, <e1>bacitracin</e1>, <e2>polymyxin B</e2>, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",False,negative
bacitracin,colistin,152,161,177,184,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, <e1>bacitracin</e1>, polymyxin B, <e2>colistin</e2>, viomycin, or cisplatin, when indicated, requires careful monitoring.",False,negative
bacitracin,viomycin,152,161,187,194,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, <e1>bacitracin</e1>, polymyxin B, colistin, <e2>viomycin</e2>, or cisplatin, when indicated, requires careful monitoring.",False,negative
bacitracin,cisplatin,152,161,200,208,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, <e1>bacitracin</e1>, polymyxin B, colistin, viomycin, or <e2>cisplatin</e2>, when indicated, requires careful monitoring.",False,negative
polymyxin B,colistin,164,174,177,184,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, <e1>polymyxin B</e1>, <e2>colistin</e2>, viomycin, or cisplatin, when indicated, requires careful monitoring.",False,negative
polymyxin B,viomycin,164,174,187,194,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, <e1>polymyxin B</e1>, colistin, <e2>viomycin</e2>, or cisplatin, when indicated, requires careful monitoring.",False,negative
polymyxin B,cisplatin,164,174,200,208,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, <e1>polymyxin B</e1>, colistin, viomycin, or <e2>cisplatin</e2>, when indicated, requires careful monitoring.",False,negative
colistin,viomycin,177,184,187,194,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, <e1>colistin</e1>, <e2>viomycin</e2>, or cisplatin, when indicated, requires careful monitoring.",False,negative
colistin,cisplatin,177,184,200,208,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, <e1>colistin</e1>, viomycin, or <e2>cisplatin</e2>, when indicated, requires careful monitoring.",False,negative
viomycin,cisplatin,187,194,200,208,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, <e1>viomycin</e1>, or <e2>cisplatin</e2>, when indicated, requires careful monitoring.",False,negative
vigabatrin,carbamazepine,37,46,115,127,A study published in 2002 found that <e1>vigabatrin</e1> causes a statistically significant increase in plasma clearance of <e2>carbamazepine</e2>. ,True,mechanism
vigabatrin,phenytoin,87,96,103,111,"In 1984, Drs Rimmer and Richens at the University of Wales reported that administering <e1>vigabatrin</e1> with <e2>phenytoin</e2> lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy. ",True,mechanism
vigabatrin,phenytoin,87,96,131,139,"In 1984, Drs Rimmer and Richens at the University of Wales reported that administering <e1>vigabatrin</e1> with phenytoin lowered the serum <e2>phenytoin</e2> concentration in patients with treatment-resistant epilepsy. ",False,negative
phenytoin,phenytoin,103,111,131,139,"In 1984, Drs Rimmer and Richens at the University of Wales reported that administering vigabatrin with <e1>phenytoin</e1> lowered the serum <e2>phenytoin</e2> concentration in patients with treatment-resistant epilepsy. ",False,negative
Vindesine,Phenytoin,0,8,310,318,"<e1>Vindesine</e1> can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - <e2>Phenytoin</e2>: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",True,int
Vindesine,Live virus vaccines,0,8,353,371,"<e1>Vindesine</e1> can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - <e2>Live virus vaccines</e2>: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",True,int
Vindesine,vaccine,0,8,412,418,"<e1>Vindesine</e1> can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the <e2>vaccine</e2> virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",False,negative
Vindesine,Mitomycin-C,0,8,526,536,"<e1>Vindesine</e1> can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - <e2>Mitomycin-C</e2>: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",True,int
Vindesine,Killed virus vaccines,0,8,588,608,"<e1>Vindesine</e1> can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - <e2>Killed virus vaccines</e2>: may decrease patient's response to the vaccine",True,int
Vindesine,vaccine,0,8,650,656,"<e1>Vindesine</e1> can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the <e2>vaccine</e2>",False,negative
Phenytoin,Live virus vaccines,310,318,353,371,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - <e1>Phenytoin</e1>: can increase seizure activity - <e2>Live virus vaccines</e2>: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",False,negative
Phenytoin,vaccine,310,318,412,418,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - <e1>Phenytoin</e1>: can increase seizure activity - Live virus vaccines: may potentiate the replication of the <e2>vaccine</e2> virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",False,negative
Phenytoin,Mitomycin-C,310,318,526,536,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - <e1>Phenytoin</e1>: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - <e2>Mitomycin-C</e2>: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",False,negative
Phenytoin,Killed virus vaccines,310,318,588,608,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - <e1>Phenytoin</e1>: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - <e2>Killed virus vaccines</e2>: may decrease patient's response to the vaccine",False,negative
Phenytoin,vaccine,310,318,650,656,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - <e1>Phenytoin</e1>: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the <e2>vaccine</e2>",False,negative
Live virus vaccines,vaccine,353,371,412,418,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - <e1>Live virus vaccines</e1>: may potentiate the replication of the <e2>vaccine</e2> virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",False,negative
Live virus vaccines,Mitomycin-C,353,371,526,536,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - <e1>Live virus vaccines</e1>: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - <e2>Mitomycin-C</e2>: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",False,negative
Live virus vaccines,Killed virus vaccines,353,371,588,608,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - <e1>Live virus vaccines</e1>: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - <e2>Killed virus vaccines</e2>: may decrease patient's response to the vaccine",False,negative
Live virus vaccines,vaccine,353,371,650,656,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - <e1>Live virus vaccines</e1>: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the <e2>vaccine</e2>",False,negative
vaccine,Mitomycin-C,412,418,526,536,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the <e1>vaccine</e1> virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - <e2>Mitomycin-C</e2>: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",False,negative
vaccine,Killed virus vaccines,412,418,588,608,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the <e1>vaccine</e1> virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - <e2>Killed virus vaccines</e2>: may decrease patient's response to the vaccine",False,negative
vaccine,vaccine,412,418,650,656,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the <e1>vaccine</e1> virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the <e2>vaccine</e2>",False,negative
Mitomycin-C,Killed virus vaccines,526,536,588,608,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - <e1>Mitomycin-C</e1>: may cause shortness of breath and bronchospasm - <e2>Killed virus vaccines</e2>: may decrease patient's response to the vaccine",False,negative
Mitomycin-C,vaccine,526,536,650,656,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - <e1>Mitomycin-C</e1>: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the <e2>vaccine</e2>",False,negative
Killed virus vaccines,vaccine,588,608,650,656,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - <e1>Killed virus vaccines</e1>: may decrease patient's response to the <e2>vaccine</e2>",False,negative
contraceptives,vitamin A,33,46,92,100,Drug Interactions: Women on oral <e1>contraceptives</e1> have shown a significant increase in plasma <e2>vitamin A</e2> levels.,True,mechanism
ascorbic acid,bishydroxycoumarin,31,43,99,116,Limited evidence suggests that <e1>ascorbic acid</e1> may influence the intensity and duration of action of <e2>bishydroxycoumarin</e2>.,True,mechanism
Coumarin-Derivative Anticoagulants,ZOLINZA,0,33,151,157,<e1>Coumarin-Derivative Anticoagulants</e1>: Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving <e2>ZOLINZA</e2> concomitantly with coumarin-derivative anticoagulants. ,False,negative
Coumarin-Derivative Anticoagulants,coumarin-derivative anticoagulants,0,33,178,211,<e1>Coumarin-Derivative Anticoagulants</e1>: Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving ZOLINZA concomitantly with <e2>coumarin-derivative anticoagulants</e2>. ,False,negative
ZOLINZA,coumarin-derivative anticoagulants,151,157,178,211,Coumarin-Derivative Anticoagulants: Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving <e1>ZOLINZA</e1> concomitantly with <e2>coumarin-derivative anticoagulants</e2>. ,True,effect
ZOLINZA,coumarin derivatives,85,91,97,116,Physicians should carefully monitor PT and INR in patients concurrently administered <e1>ZOLINZA</e1> and <e2>coumarin derivatives</e2>. ,True,advise
HDAC Inhibitors,ZOLINZA,6,20,119,125,"Other <e1>HDAC Inhibitors</e1> Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of <e2>ZOLINZA</e2> and other HDAC inhibitors (e.g., valproic acid). ",False,negative
HDAC Inhibitors,HDAC inhibitors,6,20,137,151,"Other <e1>HDAC Inhibitors</e1> Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other <e2>HDAC inhibitors</e2> (e.g., valproic acid). ",False,negative
HDAC Inhibitors,valproic acid,6,20,160,172,"Other <e1>HDAC Inhibitors</e1> Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., <e2>valproic acid</e2>). ",False,negative
ZOLINZA,HDAC inhibitors,119,125,137,151,"Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of <e1>ZOLINZA</e1> and other <e2>HDAC inhibitors</e2> (e.g., valproic acid). ",True,effect
ZOLINZA,valproic acid,119,125,160,172,"Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of <e1>ZOLINZA</e1> and other HDAC inhibitors (e.g., <e2>valproic acid</e2>). ",True,effect
HDAC inhibitors,valproic acid,137,151,160,172,"Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other <e1>HDAC inhibitors</e1> (e.g., <e2>valproic acid</e2>). ",False,negative
"3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",106,153,281,324,"In the present study, we tested whether the highly specific metabotropic glutamate receptor 5 antagonist, <e1>3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine</e1>, reduces dopaminergic and noradrenergic neuronal loss in monkeys rendered parkinsonian by chronic treatment with low doses of <e2>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e2>. ",False,negative
"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine",21,64,150,197,"Weekly intramuscular <e1>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e1> injections (0.2-0.5 mg/kg body weight), in combination with daily administration of <e2>3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine</e2> or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). ",False,negative
"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",21,64,321,364,"Weekly intramuscular <e1>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e1> injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (<e2>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e2>/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). ",False,negative
"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine",21,64,366,413,"Weekly intramuscular <e1>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e1> injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/<e2>3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine</e2> versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). ",False,negative
"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",21,64,422,465,"Weekly intramuscular <e1>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e1> injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus <e2>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e2>/vehicle). ",False,negative
"3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",150,197,321,364,"Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of <e1>3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine</e1> or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (<e2>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e2>/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). ",False,negative
"3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine",150,197,366,413,"Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of <e1>3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine</e1> or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/<e2>3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine</e2> versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). ",False,negative
"3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",150,197,422,465,"Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of <e1>3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine</e1> or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus <e2>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e2>/vehicle). ",False,negative
"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine",321,364,366,413,"Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (<e1>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e1>/<e2>3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine</e2> versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). ",False,negative
"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",321,364,422,465,"Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (<e1>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e1>/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus <e2>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e2>/vehicle). ",False,negative
"3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",366,413,422,465,"Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/<e1>3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine</e1> versus <e2>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e2>/vehicle). ",False,negative
"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",18,61,78,121,"After 21 weeks of <e1>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e1> treatment, all <e2>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e2>/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. ",False,negative
"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",18,61,200,243,"After 21 weeks of <e1>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e1> treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the <e2>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e2>/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. ",False,negative
"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine",18,61,245,292,"After 21 weeks of <e1>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e1> treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/<e2>3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine</e2>-treated monkeys were significantly affected. ",False,negative
"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",78,121,200,243,"After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all <e1>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e1>/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the <e2>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e2>/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. ",False,negative
"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine",78,121,245,292,"After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all <e1>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e1>/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/<e2>3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine</e2>-treated monkeys were significantly affected. ",False,negative
"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine",200,243,245,292,"After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the <e1>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e1>/<e2>3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine</e2>-treated monkeys were significantly affected. ",True,effect
"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine",349,392,394,441,"These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in <e1>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e1>/<e2>3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine</e2>-treated animals than in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated monkeys. ",True,effect
"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",349,392,467,510,"These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in <e1>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e1>/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated animals than in <e2>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e2>/vehicle-treated monkeys. ",False,negative
"3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",394,441,467,510,"These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/<e1>3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine</e1>-treated animals than in <e2>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e2>/vehicle-treated monkeys. ",False,negative
"3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",4,51,100,143,"The <e1>3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine</e1> treatment also had a significant effect on the <e2>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e2>-induced loss of norepinephrine neurons in the locus coeruleus and adjoining A5 and A7 noradrenaline cell groups. ",True,effect
"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",3,46,283,326,"In <e1>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e1>/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in <e2>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e2>/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys. ",False,negative
"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine",3,46,328,375,"In <e1>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e1>/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/<e2>3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine</e2>-treated monkeys. ",False,negative
"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine",283,326,328,375,"In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in <e1>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e1>/<e2>3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine</e2>-treated monkeys. ",True,effect
"3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",99,146,171,214,"Our data demonstrate that chronic treatment with the metabotropic glutamate receptor 5 antagonist, <e1>3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine</e1>, significantly reduces <e2>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e2> toxicity towards dopaminergic and noradrenergic cell groups in non-human primates. ",True,effect
ketoconazole,panobinostat,10,21,82,93,"Effect of <e1>ketoconazole</e1>-mediated CYP3A4 inhibition on clinical pharmacokinetics of <e2>panobinostat</e2> (LBH589), an orally active histone deacetylase inhibitor.
",False,negative
ketoconazole,LBH589,10,21,96,101,"Effect of <e1>ketoconazole</e1>-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (<e2>LBH589</e2>), an orally active histone deacetylase inhibitor.
",False,negative
ketoconazole,histone deacetylase inhibitor,10,21,122,150,"Effect of <e1>ketoconazole</e1>-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active <e2>histone deacetylase inhibitor</e2>.
",False,negative
panobinostat,LBH589,82,93,96,101,"Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of <e1>panobinostat</e1> (<e2>LBH589</e2>), an orally active histone deacetylase inhibitor.
",False,negative
panobinostat,histone deacetylase inhibitor,82,93,122,150,"Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of <e1>panobinostat</e1> (LBH589), an orally active <e2>histone deacetylase inhibitor</e2>.
",False,negative
LBH589,histone deacetylase inhibitor,96,101,122,150,"Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (<e1>LBH589</e1>), an orally active <e2>histone deacetylase inhibitor</e2>.
",False,negative
ketoconazole,panobinostat,61,72,113,124,"This study evaluated the effect of a potent CYP3A inhibitor, <e1>ketoconazole</e1>, on the pharmacokinetics and safety of <e2>panobinostat</e2>.",False,negative
panobinostat,ketoconazole,19,30,62,73,"On day 8, a single <e1>panobinostat</e1> dose was co-administered with <e2>ketoconazole</e2>. ",False,negative
ketoconazole,panobinostat,19,30,92,103,"In the presence of <e1>ketoconazole</e1>, there was 1.6- and 1.8-fold increase in C (max) and AUC of <e2>panobinostat</e2>, respectively. ",True,mechanism
panobinostat,panobinostat,21,32,96,107,Co-administration of <e1>panobinostat</e1> with CYP3A inhibitors is feasible as the observed increase in <e2>panobinostat</e2> PK parameters was not considered clinically relevant. ,False,negative
panobinostat,panobinostat,104,115,176,187,"Considering the variability in exposure following enzyme inhibition and the fact that chronic dosing of <e1>panobinostat</e1> was not studied with CYP3A inhibitors, close monitoring of <e2>panobinostat</e2>-related adverse events is necessary.",False,negative
moxifloxacin,lomefloxacin,21,32,38,49,"Interaction study of <e1>moxifloxacin</e1> and <e2>lomefloxacin</e2> with co-administered drugs.
",False,negative
Moxifloxacin,lomefloxacin,0,11,17,28,<e1>Moxifloxacin</e1> and <e2>lomefloxacin</e2> are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections. ,False,negative
Moxifloxacin,fluoroquinolone antibiotics,0,11,34,60,<e1>Moxifloxacin</e1> and lomefloxacin are <e2>fluoroquinolone antibiotics</e2> used in treating urinary and respiratory tract infections. ,False,negative
lomefloxacin,fluoroquinolone antibiotics,17,28,34,60,Moxifloxacin and <e1>lomefloxacin</e1> are <e2>fluoroquinolone antibiotics</e2> used in treating urinary and respiratory tract infections. ,False,negative
moxifloxacin,fluoroquinolones,6,17,36,51,"Being <e1>moxifloxacin</e1> and lomefloxacin <e2>fluoroquinolones</e2> the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ",False,negative
moxifloxacin,sucralfate,6,17,99,108,"Being <e1>moxifloxacin</e1> and lomefloxacin fluoroquinolones the interaction study of was carried out with <e2>sucralfate</e2>, gelusil, erythromycin and multi minerals. ",False,negative
moxifloxacin,gelusil,6,17,111,117,"Being <e1>moxifloxacin</e1> and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, <e2>gelusil</e2>, erythromycin and multi minerals. ",False,negative
moxifloxacin,erythromycin,6,17,120,131,"Being <e1>moxifloxacin</e1> and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, <e2>erythromycin</e2> and multi minerals. ",False,negative
moxifloxacin,multi minerals,6,17,137,150,"Being <e1>moxifloxacin</e1> and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and <e2>multi minerals</e2>. ",False,negative
fluoroquinolones,sucralfate,36,51,99,108,"Being moxifloxacin and lomefloxacin <e1>fluoroquinolones</e1> the interaction study of was carried out with <e2>sucralfate</e2>, gelusil, erythromycin and multi minerals. ",False,negative
fluoroquinolones,gelusil,36,51,111,117,"Being moxifloxacin and lomefloxacin <e1>fluoroquinolones</e1> the interaction study of was carried out with sucralfate, <e2>gelusil</e2>, erythromycin and multi minerals. ",False,negative
fluoroquinolones,erythromycin,36,51,120,131,"Being moxifloxacin and lomefloxacin <e1>fluoroquinolones</e1> the interaction study of was carried out with sucralfate, gelusil, <e2>erythromycin</e2> and multi minerals. ",False,negative
fluoroquinolones,multi minerals,36,51,137,150,"Being moxifloxacin and lomefloxacin <e1>fluoroquinolones</e1> the interaction study of was carried out with sucralfate, gelusil, erythromycin and <e2>multi minerals</e2>. ",False,negative
sucralfate,gelusil,99,108,111,117,"Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with <e1>sucralfate</e1>, <e2>gelusil</e2>, erythromycin and multi minerals. ",False,negative
sucralfate,erythromycin,99,108,120,131,"Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with <e1>sucralfate</e1>, gelusil, <e2>erythromycin</e2> and multi minerals. ",False,negative
sucralfate,multi minerals,99,108,137,150,"Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with <e1>sucralfate</e1>, gelusil, erythromycin and <e2>multi minerals</e2>. ",False,negative
gelusil,erythromycin,111,117,120,131,"Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, <e1>gelusil</e1>, <e2>erythromycin</e2> and multi minerals. ",False,negative
gelusil,multi minerals,111,117,137,150,"Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, <e1>gelusil</e1>, erythromycin and <e2>multi minerals</e2>. ",False,negative
erythromycin,multi minerals,120,131,137,150,"Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, <e1>erythromycin</e1> and <e2>multi minerals</e2>. ",False,negative
moxifloxacin,lomefloxacin,16,27,33,44,The response of <e1>moxifloxacin</e1> and <e2>lomefloxacin</e2> after interaction with co-administered drugs at different conditions and temperature were noted using a Shimadzu HPLC system with PDA detector. ,False,negative
Moxifloxacin,Lomefloxacin,0,11,17,28,<e1>Moxifloxacin</e1> and <e2>Lomefloxacin</e2> reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,False,negative
Moxifloxacin,sucralfate,0,11,49,58,<e1>Moxifloxacin</e1> and Lomefloxacin reacts faster with <e2>sucralfate</e2> and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,True,mechanism
Moxifloxacin,gelusil,0,11,64,70,<e1>Moxifloxacin</e1> and Lomefloxacin reacts faster with sucralfate and <e2>gelusil</e2> in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,True,mechanism
Moxifloxacin,erythromycin,0,11,101,112,<e1>Moxifloxacin</e1> and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with <e2>erythromycin</e2> in basic media and multi-minerals in neutral media. ,True,mechanism
Moxifloxacin,multi-minerals,0,11,133,146,<e1>Moxifloxacin</e1> and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and <e2>multi-minerals</e2> in neutral media. ,True,mechanism
Lomefloxacin,sucralfate,17,28,49,58,Moxifloxacin and <e1>Lomefloxacin</e1> reacts faster with <e2>sucralfate</e2> and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,True,mechanism
Lomefloxacin,gelusil,17,28,64,70,Moxifloxacin and <e1>Lomefloxacin</e1> reacts faster with sucralfate and <e2>gelusil</e2> in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,True,mechanism
Lomefloxacin,erythromycin,17,28,101,112,Moxifloxacin and <e1>Lomefloxacin</e1> reacts faster with sucralfate and gelusil in acidic media whereas with <e2>erythromycin</e2> in basic media and multi-minerals in neutral media. ,True,mechanism
Lomefloxacin,multi-minerals,17,28,133,146,Moxifloxacin and <e1>Lomefloxacin</e1> reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and <e2>multi-minerals</e2> in neutral media. ,True,mechanism
sucralfate,gelusil,49,58,64,70,Moxifloxacin and Lomefloxacin reacts faster with <e1>sucralfate</e1> and <e2>gelusil</e2> in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,False,negative
sucralfate,erythromycin,49,58,101,112,Moxifloxacin and Lomefloxacin reacts faster with <e1>sucralfate</e1> and gelusil in acidic media whereas with <e2>erythromycin</e2> in basic media and multi-minerals in neutral media. ,False,negative
sucralfate,multi-minerals,49,58,133,146,Moxifloxacin and Lomefloxacin reacts faster with <e1>sucralfate</e1> and gelusil in acidic media whereas with erythromycin in basic media and <e2>multi-minerals</e2> in neutral media. ,False,negative
gelusil,erythromycin,64,70,101,112,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and <e1>gelusil</e1> in acidic media whereas with <e2>erythromycin</e2> in basic media and multi-minerals in neutral media. ,False,negative
gelusil,multi-minerals,64,70,133,146,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and <e1>gelusil</e1> in acidic media whereas with erythromycin in basic media and <e2>multi-minerals</e2> in neutral media. ,False,negative
erythromycin,multi-minerals,101,112,133,146,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with <e1>erythromycin</e1> in basic media and <e2>multi-minerals</e2> in neutral media. ,False,negative
S-ketamine,itraconazole,17,26,45,56,"Exposure to oral <e1>S-ketamine</e1> is unaffected by <e2>itraconazole</e2> but greatly increased by ticlopidine.
",False,negative
S-ketamine,ticlopidine,17,26,83,93,"Exposure to oral <e1>S-ketamine</e1> is unaffected by itraconazole but greatly increased by <e2>ticlopidine</e2>.
",True,effect
itraconazole,ticlopidine,45,56,83,93,"Exposure to oral S-ketamine is unaffected by <e1>itraconazole</e1> but greatly increased by <e2>ticlopidine</e2>.
",False,negative
S-ketamine,ticlopidine,51,60,107,117,This study examined drug-drug interactions of oral <e1>S-ketamine</e1> with the cytochrome P450 (CYP) 2B6 inhibitor <e2>ticlopidine</e2> and the CYP3A inhibitor itraconazole. ,False,negative
S-ketamine,itraconazole,51,60,143,154,This study examined drug-drug interactions of oral <e1>S-ketamine</e1> with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor <e2>itraconazole</e2>. ,False,negative
ticlopidine,itraconazole,107,117,143,154,This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor <e1>ticlopidine</e1> and the CYP3A inhibitor <e2>itraconazole</e2>. ,False,negative
S-ketamine,ticlopidine,87,96,128,138,"In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg <e1>S-ketamine</e1> after pretreatments with oral <e2>ticlopidine</e2> (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. ",False,negative
S-ketamine,itraconazole,87,96,162,173,"In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg <e1>S-ketamine</e1> after pretreatments with oral ticlopidine (250 mg twice daily), <e2>itraconazole</e2> (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. ",False,negative
ticlopidine,itraconazole,128,138,162,173,"In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral <e1>ticlopidine</e1> (250 mg twice daily), <e2>itraconazole</e2> (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. ",False,negative
Ticlopidine,ketamine,0,10,134,141,"<e1>Ticlopidine</e1> treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral <e2>ketamine</e2> by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. ",True,mechanism
Ticlopidine,itraconazole,0,10,164,175,"<e1>Ticlopidine</e1> treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas <e2>itraconazole</e2> treatment did not increase the exposure to S-ketamine. ",False,negative
Ticlopidine,S-ketamine,0,10,220,229,"<e1>Ticlopidine</e1> treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to <e2>S-ketamine</e2>. ",False,negative
ketamine,itraconazole,134,141,164,175,"Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral <e1>ketamine</e1> by 2.4-fold, whereas <e2>itraconazole</e2> treatment did not increase the exposure to S-ketamine. ",False,negative
ketamine,S-ketamine,134,141,220,229,"Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral <e1>ketamine</e1> by 2.4-fold, whereas itraconazole treatment did not increase the exposure to <e2>S-ketamine</e2>. ",False,negative
itraconazole,S-ketamine,164,175,220,229,"Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas <e1>itraconazole</e1> treatment did not increase the exposure to <e2>S-ketamine</e2>. ",False,negative
norketamine,ketamine,13,23,39,46,The ratio of <e1>norketamine</e1> AUC(0-   ) to <e2>ketamine</e2> AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. ,False,negative
norketamine,ticlopidine,13,23,94,104,The ratio of <e1>norketamine</e1> AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the <e2>ticlopidine</e2> (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. ,False,negative
norketamine,itraconazole,13,23,125,136,The ratio of <e1>norketamine</e1> AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and <e2>itraconazole</e2> phases (P = 0.006) as compared to placebo. ,False,negative
ketamine,ticlopidine,39,46,94,104,The ratio of norketamine AUC(0-   ) to <e1>ketamine</e1> AUC(0-   ) was significantly decreased in the <e2>ticlopidine</e2> (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. ,False,negative
ketamine,itraconazole,39,46,125,136,The ratio of norketamine AUC(0-   ) to <e1>ketamine</e1> AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and <e2>itraconazole</e2> phases (P = 0.006) as compared to placebo. ,False,negative
ticlopidine,itraconazole,94,104,125,136,The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the <e1>ticlopidine</e1> (P &lt; 0.001) and <e2>itraconazole</e2> phases (P = 0.006) as compared to placebo. ,False,negative
ticlopidine,itraconazole,7,17,23,34,"In the <e1>ticlopidine</e1> and <e2>itraconazole</e2> phases, the areas under the effect-time curves (self-reported drowsiness and performance) were significantly higher than those in the placebo phase (P < 0.05). ",False,negative
S-ketamine,ticlopidine,40,49,91,101,The findings suggest that the dosage of <e1>S-ketamine</e1> should be reduced in patients receiving <e2>ticlopidine</e2>.,True,advise
3-Deazaneplanocin A,DZNep,4,22,25,29,"The <e1>3-Deazaneplanocin A</e1> (<e2>DZNep</e2>), one of S-adenosylhomocysteine (AdoHcy) hydrolase inhibitors, has shown antitumor activities in a broad range of solid tumors and acute myeloid leukemia. ",False,negative
DZNep,DZNep,46,50,92,96,"We also found that Bcl-2 was overexpressed in <e1>DZNep</e1> insensitive cells, and cotreatment with <e2>DZNep</e2> and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. ",False,negative
DZNep,ABT-737,46,50,102,108,"We also found that Bcl-2 was overexpressed in <e1>DZNep</e1> insensitive cells, and cotreatment with DZNep and <e2>ABT-737</e2>, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. ",False,negative
DZNep,DZNep,46,50,195,199,"We also found that Bcl-2 was overexpressed in <e1>DZNep</e1> insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of <e2>DZNep</e2> insensitive MM cells. ",False,negative
DZNep,ABT-737,92,96,102,108,"We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with <e1>DZNep</e1> and <e2>ABT-737</e2>, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. ",True,effect
DZNep,DZNep,92,96,195,199,"We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with <e1>DZNep</e1> and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of <e2>DZNep</e2> insensitive MM cells. ",False,negative
ABT-737,DZNep,102,108,195,199,"We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and <e1>ABT-737</e1>, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of <e2>DZNep</e2> insensitive MM cells. ",False,negative
DZNep,ABT-737,13,17,106,112,"In addition, <e1>DZNep</e1> insensitivity might be associated with overexpression of Bcl-2, and the combination of <e2>ABT-737</e2> and DZNep could synergistically induced apoptosis. ",False,negative
DZNep,DZNep,13,17,118,122,"In addition, <e1>DZNep</e1> insensitivity might be associated with overexpression of Bcl-2, and the combination of ABT-737 and <e2>DZNep</e2> could synergistically induced apoptosis. ",False,negative
ABT-737,DZNep,106,112,118,122,"In addition, DZNep insensitivity might be associated with overexpression of Bcl-2, and the combination of <e1>ABT-737</e1> and <e2>DZNep</e2> could synergistically induced apoptosis. ",True,effect
Implanon,antiretroviral,0,7,47,60,<e1>Implanon</e1>   failure in an HIV-positive woman on <e2>antiretroviral</e2> therapy resulting in two ectopic pregnancies.,True,effect
antiretroviral,Implanon,59,72,138,145,We present an interesting case of an HIV-positive woman on <e1>antiretroviral</e1> therapy having tubal pregnancies on two separate occasions with <e2>Implanon</e2> in place.,True,effect
Antidepressant,warfarin,0,13,15,22,"<e1>Antidepressant</e1>-<e2>warfarin</e2> interaction and associated gastrointestinal bleeding risk in a case-control study.
",False,negative
antidepressant,warfarin,47,60,133,140,We sought to evaluate whether initiation of an <e1>antidepressant</e1> increases the risk of hospitalization for gastrointestinal bleeding in <e2>warfarin</e2> users.,False,negative
warfarin,warfarin,18,25,69,76,"In total, 430,455 <e1>warfarin</e1> users contributed 407,370 person-years of <e2>warfarin</e2> use. ",False,negative
Warfarin,citalopram,0,7,91,100,"<e1>Warfarin</e1> users had an increased odds ratio of gastrointestinal bleeding upon initiation of <e2>citalopram</e2> (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",True,effect
Warfarin,fluoxetine,0,7,139,148,"<e1>Warfarin</e1> users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), <e2>fluoxetine</e2> (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",True,effect
Warfarin,paroxetine,0,7,187,196,"<e1>Warfarin</e1> users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), <e2>paroxetine</e2> (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",True,effect
Warfarin,amitriptyline,0,7,235,247,"<e1>Warfarin</e1> users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), <e2>amitriptyline</e2> (OR   =   1.47 [95% CI, 1.02-2.11]). ",True,effect
citalopram,fluoxetine,91,100,139,148,"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of <e1>citalopram</e1> (OR   =   1.73 [95% CI, 1.25-2.38]), <e2>fluoxetine</e2> (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",False,negative
citalopram,paroxetine,91,100,187,196,"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of <e1>citalopram</e1> (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), <e2>paroxetine</e2> (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",False,negative
citalopram,amitriptyline,91,100,235,247,"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of <e1>citalopram</e1> (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), <e2>amitriptyline</e2> (OR   =   1.47 [95% CI, 1.02-2.11]). ",False,negative
fluoxetine,paroxetine,139,148,187,196,"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), <e1>fluoxetine</e1> (OR   =   1.63 [95% CI, 1.11-2.38]), <e2>paroxetine</e2> (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",False,negative
fluoxetine,amitriptyline,139,148,235,247,"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), <e1>fluoxetine</e1> (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), <e2>amitriptyline</e2> (OR   =   1.47 [95% CI, 1.02-2.11]). ",False,negative
paroxetine,amitriptyline,187,196,235,247,"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), <e1>paroxetine</e1> (OR   =   1.64 [95% CI, 1.27-2.12]), <e2>amitriptyline</e2> (OR   =   1.47 [95% CI, 1.02-2.11]). ",False,negative
mirtazapine,warfarin,5,15,57,64,"Also <e1>mirtazapine</e1>, which is not believed to interact with <e2>warfarin</e2>, increased the risk of GI bleeding (OR   =   1.75 [95% CI, 1.30-2.35]). ",True,effect
Warfarin,citalopram,0,7,29,38,"<e1>Warfarin</e1> users who initiated <e2>citalopram</e2>, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",True,effect
Warfarin,fluoxetine,0,7,41,50,"<e1>Warfarin</e1> users who initiated citalopram, <e2>fluoxetine</e2>, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",True,effect
Warfarin,paroxetine,0,7,53,62,"<e1>Warfarin</e1> users who initiated citalopram, fluoxetine, <e2>paroxetine</e2>, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",True,effect
Warfarin,amitriptyline,0,7,65,77,"<e1>Warfarin</e1> users who initiated citalopram, fluoxetine, paroxetine, <e2>amitriptyline</e2>, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",True,effect
Warfarin,mirtazapine,0,7,83,93,"<e1>Warfarin</e1> users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or <e2>mirtazapine</e2> had an increased risk of hospitalization for gastrointestinal bleeding. ",True,effect
citalopram,fluoxetine,29,38,41,50,"Warfarin users who initiated <e1>citalopram</e1>, <e2>fluoxetine</e2>, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",False,negative
citalopram,paroxetine,29,38,53,62,"Warfarin users who initiated <e1>citalopram</e1>, fluoxetine, <e2>paroxetine</e2>, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",False,negative
citalopram,amitriptyline,29,38,65,77,"Warfarin users who initiated <e1>citalopram</e1>, fluoxetine, paroxetine, <e2>amitriptyline</e2>, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",False,negative
citalopram,mirtazapine,29,38,83,93,"Warfarin users who initiated <e1>citalopram</e1>, fluoxetine, paroxetine, amitriptyline, or <e2>mirtazapine</e2> had an increased risk of hospitalization for gastrointestinal bleeding. ",False,negative
fluoxetine,paroxetine,41,50,53,62,"Warfarin users who initiated citalopram, <e1>fluoxetine</e1>, <e2>paroxetine</e2>, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",False,negative
fluoxetine,amitriptyline,41,50,65,77,"Warfarin users who initiated citalopram, <e1>fluoxetine</e1>, paroxetine, <e2>amitriptyline</e2>, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",False,negative
fluoxetine,mirtazapine,41,50,83,93,"Warfarin users who initiated citalopram, <e1>fluoxetine</e1>, paroxetine, amitriptyline, or <e2>mirtazapine</e2> had an increased risk of hospitalization for gastrointestinal bleeding. ",False,negative
paroxetine,amitriptyline,53,62,65,77,"Warfarin users who initiated citalopram, fluoxetine, <e1>paroxetine</e1>, <e2>amitriptyline</e2>, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",False,negative
paroxetine,mirtazapine,53,62,83,93,"Warfarin users who initiated citalopram, fluoxetine, <e1>paroxetine</e1>, amitriptyline, or <e2>mirtazapine</e2> had an increased risk of hospitalization for gastrointestinal bleeding. ",False,negative
amitriptyline,mirtazapine,65,77,83,93,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, <e1>amitriptyline</e1>, or <e2>mirtazapine</e2> had an increased risk of hospitalization for gastrointestinal bleeding. ",False,negative
1-aminobenzotriazole,ABT,94,113,116,118,"The incubations were performed in the absence and presence of the non-specific CYP inhibitor, <e1>1-aminobenzotriazole</e1> (<e2>ABT</e2>) and isoform-specific inhibitors. ",False,negative
ABT,precocene I,0,2,30,40,"<e1>ABT</e1> decreased the toxicity of <e2>precocene I</e2>, increased exposure to parent compound, and decreased metabolite levels in a dose-dependent manner. ",True,effect
precocene I,tranylcypromine,67,77,104,118,"Of the isoform-specific CYP inhibitors tested for an effect on the <e1>precocene I</e1> metabolite profile, only <e2>tranylcypromine</e2> was noticeably effective, indicating a role of CYPs 2A6, 2C9, 2Cl9, and 2E1. ",False,negative
ABT,diethyldithiocarbamate,71,73,75,96,"With respect to toxicity, the order of CYP inhibitor effectiveness was <e1>ABT</e1>><e2>diethyldithiocarbamate</e2>~tranylcypromine>ketoconazole. ",False,negative
ABT,tranylcypromine,71,73,98,112,"With respect to toxicity, the order of CYP inhibitor effectiveness was <e1>ABT</e1>>diethyldithiocarbamate~<e2>tranylcypromine</e2>>ketoconazole. ",False,negative
ABT,ketoconazole,71,73,114,125,"With respect to toxicity, the order of CYP inhibitor effectiveness was <e1>ABT</e1>>diethyldithiocarbamate~tranylcypromine><e2>ketoconazole</e2>. ",False,negative
diethyldithiocarbamate,tranylcypromine,75,96,98,112,"With respect to toxicity, the order of CYP inhibitor effectiveness was ABT><e1>diethyldithiocarbamate</e1>~<e2>tranylcypromine</e2>>ketoconazole. ",False,negative
diethyldithiocarbamate,ketoconazole,75,96,114,125,"With respect to toxicity, the order of CYP inhibitor effectiveness was ABT><e1>diethyldithiocarbamate</e1>~tranylcypromine><e2>ketoconazole</e2>. ",False,negative
tranylcypromine,ketoconazole,98,112,114,125,"With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~<e1>tranylcypromine</e1>><e2>ketoconazole</e2>. ",False,negative
Furafylline,sulfaphenazole,0,10,16,29,"<e1>Furafylline</e1> and <e2>sulfaphenazole</e2> had no effect, while quinidine appeared to augment precocene I toxicity. ",False,negative
Furafylline,quinidine,0,10,52,60,"<e1>Furafylline</e1> and sulfaphenazole had no effect, while <e2>quinidine</e2> appeared to augment precocene I toxicity. ",False,negative
Furafylline,precocene I,0,10,82,92,"<e1>Furafylline</e1> and sulfaphenazole had no effect, while quinidine appeared to augment <e2>precocene I</e2> toxicity. ",False,negative
sulfaphenazole,quinidine,16,29,52,60,"Furafylline and <e1>sulfaphenazole</e1> had no effect, while <e2>quinidine</e2> appeared to augment precocene I toxicity. ",False,negative
sulfaphenazole,precocene I,16,29,82,92,"Furafylline and <e1>sulfaphenazole</e1> had no effect, while quinidine appeared to augment <e2>precocene I</e2> toxicity. ",False,negative
quinidine,precocene I,52,60,82,92,"Furafylline and sulfaphenazole had no effect, while <e1>quinidine</e1> appeared to augment <e2>precocene I</e2> toxicity. ",True,effect
precocene I,precocene I,103,113,165,175,These results suggest that rat liver slices do not reproduce the reported in vivo biotransformation of <e1>precocene I</e1> and therefore may not be an appropriate model for <e2>precocene I</e2> metabolism. ,False,negative
adeno-associated virus-2,AAV2,145,168,171,174,To determine whether the co-injection of extracellular matrix degrading enzymes improves retinal transduction following intravitreal delivery of <e1>adeno-associated virus-2</e1> (<e2>AAV2</e2>).,False,negative
AAV2,collagenase,0,3,214,224,"<e1>AAV2</e1> containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including <e2>collagenase</e2>, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. ",False,negative
AAV2,hyaluronan lyase,0,3,227,242,"<e1>AAV2</e1> containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, <e2>hyaluronan lyase</e2>, heparinase III, or chondroitin ABC lyase. ",False,negative
AAV2,heparinase III,0,3,245,258,"<e1>AAV2</e1> containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, <e2>heparinase III</e2>, or chondroitin ABC lyase. ",False,negative
AAV2,chondroitin ABC lyase,0,3,264,284,"<e1>AAV2</e1> containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or <e2>chondroitin ABC lyase</e2>. ",False,negative
collagenase,hyaluronan lyase,214,224,227,242,"AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including <e1>collagenase</e1>, <e2>hyaluronan lyase</e2>, heparinase III, or chondroitin ABC lyase. ",False,negative
collagenase,heparinase III,214,224,245,258,"AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including <e1>collagenase</e1>, hyaluronan lyase, <e2>heparinase III</e2>, or chondroitin ABC lyase. ",False,negative
collagenase,chondroitin ABC lyase,214,224,264,284,"AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including <e1>collagenase</e1>, hyaluronan lyase, heparinase III, or <e2>chondroitin ABC lyase</e2>. ",False,negative
hyaluronan lyase,heparinase III,227,242,245,258,"AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, <e1>hyaluronan lyase</e1>, <e2>heparinase III</e2>, or chondroitin ABC lyase. ",False,negative
hyaluronan lyase,chondroitin ABC lyase,227,242,264,284,"AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, <e1>hyaluronan lyase</e1>, heparinase III, or <e2>chondroitin ABC lyase</e2>. ",False,negative
heparinase III,chondroitin ABC lyase,245,258,264,284,"AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, <e1>heparinase III</e1>, or <e2>chondroitin ABC lyase</e2>. ",False,negative
heparinase III,chondroitin ABC lyase,16,29,34,54,The addition of <e1>heparinase III</e1> or <e2>chondroitin ABC lyase</e2> greatly enhanced transduction of the retinal ganglion cell layer and increased the depth of transduction into the outer retina. ,False,negative
Hyaluronan lyase,collagenase,0,15,42,52,<e1>Hyaluronan lyase</e1> had a limited effect and <e2>collagenase</e2> was ineffective. ,False,negative
heparinase III,chondroitin ABC lyase,58,71,77,97,Electroretinograms survived with higher concentrations of <e1>heparinase III</e1> and <e2>chondroitin ABC lyase</e2> than were required for optimal retinal transduction. ,False,negative
AAV2,heparinase III,0,3,66,79,<e1>AAV2</e1>-mediated retinal transduction is improved by co-injection of <e2>heparinase III</e2> or chondroitin ABC lyase. ,True,effect
AAV2,chondroitin ABC lyase,0,3,84,104,<e1>AAV2</e1>-mediated retinal transduction is improved by co-injection of heparinase III or <e2>chondroitin ABC lyase</e2>. ,True,effect
heparinase III,chondroitin ABC lyase,66,79,84,104,AAV2-mediated retinal transduction is improved by co-injection of <e1>heparinase III</e1> or <e2>chondroitin ABC lyase</e2>. ,False,negative
ketamine,propofol,71,78,84,91,"Prevention of emergence agitation in seven children receiving low-dose <e1>ketamine</e1> and <e2>propofol</e2> total intravenous anesthesia.
",False,negative
ketamine,propofol,95,102,124,131,We retrospectively reviewed the records of 7 pediatric oncology patients who received low-dose <e1>ketamine</e1> in conjunction with <e2>propofol</e2> for total intravenous anesthesia (TIVA) repeatedly for radiation therapy. ,False,negative
propofol,ketamine,61,68,161,168,EA signs were observed in all 7 patients in association with <e1>propofol</e1> TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose <e2>ketamine</e2> was added to propofol. ,False,negative
propofol,propofol,61,68,183,190,EA signs were observed in all 7 patients in association with <e1>propofol</e1> TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose ketamine was added to <e2>propofol</e2>. ,False,negative
ketamine,propofol,161,168,183,190,EA signs were observed in all 7 patients in association with propofol TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose <e1>ketamine</e1> was added to <e2>propofol</e2>. ,False,negative
ketamine,propofol,51,58,69,76,"Based on this experience, we suggest that low-dose <e1>ketamine</e1> added to <e2>propofol</e2> may be associated with prevention of EA in children with a history of EA with propofol TIVA.",True,effect
ketamine,propofol,51,58,156,163,"Based on this experience, we suggest that low-dose <e1>ketamine</e1> added to propofol may be associated with prevention of EA in children with a history of EA with <e2>propofol</e2> TIVA.",False,negative
propofol,propofol,69,76,156,163,"Based on this experience, we suggest that low-dose ketamine added to <e1>propofol</e1> may be associated with prevention of EA in children with a history of EA with <e2>propofol</e2> TIVA.",False,negative
Tamoxifen,estrogen antagonist,0,8,14,32,"<e1>Tamoxifen</e1>, an <e2>estrogen antagonist</e2>, is the standard hormone treatment for breast cancer. ",False,negative
Paroxetine,fluoxetine,0,9,15,24,<e1>Paroxetine</e1> and <e2>fluoxetine</e2> reduce the plasma concentration of endoxifen by about 50%. ,False,negative
Paroxetine,endoxifen,0,9,61,69,<e1>Paroxetine</e1> and fluoxetine reduce the plasma concentration of <e2>endoxifen</e2> by about 50%. ,True,mechanism
fluoxetine,endoxifen,15,24,61,69,Paroxetine and <e1>fluoxetine</e1> reduce the plasma concentration of <e2>endoxifen</e2> by about 50%. ,True,mechanism
tamoxifen,SSRI antidepressants,85,93,125,144,"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with <e1>tamoxifen</e1> for breast cancer, especially <e2>SSRI antidepressants</e2> such as paroxetine and fluoxetine. ",True,advise
tamoxifen,paroxetine,85,93,154,163,"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with <e1>tamoxifen</e1> for breast cancer, especially SSRI antidepressants such as <e2>paroxetine</e2> and fluoxetine. ",True,advise
tamoxifen,fluoxetine,85,93,169,178,"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with <e1>tamoxifen</e1> for breast cancer, especially SSRI antidepressants such as paroxetine and <e2>fluoxetine</e2>. ",True,advise
SSRI antidepressants,paroxetine,125,144,154,163,"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially <e1>SSRI antidepressants</e1> such as <e2>paroxetine</e2> and fluoxetine. ",False,negative
SSRI antidepressants,fluoxetine,125,144,169,178,"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially <e1>SSRI antidepressants</e1> such as paroxetine and <e2>fluoxetine</e2>. ",False,negative
paroxetine,fluoxetine,154,163,169,178,"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as <e1>paroxetine</e1> and <e2>fluoxetine</e2>. ",False,negative
antidepressant drug,antidepressants,35,53,68,82,"Depression does not always require <e1>antidepressant drug</e1> therapy, and <e2>antidepressants</e2> have no proven preventive impact on hot flushes linked to the menopause. ",False,negative
antidepressant,tamoxifen,24,37,95,103,"If in certain cases, an <e1>antidepressant</e1> is considered necessary, it may be advisable to replace <e2>tamoxifen</e2> with anastrozole.",True,advise
antidepressant,anastrozole,24,37,110,120,"If in certain cases, an <e1>antidepressant</e1> is considered necessary, it may be advisable to replace tamoxifen with <e2>anastrozole</e2>.",False,negative
tamoxifen,anastrozole,95,103,110,120,"If in certain cases, an antidepressant is considered necessary, it may be advisable to replace <e1>tamoxifen</e1> with <e2>anastrozole</e2>.",False,negative
Amphetamine,quinpirole,0,10,128,137,"<e1>Amphetamine</e1> locomotor sensitization and conditioned place preference in adolescent male and female rats neonatally treated with <e2>quinpirole</e2>.
",False,negative
quinpirole,amphetamine,53,62,88,98,The objective was to analyze the effects of neonatal <e1>quinpirole</e1> treatment on effects of <e2>amphetamine</e2> in adolescent rats using locomotor sensitization and conditioned place preference procedures. ,False,negative
quinpirole,amphetamine,25,34,55,65,"In female rats, neonatal <e1>quinpirole</e1> treatment enhanced <e2>amphetamine</e2> locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. ",True,effect
quinpirole,quinpirole,25,34,105,114,"In female rats, neonatal <e1>quinpirole</e1> treatment enhanced amphetamine locomotor sensitization compared with <e2>quinpirole</e2>-free controls sensitized to amphetamine. ",False,negative
quinpirole,amphetamine,25,34,144,154,"In female rats, neonatal <e1>quinpirole</e1> treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to <e2>amphetamine</e2>. ",False,negative
amphetamine,quinpirole,55,65,105,114,"In female rats, neonatal quinpirole treatment enhanced <e1>amphetamine</e1> locomotor sensitization compared with <e2>quinpirole</e2>-free controls sensitized to amphetamine. ",False,negative
amphetamine,amphetamine,55,65,144,154,"In female rats, neonatal quinpirole treatment enhanced <e1>amphetamine</e1> locomotor sensitization compared with quinpirole-free controls sensitized to <e2>amphetamine</e2>. ",False,negative
quinpirole,amphetamine,105,114,144,154,"In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with <e1>quinpirole</e1>-free controls sensitized to <e2>amphetamine</e2>. ",False,negative
amphetamine,quinpirole,40,50,136,145,"Male rats demonstrated sensitization to <e1>amphetamine</e1>, although this was muted compared with female rats, and were unaffected by neonatal <e2>quinpirole</e2>. ",False,negative
quinpirole,amphetamine,27,36,65,75,"Rats treated with neonatal <e1>quinpirole</e1> enhanced time spent in the <e2>amphetamine</e2>-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ",False,negative
quinpirole,quinpirole,27,36,106,115,"Rats treated with neonatal <e1>quinpirole</e1> enhanced time spent in the amphetamine-paired context compared with <e2>quinpirole</e2>-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ",False,negative
quinpirole,amphetamine,27,36,148,158,"Rats treated with neonatal <e1>quinpirole</e1> enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with <e2>amphetamine</e2>, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ",False,negative
quinpirole,amphetamine,27,36,203,213,"Rats treated with neonatal <e1>quinpirole</e1> enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with <e2>amphetamine</e2> spent more time in the drug-paired context compared with saline-treated controls. ",False,negative
amphetamine,quinpirole,65,75,106,115,"Rats treated with neonatal quinpirole enhanced time spent in the <e1>amphetamine</e1>-paired context compared with <e2>quinpirole</e2>-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ",False,negative
amphetamine,amphetamine,65,75,148,158,"Rats treated with neonatal quinpirole enhanced time spent in the <e1>amphetamine</e1>-paired context compared with quinpirole-free controls conditioned with <e2>amphetamine</e2>, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ",False,negative
amphetamine,amphetamine,65,75,203,213,"Rats treated with neonatal quinpirole enhanced time spent in the <e1>amphetamine</e1>-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with <e2>amphetamine</e2> spent more time in the drug-paired context compared with saline-treated controls. ",False,negative
quinpirole,amphetamine,106,115,148,158,"Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with <e1>quinpirole</e1>-free controls conditioned with <e2>amphetamine</e2>, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ",False,negative
quinpirole,amphetamine,106,115,203,213,"Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with <e1>quinpirole</e1>-free controls conditioned with amphetamine, but only female controls conditioned with <e2>amphetamine</e2> spent more time in the drug-paired context compared with saline-treated controls. ",False,negative
amphetamine,amphetamine,148,158,203,213,"Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with <e1>amphetamine</e1>, but only female controls conditioned with <e2>amphetamine</e2> spent more time in the drug-paired context compared with saline-treated controls. ",False,negative
cyclosporine,tacrolimus,49,60,87,96,"In vivo CYP3A activity is significantly lower in <e1>cyclosporine</e1>-treated as compared with <e2>tacrolimus</e2>-treated renal allograft recipients.
",False,negative
cyclosporine,tacrolimus,33,44,50,59,In vitro studies have identified <e1>cyclosporine</e1> and <e2>tacrolimus</e2> as CYP3A inhibitors. ,False,negative
midazolam,cyclosporine,27,35,181,192,"Systemic and apparent oral <e1>midazolam</e1> clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in <e2>cyclosporine</e2>-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20). ",True,mechanism
midazolam,tacrolimus,27,35,236,245,"Systemic and apparent oral <e1>midazolam</e1> clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched <e2>tacrolimus</e2>-treated patients (n = 20). ",False,negative
cyclosporine,tacrolimus,181,192,236,245,"Systemic and apparent oral midazolam clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in <e1>cyclosporine</e1>-treated patients (n = 20) than in matched <e2>tacrolimus</e2>-treated patients (n = 20). ",False,negative
midazolam,tacrolimus,21,29,95,104,The latter displayed <e1>midazolam</e1> clearances similar to those in two larger cohorts of nonmatched <e2>tacrolimus</e2>-treated patients (n = 58 and n = 80) and to those receiving a calcineurin inhibitor-free regimen (n = 6). ,False,negative
midazolam,calcineurin inhibitor,21,29,168,188,The latter displayed <e1>midazolam</e1> clearances similar to those in two larger cohorts of nonmatched tacrolimus-treated patients (n = 58 and n = 80) and to those receiving a <e2>calcineurin inhibitor</e2>-free regimen (n = 6). ,False,negative
tacrolimus,calcineurin inhibitor,95,104,168,188,The latter displayed midazolam clearances similar to those in two larger cohorts of nonmatched <e1>tacrolimus</e1>-treated patients (n = 58 and n = 80) and to those receiving a <e2>calcineurin inhibitor</e2>-free regimen (n = 6). ,False,negative
cyclosporine,tacrolimus,112,123,149,158,"This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving <e1>cyclosporine</e1> than in those receiving <e2>tacrolimus</e2>, indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to CYP3A inhibition. ",False,negative
cyclosporine,cyclosporine,112,123,228,239,"This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving <e1>cyclosporine</e1> than in those receiving tacrolimus, indicating that, at the doses generally used in clinical practice, <e2>cyclosporine</e2> is the stronger of the two with respect to CYP3A inhibition. ",False,negative
tacrolimus,cyclosporine,149,158,228,239,"This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving cyclosporine than in those receiving <e1>tacrolimus</e1>, indicating that, at the doses generally used in clinical practice, <e2>cyclosporine</e2> is the stronger of the two with respect to CYP3A inhibition. ",False,negative
cinacalcet,darbepoetin,40,49,83,93,"Improved parathyroid hormone control by <e1>cinacalcet</e1> is associated with reduction in <e2>darbepoetin</e2> requirement in patients with end-stage renal disease.
",False,negative
erythropoietin,EPO,75,88,91,93,"Uncontrolled hy-per-parathyroidism causes bone marrow fibrosis, leading to <e1>erythropoietin</e1> (<e2>EPO</e2>) resistance. ",False,negative
cinacalcet,darbepoetin,23,32,118,128,"Medical treatment with <e1>cinacalcet</e1> is effective in reducing plasma parathyroid hormone (PTH) levels, but its effect on <e2>darbepoetin</e2> dosing is unknown. ",False,negative
darbepoetin,cinacalcet,70,80,127,136,The primary objective of the study was to ascertain the difference in <e1>darbepoetin</e1> responsiveness before and after 12 months of <e2>cinacalcet</e2> therapy. ,False,negative
cinacalcet,darbepoetin,20,29,64,74,Reduction of PTH by <e1>cinacalcet</e1> is associated with a decrease in <e2>darbepoetin</e2> requirement. ,True,effect
celecoxib,anti-cancer drugs,15,23,40,56,"Interaction of <e1>celecoxib</e1> with different <e2>anti-cancer drugs</e2> is antagonistic in breast but not in other cancer cells.
",True,effect
cyclooxygenase-2 inhibitors,chemotherapeutic agents,39,65,120,142,This study investigates the ability of <e1>cyclooxygenase-2 inhibitors</e1> to sensitize cells from different origins to several <e2>chemotherapeutic agents</e2>. ,False,negative
5-FU,cisplatin,130,133,136,144,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to <e1>5-FU</e1>, <e2>cisplatin</e2>, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.",False,negative
5-FU,doxorubicin,130,133,147,157,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to <e1>5-FU</e1>, cisplatin, <e2>doxorubicin</e2> and etoposide   celecoxib following different incubation schedules were analyzed.",False,negative
5-FU,etoposide,130,133,163,171,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to <e1>5-FU</e1>, cisplatin, doxorubicin and <e2>etoposide</e2>   celecoxib following different incubation schedules were analyzed.",False,negative
5-FU,celecoxib,130,133,175,183,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to <e1>5-FU</e1>, cisplatin, doxorubicin and etoposide   <e2>celecoxib</e2> following different incubation schedules were analyzed.",False,negative
cisplatin,doxorubicin,136,144,147,157,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, <e1>cisplatin</e1>, <e2>doxorubicin</e2> and etoposide   celecoxib following different incubation schedules were analyzed.",False,negative
cisplatin,etoposide,136,144,163,171,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, <e1>cisplatin</e1>, doxorubicin and <e2>etoposide</e2>   celecoxib following different incubation schedules were analyzed.",False,negative
cisplatin,celecoxib,136,144,175,183,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, <e1>cisplatin</e1>, doxorubicin and etoposide   <e2>celecoxib</e2> following different incubation schedules were analyzed.",False,negative
doxorubicin,etoposide,147,157,163,171,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, <e1>doxorubicin</e1> and <e2>etoposide</e2>   celecoxib following different incubation schedules were analyzed.",False,negative
doxorubicin,celecoxib,147,157,175,183,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, <e1>doxorubicin</e1> and etoposide   <e2>celecoxib</e2> following different incubation schedules were analyzed.",False,negative
etoposide,celecoxib,163,171,175,183,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and <e1>etoposide</e1>   <e2>celecoxib</e2> following different incubation schedules were analyzed.",False,negative
celecoxib,celecoxib,28,36,136,144,We found antagonism between <e1>celecoxib</e1> and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between <e2>celecoxib</e2> and doxorubicin in all cell lines except for two combinations in HCT116 cells. ,False,negative
celecoxib,doxorubicin,28,36,150,160,We found antagonism between <e1>celecoxib</e1> and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and <e2>doxorubicin</e2> in all cell lines except for two combinations in HCT116 cells. ,False,negative
celecoxib,doxorubicin,136,144,150,160,We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between <e1>celecoxib</e1> and <e2>doxorubicin</e2> in all cell lines except for two combinations in HCT116 cells. ,True,effect
celecoxib,doxorubicin,51,59,121,131,"These results, if confirmed in-vivo, indicate that <e1>celecoxib</e1> is not a suitable chemosensitizer for breast cancer or with <e2>doxorubicin</e2> for other cancers. ",False,negative
clopidogrel,proton pump inhibitors,21,31,37,58,"[Interaction between <e1>clopidogrel</e1> and <e2>proton pump inhibitors</e2>].
",False,negative
proton pump inhibitors,clopidogrel,29,50,56,66,The drug interaction between <e1>proton pump inhibitors</e1> and <e2>clopidogrel</e2> has been the subject of much study in recent years. ,False,negative
proton pump inhibitors,clopidogrel,46,67,119,129,Contradictory results regarding the effect of <e1>proton pump inhibitors</e1> on platelet reactivity and on clinical outcome in <e2>clopidogrel</e2>-treated patients have been reported in literature. ,False,negative
omeprazole,clopidogrel,19,28,34,44,"Concomitant use of <e1>omeprazole</e1> and <e2>clopidogrel</e2> was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of CYP2C19, a cytochrome P450 (CYP) enzyme. ",True,mechanism
omeprazole,omeprazole,19,28,203,212,"Concomitant use of <e1>omeprazole</e1> and clopidogrel was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by <e2>omeprazole</e2> of CYP2C19, a cytochrome P450 (CYP) enzyme. ",False,negative
clopidogrel,omeprazole,34,44,203,212,"Concomitant use of omeprazole and <e1>clopidogrel</e1> was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by <e2>omeprazole</e2> of CYP2C19, a cytochrome P450 (CYP) enzyme. ",False,negative
Pantoprazole,clopidogrel,0,11,41,51,<e1>Pantoprazole</e1> has a much weaker effect on <e2>clopidogrel</e2>'s pharmacokinetics and on platelet reactivity during concomitant use. ,True,mechanism
proton pump inhibitors,clopidogrel,27,48,80,90,The influence of the other <e1>proton pump inhibitors</e1> when used simultaneously with <e2>clopidogrel</e2> has not yet been investigated in adequately randomized studies. ,False,negative
clopidogrel,omeprazole,50,60,89,98,Regulatory agencies state that the combination of <e1>clopidogrel</e1> and the CYP2C19 inhibitors <e2>omeprazole</e2> and esomeprazole should be avoided. ,True,advise
clopidogrel,esomeprazole,50,60,104,115,Regulatory agencies state that the combination of <e1>clopidogrel</e1> and the CYP2C19 inhibitors omeprazole and <e2>esomeprazole</e2> should be avoided. ,True,advise
omeprazole,esomeprazole,89,98,104,115,Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors <e1>omeprazole</e1> and <e2>esomeprazole</e2> should be avoided. ,False,negative
proton pump inhibitors,clopidogrel,97,118,124,134,"To date, there is no conclusive evidence of a clinically-relevant interaction between any of the <e1>proton pump inhibitors</e1> and <e2>clopidogrel</e2>.",False,negative
minocycline,fosfomycin,21,31,47,56,"In vitro activity of <e1>minocycline</e1> combined with <e2>fosfomycin</e2> against clinical isolates of methicillin-resistant Staphylococcus aureus.
",False,negative
minocycline,methicillin,21,31,87,97,"In vitro activity of <e1>minocycline</e1> combined with fosfomycin against clinical isolates of <e2>methicillin</e2>-resistant Staphylococcus aureus.
",False,negative
fosfomycin,methicillin,47,56,87,97,"In vitro activity of minocycline combined with <e1>fosfomycin</e1> against clinical isolates of <e2>methicillin</e2>-resistant Staphylococcus aureus.
",False,negative
minocycline,fosfomycin,54,64,80,89,This study aimed to evaluate the in vitro activity of <e1>minocycline</e1> combined with <e2>fosfomycin</e2> against isolates of methicillin-resistant Staphylococcus aureus (MRSA). ,False,negative
minocycline,methicillin,54,64,111,121,This study aimed to evaluate the in vitro activity of <e1>minocycline</e1> combined with fosfomycin against isolates of <e2>methicillin</e2>-resistant Staphylococcus aureus (MRSA). ,False,negative
fosfomycin,methicillin,80,89,111,121,This study aimed to evaluate the in vitro activity of minocycline combined with <e1>fosfomycin</e1> against isolates of <e2>methicillin</e2>-resistant Staphylococcus aureus (MRSA). ,False,negative
minocycline,fosfomycin,31,41,47,56,The susceptibility results for <e1>minocycline</e1> and <e2>fosfomycin</e2> were interpreted according to the most relevant criteria. ,False,negative
minocycline,fosfomycin,19,29,35,44,The combination of <e1>minocycline</e1> and <e2>fosfomycin</e2> can be synergistic against MRSA. ,True,effect
levothyroxine,simeticone,85,97,148,157,The authors report the case of an infant with confirmed congenital hypothyroidism on <e1>levothyroxine</e1> who experienced a possible drug interaction with <e2>simeticone</e2>. ,True,int
Infacol,levothyroxine,42,48,78,90,Questioning revealed the child was taking <e1>Infacol</e1> drops before feeds while on <e2>levothyroxine</e2>. ,False,negative
thyroxine,simeticone,20,28,35,44,Drug interaction of <e1>thyroxine</e1> with <e2>simeticone</e2> has not been reported previously and is not listed in the British National Formulary for Children. ,False,negative
Calcium,nonheme iron,0,6,59,65,<e1>Calcium</e1> does not inhibit the absorption of 5 milligrams of <e2>nonheme iron</e2> or heme iron at doses less than 800 milligrams in nonpregnant women.,False,negative
Calcium,heme iron,0,6,70,78,<e1>Calcium</e1> does not inhibit the absorption of 5 milligrams of nonheme or <e2>heme iron</e2> at doses less than 800 milligrams in nonpregnant women.,False,negative
nonheme iron,heme iron,59,65,70,78,Calcium does not inhibit the absorption of 5 milligrams of <e1>nonheme iron</e1> or <e2>heme iron</e2> at doses less than 800 milligrams in nonpregnant women.,False,negative
Calcium,nonheme iron,0,6,83,89,<e1>Calcium</e1> is the only known component in the diet that may affect absorption of both <e2>nonheme iron</e2> and heme iron. ,True,mechanism
Calcium,heme iron,0,6,95,103,<e1>Calcium</e1> is the only known component in the diet that may affect absorption of both nonheme and <e2>heme iron</e2>. ,True,mechanism
nonheme iron,heme iron,83,89,95,103,Calcium is the only known component in the diet that may affect absorption of both <e1>nonheme iron</e1> and <e2>heme iron</e2>. ,False,negative
calcium,iron,28,34,46,49,"However, the evidence for a <e1>calcium</e1> effect on <e2>iron</e2> absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies. ",True,mechanism
calcium,calcium,28,34,123,129,"However, the evidence for a <e1>calcium</e1> effect on iron absorption mainly comes from studies that did not isolate the effect of <e2>calcium</e2> from that of other dietary components, because it was detected in single-meal studies. ",False,negative
iron,calcium,46,49,123,129,"However, the evidence for a calcium effect on <e1>iron</e1> absorption mainly comes from studies that did not isolate the effect of <e2>calcium</e2> from that of other dietary components, because it was detected in single-meal studies. ",False,negative
calcium,nonheme iron,52,58,77,83,Our objective was to establish potential effects of <e1>calcium</e1> on absorption of <e2>nonheme iron</e2> and heme iron and the dose response for this effect in the absence of a meal. ,False,negative
calcium,heme iron,52,58,89,97,Our objective was to establish potential effects of <e1>calcium</e1> on absorption of nonheme and <e2>heme iron</e2> and the dose response for this effect in the absence of a meal. ,False,negative
nonheme iron,heme iron,77,83,89,97,Our objective was to establish potential effects of calcium on absorption of <e1>nonheme iron</e1> and <e2>heme iron</e2> and the dose response for this effect in the absence of a meal. ,False,negative
calcium,nonheme iron,28,34,88,99,We evaluated the effects of <e1>calcium</e1> doses between 200 and 1500 mg on absorption of 5 mg <e2>nonheme iron</e2> (as ferrous sulfate). ,False,negative
calcium,ferrous sulfate,28,34,105,119,We evaluated the effects of <e1>calcium</e1> doses between 200 and 1500 mg on absorption of 5 mg nonheme iron (as <e2>ferrous sulfate</e2>). ,False,negative
nonheme iron,ferrous sulfate,88,99,105,119,We evaluated the effects of calcium doses between 200 and 1500 mg on absorption of 5 mg <e1>nonheme iron</e1> (as <e2>ferrous sulfate</e2>). ,False,negative
calcium,heme iron,33,39,92,100,We also evaluated the effects of <e1>calcium</e1> doses between 200 and 800 mg on absorption of 5 mg <e2>heme iron</e2> [as concentrated RBC (CRBC)]. ,False,negative
Calcium,calcium chloride,0,6,28,43,<e1>Calcium</e1> was administered as <e2>calcium chloride</e2> in all studies and minerals were ingested on an empty stomach. ,False,negative
Calcium,minerals,0,6,64,71,<e1>Calcium</e1> was administered as calcium chloride in all studies and <e2>minerals</e2> were ingested on an empty stomach. ,False,negative
calcium chloride,minerals,28,43,64,71,Calcium was administered as <e1>calcium chloride</e1> in all studies and <e2>minerals</e2> were ingested on an empty stomach. ,False,negative
Calcium,nonheme iron,0,6,35,46,<e1>Calcium</e1> doses   1000 mg diminished <e2>nonheme iron</e2> absorption by an average of 49.6%.,True,mechanism
calcium,heme iron,2,8,55,63,A <e1>calcium</e1> dose of 800 mg diminished absorption of 5 mg <e2>heme iron</e2> by 37.7%. ,True,mechanism
calcium,nonheme iron,53,59,117,123,"In conclusion, we demonstrated an isolated effect of <e1>calcium</e1> (as chloride) on absorption of 5 mg of iron provided as <e2>nonheme iron</e2> (as sulfate) and heme (as CRBC) iron. ",True,mechanism
calcium,heme iron,53,59,142,145,"In conclusion, we demonstrated an isolated effect of <e1>calcium</e1> (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and <e2>heme iron</e2> (as CRBC) iron. ",True,mechanism
nonheme iron,heme iron,117,123,142,145,"In conclusion, we demonstrated an isolated effect of calcium (as chloride) on absorption of 5 mg of iron provided as <e1>nonheme iron</e1> (as sulfate) and <e2>heme iron</e2> (as CRBC) iron. ",False,negative
sunitinib,docetaxel,32,40,46,54,Synergistic interaction between <e1>sunitinib</e1> and <e2>docetaxel</e2> is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.,True,int
sunitinib,sunitinib,66,74,131,139,This study was aimed to investigate the efficacy of single use of <e1>sunitinib</e1> and that of concurrent or sequential administration of <e2>sunitinib</e2> and docetaxel in NSCLC cell lines that are resistant to EGFR TKIs.,False,negative
sunitinib,docetaxel,66,74,145,153,This study was aimed to investigate the efficacy of single use of <e1>sunitinib</e1> and that of concurrent or sequential administration of sunitinib and <e2>docetaxel</e2> in NSCLC cell lines that are resistant to EGFR TKIs.,False,negative
sunitinib,docetaxel,131,139,145,153,This study was aimed to investigate the efficacy of single use of sunitinib and that of concurrent or sequential administration of <e1>sunitinib</e1> and <e2>docetaxel</e2> in NSCLC cell lines that are resistant to EGFR TKIs.,False,negative
sunitinib,docetaxel,84,92,97,105,NSCLC cell lines with EGFR T790M mutation and K-ras mutation were exposed to either <e1>sunitinib</e1> or <e2>docetaxel</e2> or both based on various sequential administrations. ,False,negative
Sunitinib,docetaxel,0,8,118,126,"<e1>Sunitinib</e1> exhibited dose-dependent growth inhibition in NSCLC cell lines and arrested cell cycle at G1 phase, whereas <e2>docetaxel</e2> arrested at S phase. ",False,negative
sunitinib,docetaxel,37,45,51,59,"Although single or concurrent use of <e1>sunitinib</e1> and <e2>docetaxel</e2> has some anti-proliferative effects, the sequential administrations of both drugs remarkably enhanced anti-tumor activity. ",True,effect
docetaxel,sunitinib,27,35,49,57,"When cells were exposed to <e1>docetaxel</e1> followed by <e2>sunitinib</e2>, synergism was observed. ",True,effect
docetaxel,sunitinib,102,110,179,187,The molecular basis of this synergism is that the signaling pathways that were initially activated by <e1>docetaxel</e1> exposure were efficiently suppressed by the subsequent exposure to <e2>sunitinib</e2>. ,True,effect
Sunitinib,docetaxel,0,8,166,174,<e1>Sunitinib</e1> as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of <e2>docetaxel</e2> followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.,False,negative
Sunitinib,sunitinib,0,8,188,196,<e1>Sunitinib</e1> as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by <e2>sunitinib</e2> is superior to sunitinib followed by docetaxel and concurrent administration.,False,negative
Sunitinib,sunitinib,0,8,213,221,<e1>Sunitinib</e1> as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to <e2>sunitinib</e2> followed by docetaxel and concurrent administration.,False,negative
Sunitinib,docetaxel,0,8,235,243,<e1>Sunitinib</e1> as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by <e2>docetaxel</e2> and concurrent administration.,False,negative
docetaxel,sunitinib,166,174,188,196,Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of <e1>docetaxel</e1> followed by <e2>sunitinib</e2> is superior to sunitinib followed by docetaxel and concurrent administration.,True,effect
docetaxel,sunitinib,166,174,213,221,Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of <e1>docetaxel</e1> followed by sunitinib is superior to <e2>sunitinib</e2> followed by docetaxel and concurrent administration.,False,negative
docetaxel,docetaxel,166,174,235,243,Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of <e1>docetaxel</e1> followed by sunitinib is superior to sunitinib followed by <e2>docetaxel</e2> and concurrent administration.,False,negative
sunitinib,sunitinib,188,196,213,221,Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by <e1>sunitinib</e1> is superior to <e2>sunitinib</e2> followed by docetaxel and concurrent administration.,False,negative
sunitinib,docetaxel,188,196,235,243,Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by <e1>sunitinib</e1> is superior to sunitinib followed by <e2>docetaxel</e2> and concurrent administration.,False,negative
sunitinib,docetaxel,213,221,235,243,Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to <e1>sunitinib</e1> followed by <e2>docetaxel</e2> and concurrent administration.,False,negative
piperacillin,methylglyoxal,31,42,48,60,"Distinct synergistic action of <e1>piperacillin</e1> and <e2>methylglyoxal</e2> against Pseudomonas aeruginosa.
",False,negative
piperacillin,carbenicillin,84,95,98,110,"Results revealed that the strains were resistant to many drugs at high levels, only <e1>piperacillin</e1>, <e2>carbenicillin</e2>, amikacin and ciprofloxacin showed resistances at comparatively lower levels. ",False,negative
piperacillin,amikacin,84,95,113,120,"Results revealed that the strains were resistant to many drugs at high levels, only <e1>piperacillin</e1>, carbenicillin, <e2>amikacin</e2> and ciprofloxacin showed resistances at comparatively lower levels. ",False,negative
piperacillin,ciprofloxacin,84,95,126,138,"Results revealed that the strains were resistant to many drugs at high levels, only <e1>piperacillin</e1>, carbenicillin, amikacin and <e2>ciprofloxacin</e2> showed resistances at comparatively lower levels. ",False,negative
carbenicillin,amikacin,98,110,113,120,"Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, <e1>carbenicillin</e1>, <e2>amikacin</e2> and ciprofloxacin showed resistances at comparatively lower levels. ",False,negative
carbenicillin,ciprofloxacin,98,110,126,138,"Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, <e1>carbenicillin</e1>, amikacin and <e2>ciprofloxacin</e2> showed resistances at comparatively lower levels. ",False,negative
amikacin,ciprofloxacin,113,120,126,138,"Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, <e1>amikacin</e1> and <e2>ciprofloxacin</e2> showed resistances at comparatively lower levels. ",False,negative
methylglyoxal,piperacillin,70,82,88,99,Distinct and statistically significant synergism was observed between <e1>methylglyoxal</e1> and <e2>piperacillin</e2> by disc diffusion tests when compared with their individual effects. ,True,effect
methylglyoxal,carbenicillin,30,42,62,74,Synergism was also noted when <e1>methylglyoxal</e1> was combined with <e2>carbenicillin</e2> and amikacin.,True,effect
methylglyoxal,amikacin,30,42,80,87,Synergism was also noted when <e1>methylglyoxal</e1> was combined with carbenicillin and <e2>amikacin</e2>.,True,effect
carbenicillin,amikacin,62,74,80,87,Synergism was also noted when methylglyoxal was combined with <e1>carbenicillin</e1> and <e2>amikacin</e2>.,False,negative
acetyl-l-carnitine,alpha lipoic acid,21,38,45,61,Protective effect of <e1>acetyl-l-carnitine</e1> and  <e2>alpha lipoic acid</e2> against the acute toxicity of diepoxybutane to human lymphocytes.,False,negative
acetyl-l-carnitine,alpha-lipoic acid,5,22,115,131,"(ii) <e1>acetyl-l-carnitine</e1> elicits a significant protective effect on DEB induced toxicity, which was potentiated by  <e2>alpha-lipoic acid</e2>.",True,effect
hemantane,doxycycline,14,22,28,38,"[Influence of <e1>hemantane</e1> and <e2>doxycycline</e2> on MPTP-evoked behavior violations in C57BL/6 mice].
",False,negative
anti-parkinsonian drug,hemantane,15,36,38,46,"The effects of <e1>anti-parkinsonian drug</e1> <e2>hemantane</e2> [(2-adamantyl)hexamethylenimine] (10 mg/kg, p. o.) ",False,negative
anti-parkinsonian drug,(2-adamantyl)hexamethylenimine,15,36,49,78,"The effects of <e1>anti-parkinsonian drug</e1> hemantane [<e2>(2-adamantyl)hexamethylenimine</e2>] (10 mg/kg, p. o.) ",False,negative
hemantane,(2-adamantyl)hexamethylenimine,38,46,49,78,"The effects of anti-parkinsonian drug <e1>hemantane</e1> [<e2>(2-adamantyl)hexamethylenimine</e2>] (10 mg/kg, p. o.) ",False,negative
antibiotic drug,doxycycline,7,21,23,33,"and/or <e1>antibiotic drug</e1> <e2>doxycycline</e2> (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.) ",False,negative
antibiotic drug,"1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine",7,21,85,128,"and/or <e1>antibiotic drug</e1> doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin <e2>1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine</e2> (MPTP) (4 x 20 mg/kg, i. p.) ",False,negative
antibiotic drug,MPTP,7,21,131,134,"and/or <e1>antibiotic drug</e1> doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (<e2>MPTP</e2>) (4 x 20 mg/kg, i. p.) ",False,negative
doxycycline,"1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine",23,33,85,128,"and/or antibiotic drug <e1>doxycycline</e1> (100 mg/kg, p. o.), as well as that of neurotoxin <e2>1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine</e2> (MPTP) (4 x 20 mg/kg, i. p.) ",False,negative
doxycycline,MPTP,23,33,131,134,"and/or antibiotic drug <e1>doxycycline</e1> (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (<e2>MPTP</e2>) (4 x 20 mg/kg, i. p.) ",False,negative
"1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine",MPTP,85,128,131,134,"and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin <e1>1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine</e1> (<e2>MPTP</e2>) (4 x 20 mg/kg, i. p.) ",False,negative
hemantane,doxycycline,24,32,37,47,"Acute administration of <e1>hemantane</e1> or <e2>doxycycline</e2> failed to influence locomotion in mice, while their combination normalized motor activity. ",True,effect
dasatinib,paclitaxel,25,33,44,53,"The role of p27(Kip1) in <e1>dasatinib</e1>-enhanced <e2>paclitaxel</e2> cytotoxicity in human ovarian cancer cells.
",True,effect
dasatinib,paclitaxel,14,22,65,74,"The effect of <e1>dasatinib</e1>, an inhibitor of Src and Abl kinases, on <e2>paclitaxel</e2> sensitivity was measured in ovarian cancer cells and HEY xenografts. ",False,negative
dasatinib,paclitaxel,64,72,78,87,"The roles of p27(Kip1), Bcl-2, and Cdk1 in apoptosis induced by <e1>dasatinib</e1> and <e2>paclitaxel</e2> were assessed using a terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay, siRNA knockdown of gene expression, transfection with Bcl-2 and Cdk1 expression vectors, and flow cytometry. ",False,negative
dasatinib,paclitaxel,23,31,38,47,HEY cells treated with <e1>dasatinib</e1> plus <e2>paclitaxel</e2> formed fewer colonies than did cells treated with either agent alone. ,True,effect
dasatinib,paclitaxel,45,53,60,69,"Treatment of HEY xenograft-bearing mice with <e1>dasatinib</e1> plus <e2>paclitaxel</e2> inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",True,effect
dasatinib,dasatinib,45,53,171,179,"Treatment of HEY xenograft-bearing mice with <e1>dasatinib</e1> plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, <e2>dasatinib</e2> + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",False,negative
dasatinib,paclitaxel,45,53,183,192,"Treatment of HEY xenograft-bearing mice with <e1>dasatinib</e1> plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + <e2>paclitaxel</e2> vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",False,negative
dasatinib,paclitaxel,45,53,197,206,"Treatment of HEY xenograft-bearing mice with <e1>dasatinib</e1> plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs <e2>paclitaxel</e2>: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",False,negative
paclitaxel,dasatinib,60,69,171,179,"Treatment of HEY xenograft-bearing mice with dasatinib plus <e1>paclitaxel</e1> inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, <e2>dasatinib</e2> + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",False,negative
paclitaxel,paclitaxel,60,69,183,192,"Treatment of HEY xenograft-bearing mice with dasatinib plus <e1>paclitaxel</e1> inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + <e2>paclitaxel</e2> vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",False,negative
paclitaxel,paclitaxel,60,69,197,206,"Treatment of HEY xenograft-bearing mice with dasatinib plus <e1>paclitaxel</e1> inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs <e2>paclitaxel</e2>: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",False,negative
dasatinib,paclitaxel,171,179,183,192,"Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, <e1>dasatinib</e1> + <e2>paclitaxel</e2> vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",False,negative
dasatinib,paclitaxel,171,179,197,206,"Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, <e1>dasatinib</e1> + paclitaxel vs <e2>paclitaxel</e2>: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",False,negative
paclitaxel,paclitaxel,183,192,197,206,"Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + <e1>paclitaxel</e1> vs <e2>paclitaxel</e2>: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",False,negative
dasatinib,paclitaxel,0,8,12,21,<e1>dasatinib</e1> + <e2>paclitaxel</e2> vs. ,False,negative
dasatinib,paclitaxel,43,51,58,67,"The siRNA knockdown of p27(Kip1) decreased <e1>dasatinib</e1>- and <e2>paclitaxel</e2>-induced apoptosis compared with a negative control siRNA (sub-G1 fraction, control siRNA vs. p27(Kip1) siRNA: 42.5% vs. 20.1%, difference = 22.4%, 95% CI = 20.1% to 24.7%, P = .017). ",False,negative
dasatinib,paclitaxel,82,90,133,142,Studies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that <e1>dasatinib</e1>-mediated induction of p27(Kip1) enhanced <e2>paclitaxel</e2>-induced apoptosis by negatively regulating Bcl-2 and Cdk1 expression. ,True,effect
dasatinib,paclitaxel,63,71,82,91,Inhibition of Src family and Abl kinases with either siRNAs or <e1>dasatinib</e1> enhances <e2>paclitaxel</e2> sensitivity of ovarian cancer cells through p27(Kip1)-mediated suppression of Bcl-2 and Cdk1 expression.,True,effect
lenalidomide,CCI-779,17,28,34,40,"Phase I trial of <e1>lenalidomide</e1> and <e2>CCI-779</e2> in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
",False,negative
lenalidomide,lenalidomide,17,28,99,110,"Phase I trial of <e1>lenalidomide</e1> and CCI-779 in patients with relapsed multiple myeloma: evidence for <e2>lenalidomide</e2>-CCI-779 interaction via P-glycoprotein.
",False,negative
lenalidomide,CCI-779,17,28,112,118,"Phase I trial of <e1>lenalidomide</e1> and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-<e2>CCI-779</e2> interaction via P-glycoprotein.
",False,negative
CCI-779,lenalidomide,34,40,99,110,"Phase I trial of lenalidomide and <e1>CCI-779</e1> in patients with relapsed multiple myeloma: evidence for <e2>lenalidomide</e2>-CCI-779 interaction via P-glycoprotein.
",False,negative
CCI-779,CCI-779,34,40,112,118,"Phase I trial of lenalidomide and <e1>CCI-779</e1> in patients with relapsed multiple myeloma: evidence for lenalidomide-<e2>CCI-779</e2> interaction via P-glycoprotein.
",False,negative
lenalidomide,CCI-779,99,110,112,118,"Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for <e1>lenalidomide</e1>-<e2>CCI-779</e2> interaction via P-glycoprotein.
",False,negative
lenalidomide,CCI-779,31,42,68,74,The preclinical combination of <e1>lenalidomide</e1> with the mTOR inhibitor <e2>CCI-779</e2> has displayed synergy in vitro and represents a novel combination in MM.,True,effect
avian influenza vaccines,ginseng stem-and-leaf saponins,77,100,128,157,"Enhancement of humoral immune responses to inactivated Newcastle disease and <e1>avian influenza vaccines</e1> by oral administration of <e2>ginseng stem-and-leaf saponins</e2> in chickens.
",False,negative
ginseng stem-and-leaf saponins,GSLS,81,110,113,116,The objective of this study was to evaluate the effect of oral administration of <e1>ginseng stem-and-leaf saponins</e1> (<e2>GSLS</e2>) on the humoral immune responses of chickens to inactivated ND and AI vaccines. ,False,negative
ginseng stem-and-leaf saponins,inactivated ND vaccines,81,110,166,179,The objective of this study was to evaluate the effect of oral administration of <e1>ginseng stem-and-leaf saponins</e1> (GSLS) on the humoral immune responses of chickens to <e2>inactivated ND vaccines</e2> and AI vaccines. ,False,negative
ginseng stem-and-leaf saponins,inactivated AI vaccines,81,110,166,176,The objective of this study was to evaluate the effect of oral administration of <e1>ginseng stem-and-leaf saponins</e1> (GSLS) on the humoral immune responses of chickens to <e2>inactivated AI vaccines</e2> ND and AI vaccines. ,False,negative
GSLS,inactivated ND vaccines,113,116,166,179,The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (<e1>GSLS</e1>) on the humoral immune responses of chickens to <e2>inactivated ND vaccines</e2> and AI vaccines. ,False,negative
GSLS,inactivated AI vaccines,113,116,166,176,The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (<e1>GSLS</e1>) on the humoral immune responses of chickens to <e2>inactivated AI vaccines</e2> ND and AI vaccines. ,False,negative
inactivated ND vaccines,inactivated AI vaccines,166,179,166,176,The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to <e1>inactivated ND vaccines</e1><e2>inactivated AI vaccines</e2> ND and AI vaccines. ,False,negative
GSLS,inactivated ND vaccine,40,43,145,166,"In experiment 1, oral administration of <e1>GSLS</e1> at a dose of 5 mg/kg of BW for 7 d on the immune response in chickens intramuscularly injected with <e2>inactivated ND vaccine</e2> was evaluated. ",False,negative
GSLS,inactivated AI vaccines,37,40,87,109,"In experiment 2, the same regimen of <e1>GSLS</e1> was administered to chickens inoculated with <e2>inactivated AI vaccines</e2>, and an enhanced serum antibody response to AI vaccination was also observed. ",True,effect
GSLS,GSLS,26,29,96,99,"Considering the safety of <e1>GSLS</e1>, because no adverse effect was found throughout the experiments, <e2>GSLS</e2> may be a promising oral adjuvant to improve immunization in poultry.",False,negative
dacarbazine,imexon,15,25,31,36,"Interaction of <e1>dacarbazine</e1> and <e2>imexon</e2>, in vitro and in vivo, in human A375 melanoma cells.
",False,negative
dacarbazine,DTIC,67,77,80,83,"We evaluated mechanisms of interaction between the alkyating agent <e1>dacarbazine</e1> (<e2>DTIC</e2>) and the pro-oxidant, imexon, in the human A375 melanoma cell line.",False,negative
dacarbazine,imexon,67,77,107,112,"We evaluated mechanisms of interaction between the alkyating agent <e1>dacarbazine</e1> (DTIC) and the pro-oxidant, <e2>imexon</e2>, in the human A375 melanoma cell line.",False,negative
DTIC,imexon,80,83,107,112,"We evaluated mechanisms of interaction between the alkyating agent dacarbazine (<e1>DTIC</e1>) and the pro-oxidant, <e2>imexon</e2>, in the human A375 melanoma cell line.",False,negative
DTIC,imexon,14,17,23,28,"The effect of <e1>DTIC</e1> and <e2>imexon</e2>, alone and in combination, was evaluated for growth inhibition (MTT), radiolabeled drug uptake, cellular thiol content (HPLC), and DNA strand breaks (Comet assay). ",False,negative
imexon,DTIC,69,74,84,87,There was a >75% reduction in cellular glutathione and cysteine with <e1>imexon</e1> but not <e2>DTIC</e2>. ,False,negative
Imexon,dacarbazine,0,5,11,21,<e1>Imexon</e1> and <e2>dacarbazine</e2> show additive effects in vitro but not in vivo in human A375 melanoma cells.,True,effect
Lapatinib,herceptin,0,8,19,27,"<e1>Lapatinib</e1> enhances <e2>herceptin</e2>-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression.
",True,effect
lapatinib,Herceptin,41,49,65,73,"Although it was previously reported that <e1>lapatinib</e1> combined with <e2>Herceptin</e2> improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.",True,effect
lapatinib,lapatinib,41,49,133,141,"Although it was previously reported that <e1>lapatinib</e1> combined with Herceptin improved the progression-free survival rate compared with <e2>lapatinib</e2> alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.",False,negative
lapatinib,Herceptin,41,49,167,175,"Although it was previously reported that <e1>lapatinib</e1> combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with <e2>Herceptin</e2>-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.",False,negative
Herceptin,lapatinib,65,73,133,141,"Although it was previously reported that lapatinib combined with <e1>Herceptin</e1> improved the progression-free survival rate compared with <e2>lapatinib</e2> alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.",False,negative
Herceptin,Herceptin,65,73,167,175,"Although it was previously reported that lapatinib combined with <e1>Herceptin</e1> improved the progression-free survival rate compared with lapatinib alone for patients with <e2>Herceptin</e2>-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.",False,negative
lapatinib,Herceptin,133,141,167,175,"Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with <e1>lapatinib</e1> alone for patients with <e2>Herceptin</e2>-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.",False,negative
lapatinib,Herceptin,17,25,42,50,"We evaluated how <e1>lapatinib</e1> interacts with <e2>Herceptin</e2> in HER2-positive breast cancer, with a particular focus on Herceptin-mediated antibody-dependent cellular cytotoxicity (ADCC). ",False,negative
lapatinib,Herceptin,17,25,111,119,"We evaluated how <e1>lapatinib</e1> interacts with Herceptin in HER2-positive breast cancer, with a particular focus on <e2>Herceptin</e2>-mediated antibody-dependent cellular cytotoxicity (ADCC). ",False,negative
Herceptin,Herceptin,42,50,111,119,"We evaluated how lapatinib interacts with <e1>Herceptin</e1> in HER2-positive breast cancer, with a particular focus on <e2>Herceptin</e2>-mediated antibody-dependent cellular cytotoxicity (ADCC). ",False,negative
lapatinib,Herceptin,22,30,149,157,"In an in vitro assay, <e1>lapatinib</e1> induced HER2 expression at the cell surface of HER2-positive breast cancer cell lines, leading to the enhancement of <e2>Herceptin</e2>-mediated ADCC. ",True,effect
Herceptin,lapatinib,56,64,86,94,"Furthermore, we present a case report in which a second <e1>Herceptin</e1> treatment following <e2>lapatinib</e2> resulted in the marked shrinkage of multiple metastatic tumors in HER2-positive breast cancer. ",True,effect
Lapatinib,Herceptin,0,8,44,52,<e1>Lapatinib</e1> may have the potential to convert <e2>Herceptin</e2>-refractory to Herceptin-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.,False,negative
Lapatinib,Herceptin,0,8,68,76,<e1>Lapatinib</e1> may have the potential to convert Herceptin-refractory to <e2>Herceptin</e2>-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.,False,negative
Herceptin,Herceptin,44,52,68,76,Lapatinib may have the potential to convert <e1>Herceptin</e1>-refractory to <e2>Herceptin</e2>-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.,False,negative
cross-reacting material 197,CRM197,180,206,209,214,"The aim of the present study was to investigate whether HB-EGF is a therapeutic target for T-ALL, and to further elucidate the antitumor effects of a specific inhibitor of HB-EGF, <e1>cross-reacting material 197</e1> (<e2>CRM197</e2>). ",False,negative
CRM197,anticancer agent,88,93,139,154,"We elucidated the expression of HB-EGF in T-ALL cell lines, and evaluated the effect of <e1>CRM197</e1> on these cells alone or in combination with <e2>anticancer agent</e2>. ",False,negative
CRM197,CRM197,0,5,62,67,"<e1>CRM197</e1> induced apoptosis, and furthermore, the combination of <e2>CRM197</e2> plus doxorubicin enhanced cytotoxicity in a T-ALL cell line. ",False,negative
CRM197,doxorubicin,0,5,74,84,"<e1>CRM197</e1> induced apoptosis, and furthermore, the combination of CRM197 plus <e2>doxorubicin</e2> enhanced cytotoxicity in a T-ALL cell line. ",False,negative
CRM197,doxorubicin,62,67,74,84,"CRM197 induced apoptosis, and furthermore, the combination of <e1>CRM197</e1> plus <e2>doxorubicin</e2> enhanced cytotoxicity in a T-ALL cell line. ",True,effect
Ephedrine,dexmedetomidine,0,8,49,63,"<e1>Ephedrine</e1> enhances the antinociceptive effect of <e2>dexmedetomidine</e2> in mice.
",True,effect
ephedrine,dexmedetomidine,75,83,103,117,The purpose of this study was to evaluate whether the psychostimulant drug <e1>ephedrine</e1> has any effect on <e2>dexmedetomidine</e2>-induced antinociception and locomotor inhibitor activity in mice in acute application.,False,negative
ephedrine,dexmedetomidine,17,25,59,73,"saline + saline, <e1>ephedrine</e1> (10   mg/kg) + saline, saline + <e2>dexmedetomidine</e2> (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ",False,negative
ephedrine,ephedrine,17,25,93,101,"saline + saline, <e1>ephedrine</e1> (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and <e2>ephedrine</e2> (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ",False,negative
ephedrine,dexmedetomidine,17,25,118,132,"saline + saline, <e1>ephedrine</e1> (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + <e2>dexmedetomidine</e2> (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ",False,negative
dexmedetomidine,ephedrine,59,73,93,101,"saline + saline, ephedrine (10   mg/kg) + saline, saline + <e1>dexmedetomidine</e1> (15     g/kg) and <e2>ephedrine</e2> (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ",False,negative
dexmedetomidine,dexmedetomidine,59,73,118,132,"saline + saline, ephedrine (10   mg/kg) + saline, saline + <e1>dexmedetomidine</e1> (15     g/kg) and ephedrine (10   mg/kg) + <e2>dexmedetomidine</e2> (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ",False,negative
ephedrine,dexmedetomidine,93,101,118,132,"saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and <e1>ephedrine</e1> (10   mg/kg) + <e2>dexmedetomidine</e2> (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ",False,negative
dexmedetomidine,ephedrine,64,78,96,104,"In the hot plate test in mice, co-administration of 15     g/kg <e1>dexmedetomidine</e1> with 10   mg/kg <e2>ephedrine</e2> intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine. ",True,effect
dexmedetomidine,dexmedetomidine,64,78,205,219,"In the hot plate test in mice, co-administration of 15     g/kg <e1>dexmedetomidine</e1> with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by <e2>dexmedetomidine</e2>. ",False,negative
ephedrine,dexmedetomidine,96,104,205,219,"In the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg <e1>ephedrine</e1> intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by <e2>dexmedetomidine</e2>. ",False,negative
dexmedetomidine,ephedrine,53,67,89,97,"At the same time, the locomotor inhibitory effect of <e1>dexmedetomidine</e1> was counteracted by <e2>ephedrine</e2>. ",True,effect
dexmedetomidine,ephedrine,49,63,70,78,"We concluded that the combined administration of <e1>dexmedetomidine</e1> with <e2>ephedrine</e2> may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.",True,effect
dexmedetomidine,dexmedetomidine,49,63,183,197,"We concluded that the combined administration of <e1>dexmedetomidine</e1> with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of <e2>dexmedetomidine</e2> as an analgesic in humans.",False,negative
dexmedetomidine,analgesic,49,63,205,213,"We concluded that the combined administration of <e1>dexmedetomidine</e1> with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an <e2>analgesic</e2> in humans.",False,negative
ephedrine,dexmedetomidine,70,78,183,197,"We concluded that the combined administration of dexmedetomidine with <e1>ephedrine</e1> may have beneficial effects in the treatment of pain without causing sedation, which limits the use of <e2>dexmedetomidine</e2> as an analgesic in humans.",False,negative
ephedrine,analgesic,70,78,205,213,"We concluded that the combined administration of dexmedetomidine with <e1>ephedrine</e1> may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an <e2>analgesic</e2> in humans.",False,negative
dexmedetomidine,analgesic,183,197,205,213,"We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of <e1>dexmedetomidine</e1> as an <e2>analgesic</e2> in humans.",False,negative
amlodipine,valsartan,31,40,42,50,[Efficacy of fixed combination <e1>amlodipine</e1>/<e2>valsartan</e2> in hospitalized patients with hypertensive disease],False,negative
amlodipine,valsartan,35,44,46,54,Efficacy and tolerability of fixed <e1>amlodipine</e1>/<e2>valsartan</e2> combination was studied in 86 patients with hypertensive disease hospitalized in departments of general internal medicine or cardiology. ,False,negative
amlodipine,valsartan,106,115,117,125,All patients had indications for antihypertensive therapy and were randomized either to fixed combination <e1>amlodipine</e1>/<e2>valsartan</e2> (n=43) or to therapy which corresponded to the hospital formulary (n=43). ,False,negative
amlodipine,valsartan,56,65,67,75,Rate of achievement of target BP with fixed combination <e1>amlodipine</e1>/<e2>valsartan</e2> (93%) was comparable with that on traditional therapy (90%). ,False,negative
amlodipine,valsartan,33,42,44,52,"But the use of fixed combination <e1>amlodipine</e1>/<e2>valsartan</e2> compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). ",True,effect
amlodipine,antihypertensive drugs,33,42,247,268,"But the use of fixed combination <e1>amlodipine</e1>/valsartan compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of <e2>antihypertensive drugs</e2> (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). ",False,negative
valsartan,antihypertensive drugs,44,52,247,268,"But the use of fixed combination amlodipine/<e1>valsartan</e1> compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of <e2>antihypertensive drugs</e2> (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). ",False,negative
amlodipine,valsartan,75,84,86,94,"We have demonstrated appropriateness of inhospital administration of fixed <e1>amlodipine</e1>/<e2>valsartan</e2> combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.",True,effect
amlodipine,antihypertensive drugs,75,84,192,213,"We have demonstrated appropriateness of inhospital administration of fixed <e1>amlodipine</e1>/valsartan combination as an approach allowing to achieve target BP in shorter time, with the use of fewer <e2>antihypertensive drugs</e2>, and diminishing concealed inefficacy of treatment.",False,negative
valsartan,antihypertensive drugs,86,94,192,213,"We have demonstrated appropriateness of inhospital administration of fixed amlodipine/<e1>valsartan</e1> combination as an approach allowing to achieve target BP in shorter time, with the use of fewer <e2>antihypertensive drugs</e2>, and diminishing concealed inefficacy of treatment.",False,negative
Ticagrelor,Brilinta,0,9,12,19,<e1>Ticagrelor</e1> (<e2>Brilinta</e2>)--better than clopidogrel (Plavix),False,negative
Ticagrelor,clopidogrel,0,9,35,45,<e1>Ticagrelor</e1> (Brilinta)--better than <e2>clopidogrel</e2> (Plavix),False,negative
Ticagrelor,Plavix,0,9,48,53,<e1>Ticagrelor</e1> (Brilinta)--better than clopidogrel (<e2>Plavix</e2>),False,negative
Brilinta,clopidogrel,12,19,35,45,Ticagrelor (<e1>Brilinta</e1>)--better than <e2>clopidogrel</e2> (Plavix),False,negative
Brilinta,Plavix,12,19,48,53,Ticagrelor (<e1>Brilinta</e1>)--better than clopidogrel (<e2>Plavix</e2>),False,negative
clopidogrel,Plavix,35,45,48,53,Ticagrelor (Brilinta)--better than <e1>clopidogrel</e1> (<e2>Plavix</e2>),False,negative
ticagrelor,Brilinta,21,30,33,40,"The FDA has approved <e1>ticagrelor</e1> (<e2>Brilinta</e2>-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ",False,negative
ticagrelor,antiplatelet drug,21,30,64,80,"The FDA has approved <e1>ticagrelor</e1> (Brilinta-AstraZeneca), an oral <e2>antiplatelet drug</e2>, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ",False,negative
ticagrelor,aspirin,21,30,105,111,"The FDA has approved <e1>ticagrelor</e1> (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose <e2>aspirin</e2> to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ",True,effect
Brilinta,antiplatelet drug,33,40,64,80,"The FDA has approved ticagrelor (<e1>Brilinta</e1>-AstraZeneca), an oral <e2>antiplatelet drug</e2>, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ",False,negative
Brilinta,aspirin,33,40,105,111,"The FDA has approved ticagrelor (<e1>Brilinta</e1>-AstraZeneca), an oral antiplatelet drug, for use with low-dose <e2>aspirin</e2> to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ",True,effect
antiplatelet drug,aspirin,64,80,105,111,"The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral <e1>antiplatelet drug</e1>, for use with low-dose <e2>aspirin</e2> to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ",False,negative
clopidogrel,Plavix,21,31,34,39,It will compete with <e1>clopidogrel</e1> (<e2>Plavix</e2>) and prasugrel (Effient) for such use. ,False,negative
clopidogrel,prasugrel,21,31,46,54,It will compete with <e1>clopidogrel</e1> (Plavix) and <e2>prasugrel</e2> (Effient) for such use. ,False,negative
clopidogrel,Effient,21,31,57,63,It will compete with <e1>clopidogrel</e1> (Plavix) and prasugrel (<e2>Effient</e2>) for such use. ,False,negative
Plavix,prasugrel,34,39,46,54,It will compete with clopidogrel (<e1>Plavix</e1>) and <e2>prasugrel</e2> (Effient) for such use. ,False,negative
Plavix,Effient,34,39,57,63,It will compete with clopidogrel (<e1>Plavix</e1>) and prasugrel (<e2>Effient</e2>) for such use. ,False,negative
prasugrel,Effient,46,54,57,63,It will compete with clopidogrel (Plavix) and <e1>prasugrel</e1> (<e2>Effient</e2>) for such use. ,False,negative
piperine,ibuprofen,13,20,25,33,"Influence of <e1>piperine</e1> on <e2>ibuprofen</e2> induced antinociception and its pharmacokinetics.
",False,negative
piperine,ibuprofen,21,28,112,120,"In the present study <e1>piperine</e1> (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of <e2>ibuprofen</e2> evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen. ",True,effect
piperine,acetic acid,21,28,140,150,"In the present study <e1>piperine</e1> (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both <e2>acetic acid</e2> writhing and formalin test, when it was administered with ibuprofen. ",False,negative
piperine,ibuprofen,21,28,210,218,"In the present study <e1>piperine</e1> (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with <e2>ibuprofen</e2>. ",False,negative
ibuprofen,acetic acid,112,120,140,150,"In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of <e1>ibuprofen</e1> evaluated by both <e2>acetic acid</e2> writhing and formalin test, when it was administered with ibuprofen. ",False,negative
ibuprofen,ibuprofen,112,120,210,218,"In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of <e1>ibuprofen</e1> evaluated by both acetic acid writhing and formalin test, when it was administered with <e2>ibuprofen</e2>. ",False,negative
acetic acid,ibuprofen,140,150,210,218,"In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both <e1>acetic acid</e1> writhing and formalin test, when it was administered with <e2>ibuprofen</e2>. ",False,negative
Ibuprofen,piperine,0,8,80,87,<e1>Ibuprofen</e1> plasma concentration was also increased when it was administered with <e2>piperine</e2>. ,True,mechanism
ibuprofen,piperine,44,52,77,84,The synergistic antinociception activity of <e1>ibuprofen</e1> when administered with <e2>piperine</e2> can be attributed to increased plasma concentration of ibuprofen. ,True,mechanism
ibuprofen,ibuprofen,44,52,141,149,The synergistic antinociception activity of <e1>ibuprofen</e1> when administered with piperine can be attributed to increased plasma concentration of <e2>ibuprofen</e2>. ,False,negative
piperine,ibuprofen,77,84,141,149,The synergistic antinociception activity of ibuprofen when administered with <e1>piperine</e1> can be attributed to increased plasma concentration of <e2>ibuprofen</e2>. ,False,negative
piperine,ibuprofen,41,48,90,98,From this study it can be concluded that <e1>piperine</e1> can be used as a bioenhancer along with <e2>ibuprofen</e2>.,True,effect
Rifampin,barbiturates,62,69,71,82,Drugs that may decrease the effects of this medicine include: <e1>Rifampin</e1> <e2>barbiturates</e2> phenytoin (Dilantin) carbamazepine (Tegretol) Estrogens may decrease the effects of benzodiazepines (lorezepam oxezepam temezepam). ,False,negative
Rifampin,phenytoin,62,69,84,92,Drugs that may decrease the effects of this medicine include: <e1>Rifampin</e1> barbiturates <e2>phenytoin</e2> (Dilantin) carbamazepine (Tegretol) Estrogens may decrease the effects of benzodiazepines (lorezepam oxezepam temezepam). ,False,negative
Rifampin,Dilantin,62,69,95,102,Drugs that may decrease the effects of this medicine include: <e1>Rifampin</e1> barbiturates phenytoin (<e2>Dilantin</e2>) carbamazepine (Tegretol) Estrogens may decrease the effects of benzodiazepines (lorezepam oxezepam temezepam). ,False,negative
Rifampin,carbamazepine,62,69,105,117,Drugs that may decrease the effects of this medicine include: <e1>Rifampin</e1> barbiturates phenytoin (Dilantin) <e2>carbamazepine</e2> (Tegretol) Estrogens may decrease the effects of benzodiazepines (lorezepam oxezepam temezepam). ,False,negative
Rifampin,Tegretol,62,69,120,127,Drugs that may decrease the effects of this medicine include: <e1>Rifampin</e1> barbiturates phenytoin (Dilantin) carbamazepine (<e2>Tegretol</e2>) Estrogens may decrease the effects of benzodiazepines (lorezepam oxezepam temezepam). ,False,negative
Rifampin,Estrogens,62,69,130,138,Drugs that may decrease the effects of this medicine include: <e1>Rifampin</e1> barbiturates phenytoin (Dilantin) carbamazepine (Tegretol) <e2>Estrogens</e2> may decrease the effects of benzodiazepines (lorezepam oxezepam temezepam). ,False,negative
Rifampin,benzodiazepines,62,69,168,182,Drugs that may decrease the effects of this medicine include: <e1>Rifampin</e1> barbiturates phenytoin (Dilantin) carbamazepine (Tegretol) Estrogens may decrease the effects of <e2>benzodiazepines</e2> (lorezepam oxezepam temezepam). ,False,negative
Rifampin,lorezepam,62,69,185,193,Drugs that may decrease the effects of this medicine include: <e1>Rifampin</e1> barbiturates phenytoin (Dilantin) carbamazepine (Tegretol) Estrogens may decrease the effects of benzodiazepines (<e2>lorezepam</e2> oxezepam temezepam). ,False,negative
Rifampin,oxezepam,62,69,195,202,Drugs that may decrease the effects of this medicine include: <e1>Rifampin</e1> barbiturates phenytoin (Dilantin) carbamazepine (Tegretol) Estrogens may decrease the effects of benzodiazepines (lorezepam <e2>oxezepam</e2> temezepam). ,False,negative
Rifampin,temezepam,62,69,204,212,Drugs that may decrease the effects of this medicine include: <e1>Rifampin</e1> barbiturates phenytoin (Dilantin) carbamazepine (Tegretol) Estrogens may decrease the effects of benzodiazepines (lorezepam oxezepam <e2>temezepam</e2>). ,False,negative
barbiturates,phenytoin,71,82,84,92,Drugs that may decrease the effects of this medicine include: Rifampin <e1>barbiturates</e1> <e2>phenytoin</e2> (Dilantin) carbamazepine (Tegretol) Estrogens may decrease the effects of benzodiazepines (lorezepam oxezepam temezepam). ,False,negative
barbiturates,Dilantin,71,82,95,102,Drugs that may decrease the effects of this medicine include: Rifampin <e1>barbiturates</e1> phenytoin (<e2>Dilantin</e2>) carbamazepine (Tegretol) Estrogens may decrease the effects of benzodiazepines (lorezepam oxezepam temezepam). ,False,negative
barbiturates,carbamazepine,71,82,105,117,Drugs that may decrease the effects of this medicine include: Rifampin <e1>barbiturates</e1> phenytoin (Dilantin) <e2>carbamazepine</e2> (Tegretol) Estrogens may decrease the effects of benzodiazepines (lorezepam oxezepam temezepam). ,False,negative
barbiturates,Tegretol,71,82,120,127,Drugs that may decrease the effects of this medicine include: Rifampin <e1>barbiturates</e1> phenytoin (Dilantin) carbamazepine (<e2>Tegretol</e2>) Estrogens may decrease the effects of benzodiazepines (lorezepam oxezepam temezepam). ,False,negative
barbiturates,Estrogens,71,82,130,138,Drugs that may decrease the effects of this medicine include: Rifampin <e1>barbiturates</e1> phenytoin (Dilantin) carbamazepine (Tegretol) <e2>Estrogens</e2> may decrease the effects of benzodiazepines (lorezepam oxezepam temezepam). ,False,negative
barbiturates,benzodiazepines,71,82,168,182,Drugs that may decrease the effects of this medicine include: Rifampin <e1>barbiturates</e1> phenytoin (Dilantin) carbamazepine (Tegretol) Estrogens may decrease the effects of <e2>benzodiazepines</e2> (lorezepam oxezepam temezepam). ,False,negative
barbiturates,lorezepam,71,82,185,193,Drugs that may decrease the effects of this medicine include: Rifampin <e1>barbiturates</e1> phenytoin (Dilantin) carbamazepine (Tegretol) Estrogens may decrease the effects of benzodiazepines (<e2>lorezepam</e2> oxezepam temezepam). ,False,negative
barbiturates,oxezepam,71,82,195,202,Drugs that may decrease the effects of this medicine include: Rifampin <e1>barbiturates</e1> phenytoin (Dilantin) carbamazepine (Tegretol) Estrogens may decrease the effects of benzodiazepines (lorezepam <e2>oxezepam</e2> temezepam). ,False,negative
barbiturates,temezepam,71,82,204,212,Drugs that may decrease the effects of this medicine include: Rifampin <e1>barbiturates</e1> phenytoin (Dilantin) carbamazepine (Tegretol) Estrogens may decrease the effects of benzodiazepines (lorezepam oxezepam <e2>temezepam</e2>). ,False,negative
phenytoin,Dilantin,84,92,95,102,Drugs that may decrease the effects of this medicine include: Rifampin barbiturates <e1>phenytoin</e1> (<e2>Dilantin</e2>) carbamazepine (Tegretol) Estrogens may decrease the effects of benzodiazepines (lorezepam oxezepam temezepam). ,False,negative
phenytoin,carbamazepine,84,92,105,117,Drugs that may decrease the effects of this medicine include: Rifampin barbiturates <e1>phenytoin</e1> (Dilantin) <e2>carbamazepine</e2> (Tegretol) Estrogens may decrease the effects of benzodiazepines (lorezepam oxezepam temezepam). ,False,negative
phenytoin,Tegretol,84,92,120,127,Drugs that may decrease the effects of this medicine include: Rifampin barbiturates <e1>phenytoin</e1> (Dilantin) carbamazepine (<e2>Tegretol</e2>) Estrogens may decrease the effects of benzodiazepines (lorezepam oxezepam temezepam). ,False,negative
phenytoin,Estrogens,84,92,130,138,Drugs that may decrease the effects of this medicine include: Rifampin barbiturates <e1>phenytoin</e1> (Dilantin) carbamazepine (Tegretol) <e2>Estrogens</e2> may decrease the effects of benzodiazepines (lorezepam oxezepam temezepam). ,False,negative
phenytoin,benzodiazepines,84,92,168,182,Drugs that may decrease the effects of this medicine include: Rifampin barbiturates <e1>phenytoin</e1> (Dilantin) carbamazepine (Tegretol) Estrogens may decrease the effects of <e2>benzodiazepines</e2> (lorezepam oxezepam temezepam). ,False,negative
phenytoin,lorezepam,84,92,185,193,Drugs that may decrease the effects of this medicine include: Rifampin barbiturates <e1>phenytoin</e1> (Dilantin) carbamazepine (Tegretol) Estrogens may decrease the effects of benzodiazepines (<e2>lorezepam</e2> oxezepam temezepam). ,False,negative
phenytoin,oxezepam,84,92,195,202,Drugs that may decrease the effects of this medicine include: Rifampin barbiturates <e1>phenytoin</e1> (Dilantin) carbamazepine (Tegretol) Estrogens may decrease the effects of benzodiazepines (lorezepam <e2>oxezepam</e2> temezepam). ,False,negative
phenytoin,temezepam,84,92,204,212,Drugs that may decrease the effects of this medicine include: Rifampin barbiturates <e1>phenytoin</e1> (Dilantin) carbamazepine (Tegretol) Estrogens may decrease the effects of benzodiazepines (lorezepam oxezepam <e2>temezepam</e2>). ,False,negative
Dilantin,carbamazepine,95,102,105,117,Drugs that may decrease the effects of this medicine include: Rifampin barbiturates phenytoin (<e1>Dilantin</e1>) <e2>carbamazepine</e2> (Tegretol) Estrogens may decrease the effects of benzodiazepines (lorezepam oxezepam temezepam). ,False,negative
Dilantin,Tegretol,95,102,120,127,Drugs that may decrease the effects of this medicine include: Rifampin barbiturates phenytoin (<e1>Dilantin</e1>) carbamazepine (<e2>Tegretol</e2>) Estrogens may decrease the effects of benzodiazepines (lorezepam oxezepam temezepam). ,False,negative
Dilantin,Estrogens,95,102,130,138,Drugs that may decrease the effects of this medicine include: Rifampin barbiturates phenytoin (<e1>Dilantin</e1>) carbamazepine (Tegretol) <e2>Estrogens</e2> may decrease the effects of benzodiazepines (lorezepam oxezepam temezepam). ,False,negative
Dilantin,benzodiazepines,95,102,168,182,Drugs that may decrease the effects of this medicine include: Rifampin barbiturates phenytoin (<e1>Dilantin</e1>) carbamazepine (Tegretol) Estrogens may decrease the effects of <e2>benzodiazepines</e2> (lorezepam oxezepam temezepam). ,False,negative
Dilantin,lorezepam,95,102,185,193,Drugs that may decrease the effects of this medicine include: Rifampin barbiturates phenytoin (<e1>Dilantin</e1>) carbamazepine (Tegretol) Estrogens may decrease the effects of benzodiazepines (<e2>lorezepam</e2> oxezepam temezepam). ,False,negative
Dilantin,oxezepam,95,102,195,202,Drugs that may decrease the effects of this medicine include: Rifampin barbiturates phenytoin (<e1>Dilantin</e1>) carbamazepine (Tegretol) Estrogens may decrease the effects of benzodiazepines (lorezepam <e2>oxezepam</e2> temezepam). ,False,negative
Dilantin,temezepam,95,102,204,212,Drugs that may decrease the effects of this medicine include: Rifampin barbiturates phenytoin (<e1>Dilantin</e1>) carbamazepine (Tegretol) Estrogens may decrease the effects of benzodiazepines (lorezepam oxezepam <e2>temezepam</e2>). ,False,negative
carbamazepine,Tegretol,105,117,120,127,Drugs that may decrease the effects of this medicine include: Rifampin barbiturates phenytoin (Dilantin) <e1>carbamazepine</e1> (<e2>Tegretol</e2>) Estrogens may decrease the effects of benzodiazepines (lorezepam oxezepam temezepam). ,False,negative
carbamazepine,Estrogens,105,117,130,138,Drugs that may decrease the effects of this medicine include: Rifampin barbiturates phenytoin (Dilantin) <e1>carbamazepine</e1> (Tegretol) <e2>Estrogens</e2> may decrease the effects of benzodiazepines (lorezepam oxezepam temezepam). ,False,negative
carbamazepine,benzodiazepines,105,117,168,182,Drugs that may decrease the effects of this medicine include: Rifampin barbiturates phenytoin (Dilantin) <e1>carbamazepine</e1> (Tegretol) Estrogens may decrease the effects of <e2>benzodiazepines</e2> (lorezepam oxezepam temezepam). ,False,negative
carbamazepine,lorezepam,105,117,185,193,Drugs that may decrease the effects of this medicine include: Rifampin barbiturates phenytoin (Dilantin) <e1>carbamazepine</e1> (Tegretol) Estrogens may decrease the effects of benzodiazepines (<e2>lorezepam</e2> oxezepam temezepam). ,False,negative
carbamazepine,oxezepam,105,117,195,202,Drugs that may decrease the effects of this medicine include: Rifampin barbiturates phenytoin (Dilantin) <e1>carbamazepine</e1> (Tegretol) Estrogens may decrease the effects of benzodiazepines (lorezepam <e2>oxezepam</e2> temezepam). ,False,negative
carbamazepine,temezepam,105,117,204,212,Drugs that may decrease the effects of this medicine include: Rifampin barbiturates phenytoin (Dilantin) <e1>carbamazepine</e1> (Tegretol) Estrogens may decrease the effects of benzodiazepines (lorezepam oxezepam <e2>temezepam</e2>). ,False,negative
Tegretol,Estrogens,120,127,130,138,Drugs that may decrease the effects of this medicine include: Rifampin barbiturates phenytoin (Dilantin) carbamazepine (<e1>Tegretol</e1>) <e2>Estrogens</e2> may decrease the effects of benzodiazepines (lorezepam oxezepam temezepam). ,False,negative
Tegretol,benzodiazepines,120,127,168,182,Drugs that may decrease the effects of this medicine include: Rifampin barbiturates phenytoin (Dilantin) carbamazepine (<e1>Tegretol</e1>) Estrogens may decrease the effects of <e2>benzodiazepines</e2> (lorezepam oxezepam temezepam). ,False,negative
Tegretol,lorezepam,120,127,185,193,Drugs that may decrease the effects of this medicine include: Rifampin barbiturates phenytoin (Dilantin) carbamazepine (<e1>Tegretol</e1>) Estrogens may decrease the effects of benzodiazepines (<e2>lorezepam</e2> oxezepam temezepam). ,False,negative
Tegretol,oxezepam,120,127,195,202,Drugs that may decrease the effects of this medicine include: Rifampin barbiturates phenytoin (Dilantin) carbamazepine (<e1>Tegretol</e1>) Estrogens may decrease the effects of benzodiazepines (lorezepam <e2>oxezepam</e2> temezepam). ,False,negative
Tegretol,temezepam,120,127,204,212,Drugs that may decrease the effects of this medicine include: Rifampin barbiturates phenytoin (Dilantin) carbamazepine (<e1>Tegretol</e1>) Estrogens may decrease the effects of benzodiazepines (lorezepam oxezepam <e2>temezepam</e2>). ,False,negative
Estrogens,benzodiazepines,130,138,168,182,Drugs that may decrease the effects of this medicine include: Rifampin barbiturates phenytoin (Dilantin) carbamazepine (Tegretol) <e1>Estrogens</e1> may decrease the effects of <e2>benzodiazepines</e2> (lorezepam oxezepam temezepam). ,False,negative
Estrogens,lorezepam,130,138,185,193,Drugs that may decrease the effects of this medicine include: Rifampin barbiturates phenytoin (Dilantin) carbamazepine (Tegretol) <e1>Estrogens</e1> may decrease the effects of benzodiazepines (<e2>lorezepam</e2> oxezepam temezepam). ,False,negative
Estrogens,oxezepam,130,138,195,202,Drugs that may decrease the effects of this medicine include: Rifampin barbiturates phenytoin (Dilantin) carbamazepine (Tegretol) <e1>Estrogens</e1> may decrease the effects of benzodiazepines (lorezepam <e2>oxezepam</e2> temezepam). ,False,negative
Estrogens,temezepam,130,138,204,212,Drugs that may decrease the effects of this medicine include: Rifampin barbiturates phenytoin (Dilantin) carbamazepine (Tegretol) <e1>Estrogens</e1> may decrease the effects of benzodiazepines (lorezepam oxezepam <e2>temezepam</e2>). ,False,negative
benzodiazepines,lorezepam,168,182,185,193,Drugs that may decrease the effects of this medicine include: Rifampin barbiturates phenytoin (Dilantin) carbamazepine (Tegretol) Estrogens may decrease the effects of <e1>benzodiazepines</e1> (<e2>lorezepam</e2> oxezepam temezepam). ,False,negative
benzodiazepines,oxezepam,168,182,195,202,Drugs that may decrease the effects of this medicine include: Rifampin barbiturates phenytoin (Dilantin) carbamazepine (Tegretol) Estrogens may decrease the effects of <e1>benzodiazepines</e1> (lorezepam <e2>oxezepam</e2> temezepam). ,False,negative
benzodiazepines,temezepam,168,182,204,212,Drugs that may decrease the effects of this medicine include: Rifampin barbiturates phenytoin (Dilantin) carbamazepine (Tegretol) Estrogens may decrease the effects of <e1>benzodiazepines</e1> (lorezepam oxezepam <e2>temezepam</e2>). ,False,negative
lorezepam,oxezepam,185,193,195,202,Drugs that may decrease the effects of this medicine include: Rifampin barbiturates phenytoin (Dilantin) carbamazepine (Tegretol) Estrogens may decrease the effects of benzodiazepines (<e1>lorezepam</e1> <e2>oxezepam</e2> temezepam). ,False,negative
lorezepam,temezepam,185,193,204,212,Drugs that may decrease the effects of this medicine include: Rifampin barbiturates phenytoin (Dilantin) carbamazepine (Tegretol) Estrogens may decrease the effects of benzodiazepines (<e1>lorezepam</e1> oxezepam <e2>temezepam</e2>). ,False,negative
oxezepam,temezepam,195,202,204,212,Drugs that may decrease the effects of this medicine include: Rifampin barbiturates phenytoin (Dilantin) carbamazepine (Tegretol) Estrogens may decrease the effects of benzodiazepines (lorezepam <e1>oxezepam</e1> <e2>temezepam</e2>). ,False,negative
antibiotics,warfarin,94,104,106,113,Consult your doctor or pharmacist if you are taking any of the following: seizure medications <e1>antibiotics</e1> <e2>warfarin</e2> medications to help you sleep,False,negative
Dronabinol,MARINOL,17,26,85,91,"Interactions for <e1>Dronabinol</e1>:  In studies involving patients with AIDS and/or cancer, <e2>MARINOL</e2> (Dronabinol) Capsules has been co-administered with a variety of medications (e.g., cytotoxic agents, anti-infective agents, sedatives, or opioid analgesics) without resulting in any clinically significant drug/drug interactions. ",False,negative
Dronabinol,Dronabinol,17,26,94,103,"Interactions for <e1>Dronabinol</e1>:  In studies involving patients with AIDS and/or cancer, MARINOL (<e2>Dronabinol</e2>) Capsules has been co-administered with a variety of medications (e.g., cytotoxic agents, anti-infective agents, sedatives, or opioid analgesics) without resulting in any clinically significant drug/drug interactions. ",False,negative
Dronabinol,anti-infective,17,26,195,208,"Interactions for <e1>Dronabinol</e1>:  In studies involving patients with AIDS and/or cancer, MARINOL (Dronabinol) Capsules has been co-administered with a variety of medications (e.g., cytotoxic agents, <e2>anti-infective</e2> agents, sedatives, or opioid analgesics) without resulting in any clinically significant drug/drug interactions. ",False,negative
Dronabinol,sedatives,17,26,218,226,"Interactions for <e1>Dronabinol</e1>:  In studies involving patients with AIDS and/or cancer, MARINOL (Dronabinol) Capsules has been co-administered with a variety of medications (e.g., cytotoxic agents, anti-infective agents, <e2>sedatives</e2>, or opioid analgesics) without resulting in any clinically significant drug/drug interactions. ",False,negative
Dronabinol,opioid analgesics,17,26,232,248,"Interactions for <e1>Dronabinol</e1>:  In studies involving patients with AIDS and/or cancer, MARINOL (Dronabinol) Capsules has been co-administered with a variety of medications (e.g., cytotoxic agents, anti-infective agents, sedatives, or <e2>opioid analgesics</e2>) without resulting in any clinically significant drug/drug interactions. ",False,negative
MARINOL,Dronabinol,85,91,94,103,"Interactions for Dronabinol:  In studies involving patients with AIDS and/or cancer, <e1>MARINOL</e1> (<e2>Dronabinol</e2>) Capsules has been co-administered with a variety of medications (e.g., cytotoxic agents, anti-infective agents, sedatives, or opioid analgesics) without resulting in any clinically significant drug/drug interactions. ",False,negative
MARINOL,anti-infective,85,91,195,208,"Interactions for Dronabinol:  In studies involving patients with AIDS and/or cancer, <e1>MARINOL</e1> (Dronabinol) Capsules has been co-administered with a variety of medications (e.g., cytotoxic agents, <e2>anti-infective</e2> agents, sedatives, or opioid analgesics) without resulting in any clinically significant drug/drug interactions. ",False,negative
MARINOL,sedatives,85,91,218,226,"Interactions for Dronabinol:  In studies involving patients with AIDS and/or cancer, <e1>MARINOL</e1> (Dronabinol) Capsules has been co-administered with a variety of medications (e.g., cytotoxic agents, anti-infective agents, <e2>sedatives</e2>, or opioid analgesics) without resulting in any clinically significant drug/drug interactions. ",False,negative
MARINOL,opioid analgesics,85,91,232,248,"Interactions for Dronabinol:  In studies involving patients with AIDS and/or cancer, <e1>MARINOL</e1> (Dronabinol) Capsules has been co-administered with a variety of medications (e.g., cytotoxic agents, anti-infective agents, sedatives, or <e2>opioid analgesics</e2>) without resulting in any clinically significant drug/drug interactions. ",False,negative
Dronabinol,anti-infective,94,103,195,208,"Interactions for Dronabinol:  In studies involving patients with AIDS and/or cancer, MARINOL (<e1>Dronabinol</e1>) Capsules has been co-administered with a variety of medications (e.g., cytotoxic agents, <e2>anti-infective</e2> agents, sedatives, or opioid analgesics) without resulting in any clinically significant drug/drug interactions. ",False,negative
Dronabinol,sedatives,94,103,218,226,"Interactions for Dronabinol:  In studies involving patients with AIDS and/or cancer, MARINOL (<e1>Dronabinol</e1>) Capsules has been co-administered with a variety of medications (e.g., cytotoxic agents, anti-infective agents, <e2>sedatives</e2>, or opioid analgesics) without resulting in any clinically significant drug/drug interactions. ",False,negative
Dronabinol,opioid analgesics,94,103,232,248,"Interactions for Dronabinol:  In studies involving patients with AIDS and/or cancer, MARINOL (<e1>Dronabinol</e1>) Capsules has been co-administered with a variety of medications (e.g., cytotoxic agents, anti-infective agents, sedatives, or <e2>opioid analgesics</e2>) without resulting in any clinically significant drug/drug interactions. ",False,negative
anti-infective,sedatives,195,208,218,226,"Interactions for Dronabinol:  In studies involving patients with AIDS and/or cancer, MARINOL (Dronabinol) Capsules has been co-administered with a variety of medications (e.g., cytotoxic agents, <e1>anti-infective</e1> agents, <e2>sedatives</e2>, or opioid analgesics) without resulting in any clinically significant drug/drug interactions. ",False,negative
anti-infective,opioid analgesics,195,208,232,248,"Interactions for Dronabinol:  In studies involving patients with AIDS and/or cancer, MARINOL (Dronabinol) Capsules has been co-administered with a variety of medications (e.g., cytotoxic agents, <e1>anti-infective</e1> agents, sedatives, or <e2>opioid analgesics</e2>) without resulting in any clinically significant drug/drug interactions. ",False,negative
sedatives,opioid analgesics,218,226,232,248,"Interactions for Dronabinol:  In studies involving patients with AIDS and/or cancer, MARINOL (Dronabinol) Capsules has been co-administered with a variety of medications (e.g., cytotoxic agents, anti-infective agents, <e1>sedatives</e1>, or <e2>opioid analgesics</e2>) without resulting in any clinically significant drug/drug interactions. ",False,negative
MARINOL,cannabinoids,81,87,99,110,"Although no drug/drug interactions were discovered during the clinical trials of <e1>MARINOL</e1> Capsules, <e2>cannabinoids</e2> may interact with other medications through both metabolic and pharmacodynamic mechanisms. ",False,negative
anthralin,coal tar,191,199,202,209,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as <e1>anthralin</e1>, <e2>coal tar</e2> or coal tar derivatives, griseofulvin, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
anthralin,coal tar derivatives,191,199,214,233,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as <e1>anthralin</e1>, coal tar or <e2>coal tar derivatives</e2>, griseofulvin, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
anthralin,griseofulvin,191,199,236,247,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as <e1>anthralin</e1>, coal tar or coal tar derivatives, <e2>griseofulvin</e2>, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
anthralin,phenothiazines,191,199,250,263,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as <e1>anthralin</e1>, coal tar or coal tar derivatives, griseofulvin, <e2>phenothiazines</e2>, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
anthralin,nalidixic acid,191,199,266,279,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as <e1>anthralin</e1>, coal tar or coal tar derivatives, griseofulvin, phenothiazines, <e2>nalidixic acid</e2>, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
anthralin,halogenated salicylanilides,191,199,282,308,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as <e1>anthralin</e1>, coal tar or coal tar derivatives, griseofulvin, phenothiazines, nalidixic acid, <e2>halogenated salicylanilides</e2> (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
anthralin,sulfonamides,191,199,334,345,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as <e1>anthralin</e1>, coal tar or coal tar derivatives, griseofulvin, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), <e2>sulfonamides</e2>, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
anthralin,tetracyclines,191,199,348,360,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as <e1>anthralin</e1>, coal tar or coal tar derivatives, griseofulvin, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, <e2>tetracyclines</e2>, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
anthralin,thiazides,191,199,363,371,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as <e1>anthralin</e1>, coal tar or coal tar derivatives, griseofulvin, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, <e2>thiazides</e2>, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
anthralin,methylene blue,191,199,416,429,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as <e1>anthralin</e1>, coal tar or coal tar derivatives, griseofulvin, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as <e2>methylene blue</e2>, toluidine blue, rose bengal and methyl orange.",False,negative
anthralin,toluidine blue,191,199,432,445,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as <e1>anthralin</e1>, coal tar or coal tar derivatives, griseofulvin, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, <e2>toluidine blue</e2>, rose bengal and methyl orange.",False,negative
coal tar,coal tar derivatives,202,209,214,233,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, <e1>coal tar</e1> or <e2>coal tar derivatives</e2>, griseofulvin, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
coal tar,griseofulvin,202,209,236,247,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, <e1>coal tar</e1> or coal tar derivatives, <e2>griseofulvin</e2>, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
coal tar,phenothiazines,202,209,250,263,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, <e1>coal tar</e1> or coal tar derivatives, griseofulvin, <e2>phenothiazines</e2>, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
coal tar,nalidixic acid,202,209,266,279,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, <e1>coal tar</e1> or coal tar derivatives, griseofulvin, phenothiazines, <e2>nalidixic acid</e2>, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
coal tar,halogenated salicylanilides,202,209,282,308,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, <e1>coal tar</e1> or coal tar derivatives, griseofulvin, phenothiazines, nalidixic acid, <e2>halogenated salicylanilides</e2> (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
coal tar,sulfonamides,202,209,334,345,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, <e1>coal tar</e1> or coal tar derivatives, griseofulvin, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), <e2>sulfonamides</e2>, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
coal tar,tetracyclines,202,209,348,360,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, <e1>coal tar</e1> or coal tar derivatives, griseofulvin, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, <e2>tetracyclines</e2>, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
coal tar,thiazides,202,209,363,371,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, <e1>coal tar</e1> or coal tar derivatives, griseofulvin, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, <e2>thiazides</e2>, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
coal tar,methylene blue,202,209,416,429,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, <e1>coal tar</e1> or coal tar derivatives, griseofulvin, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as <e2>methylene blue</e2>, toluidine blue, rose bengal and methyl orange.",False,negative
coal tar,toluidine blue,202,209,432,445,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, <e1>coal tar</e1> or coal tar derivatives, griseofulvin, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, <e2>toluidine blue</e2>, rose bengal and methyl orange.",False,negative
coal tar derivatives,griseofulvin,214,233,236,247,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or <e1>coal tar derivatives</e1>, <e2>griseofulvin</e2>, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
coal tar derivatives,phenothiazines,214,233,250,263,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or <e1>coal tar derivatives</e1>, griseofulvin, <e2>phenothiazines</e2>, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
coal tar derivatives,nalidixic acid,214,233,266,279,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or <e1>coal tar derivatives</e1>, griseofulvin, phenothiazines, <e2>nalidixic acid</e2>, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
coal tar derivatives,halogenated salicylanilides,214,233,282,308,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or <e1>coal tar derivatives</e1>, griseofulvin, phenothiazines, nalidixic acid, <e2>halogenated salicylanilides</e2> (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
coal tar derivatives,sulfonamides,214,233,334,345,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or <e1>coal tar derivatives</e1>, griseofulvin, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), <e2>sulfonamides</e2>, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
coal tar derivatives,tetracyclines,214,233,348,360,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or <e1>coal tar derivatives</e1>, griseofulvin, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, <e2>tetracyclines</e2>, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
coal tar derivatives,thiazides,214,233,363,371,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or <e1>coal tar derivatives</e1>, griseofulvin, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, <e2>thiazides</e2>, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
coal tar derivatives,methylene blue,214,233,416,429,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or <e1>coal tar derivatives</e1>, griseofulvin, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as <e2>methylene blue</e2>, toluidine blue, rose bengal and methyl orange.",False,negative
coal tar derivatives,toluidine blue,214,233,432,445,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or <e1>coal tar derivatives</e1>, griseofulvin, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, <e2>toluidine blue</e2>, rose bengal and methyl orange.",False,negative
griseofulvin,phenothiazines,236,247,250,263,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, <e1>griseofulvin</e1>, <e2>phenothiazines</e2>, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
griseofulvin,nalidixic acid,236,247,266,279,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, <e1>griseofulvin</e1>, phenothiazines, <e2>nalidixic acid</e2>, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
griseofulvin,halogenated salicylanilides,236,247,282,308,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, <e1>griseofulvin</e1>, phenothiazines, nalidixic acid, <e2>halogenated salicylanilides</e2> (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
griseofulvin,sulfonamides,236,247,334,345,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, <e1>griseofulvin</e1>, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), <e2>sulfonamides</e2>, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
griseofulvin,tetracyclines,236,247,348,360,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, <e1>griseofulvin</e1>, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, <e2>tetracyclines</e2>, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
griseofulvin,thiazides,236,247,363,371,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, <e1>griseofulvin</e1>, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, <e2>thiazides</e2>, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
griseofulvin,methylene blue,236,247,416,429,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, <e1>griseofulvin</e1>, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as <e2>methylene blue</e2>, toluidine blue, rose bengal and methyl orange.",False,negative
griseofulvin,toluidine blue,236,247,432,445,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, <e1>griseofulvin</e1>, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, <e2>toluidine blue</e2>, rose bengal and methyl orange.",False,negative
phenothiazines,nalidixic acid,250,263,266,279,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, griseofulvin, <e1>phenothiazines</e1>, <e2>nalidixic acid</e2>, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
phenothiazines,halogenated salicylanilides,250,263,282,308,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, griseofulvin, <e1>phenothiazines</e1>, nalidixic acid, <e2>halogenated salicylanilides</e2> (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
phenothiazines,sulfonamides,250,263,334,345,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, griseofulvin, <e1>phenothiazines</e1>, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), <e2>sulfonamides</e2>, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
phenothiazines,tetracyclines,250,263,348,360,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, griseofulvin, <e1>phenothiazines</e1>, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, <e2>tetracyclines</e2>, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
phenothiazines,thiazides,250,263,363,371,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, griseofulvin, <e1>phenothiazines</e1>, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, <e2>thiazides</e2>, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
phenothiazines,methylene blue,250,263,416,429,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, griseofulvin, <e1>phenothiazines</e1>, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as <e2>methylene blue</e2>, toluidine blue, rose bengal and methyl orange.",False,negative
phenothiazines,toluidine blue,250,263,432,445,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, griseofulvin, <e1>phenothiazines</e1>, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, <e2>toluidine blue</e2>, rose bengal and methyl orange.",False,negative
nalidixic acid,halogenated salicylanilides,266,279,282,308,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, griseofulvin, phenothiazines, <e1>nalidixic acid</e1>, <e2>halogenated salicylanilides</e2> (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
nalidixic acid,sulfonamides,266,279,334,345,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, griseofulvin, phenothiazines, <e1>nalidixic acid</e1>, halogenated salicylanilides (bacteriostatic soaps), <e2>sulfonamides</e2>, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
nalidixic acid,tetracyclines,266,279,348,360,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, griseofulvin, phenothiazines, <e1>nalidixic acid</e1>, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, <e2>tetracyclines</e2>, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
nalidixic acid,thiazides,266,279,363,371,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, griseofulvin, phenothiazines, <e1>nalidixic acid</e1>, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, <e2>thiazides</e2>, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
nalidixic acid,methylene blue,266,279,416,429,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, griseofulvin, phenothiazines, <e1>nalidixic acid</e1>, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as <e2>methylene blue</e2>, toluidine blue, rose bengal and methyl orange.",False,negative
nalidixic acid,toluidine blue,266,279,432,445,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, griseofulvin, phenothiazines, <e1>nalidixic acid</e1>, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, <e2>toluidine blue</e2>, rose bengal and methyl orange.",False,negative
halogenated salicylanilides,sulfonamides,282,308,334,345,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, griseofulvin, phenothiazines, nalidixic acid, <e1>halogenated salicylanilides</e1> (bacteriostatic soaps), <e2>sulfonamides</e2>, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
halogenated salicylanilides,tetracyclines,282,308,348,360,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, griseofulvin, phenothiazines, nalidixic acid, <e1>halogenated salicylanilides</e1> (bacteriostatic soaps), sulfonamides, <e2>tetracyclines</e2>, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
halogenated salicylanilides,thiazides,282,308,363,371,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, griseofulvin, phenothiazines, nalidixic acid, <e1>halogenated salicylanilides</e1> (bacteriostatic soaps), sulfonamides, tetracyclines, <e2>thiazides</e2>, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
halogenated salicylanilides,methylene blue,282,308,416,429,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, griseofulvin, phenothiazines, nalidixic acid, <e1>halogenated salicylanilides</e1> (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as <e2>methylene blue</e2>, toluidine blue, rose bengal and methyl orange.",False,negative
halogenated salicylanilides,toluidine blue,282,308,432,445,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, griseofulvin, phenothiazines, nalidixic acid, <e1>halogenated salicylanilides</e1> (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, <e2>toluidine blue</e2>, rose bengal and methyl orange.",False,negative
sulfonamides,tetracyclines,334,345,348,360,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, griseofulvin, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), <e1>sulfonamides</e1>, <e2>tetracyclines</e2>, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
sulfonamides,thiazides,334,345,363,371,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, griseofulvin, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), <e1>sulfonamides</e1>, tetracyclines, <e2>thiazides</e2>, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
sulfonamides,methylene blue,334,345,416,429,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, griseofulvin, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), <e1>sulfonamides</e1>, tetracyclines, thiazides, and certain organic staining dyes such as <e2>methylene blue</e2>, toluidine blue, rose bengal and methyl orange.",False,negative
sulfonamides,toluidine blue,334,345,432,445,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, griseofulvin, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), <e1>sulfonamides</e1>, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, <e2>toluidine blue</e2>, rose bengal and methyl orange.",False,negative
tetracyclines,thiazides,348,360,363,371,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, griseofulvin, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, <e1>tetracyclines</e1>, <e2>thiazides</e2>, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.",False,negative
tetracyclines,methylene blue,348,360,416,429,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, griseofulvin, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, <e1>tetracyclines</e1>, thiazides, and certain organic staining dyes such as <e2>methylene blue</e2>, toluidine blue, rose bengal and methyl orange.",False,negative
tetracyclines,toluidine blue,348,360,432,445,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, griseofulvin, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, <e1>tetracyclines</e1>, thiazides, and certain organic staining dyes such as methylene blue, <e2>toluidine blue</e2>, rose bengal and methyl orange.",False,negative
thiazides,methylene blue,363,371,416,429,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, griseofulvin, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, <e1>thiazides</e1>, and certain organic staining dyes such as <e2>methylene blue</e2>, toluidine blue, rose bengal and methyl orange.",False,negative
thiazides,toluidine blue,363,371,432,445,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, griseofulvin, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, <e1>thiazides</e1>, and certain organic staining dyes such as methylene blue, <e2>toluidine blue</e2>, rose bengal and methyl orange.",False,negative
methylene blue,toluidine blue,416,429,432,445,"Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, griseofulvin, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as <e1>methylene blue</e1>, <e2>toluidine blue</e2>, rose bengal and methyl orange.",False,negative
methyl aminolevulinate,anesthetics,49,70,116,126,"There have been no studies of the interaction of <e1>methyl aminolevulinate</e1> cream with any other drugs, including local <e2>anesthetics</e2>. ",False,negative
PRIMACOR,digitalis glycosides,99,106,156,175,No untoward clinical manifestations have been observed in limited experience with patients in whom <e1>PRIMACOR</e1> was used concurrently with the following drugs: <e2>digitalis glycosides</e2>; ,False,negative
lidocaine,quinidine,0,8,11,19,"<e1>lidocaine</e1>, <e2>quinidine</e2>; ",False,negative
hydralazine,prazosin,0,10,13,20,"<e1>hydralazine</e1>, <e2>prazosin</e2>; ",False,negative
isosorbide dinitrate,nitroglycerin,0,19,22,34,"<e1>isosorbide dinitrate</e1>, <e2>nitroglycerin</e2>; ",False,negative
chlorthalidone,furosemide,0,13,16,25,"<e1>chlorthalidone</e1>, <e2>furosemide</e2>, hydrochlorothiazide, spironolactone; ",False,negative
chlorthalidone,hydrochlorothiazide,0,13,28,46,"<e1>chlorthalidone</e1>, furosemide, <e2>hydrochlorothiazide</e2>, spironolactone; ",False,negative
chlorthalidone,spironolactone,0,13,49,62,"<e1>chlorthalidone</e1>, furosemide, hydrochlorothiazide, <e2>spironolactone</e2>; ",False,negative
furosemide,hydrochlorothiazide,16,25,28,46,"chlorthalidone, <e1>furosemide</e1>, <e2>hydrochlorothiazide</e2>, spironolactone; ",False,negative
furosemide,spironolactone,16,25,49,62,"chlorthalidone, <e1>furosemide</e1>, hydrochlorothiazide, <e2>spironolactone</e2>; ",False,negative
hydrochlorothiazide,spironolactone,28,46,49,62,"chlorthalidone, furosemide, <e1>hydrochlorothiazide</e1>, <e2>spironolactone</e2>; ",False,negative
heparin,warfarin,0,6,9,16,"<e1>heparin</e1>, <e2>warfarin</e2>, diazepam, insulin; ",False,negative
heparin,diazepam,0,6,19,26,"<e1>heparin</e1>, warfarin, <e2>diazepam</e2>, insulin; ",False,negative
heparin,insulin,0,6,29,35,"<e1>heparin</e1>, warfarin, diazepam, <e2>insulin</e2>; ",False,negative
warfarin,diazepam,9,16,19,26,"heparin, <e1>warfarin</e1>, <e2>diazepam</e2>, insulin; ",False,negative
warfarin,insulin,9,16,29,35,"heparin, <e1>warfarin</e1>, diazepam, <e2>insulin</e2>; ",False,negative
diazepam,insulin,19,26,29,35,"heparin, warfarin, <e1>diazepam</e1>, <e2>insulin</e2>; ",False,negative
furosemide,PRIMACOR,123,132,189,196,Chemical Interactions There is an immediate chemical interaction which is evidenced by the formation of a precipitate when <e1>furosemide</e1> is injected into an intravenous line of an infusion of <e2>PRIMACOR</e2>. ,False,negative
furosemide,PRIMACOR,11,20,81,88,"Therefore, <e1>furosemide</e1> should not be administered in intravenous lines containing <e2>PRIMACOR</e2>.",False,negative
Misoprostol,aspirin,0,10,75,81,<e1>Misoprostol</e1> has not been shown to interfere with the beneficial effects of <e2>aspirin</e2> on signs and symptoms of rheumatoid arthritis. ,False,negative
Misoprostol,aspirin,0,10,141,147,"<e1>Misoprostol</e1> does not exert clinically significant effects on the absorption, blood levels, and anti-platelet effects of therapeutic doses of <e2>aspirin</e2>. ",False,negative
Misoprostol,diclofenac,0,10,68,77,<e1>Misoprostol</e1> has no clinically significant effect on the kinetics of <e2>diclofenac</e2> or ibuprofen.,False,negative
Misoprostol,ibuprofen,0,10,82,90,<e1>Misoprostol</e1> has no clinically significant effect on the kinetics of diclofenac or <e2>ibuprofen</e2>.,False,negative
diclofenac,ibuprofen,68,77,82,90,Misoprostol has no clinically significant effect on the kinetics of <e1>diclofenac</e1> or <e2>ibuprofen</e2>.,False,negative
Mitoxantrone,mitoxantrone,0,11,179,190,"<e1>Mitoxantrone</e1> and its metabolites are excreted in bile and urine, but it is not known whether the metabolic or excretory pathways are saturable, may be inhibited or induced, or if <e2>mitoxantrone</e2> and its metabolites undergo enterohepatic circulation. ",False,negative
NOVANTRONE,corticosteroids,39,48,58,72,"Following concurrent administration of <e1>NOVANTRONE</e1>    with <e2>corticosteroids</e2>, no evidence of drug interactions has been observed.",False,negative
cimetidine,digoxin,18,27,30,36,"May interact with <e1>cimetidine</e1>, <e2>digoxin</e2>, medicines to control heart rhythm, sevelamer, and theophylline.",False,negative
cimetidine,sevelamer,18,27,74,82,"May interact with <e1>cimetidine</e1>, digoxin, medicines to control heart rhythm, <e2>sevelamer</e2>, and theophylline.",False,negative
cimetidine,theophylline,18,27,89,100,"May interact with <e1>cimetidine</e1>, digoxin, medicines to control heart rhythm, sevelamer, and <e2>theophylline</e2>.",False,negative
digoxin,sevelamer,30,36,74,82,"May interact with cimetidine, <e1>digoxin</e1>, medicines to control heart rhythm, <e2>sevelamer</e2>, and theophylline.",False,negative
digoxin,theophylline,30,36,89,100,"May interact with cimetidine, <e1>digoxin</e1>, medicines to control heart rhythm, sevelamer, and <e2>theophylline</e2>.",False,negative
sevelamer,theophylline,74,82,89,100,"May interact with cimetidine, digoxin, medicines to control heart rhythm, <e1>sevelamer</e1>, and <e2>theophylline</e2>.",False,negative
moxifloxacin,moxifloxacin,31,42,120,131,"In vitro studies indicate that <e1>moxifloxacin</e1> does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2 indicating that <e2>moxifloxacin</e2> is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.",False,negative
olmesartan medoxomil,digoxin,67,86,113,119,No significant drug interactions were reported in studies in which <e1>olmesartan medoxomil</e1> was co-administered with <e2>digoxin</e2> or warfarin in healthy volunteers. ,False,negative
olmesartan medoxomil,warfarin,67,86,124,131,No significant drug interactions were reported in studies in which <e1>olmesartan medoxomil</e1> was co-administered with digoxin or <e2>warfarin</e2> in healthy volunteers. ,False,negative
digoxin,warfarin,113,119,124,131,No significant drug interactions were reported in studies in which olmesartan medoxomil was co-administered with <e1>digoxin</e1> or <e2>warfarin</e2> in healthy volunteers. ,False,negative
olmesartan,antacids,23,32,92,99,The bioavailability of <e1>olmesartan</e1> was not significantly altered by the co-administration of <e2>antacids</e2> [Al(OH)3/Mg(OH)2]. ,False,negative
oxytocin,vasoconstrictor,43,50,125,139,Severe hypertension has been reported when <e1>oxytocin</e1> was given three to four hours following prophylactic administration of a <e2>vasoconstrictor</e2> in conjunction with caudal block anesthesia. ,False,negative
Synagis,vaccines,59,65,108,115,"In Trial 1, the proportions of patients in the placebo and <e1>Synagis</e1>    groups who received routine childhood <e2>vaccines</e2>, influenza vaccine, bronchodilators or corticosteroids were similar and no incremental increase in adverse reactions was observed among patients receiving these agents.    ",False,negative
Synagis,influenza vaccine,59,65,118,134,"In Trial 1, the proportions of patients in the placebo and <e1>Synagis</e1>    groups who received routine childhood vaccines, <e2>influenza vaccine</e2>, bronchodilators or corticosteroids were similar and no incremental increase in adverse reactions was observed among patients receiving these agents.    ",False,negative
Synagis,bronchodilators,59,65,137,151,"In Trial 1, the proportions of patients in the placebo and <e1>Synagis</e1>    groups who received routine childhood vaccines, influenza vaccine, <e2>bronchodilators</e2> or corticosteroids were similar and no incremental increase in adverse reactions was observed among patients receiving these agents.    ",False,negative
Synagis,corticosteroids,59,65,156,170,"In Trial 1, the proportions of patients in the placebo and <e1>Synagis</e1>    groups who received routine childhood vaccines, influenza vaccine, bronchodilators or <e2>corticosteroids</e2> were similar and no incremental increase in adverse reactions was observed among patients receiving these agents.    ",False,negative
vaccines,influenza vaccine,108,115,118,134,"In Trial 1, the proportions of patients in the placebo and Synagis    groups who received routine childhood <e1>vaccines</e1>, <e2>influenza vaccine</e2>, bronchodilators or corticosteroids were similar and no incremental increase in adverse reactions was observed among patients receiving these agents.    ",False,negative
vaccines,bronchodilators,108,115,137,151,"In Trial 1, the proportions of patients in the placebo and Synagis    groups who received routine childhood <e1>vaccines</e1>, influenza vaccine, <e2>bronchodilators</e2> or corticosteroids were similar and no incremental increase in adverse reactions was observed among patients receiving these agents.    ",False,negative
vaccines,corticosteroids,108,115,156,170,"In Trial 1, the proportions of patients in the placebo and Synagis    groups who received routine childhood <e1>vaccines</e1>, influenza vaccine, bronchodilators or <e2>corticosteroids</e2> were similar and no incremental increase in adverse reactions was observed among patients receiving these agents.    ",False,negative
influenza vaccine,bronchodilators,118,134,137,151,"In Trial 1, the proportions of patients in the placebo and Synagis    groups who received routine childhood vaccines, <e1>influenza vaccine</e1>, <e2>bronchodilators</e2> or corticosteroids were similar and no incremental increase in adverse reactions was observed among patients receiving these agents.    ",False,negative
influenza vaccine,corticosteroids,118,134,156,170,"In Trial 1, the proportions of patients in the placebo and Synagis    groups who received routine childhood vaccines, <e1>influenza vaccine</e1>, bronchodilators or <e2>corticosteroids</e2> were similar and no incremental increase in adverse reactions was observed among patients receiving these agents.    ",False,negative
bronchodilators,corticosteroids,137,151,156,170,"In Trial 1, the proportions of patients in the placebo and Synagis    groups who received routine childhood vaccines, influenza vaccine, <e1>bronchodilators</e1> or <e2>corticosteroids</e2> were similar and no incremental increase in adverse reactions was observed among patients receiving these agents.    ",False,negative
palonosetron,metoclopramide,55,66,100,113,A study in healthy volunteers involving single-dose IV <e1>palonosetron</e1> (0.75 mg) and steady state oral <e2>metoclopramide</e2> (10 mg four times daily) demonstrated no significant pharmacokinetic interaction. ,False,negative
ALOXI,corticosteroids,31,35,81,95,"In controlled clinical trials, <e1>ALOXI</e1> injection has been safely administered with <e2>corticosteroids</e2>, analgesics, antiemetics/antinauseants, antispasmodics and anticholinergic agents. ",False,negative
ALOXI,analgesics,31,35,98,107,"In controlled clinical trials, <e1>ALOXI</e1> injection has been safely administered with corticosteroids, <e2>analgesics</e2>, antiemetics/antinauseants, antispasmodics and anticholinergic agents. ",False,negative
ALOXI,antiemetics,31,35,110,120,"In controlled clinical trials, <e1>ALOXI</e1> injection has been safely administered with corticosteroids, analgesics, <e2>antiemetics</e2>/antinauseants, antispasmodics and anticholinergic agents. ",False,negative
ALOXI,antinauseants,31,35,122,134,"In controlled clinical trials, <e1>ALOXI</e1> injection has been safely administered with corticosteroids, analgesics, antiemetics/<e2>antinauseants</e2>, antispasmodics and anticholinergic agents. ",False,negative
ALOXI,antispasmodics,31,35,137,150,"In controlled clinical trials, <e1>ALOXI</e1> injection has been safely administered with corticosteroids, analgesics, antiemetics/antinauseants, <e2>antispasmodics</e2> and anticholinergic agents. ",False,negative
ALOXI,anticholinergic agents,31,35,156,177,"In controlled clinical trials, <e1>ALOXI</e1> injection has been safely administered with corticosteroids, analgesics, antiemetics/antinauseants, antispasmodics and <e2>anticholinergic agents</e2>. ",False,negative
corticosteroids,analgesics,81,95,98,107,"In controlled clinical trials, ALOXI injection has been safely administered with <e1>corticosteroids</e1>, <e2>analgesics</e2>, antiemetics/antinauseants, antispasmodics and anticholinergic agents. ",False,negative
corticosteroids,antiemetics,81,95,110,120,"In controlled clinical trials, ALOXI injection has been safely administered with <e1>corticosteroids</e1>, analgesics, <e2>antiemetics</e2>/antinauseants, antispasmodics and anticholinergic agents. ",False,negative
corticosteroids,antinauseants,81,95,122,134,"In controlled clinical trials, ALOXI injection has been safely administered with <e1>corticosteroids</e1>, analgesics, antiemetics/<e2>antinauseants</e2>, antispasmodics and anticholinergic agents. ",False,negative
corticosteroids,antispasmodics,81,95,137,150,"In controlled clinical trials, ALOXI injection has been safely administered with <e1>corticosteroids</e1>, analgesics, antiemetics/antinauseants, <e2>antispasmodics</e2> and anticholinergic agents. ",False,negative
corticosteroids,anticholinergic agents,81,95,156,177,"In controlled clinical trials, ALOXI injection has been safely administered with <e1>corticosteroids</e1>, analgesics, antiemetics/antinauseants, antispasmodics and <e2>anticholinergic agents</e2>. ",False,negative
analgesics,antiemetics,98,107,110,120,"In controlled clinical trials, ALOXI injection has been safely administered with corticosteroids, <e1>analgesics</e1>, <e2>antiemetics</e2>/antinauseants, antispasmodics and anticholinergic agents. ",False,negative
analgesics,antinauseants,98,107,122,134,"In controlled clinical trials, ALOXI injection has been safely administered with corticosteroids, <e1>analgesics</e1>, antiemetics/<e2>antinauseants</e2>, antispasmodics and anticholinergic agents. ",False,negative
analgesics,antispasmodics,98,107,137,150,"In controlled clinical trials, ALOXI injection has been safely administered with corticosteroids, <e1>analgesics</e1>, antiemetics/antinauseants, <e2>antispasmodics</e2> and anticholinergic agents. ",False,negative
analgesics,anticholinergic agents,98,107,156,177,"In controlled clinical trials, ALOXI injection has been safely administered with corticosteroids, <e1>analgesics</e1>, antiemetics/antinauseants, antispasmodics and <e2>anticholinergic agents</e2>. ",False,negative
antiemetics,antinauseants,110,120,122,134,"In controlled clinical trials, ALOXI injection has been safely administered with corticosteroids, analgesics, <e1>antiemetics</e1>/<e2>antinauseants</e2>, antispasmodics and anticholinergic agents. ",False,negative
antiemetics,antispasmodics,110,120,137,150,"In controlled clinical trials, ALOXI injection has been safely administered with corticosteroids, analgesics, <e1>antiemetics</e1>/antinauseants, <e2>antispasmodics</e2> and anticholinergic agents. ",False,negative
antiemetics,anticholinergic agents,110,120,156,177,"In controlled clinical trials, ALOXI injection has been safely administered with corticosteroids, analgesics, <e1>antiemetics</e1>/antinauseants, antispasmodics and <e2>anticholinergic agents</e2>. ",False,negative
antinauseants,antispasmodics,122,134,137,150,"In controlled clinical trials, ALOXI injection has been safely administered with corticosteroids, analgesics, antiemetics/<e1>antinauseants</e1>, <e2>antispasmodics</e2> and anticholinergic agents. ",False,negative
antinauseants,anticholinergic agents,122,134,156,177,"In controlled clinical trials, ALOXI injection has been safely administered with corticosteroids, analgesics, antiemetics/<e1>antinauseants</e1>, antispasmodics and <e2>anticholinergic agents</e2>. ",False,negative
antispasmodics,anticholinergic agents,137,150,156,177,"In controlled clinical trials, ALOXI injection has been safely administered with corticosteroids, analgesics, antiemetics/antinauseants, <e1>antispasmodics</e1> and <e2>anticholinergic agents</e2>. ",False,negative
Palonosetron,chemotherapeutic agents,0,11,64,86,"<e1>Palonosetron</e1> did not inhibit the antitumor activity of the five <e2>chemotherapeutic agents</e2> tested (cisplatin, cyclophosphamide, cytarabine, doxorubicin and mitomycin C) in murine tumor models.",False,negative
Palonosetron,cisplatin,0,11,96,104,"<e1>Palonosetron</e1> did not inhibit the antitumor activity of the five chemotherapeutic agents tested (<e2>cisplatin</e2>, cyclophosphamide, cytarabine, doxorubicin and mitomycin C) in murine tumor models.",False,negative
Palonosetron,cyclophosphamide,0,11,107,122,"<e1>Palonosetron</e1> did not inhibit the antitumor activity of the five chemotherapeutic agents tested (cisplatin, <e2>cyclophosphamide</e2>, cytarabine, doxorubicin and mitomycin C) in murine tumor models.",False,negative
Palonosetron,cytarabine,0,11,125,134,"<e1>Palonosetron</e1> did not inhibit the antitumor activity of the five chemotherapeutic agents tested (cisplatin, cyclophosphamide, <e2>cytarabine</e2>, doxorubicin and mitomycin C) in murine tumor models.",False,negative
Palonosetron,doxorubicin,0,11,137,147,"<e1>Palonosetron</e1> did not inhibit the antitumor activity of the five chemotherapeutic agents tested (cisplatin, cyclophosphamide, cytarabine, <e2>doxorubicin</e2> and mitomycin C) in murine tumor models.",False,negative
Palonosetron,mitomycin C,0,11,153,163,"<e1>Palonosetron</e1> did not inhibit the antitumor activity of the five chemotherapeutic agents tested (cisplatin, cyclophosphamide, cytarabine, doxorubicin and <e2>mitomycin C</e2>) in murine tumor models.",False,negative
chemotherapeutic agents,cisplatin,64,86,96,104,"Palonosetron did not inhibit the antitumor activity of the five <e1>chemotherapeutic agents</e1> tested (<e2>cisplatin</e2>, cyclophosphamide, cytarabine, doxorubicin and mitomycin C) in murine tumor models.",False,negative
chemotherapeutic agents,cyclophosphamide,64,86,107,122,"Palonosetron did not inhibit the antitumor activity of the five <e1>chemotherapeutic agents</e1> tested (cisplatin, <e2>cyclophosphamide</e2>, cytarabine, doxorubicin and mitomycin C) in murine tumor models.",False,negative
chemotherapeutic agents,cytarabine,64,86,125,134,"Palonosetron did not inhibit the antitumor activity of the five <e1>chemotherapeutic agents</e1> tested (cisplatin, cyclophosphamide, <e2>cytarabine</e2>, doxorubicin and mitomycin C) in murine tumor models.",False,negative
chemotherapeutic agents,doxorubicin,64,86,137,147,"Palonosetron did not inhibit the antitumor activity of the five <e1>chemotherapeutic agents</e1> tested (cisplatin, cyclophosphamide, cytarabine, <e2>doxorubicin</e2> and mitomycin C) in murine tumor models.",False,negative
chemotherapeutic agents,mitomycin C,64,86,153,163,"Palonosetron did not inhibit the antitumor activity of the five <e1>chemotherapeutic agents</e1> tested (cisplatin, cyclophosphamide, cytarabine, doxorubicin and <e2>mitomycin C</e2>) in murine tumor models.",False,negative
cisplatin,cyclophosphamide,96,104,107,122,"Palonosetron did not inhibit the antitumor activity of the five chemotherapeutic agents tested (<e1>cisplatin</e1>, <e2>cyclophosphamide</e2>, cytarabine, doxorubicin and mitomycin C) in murine tumor models.",False,negative
cisplatin,cytarabine,96,104,125,134,"Palonosetron did not inhibit the antitumor activity of the five chemotherapeutic agents tested (<e1>cisplatin</e1>, cyclophosphamide, <e2>cytarabine</e2>, doxorubicin and mitomycin C) in murine tumor models.",False,negative
cisplatin,doxorubicin,96,104,137,147,"Palonosetron did not inhibit the antitumor activity of the five chemotherapeutic agents tested (<e1>cisplatin</e1>, cyclophosphamide, cytarabine, <e2>doxorubicin</e2> and mitomycin C) in murine tumor models.",False,negative
cisplatin,mitomycin C,96,104,153,163,"Palonosetron did not inhibit the antitumor activity of the five chemotherapeutic agents tested (<e1>cisplatin</e1>, cyclophosphamide, cytarabine, doxorubicin and <e2>mitomycin C</e2>) in murine tumor models.",False,negative
cyclophosphamide,cytarabine,107,122,125,134,"Palonosetron did not inhibit the antitumor activity of the five chemotherapeutic agents tested (cisplatin, <e1>cyclophosphamide</e1>, <e2>cytarabine</e2>, doxorubicin and mitomycin C) in murine tumor models.",False,negative
cyclophosphamide,doxorubicin,107,122,137,147,"Palonosetron did not inhibit the antitumor activity of the five chemotherapeutic agents tested (cisplatin, <e1>cyclophosphamide</e1>, cytarabine, <e2>doxorubicin</e2> and mitomycin C) in murine tumor models.",False,negative
cyclophosphamide,mitomycin C,107,122,153,163,"Palonosetron did not inhibit the antitumor activity of the five chemotherapeutic agents tested (cisplatin, <e1>cyclophosphamide</e1>, cytarabine, doxorubicin and <e2>mitomycin C</e2>) in murine tumor models.",False,negative
cytarabine,doxorubicin,125,134,137,147,"Palonosetron did not inhibit the antitumor activity of the five chemotherapeutic agents tested (cisplatin, cyclophosphamide, <e1>cytarabine</e1>, <e2>doxorubicin</e2> and mitomycin C) in murine tumor models.",False,negative
cytarabine,mitomycin C,125,134,153,163,"Palonosetron did not inhibit the antitumor activity of the five chemotherapeutic agents tested (cisplatin, cyclophosphamide, <e1>cytarabine</e1>, doxorubicin and <e2>mitomycin C</e2>) in murine tumor models.",False,negative
doxorubicin,mitomycin C,137,147,153,163,"Palonosetron did not inhibit the antitumor activity of the five chemotherapeutic agents tested (cisplatin, cyclophosphamide, cytarabine, <e1>doxorubicin</e1> and <e2>mitomycin C</e2>) in murine tumor models.",False,negative
loop diuretic,Aredia,32,44,94,99,Concomitant administration of a <e1>loop diuretic</e1> had no effect on the calcium-lowering action of <e2>Aredia</e2>. ,False,negative
CNS depressants,trycyclic antidepressants,20,34,39,63,Not compatible with <e1>CNS depressants</e1> or <e2>trycyclic antidepressants</e2>,False,negative
Macugen,pegaptanib,62,68,170,179,Two early clinical studies conducted in patients who received <e1>Macugen</e1> alone and in combination with PDT revealed no apparent difference in the plasma pharmacokinetics of <e2>pegaptanib</e2>.,False,negative
fludarabine,vidarabine,37,47,53,62,"Interactions with cylcopholsphamide, <e1>fludarabine</e1> and <e2>vidarabine</e2>",False,negative
erythromycin,itraconazole,32,43,46,57,"Some examples of such drugs are <e1>erythromycin</e1>, <e2>itraconazole</e2>, ketoconazole, fluconazole, calcium channel blockers and cimetidine.",False,negative
erythromycin,ketoconazole,32,43,60,71,"Some examples of such drugs are <e1>erythromycin</e1>, itraconazole, <e2>ketoconazole</e2>, fluconazole, calcium channel blockers and cimetidine.",False,negative
erythromycin,fluconazole,32,43,74,84,"Some examples of such drugs are <e1>erythromycin</e1>, itraconazole, ketoconazole, <e2>fluconazole</e2>, calcium channel blockers and cimetidine.",False,negative
erythromycin,calcium channel blockers,32,43,87,110,"Some examples of such drugs are <e1>erythromycin</e1>, itraconazole, ketoconazole, fluconazole, <e2>calcium channel blockers</e2> and cimetidine.",False,negative
erythromycin,cimetidine,32,43,116,125,"Some examples of such drugs are <e1>erythromycin</e1>, itraconazole, ketoconazole, fluconazole, calcium channel blockers and <e2>cimetidine</e2>.",False,negative
itraconazole,ketoconazole,46,57,60,71,"Some examples of such drugs are erythromycin, <e1>itraconazole</e1>, <e2>ketoconazole</e2>, fluconazole, calcium channel blockers and cimetidine.",False,negative
itraconazole,fluconazole,46,57,74,84,"Some examples of such drugs are erythromycin, <e1>itraconazole</e1>, ketoconazole, <e2>fluconazole</e2>, calcium channel blockers and cimetidine.",False,negative
itraconazole,calcium channel blockers,46,57,87,110,"Some examples of such drugs are erythromycin, <e1>itraconazole</e1>, ketoconazole, fluconazole, <e2>calcium channel blockers</e2> and cimetidine.",False,negative
itraconazole,cimetidine,46,57,116,125,"Some examples of such drugs are erythromycin, <e1>itraconazole</e1>, ketoconazole, fluconazole, calcium channel blockers and <e2>cimetidine</e2>.",False,negative
ketoconazole,fluconazole,60,71,74,84,"Some examples of such drugs are erythromycin, itraconazole, <e1>ketoconazole</e1>, <e2>fluconazole</e2>, calcium channel blockers and cimetidine.",False,negative
ketoconazole,calcium channel blockers,60,71,87,110,"Some examples of such drugs are erythromycin, itraconazole, <e1>ketoconazole</e1>, fluconazole, <e2>calcium channel blockers</e2> and cimetidine.",False,negative
ketoconazole,cimetidine,60,71,116,125,"Some examples of such drugs are erythromycin, itraconazole, <e1>ketoconazole</e1>, fluconazole, calcium channel blockers and <e2>cimetidine</e2>.",False,negative
fluconazole,calcium channel blockers,74,84,87,110,"Some examples of such drugs are erythromycin, itraconazole, ketoconazole, <e1>fluconazole</e1>, <e2>calcium channel blockers</e2> and cimetidine.",False,negative
fluconazole,cimetidine,74,84,116,125,"Some examples of such drugs are erythromycin, itraconazole, ketoconazole, <e1>fluconazole</e1>, calcium channel blockers and <e2>cimetidine</e2>.",False,negative
calcium channel blockers,cimetidine,87,110,116,125,"Some examples of such drugs are erythromycin, itraconazole, ketoconazole, fluconazole, <e1>calcium channel blockers</e1> and <e2>cimetidine</e2>.",False,negative
Pirenzepine,Pirenzepine,20,30,102,112,"Drug Interactions:  <e1>Pirenzepine</e1> may interact with the following drugs, which may affect the effect of <e2>Pirenzepine</e2> or whose effects may be affected. ",False,negative
Antacids,kaolin,2,9,42,47,"- <e1>Antacids</e1> - Diarrhea medicine containing <e2>kaolin</e2> or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Antacids,attapulgite,2,9,52,62,"- <e1>Antacids</e1> - Diarrhea medicine containing kaolin or <e2>attapulgite</e2> - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Antacids,Ketoconazole,2,9,66,77,"- <e1>Antacids</e1> - Diarrhea medicine containing kaolin or attapulgite - <e2>Ketoconazole</e2> - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Antacids,Central nervous system (CNS) depressants,2,9,81,120,"- <e1>Antacids</e1> - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - <e2>Central nervous system (CNS) depressants</e2> - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Antacids,anticholinergics,2,9,130,145,"- <e1>Antacids</e1> - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other <e2>anticholinergics</e2> - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Antacids,Tricyclic antidepressants,2,9,149,173,"- <e1>Antacids</e1> - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - <e2>Tricyclic antidepressants</e2> (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Antacids,Elavil,2,9,182,187,"- <e1>Antacids</e1> - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., <e2>Elavil</e2>, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Antacids,Asendin,2,9,190,196,"- <e1>Antacids</e1> - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, <e2>Asendin</e2>, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Antacids,Anafranil,2,9,199,207,"- <e1>Antacids</e1> - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, <e2>Anafranil</e2>, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Antacids,Pertofrane,2,9,210,219,"- <e1>Antacids</e1> - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, <e2>Pertofrane</e2>, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Antacids,Sinequan,2,9,222,229,"- <e1>Antacids</e1> - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, <e2>Sinequan</e2>, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Antacids,Tofranil,2,9,232,239,"- <e1>Antacids</e1> - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, <e2>Tofranil</e2>, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Antacids,Aventyl,2,9,242,248,"- <e1>Antacids</e1> - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, <e2>Aventyl</e2>, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Antacids,Surmontil,2,9,251,259,"- <e1>Antacids</e1> - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, <e2>Surmontil</e2>) - Potassium chloride (e.g., Kay Ciel)",False,negative
Antacids,Potassium chloride,2,9,264,281,"- <e1>Antacids</e1> - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - <e2>Potassium chloride</e2> (e.g., Kay Ciel)",False,negative
Antacids,Kay Ciel,2,9,290,297,"- <e1>Antacids</e1> - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., <e2>Kay Ciel</e2>)",False,negative
kaolin,attapulgite,42,47,52,62,"- Antacids - Diarrhea medicine containing <e1>kaolin</e1> or <e2>attapulgite</e2> - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
kaolin,Ketoconazole,42,47,66,77,"- Antacids - Diarrhea medicine containing <e1>kaolin</e1> or attapulgite - <e2>Ketoconazole</e2> - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
kaolin,Central nervous system (CNS) depressants,42,47,81,120,"- Antacids - Diarrhea medicine containing <e1>kaolin</e1> or attapulgite - Ketoconazole - <e2>Central nervous system (CNS) depressants</e2> - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
kaolin,anticholinergics,42,47,130,145,"- Antacids - Diarrhea medicine containing <e1>kaolin</e1> or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other <e2>anticholinergics</e2> - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
kaolin,Tricyclic antidepressants,42,47,149,173,"- Antacids - Diarrhea medicine containing <e1>kaolin</e1> or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - <e2>Tricyclic antidepressants</e2> (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
kaolin,Elavil,42,47,182,187,"- Antacids - Diarrhea medicine containing <e1>kaolin</e1> or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., <e2>Elavil</e2>, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
kaolin,Asendin,42,47,190,196,"- Antacids - Diarrhea medicine containing <e1>kaolin</e1> or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, <e2>Asendin</e2>, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
kaolin,Anafranil,42,47,199,207,"- Antacids - Diarrhea medicine containing <e1>kaolin</e1> or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, <e2>Anafranil</e2>, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
kaolin,Pertofrane,42,47,210,219,"- Antacids - Diarrhea medicine containing <e1>kaolin</e1> or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, <e2>Pertofrane</e2>, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
kaolin,Sinequan,42,47,222,229,"- Antacids - Diarrhea medicine containing <e1>kaolin</e1> or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, <e2>Sinequan</e2>, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
kaolin,Tofranil,42,47,232,239,"- Antacids - Diarrhea medicine containing <e1>kaolin</e1> or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, <e2>Tofranil</e2>, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
kaolin,Aventyl,42,47,242,248,"- Antacids - Diarrhea medicine containing <e1>kaolin</e1> or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, <e2>Aventyl</e2>, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
kaolin,Surmontil,42,47,251,259,"- Antacids - Diarrhea medicine containing <e1>kaolin</e1> or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, <e2>Surmontil</e2>) - Potassium chloride (e.g., Kay Ciel)",False,negative
kaolin,Potassium chloride,42,47,264,281,"- Antacids - Diarrhea medicine containing <e1>kaolin</e1> or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - <e2>Potassium chloride</e2> (e.g., Kay Ciel)",False,negative
kaolin,Kay Ciel,42,47,290,297,"- Antacids - Diarrhea medicine containing <e1>kaolin</e1> or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., <e2>Kay Ciel</e2>)",False,negative
attapulgite,Ketoconazole,52,62,66,77,"- Antacids - Diarrhea medicine containing kaolin or <e1>attapulgite</e1> - <e2>Ketoconazole</e2> - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
attapulgite,Central nervous system (CNS) depressants,52,62,81,120,"- Antacids - Diarrhea medicine containing kaolin or <e1>attapulgite</e1> - Ketoconazole - <e2>Central nervous system (CNS) depressants</e2> - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
attapulgite,anticholinergics,52,62,130,145,"- Antacids - Diarrhea medicine containing kaolin or <e1>attapulgite</e1> - Ketoconazole - Central nervous system (CNS) depressants - Other <e2>anticholinergics</e2> - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
attapulgite,Tricyclic antidepressants,52,62,149,173,"- Antacids - Diarrhea medicine containing kaolin or <e1>attapulgite</e1> - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - <e2>Tricyclic antidepressants</e2> (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
attapulgite,Elavil,52,62,182,187,"- Antacids - Diarrhea medicine containing kaolin or <e1>attapulgite</e1> - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., <e2>Elavil</e2>, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
attapulgite,Asendin,52,62,190,196,"- Antacids - Diarrhea medicine containing kaolin or <e1>attapulgite</e1> - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, <e2>Asendin</e2>, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
attapulgite,Anafranil,52,62,199,207,"- Antacids - Diarrhea medicine containing kaolin or <e1>attapulgite</e1> - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, <e2>Anafranil</e2>, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
attapulgite,Pertofrane,52,62,210,219,"- Antacids - Diarrhea medicine containing kaolin or <e1>attapulgite</e1> - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, <e2>Pertofrane</e2>, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
attapulgite,Sinequan,52,62,222,229,"- Antacids - Diarrhea medicine containing kaolin or <e1>attapulgite</e1> - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, <e2>Sinequan</e2>, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
attapulgite,Tofranil,52,62,232,239,"- Antacids - Diarrhea medicine containing kaolin or <e1>attapulgite</e1> - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, <e2>Tofranil</e2>, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
attapulgite,Aventyl,52,62,242,248,"- Antacids - Diarrhea medicine containing kaolin or <e1>attapulgite</e1> - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, <e2>Aventyl</e2>, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
attapulgite,Surmontil,52,62,251,259,"- Antacids - Diarrhea medicine containing kaolin or <e1>attapulgite</e1> - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, <e2>Surmontil</e2>) - Potassium chloride (e.g., Kay Ciel)",False,negative
attapulgite,Potassium chloride,52,62,264,281,"- Antacids - Diarrhea medicine containing kaolin or <e1>attapulgite</e1> - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - <e2>Potassium chloride</e2> (e.g., Kay Ciel)",False,negative
attapulgite,Kay Ciel,52,62,290,297,"- Antacids - Diarrhea medicine containing kaolin or <e1>attapulgite</e1> - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., <e2>Kay Ciel</e2>)",False,negative
Ketoconazole,Central nervous system (CNS) depressants,66,77,81,120,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - <e1>Ketoconazole</e1> - <e2>Central nervous system (CNS) depressants</e2> - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Ketoconazole,anticholinergics,66,77,130,145,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - <e1>Ketoconazole</e1> - Central nervous system (CNS) depressants - Other <e2>anticholinergics</e2> - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Ketoconazole,Tricyclic antidepressants,66,77,149,173,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - <e1>Ketoconazole</e1> - Central nervous system (CNS) depressants - Other anticholinergics - <e2>Tricyclic antidepressants</e2> (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Ketoconazole,Elavil,66,77,182,187,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - <e1>Ketoconazole</e1> - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., <e2>Elavil</e2>, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Ketoconazole,Asendin,66,77,190,196,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - <e1>Ketoconazole</e1> - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, <e2>Asendin</e2>, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Ketoconazole,Anafranil,66,77,199,207,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - <e1>Ketoconazole</e1> - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, <e2>Anafranil</e2>, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Ketoconazole,Pertofrane,66,77,210,219,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - <e1>Ketoconazole</e1> - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, <e2>Pertofrane</e2>, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Ketoconazole,Sinequan,66,77,222,229,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - <e1>Ketoconazole</e1> - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, <e2>Sinequan</e2>, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Ketoconazole,Tofranil,66,77,232,239,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - <e1>Ketoconazole</e1> - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, <e2>Tofranil</e2>, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Ketoconazole,Aventyl,66,77,242,248,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - <e1>Ketoconazole</e1> - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, <e2>Aventyl</e2>, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Ketoconazole,Surmontil,66,77,251,259,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - <e1>Ketoconazole</e1> - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, <e2>Surmontil</e2>) - Potassium chloride (e.g., Kay Ciel)",False,negative
Ketoconazole,Potassium chloride,66,77,264,281,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - <e1>Ketoconazole</e1> - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - <e2>Potassium chloride</e2> (e.g., Kay Ciel)",False,negative
Ketoconazole,Kay Ciel,66,77,290,297,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - <e1>Ketoconazole</e1> - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., <e2>Kay Ciel</e2>)",False,negative
Central nervous system (CNS) depressants,anticholinergics,81,120,130,145,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - <e1>Central nervous system (CNS) depressants</e1> - Other <e2>anticholinergics</e2> - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Central nervous system (CNS) depressants,Tricyclic antidepressants,81,120,149,173,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - <e1>Central nervous system (CNS) depressants</e1> - Other anticholinergics - <e2>Tricyclic antidepressants</e2> (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Central nervous system (CNS) depressants,Elavil,81,120,182,187,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - <e1>Central nervous system (CNS) depressants</e1> - Other anticholinergics - Tricyclic antidepressants (e.g., <e2>Elavil</e2>, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Central nervous system (CNS) depressants,Asendin,81,120,190,196,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - <e1>Central nervous system (CNS) depressants</e1> - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, <e2>Asendin</e2>, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Central nervous system (CNS) depressants,Anafranil,81,120,199,207,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - <e1>Central nervous system (CNS) depressants</e1> - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, <e2>Anafranil</e2>, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Central nervous system (CNS) depressants,Pertofrane,81,120,210,219,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - <e1>Central nervous system (CNS) depressants</e1> - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, <e2>Pertofrane</e2>, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Central nervous system (CNS) depressants,Sinequan,81,120,222,229,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - <e1>Central nervous system (CNS) depressants</e1> - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, <e2>Sinequan</e2>, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Central nervous system (CNS) depressants,Tofranil,81,120,232,239,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - <e1>Central nervous system (CNS) depressants</e1> - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, <e2>Tofranil</e2>, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Central nervous system (CNS) depressants,Aventyl,81,120,242,248,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - <e1>Central nervous system (CNS) depressants</e1> - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, <e2>Aventyl</e2>, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Central nervous system (CNS) depressants,Surmontil,81,120,251,259,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - <e1>Central nervous system (CNS) depressants</e1> - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, <e2>Surmontil</e2>) - Potassium chloride (e.g., Kay Ciel)",False,negative
Central nervous system (CNS) depressants,Potassium chloride,81,120,264,281,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - <e1>Central nervous system (CNS) depressants</e1> - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - <e2>Potassium chloride</e2> (e.g., Kay Ciel)",False,negative
Central nervous system (CNS) depressants,Kay Ciel,81,120,290,297,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - <e1>Central nervous system (CNS) depressants</e1> - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., <e2>Kay Ciel</e2>)",False,negative
anticholinergics,Tricyclic antidepressants,130,145,149,173,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other <e1>anticholinergics</e1> - <e2>Tricyclic antidepressants</e2> (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
anticholinergics,Elavil,130,145,182,187,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other <e1>anticholinergics</e1> - Tricyclic antidepressants (e.g., <e2>Elavil</e2>, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
anticholinergics,Asendin,130,145,190,196,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other <e1>anticholinergics</e1> - Tricyclic antidepressants (e.g., Elavil, <e2>Asendin</e2>, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
anticholinergics,Anafranil,130,145,199,207,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other <e1>anticholinergics</e1> - Tricyclic antidepressants (e.g., Elavil, Asendin, <e2>Anafranil</e2>, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
anticholinergics,Pertofrane,130,145,210,219,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other <e1>anticholinergics</e1> - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, <e2>Pertofrane</e2>, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
anticholinergics,Sinequan,130,145,222,229,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other <e1>anticholinergics</e1> - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, <e2>Sinequan</e2>, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
anticholinergics,Tofranil,130,145,232,239,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other <e1>anticholinergics</e1> - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, <e2>Tofranil</e2>, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
anticholinergics,Aventyl,130,145,242,248,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other <e1>anticholinergics</e1> - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, <e2>Aventyl</e2>, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
anticholinergics,Surmontil,130,145,251,259,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other <e1>anticholinergics</e1> - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, <e2>Surmontil</e2>) - Potassium chloride (e.g., Kay Ciel)",False,negative
anticholinergics,Potassium chloride,130,145,264,281,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other <e1>anticholinergics</e1> - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - <e2>Potassium chloride</e2> (e.g., Kay Ciel)",False,negative
anticholinergics,Kay Ciel,130,145,290,297,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other <e1>anticholinergics</e1> - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., <e2>Kay Ciel</e2>)",False,negative
Tricyclic antidepressants,Elavil,149,173,182,187,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - <e1>Tricyclic antidepressants</e1> (e.g., <e2>Elavil</e2>, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Tricyclic antidepressants,Asendin,149,173,190,196,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - <e1>Tricyclic antidepressants</e1> (e.g., Elavil, <e2>Asendin</e2>, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Tricyclic antidepressants,Anafranil,149,173,199,207,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - <e1>Tricyclic antidepressants</e1> (e.g., Elavil, Asendin, <e2>Anafranil</e2>, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Tricyclic antidepressants,Pertofrane,149,173,210,219,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - <e1>Tricyclic antidepressants</e1> (e.g., Elavil, Asendin, Anafranil, <e2>Pertofrane</e2>, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Tricyclic antidepressants,Sinequan,149,173,222,229,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - <e1>Tricyclic antidepressants</e1> (e.g., Elavil, Asendin, Anafranil, Pertofrane, <e2>Sinequan</e2>, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Tricyclic antidepressants,Tofranil,149,173,232,239,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - <e1>Tricyclic antidepressants</e1> (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, <e2>Tofranil</e2>, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Tricyclic antidepressants,Aventyl,149,173,242,248,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - <e1>Tricyclic antidepressants</e1> (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, <e2>Aventyl</e2>, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Tricyclic antidepressants,Surmontil,149,173,251,259,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - <e1>Tricyclic antidepressants</e1> (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, <e2>Surmontil</e2>) - Potassium chloride (e.g., Kay Ciel)",False,negative
Tricyclic antidepressants,Potassium chloride,149,173,264,281,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - <e1>Tricyclic antidepressants</e1> (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - <e2>Potassium chloride</e2> (e.g., Kay Ciel)",False,negative
Tricyclic antidepressants,Kay Ciel,149,173,290,297,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - <e1>Tricyclic antidepressants</e1> (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., <e2>Kay Ciel</e2>)",False,negative
Elavil,Asendin,182,187,190,196,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., <e1>Elavil</e1>, <e2>Asendin</e2>, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Elavil,Anafranil,182,187,199,207,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., <e1>Elavil</e1>, Asendin, <e2>Anafranil</e2>, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Elavil,Pertofrane,182,187,210,219,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., <e1>Elavil</e1>, Asendin, Anafranil, <e2>Pertofrane</e2>, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Elavil,Sinequan,182,187,222,229,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., <e1>Elavil</e1>, Asendin, Anafranil, Pertofrane, <e2>Sinequan</e2>, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Elavil,Tofranil,182,187,232,239,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., <e1>Elavil</e1>, Asendin, Anafranil, Pertofrane, Sinequan, <e2>Tofranil</e2>, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Elavil,Aventyl,182,187,242,248,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., <e1>Elavil</e1>, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, <e2>Aventyl</e2>, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Elavil,Surmontil,182,187,251,259,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., <e1>Elavil</e1>, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, <e2>Surmontil</e2>) - Potassium chloride (e.g., Kay Ciel)",False,negative
Elavil,Potassium chloride,182,187,264,281,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., <e1>Elavil</e1>, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - <e2>Potassium chloride</e2> (e.g., Kay Ciel)",False,negative
Elavil,Kay Ciel,182,187,290,297,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., <e1>Elavil</e1>, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., <e2>Kay Ciel</e2>)",False,negative
Asendin,Anafranil,190,196,199,207,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, <e1>Asendin</e1>, <e2>Anafranil</e2>, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Asendin,Pertofrane,190,196,210,219,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, <e1>Asendin</e1>, Anafranil, <e2>Pertofrane</e2>, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Asendin,Sinequan,190,196,222,229,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, <e1>Asendin</e1>, Anafranil, Pertofrane, <e2>Sinequan</e2>, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Asendin,Tofranil,190,196,232,239,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, <e1>Asendin</e1>, Anafranil, Pertofrane, Sinequan, <e2>Tofranil</e2>, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Asendin,Aventyl,190,196,242,248,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, <e1>Asendin</e1>, Anafranil, Pertofrane, Sinequan, Tofranil, <e2>Aventyl</e2>, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Asendin,Surmontil,190,196,251,259,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, <e1>Asendin</e1>, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, <e2>Surmontil</e2>) - Potassium chloride (e.g., Kay Ciel)",False,negative
Asendin,Potassium chloride,190,196,264,281,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, <e1>Asendin</e1>, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - <e2>Potassium chloride</e2> (e.g., Kay Ciel)",False,negative
Asendin,Kay Ciel,190,196,290,297,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, <e1>Asendin</e1>, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., <e2>Kay Ciel</e2>)",False,negative
Anafranil,Pertofrane,199,207,210,219,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, <e1>Anafranil</e1>, <e2>Pertofrane</e2>, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Anafranil,Sinequan,199,207,222,229,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, <e1>Anafranil</e1>, Pertofrane, <e2>Sinequan</e2>, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Anafranil,Tofranil,199,207,232,239,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, <e1>Anafranil</e1>, Pertofrane, Sinequan, <e2>Tofranil</e2>, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Anafranil,Aventyl,199,207,242,248,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, <e1>Anafranil</e1>, Pertofrane, Sinequan, Tofranil, <e2>Aventyl</e2>, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Anafranil,Surmontil,199,207,251,259,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, <e1>Anafranil</e1>, Pertofrane, Sinequan, Tofranil, Aventyl, <e2>Surmontil</e2>) - Potassium chloride (e.g., Kay Ciel)",False,negative
Anafranil,Potassium chloride,199,207,264,281,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, <e1>Anafranil</e1>, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - <e2>Potassium chloride</e2> (e.g., Kay Ciel)",False,negative
Anafranil,Kay Ciel,199,207,290,297,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, <e1>Anafranil</e1>, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., <e2>Kay Ciel</e2>)",False,negative
Pertofrane,Sinequan,210,219,222,229,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, <e1>Pertofrane</e1>, <e2>Sinequan</e2>, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Pertofrane,Tofranil,210,219,232,239,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, <e1>Pertofrane</e1>, Sinequan, <e2>Tofranil</e2>, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Pertofrane,Aventyl,210,219,242,248,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, <e1>Pertofrane</e1>, Sinequan, Tofranil, <e2>Aventyl</e2>, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Pertofrane,Surmontil,210,219,251,259,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, <e1>Pertofrane</e1>, Sinequan, Tofranil, Aventyl, <e2>Surmontil</e2>) - Potassium chloride (e.g., Kay Ciel)",False,negative
Pertofrane,Potassium chloride,210,219,264,281,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, <e1>Pertofrane</e1>, Sinequan, Tofranil, Aventyl, Surmontil) - <e2>Potassium chloride</e2> (e.g., Kay Ciel)",False,negative
Pertofrane,Kay Ciel,210,219,290,297,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, <e1>Pertofrane</e1>, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., <e2>Kay Ciel</e2>)",False,negative
Sinequan,Tofranil,222,229,232,239,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, <e1>Sinequan</e1>, <e2>Tofranil</e2>, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Sinequan,Aventyl,222,229,242,248,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, <e1>Sinequan</e1>, Tofranil, <e2>Aventyl</e2>, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Sinequan,Surmontil,222,229,251,259,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, <e1>Sinequan</e1>, Tofranil, Aventyl, <e2>Surmontil</e2>) - Potassium chloride (e.g., Kay Ciel)",False,negative
Sinequan,Potassium chloride,222,229,264,281,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, <e1>Sinequan</e1>, Tofranil, Aventyl, Surmontil) - <e2>Potassium chloride</e2> (e.g., Kay Ciel)",False,negative
Sinequan,Kay Ciel,222,229,290,297,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, <e1>Sinequan</e1>, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., <e2>Kay Ciel</e2>)",False,negative
Tofranil,Aventyl,232,239,242,248,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, <e1>Tofranil</e1>, <e2>Aventyl</e2>, Surmontil) - Potassium chloride (e.g., Kay Ciel)",False,negative
Tofranil,Surmontil,232,239,251,259,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, <e1>Tofranil</e1>, Aventyl, <e2>Surmontil</e2>) - Potassium chloride (e.g., Kay Ciel)",False,negative
Tofranil,Potassium chloride,232,239,264,281,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, <e1>Tofranil</e1>, Aventyl, Surmontil) - <e2>Potassium chloride</e2> (e.g., Kay Ciel)",False,negative
Tofranil,Kay Ciel,232,239,290,297,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, <e1>Tofranil</e1>, Aventyl, Surmontil) - Potassium chloride (e.g., <e2>Kay Ciel</e2>)",False,negative
Aventyl,Surmontil,242,248,251,259,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, <e1>Aventyl</e1>, <e2>Surmontil</e2>) - Potassium chloride (e.g., Kay Ciel)",False,negative
Aventyl,Potassium chloride,242,248,264,281,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, <e1>Aventyl</e1>, Surmontil) - <e2>Potassium chloride</e2> (e.g., Kay Ciel)",False,negative
Aventyl,Kay Ciel,242,248,290,297,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, <e1>Aventyl</e1>, Surmontil) - Potassium chloride (e.g., <e2>Kay Ciel</e2>)",False,negative
Surmontil,Potassium chloride,251,259,264,281,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, <e1>Surmontil</e1>) - <e2>Potassium chloride</e2> (e.g., Kay Ciel)",False,negative
Surmontil,Kay Ciel,251,259,290,297,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, <e1>Surmontil</e1>) - Potassium chloride (e.g., <e2>Kay Ciel</e2>)",False,negative
Potassium chloride,Kay Ciel,264,281,290,297,"- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - <e1>Potassium chloride</e1> (e.g., <e2>Kay Ciel</e2>)",False,negative
photosensitizing agents,tetracyclines,54,76,85,97,"However, it is possible that concomitant use of other <e1>photosensitizing agents</e1> (e.g., <e2>tetracyclines</e2>, sulfonamides, phenothiazines, sulfonylurea hypoglycemia agents, thiazide diuretics, and griseofulvin) could increase the photosensitivity reaction. ",False,negative
photosensitizing agents,sulfonamides,54,76,100,111,"However, it is possible that concomitant use of other <e1>photosensitizing agents</e1> (e.g., tetracyclines, <e2>sulfonamides</e2>, phenothiazines, sulfonylurea hypoglycemia agents, thiazide diuretics, and griseofulvin) could increase the photosensitivity reaction. ",False,negative
photosensitizing agents,phenothiazines,54,76,114,127,"However, it is possible that concomitant use of other <e1>photosensitizing agents</e1> (e.g., tetracyclines, sulfonamides, <e2>phenothiazines</e2>, sulfonylurea hypoglycemia agents, thiazide diuretics, and griseofulvin) could increase the photosensitivity reaction. ",False,negative
photosensitizing agents,sulfonylurea,54,76,130,141,"However, it is possible that concomitant use of other <e1>photosensitizing agents</e1> (e.g., tetracyclines, sulfonamides, phenothiazines, <e2>sulfonylurea</e2> hypoglycemia agents, thiazide diuretics, and griseofulvin) could increase the photosensitivity reaction. ",False,negative
photosensitizing agents,thiazide diuretics,54,76,164,181,"However, it is possible that concomitant use of other <e1>photosensitizing agents</e1> (e.g., tetracyclines, sulfonamides, phenothiazines, sulfonylurea hypoglycemia agents, <e2>thiazide diuretics</e2>, and griseofulvin) could increase the photosensitivity reaction. ",False,negative
photosensitizing agents,griseofulvin,54,76,188,199,"However, it is possible that concomitant use of other <e1>photosensitizing agents</e1> (e.g., tetracyclines, sulfonamides, phenothiazines, sulfonylurea hypoglycemia agents, thiazide diuretics, and <e2>griseofulvin</e2>) could increase the photosensitivity reaction. ",False,negative
tetracyclines,sulfonamides,85,97,100,111,"However, it is possible that concomitant use of other photosensitizing agents (e.g., <e1>tetracyclines</e1>, <e2>sulfonamides</e2>, phenothiazines, sulfonylurea hypoglycemia agents, thiazide diuretics, and griseofulvin) could increase the photosensitivity reaction. ",False,negative
tetracyclines,phenothiazines,85,97,114,127,"However, it is possible that concomitant use of other photosensitizing agents (e.g., <e1>tetracyclines</e1>, sulfonamides, <e2>phenothiazines</e2>, sulfonylurea hypoglycemia agents, thiazide diuretics, and griseofulvin) could increase the photosensitivity reaction. ",False,negative
tetracyclines,sulfonylurea,85,97,130,141,"However, it is possible that concomitant use of other photosensitizing agents (e.g., <e1>tetracyclines</e1>, sulfonamides, phenothiazines, <e2>sulfonylurea</e2> hypoglycemia agents, thiazide diuretics, and griseofulvin) could increase the photosensitivity reaction. ",False,negative
tetracyclines,thiazide diuretics,85,97,164,181,"However, it is possible that concomitant use of other photosensitizing agents (e.g., <e1>tetracyclines</e1>, sulfonamides, phenothiazines, sulfonylurea hypoglycemia agents, <e2>thiazide diuretics</e2>, and griseofulvin) could increase the photosensitivity reaction. ",False,negative
tetracyclines,griseofulvin,85,97,188,199,"However, it is possible that concomitant use of other photosensitizing agents (e.g., <e1>tetracyclines</e1>, sulfonamides, phenothiazines, sulfonylurea hypoglycemia agents, thiazide diuretics, and <e2>griseofulvin</e2>) could increase the photosensitivity reaction. ",False,negative
sulfonamides,phenothiazines,100,111,114,127,"However, it is possible that concomitant use of other photosensitizing agents (e.g., tetracyclines, <e1>sulfonamides</e1>, <e2>phenothiazines</e2>, sulfonylurea hypoglycemia agents, thiazide diuretics, and griseofulvin) could increase the photosensitivity reaction. ",False,negative
sulfonamides,sulfonylurea,100,111,130,141,"However, it is possible that concomitant use of other photosensitizing agents (e.g., tetracyclines, <e1>sulfonamides</e1>, phenothiazines, <e2>sulfonylurea</e2> hypoglycemia agents, thiazide diuretics, and griseofulvin) could increase the photosensitivity reaction. ",False,negative
sulfonamides,thiazide diuretics,100,111,164,181,"However, it is possible that concomitant use of other photosensitizing agents (e.g., tetracyclines, <e1>sulfonamides</e1>, phenothiazines, sulfonylurea hypoglycemia agents, <e2>thiazide diuretics</e2>, and griseofulvin) could increase the photosensitivity reaction. ",False,negative
sulfonamides,griseofulvin,100,111,188,199,"However, it is possible that concomitant use of other photosensitizing agents (e.g., tetracyclines, <e1>sulfonamides</e1>, phenothiazines, sulfonylurea hypoglycemia agents, thiazide diuretics, and <e2>griseofulvin</e2>) could increase the photosensitivity reaction. ",False,negative
phenothiazines,sulfonylurea,114,127,130,141,"However, it is possible that concomitant use of other photosensitizing agents (e.g., tetracyclines, sulfonamides, <e1>phenothiazines</e1>, <e2>sulfonylurea</e2> hypoglycemia agents, thiazide diuretics, and griseofulvin) could increase the photosensitivity reaction. ",False,negative
phenothiazines,thiazide diuretics,114,127,164,181,"However, it is possible that concomitant use of other photosensitizing agents (e.g., tetracyclines, sulfonamides, <e1>phenothiazines</e1>, sulfonylurea hypoglycemia agents, <e2>thiazide diuretics</e2>, and griseofulvin) could increase the photosensitivity reaction. ",False,negative
phenothiazines,griseofulvin,114,127,188,199,"However, it is possible that concomitant use of other photosensitizing agents (e.g., tetracyclines, sulfonamides, <e1>phenothiazines</e1>, sulfonylurea hypoglycemia agents, thiazide diuretics, and <e2>griseofulvin</e2>) could increase the photosensitivity reaction. ",False,negative
sulfonylurea,thiazide diuretics,130,141,164,181,"However, it is possible that concomitant use of other photosensitizing agents (e.g., tetracyclines, sulfonamides, phenothiazines, <e1>sulfonylurea</e1> hypoglycemia agents, <e2>thiazide diuretics</e2>, and griseofulvin) could increase the photosensitivity reaction. ",False,negative
sulfonylurea,griseofulvin,130,141,188,199,"However, it is possible that concomitant use of other photosensitizing agents (e.g., tetracyclines, sulfonamides, phenothiazines, <e1>sulfonylurea</e1> hypoglycemia agents, thiazide diuretics, and <e2>griseofulvin</e2>) could increase the photosensitivity reaction. ",False,negative
thiazide diuretics,griseofulvin,164,181,188,199,"However, it is possible that concomitant use of other photosensitizing agents (e.g., tetracyclines, sulfonamides, phenothiazines, sulfonylurea hypoglycemia agents, <e1>thiazide diuretics</e1>, and <e2>griseofulvin</e2>) could increase the photosensitivity reaction. ",False,negative
dimethyl sufloxide,b-carotene,74,91,94,103,"Compounds that quench active oxygen species or scavenge radicals, such as <e1>dimethyl sufloxide</e1>, <e2>b-carotene</e2>, ethanol, formate and mannitol would be expected to decrease PDT activity. ",False,negative
dimethyl sufloxide,ethanol,74,91,106,112,"Compounds that quench active oxygen species or scavenge radicals, such as <e1>dimethyl sufloxide</e1>, b-carotene, <e2>ethanol</e2>, formate and mannitol would be expected to decrease PDT activity. ",False,negative
dimethyl sufloxide,formate,74,91,115,121,"Compounds that quench active oxygen species or scavenge radicals, such as <e1>dimethyl sufloxide</e1>, b-carotene, ethanol, <e2>formate</e2> and mannitol would be expected to decrease PDT activity. ",False,negative
dimethyl sufloxide,mannitol,74,91,127,134,"Compounds that quench active oxygen species or scavenge radicals, such as <e1>dimethyl sufloxide</e1>, b-carotene, ethanol, formate and <e2>mannitol</e2> would be expected to decrease PDT activity. ",False,negative
b-carotene,ethanol,94,103,106,112,"Compounds that quench active oxygen species or scavenge radicals, such as dimethyl sufloxide, <e1>b-carotene</e1>, <e2>ethanol</e2>, formate and mannitol would be expected to decrease PDT activity. ",False,negative
b-carotene,formate,94,103,115,121,"Compounds that quench active oxygen species or scavenge radicals, such as dimethyl sufloxide, <e1>b-carotene</e1>, ethanol, <e2>formate</e2> and mannitol would be expected to decrease PDT activity. ",False,negative
b-carotene,mannitol,94,103,127,134,"Compounds that quench active oxygen species or scavenge radicals, such as dimethyl sufloxide, <e1>b-carotene</e1>, ethanol, formate and <e2>mannitol</e2> would be expected to decrease PDT activity. ",False,negative
ethanol,formate,106,112,115,121,"Compounds that quench active oxygen species or scavenge radicals, such as dimethyl sufloxide, b-carotene, <e1>ethanol</e1>, <e2>formate</e2> and mannitol would be expected to decrease PDT activity. ",False,negative
ethanol,mannitol,106,112,127,134,"Compounds that quench active oxygen species or scavenge radicals, such as dimethyl sufloxide, b-carotene, <e1>ethanol</e1>, formate and <e2>mannitol</e2> would be expected to decrease PDT activity. ",False,negative
formate,mannitol,115,121,127,134,"Compounds that quench active oxygen species or scavenge radicals, such as dimethyl sufloxide, b-carotene, ethanol, <e1>formate</e1> and <e2>mannitol</e2> would be expected to decrease PDT activity. ",False,negative
allopurinol,calcium channel blockers,52,62,65,88,"Preclinical data also suggest that tissue ischemia, <e1>allopurinol</e1>, <e2>calcium channel blockers</e2> and some prostaglandin synthesis inhibitors could interfere with PHOTOFRIN    PDT. ",False,negative
blood thinners,warfarin,32,45,60,67,"May increase the effect of oral <e1>blood thinners</e1>, for example <e2>warfarin</e2> (Coumadin). ",False,negative
blood thinners,Coumadin,32,45,70,77,"May increase the effect of oral <e1>blood thinners</e1>, for example warfarin (<e2>Coumadin</e2>). ",False,negative
warfarin,Coumadin,60,67,70,77,"May increase the effect of oral blood thinners, for example <e1>warfarin</e1> (<e2>Coumadin</e2>). ",False,negative
warfarin,warfarin,11,18,67,74,"Therefore, <e1>warfarin</e1> dose changes and monitoring for the effects of <e2>warfarin</e2> on blood clotting are necessary.",False,negative
Alcohol,primaquine,0,6,54,63,<e1>Alcohol</e1> (this combination may make you very sick) and <e2>primaquine</e2>,False,negative
LUCENTIS,verteporfin,0,7,64,74,<e1>LUCENTIS</e1> intravitreal injection has been used adjunctively with <e2>verteporfin</e2> photodynamic therapy (PDT). ,False,negative
LUCENTIS,verteporfin,45,52,96,106,"in 10 of the 12 patients, this occurred when <e1>LUCENTIS</e1> was administered 7 days (   2 days) after <e2>verteporfin</e2> PDT.",False,negative
succinylcholine,remifentanil,49,63,85,96,In animals the duration of muscle paralysis from <e1>succinylcholine</e1> is not prolonged by <e2>remifentanil</e2>. ,False,negative
Remifentanil,thiopental,0,11,71,80,"<e1>Remifentanil</e1> clearance is not altered by concomitant administration of <e2>thiopental</e2>, isoflurane, propofol, or temazepam during anesthesia. ",False,negative
Remifentanil,isoflurane,0,11,83,92,"<e1>Remifentanil</e1> clearance is not altered by concomitant administration of thiopental, <e2>isoflurane</e2>, propofol, or temazepam during anesthesia. ",False,negative
Remifentanil,propofol,0,11,95,102,"<e1>Remifentanil</e1> clearance is not altered by concomitant administration of thiopental, isoflurane, <e2>propofol</e2>, or temazepam during anesthesia. ",False,negative
Remifentanil,temazepam,0,11,108,116,"<e1>Remifentanil</e1> clearance is not altered by concomitant administration of thiopental, isoflurane, propofol, or <e2>temazepam</e2> during anesthesia. ",False,negative
thiopental,isoflurane,71,80,83,92,"Remifentanil clearance is not altered by concomitant administration of <e1>thiopental</e1>, <e2>isoflurane</e2>, propofol, or temazepam during anesthesia. ",False,negative
thiopental,propofol,71,80,95,102,"Remifentanil clearance is not altered by concomitant administration of <e1>thiopental</e1>, isoflurane, <e2>propofol</e2>, or temazepam during anesthesia. ",False,negative
thiopental,temazepam,71,80,108,116,"Remifentanil clearance is not altered by concomitant administration of <e1>thiopental</e1>, isoflurane, propofol, or <e2>temazepam</e2> during anesthesia. ",False,negative
isoflurane,propofol,83,92,95,102,"Remifentanil clearance is not altered by concomitant administration of thiopental, <e1>isoflurane</e1>, <e2>propofol</e2>, or temazepam during anesthesia. ",False,negative
isoflurane,temazepam,83,92,108,116,"Remifentanil clearance is not altered by concomitant administration of thiopental, <e1>isoflurane</e1>, propofol, or <e2>temazepam</e2> during anesthesia. ",False,negative
propofol,temazepam,95,102,108,116,"Remifentanil clearance is not altered by concomitant administration of thiopental, isoflurane, <e1>propofol</e1>, or <e2>temazepam</e2> during anesthesia. ",False,negative
atracurium,mivacurium,22,31,34,43,"In vitro studies with <e1>atracurium</e1>, <e2>mivacurium</e2>, esmolol, echothiophate, neostigmine, physostigmine, and midazolam revealed no inhibition of remifentanil hydrolysis in whole human blood by these drugs.",False,negative
atracurium,esmolol,22,31,46,52,"In vitro studies with <e1>atracurium</e1>, mivacurium, <e2>esmolol</e2>, echothiophate, neostigmine, physostigmine, and midazolam revealed no inhibition of remifentanil hydrolysis in whole human blood by these drugs.",False,negative
atracurium,echothiophate,22,31,55,67,"In vitro studies with <e1>atracurium</e1>, mivacurium, esmolol, <e2>echothiophate</e2>, neostigmine, physostigmine, and midazolam revealed no inhibition of remifentanil hydrolysis in whole human blood by these drugs.",False,negative
atracurium,neostigmine,22,31,70,80,"In vitro studies with <e1>atracurium</e1>, mivacurium, esmolol, echothiophate, <e2>neostigmine</e2>, physostigmine, and midazolam revealed no inhibition of remifentanil hydrolysis in whole human blood by these drugs.",False,negative
atracurium,physostigmine,22,31,83,95,"In vitro studies with <e1>atracurium</e1>, mivacurium, esmolol, echothiophate, neostigmine, <e2>physostigmine</e2>, and midazolam revealed no inhibition of remifentanil hydrolysis in whole human blood by these drugs.",False,negative
atracurium,midazolam,22,31,102,110,"In vitro studies with <e1>atracurium</e1>, mivacurium, esmolol, echothiophate, neostigmine, physostigmine, and <e2>midazolam</e2> revealed no inhibition of remifentanil hydrolysis in whole human blood by these drugs.",False,negative
atracurium,remifentanil,22,31,138,149,"In vitro studies with <e1>atracurium</e1>, mivacurium, esmolol, echothiophate, neostigmine, physostigmine, and midazolam revealed no inhibition of <e2>remifentanil</e2> hydrolysis in whole human blood by these drugs.",False,negative
mivacurium,esmolol,34,43,46,52,"In vitro studies with atracurium, <e1>mivacurium</e1>, <e2>esmolol</e2>, echothiophate, neostigmine, physostigmine, and midazolam revealed no inhibition of remifentanil hydrolysis in whole human blood by these drugs.",False,negative
mivacurium,echothiophate,34,43,55,67,"In vitro studies with atracurium, <e1>mivacurium</e1>, esmolol, <e2>echothiophate</e2>, neostigmine, physostigmine, and midazolam revealed no inhibition of remifentanil hydrolysis in whole human blood by these drugs.",False,negative
mivacurium,neostigmine,34,43,70,80,"In vitro studies with atracurium, <e1>mivacurium</e1>, esmolol, echothiophate, <e2>neostigmine</e2>, physostigmine, and midazolam revealed no inhibition of remifentanil hydrolysis in whole human blood by these drugs.",False,negative
mivacurium,physostigmine,34,43,83,95,"In vitro studies with atracurium, <e1>mivacurium</e1>, esmolol, echothiophate, neostigmine, <e2>physostigmine</e2>, and midazolam revealed no inhibition of remifentanil hydrolysis in whole human blood by these drugs.",False,negative
mivacurium,midazolam,34,43,102,110,"In vitro studies with atracurium, <e1>mivacurium</e1>, esmolol, echothiophate, neostigmine, physostigmine, and <e2>midazolam</e2> revealed no inhibition of remifentanil hydrolysis in whole human blood by these drugs.",False,negative
mivacurium,remifentanil,34,43,138,149,"In vitro studies with atracurium, <e1>mivacurium</e1>, esmolol, echothiophate, neostigmine, physostigmine, and midazolam revealed no inhibition of <e2>remifentanil</e2> hydrolysis in whole human blood by these drugs.",False,negative
esmolol,echothiophate,46,52,55,67,"In vitro studies with atracurium, mivacurium, <e1>esmolol</e1>, <e2>echothiophate</e2>, neostigmine, physostigmine, and midazolam revealed no inhibition of remifentanil hydrolysis in whole human blood by these drugs.",False,negative
esmolol,neostigmine,46,52,70,80,"In vitro studies with atracurium, mivacurium, <e1>esmolol</e1>, echothiophate, <e2>neostigmine</e2>, physostigmine, and midazolam revealed no inhibition of remifentanil hydrolysis in whole human blood by these drugs.",False,negative
esmolol,physostigmine,46,52,83,95,"In vitro studies with atracurium, mivacurium, <e1>esmolol</e1>, echothiophate, neostigmine, <e2>physostigmine</e2>, and midazolam revealed no inhibition of remifentanil hydrolysis in whole human blood by these drugs.",False,negative
esmolol,midazolam,46,52,102,110,"In vitro studies with atracurium, mivacurium, <e1>esmolol</e1>, echothiophate, neostigmine, physostigmine, and <e2>midazolam</e2> revealed no inhibition of remifentanil hydrolysis in whole human blood by these drugs.",False,negative
esmolol,remifentanil,46,52,138,149,"In vitro studies with atracurium, mivacurium, <e1>esmolol</e1>, echothiophate, neostigmine, physostigmine, and midazolam revealed no inhibition of <e2>remifentanil</e2> hydrolysis in whole human blood by these drugs.",False,negative
echothiophate,neostigmine,55,67,70,80,"In vitro studies with atracurium, mivacurium, esmolol, <e1>echothiophate</e1>, <e2>neostigmine</e2>, physostigmine, and midazolam revealed no inhibition of remifentanil hydrolysis in whole human blood by these drugs.",False,negative
echothiophate,physostigmine,55,67,83,95,"In vitro studies with atracurium, mivacurium, esmolol, <e1>echothiophate</e1>, neostigmine, <e2>physostigmine</e2>, and midazolam revealed no inhibition of remifentanil hydrolysis in whole human blood by these drugs.",False,negative
echothiophate,midazolam,55,67,102,110,"In vitro studies with atracurium, mivacurium, esmolol, <e1>echothiophate</e1>, neostigmine, physostigmine, and <e2>midazolam</e2> revealed no inhibition of remifentanil hydrolysis in whole human blood by these drugs.",False,negative
echothiophate,remifentanil,55,67,138,149,"In vitro studies with atracurium, mivacurium, esmolol, <e1>echothiophate</e1>, neostigmine, physostigmine, and midazolam revealed no inhibition of <e2>remifentanil</e2> hydrolysis in whole human blood by these drugs.",False,negative
neostigmine,physostigmine,70,80,83,95,"In vitro studies with atracurium, mivacurium, esmolol, echothiophate, <e1>neostigmine</e1>, <e2>physostigmine</e2>, and midazolam revealed no inhibition of remifentanil hydrolysis in whole human blood by these drugs.",False,negative
neostigmine,midazolam,70,80,102,110,"In vitro studies with atracurium, mivacurium, esmolol, echothiophate, <e1>neostigmine</e1>, physostigmine, and <e2>midazolam</e2> revealed no inhibition of remifentanil hydrolysis in whole human blood by these drugs.",False,negative
neostigmine,remifentanil,70,80,138,149,"In vitro studies with atracurium, mivacurium, esmolol, echothiophate, <e1>neostigmine</e1>, physostigmine, and midazolam revealed no inhibition of <e2>remifentanil</e2> hydrolysis in whole human blood by these drugs.",False,negative
physostigmine,midazolam,83,95,102,110,"In vitro studies with atracurium, mivacurium, esmolol, echothiophate, neostigmine, <e1>physostigmine</e1>, and <e2>midazolam</e2> revealed no inhibition of remifentanil hydrolysis in whole human blood by these drugs.",False,negative
physostigmine,remifentanil,83,95,138,149,"In vitro studies with atracurium, mivacurium, esmolol, echothiophate, neostigmine, <e1>physostigmine</e1>, and midazolam revealed no inhibition of <e2>remifentanil</e2> hydrolysis in whole human blood by these drugs.",False,negative
midazolam,remifentanil,102,110,138,149,"In vitro studies with atracurium, mivacurium, esmolol, echothiophate, neostigmine, physostigmine, and <e1>midazolam</e1> revealed no inhibition of <e2>remifentanil</e2> hydrolysis in whole human blood by these drugs.",False,negative
VIRAZOLE,digoxin,36,43,122,128,"Clinical studies of interactions of <e1>VIRAZOLE</e1> with other drugs commonly used to treat infants with RSV infections, such as <e2>digoxin</e2>, bronchodilators, other antiviral agents, antibiotics, or anti-metabolites have not been conducted. ",False,negative
VIRAZOLE,bronchodilators,36,43,131,145,"Clinical studies of interactions of <e1>VIRAZOLE</e1> with other drugs commonly used to treat infants with RSV infections, such as digoxin, <e2>bronchodilators</e2>, other antiviral agents, antibiotics, or anti-metabolites have not been conducted. ",False,negative
VIRAZOLE,antiviral agents,36,43,154,169,"Clinical studies of interactions of <e1>VIRAZOLE</e1> with other drugs commonly used to treat infants with RSV infections, such as digoxin, bronchodilators, other <e2>antiviral agents</e2>, antibiotics, or anti-metabolites have not been conducted. ",False,negative
VIRAZOLE,antibiotics,36,43,172,182,"Clinical studies of interactions of <e1>VIRAZOLE</e1> with other drugs commonly used to treat infants with RSV infections, such as digoxin, bronchodilators, other antiviral agents, <e2>antibiotics</e2>, or anti-metabolites have not been conducted. ",False,negative
VIRAZOLE,anti-metabolites,36,43,188,203,"Clinical studies of interactions of <e1>VIRAZOLE</e1> with other drugs commonly used to treat infants with RSV infections, such as digoxin, bronchodilators, other antiviral agents, antibiotics, or <e2>anti-metabolites</e2> have not been conducted. ",False,negative
digoxin,bronchodilators,122,128,131,145,"Clinical studies of interactions of VIRAZOLE with other drugs commonly used to treat infants with RSV infections, such as <e1>digoxin</e1>, <e2>bronchodilators</e2>, other antiviral agents, antibiotics, or anti-metabolites have not been conducted. ",False,negative
digoxin,antiviral agents,122,128,154,169,"Clinical studies of interactions of VIRAZOLE with other drugs commonly used to treat infants with RSV infections, such as <e1>digoxin</e1>, bronchodilators, other <e2>antiviral agents</e2>, antibiotics, or anti-metabolites have not been conducted. ",False,negative
digoxin,antibiotics,122,128,172,182,"Clinical studies of interactions of VIRAZOLE with other drugs commonly used to treat infants with RSV infections, such as <e1>digoxin</e1>, bronchodilators, other antiviral agents, <e2>antibiotics</e2>, or anti-metabolites have not been conducted. ",False,negative
digoxin,anti-metabolites,122,128,188,203,"Clinical studies of interactions of VIRAZOLE with other drugs commonly used to treat infants with RSV infections, such as <e1>digoxin</e1>, bronchodilators, other antiviral agents, antibiotics, or <e2>anti-metabolites</e2> have not been conducted. ",False,negative
bronchodilators,antiviral agents,131,145,154,169,"Clinical studies of interactions of VIRAZOLE with other drugs commonly used to treat infants with RSV infections, such as digoxin, <e1>bronchodilators</e1>, other <e2>antiviral agents</e2>, antibiotics, or anti-metabolites have not been conducted. ",False,negative
bronchodilators,antibiotics,131,145,172,182,"Clinical studies of interactions of VIRAZOLE with other drugs commonly used to treat infants with RSV infections, such as digoxin, <e1>bronchodilators</e1>, other antiviral agents, <e2>antibiotics</e2>, or anti-metabolites have not been conducted. ",False,negative
bronchodilators,anti-metabolites,131,145,188,203,"Clinical studies of interactions of VIRAZOLE with other drugs commonly used to treat infants with RSV infections, such as digoxin, <e1>bronchodilators</e1>, other antiviral agents, antibiotics, or <e2>anti-metabolites</e2> have not been conducted. ",False,negative
antiviral agents,antibiotics,154,169,172,182,"Clinical studies of interactions of VIRAZOLE with other drugs commonly used to treat infants with RSV infections, such as digoxin, bronchodilators, other <e1>antiviral agents</e1>, <e2>antibiotics</e2>, or anti-metabolites have not been conducted. ",False,negative
antiviral agents,anti-metabolites,154,169,188,203,"Clinical studies of interactions of VIRAZOLE with other drugs commonly used to treat infants with RSV infections, such as digoxin, bronchodilators, other <e1>antiviral agents</e1>, antibiotics, or <e2>anti-metabolites</e2> have not been conducted. ",False,negative
antibiotics,anti-metabolites,172,182,188,203,"Clinical studies of interactions of VIRAZOLE with other drugs commonly used to treat infants with RSV infections, such as digoxin, bronchodilators, other antiviral agents, <e1>antibiotics</e1>, or <e2>anti-metabolites</e2> have not been conducted. ",False,negative
rifaximin,rifaximin,79,87,193,201,"Drug-Drug Interactions Although in vitro studies demonstrated the potential of <e1>rifaximin</e1> to interact with cytochrome P450 3A4 (CYP3A4), a clinical drug-drug interaction study demonstrated that <e2>rifaximin</e2> did not significantly affect the pharmacokinetics of midazolam either presystemically or systemically. ",False,negative
rifaximin,midazolam,79,87,256,264,"Drug-Drug Interactions Although in vitro studies demonstrated the potential of <e1>rifaximin</e1> to interact with cytochrome P450 3A4 (CYP3A4), a clinical drug-drug interaction study demonstrated that rifaximin did not significantly affect the pharmacokinetics of <e2>midazolam</e2> either presystemically or systemically. ",False,negative
rifaximin,midazolam,193,201,256,264,"Drug-Drug Interactions Although in vitro studies demonstrated the potential of rifaximin to interact with cytochrome P450 3A4 (CYP3A4), a clinical drug-drug interaction study demonstrated that <e1>rifaximin</e1> did not significantly affect the pharmacokinetics of <e2>midazolam</e2> either presystemically or systemically. ",False,negative
rifaximin,contraceptive,71,79,122,134,An additional clinical drug-drug interaction study showed no effect of <e1>rifaximin</e1> on the presystemic metabolism of an oral <e2>contraceptive</e2> containing ethinyl estradiol and norgestimate. ,False,negative
rifaximin,ethinyl estradiol,71,79,147,163,An additional clinical drug-drug interaction study showed no effect of <e1>rifaximin</e1> on the presystemic metabolism of an oral contraceptive containing <e2>ethinyl estradiol</e2> and norgestimate. ,False,negative
rifaximin,norgestimate,71,79,169,180,An additional clinical drug-drug interaction study showed no effect of <e1>rifaximin</e1> on the presystemic metabolism of an oral contraceptive containing ethinyl estradiol and <e2>norgestimate</e2>. ,False,negative
contraceptive,ethinyl estradiol,122,134,147,163,An additional clinical drug-drug interaction study showed no effect of rifaximin on the presystemic metabolism of an oral <e1>contraceptive</e1> containing <e2>ethinyl estradiol</e2> and norgestimate. ,False,negative
contraceptive,norgestimate,122,134,169,180,An additional clinical drug-drug interaction study showed no effect of rifaximin on the presystemic metabolism of an oral <e1>contraceptive</e1> containing ethinyl estradiol and <e2>norgestimate</e2>. ,False,negative
ethinyl estradiol,norgestimate,147,163,169,180,An additional clinical drug-drug interaction study showed no effect of rifaximin on the presystemic metabolism of an oral contraceptive containing <e1>ethinyl estradiol</e1> and <e2>norgestimate</e2>. ,False,negative
Geref,Geref,63,67,124,128,Concomitant glucocorticoid therapy may inhibit the response to <e1>Geref</e1>   . There was no evidence in the controlled studies of <e2>Geref</e2>   's interaction with drugs commonly used in the treatment of routine pediatric problems/illnesses. ,False,negative
Heparin,Sodium Tetradecyl Sulfate,0,6,54,78,"<e1>Heparin</e1> should not be included in the same syringe as <e2>Sodium Tetradecyl Sulfate</e2>, since the two are incompatible.",False,negative
Digoxin,Sparfloxacin,0,6,9,20,<e1>Digoxin</e1>: <e2>Sparfloxacin</e2> has no effect on the pharmacokinetics of digoxin. ,False,negative
Digoxin,digoxin,0,6,63,69,<e1>Digoxin</e1>: Sparfloxacin has no effect on the pharmacokinetics of <e2>digoxin</e2>. ,False,negative
Sparfloxacin,digoxin,9,20,63,69,Digoxin: <e1>Sparfloxacin</e1> has no effect on the pharmacokinetics of <e2>digoxin</e2>. ,False,negative
Methylxanthines,Sparfloxacin,0,14,17,28,<e1>Methylxanthines</e1>: <e2>Sparfloxacin</e2> does not increase plasma theophylline concentrations. ,False,negative
Methylxanthines,theophylline,0,14,55,66,<e1>Methylxanthines</e1>: Sparfloxacin does not increase plasma <e2>theophylline</e2> concentrations. ,False,negative
Sparfloxacin,theophylline,17,28,55,66,Methylxanthines: <e1>Sparfloxacin</e1> does not increase plasma <e2>theophylline</e2> concentrations. ,False,negative
theophylline,methylxanthines,35,46,72,86,"Since there is no interaction with <e1>theophylline</e1>, interaction with other <e2>methylxanthines</e2> such as caffeine is unlikely. ",False,negative
theophylline,caffeine,35,46,96,103,"Since there is no interaction with <e1>theophylline</e1>, interaction with other methylxanthines such as <e2>caffeine</e2> is unlikely. ",False,negative
methylxanthines,caffeine,72,86,96,103,"Since there is no interaction with theophylline, interaction with other <e1>methylxanthines</e1> such as <e2>caffeine</e2> is unlikely. ",False,negative
Warfarin,Sparfloxacin,0,7,10,21,<e1>Warfarin</e1>: <e2>Sparfloxacin</e2> does not increase the anti-coagulant effect of warfarin. ,False,negative
Warfarin,warfarin,0,7,70,77,<e1>Warfarin</e1>: Sparfloxacin does not increase the anti-coagulant effect of <e2>warfarin</e2>. ,False,negative
Sparfloxacin,warfarin,10,21,70,77,Warfarin: <e1>Sparfloxacin</e1> does not increase the anti-coagulant effect of <e2>warfarin</e2>. ,False,negative
Cimetidine,Cimetidine,0,9,12,21,<e1>Cimetidine</e1>: <e2>Cimetidine</e2> does not affect the pharmacokinetics of sparfloxacin. ,False,negative
Cimetidine,sparfloxacin,0,9,63,74,<e1>Cimetidine</e1>: Cimetidine does not affect the pharmacokinetics of <e2>sparfloxacin</e2>. ,False,negative
Cimetidine,sparfloxacin,12,21,63,74,Cimetidine: <e1>Cimetidine</e1> does not affect the pharmacokinetics of <e2>sparfloxacin</e2>. ,False,negative
sparfloxacin,aluminum,28,39,65,72,The oral bioavailability of <e1>sparfloxacin</e1> is not reduced when the <e2>aluminum</e2>-magnesium suspension is administered 4 hours following sparfloxacin administration. ,False,negative
sparfloxacin,magnesium,28,39,74,82,The oral bioavailability of <e1>sparfloxacin</e1> is not reduced when the aluminum-<e2>magnesium</e2> suspension is administered 4 hours following sparfloxacin administration. ,False,negative
aluminum,magnesium,65,72,74,82,The oral bioavailability of sparfloxacin is not reduced when the <e1>aluminum</e1>-<e2>magnesium</e2> suspension is administered 4 hours following sparfloxacin administration. ,False,negative
Zinc,iron,0,3,5,8,<e1>Zinc</e1>/<e2>iron</e2> salts: Absorption of quinolones is reduced significantly by these preparations. ,False,negative
Zinc,quinolones,0,3,31,40,<e1>Zinc</e1>/iron salts: Absorption of <e2>quinolones</e2> is reduced significantly by these preparations. ,False,negative
iron,quinolones,5,8,31,40,Zinc/<e1>iron</e1> salts: Absorption of <e2>quinolones</e2> is reduced significantly by these preparations. ,False,negative
Probenecid,Probenecid,0,9,12,21,<e1>Probenecid</e1>: <e2>Probenecid</e2> does not alter the pharmacokinetics of sparfloxacin.,False,negative
Probenecid,sparfloxacin,0,9,62,73,<e1>Probenecid</e1>: Probenecid does not alter the pharmacokinetics of <e2>sparfloxacin</e2>.,False,negative
Probenecid,sparfloxacin,12,21,62,73,Probenecid: <e1>Probenecid</e1> does not alter the pharmacokinetics of <e2>sparfloxacin</e2>.,False,negative
anticoagulant,cyclosporin,142,154,158,168,"This medicine is generally safe with other medications, but patient should consult doctor or pharmacist if patient is taking a blood thinner (<e1>anticoagulant</e1>), <e2>cyclosporin</e2>, phenytoin, or methotrexate.",False,negative
anticoagulant,phenytoin,142,154,171,179,"This medicine is generally safe with other medications, but patient should consult doctor or pharmacist if patient is taking a blood thinner (<e1>anticoagulant</e1>), cyclosporin, <e2>phenytoin</e2>, or methotrexate.",False,negative
anticoagulant,methotrexate,142,154,185,196,"This medicine is generally safe with other medications, but patient should consult doctor or pharmacist if patient is taking a blood thinner (<e1>anticoagulant</e1>), cyclosporin, phenytoin, or <e2>methotrexate</e2>.",False,negative
cyclosporin,phenytoin,158,168,171,179,"This medicine is generally safe with other medications, but patient should consult doctor or pharmacist if patient is taking a blood thinner (anticoagulant), <e1>cyclosporin</e1>, <e2>phenytoin</e2>, or methotrexate.",False,negative
cyclosporin,methotrexate,158,168,185,196,"This medicine is generally safe with other medications, but patient should consult doctor or pharmacist if patient is taking a blood thinner (anticoagulant), <e1>cyclosporin</e1>, phenytoin, or <e2>methotrexate</e2>.",False,negative
phenytoin,methotrexate,171,179,185,196,"This medicine is generally safe with other medications, but patient should consult doctor or pharmacist if patient is taking a blood thinner (anticoagulant), cyclosporin, <e1>phenytoin</e1>, or <e2>methotrexate</e2>.",False,negative
erythromycin,itraconazole,32,43,46,57,"Some examples of such drugs are <e1>erythromycin</e1>, <e2>itraconazole</e2>, ketoconazole, fluconazole, calcium channel blockers and cimetidine.    ",False,negative
erythromycin,ketoconazole,32,43,60,71,"Some examples of such drugs are <e1>erythromycin</e1>, itraconazole, <e2>ketoconazole</e2>, fluconazole, calcium channel blockers and cimetidine.    ",False,negative
erythromycin,fluconazole,32,43,74,84,"Some examples of such drugs are <e1>erythromycin</e1>, itraconazole, ketoconazole, <e2>fluconazole</e2>, calcium channel blockers and cimetidine.    ",False,negative
erythromycin,calcium channel blockers,32,43,87,110,"Some examples of such drugs are <e1>erythromycin</e1>, itraconazole, ketoconazole, fluconazole, <e2>calcium channel blockers</e2> and cimetidine.    ",False,negative
erythromycin,cimetidine,32,43,116,125,"Some examples of such drugs are <e1>erythromycin</e1>, itraconazole, ketoconazole, fluconazole, calcium channel blockers and <e2>cimetidine</e2>.    ",False,negative
itraconazole,ketoconazole,46,57,60,71,"Some examples of such drugs are erythromycin, <e1>itraconazole</e1>, <e2>ketoconazole</e2>, fluconazole, calcium channel blockers and cimetidine.    ",False,negative
itraconazole,fluconazole,46,57,74,84,"Some examples of such drugs are erythromycin, <e1>itraconazole</e1>, ketoconazole, <e2>fluconazole</e2>, calcium channel blockers and cimetidine.    ",False,negative
itraconazole,calcium channel blockers,46,57,87,110,"Some examples of such drugs are erythromycin, <e1>itraconazole</e1>, ketoconazole, fluconazole, <e2>calcium channel blockers</e2> and cimetidine.    ",False,negative
itraconazole,cimetidine,46,57,116,125,"Some examples of such drugs are erythromycin, <e1>itraconazole</e1>, ketoconazole, fluconazole, calcium channel blockers and <e2>cimetidine</e2>.    ",False,negative
ketoconazole,fluconazole,60,71,74,84,"Some examples of such drugs are erythromycin, itraconazole, <e1>ketoconazole</e1>, <e2>fluconazole</e2>, calcium channel blockers and cimetidine.    ",False,negative
ketoconazole,calcium channel blockers,60,71,87,110,"Some examples of such drugs are erythromycin, itraconazole, <e1>ketoconazole</e1>, fluconazole, <e2>calcium channel blockers</e2> and cimetidine.    ",False,negative
ketoconazole,cimetidine,60,71,116,125,"Some examples of such drugs are erythromycin, itraconazole, <e1>ketoconazole</e1>, fluconazole, calcium channel blockers and <e2>cimetidine</e2>.    ",False,negative
fluconazole,calcium channel blockers,74,84,87,110,"Some examples of such drugs are erythromycin, itraconazole, ketoconazole, <e1>fluconazole</e1>, <e2>calcium channel blockers</e2> and cimetidine.    ",False,negative
fluconazole,cimetidine,74,84,116,125,"Some examples of such drugs are erythromycin, itraconazole, ketoconazole, <e1>fluconazole</e1>, calcium channel blockers and <e2>cimetidine</e2>.    ",False,negative
calcium channel blockers,cimetidine,87,110,116,125,"Some examples of such drugs are erythromycin, itraconazole, ketoconazole, fluconazole, <e1>calcium channel blockers</e1> and <e2>cimetidine</e2>.    ",False,negative
Telbivudine,telbivudine,0,10,94,104,<e1>Telbivudine</e1> is excreted mainly by passive diffusion so the potential for interactions between <e2>telbivudine</e2> and other drugs eliminated by renal excretion is low. ,False,negative
telbivudine,telbivudine,17,27,96,106,"However, because <e1>telbivudine</e1> is eliminated primarily by renal excretion, co   administration of <e2>telbivudine</e2> with drugs that alter renal function may alter plasma concentrations of telbivudine.",False,negative
telbivudine,telbivudine,17,27,180,190,"However, because <e1>telbivudine</e1> is eliminated primarily by renal excretion, co   administration of telbivudine with drugs that alter renal function may alter plasma concentrations of <e2>telbivudine</e2>.",False,negative
telbivudine,telbivudine,96,106,180,190,"However, because telbivudine is eliminated primarily by renal excretion, co   administration of <e1>telbivudine</e1> with drugs that alter renal function may alter plasma concentrations of <e2>telbivudine</e2>.",False,negative
temazepam,cimetidine,31,39,94,103,The pharmacokinetic profile of <e1>temazepam</e1> does not appear to be altered by orally administered <e2>cimetidine</e2> dosed according to labeling.,False,negative
TERAZOL,TERAZOL,0,6,33,39,<e1>TERAZOL</e1> 7 Vaginal Cream 0.4% and <e2>TERAZOL</e2> 3 Vaginal Suppositories 80 mg The therapeutic effect of these products is not affected by oral contraceptive usage. ,False,negative
TERAZOL,contraceptive,0,6,136,148,<e1>TERAZOL</e1> 7 Vaginal Cream 0.4% and TERAZOL 3 Vaginal Suppositories 80 mg The therapeutic effect of these products is not affected by oral <e2>contraceptive</e2> usage. ,False,negative
TERAZOL,contraceptive,33,39,136,148,TERAZOL 7 Vaginal Cream 0.4% and <e1>TERAZOL</e1> 3 Vaginal Suppositories 80 mg The therapeutic effect of these products is not affected by oral <e2>contraceptive</e2> usage. ,False,negative
TERAZOL,estradiol,0,6,43,51,<e1>TERAZOL</e1> 3 Vaginal Cream 0.8% The levels of <e2>estradiol</e2> (E2) and progesterone did not differ significantly when 0.8% terconazole vaginal cream was administered to healthy female volunteers established on a low dose oral contraceptive.    ,False,negative
TERAZOL,progesterone,0,6,62,73,<e1>TERAZOL</e1> 3 Vaginal Cream 0.8% The levels of estradiol (E2) and <e2>progesterone</e2> did not differ significantly when 0.8% terconazole vaginal cream was administered to healthy female volunteers established on a low dose oral contraceptive.    ,False,negative
TERAZOL,terconazole,0,6,114,124,<e1>TERAZOL</e1> 3 Vaginal Cream 0.8% The levels of estradiol (E2) and progesterone did not differ significantly when 0.8% <e2>terconazole</e2> vaginal cream was administered to healthy female volunteers established on a low dose oral contraceptive.    ,False,negative
TERAZOL,contraceptive,0,6,217,229,<e1>TERAZOL</e1> 3 Vaginal Cream 0.8% The levels of estradiol (E2) and progesterone did not differ significantly when 0.8% terconazole vaginal cream was administered to healthy female volunteers established on a low dose oral <e2>contraceptive</e2>.    ,False,negative
estradiol,progesterone,43,51,62,73,TERAZOL 3 Vaginal Cream 0.8% The levels of <e1>estradiol</e1> (E2) and <e2>progesterone</e2> did not differ significantly when 0.8% terconazole vaginal cream was administered to healthy female volunteers established on a low dose oral contraceptive.    ,False,negative
estradiol,terconazole,43,51,114,124,TERAZOL 3 Vaginal Cream 0.8% The levels of <e1>estradiol</e1> (E2) and progesterone did not differ significantly when 0.8% <e2>terconazole</e2> vaginal cream was administered to healthy female volunteers established on a low dose oral contraceptive.    ,False,negative
estradiol,contraceptive,43,51,217,229,TERAZOL 3 Vaginal Cream 0.8% The levels of <e1>estradiol</e1> (E2) and progesterone did not differ significantly when 0.8% terconazole vaginal cream was administered to healthy female volunteers established on a low dose oral <e2>contraceptive</e2>.    ,False,negative
progesterone,terconazole,62,73,114,124,TERAZOL 3 Vaginal Cream 0.8% The levels of estradiol (E2) and <e1>progesterone</e1> did not differ significantly when 0.8% <e2>terconazole</e2> vaginal cream was administered to healthy female volunteers established on a low dose oral contraceptive.    ,False,negative
progesterone,contraceptive,62,73,217,229,TERAZOL 3 Vaginal Cream 0.8% The levels of estradiol (E2) and <e1>progesterone</e1> did not differ significantly when 0.8% terconazole vaginal cream was administered to healthy female volunteers established on a low dose oral <e2>contraceptive</e2>.    ,False,negative
terconazole,contraceptive,114,124,217,229,TERAZOL 3 Vaginal Cream 0.8% The levels of estradiol (E2) and progesterone did not differ significantly when 0.8% <e1>terconazole</e1> vaginal cream was administered to healthy female volunteers established on a low dose oral <e2>contraceptive</e2>.    ,False,negative
Antacids,Calcium,41,48,51,57,"Interactions  Interaction may occur with <e1>Antacids</e1>, <e2>Calcium</e2> supplements, Cholestyramine, Choline and magnesium salicylates, Colestipol, Iron-containing drugs, Laxatives, Magnesium salicylate: these drugs may decrease the potency of tetracyclines. ",False,negative
Antacids,Cholestyramine,41,48,72,85,"Interactions  Interaction may occur with <e1>Antacids</e1>, Calcium supplements, <e2>Cholestyramine</e2>, Choline and magnesium salicylates, Colestipol, Iron-containing drugs, Laxatives, Magnesium salicylate: these drugs may decrease the potency of tetracyclines. ",False,negative
Antacids,Choline salicylate,41,48,88,94,"Interactions  Interaction may occur with <e1>Antacids</e1>, Calcium supplements, Cholestyramine, <e2>Choline salicylate</e2> and magnesium salicylates, Colestipol, Iron-containing drugs, Laxatives, Magnesium salicylate: these drugs may decrease the potency of tetracyclines. ",False,negative
Antacids,magnesium salicylate,41,48,100,119,"Interactions  Interaction may occur with <e1>Antacids</e1>, Calcium supplements, Cholestyramine, Choline and <e2>magnesium salicylate</e2>s, Colestipol, Iron-containing drugs, Laxatives, Magnesium salicylate: these drugs may decrease the potency of tetracyclines. ",False,negative
Antacids,Colestipol,41,48,123,132,"Interactions  Interaction may occur with <e1>Antacids</e1>, Calcium supplements, Cholestyramine, Choline and magnesium salicylates, <e2>Colestipol</e2>, Iron-containing drugs, Laxatives, Magnesium salicylate: these drugs may decrease the potency of tetracyclines. ",False,negative
Antacids,Iron,41,48,135,138,"Interactions  Interaction may occur with <e1>Antacids</e1>, Calcium supplements, Cholestyramine, Choline and magnesium salicylates, Colestipol, <e2>Iron</e2>-containing drugs, Laxatives, Magnesium salicylate: these drugs may decrease the potency of tetracyclines. ",False,negative
Antacids,Laxatives,41,48,158,166,"Interactions  Interaction may occur with <e1>Antacids</e1>, Calcium supplements, Cholestyramine, Choline and magnesium salicylates, Colestipol, Iron-containing drugs, <e2>Laxatives</e2>, Magnesium salicylate: these drugs may decrease the potency of tetracyclines. ",False,negative
Antacids,Magnesium salicylate,41,48,169,188,"Interactions  Interaction may occur with <e1>Antacids</e1>, Calcium supplements, Cholestyramine, Choline and magnesium salicylates, Colestipol, Iron-containing drugs, Laxatives, <e2>Magnesium salicylate</e2>: these drugs may decrease the potency of tetracyclines. ",False,negative
Antacids,tetracyclines,41,48,231,243,"Interactions  Interaction may occur with <e1>Antacids</e1>, Calcium supplements, Cholestyramine, Choline and magnesium salicylates, Colestipol, Iron-containing drugs, Laxatives, Magnesium salicylate: these drugs may decrease the potency of <e2>tetracyclines</e2>. ",False,negative
Calcium,Cholestyramine,51,57,72,85,"Interactions  Interaction may occur with Antacids, <e1>Calcium</e1> supplements, <e2>Cholestyramine</e2>, Choline and magnesium salicylates, Colestipol, Iron-containing drugs, Laxatives, Magnesium salicylate: these drugs may decrease the potency of tetracyclines. ",False,negative
Calcium,Choline salicylate,51,57,88,94,"Interactions  Interaction may occur with Antacids, <e1>Calcium</e1> supplements, Cholestyramine, <e2>Choline salicylate</e2> and magnesium salicylates, Colestipol, Iron-containing drugs, Laxatives, Magnesium salicylate: these drugs may decrease the potency of tetracyclines. ",False,negative
Calcium,magnesium salicylate,51,57,100,119,"Interactions  Interaction may occur with Antacids, <e1>Calcium</e1> supplements, Cholestyramine, Choline and <e2>magnesium salicylate</e2>s, Colestipol, Iron-containing drugs, Laxatives, Magnesium salicylate: these drugs may decrease the potency of tetracyclines. ",False,negative
Calcium,Colestipol,51,57,123,132,"Interactions  Interaction may occur with Antacids, <e1>Calcium</e1> supplements, Cholestyramine, Choline and magnesium salicylates, <e2>Colestipol</e2>, Iron-containing drugs, Laxatives, Magnesium salicylate: these drugs may decrease the potency of tetracyclines. ",False,negative
Calcium,Iron,51,57,135,138,"Interactions  Interaction may occur with Antacids, <e1>Calcium</e1> supplements, Cholestyramine, Choline and magnesium salicylates, Colestipol, <e2>Iron</e2>-containing drugs, Laxatives, Magnesium salicylate: these drugs may decrease the potency of tetracyclines. ",False,negative
Calcium,Laxatives,51,57,158,166,"Interactions  Interaction may occur with Antacids, <e1>Calcium</e1> supplements, Cholestyramine, Choline and magnesium salicylates, Colestipol, Iron-containing drugs, <e2>Laxatives</e2>, Magnesium salicylate: these drugs may decrease the potency of tetracyclines. ",False,negative
Calcium,Magnesium salicylate,51,57,169,188,"Interactions  Interaction may occur with Antacids, <e1>Calcium</e1> supplements, Cholestyramine, Choline and magnesium salicylates, Colestipol, Iron-containing drugs, Laxatives, <e2>Magnesium salicylate</e2>: these drugs may decrease the potency of tetracyclines. ",False,negative
Calcium,tetracyclines,51,57,231,243,"Interactions  Interaction may occur with Antacids, <e1>Calcium</e1> supplements, Cholestyramine, Choline and magnesium salicylates, Colestipol, Iron-containing drugs, Laxatives, Magnesium salicylate: these drugs may decrease the potency of <e2>tetracyclines</e2>. ",False,negative
Cholestyramine,Choline salicylate,72,85,88,94,"Interactions  Interaction may occur with Antacids, Calcium supplements, <e1>Cholestyramine</e1>, <e2>Choline salicylate</e2> and magnesium salicylates, Colestipol, Iron-containing drugs, Laxatives, Magnesium salicylate: these drugs may decrease the potency of tetracyclines. ",False,negative
Cholestyramine,magnesium salicylate,72,85,100,119,"Interactions  Interaction may occur with Antacids, Calcium supplements, <e1>Cholestyramine</e1>, Choline and <e2>magnesium salicylate</e2>s, Colestipol, Iron-containing drugs, Laxatives, Magnesium salicylate: these drugs may decrease the potency of tetracyclines. ",False,negative
Cholestyramine,Colestipol,72,85,123,132,"Interactions  Interaction may occur with Antacids, Calcium supplements, <e1>Cholestyramine</e1>, Choline and magnesium salicylates, <e2>Colestipol</e2>, Iron-containing drugs, Laxatives, Magnesium salicylate: these drugs may decrease the potency of tetracyclines. ",False,negative
Cholestyramine,Iron,72,85,135,138,"Interactions  Interaction may occur with Antacids, Calcium supplements, <e1>Cholestyramine</e1>, Choline and magnesium salicylates, Colestipol, <e2>Iron</e2>-containing drugs, Laxatives, Magnesium salicylate: these drugs may decrease the potency of tetracyclines. ",False,negative
Cholestyramine,Laxatives,72,85,158,166,"Interactions  Interaction may occur with Antacids, Calcium supplements, <e1>Cholestyramine</e1>, Choline and magnesium salicylates, Colestipol, Iron-containing drugs, <e2>Laxatives</e2>, Magnesium salicylate: these drugs may decrease the potency of tetracyclines. ",False,negative
Cholestyramine,Magnesium salicylate,72,85,169,188,"Interactions  Interaction may occur with Antacids, Calcium supplements, <e1>Cholestyramine</e1>, Choline and magnesium salicylates, Colestipol, Iron-containing drugs, Laxatives, <e2>Magnesium salicylate</e2>: these drugs may decrease the potency of tetracyclines. ",False,negative
Cholestyramine,tetracyclines,72,85,231,243,"Interactions  Interaction may occur with Antacids, Calcium supplements, <e1>Cholestyramine</e1>, Choline and magnesium salicylates, Colestipol, Iron-containing drugs, Laxatives, Magnesium salicylate: these drugs may decrease the potency of <e2>tetracyclines</e2>. ",False,negative
Choline salicylate,magnesium salicylate,88,94,100,119,"Interactions  Interaction may occur with Antacids, Calcium supplements, Cholestyramine, <e1>Choline salicylate</e1> and <e2>magnesium salicylate</e2>s, Colestipol, Iron-containing drugs, Laxatives, Magnesium salicylate: these drugs may decrease the potency of tetracyclines. ",False,negative
Choline salicylate,Colestipol,88,94,123,132,"Interactions  Interaction may occur with Antacids, Calcium supplements, Cholestyramine, <e1>Choline salicylate</e1> and magnesium salicylates, <e2>Colestipol</e2>, Iron-containing drugs, Laxatives, Magnesium salicylate: these drugs may decrease the potency of tetracyclines. ",False,negative
Choline salicylate,Iron,88,94,135,138,"Interactions  Interaction may occur with Antacids, Calcium supplements, Cholestyramine, <e1>Choline salicylate</e1> and magnesium salicylates, Colestipol, <e2>Iron</e2>-containing drugs, Laxatives, Magnesium salicylate: these drugs may decrease the potency of tetracyclines. ",False,negative
Choline salicylate,Laxatives,88,94,158,166,"Interactions  Interaction may occur with Antacids, Calcium supplements, Cholestyramine, <e1>Choline salicylate</e1> and magnesium salicylates, Colestipol, Iron-containing drugs, <e2>Laxatives</e2>, Magnesium salicylate: these drugs may decrease the potency of tetracyclines. ",False,negative
Choline salicylate,Magnesium salicylate,88,94,169,188,"Interactions  Interaction may occur with Antacids, Calcium supplements, Cholestyramine, <e1>Choline salicylate</e1> and magnesium salicylates, Colestipol, Iron-containing drugs, Laxatives, <e2>Magnesium salicylate</e2>: these drugs may decrease the potency of tetracyclines. ",False,negative
Choline salicylate,tetracyclines,88,94,231,243,"Interactions  Interaction may occur with Antacids, Calcium supplements, Cholestyramine, <e1>Choline salicylate</e1> and magnesium salicylates, Colestipol, Iron-containing drugs, Laxatives, Magnesium salicylate: these drugs may decrease the potency of <e2>tetracyclines</e2>. ",False,negative
magnesium salicylate,Colestipol,100,119,123,132,"Interactions  Interaction may occur with Antacids, Calcium supplements, Cholestyramine, Choline and <e1>magnesium salicylate</e1>s, <e2>Colestipol</e2>, Iron-containing drugs, Laxatives, Magnesium salicylate: these drugs may decrease the potency of tetracyclines. ",False,negative
magnesium salicylate,Iron,100,119,135,138,"Interactions  Interaction may occur with Antacids, Calcium supplements, Cholestyramine, Choline and <e1>magnesium salicylate</e1>s, Colestipol, <e2>Iron</e2>-containing drugs, Laxatives, Magnesium salicylate: these drugs may decrease the potency of tetracyclines. ",False,negative
magnesium salicylate,Laxatives,100,119,158,166,"Interactions  Interaction may occur with Antacids, Calcium supplements, Cholestyramine, Choline and <e1>magnesium salicylate</e1>s, Colestipol, Iron-containing drugs, <e2>Laxatives</e2>, Magnesium salicylate: these drugs may decrease the potency of tetracyclines. ",False,negative
magnesium salicylate,Magnesium salicylate,100,119,169,188,"Interactions  Interaction may occur with Antacids, Calcium supplements, Cholestyramine, Choline and <e1>magnesium salicylate</e1>s, Colestipol, Iron-containing drugs, Laxatives, <e2>Magnesium salicylate</e2>: these drugs may decrease the potency of tetracyclines. ",False,negative
magnesium salicylate,tetracyclines,100,119,231,243,"Interactions  Interaction may occur with Antacids, Calcium supplements, Cholestyramine, Choline and <e1>magnesium salicylate</e1>s, Colestipol, Iron-containing drugs, Laxatives, Magnesium salicylate: these drugs may decrease the potency of <e2>tetracyclines</e2>. ",False,negative
Colestipol,Iron,123,132,135,138,"Interactions  Interaction may occur with Antacids, Calcium supplements, Cholestyramine, Choline and magnesium salicylates, <e1>Colestipol</e1>, <e2>Iron</e2>-containing drugs, Laxatives, Magnesium salicylate: these drugs may decrease the potency of tetracyclines. ",False,negative
Colestipol,Laxatives,123,132,158,166,"Interactions  Interaction may occur with Antacids, Calcium supplements, Cholestyramine, Choline and magnesium salicylates, <e1>Colestipol</e1>, Iron-containing drugs, <e2>Laxatives</e2>, Magnesium salicylate: these drugs may decrease the potency of tetracyclines. ",False,negative
Colestipol,Magnesium salicylate,123,132,169,188,"Interactions  Interaction may occur with Antacids, Calcium supplements, Cholestyramine, Choline and magnesium salicylates, <e1>Colestipol</e1>, Iron-containing drugs, Laxatives, <e2>Magnesium salicylate</e2>: these drugs may decrease the potency of tetracyclines. ",False,negative
Colestipol,tetracyclines,123,132,231,243,"Interactions  Interaction may occur with Antacids, Calcium supplements, Cholestyramine, Choline and magnesium salicylates, <e1>Colestipol</e1>, Iron-containing drugs, Laxatives, Magnesium salicylate: these drugs may decrease the potency of <e2>tetracyclines</e2>. ",False,negative
Iron,Laxatives,135,138,158,166,"Interactions  Interaction may occur with Antacids, Calcium supplements, Cholestyramine, Choline and magnesium salicylates, Colestipol, <e1>Iron</e1>-containing drugs, <e2>Laxatives</e2>, Magnesium salicylate: these drugs may decrease the potency of tetracyclines. ",False,negative
Iron,Magnesium salicylate,135,138,169,188,"Interactions  Interaction may occur with Antacids, Calcium supplements, Cholestyramine, Choline and magnesium salicylates, Colestipol, <e1>Iron</e1>-containing drugs, Laxatives, <e2>Magnesium salicylate</e2>: these drugs may decrease the potency of tetracyclines. ",False,negative
Iron,tetracyclines,135,138,231,243,"Interactions  Interaction may occur with Antacids, Calcium supplements, Cholestyramine, Choline and magnesium salicylates, Colestipol, <e1>Iron</e1>-containing drugs, Laxatives, Magnesium salicylate: these drugs may decrease the potency of <e2>tetracyclines</e2>. ",False,negative
Laxatives,Magnesium salicylate,158,166,169,188,"Interactions  Interaction may occur with Antacids, Calcium supplements, Cholestyramine, Choline and magnesium salicylates, Colestipol, Iron-containing drugs, <e1>Laxatives</e1>, <e2>Magnesium salicylate</e2>: these drugs may decrease the potency of tetracyclines. ",False,negative
Laxatives,tetracyclines,158,166,231,243,"Interactions  Interaction may occur with Antacids, Calcium supplements, Cholestyramine, Choline and magnesium salicylates, Colestipol, Iron-containing drugs, <e1>Laxatives</e1>, Magnesium salicylate: these drugs may decrease the potency of <e2>tetracyclines</e2>. ",False,negative
Magnesium salicylate,tetracyclines,169,188,231,243,"Interactions  Interaction may occur with Antacids, Calcium supplements, Cholestyramine, Choline and magnesium salicylates, Colestipol, Iron-containing drugs, Laxatives, <e1>Magnesium salicylate</e1>: these drugs may decrease the potency of <e2>tetracyclines</e2>. ",False,negative
contraceptives,estrogen,5,18,31,38,Oral <e1>contraceptives</e1> containing <e2>estrogen</e2>: tetracyclines may decrease the contraceptive effect and increase the chance of unwanted pregnancy.,False,negative
contraceptives,tetracyclines,5,18,41,53,Oral <e1>contraceptives</e1> containing estrogen: <e2>tetracyclines</e2> may decrease the contraceptive effect and increase the chance of unwanted pregnancy.,False,negative
estrogen,tetracyclines,31,38,41,53,Oral contraceptives containing <e1>estrogen</e1>: <e2>tetracyclines</e2> may decrease the contraceptive effect and increase the chance of unwanted pregnancy.,False,negative
colestipol,cholestyramine,26,35,38,51,"- Decreased absorption of <e1>colestipol</e1>, <e2>cholestyramine</e2>, mineral oil, and sucralfate.",False,negative
colestipol,mineral oil,26,35,54,64,"- Decreased absorption of <e1>colestipol</e1>, cholestyramine, <e2>mineral oil</e2>, and sucralfate.",False,negative
colestipol,sucralfate,26,35,71,80,"- Decreased absorption of <e1>colestipol</e1>, cholestyramine, mineral oil, and <e2>sucralfate</e2>.",False,negative
cholestyramine,mineral oil,38,51,54,64,"- Decreased absorption of colestipol, <e1>cholestyramine</e1>, <e2>mineral oil</e2>, and sucralfate.",False,negative
cholestyramine,sucralfate,38,51,71,80,"- Decreased absorption of colestipol, <e1>cholestyramine</e1>, mineral oil, and <e2>sucralfate</e2>.",False,negative
mineral oil,sucralfate,54,64,71,80,"- Decreased absorption of colestipol, cholestyramine, <e1>mineral oil</e1>, and <e2>sucralfate</e2>.",False,negative
fenofibric acid,fenofibrate,37,51,75,85,"Single-dose bioequivalence of 105-mg <e1>fenofibric acid</e1> tablets versus 145-mg <e2>fenofibrate</e2> tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trials.
",False,negative
Fenofibrate,fenofibric acid,0,10,70,84,"<e1>Fenofibrate</e1> is a prodrug that is rapidly and completely hydrolyzed to <e2>fenofibric acid</e2>, the active moiety. ",False,negative
fenofibric acid,fenofibrate,33,47,85,95,"A new orally administered agent, <e1>fenofibric acid</e1>, was developed as an alternative to <e2>fenofibrate</e2>.",False,negative
fenofibric acid,fenofibrate,70,84,98,108,"Two separate studies were conducted to evaluate the bioequivalence of <e1>fenofibric acid</e1> relative to <e2>fenofibrate</e2> under fasted and fed (standard breakfast) conditions, characterize the pharmacokinetic profile, and assess the safety and tolerability of fenofibric acid. ",False,negative
fenofibric acid,fenofibric acid,70,84,248,262,"Two separate studies were conducted to evaluate the bioequivalence of <e1>fenofibric acid</e1> relative to fenofibrate under fasted and fed (standard breakfast) conditions, characterize the pharmacokinetic profile, and assess the safety and tolerability of <e2>fenofibric acid</e2>. ",False,negative
fenofibrate,fenofibric acid,98,108,248,262,"Two separate studies were conducted to evaluate the bioequivalence of fenofibric acid relative to <e1>fenofibrate</e1> under fasted and fed (standard breakfast) conditions, characterize the pharmacokinetic profile, and assess the safety and tolerability of <e2>fenofibric acid</e2>. ",False,negative
fenofibric acid,fenofibrate,91,105,132,142,"In study 1 (fasted), during each study period, volunteers received a single 105-mg dose of <e1>fenofibric acid</e1> or single 145-mg dose of <e2>fenofibrate</e2> (depending on their randomization scheme) after an overnight fast (a minimum fast of 10 hours). ",False,negative
fenofibric acid,fenofibrate,99,113,115,125,"The criterion for a lack of difference between products was a 90% CI between 0.80 and 1.25 for the <e1>fenofibric acid</e1>:<e2>fenofibrate</e2> ratios for AUC(0-t), AUC(0-   ), and C(max.) ",False,negative
fenofibric acid,fenofibrate,35,49,73,83,"The 90% CIs about the ratio of the <e1>fenofibric acid</e1> geometric mean to the <e2>fenofibrate</e2> geometric mean were within the 80% and 125% limits for the pharmacokinetic parameters C(max), AUC(0-t), and AUC(0-   ) of the ln-transformed data in both study 1 (fasted) and study 2. ",False,negative
fenofibric acid,fenofibrate,99,113,235,245,"In these 2 single-dose studies, these healthy volunteers administered a single oral dose of 105-mg <e1>fenofibric acid</e1> met the US Food and Drug Administration regulatory criteria for assuming bioequivalence to a single oral dose of 145-mg <e2>fenofibrate</e2> tablets with respect to the rate and extent of fenofibric acid absorption in both fed and fasted states. ",False,negative
fenofibric acid,fenofibric acid,99,113,294,308,"In these 2 single-dose studies, these healthy volunteers administered a single oral dose of 105-mg <e1>fenofibric acid</e1> met the US Food and Drug Administration regulatory criteria for assuming bioequivalence to a single oral dose of 145-mg fenofibrate tablets with respect to the rate and extent of <e2>fenofibric acid</e2> absorption in both fed and fasted states. ",False,negative
fenofibrate,fenofibric acid,235,245,294,308,"In these 2 single-dose studies, these healthy volunteers administered a single oral dose of 105-mg fenofibric acid met the US Food and Drug Administration regulatory criteria for assuming bioequivalence to a single oral dose of 145-mg <e1>fenofibrate</e1> tablets with respect to the rate and extent of <e2>fenofibric acid</e2> absorption in both fed and fasted states. ",False,negative
immunosupressive drug,immunosuppressive,60,80,149,165,Conventional therapeutic drug monitoring based on measuring <e1>immunosupressive drug</e1> concentrations in blood is important in the clinical management of <e2>immunosuppressive</e2> therapy in transplantation medicine. ,False,negative
antituberculosis drugs,antiretroviral drugs,46,61,67,86,The treatment of coinfected patients requires <e1>antituberculosis drugs</e1> and <e2>antiretroviral drugs</e2> to be administered concomittantly; ,False,negative
antiretroviral,antituberculosis,38,51,85,100,Current guidelines recommend starting <e1>antiretroviral</e1> treatment within a few weeks of <e2>antituberculosis</e2> therapy for patients with CD4 cell counts,False,negative
neferine,amiodarone,11,18,47,56,"Effects of <e1>neferine</e1> on the pharmacokinetics of <e2>amiodarone</e2> in rats.
",False,negative
neferine,amiodarone,57,64,212,221,"The purpose of this study was to assess the potential of <e1>neferine</e1>, an effective anti-pulmonary fibrosis drug isolated from the embryo of Nelumbo nucifera Gaertner's seeds, to alter the pharmacokinetic profile of <e2>amiodarone</e2>. ",False,negative
amiodarone,neferine,19,28,116,123,"In groups 1 and 2, <e1>amiodarone</e1> was given to rats by intragastric and intravenous administration, respectively, while <e2>neferine</e2> was co-administratered by intragastric administration. ",False,negative
amiodarone,neferine,81,90,164,171,"There were no significant differences between the pharmacokinetics parameters of <e1>amiodarone</e1> administered intravenously or intragastrically and the control (without <e2>neferine</e2>) group (with ratios of 0.7-1.4 in all experimental groups), suggesting that neferine had no effect on amiodarone plasma pharmacokinetics. ",False,negative
amiodarone,neferine,81,90,249,256,"There were no significant differences between the pharmacokinetics parameters of <e1>amiodarone</e1> administered intravenously or intragastrically and the control (without neferine) group (with ratios of 0.7-1.4 in all experimental groups), suggesting that <e2>neferine</e2> had no effect on amiodarone plasma pharmacokinetics. ",False,negative
amiodarone,amiodarone,81,90,275,284,"There were no significant differences between the pharmacokinetics parameters of <e1>amiodarone</e1> administered intravenously or intragastrically and the control (without neferine) group (with ratios of 0.7-1.4 in all experimental groups), suggesting that neferine had no effect on <e2>amiodarone</e2> plasma pharmacokinetics. ",False,negative
neferine,neferine,164,171,249,256,"There were no significant differences between the pharmacokinetics parameters of amiodarone administered intravenously or intragastrically and the control (without <e1>neferine</e1>) group (with ratios of 0.7-1.4 in all experimental groups), suggesting that <e2>neferine</e2> had no effect on amiodarone plasma pharmacokinetics. ",False,negative
neferine,amiodarone,164,171,275,284,"There were no significant differences between the pharmacokinetics parameters of amiodarone administered intravenously or intragastrically and the control (without <e1>neferine</e1>) group (with ratios of 0.7-1.4 in all experimental groups), suggesting that neferine had no effect on <e2>amiodarone</e2> plasma pharmacokinetics. ",False,negative
neferine,amiodarone,249,256,275,284,"There were no significant differences between the pharmacokinetics parameters of amiodarone administered intravenously or intragastrically and the control (without neferine) group (with ratios of 0.7-1.4 in all experimental groups), suggesting that <e1>neferine</e1> had no effect on <e2>amiodarone</e2> plasma pharmacokinetics. ",False,negative
amiodarone,neferine,22,31,97,104,The dosage regimen of <e1>amiodarone</e1> does not need to be taken into consideration when combined with <e2>neferine</e2>.,False,negative
methanol,ethanol,105,112,118,124,"We observed that GLIC recapitulates bimodal modulation by n-alcohols, similar to some eukaryotic pLGICs: <e1>methanol</e1> and <e2>ethanol</e2> weakly potentiated proton-activated currents in GLIC, whereas n-alcohols larger than ethanol inhibited them. ",False,negative
alcohol,alcohol,33,39,223,229,"Mapping of residues important to <e1>alcohol</e1> modulation of ionotropic receptors for glycine,   -aminobutyric acid, and acetylcholine onto GLIC revealed their proximity to transmembrane cavities that may accommodate one or more <e2>alcohol</e2> molecules. ",False,negative
MPTP,"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine",38,41,44,88,"Neuropharmacological approach against <e1>MPTP</e1> (<e2>1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine</e2>)-induced mouse model of Parkinson's disease.
",False,negative
"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine",MPTP,58,102,105,108,"The biochemical and cellular alterations that occur after <e1>1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine</e1> (<e2>MPTP</e2>) treatment are remarkably similar to that observed in idiopathic PD. ",False,negative
MPTP,MPTP,56,59,222,225,"Furthermore, it is well known that acute treatment with <e1>MPTP</e1> can cause a severe loss of tyrosine hydroxylase and dopamine transporter protein levels and dopamine contents in the striatum of mice, as compared to continuous <e2>MPTP</e2> treatment. ",False,negative
colchicine,colchicine,44,53,99,108,"We sought to determine (1) the frequency of <e1>colchicine</e1> toxicity among hospitalized patients taking <e2>colchicine</e2> who died during an admission, (2) the likelihood that colchicine contributed to death, (3) whether patients were taking interacting medications that could have contributed to toxicity, and (4) whether colchicine dosing among these patients adhered to established guidelines. ",False,negative
colchicine,colchicine,44,53,164,173,"We sought to determine (1) the frequency of <e1>colchicine</e1> toxicity among hospitalized patients taking colchicine who died during an admission, (2) the likelihood that <e2>colchicine</e2> contributed to death, (3) whether patients were taking interacting medications that could have contributed to toxicity, and (4) whether colchicine dosing among these patients adhered to established guidelines. ",False,negative
colchicine,colchicine,44,53,311,320,"We sought to determine (1) the frequency of <e1>colchicine</e1> toxicity among hospitalized patients taking colchicine who died during an admission, (2) the likelihood that colchicine contributed to death, (3) whether patients were taking interacting medications that could have contributed to toxicity, and (4) whether <e2>colchicine</e2> dosing among these patients adhered to established guidelines. ",False,negative
colchicine,colchicine,99,108,164,173,"We sought to determine (1) the frequency of colchicine toxicity among hospitalized patients taking <e1>colchicine</e1> who died during an admission, (2) the likelihood that <e2>colchicine</e2> contributed to death, (3) whether patients were taking interacting medications that could have contributed to toxicity, and (4) whether colchicine dosing among these patients adhered to established guidelines. ",False,negative
colchicine,colchicine,99,108,311,320,"We sought to determine (1) the frequency of colchicine toxicity among hospitalized patients taking <e1>colchicine</e1> who died during an admission, (2) the likelihood that colchicine contributed to death, (3) whether patients were taking interacting medications that could have contributed to toxicity, and (4) whether <e2>colchicine</e2> dosing among these patients adhered to established guidelines. ",False,negative
colchicine,colchicine,164,173,311,320,"We sought to determine (1) the frequency of colchicine toxicity among hospitalized patients taking colchicine who died during an admission, (2) the likelihood that <e1>colchicine</e1> contributed to death, (3) whether patients were taking interacting medications that could have contributed to toxicity, and (4) whether <e2>colchicine</e2> dosing among these patients adhered to established guidelines. ",False,negative
colchicine,colchicine,68,77,124,133,"An expert panel reviewed each case and classified the likelihood of <e1>colchicine</e1> toxicity, the likelihood of a causal role of <e2>colchicine</e2> in the death using the WHO classification system, and the appropriateness of colchicine dosing. ",False,negative
colchicine,colchicine,68,77,212,221,"An expert panel reviewed each case and classified the likelihood of <e1>colchicine</e1> toxicity, the likelihood of a causal role of colchicine in the death using the WHO classification system, and the appropriateness of <e2>colchicine</e2> dosing. ",False,negative
colchicine,colchicine,124,133,212,221,"An expert panel reviewed each case and classified the likelihood of colchicine toxicity, the likelihood of a causal role of <e1>colchicine</e1> in the death using the WHO classification system, and the appropriateness of <e2>colchicine</e2> dosing. ",False,negative
antithrombotic,vitamin K antagonist,106,119,141,160,"According to the calculated level of risk, guidelines recommend patients with atrial fibrillation receive <e1>antithrombotic</e1> therapy either as a <e2>vitamin K antagonist</e2> or aspirin. ",False,negative
antithrombotic,aspirin,106,119,165,171,"According to the calculated level of risk, guidelines recommend patients with atrial fibrillation receive <e1>antithrombotic</e1> therapy either as a vitamin K antagonist or <e2>aspirin</e2>. ",False,negative
vitamin K antagonist,aspirin,141,160,165,171,"According to the calculated level of risk, guidelines recommend patients with atrial fibrillation receive antithrombotic therapy either as a <e1>vitamin K antagonist</e1> or <e2>aspirin</e2>. ",False,negative
anticoagulants,vitamin K antagonists,15,28,85,105,The novel oral <e1>anticoagulants</e1> in development may overcome some of the limitations of <e2>vitamin K antagonists</e2> and address their underuse and safety concerns.,False,negative
"N-[N-(3, 5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester",DAPT,179,248,251,254,"All mRPCs of 20 passages or less were transplanted into the subretinal space of B6 mice together with chondroitinase ABC, and into Rho(-/-) mice combined with chondroitinase ABC, <e1>N-[N-(3, 5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester</e1> (<e2>DAPT</e2>), and insulin growth factor (IGF)-1. ",False,negative
"N-[N-(3, 5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester",insulin growth factor,179,248,262,282,"All mRPCs of 20 passages or less were transplanted into the subretinal space of B6 mice together with chondroitinase ABC, and into Rho(-/-) mice combined with chondroitinase ABC, <e1>N-[N-(3, 5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester</e1> (DAPT), and <e2>insulin growth factor</e2> (IGF)-1. ",False,negative
"N-[N-(3, 5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester",(IGF)-1,179,248,284,290,"All mRPCs of 20 passages or less were transplanted into the subretinal space of B6 mice together with chondroitinase ABC, and into Rho(-/-) mice combined with chondroitinase ABC, <e1>N-[N-(3, 5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester</e1> (DAPT), and insulin growth factor <e2>(IGF)-1</e2>. ",False,negative
DAPT,insulin growth factor,251,254,262,282,"All mRPCs of 20 passages or less were transplanted into the subretinal space of B6 mice together with chondroitinase ABC, and into Rho(-/-) mice combined with chondroitinase ABC, N-[N-(3, 5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (<e1>DAPT</e1>), and <e2>insulin growth factor</e2> (IGF)-1. ",False,negative
DAPT,(IGF)-1,251,254,284,290,"All mRPCs of 20 passages or less were transplanted into the subretinal space of B6 mice together with chondroitinase ABC, and into Rho(-/-) mice combined with chondroitinase ABC, N-[N-(3, 5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (<e1>DAPT</e1>), and insulin growth factor <e2>(IGF)-1</e2>. ",False,negative
insulin growth factor,(IGF)-1,262,282,284,290,"All mRPCs of 20 passages or less were transplanted into the subretinal space of B6 mice together with chondroitinase ABC, and into Rho(-/-) mice combined with chondroitinase ABC, N-[N-(3, 5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT), and <e1>insulin growth factor</e1> <e2>(IGF)-1</e2>. ",False,negative
antiagregants,anticoagulants,64,76,82,95,"The risk of gastrointestinal bleeding during the treatment with <e1>antiagregants</e1> and <e2>anticoagulants</e2>, the risk of bradycardia in beta-blockade, possible interactions with other medications lowering the heart rate are discussed. ",False,negative
calcium channel blockers,diuretics,21,44,47,55,"Attention is paid to <e1>calcium channel blockers</e1>, <e2>diuretics</e2> and digoxin. ",False,negative
calcium channel blockers,digoxin,21,44,61,67,"Attention is paid to <e1>calcium channel blockers</e1>, diuretics and <e2>digoxin</e2>. ",False,negative
diuretics,digoxin,47,55,61,67,"Attention is paid to calcium channel blockers, <e1>diuretics</e1> and <e2>digoxin</e2>. ",False,negative
oseltamivir,immunosuppresive drug,40,50,113,133,"Post-exposure prophylaxis for H1N1 with <e1>oseltamivir</e1> in renal allograft recipient--safe and effective without any <e2>immunosuppresive drug</e2> interaction.
",False,negative
oseltamivir,tacrolimus,39,49,246,255,"Post-exposure prophylaxis of H1N1 with <e1>oseltamivir</e1> was safe, effective and well tolerated to prevent H1N1 influenza A virus infection in newly transplanted renal allograft recipient receiving triple immunosuppression without any interaction with <e2>tacrolimus</e2> level. ",False,negative
colchicine,eugenol,15,24,64,70,"Improvement of <e1>colchicine</e1> oral bioavailability by incorporating <e2>eugenol</e2> in the nanoemulsion as an oil excipient and enhancer.
",False,negative
eugenol,colchicine,14,20,25,34,The effect of <e1>eugenol</e1> on <e2>colchicine</e2> transport across an isolated rat intestinal membrane was studied using an in vitro diffusion chamber system. ,False,negative
eugenol,colchicine,14,20,50,59,The effect of <e1>eugenol</e1> on intestinal absorption of <e2>colchicine</e2> in an oral administrative nanoemulsion formulation was also demonstrated in vivo. ,False,negative
colchicine,isopropyl myristate,4,13,46,64,"The <e1>colchicine</e1> nanoemulsion was prepared with <e2>isopropyl myristate</e2>, eugenol, Tween80, ethanol and water, and eugenol was used as an oil phase in the formulation; ",False,negative
colchicine,eugenol,4,13,67,73,"The <e1>colchicine</e1> nanoemulsion was prepared with isopropyl myristate, <e2>eugenol</e2>, Tween80, ethanol and water, and eugenol was used as an oil phase in the formulation; ",False,negative
colchicine,Tween80,4,13,76,82,"The <e1>colchicine</e1> nanoemulsion was prepared with isopropyl myristate, eugenol, <e2>Tween80</e2>, ethanol and water, and eugenol was used as an oil phase in the formulation; ",False,negative
colchicine,ethanol,4,13,85,91,"The <e1>colchicine</e1> nanoemulsion was prepared with isopropyl myristate, eugenol, Tween80, <e2>ethanol</e2> and water, and eugenol was used as an oil phase in the formulation; ",False,negative
colchicine,eugenol,4,13,108,114,"The <e1>colchicine</e1> nanoemulsion was prepared with isopropyl myristate, eugenol, Tween80, ethanol and water, and <e2>eugenol</e2> was used as an oil phase in the formulation; ",False,negative
isopropyl myristate,eugenol,46,64,67,73,"The colchicine nanoemulsion was prepared with <e1>isopropyl myristate</e1>, <e2>eugenol</e2>, Tween80, ethanol and water, and eugenol was used as an oil phase in the formulation; ",False,negative
isopropyl myristate,Tween80,46,64,76,82,"The colchicine nanoemulsion was prepared with <e1>isopropyl myristate</e1>, eugenol, <e2>Tween80</e2>, ethanol and water, and eugenol was used as an oil phase in the formulation; ",False,negative
isopropyl myristate,ethanol,46,64,85,91,"The colchicine nanoemulsion was prepared with <e1>isopropyl myristate</e1>, eugenol, Tween80, <e2>ethanol</e2> and water, and eugenol was used as an oil phase in the formulation; ",False,negative
isopropyl myristate,eugenol,46,64,108,114,"The colchicine nanoemulsion was prepared with <e1>isopropyl myristate</e1>, eugenol, Tween80, ethanol and water, and <e2>eugenol</e2> was used as an oil phase in the formulation; ",False,negative
eugenol,Tween80,67,73,76,82,"The colchicine nanoemulsion was prepared with isopropyl myristate, <e1>eugenol</e1>, <e2>Tween80</e2>, ethanol and water, and eugenol was used as an oil phase in the formulation; ",False,negative
eugenol,ethanol,67,73,85,91,"The colchicine nanoemulsion was prepared with isopropyl myristate, <e1>eugenol</e1>, Tween80, <e2>ethanol</e2> and water, and eugenol was used as an oil phase in the formulation; ",False,negative
eugenol,eugenol,67,73,108,114,"The colchicine nanoemulsion was prepared with isopropyl myristate, <e1>eugenol</e1>, Tween80, ethanol and water, and <e2>eugenol</e2> was used as an oil phase in the formulation; ",False,negative
Tween80,ethanol,76,82,85,91,"The colchicine nanoemulsion was prepared with isopropyl myristate, eugenol, <e1>Tween80</e1>, <e2>ethanol</e2> and water, and eugenol was used as an oil phase in the formulation; ",False,negative
Tween80,eugenol,76,82,108,114,"The colchicine nanoemulsion was prepared with isopropyl myristate, eugenol, <e1>Tween80</e1>, ethanol and water, and <e2>eugenol</e2> was used as an oil phase in the formulation; ",False,negative
ethanol,eugenol,85,91,108,114,"The colchicine nanoemulsion was prepared with isopropyl myristate, eugenol, Tween80, <e1>ethanol</e1> and water, and <e2>eugenol</e2> was used as an oil phase in the formulation; ",False,negative
colchicine,colchicine,18,27,147,156,The permeation of <e1>colchicine</e1> in the nanoemulsion across the intestinal membrane was significantly different from that of the control group (0.2 mM <e2>colchicine</e2>). ,False,negative
eugenol,colchicine,30,36,41,50,"Finally, co-administration of <e1>eugenol</e1> in <e2>colchicine</e2> nanoemulsion to enhance the colchicine bioavailability was investigated by an oral administration method. ",False,negative
eugenol,colchicine,30,36,80,89,"Finally, co-administration of <e1>eugenol</e1> in colchicine nanoemulsion to enhance the <e2>colchicine</e2> bioavailability was investigated by an oral administration method. ",False,negative
colchicine,colchicine,41,50,80,89,"Finally, co-administration of eugenol in <e1>colchicine</e1> nanoemulsion to enhance the <e2>colchicine</e2> bioavailability was investigated by an oral administration method. ",False,negative
colchicine,colchicine,29,38,100,109,"After oral administration of <e1>colchicine</e1> (8 mg/kg) in the form of either the nanoemulsion or in free <e2>colchicine</e2> solution, the relative bioavailability of nanoemulsion and eugenol-nanoemulsion were enhanced by about 1.6- and 2.1-fold, respectively, compared with free colchicine solution. ",False,negative
colchicine,eugenol,29,38,170,176,"After oral administration of <e1>colchicine</e1> (8 mg/kg) in the form of either the nanoemulsion or in free colchicine solution, the relative bioavailability of nanoemulsion and <e2>eugenol</e2>-nanoemulsion were enhanced by about 1.6- and 2.1-fold, respectively, compared with free colchicine solution. ",False,negative
colchicine,colchicine,29,38,266,275,"After oral administration of <e1>colchicine</e1> (8 mg/kg) in the form of either the nanoemulsion or in free colchicine solution, the relative bioavailability of nanoemulsion and eugenol-nanoemulsion were enhanced by about 1.6- and 2.1-fold, respectively, compared with free <e2>colchicine</e2> solution. ",False,negative
colchicine,eugenol,100,109,170,176,"After oral administration of colchicine (8 mg/kg) in the form of either the nanoemulsion or in free <e1>colchicine</e1> solution, the relative bioavailability of nanoemulsion and <e2>eugenol</e2>-nanoemulsion were enhanced by about 1.6- and 2.1-fold, respectively, compared with free colchicine solution. ",False,negative
colchicine,colchicine,100,109,266,275,"After oral administration of colchicine (8 mg/kg) in the form of either the nanoemulsion or in free <e1>colchicine</e1> solution, the relative bioavailability of nanoemulsion and eugenol-nanoemulsion were enhanced by about 1.6- and 2.1-fold, respectively, compared with free <e2>colchicine</e2> solution. ",False,negative
eugenol,colchicine,170,176,266,275,"After oral administration of colchicine (8 mg/kg) in the form of either the nanoemulsion or in free colchicine solution, the relative bioavailability of nanoemulsion and <e1>eugenol</e1>-nanoemulsion were enhanced by about 1.6- and 2.1-fold, respectively, compared with free <e2>colchicine</e2> solution. ",False,negative
colchicine,eugenol,58,67,99,105,The procedure indicated that the intestinal absorption of <e1>colchicine</e1> was enhanced significantly by <e2>eugenol</e2> in the tested nanoemulsion. ,False,negative
eugenol,colchicine,31,37,146,155,All the results suggested that <e1>eugenol</e1> is an efficient component in an oral administrative formulation for improving the intestinal absorption of <e2>colchicine</e2>.,False,negative
ginseng,ginko,23,29,31,35,"[Protective effects of <e1>ginseng</e1>-<e2>ginko</e2> extracts combination on rat primary cultured neurons induced by Abeta(1-40)].
",False,negative
ginseng,Abeta(1-40),23,29,101,111,"[Protective effects of <e1>ginseng</e1>-ginko extracts combination on rat primary cultured neurons induced by <e2>Abeta(1-40)</e2>].
",False,negative
ginko,Abeta(1-40),31,35,101,111,"[Protective effects of ginseng-<e1>ginko</e1> extracts combination on rat primary cultured neurons induced by <e2>Abeta(1-40)</e2>].
",False,negative
Abeta(1-40),ginseng,65,75,122,128,To observe the injury in rat primary cultured neurons induced by <e1>Abeta(1-40)</e1> and the protective effects of combination of <e2>ginseng</e2> and ginko extracts.,False,negative
Abeta(1-40),ginko,65,75,134,138,To observe the injury in rat primary cultured neurons induced by <e1>Abeta(1-40)</e1> and the protective effects of combination of ginseng and <e2>ginko</e2> extracts.,False,negative
ginseng,ginko,122,128,134,138,To observe the injury in rat primary cultured neurons induced by Abeta(1-40) and the protective effects of combination of <e1>ginseng</e1> and <e2>ginko</e2> extracts.,False,negative
ginseng,ginko,27,33,39,43,"The effects of extracts of <e1>ginseng</e1> and <e2>ginko</e2> (EGGB) on cellular proliferative activity, apoptotic rate, ultrastructure and caspase-3 expression were detected. ",False,negative
ginseng,EGGB,27,33,46,49,"The effects of extracts of <e1>ginseng</e1> and ginko (<e2>EGGB</e2>) on cellular proliferative activity, apoptotic rate, ultrastructure and caspase-3 expression were detected. ",False,negative
ginko,EGGB,39,43,46,49,"The effects of extracts of ginseng and <e1>ginko</e1> (<e2>EGGB</e2>) on cellular proliferative activity, apoptotic rate, ultrastructure and caspase-3 expression were detected. ",False,negative
glycyrrhiza extract,daphnetin,12,30,64,72,"[Effects of <e1>glycyrrhiza extract</e1> on pharmacokinetics property of <e2>daphnetin</e2> in rats].
",False,negative
glycyrrhiza extract,daphnetin,29,47,102,110,"To research the influence of <e1>glycyrrhiza extract</e1> on the pharmacokinetics characteristic parameters of <e2>daphnetin</e2>, which was aimed to explore the rationality of concert application of drugs.",False,negative
daphnetin,glycyrrhiza extract,49,57,63,81,The rats received intragastric administration of <e1>daphnetin</e1> and <e2>glycyrrhiza extract</e2> containing the same daphnetin respectively. ,False,negative
daphnetin,daphnetin,49,57,103,111,The rats received intragastric administration of <e1>daphnetin</e1> and glycyrrhiza extract containing the same <e2>daphnetin</e2> respectively. ,False,negative
glycyrrhiza extract,daphnetin,63,81,103,111,The rats received intragastric administration of daphnetin and <e1>glycyrrhiza extract</e1> containing the same <e2>daphnetin</e2> respectively. ,False,negative
o-cymen-5-ol,zinc,25,36,42,45,"Antimicrobial effects of <e1>o-cymen-5-ol</e1> and <e2>zinc</e2>, alone &",False,negative
o-cymen-5-ol,zinc,57,68,70,73,This study aimed to evaluate antimicrobial effects of an <e1>o-cymen-5-ol</e1>/<e2>zinc</e2> system.,False,negative
o-Cymen-5-ol,zinc gluconate,0,11,17,30,"<e1>o-Cymen-5-ol</e1> and <e2>zinc gluconate</e2> minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were determined against Streptococcus mutans, Actinomyces viscosus, Porphyromonas gingivalis, Fusobacterium nucleatum and Candida albicans. ",False,negative
o-cymen-5-ol,zinc gluconate,43,54,56,69,"nucleatum, with MIC of 0.42 mM/0.69 mM for <e1>o-cymen-5-ol</e1>/<e2>zinc gluconate</e2>, respectively. ",False,negative
Zinc,o-cymen-5-ol,0,3,64,75,<e1>Zinc</e1> inhibited glycolysis and protease to a greater degree than <e2>o-cymen-5-ol</e2>; ,False,negative
o-Cymen-5-ol,zinc chloride,0,11,13,25,"<e1>o-Cymen-5-ol</e1>/<e2>zinc chloride</e2> in toothpaste showed greater effects than placebo (120s log10 kill=7.35  0.40 and 4.02  0.40, respectively). ",False,negative
zinc,o-cymen-5-ol,4,7,9,20,The <e1>zinc</e1>/<e2>o-cymen-5-ol</e2> system has direct antimicrobial effects and inhibits oral disease-related processes. ,False,negative
o-cymen-5-ol,zinc,19,30,36,39,A system combining <e1>o-cymen-5-ol</e1> and <e2>zinc</e2> shows properties desirable for incorporation in toothpastes.,False,negative
moxidectin,moxidectin,21,30,107,116,Co-administration of <e1>moxidectin</e1> with inhibitors of ABC transporter function did not enhance sensitivity to <e2>moxidectin</e2> in males; ,False,negative
manganese gluconate,carbamide peroxide,53,71,171,188,"The aim of this study was to assess the influence of <e1>manganese gluconate</e1>, a chemical activator of bleaching agents, at a concentration of 0.01% on the efficiency of a 10% <e2>carbamide peroxide</e2>-based bleaching agent. ",False,negative
carbamide peroxide,manganese gluconate,25,42,74,92,Group 2 consisted of 10% <e1>carbamide peroxide</e1>-based bleaching gel and 0.01% <e2>manganese gluconate</e2>. ,False,negative
manganese gluconate,carbamide peroxide,13,31,40,57,Adding 0.01% <e1>manganese gluconate</e1> to 10% <e2>carbamide peroxide</e2> bleaching gel increased the degree of tooth bleaching after a seven-day treatment and did not influence the resulting shade after 14 days.,False,negative
methanol,ethylene glycol,181,188,191,205,"An increase in serum osmolality and serum osmolal gap with or without high-anion-gap metabolic acidosis is an important clue to exposure to one of the toxic alcohols, which include <e1>methanol</e1>, <e2>ethylene glycol</e2>, diethylene glycol, propylene glycol, or isopropanol. ",False,negative
methanol,diethylene glycol,181,188,208,224,"An increase in serum osmolality and serum osmolal gap with or without high-anion-gap metabolic acidosis is an important clue to exposure to one of the toxic alcohols, which include <e1>methanol</e1>, ethylene glycol, <e2>diethylene glycol</e2>, propylene glycol, or isopropanol. ",False,negative
methanol,propylene glycol,181,188,227,242,"An increase in serum osmolality and serum osmolal gap with or without high-anion-gap metabolic acidosis is an important clue to exposure to one of the toxic alcohols, which include <e1>methanol</e1>, ethylene glycol, diethylene glycol, <e2>propylene glycol</e2>, or isopropanol. ",False,negative
methanol,isopropanol,181,188,248,258,"An increase in serum osmolality and serum osmolal gap with or without high-anion-gap metabolic acidosis is an important clue to exposure to one of the toxic alcohols, which include <e1>methanol</e1>, ethylene glycol, diethylene glycol, propylene glycol, or <e2>isopropanol</e2>. ",False,negative
ethylene glycol,diethylene glycol,191,205,208,224,"An increase in serum osmolality and serum osmolal gap with or without high-anion-gap metabolic acidosis is an important clue to exposure to one of the toxic alcohols, which include methanol, <e1>ethylene glycol</e1>, <e2>diethylene glycol</e2>, propylene glycol, or isopropanol. ",False,negative
ethylene glycol,propylene glycol,191,205,227,242,"An increase in serum osmolality and serum osmolal gap with or without high-anion-gap metabolic acidosis is an important clue to exposure to one of the toxic alcohols, which include methanol, <e1>ethylene glycol</e1>, diethylene glycol, <e2>propylene glycol</e2>, or isopropanol. ",False,negative
ethylene glycol,isopropanol,191,205,248,258,"An increase in serum osmolality and serum osmolal gap with or without high-anion-gap metabolic acidosis is an important clue to exposure to one of the toxic alcohols, which include methanol, <e1>ethylene glycol</e1>, diethylene glycol, propylene glycol, or <e2>isopropanol</e2>. ",False,negative
diethylene glycol,propylene glycol,208,224,227,242,"An increase in serum osmolality and serum osmolal gap with or without high-anion-gap metabolic acidosis is an important clue to exposure to one of the toxic alcohols, which include methanol, ethylene glycol, <e1>diethylene glycol</e1>, <e2>propylene glycol</e2>, or isopropanol. ",False,negative
diethylene glycol,isopropanol,208,224,248,258,"An increase in serum osmolality and serum osmolal gap with or without high-anion-gap metabolic acidosis is an important clue to exposure to one of the toxic alcohols, which include methanol, ethylene glycol, <e1>diethylene glycol</e1>, propylene glycol, or <e2>isopropanol</e2>. ",False,negative
propylene glycol,isopropanol,227,242,248,258,"An increase in serum osmolality and serum osmolal gap with or without high-anion-gap metabolic acidosis is an important clue to exposure to one of the toxic alcohols, which include methanol, ethylene glycol, diethylene glycol, <e1>propylene glycol</e1>, or <e2>isopropanol</e2>. ",False,negative
Ticagrelor,antiplatelet agent,1,10,21,38,"[<e1>Ticagrelor</e1>: a novel <e2>antiplatelet agent</e2> for patients with acute coronary syndrome].
",False,negative
antiplatelet agent,clopidogrel,23,40,125,135,In clinical trials the <e1>antiplatelet agent</e1> reduced significantly vascular mortality and death from any cause when compared to <e2>clopidogrel</e2> in patients with acute coronary syndrome.,False,negative
nucleoside or nucleotide reverse transcriptase inhibitors,NRTI,38,94,97,100,"In most cases, the application of two <e1>nucleoside or nucleotide reverse transcriptase inhibitors</e1> (<e2>NRTI</e2>) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI) or an integrase inhibitor (II) is recommended. ",False,negative
nucleoside or nucleotide reverse transcriptase inhibitors,non-nucleoside reverse transcriptase inhibitor,38,94,119,164,"In most cases, the application of two <e1>nucleoside or nucleotide reverse transcriptase inhibitors</e1> (NRTI) together with a <e2>non-nucleoside reverse transcriptase inhibitor</e2> (NNRTI), a protease inhibitor (PI) or an integrase inhibitor (II) is recommended. ",False,negative
nucleoside or nucleotide reverse transcriptase inhibitors,NNRTI,38,94,167,171,"In most cases, the application of two <e1>nucleoside or nucleotide reverse transcriptase inhibitors</e1> (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (<e2>NNRTI</e2>), a protease inhibitor (PI) or an integrase inhibitor (II) is recommended. ",False,negative
nucleoside or nucleotide reverse transcriptase inhibitors,protease inhibitor,38,94,177,194,"In most cases, the application of two <e1>nucleoside or nucleotide reverse transcriptase inhibitors</e1> (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a <e2>protease inhibitor</e2> (PI) or an integrase inhibitor (II) is recommended. ",False,negative
nucleoside or nucleotide reverse transcriptase inhibitors,PI,38,94,197,198,"In most cases, the application of two <e1>nucleoside or nucleotide reverse transcriptase inhibitors</e1> (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (<e2>PI</e2>) or an integrase inhibitor (II) is recommended. ",False,negative
nucleoside or nucleotide reverse transcriptase inhibitors,integrase inhibitor,38,94,207,225,"In most cases, the application of two <e1>nucleoside or nucleotide reverse transcriptase inhibitors</e1> (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI) or an <e2>integrase inhibitor</e2> (II) is recommended. ",False,negative
nucleoside or nucleotide reverse transcriptase inhibitors,II,38,94,228,229,"In most cases, the application of two <e1>nucleoside or nucleotide reverse transcriptase inhibitors</e1> (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI) or an integrase inhibitor (<e2>II</e2>) is recommended. ",False,negative
NRTI,non-nucleoside reverse transcriptase inhibitor,97,100,119,164,"In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (<e1>NRTI</e1>) together with a <e2>non-nucleoside reverse transcriptase inhibitor</e2> (NNRTI), a protease inhibitor (PI) or an integrase inhibitor (II) is recommended. ",False,negative
NRTI,NNRTI,97,100,167,171,"In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (<e1>NRTI</e1>) together with a non-nucleoside reverse transcriptase inhibitor (<e2>NNRTI</e2>), a protease inhibitor (PI) or an integrase inhibitor (II) is recommended. ",False,negative
NRTI,protease inhibitor,97,100,177,194,"In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (<e1>NRTI</e1>) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a <e2>protease inhibitor</e2> (PI) or an integrase inhibitor (II) is recommended. ",False,negative
NRTI,PI,97,100,197,198,"In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (<e1>NRTI</e1>) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (<e2>PI</e2>) or an integrase inhibitor (II) is recommended. ",False,negative
NRTI,integrase inhibitor,97,100,207,225,"In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (<e1>NRTI</e1>) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI) or an <e2>integrase inhibitor</e2> (II) is recommended. ",False,negative
NRTI,II,97,100,228,229,"In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (<e1>NRTI</e1>) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI) or an integrase inhibitor (<e2>II</e2>) is recommended. ",False,negative
non-nucleoside reverse transcriptase inhibitor,NNRTI,119,164,167,171,"In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a <e1>non-nucleoside reverse transcriptase inhibitor</e1> (<e2>NNRTI</e2>), a protease inhibitor (PI) or an integrase inhibitor (II) is recommended. ",False,negative
non-nucleoside reverse transcriptase inhibitor,protease inhibitor,119,164,177,194,"In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a <e1>non-nucleoside reverse transcriptase inhibitor</e1> (NNRTI), a <e2>protease inhibitor</e2> (PI) or an integrase inhibitor (II) is recommended. ",False,negative
non-nucleoside reverse transcriptase inhibitor,PI,119,164,197,198,"In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a <e1>non-nucleoside reverse transcriptase inhibitor</e1> (NNRTI), a protease inhibitor (<e2>PI</e2>) or an integrase inhibitor (II) is recommended. ",False,negative
non-nucleoside reverse transcriptase inhibitor,integrase inhibitor,119,164,207,225,"In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a <e1>non-nucleoside reverse transcriptase inhibitor</e1> (NNRTI), a protease inhibitor (PI) or an <e2>integrase inhibitor</e2> (II) is recommended. ",False,negative
non-nucleoside reverse transcriptase inhibitor,II,119,164,228,229,"In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a <e1>non-nucleoside reverse transcriptase inhibitor</e1> (NNRTI), a protease inhibitor (PI) or an integrase inhibitor (<e2>II</e2>) is recommended. ",False,negative
NNRTI,protease inhibitor,167,171,177,194,"In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (<e1>NNRTI</e1>), a <e2>protease inhibitor</e2> (PI) or an integrase inhibitor (II) is recommended. ",False,negative
NNRTI,PI,167,171,197,198,"In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (<e1>NNRTI</e1>), a protease inhibitor (<e2>PI</e2>) or an integrase inhibitor (II) is recommended. ",False,negative
NNRTI,integrase inhibitor,167,171,207,225,"In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (<e1>NNRTI</e1>), a protease inhibitor (PI) or an <e2>integrase inhibitor</e2> (II) is recommended. ",False,negative
NNRTI,II,167,171,228,229,"In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (<e1>NNRTI</e1>), a protease inhibitor (PI) or an integrase inhibitor (<e2>II</e2>) is recommended. ",False,negative
protease inhibitor,PI,177,194,197,198,"In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a <e1>protease inhibitor</e1> (<e2>PI</e2>) or an integrase inhibitor (II) is recommended. ",False,negative
protease inhibitor,integrase inhibitor,177,194,207,225,"In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a <e1>protease inhibitor</e1> (PI) or an <e2>integrase inhibitor</e2> (II) is recommended. ",False,negative
protease inhibitor,II,177,194,228,229,"In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a <e1>protease inhibitor</e1> (PI) or an integrase inhibitor (<e2>II</e2>) is recommended. ",False,negative
PI,integrase inhibitor,197,198,207,225,"In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (<e1>PI</e1>) or an <e2>integrase inhibitor</e2> (II) is recommended. ",False,negative
PI,II,197,198,228,229,"In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (<e1>PI</e1>) or an integrase inhibitor (<e2>II</e2>) is recommended. ",False,negative
integrase inhibitor,II,207,225,228,229,"In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI) or an <e1>integrase inhibitor</e1> (<e2>II</e2>) is recommended. ",False,negative
antiretroviral,antiretroviral,18,31,44,57,"Before and during <e1>antiretroviral</e1> treatment, <e2>antiretroviral</e2> drug resistances, individual tolerance profiles and the needs of the individual patient, as well as several interactions with other drugs have to be considered. ",False,negative
opiate,opiate,33,38,144,149,"In direct contrast, in rats made <e1>opiate</e1> dependent and conditioned in a state of withdrawal, intra-BLA D2, but not D1, receptor blockade blocked <e2>opiate</e2> reward encoding. ",False,negative
opiate,morphine,90,95,182,189,Single-unit in vivo extracellular recordings performed in neurons of the NAc confirmed an <e1>opiate</e1>-state-dependent role for BLA D1/D2 transmission in NAc neuronal response patterns to <e2>morphine</e2>. ,False,negative
opiate,opiate,46,51,138,143,Our results characterize and identify a novel <e1>opiate</e1> addiction switching mechanism directly in the BLA that can control the processing of <e2>opiate</e2> reward information as a direct function of opiate exposure state via D1 or D2 receptor signaling substrates.,False,negative
opiate,opiate,46,51,188,193,Our results characterize and identify a novel <e1>opiate</e1> addiction switching mechanism directly in the BLA that can control the processing of opiate reward information as a direct function of <e2>opiate</e2> exposure state via D1 or D2 receptor signaling substrates.,False,negative
opiate,opiate,138,143,188,193,Our results characterize and identify a novel opiate addiction switching mechanism directly in the BLA that can control the processing of <e1>opiate</e1> reward information as a direct function of <e2>opiate</e2> exposure state via D1 or D2 receptor signaling substrates.,False,negative
Selective serotonin reuptake inhibitors,antidepressant,0,38,74,87,<e1>Selective serotonin reuptake inhibitors</e1> were the most commonly prescribed <e2>antidepressant</e2>. ,False,negative
anxiolytic,hypnotic,87,96,101,108,"Having moderate to severe pain (ARRR=1.54, 95% CI=1.08-2.20) and the prescribing of an <e1>anxiolytic</e1> or <e2>hypnotic</e2> (ARRR=1.33, 95% CI=1.02-1.74) increased the risk of potential inappropriate antidepressant use. ",False,negative
anxiolytic,antidepressant,87,96,186,199,"Having moderate to severe pain (ARRR=1.54, 95% CI=1.08-2.20) and the prescribing of an <e1>anxiolytic</e1> or hypnotic (ARRR=1.33, 95% CI=1.02-1.74) increased the risk of potential inappropriate <e2>antidepressant</e2> use. ",False,negative
hypnotic,antidepressant,101,108,186,199,"Having moderate to severe pain (ARRR=1.54, 95% CI=1.08-2.20) and the prescribing of an anxiolytic or <e1>hypnotic</e1> (ARRR=1.33, 95% CI=1.02-1.74) increased the risk of potential inappropriate <e2>antidepressant</e2> use. ",False,negative
nicotine,Chantix,13,20,38,44,"Treatment of <e1>nicotine</e1> dependence with <e2>Chantix</e2> (varenicline).
",False,negative
nicotine,varenicline,13,20,47,57,"Treatment of <e1>nicotine</e1> dependence with Chantix (<e2>varenicline</e2>).
",False,negative
Chantix,varenicline,38,44,47,57,"Treatment of nicotine dependence with <e1>Chantix</e1> (<e2>varenicline</e2>).
",False,negative
Varenicline,Chantix,0,10,36,42,"<e1>Varenicline</e1> is the generic name for <e2>Chantix</e2>, the newest drug available for the treatment of tobacco dependence. ",False,negative
varencline,bupropion SR,92,101,155,166,"In a randomized controlled clinical trial, the abstinence rate at 1 year for patients using <e1>varencline</e1> was superior to that of patients in the group using <e2>bupropion SR</e2> (Zyban) and in the placebo group (11). ",False,negative
varencline,Zyban,92,101,169,173,"In a randomized controlled clinical trial, the abstinence rate at 1 year for patients using <e1>varencline</e1> was superior to that of patients in the group using bupropion SR (<e2>Zyban</e2>) and in the placebo group (11). ",False,negative
bupropion SR,Zyban,155,166,169,173,"In a randomized controlled clinical trial, the abstinence rate at 1 year for patients using varencline was superior to that of patients in the group using <e1>bupropion SR</e1> (<e2>Zyban</e2>) and in the placebo group (11). ",False,negative
Varenicline,nicotine,0,10,20,27,"<e1>Varenicline</e1> reduces <e2>nicotine</e2> withdrawal symptoms, cigarette craving and nicotine satisfaction. ",False,negative
Varenicline,nicotine,0,10,72,79,"<e1>Varenicline</e1> reduces nicotine withdrawal symptoms, cigarette craving and <e2>nicotine</e2> satisfaction. ",False,negative
nicotine,nicotine,20,27,72,79,"Varenicline reduces <e1>nicotine</e1> withdrawal symptoms, cigarette craving and <e2>nicotine</e2> satisfaction. ",False,negative
cisplatin,cisplatin,15,23,131,139,"Combining with <e1>cisplatin</e1> and MWCHCP caused a tendency of increasing the tumor growth inhibition rate and significant attenution of <e2>cisplatin</e2>-induced diarrhea, visceral organ injury, gastric mucosal injury and decreased TNF-alpha mRNA level of intestine. ",False,negative
cisplatin,cisplatin,90,98,169,177,The present findings suggest that MWCHCP increases the inhibition rate of tumor growth of <e1>cisplatin</e1> and has a beneficial influence on gastrointestinal lesion induced by <e2>cisplatin</e2>.,False,negative
calcium,phosphate,59,65,71,79,This complex has a unique ability to deliver bio-available <e1>calcium</e1> and <e2>phosphate</e2> when they are needed most. ,False,negative
tyrphostin AG1024,doxorubicin,99,115,147,157,The purpose of this study was to investigate both the effect and mechanisms of IGF1R inhibition by <e1>tyrphostin AG1024</e1> in the presence or absence of <e2>doxorubicin</e2> in a panel of six osteosarcoma cell lines and a self-established doxorubicin-resistant cell line. ,False,negative
tyrphostin AG1024,doxorubicin,99,115,224,234,The purpose of this study was to investigate both the effect and mechanisms of IGF1R inhibition by <e1>tyrphostin AG1024</e1> in the presence or absence of doxorubicin in a panel of six osteosarcoma cell lines and a self-established <e2>doxorubicin</e2>-resistant cell line. ,False,negative
doxorubicin,doxorubicin,147,157,224,234,The purpose of this study was to investigate both the effect and mechanisms of IGF1R inhibition by tyrphostin AG1024 in the presence or absence of <e1>doxorubicin</e1> in a panel of six osteosarcoma cell lines and a self-established <e2>doxorubicin</e2>-resistant cell line. ,False,negative
phytocannabinoids,THC,76,92,141,143,"Different chemical structures of precursors, smoking dynamics, pyrolysis of <e1>phytocannabinoids</e1> and frequency of drug use affect the amount of <e2>THC</e2> absorbed. ",False,negative
cannabinoids,THC,33,44,87,89,Pharmacological effects of other <e1>cannabinoids</e1> or medication on the pharmacokinetics of <e2>THC</e2> have not yet been studied in detail. ,False,negative
Cyclooxygenase inhibitors,acetylsalicylic acid,1,25,54,73,"[<e1>Cyclooxygenase inhibitors</e1> and antiplatelet effect of <e2>acetylsalicylic acid</e2>. selective approach to nonsteroidal anti-inflammatory drugs in cardiological practice].
",False,negative
Cyclooxygenase inhibitors,nonsteroidal anti-inflammatory drugs,1,25,98,133,"[<e1>Cyclooxygenase inhibitors</e1> and antiplatelet effect of acetylsalicylic acid. selective approach to <e2>nonsteroidal anti-inflammatory drugs</e2> in cardiological practice].
",False,negative
acetylsalicylic acid,nonsteroidal anti-inflammatory drugs,54,73,98,133,"[Cyclooxygenase inhibitors and antiplatelet effect of <e1>acetylsalicylic acid</e1>. selective approach to <e2>nonsteroidal anti-inflammatory drugs</e2> in cardiological practice].
",False,negative
Nonsteroidal anti-inflammatory drugs,NSAIDs,0,35,38,43,<e1>Nonsteroidal anti-inflammatory drugs</e1> (<e2>NSAIDs</e2>) represent class of medicines which is wide concerning chemical structure and mechanism of action. ,False,negative
NSAID,NSAID,61,65,124,128,In the light of contradictory data on efficacy and safety of <e1>NSAID</e1> in cardiovascular patients selection of most appropriate <e2>NSAID</e2> (basing on profile of efficacy and safety) in patients receiving continuous therapy with low dose aspirin appears to be a problem. ,False,negative
NSAID,aspirin,61,65,228,234,In the light of contradictory data on efficacy and safety of <e1>NSAID</e1> in cardiovascular patients selection of most appropriate NSAID (basing on profile of efficacy and safety) in patients receiving continuous therapy with low dose <e2>aspirin</e2> appears to be a problem. ,False,negative
NSAID,aspirin,124,128,228,234,In the light of contradictory data on efficacy and safety of NSAID in cardiovascular patients selection of most appropriate <e1>NSAID</e1> (basing on profile of efficacy and safety) in patients receiving continuous therapy with low dose <e2>aspirin</e2> appears to be a problem. ,False,negative
cyclooxygenase inhibitors,acetylsalicylic acid,67,91,97,116,"In this paper we discuss peculiarities of drug interaction between <e1>cyclooxygenase inhibitors</e1> and <e2>acetylsalicylic acid</e2>, and principles of selection of adequate NSAI.",False,negative
cyclooxygenase inhibitors,NSAI,67,91,159,162,"In this paper we discuss peculiarities of drug interaction between <e1>cyclooxygenase inhibitors</e1> and acetylsalicylic acid, and principles of selection of adequate <e2>NSAI</e2>.",False,negative
acetylsalicylic acid,NSAI,97,116,159,162,"In this paper we discuss peculiarities of drug interaction between cyclooxygenase inhibitors and <e1>acetylsalicylic acid</e1>, and principles of selection of adequate <e2>NSAI</e2>.",False,negative
etizolam,phenobarbital,33,40,43,55,"A fatal poisoning case involving <e1>etizolam</e1>, <e2>phenobarbital</e2>, promethazine and chlorpromazine is presented. ",False,negative
etizolam,promethazine,33,40,58,69,"A fatal poisoning case involving <e1>etizolam</e1>, phenobarbital, <e2>promethazine</e2> and chlorpromazine is presented. ",False,negative
etizolam,chlorpromazine,33,40,75,88,"A fatal poisoning case involving <e1>etizolam</e1>, phenobarbital, promethazine and <e2>chlorpromazine</e2> is presented. ",False,negative
phenobarbital,promethazine,43,55,58,69,"A fatal poisoning case involving etizolam, <e1>phenobarbital</e1>, <e2>promethazine</e2> and chlorpromazine is presented. ",False,negative
phenobarbital,chlorpromazine,43,55,75,88,"A fatal poisoning case involving etizolam, <e1>phenobarbital</e1>, promethazine and <e2>chlorpromazine</e2> is presented. ",False,negative
promethazine,chlorpromazine,58,69,75,88,"A fatal poisoning case involving etizolam, phenobarbital, <e1>promethazine</e1> and <e2>chlorpromazine</e2> is presented. ",False,negative
etizolam,phenobarbital,70,77,80,92,"Quantitative toxicological analysis showed that the concentrations of <e1>etizolam</e1>, <e2>phenobarbital</e2>, promethazine and chlorpromazine in the femoral blood were 86 ng/ml, 5082 microg/ml, 0.107 microg/ml and 0.144 microg/ml, respectively, and large amounts of drugs were also detected in the stomach contents. ",False,negative
etizolam,promethazine,70,77,95,106,"Quantitative toxicological analysis showed that the concentrations of <e1>etizolam</e1>, phenobarbital, <e2>promethazine</e2> and chlorpromazine in the femoral blood were 86 ng/ml, 5082 microg/ml, 0.107 microg/ml and 0.144 microg/ml, respectively, and large amounts of drugs were also detected in the stomach contents. ",False,negative
etizolam,chlorpromazine,70,77,112,125,"Quantitative toxicological analysis showed that the concentrations of <e1>etizolam</e1>, phenobarbital, promethazine and <e2>chlorpromazine</e2> in the femoral blood were 86 ng/ml, 5082 microg/ml, 0.107 microg/ml and 0.144 microg/ml, respectively, and large amounts of drugs were also detected in the stomach contents. ",False,negative
phenobarbital,promethazine,80,92,95,106,"Quantitative toxicological analysis showed that the concentrations of etizolam, <e1>phenobarbital</e1>, <e2>promethazine</e2> and chlorpromazine in the femoral blood were 86 ng/ml, 5082 microg/ml, 0.107 microg/ml and 0.144 microg/ml, respectively, and large amounts of drugs were also detected in the stomach contents. ",False,negative
phenobarbital,chlorpromazine,80,92,112,125,"Quantitative toxicological analysis showed that the concentrations of etizolam, <e1>phenobarbital</e1>, promethazine and <e2>chlorpromazine</e2> in the femoral blood were 86 ng/ml, 5082 microg/ml, 0.107 microg/ml and 0.144 microg/ml, respectively, and large amounts of drugs were also detected in the stomach contents. ",False,negative
promethazine,chlorpromazine,95,106,112,125,"Quantitative toxicological analysis showed that the concentrations of etizolam, phenobarbital, <e1>promethazine</e1> and <e2>chlorpromazine</e2> in the femoral blood were 86 ng/ml, 5082 microg/ml, 0.107 microg/ml and 0.144 microg/ml, respectively, and large amounts of drugs were also detected in the stomach contents. ",False,negative
antibiotic,Gentamicin,9,18,28,37,"Standard <e1>antibiotic</e1> such as <e2>Gentamicin</e2> (10 microg), Cephalothin (30 microg), Ceftriaxone (10 microg), Nystatin (10 U) discs were used for comparison with the antimicrobial activities of essential oils of these plants. ",False,negative
antibiotic,Cephalothin,9,18,52,62,"Standard <e1>antibiotic</e1> such as Gentamicin (10 microg), <e2>Cephalothin</e2> (30 microg), Ceftriaxone (10 microg), Nystatin (10 U) discs were used for comparison with the antimicrobial activities of essential oils of these plants. ",False,negative
antibiotic,Ceftriaxone,9,18,77,87,"Standard <e1>antibiotic</e1> such as Gentamicin (10 microg), Cephalothin (30 microg), <e2>Ceftriaxone</e2> (10 microg), Nystatin (10 U) discs were used for comparison with the antimicrobial activities of essential oils of these plants. ",False,negative
antibiotic,Nystatin,9,18,102,109,"Standard <e1>antibiotic</e1> such as Gentamicin (10 microg), Cephalothin (30 microg), Ceftriaxone (10 microg), <e2>Nystatin</e2> (10 U) discs were used for comparison with the antimicrobial activities of essential oils of these plants. ",False,negative
Gentamicin,Cephalothin,28,37,52,62,"Standard antibiotic such as <e1>Gentamicin</e1> (10 microg), <e2>Cephalothin</e2> (30 microg), Ceftriaxone (10 microg), Nystatin (10 U) discs were used for comparison with the antimicrobial activities of essential oils of these plants. ",False,negative
Gentamicin,Ceftriaxone,28,37,77,87,"Standard antibiotic such as <e1>Gentamicin</e1> (10 microg), Cephalothin (30 microg), <e2>Ceftriaxone</e2> (10 microg), Nystatin (10 U) discs were used for comparison with the antimicrobial activities of essential oils of these plants. ",False,negative
Gentamicin,Nystatin,28,37,102,109,"Standard antibiotic such as <e1>Gentamicin</e1> (10 microg), Cephalothin (30 microg), Ceftriaxone (10 microg), <e2>Nystatin</e2> (10 U) discs were used for comparison with the antimicrobial activities of essential oils of these plants. ",False,negative
Cephalothin,Ceftriaxone,52,62,77,87,"Standard antibiotic such as Gentamicin (10 microg), <e1>Cephalothin</e1> (30 microg), <e2>Ceftriaxone</e2> (10 microg), Nystatin (10 U) discs were used for comparison with the antimicrobial activities of essential oils of these plants. ",False,negative
Cephalothin,Nystatin,52,62,102,109,"Standard antibiotic such as Gentamicin (10 microg), <e1>Cephalothin</e1> (30 microg), Ceftriaxone (10 microg), <e2>Nystatin</e2> (10 U) discs were used for comparison with the antimicrobial activities of essential oils of these plants. ",False,negative
Ceftriaxone,Nystatin,77,87,102,109,"Standard antibiotic such as Gentamicin (10 microg), Cephalothin (30 microg), <e1>Ceftriaxone</e1> (10 microg), <e2>Nystatin</e2> (10 U) discs were used for comparison with the antimicrobial activities of essential oils of these plants. ",False,negative
luteolin,apigenin,62,69,75,82,"Evaluation of hepatic clearance and drug-drug interactions of <e1>luteolin</e1> and <e2>apigenin</e2> by using primary cultured rat hepatocytes.
",False,negative
luteolin,apigenin,52,59,65,72,The hepatic clearance and drug-drug interactions of <e1>luteolin</e1> and <e2>apigenin</e2> were studied by using primary cultured rat hepatocytes. ,False,negative
Luteolin,apigenin,0,7,13,20,<e1>Luteolin</e1> and <e2>apigenin</e2> experienced extensive first-pass metabolism. ,False,negative
luteolin,apigenin,27,34,40,47,The elimination percent of <e1>luteolin</e1> and <e2>apigenin</e2> was found to be 91.9% and 86.7% after 120 min of incubation. ,False,negative
luteolin,apigenin,57,64,70,77,"The predicted % liver blood flow was 82.3% and 85.4% for <e1>luteolin</e1> and <e2>apigenin</e2>, respectively. ",False,negative
luteolin,apigenin,38,45,51,58,"Compared with the elimination of pure <e1>luteolin</e1> and <e2>apigenin</e2>, the elimination of luteolin and apigenin was much lower in hydrolyzed Flos Chrysanthemi extract (FCE) containing comparable amounts of luteolin and apigenin. ",False,negative
luteolin,luteolin,38,45,80,87,"Compared with the elimination of pure <e1>luteolin</e1> and apigenin, the elimination of <e2>luteolin</e2> and apigenin was much lower in hydrolyzed Flos Chrysanthemi extract (FCE) containing comparable amounts of luteolin and apigenin. ",False,negative
luteolin,apigenin,38,45,93,100,"Compared with the elimination of pure <e1>luteolin</e1> and apigenin, the elimination of luteolin and <e2>apigenin</e2> was much lower in hydrolyzed Flos Chrysanthemi extract (FCE) containing comparable amounts of luteolin and apigenin. ",False,negative
luteolin,luteolin,38,45,196,203,"Compared with the elimination of pure <e1>luteolin</e1> and apigenin, the elimination of luteolin and apigenin was much lower in hydrolyzed Flos Chrysanthemi extract (FCE) containing comparable amounts of <e2>luteolin</e2> and apigenin. ",False,negative
luteolin,apigenin,38,45,209,216,"Compared with the elimination of pure <e1>luteolin</e1> and apigenin, the elimination of luteolin and apigenin was much lower in hydrolyzed Flos Chrysanthemi extract (FCE) containing comparable amounts of luteolin and <e2>apigenin</e2>. ",False,negative
apigenin,luteolin,51,58,80,87,"Compared with the elimination of pure luteolin and <e1>apigenin</e1>, the elimination of <e2>luteolin</e2> and apigenin was much lower in hydrolyzed Flos Chrysanthemi extract (FCE) containing comparable amounts of luteolin and apigenin. ",False,negative
apigenin,apigenin,51,58,93,100,"Compared with the elimination of pure luteolin and <e1>apigenin</e1>, the elimination of luteolin and <e2>apigenin</e2> was much lower in hydrolyzed Flos Chrysanthemi extract (FCE) containing comparable amounts of luteolin and apigenin. ",False,negative
apigenin,luteolin,51,58,196,203,"Compared with the elimination of pure luteolin and <e1>apigenin</e1>, the elimination of luteolin and apigenin was much lower in hydrolyzed Flos Chrysanthemi extract (FCE) containing comparable amounts of <e2>luteolin</e2> and apigenin. ",False,negative
apigenin,apigenin,51,58,209,216,"Compared with the elimination of pure luteolin and <e1>apigenin</e1>, the elimination of luteolin and apigenin was much lower in hydrolyzed Flos Chrysanthemi extract (FCE) containing comparable amounts of luteolin and <e2>apigenin</e2>. ",False,negative
luteolin,apigenin,80,87,93,100,"Compared with the elimination of pure luteolin and apigenin, the elimination of <e1>luteolin</e1> and <e2>apigenin</e2> was much lower in hydrolyzed Flos Chrysanthemi extract (FCE) containing comparable amounts of luteolin and apigenin. ",False,negative
luteolin,luteolin,80,87,196,203,"Compared with the elimination of pure luteolin and apigenin, the elimination of <e1>luteolin</e1> and apigenin was much lower in hydrolyzed Flos Chrysanthemi extract (FCE) containing comparable amounts of <e2>luteolin</e2> and apigenin. ",False,negative
luteolin,apigenin,80,87,209,216,"Compared with the elimination of pure luteolin and apigenin, the elimination of <e1>luteolin</e1> and apigenin was much lower in hydrolyzed Flos Chrysanthemi extract (FCE) containing comparable amounts of luteolin and <e2>apigenin</e2>. ",False,negative
apigenin,luteolin,93,100,196,203,"Compared with the elimination of pure luteolin and apigenin, the elimination of luteolin and <e1>apigenin</e1> was much lower in hydrolyzed Flos Chrysanthemi extract (FCE) containing comparable amounts of <e2>luteolin</e2> and apigenin. ",False,negative
apigenin,apigenin,93,100,209,216,"Compared with the elimination of pure luteolin and apigenin, the elimination of luteolin and <e1>apigenin</e1> was much lower in hydrolyzed Flos Chrysanthemi extract (FCE) containing comparable amounts of luteolin and <e2>apigenin</e2>. ",False,negative
luteolin,apigenin,196,203,209,216,"Compared with the elimination of pure luteolin and apigenin, the elimination of luteolin and apigenin was much lower in hydrolyzed Flos Chrysanthemi extract (FCE) containing comparable amounts of <e1>luteolin</e1> and <e2>apigenin</e2>. ",False,negative
flavonoids,flavonols,26,35,48,56,"The effect of a series of <e1>flavonoids</e1>, including <e2>flavonols</e2>, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ",False,negative
flavonoids,flavones,26,35,59,66,"The effect of a series of <e1>flavonoids</e1>, including flavonols, <e2>flavones</e2>, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ",False,negative
flavonoids,isoflavone,26,35,69,78,"The effect of a series of <e1>flavonoids</e1>, including flavonols, flavones, <e2>isoflavone</e2>, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ",False,negative
flavonoids,flavanone,26,35,81,89,"The effect of a series of <e1>flavonoids</e1>, including flavonols, flavones, isoflavone, <e2>flavanone</e2>, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ",False,negative
flavonoids,flavanonols,26,35,92,102,"The effect of a series of <e1>flavonoids</e1>, including flavonols, flavones, isoflavone, flavanone, <e2>flavanonols</e2> and catechins, on the elimination of luteolin and apigenin was studied. ",False,negative
flavonoids,catechins,26,35,108,116,"The effect of a series of <e1>flavonoids</e1>, including flavonols, flavones, isoflavone, flavanone, flavanonols and <e2>catechins</e2>, on the elimination of luteolin and apigenin was studied. ",False,negative
flavonoids,luteolin,26,35,141,148,"The effect of a series of <e1>flavonoids</e1>, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of <e2>luteolin</e2> and apigenin was studied. ",False,negative
flavonoids,apigenin,26,35,154,161,"The effect of a series of <e1>flavonoids</e1>, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and <e2>apigenin</e2> was studied. ",False,negative
flavonols,flavones,48,56,59,66,"The effect of a series of flavonoids, including <e1>flavonols</e1>, <e2>flavones</e2>, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ",False,negative
flavonols,isoflavone,48,56,69,78,"The effect of a series of flavonoids, including <e1>flavonols</e1>, flavones, <e2>isoflavone</e2>, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ",False,negative
flavonols,flavanone,48,56,81,89,"The effect of a series of flavonoids, including <e1>flavonols</e1>, flavones, isoflavone, <e2>flavanone</e2>, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ",False,negative
flavonols,flavanonols,48,56,92,102,"The effect of a series of flavonoids, including <e1>flavonols</e1>, flavones, isoflavone, flavanone, <e2>flavanonols</e2> and catechins, on the elimination of luteolin and apigenin was studied. ",False,negative
flavonols,catechins,48,56,108,116,"The effect of a series of flavonoids, including <e1>flavonols</e1>, flavones, isoflavone, flavanone, flavanonols and <e2>catechins</e2>, on the elimination of luteolin and apigenin was studied. ",False,negative
flavonols,luteolin,48,56,141,148,"The effect of a series of flavonoids, including <e1>flavonols</e1>, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of <e2>luteolin</e2> and apigenin was studied. ",False,negative
flavonols,apigenin,48,56,154,161,"The effect of a series of flavonoids, including <e1>flavonols</e1>, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and <e2>apigenin</e2> was studied. ",False,negative
flavones,isoflavone,59,66,69,78,"The effect of a series of flavonoids, including flavonols, <e1>flavones</e1>, <e2>isoflavone</e2>, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ",False,negative
flavones,flavanone,59,66,81,89,"The effect of a series of flavonoids, including flavonols, <e1>flavones</e1>, isoflavone, <e2>flavanone</e2>, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ",False,negative
flavones,flavanonols,59,66,92,102,"The effect of a series of flavonoids, including flavonols, <e1>flavones</e1>, isoflavone, flavanone, <e2>flavanonols</e2> and catechins, on the elimination of luteolin and apigenin was studied. ",False,negative
flavones,catechins,59,66,108,116,"The effect of a series of flavonoids, including flavonols, <e1>flavones</e1>, isoflavone, flavanone, flavanonols and <e2>catechins</e2>, on the elimination of luteolin and apigenin was studied. ",False,negative
flavones,luteolin,59,66,141,148,"The effect of a series of flavonoids, including flavonols, <e1>flavones</e1>, isoflavone, flavanone, flavanonols and catechins, on the elimination of <e2>luteolin</e2> and apigenin was studied. ",False,negative
flavones,apigenin,59,66,154,161,"The effect of a series of flavonoids, including flavonols, <e1>flavones</e1>, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and <e2>apigenin</e2> was studied. ",False,negative
isoflavone,flavanone,69,78,81,89,"The effect of a series of flavonoids, including flavonols, flavones, <e1>isoflavone</e1>, <e2>flavanone</e2>, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ",False,negative
isoflavone,flavanonols,69,78,92,102,"The effect of a series of flavonoids, including flavonols, flavones, <e1>isoflavone</e1>, flavanone, <e2>flavanonols</e2> and catechins, on the elimination of luteolin and apigenin was studied. ",False,negative
isoflavone,catechins,69,78,108,116,"The effect of a series of flavonoids, including flavonols, flavones, <e1>isoflavone</e1>, flavanone, flavanonols and <e2>catechins</e2>, on the elimination of luteolin and apigenin was studied. ",False,negative
isoflavone,luteolin,69,78,141,148,"The effect of a series of flavonoids, including flavonols, flavones, <e1>isoflavone</e1>, flavanone, flavanonols and catechins, on the elimination of <e2>luteolin</e2> and apigenin was studied. ",False,negative
isoflavone,apigenin,69,78,154,161,"The effect of a series of flavonoids, including flavonols, flavones, <e1>isoflavone</e1>, flavanone, flavanonols and catechins, on the elimination of luteolin and <e2>apigenin</e2> was studied. ",False,negative
flavanone,flavanonols,81,89,92,102,"The effect of a series of flavonoids, including flavonols, flavones, isoflavone, <e1>flavanone</e1>, <e2>flavanonols</e2> and catechins, on the elimination of luteolin and apigenin was studied. ",False,negative
flavanone,catechins,81,89,108,116,"The effect of a series of flavonoids, including flavonols, flavones, isoflavone, <e1>flavanone</e1>, flavanonols and <e2>catechins</e2>, on the elimination of luteolin and apigenin was studied. ",False,negative
flavanone,luteolin,81,89,141,148,"The effect of a series of flavonoids, including flavonols, flavones, isoflavone, <e1>flavanone</e1>, flavanonols and catechins, on the elimination of <e2>luteolin</e2> and apigenin was studied. ",False,negative
flavanone,apigenin,81,89,154,161,"The effect of a series of flavonoids, including flavonols, flavones, isoflavone, <e1>flavanone</e1>, flavanonols and catechins, on the elimination of luteolin and <e2>apigenin</e2> was studied. ",False,negative
flavanonols,catechins,92,102,108,116,"The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, <e1>flavanonols</e1> and <e2>catechins</e2>, on the elimination of luteolin and apigenin was studied. ",False,negative
flavanonols,luteolin,92,102,141,148,"The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, <e1>flavanonols</e1> and catechins, on the elimination of <e2>luteolin</e2> and apigenin was studied. ",False,negative
flavanonols,apigenin,92,102,154,161,"The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, <e1>flavanonols</e1> and catechins, on the elimination of luteolin and <e2>apigenin</e2> was studied. ",False,negative
catechins,luteolin,108,116,141,148,"The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and <e1>catechins</e1>, on the elimination of <e2>luteolin</e2> and apigenin was studied. ",False,negative
catechins,apigenin,108,116,154,161,"The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and <e1>catechins</e1>, on the elimination of luteolin and <e2>apigenin</e2> was studied. ",False,negative
luteolin,apigenin,141,148,154,161,"The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of <e1>luteolin</e1> and <e2>apigenin</e2> was studied. ",False,negative
curcumin,fluoxetine,46,53,80,89,"Evaluation of antidepressant like activity of <e1>curcumin</e1> and its combination with <e2>fluoxetine</e2> and imipramine: an acute and chronic study.
",False,negative
curcumin,imipramine,46,53,95,104,"Evaluation of antidepressant like activity of <e1>curcumin</e1> and its combination with fluoxetine and <e2>imipramine</e2>: an acute and chronic study.
",False,negative
fluoxetine,imipramine,80,89,95,104,"Evaluation of antidepressant like activity of curcumin and its combination with <e1>fluoxetine</e1> and <e2>imipramine</e2>: an acute and chronic study.
",False,negative
curcumin,fluoxetine,58,65,92,101,"In the present study, the antidepressant like activity of <e1>curcumin</e1> and its combination with <e2>fluoxetine</e2> and imipramine was studied in acute model (three doses 24, 5 and 1 h before test) of forced swimming test (FST) in glass jar and tail suspension test (TST) in mice and in chronic model (14 day study) of FST with water wheel in rats. ",False,negative
curcumin,imipramine,58,65,107,116,"In the present study, the antidepressant like activity of <e1>curcumin</e1> and its combination with fluoxetine and <e2>imipramine</e2> was studied in acute model (three doses 24, 5 and 1 h before test) of forced swimming test (FST) in glass jar and tail suspension test (TST) in mice and in chronic model (14 day study) of FST with water wheel in rats. ",False,negative
fluoxetine,imipramine,92,101,107,116,"In the present study, the antidepressant like activity of curcumin and its combination with <e1>fluoxetine</e1> and <e2>imipramine</e2> was studied in acute model (three doses 24, 5 and 1 h before test) of forced swimming test (FST) in glass jar and tail suspension test (TST) in mice and in chronic model (14 day study) of FST with water wheel in rats. ",False,negative
curcumin,curcumin,155,162,184,191,"All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (<e1>curcumin</e1> 50 mg/kg), group 3 (<e2>curcumin</e2> 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). ",False,negative
curcumin,fluoxetine,155,162,214,223,"All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (<e1>curcumin</e1> 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (<e2>fluoxetine</e2> 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). ",False,negative
curcumin,imipramine,155,162,245,254,"All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (<e1>curcumin</e1> 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (<e2>imipramine</e2> 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). ",False,negative
curcumin,curcumin,155,162,276,283,"All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (<e1>curcumin</e1> 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (<e2>curcumin</e2> 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). ",False,negative
curcumin,fluoxetine,155,162,300,309,"All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (<e1>curcumin</e1> 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus <e2>fluoxetine</e2> 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). ",False,negative
curcumin,curcumin,155,162,334,341,"All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (<e1>curcumin</e1> 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (<e2>curcumin</e2> 100 mg/kg plus imipramine 15 mg/kg). ",False,negative
curcumin,imipramine,155,162,358,367,"All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (<e1>curcumin</e1> 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus <e2>imipramine</e2> 15 mg/kg). ",False,negative
curcumin,fluoxetine,184,191,214,223,"All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (<e1>curcumin</e1> 100 mg/kg), group 4 (<e2>fluoxetine</e2> 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). ",False,negative
curcumin,imipramine,184,191,245,254,"All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (<e1>curcumin</e1> 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (<e2>imipramine</e2> 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). ",False,negative
curcumin,curcumin,184,191,276,283,"All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (<e1>curcumin</e1> 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (<e2>curcumin</e2> 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). ",False,negative
curcumin,fluoxetine,184,191,300,309,"All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (<e1>curcumin</e1> 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus <e2>fluoxetine</e2> 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). ",False,negative
curcumin,curcumin,184,191,334,341,"All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (<e1>curcumin</e1> 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (<e2>curcumin</e2> 100 mg/kg plus imipramine 15 mg/kg). ",False,negative
curcumin,imipramine,184,191,358,367,"All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (<e1>curcumin</e1> 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus <e2>imipramine</e2> 15 mg/kg). ",False,negative
fluoxetine,imipramine,214,223,245,254,"All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (<e1>fluoxetine</e1> 20 mg/kg), group 5 (<e2>imipramine</e2> 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). ",False,negative
fluoxetine,curcumin,214,223,276,283,"All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (<e1>fluoxetine</e1> 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (<e2>curcumin</e2> 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). ",False,negative
fluoxetine,fluoxetine,214,223,300,309,"All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (<e1>fluoxetine</e1> 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus <e2>fluoxetine</e2> 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). ",False,negative
fluoxetine,curcumin,214,223,334,341,"All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (<e1>fluoxetine</e1> 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (<e2>curcumin</e2> 100 mg/kg plus imipramine 15 mg/kg). ",False,negative
fluoxetine,imipramine,214,223,358,367,"All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (<e1>fluoxetine</e1> 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus <e2>imipramine</e2> 15 mg/kg). ",False,negative
imipramine,curcumin,245,254,276,283,"All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (<e1>imipramine</e1> 15 mg/kg), group 6 (<e2>curcumin</e2> 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). ",False,negative
imipramine,fluoxetine,245,254,300,309,"All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (<e1>imipramine</e1> 15 mg/kg), group 6 (curcumin 100 mg/kg plus <e2>fluoxetine</e2> 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). ",False,negative
imipramine,curcumin,245,254,334,341,"All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (<e1>imipramine</e1> 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (<e2>curcumin</e2> 100 mg/kg plus imipramine 15 mg/kg). ",False,negative
imipramine,imipramine,245,254,358,367,"All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (<e1>imipramine</e1> 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus <e2>imipramine</e2> 15 mg/kg). ",False,negative
curcumin,fluoxetine,276,283,300,309,"All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (<e1>curcumin</e1> 100 mg/kg plus <e2>fluoxetine</e2> 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). ",False,negative
curcumin,curcumin,276,283,334,341,"All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (<e1>curcumin</e1> 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (<e2>curcumin</e2> 100 mg/kg plus imipramine 15 mg/kg). ",False,negative
curcumin,imipramine,276,283,358,367,"All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (<e1>curcumin</e1> 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus <e2>imipramine</e2> 15 mg/kg). ",False,negative
fluoxetine,curcumin,300,309,334,341,"All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus <e1>fluoxetine</e1> 20 mg/kg) and group 7 (<e2>curcumin</e2> 100 mg/kg plus imipramine 15 mg/kg). ",False,negative
fluoxetine,imipramine,300,309,358,367,"All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus <e1>fluoxetine</e1> 20 mg/kg) and group 7 (curcumin 100 mg/kg plus <e2>imipramine</e2> 15 mg/kg). ",False,negative
curcumin,imipramine,334,341,358,367,"All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (<e1>curcumin</e1> 100 mg/kg plus <e2>imipramine</e2> 15 mg/kg). ",False,negative
curcumin,fluoxetine,14,21,58,67,The effect of <e1>curcumin</e1> (100 mg/kg) was similar to that of <e2>fluoxetine</e2> and imipramine (p > 0.05) but its addition to fluoxetine and imipramine did not improve their antidepressant activity (p > 0.05). ,False,negative
curcumin,imipramine,14,21,73,82,The effect of <e1>curcumin</e1> (100 mg/kg) was similar to that of fluoxetine and <e2>imipramine</e2> (p > 0.05) but its addition to fluoxetine and imipramine did not improve their antidepressant activity (p > 0.05). ,False,negative
curcumin,fluoxetine,14,21,115,124,The effect of <e1>curcumin</e1> (100 mg/kg) was similar to that of fluoxetine and imipramine (p > 0.05) but its addition to <e2>fluoxetine</e2> and imipramine did not improve their antidepressant activity (p > 0.05). ,False,negative
curcumin,imipramine,14,21,130,139,The effect of <e1>curcumin</e1> (100 mg/kg) was similar to that of fluoxetine and imipramine (p > 0.05) but its addition to fluoxetine and <e2>imipramine</e2> did not improve their antidepressant activity (p > 0.05). ,False,negative
fluoxetine,imipramine,58,67,73,82,The effect of curcumin (100 mg/kg) was similar to that of <e1>fluoxetine</e1> and <e2>imipramine</e2> (p > 0.05) but its addition to fluoxetine and imipramine did not improve their antidepressant activity (p > 0.05). ,False,negative
fluoxetine,fluoxetine,58,67,115,124,The effect of curcumin (100 mg/kg) was similar to that of <e1>fluoxetine</e1> and imipramine (p > 0.05) but its addition to <e2>fluoxetine</e2> and imipramine did not improve their antidepressant activity (p > 0.05). ,False,negative
fluoxetine,imipramine,58,67,130,139,The effect of curcumin (100 mg/kg) was similar to that of <e1>fluoxetine</e1> and imipramine (p > 0.05) but its addition to fluoxetine and <e2>imipramine</e2> did not improve their antidepressant activity (p > 0.05). ,False,negative
imipramine,fluoxetine,73,82,115,124,The effect of curcumin (100 mg/kg) was similar to that of fluoxetine and <e1>imipramine</e1> (p > 0.05) but its addition to <e2>fluoxetine</e2> and imipramine did not improve their antidepressant activity (p > 0.05). ,False,negative
imipramine,imipramine,73,82,130,139,The effect of curcumin (100 mg/kg) was similar to that of fluoxetine and <e1>imipramine</e1> (p > 0.05) but its addition to fluoxetine and <e2>imipramine</e2> did not improve their antidepressant activity (p > 0.05). ,False,negative
fluoxetine,imipramine,115,124,130,139,The effect of curcumin (100 mg/kg) was similar to that of fluoxetine and imipramine (p > 0.05) but its addition to <e1>fluoxetine</e1> and <e2>imipramine</e2> did not improve their antidepressant activity (p > 0.05). ,False,negative
Curcumin,antidepressant,0,7,25,38,<e1>Curcumin</e1> can be a useful <e2>antidepressant</e2> especially in cases which respond to drugs having mixed effects on serotonin and catecholamines levels in the brain.,False,negative
antiepileptic drugs,taxol,69,87,90,94,"PXR-ligands include a wide variety of pharmaceutical agents, such as <e1>antiepileptic drugs</e1>, <e2>taxol</e2>, rifampicin, and human immunodeficiency virus protease inhibitors such as ritonavir and saquinavir. ",False,negative
antiepileptic drugs,rifampicin,69,87,97,106,"PXR-ligands include a wide variety of pharmaceutical agents, such as <e1>antiepileptic drugs</e1>, taxol, <e2>rifampicin</e2>, and human immunodeficiency virus protease inhibitors such as ritonavir and saquinavir. ",False,negative
antiepileptic drugs,human immunodeficiency virus protease inhibitors,69,87,113,160,"PXR-ligands include a wide variety of pharmaceutical agents, such as <e1>antiepileptic drugs</e1>, taxol, rifampicin, and <e2>human immunodeficiency virus protease inhibitors</e2> such as ritonavir and saquinavir. ",False,negative
antiepileptic drugs,ritonavir,69,87,170,178,"PXR-ligands include a wide variety of pharmaceutical agents, such as <e1>antiepileptic drugs</e1>, taxol, rifampicin, and human immunodeficiency virus protease inhibitors such as <e2>ritonavir</e2> and saquinavir. ",False,negative
antiepileptic drugs,saquinavir,69,87,184,193,"PXR-ligands include a wide variety of pharmaceutical agents, such as <e1>antiepileptic drugs</e1>, taxol, rifampicin, and human immunodeficiency virus protease inhibitors such as ritonavir and <e2>saquinavir</e2>. ",False,negative
taxol,rifampicin,90,94,97,106,"PXR-ligands include a wide variety of pharmaceutical agents, such as antiepileptic drugs, <e1>taxol</e1>, <e2>rifampicin</e2>, and human immunodeficiency virus protease inhibitors such as ritonavir and saquinavir. ",False,negative
taxol,human immunodeficiency virus protease inhibitors,90,94,113,160,"PXR-ligands include a wide variety of pharmaceutical agents, such as antiepileptic drugs, <e1>taxol</e1>, rifampicin, and <e2>human immunodeficiency virus protease inhibitors</e2> such as ritonavir and saquinavir. ",False,negative
taxol,ritonavir,90,94,170,178,"PXR-ligands include a wide variety of pharmaceutical agents, such as antiepileptic drugs, <e1>taxol</e1>, rifampicin, and human immunodeficiency virus protease inhibitors such as <e2>ritonavir</e2> and saquinavir. ",False,negative
taxol,saquinavir,90,94,184,193,"PXR-ligands include a wide variety of pharmaceutical agents, such as antiepileptic drugs, <e1>taxol</e1>, rifampicin, and human immunodeficiency virus protease inhibitors such as ritonavir and <e2>saquinavir</e2>. ",False,negative
rifampicin,human immunodeficiency virus protease inhibitors,97,106,113,160,"PXR-ligands include a wide variety of pharmaceutical agents, such as antiepileptic drugs, taxol, <e1>rifampicin</e1>, and <e2>human immunodeficiency virus protease inhibitors</e2> such as ritonavir and saquinavir. ",False,negative
rifampicin,ritonavir,97,106,170,178,"PXR-ligands include a wide variety of pharmaceutical agents, such as antiepileptic drugs, taxol, <e1>rifampicin</e1>, and human immunodeficiency virus protease inhibitors such as <e2>ritonavir</e2> and saquinavir. ",False,negative
rifampicin,saquinavir,97,106,184,193,"PXR-ligands include a wide variety of pharmaceutical agents, such as antiepileptic drugs, taxol, <e1>rifampicin</e1>, and human immunodeficiency virus protease inhibitors such as ritonavir and <e2>saquinavir</e2>. ",False,negative
human immunodeficiency virus protease inhibitors,ritonavir,113,160,170,178,"PXR-ligands include a wide variety of pharmaceutical agents, such as antiepileptic drugs, taxol, rifampicin, and <e1>human immunodeficiency virus protease inhibitors</e1> such as <e2>ritonavir</e2> and saquinavir. ",False,negative
human immunodeficiency virus protease inhibitors,saquinavir,113,160,184,193,"PXR-ligands include a wide variety of pharmaceutical agents, such as antiepileptic drugs, taxol, rifampicin, and <e1>human immunodeficiency virus protease inhibitors</e1> such as ritonavir and <e2>saquinavir</e2>. ",False,negative
ritonavir,saquinavir,170,178,184,193,"PXR-ligands include a wide variety of pharmaceutical agents, such as antiepileptic drugs, taxol, rifampicin, and human immunodeficiency virus protease inhibitors such as <e1>ritonavir</e1> and <e2>saquinavir</e2>. ",False,negative
vitamin D,bisphosphonates,56,64,134,148,"Beside this, the medication oriented supplementation of <e1>vitamin D</e1> can also ameliorate the pharmacologic action of many drugs, such as <e2>bisphosphonates</e2>, statins and cytostatic drugs.",False,negative
vitamin D,statins,56,64,151,157,"Beside this, the medication oriented supplementation of <e1>vitamin D</e1> can also ameliorate the pharmacologic action of many drugs, such as bisphosphonates, <e2>statins</e2> and cytostatic drugs.",False,negative
vitamin D,cytostatic drugs,56,64,163,178,"Beside this, the medication oriented supplementation of <e1>vitamin D</e1> can also ameliorate the pharmacologic action of many drugs, such as bisphosphonates, statins and <e2>cytostatic drugs</e2>.",False,negative
bisphosphonates,statins,134,148,151,157,"Beside this, the medication oriented supplementation of vitamin D can also ameliorate the pharmacologic action of many drugs, such as <e1>bisphosphonates</e1>, <e2>statins</e2> and cytostatic drugs.",False,negative
bisphosphonates,cytostatic drugs,134,148,163,178,"Beside this, the medication oriented supplementation of vitamin D can also ameliorate the pharmacologic action of many drugs, such as <e1>bisphosphonates</e1>, statins and <e2>cytostatic drugs</e2>.",False,negative
statins,cytostatic drugs,151,157,163,178,"Beside this, the medication oriented supplementation of vitamin D can also ameliorate the pharmacologic action of many drugs, such as bisphosphonates, <e1>statins</e1> and <e2>cytostatic drugs</e2>.",False,negative
propiverine hydrochloride,cetirizine di-hydrochloride,169,193,234,260,"A rapid, sensitive and reliable high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method was developed and validated for the determination of <e1>propiverine hydrochloride</e1> (CAS 54556-98-8) in human plasma using <e2>cetirizine di-hydrochloride</e2> as internal standard (IS, CAS 8388-51-0). ",False,negative
ethyl acetate,methanol-ammonium acetate,40,52,147,171,"Following liquid-liquid extraction with <e1>ethyl acetate</e1>, the separation was performed on a reverse phase C18 column with a mobile phase consisted of <e2>methanol-ammonium acetate</e2> (pH 4.0; 10 mM) (70:30, v/v). ",False,negative
